<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>384363</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384363]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Aetiology and epidemiology</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Aetiology and epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Dougall McCorry, Consultant Neurologist, &lt;/EM&gt;&lt;EM&gt;Queen Elizabeth Hospital Birmingham&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. &lt;A href="nelh:386655:0" name=internalLink&gt;Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis&lt;/A&gt;. &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(4):898-903&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; After initial excitement back in 2003, Bournissen et al have further confirmed that there is no association between high expression of the multidrug efflux ABCB1 (MDR1) drug-transporter and drug resistant epilepsy. They reviewed 11 case-control studies involving 3,371 patients finding no association between the MDR1 polymorphism and drug resistance. While the hypothesis that those with the 3435CC genotype have higher efflux of anti epilepsy drugs out of brain tissue and lower concentrations in the central nervous system, sounded convincing the search continues to better understand drug-resistant epilepsy.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Tan NC, Berkovic SF. (2010) &lt;A href="nelh:386657:0" name=internalLink&gt;The Epilepsy Genetic Association Database (epiGAD): analysis of 165 genetic association studies, 1996-2008&lt;/A&gt;. &lt;EM&gt;Epilepsia&lt;/EM&gt; 51(4):686-689&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt;Tan and Berkovic have systematically searched the genetic association studies in epilepsy finding 165 in total. They noted sample sizes were low, with the majority below 200. No association was judged as ’strong’ using standard criteria. They considered sample sizes are too small for which they hope the creation of the Epilepsy Genetic Association Database will facilitate further meta-analysis. Association studies have not, as yet, helped explain susceptibility to the common epilepsies or drug-resistance.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Quet F, Guerchet M, Pion SDS, Ngoungou EB, Nicoletti A, Preux P-M. (2009) &lt;A href="nelh:386656:0" name=internalLink&gt;Meta-analysis of the association between cysticercosis and epilepsy in Africa&lt;/A&gt;. &lt;EM&gt;Epilepsia&lt;/EM&gt; 51(5):830-837&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/neurological/ViewResource.aspx?resID=386656" target="_blank"&gt;&lt;/A&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction &lt;/A&gt;
&lt;DT&gt;&lt;STRONG&gt;Aetiology and epidemiology&lt;/STRONG&gt; 
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384381</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384381]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Diagnosis</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Heather Angus-Leppan, Consultant Neurologist, Honorary Senior Lecturer and Epilepsy Lead, Royal Free Hospital&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Guidelines&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Burgunder JM, Finsterer J, Szolnoki Z, Fontaine B, Baets J, Van BC, et al. &lt;A href="nelh:386649:0" name=internalLink&gt;EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias&lt;/A&gt;. &lt;EM&gt;European Journal of Neurology&lt;/EM&gt; 17(5):641-8, 2010 May.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; This article is a commendable attempt to provide a regularly reviewed consensus statement on genetic testing for channelopathies, epilepsies, migraine, stroke and dementias.&amp;nbsp; A number of databases were searched but the study does not appear to have looked at non- English speaking articles systematically, nor is there mention of hand searches of articles.&amp;nbsp; Analysis was done carefully by a number of experts and discussion used to arrive at consensus.&amp;nbsp;At best the evidence base is Class B, and the authors discuss this shortcoming of all the literature pragmatically. It is disappointing that the tables are not more comprehensive – the utility of the study would have been greatly enhanced by adding details of incidence of the genetic forms of each mutation to summary tables.&amp;nbsp; The article does not highlight clinical features which should alert the physician to consideration of a genetic cause, or alternatively comment when there are no specific distinguishing features, and future statements should do so.&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;STRONG&gt;Diagnosis &lt;/STRONG&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384387</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384387]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Foreign language articles</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Foreign language articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note:&lt;/STRONG&gt; Links to the full text are provided where available, or to the English abstract where no full text is available. Where neither full text nor an English abstract were freely available, no links have been provided.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ben Hamouda I, Mrabet A. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19522441" target="_blank"&gt;Epilepsy progress in the dawn of the 21st century&lt;/A&gt;. &lt;EM&gt;Tunisie Medicale&lt;/EM&gt; 87(2):105-10&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; French&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ben Hamouda, I, Mrabet A. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19537007" target="_blank"&gt;Particularities of epileptic women's care&lt;/A&gt;.&amp;nbsp;&lt;EM&gt;Tunisie Medicale&lt;/EM&gt; 87(3):169-72&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; French&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Canadillas-Hidalgo FM, Sanchez-Alvarez JC, Serrano-Castro PJ, Mercade-Cerda JM, en representacion de la Sociedad Andaluza de Epilepsia. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19557699" target="_blank"&gt;Consensus clinical practice guidelines of the Andalusian Epilepsy Society on prescribing generic antiepileptic drugs&lt;/A&gt;.&amp;nbsp;&lt;EM&gt;Revista de Neurologia&lt;/EM&gt; 49(1):41-7&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Da Costa CRCM, Maia Filho HDS, Gomes MDM. (2009) &lt;A href="http://www.scielo.br/scielo.php?pid=S1676-26492009000200006&amp;amp;script=sci_abstract" target="_blank"&gt;Clinical and neuropsychological evaluation of attention in children and adolescents with epilepsy: A systematic review&lt;/A&gt;. &lt;EM&gt;Journal of Epilepsy and Clinical Neurophysiology&lt;/EM&gt; 15(2):77-82&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Portuguese&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dai J, Han L, Wang L, Zhang LL. (2010) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20199730" target="_blank"&gt;Levetiracetam therapy for childhood epilepsy: a systematic review&lt;/A&gt;.&amp;nbsp;&lt;EM&gt;Zhongguo Dangdai Erke Zazhi&lt;/EM&gt; 12(2):128-131&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Chinese&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dupont S, Verny M, Harston S, Cartz-Piver L, Puisieux F, Benetos A, Vespignani H, Marchal C, Derambure P (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19150724" target="_blank"&gt;Specificity of epileptic seizures in the elderly: A proposed electro-clinical scale&lt;/A&gt;. &lt;EM&gt;Revue Neurologique&lt;/EM&gt; 165(10):803-811&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; French&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Mercade-Cerda JM, Sanchez-Alvarez JC, Galan-Barranco JM, Moreno-Alegre V, Serrano-Castro PJ, Canadillas-Hidalgo FM, Sociedad Andaluza de Epilepsia. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19396766" target="_blank"&gt;Consensus clinical practice guidelines of the Andalusian Epilepsy Society: therapeutic recommendations when dealing with a first epileptic seizure and in epileptic status&lt;/A&gt;. &lt;EM&gt;Revista de Neurologia&lt;/EM&gt; 48(9):489-95&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Mercade-Cerda JM, Gascon-Jimenez FJ, Ramos-Lizana J, Sanchez-Alvarez JC, Serrano Castro PJ. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19714559" target="_blank"&gt;Clinical practice guidelines of the Andalusian epilepsy society on prophylaxis and treatment of acute symptomatic epileptic seizures&lt;/A&gt;. &lt;EM&gt;Revista de Neurologia &lt;/EM&gt;49(5):270-276&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Nakken KO, Tauboll E. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19823202" target="_blank"&gt;Drug-resistant epilepsy&lt;/A&gt;. &lt;EM&gt;Tidsskrift for Den Norske Laegeforening&lt;/EM&gt; 129(19):1986-1989&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Norwegian&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Schulc E. (2009) Accelerometry-based automatic detection of epileptic seizures - literature review. &lt;EM&gt;Pflegewissenschaft&lt;/EM&gt; 11(10):517-526&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; German&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Serrano-Castro PJ, Sanchez-Alvarez JC, Canadillas-Hidalgo FM, Galan-Barranco JM, Moreno-Alegre V, Mercade-Cerda JM, et al. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19145565" target="_blank"&gt;Consensus clinical practice guidelines of the Sociedad Andaluza de Epilepsia for the diagnosis and treatment of patients with their first epileptic seizure in emergencies&lt;/A&gt;. &lt;EM&gt;Revista de Neurologia&lt;/EM&gt; 48(1):39-50&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;STRONG&gt;Foreign language articles&lt;/STRONG&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384385</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384385]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Introduction</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,NEUROLOGICAL,SEIZURES,HEAD / NECK / SPINE,SEIZURE,EPILEPSY,SURGERY,SURGERY,HEAD &amp; NECK,BRAIN,EPILEPSY,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Introduction by Lionel Ginsberg&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The 2010 Epilepsy Annual Evidence Update is our third on this topic, and examines knowledge on the diagnosis and management of epilepsy published since the 2009 Update. As with previous AEUs, the focus is on systematic reviews, carefully appraised to inform clinical practice, rather than primary research.&lt;/P&gt;
&lt;P&gt;In a year when there has been no single identifiable major drug advance, it is appropriate that there have been reviews focusing on more general pharmacological issues. These include the placebo response in epilepsy, and the question of switching from branded to generic anti-epilepsy drugs – a potentially related topic! Other guidelines and reviews have tackled areas of epilepsy management usually regarded as difficult – status epilepticus, the pregnant patient, and the role of epilepsy surgery. In the diagnostic domain, there have been studies assessing the impact of molecular genetics in analysing the causes of epilepsy and the mechanisms of anti-epilepsy drug resistance. The wider aspects of epilepsy care have been well represented this year, including psychological factors influencing its management and complications. Finally, in the social realm, there have been reviews of attitudes to epilepsy, and the variable availability of care for people with epilepsy worldwide.&lt;/P&gt;
&lt;P&gt;Last year, David Chadwick, the previous Clinical Lead for the Neurological Conditions Specialist Collection, highlighted organisational changes affecting the specialist libraries, particularly their incorporation into NHS Evidence. This year, further changes are afoot, notably a centralisation of the collections into “evidence hubs”. But these changes should only strengthen the role of the AEUs as authoritative resources for healthcare professionals involved in the care of people with common long-term conditions.&lt;/P&gt;
&lt;P&gt;I thank the Topic Advisors for their expert advice and comments, and the Project Team – Sara Clarke, Ruth Muscat and Caroline De Brún – for their hard work and support. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Lionel Ginsberg is the Clinical Lead for the NHS Evidence Neurological Conditions Specialist Collection. &lt;/EM&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR width="75%"&gt;

&lt;P&gt;The 2010 Epilepsy Annual Evidence Update, our third on this topic, highlights knowledge published since the 2009 Update on the diagnosis, treatment and management of Epilepsy. By presenting this information in an easily accessible format and with additional expert commentary, we will provide busy healthcare professionals with the information they need to keep up to date. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The most robust evidence-based systematic reviews from the period under review were selected by our topic advisors after review of&amp;nbsp;&lt;STRONG&gt;51&lt;/STRONG&gt; articles (see &lt;A href="nelh:380603:0" name=internalLink&gt;&lt;STRONG&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;&lt;STRONG&gt;Methods for retrieving and evaluating the evidence&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/A&gt; for more information on this process). &lt;/P&gt;
&lt;P&gt;The evidence has been split into the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;&lt;STRONG&gt;Aetiology and epidemiology&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; 
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;&lt;STRONG&gt;Diagnosis &lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;
&lt;LI&gt;Treatment &lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;&lt;STRONG&gt;Anti-epilepsy drugs&lt;/STRONG&gt; &lt;/A&gt;&lt;/STRONG&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;&lt;STRONG&gt;General &lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;&lt;STRONG&gt;Surgery&lt;/STRONG&gt; &lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;&lt;STRONG&gt;Risk factors and adverse effects&lt;/STRONG&gt;&lt;/A&gt; &lt;/STRONG&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;&lt;STRONG&gt;Other&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest. This year we have also identifed a number of treatment uncertainties from the reviews included in this Update. These have also been fed into the &lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs database&lt;/A&gt;&lt;/STRONG&gt;. This AEU is also available in &lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=384385" target="_blank"&gt;PDF format&lt;/A&gt;&lt;/STRONG&gt; and a &lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=387051" target="_blank"&gt;poster&lt;/A&gt;&lt;/STRONG&gt; is available for downloading.&lt;/P&gt;
&lt;P&gt;The Epilepsy Annual Evidence Update has been put together by the Neurological Conditions specialist collection Project Team, with expert advice and commentaries provided by our Epilepsy Topic Advisors. These are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Lionel Ginsberg, Clinical Lead&lt;/LI&gt;
&lt;LI&gt;David Chadwick, Emeritus Professor of Neurology, Walton Centre, Liverpool&lt;/LI&gt;
&lt;LI&gt;Mel Goodwin, Nurse Specialist, Northampton General Hospital&lt;/LI&gt;
&lt;LI&gt;Margaret Jackson, Consultant Neurologist, Royal Victoria Infirmary, Newcastle upon Tyne&lt;/LI&gt;
&lt;LI&gt;Dougall McCorry, Consultant Neurologist, Queen Elizabeth Hospital, Birmingham&lt;/LI&gt;
&lt;LI&gt;Tony Marson, Professor of Neurology, Liverpool University&lt;/LI&gt;
&lt;LI&gt;Phil Smith, Consultant Neurologist, University Hospital of Wales, Cardiff&lt;/LI&gt;
&lt;LI&gt;Phil Tittensor, Clinical Nurse Specialist in Epilepsy, Stafford Hospital, Stafford&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;We wish to thank the Topic Advisors for their generous support with this project.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;STRONG&gt;Introduction &lt;/STRONG&gt;
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>380603</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=380603]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,GENERALISED EPILEPSIES,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;Methods&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The last Annual Evidence Update on Epilepsy was published in May 2009. No new guidance has been published since that date, so this AEU has focused on updating our previous one with information published in 2009 and 2010 (ensuring that papers included in the previous AEU are excluded). The Specialist Collection focuses only on secondary information of use to NHS staff and patients, so our update is focused on guidelines, systematic reviews and other high quality studies written in English. However, foreign language articles were included in the search process.&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Search strategy&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We developed a search strategy based on that of the Cochrane Epilepsy Group. The search strategy was used in combination with slightly modified SIGN systematic review filters for databases via the Ovid interface. The MEDLINE search strategy was as follows:&lt;/P&gt;
&lt;P&gt;1. epilep*5.ti,ab&lt;BR&gt;2. exp Epilepsy/&lt;BR&gt;3. seizure*1.ti,ab&lt;BR&gt;4. Exp seizures/&lt;BR&gt;5. convulsion*1.ti,ab&lt;BR&gt;6. falling ADJ1 (sickness or epilep*5).ti,ab&lt;BR&gt;7. or/1-6&lt;/P&gt;
&lt;P&gt;limit to publication year 2009-10&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Original SIGN filters available at &lt;A href="http://www.sign.ac.uk/methodology/filters.html#systematic" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html#systematic&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Modified systematic review filter for use with Ovid Medline:&lt;/P&gt;
&lt;P&gt;1. exp Meta-Analysis as Topic/&lt;BR&gt;2. exp Meta-Analysis/&lt;BR&gt;3. (metaanaly* or (meta adj1 analy*) or meta-analy*).ti,ab.&lt;BR&gt;4. (systematic adj1 (review* or overview*)).ti,ab.&lt;BR&gt;5. exp "Review Literature as Topic"/&lt;BR&gt;6. 1 or 2 or 3 or 4 or 5&lt;BR&gt;7. cochrane.ab.&lt;BR&gt;8. embase.ab.&lt;BR&gt;9. (medline or pubmed).ab.&lt;BR&gt;10. (psyclit or psychlit or psycinfo or psychinfo).ab.&lt;BR&gt;11. (cinahl or cinhal).ab.&lt;BR&gt;12. (science and citation and index).ab.&lt;BR&gt;13. bids.ab.&lt;BR&gt;14. cancerlit.ab.&lt;BR&gt;15. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14&lt;BR&gt;16. (reference and list*).ab.&lt;BR&gt;17. bibliograph*.ab.&lt;BR&gt;18. ((hand and search*) or hand-search*).ab.&lt;BR&gt;19. (relevant and journals).ab.&lt;BR&gt;20. (manual and search*).ab.&lt;BR&gt;21. 16 or 17 or 18 or 19 or 20&lt;BR&gt;22. (selection and criteria).ab.&lt;BR&gt;23. (data and extraction).ab.&lt;BR&gt;24. 22 or 23&lt;BR&gt;25. exp "Review"/&lt;BR&gt;26. 24 and 25&lt;BR&gt;27. exp Comment/&lt;BR&gt;28. exp Letter/&lt;BR&gt;29. exp Editorial/&lt;BR&gt;30. 27 or 28 or 29&lt;BR&gt;31. 6 or 15 or 21 or 26&lt;BR&gt;32. 31 not 30&lt;BR&gt;33. Animals/&lt;BR&gt;34. Humans/&lt;BR&gt;35. 33 not (33 and 34)&lt;BR&gt;36. 32 not 35 &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The search, with minor modifications demanded by differences between databases, was repeated in AMED (Allied &amp;amp; Complementary Medicine Database), EMBASE, CINAHL, PsycINFO, and British Nursing Index (BNI). AMED and the BNI were searched without a systematic review filter as they contain fewer records. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;We also searched DARE, HTA, NEED, the Cochrane Library, NICE, and SIGN. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;BR&gt;After de-duplication&amp;nbsp;311 articles were retrieved.&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&lt;BR&gt;Inclusion and exclusion criteria&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: guideline, protocol, care pathway, systematic review, meta-analysis, consensus statement, health technology assessment, economic evaluation&lt;/LI&gt;
&lt;LI&gt;Published in 2009 or 2010, and not included in the 2009 AEU&lt;/LI&gt;
&lt;LI&gt;Main condition under investigation was Epilepsy&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Once the inclusion criteria were applied,&amp;nbsp;51 articles were included for appraisal. Of these, 11 were foreign language articles and 5 were Cochrane systematic reviews&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Cochrane systematic reviews, economic evaluations and health technology assessments were automatically included in the Evidence Update. While we were not able to find reviewers for them, the titles of the foreign language articles are included in a separate section of the Evidence Update. This left&amp;nbsp;44 articles that were sent to our reviewers for appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Critical appraisal process&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Categories (diagnosis, therapy, risk, prevention etc as relevant) were provisionally assigned to articles by the Information Specialist. Each Topic Advisor or appropriate member of Editorial Board was then sent the full text of a selection of the articles. The reviewers are: &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;&amp;nbsp;AEU process&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/neurological/contentID380603/nelhImp_0000_EpilepsyAEU2010flowchart.JPG"&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;H2&gt;&amp;nbsp;&lt;/H2&gt;
&lt;H2&gt;Reviewers&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=1 width=713&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD width=155&gt;Heather Angus-Leppan&lt;/TD&gt;
&lt;TD width=542&gt;Consultant Neurologist, Honorary Senior Lecturer and&amp;nbsp;Epilepsy Lead, Royal Free Hospital&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;David Chadwick&lt;/TD&gt;
&lt;TD&gt;Walton Centre, Liverpool &lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;Mel Goodwin&lt;/TD&gt;
&lt;TD&gt;Northampton General Hospital&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;Margaret Jackson&lt;/TD&gt;
&lt;TD&gt;Consultant Neurologist, Newcastle General Hospital&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;Dougall McCorry&lt;/TD&gt;
&lt;TD&gt;Consultant Neurologist, Queen Elizabeth Hospital Birmingham&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;Tony Marson&lt;/TD&gt;
&lt;TD&gt;Professor of Neurology, Liverpool University&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;Philip Smith&lt;/TD&gt;
&lt;TD&gt;Consultant Neurologist, University Hospital of Wales, Cardiff&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD&gt;Phil Tittensor&lt;/TD&gt;
&lt;TD&gt;Clinical Nurse Specialist in Epilepsy, Stafford Hospital, Stafford&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The reviewers confirmed the article category and recommended inclusion or exclusion from the evidence update on the basis of validity and relevance. Articles were appraised as per standard commentary sheet and expert summaries were written for each category by the reviewers.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The final number of articles included was 37 (5 Cochrane reviews and 32 other articles).&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;NHS Evidence - neurological conditions Project Team, September 2010&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;
&lt;DT&gt;&lt;STRONG&gt;AEU methodology&lt;/STRONG&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384331</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384331]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Other</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Other&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Margaret Jackson, Consultant Neurologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Cochrane systematic reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Koch MW, Polman SK, Uyttenboogaart M, De KJ. &lt;A href="nelh:320796:0" name=internalLink&gt;Treatment of seizures in multiple sclerosis&lt;/A&gt;. &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt; 2009, Issue 3. Art. No.: CD007150&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Kwan J, Wood E. &lt;A href="nelh:341719:0" name=internalLink&gt;Antiepileptic drugs for the primary and secondary prevention of seizures after stroke&lt;/A&gt;. &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt; 2010, Issue 1 Art. No.: CD005398&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Other reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; &lt;/EM&gt;&lt;EM&gt;Too often, I suspect, we fail to think about wider aspects of care in long term conditions. This collection of papers should stimulate debate about the global burden of epilepsy, epilepsy care, those whom it fails to reach, the impact of epilepsy and the placebo effect of drugs used to treat it.&lt;/EM&gt; 
&lt;P&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;STRONG&gt;Ngugi et al&lt;/STRONG&gt; attempt to estimate the global burden of epilepsy in a meta-analysis of the prevalence of active and lifetime epilepsy, finding the latter about 10 per 1000. Variation in the prevalence of active epilepsy between developed/developing countries and in rural/urban districts is found and possible reasons explored.&lt;/LI&gt;
&lt;LI&gt;In a systematic review of disparities in epilepsy care in North America &lt;STRONG&gt;Burneo et al&lt;/STRONG&gt; reveal the paucity of good studies on the subject. The data they present show differences between socioeconomic and ethnic groups in their means of accessing health care and use of medication. They confirm that people with epilepsy (PWE) are more likely to be unemployed and to have low annual income, (perhaps no major surprise) and that PWE use healthcare providers more than people with other chronic conditions. Access to epilepsy surgery was found to differ between racial/ethnic groups. No conclusions are reached but the message to health workers is that disparities need to be sought and their causes addressed. &lt;/LI&gt;
&lt;LI&gt;The “treatment gap” is another way of examining delivery of care. &lt;STRONG&gt;Meyer et al&lt;/STRONG&gt; present a detailed review of global disparities in epilepsy care and show that the treatment gap is greater than 75% in rural areas of most low-income countries. Those PWE living in high income countries fare much better.&lt;/LI&gt;
&lt;LI&gt;Attitudes to epilepsy in Asia are investigated by &lt;STRONG&gt;Yi-Jing Lim et al&lt;/STRONG&gt; in a systematic review. Although study methodology was not always optimal, worrying results include 43% of respondents in one study believing “epileptics” should be isolated from the “normal” population. Differences in attitudes to PWE between countries and the beneficial effect of education are illustrated. Such studies mark the progress made in recent years in attitudes people with epilepsy but show much stigma remains, often associated with reduced quality of life for PWE.&lt;/LI&gt;
&lt;LI&gt;The risk of depression of mothers whose children have epilepsy and the impact of maternal depression on the child is assessed by &lt;STRONG&gt;Ferro et al&lt;/STRONG&gt;. Poor quality studies and inconsistent results between them limit their conclusions. But there is some evidence that maternal depression may have a negative impact on the quality of life of children with epilepsy.&lt;/LI&gt;
&lt;LI&gt;The placebo response to AEDs is explored by &lt;STRONG&gt;Guekht et al&lt;/STRONG&gt; in a systematic review. They estimate the pooled response to be 12.5% for a 50% reduction in seizures and showing no strong correlation with seizure frequency. A correlation between placebo response and tested drug efficacy intrigues but is not satisfactorily explained.&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Burneo JG, Jette N, Theodore W, Begley C, Parko K, Thurman DJ, Wiebe S; Task Force on Disparities in Epilepsy Care. (2009) &lt;A href="nelh:384229:0" name=internalLink&gt;Disparities in epilepsy: report of a systematic review by the North American Commission of the International League Against Epilepsy&lt;/A&gt;. &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(10):2285-95. Epub 2009 Sep 3.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ferro MA, Speechley KN. (2009) &lt;A href="nelh:384276:0" name=internalLink&gt;Depressive symptoms among mothers of children with epilepsy: a review of prevalence, associated factors, and impact on children&lt;/A&gt;. &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(11):2344-54. Epub 2009 Aug 19.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;Lim Y-J, Chan S-Y, Ko Y. (2009) &lt;A href="nelh:384279:0" name=internalLink&gt;Stigma and health-related quality of life in Asian adults with epilepsy&lt;/A&gt;. &lt;EM&gt;Epilepsy Research&lt;/EM&gt; 87(2-3):107-119&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Meyer A, Dua T, Ma J, Saxena S, Birbeck G. (2010) &lt;A href="nelh:384286:0" name=internalLink&gt;Global disparities in the epilepsy treatment gap: a systematic review&lt;/A&gt;. &lt;EM&gt;Bulletin of the World Health Organization. &lt;/EM&gt;88(4):260-73&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. (2010) &lt;A href="nelh:384288:0" name=internalLink&gt;Estimation of the burden of active and life-time epilepsy: A meta-analytic approach&lt;/A&gt;. &lt;EM&gt;Epilepsia&lt;/EM&gt; 51(5):883-890&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;STRONG&gt;Other &lt;/STRONG&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384390</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384390]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Risk factors and adverse events</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Risk factors and adverse events&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Mel Goodwin, Nurse Specialist, Northampton General Hospital, and Phil Tittensor, Clinical Nurse Specialist in Epilepsy, Stafford Hospital, Stafford&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Banach R, Boskovic R, Einarson T, Koren G. (2010) &lt;A href="nelh:386638:0" name=internalLink&gt;Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: A meta-analysis of cohort studies&lt;/A&gt;. &lt;EM&gt;Drug Safety&lt;/EM&gt; 33(1):73-79&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;MG&amp;nbsp;comments:&lt;/STRONG&gt; A clear and detailed search strategy and search terms are identified. Data analysis, collection and measurement scales are identified. Characteristics of the studies included in the meta-analysis are set out in table format. &lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This paper finds no evidence that maternal epilepsy is associated with lower IQ in offspring, although recognizes that further studies are needed to address whether confounders such as maternal IQ and socioeconomic status are responsible for these findings.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;This study confirms exposure to valproic acid in pregnancy is associated with significantly reduced intelligence in offspring and that exposure to Carbamazepine does not appear to be associated with reduced mean full scale or verbal IQ in offspring.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. (2009) &lt;/STRONG&gt;&lt;A href="nelh:384471:0" name=internalLink&gt;&lt;STRONG&gt;Suicide in people with epilepsy: how great is the risk?&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt; &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(8):1933-42&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;PT&amp;nbsp;comments:&lt;/STRONG&gt; Bell et al (2009) use a meta analysis to discuss the relative risks of suicide in people with epilepsy. While they acknowledge that their methodology will likely have missed some papers, they were able to evaluate a significant number of patient years across some specific populations of people with the condition. Some sub categories had wide confidence intervals (CI) and 28 of the 45 studies reported had lower end CI’s of less than 1. However the overall standardised mortality ratio of 3.3 (CI 2.8 – 3.7) seems robust. The authors cite a later paper not included in the meta analysis which suggests that people with epilepsy and psychiatric co-morbidities are at greatest risk of suicide, although surgical cohorts also report a high suicide rate. Recommendations are made for the identification of people with epilepsy &amp;amp; psychiatric co-morbidities in clinic in order to signpost them to appropriate services.&amp;nbsp;&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cheng LS, Prasad AN, Rieder MJ. (2010) &lt;/STRONG&gt;&lt;A href="nelh:386641:0" name=internalLink&gt;&lt;STRONG&gt;Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Canadian Journal of Clinical Pharmacology/Journal Canadien de Pharmacologie Clinique&lt;/EM&gt; 17(1):e5-46&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;MG&amp;nbsp;comments:&lt;/STRONG&gt; The search strategy and question is clearly defined and inclusions and exclusions identified. A table of the studies is clearly set out showing methodology, study population and key findings. This paper systematically reviews the effects of a number of confounders on concentrations of homocysteine and lipoprotein including length of treatment with AEDs and monotherapy/polytherapy. The results are somewhat confusing due to the limitations of the validity and reliability of the studies described. Further studies are required in different ethnic groups in the paediatric population. Further studies to assess anti-epilepsy drug therapy that leads to increases in homocysteine and lipoprotein concentrations and evaluation of the long-term effects of folic acid and multivitamin supplementation with regard to cardiovascular disease are required.&lt;/EM&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Longo B, Forinash AB, Murphy JA. (2009) &lt;/STRONG&gt;&lt;A href="nelh:386647:0" name=internalLink&gt;&lt;STRONG&gt;Levetiracetam use in pregnancy&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Annals of Pharmacotherapy&lt;/EM&gt; 43(10):1692-1695&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;MG&amp;nbsp;comments:&lt;/STRONG&gt; Inclusions/exclusions of identified papers not clear. No discussion around the number of papers identified. Quality of the included papers is not discussed. Some important outcomes excluded such as adherence and folic acid supplementation.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The following series of papers uses a panel of experts consisting of epileptologists, general neurologists, pharmacologists, and those with expertise in obstetrics, and teratology to review data.&lt;/P&gt;
&lt;P&gt;Search criteria are clearly identified. Papers identified and included in the analysis are classified according to the AAN prognostic classification of evidence scheme. Articles graded clasas III or higher were used.&lt;/P&gt;
&lt;P&gt;Each paper sets out concise questions to be answered. For each question there is an analysis of the evidence, conclusions and recommendations. Recommendations are set into a clinical context.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C. (2009) &lt;/STRONG&gt;&lt;A href="nelh:386644:0" name=internalLink&gt;&lt;STRONG&gt;Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Neurology&lt;/EM&gt; 73(2):133-141&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;MG&amp;nbsp;comments:&lt;/STRONG&gt; This paper analyses three broad questions:&lt;/EM&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;EM&gt;Risk of MCM (major congenital malformations) of neonates exposed to intrauterine AEDs (antiepileptic drugs)&lt;/EM&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;EM&gt;Risk of adverse long term cognitive outcomes in children born to WWE (women with epilepsy)&lt;/EM&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;EM&gt;The risk of death, low birth weight and low Apgar scores&lt;/EM&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;EM&gt;Valproate is associated with greatest risk from in utero exposure. Advisable if planning to switch from valproate to do so before pregnancy.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Too few patients in studies of the new AEDs&amp;nbsp;to draw conclusions. AEDs as a teratogen produce a pattern of MCMs with overlap among the individual AEDs.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Further research is needed to assess the risks of the newer AEDs. Existence of AED dose-malformation relationship needs clarifying for all AEDs, incorporating serum levels. Cognitive outcomes following exposure to all AEDs need further clarification including short and long term cognitive risks of exposure to breast milk.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Evaluation of metabolic systems and interactions between AEDs and molecular targets that may play a role in teratogenic risk.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C. &lt;/STRONG&gt;&lt;A href="nelh:386645:0" name=internalLink&gt;&lt;STRONG&gt;Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review). Obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Neurology&lt;/EM&gt; 2009;73(2):126-13&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;MG&amp;nbsp;comments:&lt;/STRONG&gt; This paper analyses two broad questions;&lt;/EM&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;&lt;EM&gt;Whether women with epilepsy (WWE) are at increased risk of pregnancy related complications compared to women without epilepsy.&lt;/EM&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;EM&gt;What are the risks of epilepsy related complications for pregnant WWE&lt;/EM&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;EM&gt;There was no conclusive evidence of many of the obstetric complications that have previously been associated with WWE. No suggestion of high rates of seizure increase, status epilepticus or risk of seizure increase in those who are seizure free.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Further research is needed to determine if there are increased risks of pre-eclampsia, pregnancy induced hypertension and spontaneous abortion.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, Hopp MD, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen C (2009) &lt;/STRONG&gt;&lt;A href="nelh:386646:0" name=internalLink&gt;&lt;STRONG&gt;Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review). &lt;/STRONG&gt;&lt;A href="nelh:386646:0" name=internalLink&gt;&lt;STRONG&gt;Vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society&lt;/STRONG&gt;&lt;/A&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Neurology&lt;/EM&gt; 73(2):142-149&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;MG&amp;nbsp;comments:&lt;/STRONG&gt; This paper analyses six questions relating to the clinical management of WWE planning pregnancy or who are pregnant.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;There is some evidence to support monitoring of AED levels in pregnancy, particularly Lamotrigine.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;More research is required on pharmacokinetic alterations in AED metabolism post partum to determine AED dosing in this period. Need to clarify whether folic acid supplementation provides additional benefit and whether late pregnancy vitamin K supplementation is beneficial.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Hughes JR. (2009) &lt;/STRONG&gt;&lt;A href="nelh:384475:0" name=internalLink&gt;&lt;STRONG&gt;A review of sudden unexpected death in epilepsy: prediction of patients at risk&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Epilepsy &amp;amp; Behavior&lt;/EM&gt; 14(2):280-7&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;PT&amp;nbsp;comments:&lt;/STRONG&gt; Hughes (2009) attempted a thorough review of the literature surrounding SUDEP (sudden unexpected death in epilepsy). He used the findings to produce a table of relative risk of SUDEP for people with epilepsy. This may help clinicians grapple with the question of whether to tell patients about SUDEP or not. Some people would appear to be at very low risk, while others have a risk factor which is so great that a discussion about SUDEP becomes mandatory. Although the studies reviewed do not point to a single cause of SUDEP, the point is well made that the cause is perhaps secondary to the identification and avoidance of the risks.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Lee RH, Lyles KW, Colon-Emeric C. (2010) &lt;/STRONG&gt;&lt;A href="nelh:384485:0" name=internalLink&gt;&lt;STRONG&gt;A review of the effect of anticonvulsant medications on bone mineral density and fracture risk&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;American Journal of Geriatric Pharmacotherapy&lt;/EM&gt; 8(1):34-46&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;PT&amp;nbsp;comments:&lt;/STRONG&gt; Low bone mineral density (BMD) has been noted in patients taking anti epileptic drugs (AED’s) for the last 40 years. Lee et al (2010) review what evidence we have for the mechanism of this observation, the anti epileptic drugs that are most closely associated with it and the evidence for treatment. The review attempts to identify the risk for people over the age of 65 but points out the paucity of evidence. The review confirms our understanding of the risks on BMD posed by AED’s but really raises more questions than answers for treating clinicians.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Thomas RH, King WH, Johnston JA, Smith PE. (2010) &lt;A href="nelh:384490:0" name=internalLink&gt;Awake seizures after pure sleep-related epilepsy: a systematic review and implications for driving law&lt;/A&gt;. &lt;EM&gt;Journal of Neurology, Neurosurgery&amp;nbsp;&amp;amp; Psychiatry&lt;/EM&gt; 81(2):130-6&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;PT&amp;nbsp;comments:&lt;/STRONG&gt; The question of when to allow driving when a person with epilepsy has seizures only in their sleep is difficult to answer. Thomas et al (2010) make the point that the driving regulations in the UK are based on evidence dating back some 35 years. People with sleep related epilepsy in 2010 are much more likely to receive treatment with AED’s. This is likely to significantly reduce the risk of seizure recurrence and indeed modern studies suggest that response to treatment is generally good. Nevertheless, there remain sub groups of patients (those with frontal lobe epilepsy) for whom control is difficult and the risks of awake seizures developing is relatively high. Perhaps future driving regulations will become more finely honed with observational periods varying depending upon the syndromic epilepsy diagnosis. In truth, this is probably some way off and more studies will be required to confirm the safety and suitability of this approach.&amp;nbsp;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;STRONG&gt;Risk factors and adverse effects&lt;/STRONG&gt; 
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384357</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384357]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Treatment - anti-epilepsy drugs</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Treatment - anti-epilepsy drugs&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by &lt;EM&gt;David Chadwick, Emeritus Professor of Neurology, Walton Centre, Liverpool, &lt;EM&gt;Margaret Jackson, Consultant Neurologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust&lt;/EM&gt;, and &lt;/EM&gt;Tony Marson, Professor of Neurology, Liverpool University&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Cochrane systematic reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Koch MW, Polman SK. &lt;A href="nelh:327182:0" name=internalLink&gt;Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures&lt;/A&gt;. &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt; 2009, Issue 4. art. No.: CD006453&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Powell G, Saunders M, Marson AG. &lt;A href="nelh:341764:0" name=internalLink&gt;Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy&lt;/A&gt;. &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt;, 2010, Issue 1. art. No.: CD007124&lt;/STRONG&gt; 
&lt;P&gt;&amp;nbsp; 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Other&amp;nbsp;reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. (2010) &lt;/STRONG&gt;&lt;A href="nelh:384466:0" name=internalLink&gt;&lt;STRONG&gt;Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Drugs&lt;/EM&gt; 70(5):605-21&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; Of the&amp;nbsp;reviews selected, the one of greatest current interest will be this systematic review comparing studies of branded and generic AEDs (anti epilepsy drugs). Currently there are vociferous campaigns being run on behalf of patient groups to justify the use of, often higher cost, branded drugs rather than switching to lower cost generics. This good quality review shows that there is an absence of evidence to show that patients are likely to suffer as a consequence of any such switches. Patients and clinicians are thus left with what can be difficult decisions, particularly in any healthcare system that&amp;nbsp;is under economic pressure. Should a switch of uncertain harm be undertaken in order to avoid the opportunity costs of prescribing a more expensive brand?&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Beyenburg S, Stavem K, Schmidt D. (2010) &lt;/STRONG&gt;&lt;A href="nelh:384458:0" name=internalLink&gt;&lt;STRONG&gt;Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Epilepsia&lt;/EM&gt; 51(1):7-26&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; The second review of interest is Beyenburg this overview of placebo controlled licensing trials of AEDs in patients with refractory epilepsy, the results of which were&amp;nbsp;sufficient&amp;nbsp;to persuade regulatory agencies to license drugs. The estimate of superiority of drug over placebo for a 50% reduction in seizure frequency was 21% (95% CI 19-24), with 6% more subjects becoming seizure free on drug than placebo. The authors conclude that the results are disappointing, which shouldn’t surprise any clinicians with experience of using newly licensed drugs over the last 10-20 years. Perhaps more interesting than overall results would have been the variance between different AEDs studied. The other issue of interest arising from this review is the fact that in trials over limited periods, numbers of placebo-treated patients do achieve the quoted improvements in seizure control. There is uncertainty as to whether there is any true placebo effect in epilepsy, but as with all chronic conditions it is likely that the phenomenon of regression to the mean plays the major role in this particular observation. It is important that clinicians are aware of this in their everyday practice. They usually will suggest a change in medication after a patient has had a particularly poor recent experience. On average the next period of time is more likely than not to be better, even if no treatment changes are made. When treatment is changed in these circumstances, both patient and doctor may wrongly attribute improvement to treatment change.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Gallop K. (2010) Review article: &lt;/STRONG&gt;&lt;A href="nelh:384461:0" name=internalLink&gt;&lt;STRONG&gt;Phenytoin use and efficacy in the ED&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Emergency Medicine Australasia&lt;/EM&gt; 22(2):108-18&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; This paper deals with the evidence base for the use of parenteral phenytoin within an emergency medicine setting, emphasising the poor evidence base supporting its use.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guekht AB, Korczyn AD, Bondareva IB, Gusev EI. (2010) &lt;A href="nelh:384291:0" name=internalLink&gt;Placebo responses in randomized trials of antiepileptic drugs&lt;/A&gt;. &lt;EM&gt;Epilepsy &amp;amp; Behavior&lt;/EM&gt; 17(1):64-9&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments: &lt;/STRONG&gt;The placebo response to AEDs is explored by Guekht et al in a systematic review. They estimate the pooled response to be 12.5% for a 50% reduction in seizures, and showing no strong correlation with seizure frequency. A correlation between placebo response and tested drug efficacy intrigues but is not satisfactorily explained.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;STRONG&gt;Anti-epilepsy drugs &lt;/STRONG&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384085</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384085]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Treatment - general</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Treatment - general&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Phil Smith, Consultant Neurologist, University Hospital of Wales, Cardiff&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Guidelines&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Kerr M, Scheepers M, Arvio M, Beavis J, Brandt C, Brown S, et al. (2009)&amp;nbsp;&lt;/STRONG&gt;&lt;A href="nelh:384047:0" name=internalLink&gt;&lt;STRONG&gt;Consensus guidelines into the management of epilepsy in adults with an intellectual disability&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Journal of Intellectual Disability Research&lt;/EM&gt; 53(8):687-94&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments: &lt;/STRONG&gt;This is a description of pragmatic consensus guidelines reflecting the dearth of RCT evidence in this field. Although drawn up by experience rather than evidence, this document represents the best available guide to the management of adults with significant intellectual disability. This is clearly a clinical area where there are many unanswered treatment questions and where more research is needed.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ma L, Yung A, Yau E, Kwong K. (2010) &lt;/STRONG&gt;&lt;A href="nelh:384052:0" name=internalLink&gt;&lt;STRONG&gt;Clinical guidelines on management of prolonged seizures, serial seizures and convulsive status epilepticus in children&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Hong Kong Journal of Paediatrics&lt;/EM&gt; 15(1):52-83&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; This is a comprehensive clinical guideline which makes recommendations (with levels of evidence for each) for the in-hospital management of convulsive status epilepticus in children (excluding neonates).&amp;nbsp; It is well referenced but the methods of literature review (systematic or otherwise) and search terms etc. are not stated in the paper.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;&lt;EM&gt;
&lt;P&gt;&lt;STRONG&gt;Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. (2010) &lt;A href="nelh:384057:0" name=internalLink&gt;EFNS guideline on the management of status epilepticus in adults&lt;/A&gt;. &lt;EM&gt;European Journal of Neurology &lt;/EM&gt;17(3):348-55&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; This is a s&lt;/EM&gt;&lt;EM&gt;ystematic literature review of the management of status epilepticus (convulsive and non-convulsive) in adults with resulting clinical management guidelines (mainly pharmacological), and developed under the auspices of the EFNS.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;&lt;/EM&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Cochrane systematic reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Li Q, Chen X, He L, Zhou D. &lt;A href="nelh:374017:0" name=internalLink&gt;&lt;A href="nelh:320765:0" name=internalLink&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD006454.pub2" target="_blank"&gt;&lt;STRONG&gt;Traditional Chinese medicine for epilepsy&lt;/STRONG&gt;&lt;/A&gt;&lt;/A&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;STRONG&gt;. &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt; 2009, Issue 3. art. No.: CD006454&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Other&amp;nbsp;reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Gaynor D, Cock H, Agr&lt;/STRONG&gt;&lt;STRONG&gt;awal N. (2009) &lt;A href="nelh:384042:0" name=internalLink&gt;Psychological treatments for functional non-epileptic attacks: A systematic review&lt;/A&gt;. &lt;EM&gt;Acta Neuropsychiatrica&lt;/EM&gt; 21(4):158-168&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&amp;nbsp;&lt;/STRONG&gt;&amp;nbsp;This is a useful and practical systematic review describing clear search methodology.&amp;nbsp; Surprisingly the authors omitted “functional” from their search terms, despite recommending this term to describe the phenomenon.&amp;nbsp; Only one RCT was identified and even here there were significant drawbacks.&amp;nbsp; Non epileptic attacks comprise a major consumer of epilepsy health resources and we urgently need clear evidence to guide its management.&amp;nbsp; This is a clinical area justifying much further research, including large RCTs of various aspects of its management.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Sofou K, Kristjansdottir R, Papachatzakis NE, Ahmadzadeh A, Uvebrant P. (2009) &lt;A href="nelh:384062:0" name=internalLink&gt;Management of prolonged seizures and status epilepticus in childhood: a systematic review&lt;/A&gt;. &lt;EM&gt;Journal of Child Neurology&lt;/EM&gt; 24(8):918-26&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments: &lt;/STRONG&gt;&lt;/EM&gt;This is a systematic review of the literature concerning the management of prolonged seizures and status epilepticus in childhood.&amp;nbsp; The results are substantially similar to those of the Cochrane review published in 2008 (Appleton et al.).&amp;nbsp; The important conclusions are:&amp;nbsp; (1) that buccal midazolam is effective and safe and may serve as first line in the treatment of prolonged seizures (2) that intranasal lorazepam is effective, easy-to-use and safe for prolonged seizures and (3) that intravenous valproate has favourable efficacy and safety as a third-line treatment of status epilepticus in children refractory to diazepam and phenytoin.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Tan G, Thornby J, Hammond DC, Strehl U, Canady B, Arnemann K, et al. (2009) &lt;A href="nelh:360391:0" name=internalLink&gt;Meta-analysis of EEG biofeedback in treating epilepsy&lt;/A&gt;. &lt;EM&gt;Clinical EEG &amp;amp; Neuroscience: Official&lt;/EM&gt; &lt;EM&gt;Journal of the EEG &amp;amp; Clinical Neuroscience Society (ENCS)&lt;/EM&gt; 40(3):173-9&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments: &lt;/STRONG&gt;This is a meta-analysis examining the efficacy of EEG biofeedback in patients with medication-resistant epilepsy.&amp;nbsp; The authors identified 10 studies (involving 87 patients) and showed an overall significant benefit with reduction in seizure frequency.&amp;nbsp; There was some evidence of publication bias in the small number of studies included.&amp;nbsp; The unanswered questions are whether the technique might have a place in milder forms of epilepsy and whether any benefit is sustained in the long term.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;STRONG&gt;General &lt;/STRONG&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384380</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384380]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Treatment - surgery</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Treatment - surgery&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Heather Angus-Leppan, Consultant Neurologist, Honorary Senior Lecturer and Epilepsy Lead, Royal Free Hospital&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;FONT size=3&gt;Reviews&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Ansari SF, Maher CO, Tubbs RS, Terry CL, Cohen-Gadol AA. (2010) &lt;A href="nelh:386650:0" name=internalLink&gt;Surgery for extratemporal nonlesional epilepsy in children: a meta-analysis&lt;/A&gt;. Childs Nervous System 26(7):945-51&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; This meta-analysis confirms previous reports that extra-temporal epilepsy has a worse outcome that temporal lobe surgery. It is easy to read, clinically relevant, and is important for both child and adult epilepsy practice.&amp;nbsp; It highlights general issues that are important in the basic understanding of mechanisms of epilepsy – particularly whether “non-lesional” epilepsy (focal epilepsy without a discrete macroscopic structural abnormality) is really that, or simply involves a more subtle microscopic abnormality.&amp;nbsp;&amp;nbsp; There is an excellent discussion of some of the factors that make localisation of extra-temporal epilepsy more difficult to treat surgically and of the maturation process of cortex which means that some patients may spontaneously remit as cortical maturation occurs, making the timing of surgical treatment problematic.&amp;nbsp; The analysis starts from 1990, which is reasonable, as “lesional” epilepsy is currently defined as epilepsy in which the abnormality is detectable on MRI scan, and prior to 1990, MRI was not always done.&amp;nbsp; Searches were through PubMed, with a careful search through references cited for additional papers; and extraction of paediatric data from those studies with adults and children included. This seems thorough, but only English literature was considered.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/EM&gt;
&lt;P&gt;&lt;STRONG&gt;Schmidt D, Stavem K. (2009) &lt;/STRONG&gt;&lt;A href="nelh:386652:0" name=internalLink&gt;&lt;STRONG&gt;Long-term seizure outcome of surgery versus no surgery for drug-resistant partial epilepsy: a review of controlled studies&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;. &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(6):1301-9&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; This meticulous review examined multiple databases, adding hand searches, and consultation with experts.&amp;nbsp; English, German and French literature was examined, but other languages were neglected.&amp;nbsp; Two reviewers worked independently before comparing and discussing results.&amp;nbsp; The chief finding, that the combination of surgery and medication was more than four times more effective than medication alone, is unsurprising.&amp;nbsp; Despite their best attempts, the authors remain unable to answer the question of how much the surgical treatment actually contributes to improvement, and how much this is a manifestation of milder epilepsy in the surgical group.&amp;nbsp; The surgical and non-surgical groups are different, and cannot be directly compared in most studies.&amp;nbsp; Certain criteria must be met before patients are even considered for surgery. They found only one randomised study in their vigorous search.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Tellez-Zenteno JF, Hernandez RL, Moien-Afshari F, Wiebe S. (2010) &lt;A href="nelh:386653:0" name=internalLink&gt;Surgical outcomes in lesional and non-lesional epilepsy: a systematic review and meta-analysis&lt;/A&gt;. &lt;EM&gt;Epilepsy Research&lt;/EM&gt; 89(2-3):310-8&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Reviewer's comments:&lt;/STRONG&gt; This review examined only English articles but used a comprehensive literature search strategy and independent reviewers, with subsequent discussion between reviewers of any disagreements. This is well documented and explained in the methods, and articles considered are laid out in the Appendix. There should have been a more explicit defining of good outcome: were seizure free patients off (Grade I Engel classification) or on medication (Grade II Engel classification)?&amp;nbsp; The main finding that lesional epilepsy surgery patients are seizure free more often than non-lesional epilepsy patients is found consistently.&amp;nbsp; The authors point out the methodological flaws in the study design of research considered, some of which can be overcome with clearly defined and agreed inclusion and exclusion criteria, definitions of outcome and follow-up end-points.&amp;nbsp; Some of the problems with interpretation are inherent in the condition studied - in particular, diversity of aetiology and small numbers of patients in each group.&lt;BR&gt;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;A href="nelh:384380:0" name=internalLink&gt; &lt;/A&gt;&lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;STRONG&gt;Surgery&lt;/STRONG&gt; 
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:384391:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>384391</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=384391]]&gt;</url>
    <title>2010 Annual Evidence Update on Epilepsy | Uncertainties</title>
    <publicationDate>2010-09-06T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Epilepsy | Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Once again, this year's Annual Evidence Update on Epilepsy has involved identifying treatment uncertainties from the papers selected by our reviewers for inclusion. These are listed below. They have also been added to the UK Database of Uncertainties about the Effects of Treatments (&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs&lt;/A&gt;), a new project which is being developed to make uncertainties explicit and to help those prioritising research in the &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:country-region w:st="on"&gt;&lt;st1:place w:st="on"&gt;UK&lt;/st1:place&gt;&lt;/st1:country-region&gt; to take account of the information needs of patients, carers and clinicians. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Click on the titles below for more information about each.&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:384965:0" name=internalLink&gt;Best psychological treatment for effective treatment of functional non-epileptic attacks&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:383825:0" name=internalLink&gt;Driving is a risk in patients with sleep-related epilepsy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:383822:0" name=internalLink&gt;Length of treatment time for patients with pure sleep-related epilepsy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:384993:0" name=internalLink&gt;Newer anti-epilepsy drugs might cause low bone mineral density&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:387203:0" name=internalLink&gt;Surgery for long-term resistant epilepsy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:384995:0" name=internalLink&gt;Switching from brand-name to generic anti-epilepsy drugs may increase risk of seizures&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:374017:0" name=internalLink&gt;&lt;A href="http://www.library.nhs.uk/neurological/ViewResource.aspx?resID=374017" name=internalLink target="_blank"&gt;Traditional Chinese medicine for epilepsy&lt;/A&gt;&lt;A href="nelh:320765:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:383821:0" name=internalLink&gt;Treatment of sleep-related epilepsy is necessary&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:384978:0" name=internalLink&gt;The best method for managing epilepsy in adults with intellectual disability&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:383823:0" name=internalLink&gt;Withdrawal of medications for sleep-related epilepsy is not an option&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Epilepsy: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:384385:0" name=internalLink&gt;Introduction &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384363:0" name=internalLink&gt;Aetiology and epidemiology &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384381:0" name=internalLink&gt;Diagnosis &lt;/A&gt;
&lt;DT&gt;Treatment &lt;BR&gt;
&lt;DD&gt;&lt;A href="nelh:384357:0" name=internalLink&gt;Anti-epilepsy drugs &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384085:0" name=internalLink&gt;General &lt;/A&gt;
&lt;DD&gt;&lt;A href="nelh:384380:0" name=internalLink&gt;Surgery &lt;/A&gt;
&lt;DT&gt;&lt;A href="nelh:384390:0" name=internalLink&gt;Risk factors and adverse effects &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384331:0" name=internalLink&gt;Other &lt;/A&gt;
&lt;DD&gt;
&lt;DT&gt;&lt;A href="nelh:384387:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;STRONG&gt;Uncertainties&lt;/STRONG&gt; &lt;/DT&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>389292</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=389292]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | Foreign language articles</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | Foreign language articles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Note:&lt;/STRONG&gt; Links to the full text are provided where available, or to the English abstract where no full text is available. Where neither full text nor an English abstract were freely available, no links have been provided.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Espo Lopez GV, Gomez Conesa A. (2010) &lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B94RS-4XWD05X-1&amp;amp;_user=125795&amp;amp;_coverDate=02%2F28%2F2010&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_origin=search&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_searchStrId=1487248797&amp;amp;_rerunOrigin=google&amp;amp;_acct=C000010182&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=125795&amp;amp;md5=363607abb819d173168100c45594e6d8&amp;amp;searchtype=a" target="_blank"&gt;&lt;STRONG&gt;Efficacy of the treatment in tension-type headache&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Fisioterapia&lt;/EM&gt; 32(1):33-40&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Goret O, Nguyem J. (2009) &lt;A href="http://www.meridiens.org/acuMoxi/entree.html" target="_blank"&gt;&lt;STRONG&gt;Meta-analyses: 1) l'acupuncture apparait superieure an traitement medicajuenteux et a tin effet additionnel positif dans le traitement de fond de la migraine. 2) L'acupuncture est superieure aux interventions factices dans les cephalees de tension&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Acupuncture et Moxibustion&lt;/EM&gt;&amp;nbsp;8(2):109-12&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; French&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Guo J. (2010) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20226140" target="_blank"&gt;&lt;STRONG&gt;Tactics of acupuncture for migraine prophylaxis&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Journal of Chinese Integrative Medicine&lt;/EM&gt; 8(3):210-214&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Chinese&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Kropp P, Niederberger U. (2010) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20563685" target="_blank"&gt;&lt;STRONG&gt;Biofeedback for headaches&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Schmerz&lt;/EM&gt; 24(3):279-289&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; German&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Slof J, Lainez JM, Comas A, Heras J. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19418289" target="_blank"&gt;Almotriptan &lt;STRONG&gt;vs ergotamine plus caffeine for acute migraine treatment: a cost-efficacy analysis&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Neurologia&lt;/EM&gt; 24(3): 147-53&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Spanish&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Verhagen AP, van Heest M, D, Lenssinck MB, Berger MY, Verkerk K, et al. (2009) &lt;STRONG&gt;Effectiveness of physiotherapy and spinal manipulation in patients with tension-type headache: an update of a systematic review&lt;/STRONG&gt;. &lt;EM&gt;Nederlands Tijdschrift Voor Fysiotherapie&lt;/EM&gt;&amp;nbsp;119(3):85-92&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Dutch&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Verhagen AP, Damen L, Berger MY, Lenssinck M-L, Passchier J, Koes BW. (2010) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20699021" target="_blank"&gt;&lt;STRONG&gt;Treatment of tension headache: Paracetamol and NSAIDs do work -&amp;nbsp;a systematic review&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Nederlands Tijdschrift voor Geneeskunde&lt;/EM&gt; 154 (27): 1268-73&lt;BR&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Dutch&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Zhao L, Ren YL, Liang FR. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19563194" target="_blank"&gt;&lt;STRONG&gt;Analysis of characteristics of meridians and acupoints selected for treating migraine in past dynasties based on data excavation&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Zhongguo Zhenjiu&lt;/EM&gt;. 29(6):467-472&lt;BR&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Chinese&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; COLOR: #ffffff; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#bc3877 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Headache: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:389283:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389289:0" name=internalLink&gt;Prevention&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389290:0" name=internalLink&gt;Treatment&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;Other&lt;/A&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;/A&gt; &lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;STRONG&gt;Foreign language articles &lt;/STRONG&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:389293:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:389296:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>389283</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=389283]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | Introduction</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Introduction by Lionel Ginsberg&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Welcome to the 2010 Annual Evidence Update on Headache. Among the topics highlighted this year are the increasingly secure role for topiramate in migraine prevention, and the potential therapeutic value of relaxation exercises in the management of temporo-mandibular disorder and tension-type headache. A more controversial area is the role of botulinum toxin, especially as it is now licensed in the UK for headache prevention in adults with chronic migraine. Its place in the treatment algorithm for this condition is yet to be fully clarified, but most specialists would try prophylactic drugs first, then escalate to sub-occipital injections of local anaesthetic and steroids before considering botulinum toxin. A similar hierarchy pertains for the drug treatment of acute migraine attacks, starting with simple analgesics and non-steroidal anti-inflammatory drugs, then moving to triptans, the choice of which will depend on pain characteristics and patient preference. Moving from headache treatment and prevention to aetiology and pathogenesis, there have been valuable reviews this year on the relationship between migraine (particularly with aura) and stroke, and the thorny topic of the association between migraine and patent foramen ovale. I thank the topic advisors for their expert advice and comments, and the Project Team - Caroline De Brún and Ruth Muscat - for their hard work and support.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;BR&gt;Lionel Ginsberg is the Clinical Lead for the NHS Evidence Neurological Conditions Specialist Collection. &lt;/EM&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR width="75%"&gt;

&lt;P&gt;The 2010&amp;nbsp;Headache Annual Evidence Update, our third on this topic, highlights knowledge published since the 2009 Update on the treatment and prevention of&amp;nbsp;Headache Disorders. By presenting this information in an easily accessible format and with additional expert commentary, we will provide busy healthcare professionals with the information they need to keep up to date. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The most robust evidence-based systematic reviews from the period under review were selected by our topic advisors after review of&amp;nbsp;&lt;STRONG&gt;29&lt;/STRONG&gt; articles (see &lt;A href="nelh:380603:0" name=internalLink&gt;&lt;STRONG&gt;&lt;A href="nelh:389296:0" name=internalLink&gt;&lt;STRONG&gt;&lt;A href="nelh:380603:0" name=internalLink&gt;&lt;STRONG&gt;Methods for retrieving and evaluating the evidence&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/A&gt; for more information on this process). &lt;/P&gt;
&lt;P&gt;The evidence has been split into the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;STRONG&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;/STRONG&gt; 
&lt;LI&gt;&lt;STRONG&gt;Treatment&lt;/STRONG&gt; 
&lt;LI&gt;&lt;STRONG&gt;Other (including Aetiology and Epidemiology, Diagnosis, and Comorbidity)&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest. This year we have also identifed a number of treatment uncertainties from the reviews included in this Update. These have also been fed into the &lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs database&lt;/A&gt;&lt;/STRONG&gt;. This AEU is also available in &lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=389283" target="_blank"&gt;PDF format&lt;/A&gt;&lt;/STRONG&gt; and a &lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=396742" name=internalLink target="_blank"&gt;&lt;STRONG&gt;poster&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; is available for downloading.&lt;/P&gt;
&lt;P&gt;The&amp;nbsp;Headache Annual Evidence Update has been put together by the Neurological Conditions specialist collection Project Team, with expert advice and commentaries provided by our&amp;nbsp;Headache Topic Advisors. These are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Professor Lionel Ginsberg, Clinical Lead&lt;/LI&gt;
&lt;LI&gt;Professor Peter J Goadsby, Institute of Neurology&lt;/LI&gt;
&lt;LI&gt;Dr FH Maniyar, Clinical Research Fellow, Institute of Neurology&lt;/LI&gt;
&lt;LI&gt;Dr Shazia Afridi, Department of Neurology, Royal Free Hampstead NHS Trust.&lt;/LI&gt;
&lt;LI&gt;Dr Andy Dowson, Clinical Lead of the East Kent Headache Service and Director of the Kings Headache Service&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;We wish to thank the Topic Advisors for their generous support with this project.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; COLOR: #ffffff; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#bc3877 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Headache: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;STRONG&gt;Introduction &lt;/STRONG&gt;
&lt;DT&gt;&lt;A href="nelh:389289:0" name=internalLink&gt;Prevention&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389290:0" name=internalLink&gt;Treatment&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;Other&lt;/A&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;/A&gt; &lt;/A&gt;&lt;/DT&gt;&lt;A href="nelh:389292:0" name=internalLink&gt;
&lt;DT&gt;Foreign language articles &lt;/DT&gt;
&lt;DT&gt;&lt;/A&gt;&lt;A href="nelh:389293:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:389296:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>389296</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=389296]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Methods&lt;/FONT&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;The last Annual Evidence Update on Headache was published in December 2009. No new guidance has been published since that date, so this AEU has focused on updating our previous one with information published in 2009 and 2010 (ensuring that papers included in the previous AEU are excluded). The Specialist Collection focuses only on secondary information of use to NHS staff and patients, so our update is focused on guidelines, systematic reviews and other high quality studies written in English. However, foreign language articles were included in the search process.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Search strategy&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;We developed a search strategy based on that of the Cochrane Pain Review Group. The search strategy was used in combination with slightly modified SIGN systematic review filters for databases via the National Core Content OVID interface. The MEDLINE search strategy was as follows:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;1. exp HEADACHE DISORDERS/ &lt;BR&gt;2. headache*1.ti &lt;BR&gt;3. migrain*2.ti &lt;BR&gt;4. cephalalgi*2.ti &lt;BR&gt;5. hemicrani*4.ti &lt;BR&gt;6. neuralgi*2.ti &lt;BR&gt;7. HEADACHE/ &lt;BR&gt;8. cephalgi*2.ti &lt;BR&gt;9. sunct.ti &lt;BR&gt;10. ((horton*2 ADJ1 syndrome*1)).ti &lt;BR&gt;11. (((head ADJ1 ache*1) OR head-ache*1)).ti &lt;BR&gt;12. ((cranial ADJ1 pain*1)).ti &lt;BR&gt;13. or/1-12 &lt;BR&gt;14. 13 [Limit to: Publication Year 2008-2009] &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Original SIGN filters available at &lt;A href="http://www.sign.ac.uk/methodology/filters.html#systematic" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html#systematic&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Modified systematic review filter for use with Search 2.0 Medline:&lt;/P&gt;
&lt;P&gt;1. exp META-ANALYSIS AS TOPIC/ &lt;BR&gt;2. exp META-ANALYSIS/ &lt;BR&gt;3. (metaanaly* OR meta ADJ1 analy* OR meta-analy*).ti,ab &lt;BR&gt;4. (systematic adj1 (review* OR overview*)).ti,ab &lt;BR&gt;5. exp "REVIEW LITERATURE AS TOPIC"/ &lt;BR&gt;6. 1 OR 2 OR 3 OR 4 OR 5 &lt;BR&gt;7. cochrane.ab &lt;BR&gt;8. embase.ab &lt;BR&gt;9. (medline OR pubmed).ab &lt;BR&gt;10. (psyclit OR psychlit OR psycinfo OR psychinfo).ab &lt;BR&gt;11. (cinahl OR cinhal).ab &lt;BR&gt;12. (science AND citation AND index).ab &lt;BR&gt;13. bids.ab &lt;BR&gt;14. cancerlit.ab &lt;BR&gt;15. 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 &lt;BR&gt;16. (reference AND list*).ab &lt;BR&gt;17. bibliograph*.ab &lt;BR&gt;18. (hand AND search* OR hand-search*).ab &lt;BR&gt;19. (relevant AND journals).ab &lt;BR&gt;20. (manual AND search*).ab &lt;BR&gt;21. 16 OR 17 OR 18 OR 19 OR 20 &lt;BR&gt;22. (selection AND criteria).ab &lt;BR&gt;23. (data AND extraction).ab &lt;BR&gt;24. 22 OR 23 &lt;BR&gt;25. exp "REVIEW"/ &lt;BR&gt;26. 24 AND 25 &lt;BR&gt;27. exp COMMENT/ &lt;BR&gt;28. exp LETTER/ &lt;BR&gt;29. exp EDITORIAL/ &lt;BR&gt;30. 27 OR 28 OR 29 &lt;BR&gt;31. 6 OR 15 OR 21 OR 26 &lt;BR&gt;32. 31 NOT 30&lt;BR&gt;33. ANIMALS/ &lt;BR&gt;34. HUMANS/ &lt;BR&gt;35. 32 AND 33 &lt;BR&gt;36. ANIMALS/ NOT (ANIMALS/ AND HUMANS/) &lt;BR&gt;37. 32 NOT 36 &lt;/P&gt;
&lt;P&gt;The search, with minor modifications demanded by differences between databases, was repeated in AMED (Allied &amp;amp; Complementary Medicine Database), EMBASE, CINAHL, PsycINFO, British Nursing Index (BNI), HMIC (Health Management Information Consortium database) and Health Business Elite. AMED, HMIC, Health Business Elite was searched without a systematic review filter as they contain fewer records. &lt;/P&gt;
&lt;P&gt;
&lt;P&gt;We also searched DARE, HTA, NEED, the NHS Evidence&amp;nbsp;Guidelines Finder, the Cochrane Library, NICE, and SIGN. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;After de-duplication&amp;nbsp;985 articles were retrieved.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Inclusion and exclusion criteria&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: guideline, protocol, care pathway, systematic review, meta-analysis, consensus statement, health technology assessment, economic evaluation &lt;/LI&gt;
&lt;LI&gt;Published in 2009 or 2010, and not included in the 2009 AEU&lt;/LI&gt;
&lt;LI&gt;Main condition under investigation was Headache&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Once the inclusion criteria were applied, 44 articles were included for appraisal. Of these,&amp;nbsp;8 were foreign language articles,&amp;nbsp;4 were Cochrane systematic reviews and&amp;nbsp;3 were clinical guidelines.&lt;/P&gt;
&lt;P&gt;Guidelines and Cochrane systematic reviews were automatically included in the Evidence Update. While we were not able to find reviewers for them, the titles of the foreign language articles are included in a separate section of the Evidence Update. This left 29 articles that were sent to our reviewers for appraisal.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Critical appraisal process&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Categories (aetiology and epidemiology, diagnosis, treatment, prevention, other) were provisionally assigned to articles by the Information Specialist. Each Topic Advisor or appropriate member of the Editorial Board was then sent the full text of a selection of the articles. The reviewers are: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Dr Shazia Afridi, Institute of Neurology, Queen Square, London&lt;/LI&gt;
&lt;LI&gt;Dr Andy Dowson, Director of Headache Services, Kings College Hospital, London&lt;/LI&gt;
&lt;LI&gt;Professor Peter J Goadsby, Institute of Neurology, Queen Square, London&lt;/LI&gt;
&lt;LI&gt;Dr FH Maniyar, Clinical Research Fellow, Institute of Neurology&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The reviewers confirmed the article category and recommended inclusion or exclusion from the evidence update on the basis of validity and relevance. Articles were appraised as per standard commentary sheet and expert summaries were written for each category by members of the Editorial Board or Topic Advisors.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The final number of articles included was&amp;nbsp;24 (39 including guidelines, Cochrane reviews, and foreign language reviews).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;AEU process&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/neurological/contentID389296/nelhImp_0000_HeadacheAEU2010flowchart.JPG"&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;I&gt;&lt;/I&gt;&lt;/P&gt;
&lt;P align=right&gt;&lt;I&gt;NHS Evidence - neurological conditions Project Team, December 2010&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; COLOR: #ffffff; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#bc3877 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Headache: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:389283:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389289:0" name=internalLink&gt;Prevention&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389290:0" name=internalLink&gt;Treatment&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;Other&lt;/A&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;/A&gt; &lt;/A&gt;&lt;/DT&gt;&lt;A href="nelh:389292:0" name=internalLink&gt;
&lt;DT&gt;Foreign language articles &lt;/DT&gt;
&lt;DT&gt;&lt;/A&gt;&lt;A href="nelh:389293:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;
&lt;DT&gt;&lt;STRONG&gt;AEU methodology&lt;/STRONG&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>389291</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=389291]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | Other</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | Other&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Dr Shazia Afridi, Department&amp;nbsp;of Neurology, Royal Free Hampstead NHS Trust.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This section will include papers on Aetiology and Epidemiology, Diagnosis, and Comorbidity.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Guidelines&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;NHS Primary Care Contracting (2009) &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=308968" target="_blank"&gt;&lt;STRONG&gt;Guidance and competences for the provision of services using practitioners with special interests: headache&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Reviews&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Chronic migraine is a disabling disorder and various studies have tried to determine the prevalence. Natoli et al looked at population based studies in the US, Europe and Taiwan and found that the prevalence rates of chronic migraine varied from 0.7% to 5.1% depending on the diagnostic criteria used and also on whether medication overuse headache was included. This highlights the need for unifying diagnostic criteria which is applicable to both researchers and clinicians. In their review, Sacco et al, propose a change to the IHS diagnostic criteria for headache in CADASIL.&lt;/P&gt;
&lt;P&gt;In recent years several studies have suggested an association between migraine and stroke. Since both conditions are relatively common it is important to establish the strength of this association. This review includes two well -conducted meta-analyses (Schurks et al, Spector et al), which come to the same conclusion that migraine is associated with a two-fold increased risk of ischaemic stroke (but not haemorrhagic stroke). It is important to note that migraine with aura has a much stronger association compared to migraine without aura ( 2.16 vs 1.23 [Schurks et al], 2.51 vs 1.29 [Spector et al] ).The risk is further increased in women, smokers, age&amp;lt;45 and with oral contraceptive use. This information is important as it may enable us to modify stroke risk factors better in certain subgroups of migraineurs. It is also important to note that there is no conclusive evidence of an increased risk of myocardial infarction or death from cardiovascular disease. Whilst there is now little doubt about the association between migraine with aura and stroke one cannot derive aetiological conclusions as the consensus of evidence suggest neural or neurovascular mechanisms for migraine rather than purely vascular ones. It is possible that genetics may play a part in the association. In fact the paper by Rubino et al does suggest there is an association between migraine with aura and the C677T polymorphism of the MTHFR gene and this gene has also been found to be associated with an increased risk of stroke [Cronin S, Furie KL, Kelly PJ. Dose –related association of MTHFR 677T allele with risk of ischaemic stroke: evidence from a cumulative meta-analysis. Stroke 2005;36:1581-7] as well as other conditions.&lt;/P&gt;
&lt;P&gt;Another controversial area in the world of migraine has been the proposed association with patent foramen ovale (PFO). There have been studies suggesting an increased prevalence of PFOs in patients with migraine with aura although it is noteworthy that these studies were generally not population-based. The paper reviewed on this subject [Butera et al] suggests a certain subgroup of migraineurs, in particular those treated after a neurological event, may benefit from percutaneous closure of the PFO. However, the authors of this metaanalysis highlight many significant limitations of the studies they included. Most relied on retrospective, subjective recall of headache characteristics, all but one were unblinded and almost all subjects were treated with aspirin and/or clopidogrel for 3-6 months post procedure which clearly could be an important confounder. A new trial looking into this subject is due to start and will hopefully provide us with better data.&lt;/P&gt;
&lt;P&gt;Finally, Bruijn et al find no conclusive evidence that children with migraine in a clinical setting exhibit a greater degree of psychiatric dysfunction.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;References&lt;BR&gt;&amp;nbsp;&lt;/H2&gt;
&lt;P&gt;Bruijn J, Locher H, Passchier J, Dijkstra N, Arts WF. (2010) &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=396500" target="_blank"&gt;&lt;STRONG&gt;Psychopathology in children and adolescents with migraine in clinical studies: a systematic review&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Pediatrics&lt;/EM&gt; 126(2):323-332&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Butera G, Biondi-Zoccai GG, Carminati M, Caputi L, Usai S, Bussone G, Meola G, Delogu AB, Sheiban I, Sangiorgi G. (2009) &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=396487" target="_blank"&gt;&lt;STRONG&gt;Systematic review and meta-analysis of currently available clinical evidence on migraine and patent foramen ovale percutaneous closure: much ado about nothing?&lt;/STRONG&gt;&lt;/A&gt; &lt;EM&gt;Catheterization and Cardiovascular Interventions&lt;/EM&gt; 75(4):494-504&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. (2010) &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=396490" target="_blank"&gt;&lt;STRONG&gt;Global prevalence of chronic migraine: a systematic review&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Cephalalgia&lt;/EM&gt; 30(5):599-609&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L. (2009) &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=396493" target="_blank"&gt;&lt;STRONG&gt;Association of the C677T Polymorphism in the MTHFR gene with migraine: a meta-analysis&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Cephalalgia&lt;/EM&gt; 29(8):818-825&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Sacco S, Degan D, Carolei A. (2010) &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=396494" target="_blank"&gt;&lt;STRONG&gt;Diagnostic criteria for CADASIL in the International Classification of Headache Disorders (ICHD-II): are they appropriate?&lt;/STRONG&gt;&lt;/A&gt; &lt;EM&gt;Journal of Headache and Pain&lt;/EM&gt; 11(3):181-186&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=396504" target="_blank"&gt;&lt;STRONG&gt;Migraine and cardiovascular disease: systematic review and meta-analysis&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;British Medical Journal&lt;/EM&gt; 339:b3914&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. (2010) &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=396508" target="_blank"&gt;&lt;STRONG&gt;Migraine headache and ischemic stroke risk: An updated meta-analysis&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;The American Journal of Medicine&lt;/EM&gt; 123(7):612-624&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; COLOR: #ffffff; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#bc3877 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Headache: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:389283:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389289:0" name=internalLink&gt;Prevention&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389290:0" name=internalLink&gt;Treatment&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;/A&gt;&lt;STRONG&gt;Other &lt;/A&gt;&lt;/STRONG&gt;&lt;/DT&gt;&lt;A href="nelh:389292:0" name=internalLink&gt;
&lt;DT&gt;Foreign language articles &lt;/DT&gt;
&lt;DT&gt;&lt;/A&gt;&lt;A href="nelh:389293:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:389296:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>397666</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=397666]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | PDF version</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | PDF version&lt;/pageTitle&gt;&lt;pageBody&gt;This is the&amp;nbsp;printable (PDF) version of the 2010 Annual Evidence Update on Headache.&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396742</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396742]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | Poster</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | Poster&lt;/pageTitle&gt;&lt;pageBody&gt;This poster provides brief details about the 2010 Annual Evidence Update on Headache.&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>389289</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=389289]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | Prevention</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | Prevention&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Dr Andy Dowson, Clinical Lead of the East Kent Headache Service and Director of the Kings Headache Service.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Cochrane Reviews&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Boonmak P, Boonmak S. &lt;A href="nelh:237095:0" name=internalLink&gt;&lt;STRONG&gt;Epidural blood patching for preventing and treating post-dural puncture headache&lt;/STRONG&gt;&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD001791. DOI: 10.1002/14651858.CD001791.pub2&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Other Reviews&lt;/H2&gt;
&lt;P&gt;At the last review it was noted that there was a need to develop outcome measures and clinical trial methodology to assist in the assessment of patients and the outcomes from headache treatments. This applied to complementary as well as conventional management options. This time the theme is reemphasised whilst the broad summary is of a group of negative reviews across temporomandibular disorder, tension type headache and migraine with some notable exceptions. &lt;/P&gt;
&lt;P&gt;Grade A data support the use of Topiramate as a migraine preventative and its place in therapy should be determined on an individual basis by assessing&amp;nbsp;efficacy, adverse events, patient preference, comorbid conditions and cost&amp;nbsp;(Sinert et al 2009).&lt;/P&gt;
&lt;P&gt;Vikelis et al ( 2010) also review the Grade A evidence supporting Topiramate and Valproate, suggest that the positive result for gabapentin needs reevaluation due to the use of a controversial and not universally accepted primary end point. Other anti-epileptic drugs are either not effective in migraine prevention or have no data from controlled trials available.&lt;/P&gt;
&lt;P&gt;A meta-analysis of exercise in temporomandibular disorder and tension type headache (Fricton et al 2009) suggest that&amp;nbsp; stretching and postural relaxation has a therapeutic value and should be included in the treatment regimen for these disorders. It is however pointed out that it is unclear what exercises work best, on what patients they work best, what outcomes can be expected, and what factors cause treatment failure. In tension type headaches in adults, prophylactic drugs are no more effective on headache intensity or frequency and analgesic use than placebo (Verhagen et al 2010).&lt;/P&gt;
&lt;P&gt;Pringsheim et al (2010) review migraine prophylaxis from a clinical perspective and&amp;nbsp;conclude that there are significant gaps in knowledge about mechanisms of action, head to head comparisons that might guide choice of medication and combination of medications in refractory patients. Grade A evidence from multiple, well-designed randomized controlled trials support valproate, topiramate, butterbur and to a lesser extent riboflavin. Botox has grade A evidence that shows it to be ineffective.&lt;/P&gt;
&lt;P&gt;Shuhendler et al (2009) present a meta-analysis of randomised, double blind, placebo controlled trials which confirms that Botox is ineffective in episodic migraine. &lt;/P&gt;
&lt;P&gt;Angiotensin-converting enzyme inhibitors (eg lisinopril) and angiotension receptor blockers (eg candestartan) have been studied but the studies are small and insufficient data exist to recommend widespread use (Gales et al 2010). &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Bakola E, Skapinakisa P, Tzoufic M, Damigosa D, Mavreas V. (2009) &lt;A href="nelh:396710:0" name=internalLink&gt;&lt;STRONG&gt;Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review&lt;/STRONG&gt;&lt;/A&gt;. European Journal of Pain 13(9):893-901&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Fricton J, Velly A, Ouyang W, Look JO. (2009) &lt;A href="nelh:396711:0" name=internalLink&gt;&lt;STRONG&gt;Does exercise therapy improve headache? A systematic review with meta-analysis&lt;/STRONG&gt;&lt;/A&gt;. Current Reports Pain and Headache 13(6):413-9&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Gales BJ, Bailey EK, Reed AN, Gales MA. (2010) &lt;A href="nelh:396712:0" name=internalLink&gt;&lt;STRONG&gt;Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Annals of Pharmacotherapy&lt;/EM&gt; 44(2):360-6&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Pringsheim T, Davenport WJ, Becker WJ. (2010) &lt;A href="nelh:396713:0" name=internalLink&gt;&lt;STRONG&gt;Prophylaxis of migraine headache&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Canadian Medical Association Journal&lt;/EM&gt; 182(7):E269-76&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. (2009) &lt;A href="nelh:396715:0" name=internalLink&gt;&lt;STRONG&gt;Feverfew for migraine prophylaxis: a systematic review&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Journal of Dietary Supplements&lt;/EM&gt; 6(2):91-103&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR. (2009) &lt;A href="nelh:396718:0" name=internalLink&gt;&lt;STRONG&gt;Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Pharmacotherapy&lt;/EM&gt; 29(7):784-91&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Sinert MR, Epstein BJ. (2009) &lt;A href="nelh:396720:0" name=internalLink&gt;&lt;STRONG&gt;Topiramate for use in adult migraine prophylaxis&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Journal of Pharmacy Technology&lt;/EM&gt; 25(2):100-10&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Verhagen AP, Damen L, Berger MY, Passchier J, Koes BW. (2009) &lt;A href="nelh:396722:0" name=internalLink&gt;&lt;STRONG&gt;Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Family Practice&lt;/EM&gt; 27(2):151-165&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Vikelis, M, Rapoport, AM. (2010) &lt;A href="nelh:396723:0" name=internalLink&gt;&lt;STRONG&gt;Role of antiepileptic drugs as preventive agents for migraine&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;CNS Drugs&lt;/EM&gt; 24(1):21-33&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Zheng H, Chen M, Wu X, Li Y, Liang FR. (2010) &lt;A href="nelh:396725:0" name=internalLink&gt;&lt;STRONG&gt;Manage migraine with acupuncture: a review of acupuncture protocols in randomized controlled trials&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;American Journal of Chinese Medicine&lt;/EM&gt;. 2010;38(4):639-50&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; COLOR: #ffffff; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#bc3877 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Headache: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:389283:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;STRONG&gt;Prevention&lt;/STRONG&gt;&lt;STRONG&gt; &lt;/STRONG&gt;
&lt;DT&gt;&lt;A href="nelh:389290:0" name=internalLink&gt;Treatment&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;Other&lt;/A&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;/A&gt; &lt;/A&gt;&lt;/DT&gt;&lt;A href="nelh:389292:0" name=internalLink&gt;
&lt;DT&gt;Foreign language articles &lt;/DT&gt;
&lt;DT&gt;&lt;/A&gt;&lt;A href="nelh:389293:0" name=internalLink&gt;Uncertainties&lt;/A&gt; &lt;/DT&gt;&lt;A href="nelh:389296:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>389290</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=389290]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | Treatment</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | Treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;EM&gt;Reviewed by Professor Peter J Goadsby, Professor of Clinical Neurology and Honory Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, and the Hospital For Sick Children, Great Ormond Street London, and Dr FH Maniyar, Institute of Neurology.&amp;nbsp;&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;/EM&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Guidelines&lt;/H2&gt;
&lt;P&gt;Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. (2009) &lt;A href="nelh:396595:0" name=internalLink&gt;&lt;STRONG&gt;EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;European Journal of Neurology&lt;/EM&gt; 16(9): 968-81&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ferguson C. (2009) &lt;A href="nelh:333979:0" name=internalLink&gt;&lt;STRONG&gt;Guideline for the management of lone acute severe headache&lt;/STRONG&gt;&lt;/A&gt;. The College of Emergency Medicine&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;&lt;BR&gt;Cochrane Reviews&lt;/H2&gt;
&lt;P&gt;Bennett MH, French C, Schnabel A, Wasiak J, Kranke P. &lt;A href="nelh:293641:0" name=internalLink&gt;&lt;STRONG&gt;Normobaric and hyperbaric oxygen therapy for migraine and cluster headache&lt;/STRONG&gt;&lt;/A&gt;. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD005219. DOI: 10.1002/14651858.CD005219.pub2&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Boonmak P, Boonmak S. &lt;A href="nelh:237095:0" name=internalLink&gt;&lt;STRONG&gt;Epidural blood patching for preventing and treating post-dural puncture headache&lt;/STRONG&gt;&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD001791. DOI: 10.1002/14651858.CD001791.pub2&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Kirthi V, Derry S, Moore RA, McQuay HJ. &lt;A href="nelh:371996:0" name=internalLink&gt;&lt;STRONG&gt;Aspirin with or without an antiemetic for acute migraine headaches in adults&lt;/STRONG&gt;&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD008041. DOI: 10.1002/14651858.CD008041.pub2&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Law S, Derry S, Moore RA. &lt;A href="nelh:371997:0" name=internalLink&gt;&lt;STRONG&gt;Triptans for acute cluster headache&lt;/STRONG&gt;&lt;/A&gt;. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD008042. DOI: 10.1002/14651858.CD008042.pub2&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;Other reviews&lt;/H2&gt;
&lt;P&gt;Patient and physicians dealing with migraine need a variety of options and fortunately there is a good evidence base for treatment of migraine. &lt;/P&gt;
&lt;P&gt;For mild to moderate attacks, simple analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) should be used. Naproxen sodium should be preferred to naproxen due to its shorter Tmax. &lt;/P&gt;
&lt;P&gt;For patients not responding to these agents and for severe attacks, triptans should be used. The choice of triptan should depend on the pain characteristics and patient preference. &lt;/P&gt;
&lt;P&gt;For rapidly developing pain, subcutaneous sumatriptan 6 mg which also has the highest rates for 2 hour headache relief or nasal zolmitriptan 10 mg should be used. Eletriptan is the most effective oral triptan but it also has the most side-effects. Longer acting triptans like naratriptan and frovatriptan have lower rates for headache recurrence within 24 hours of initial response although this is not borne out in head to head comparisons. Recurrence can also be reduced by combining sumatriptan with naproxen sodium. Triptans should be used as early as possible after pain onset for better efficacy although they can be still be effective after allodynia has developed. &lt;/P&gt;
&lt;P&gt;Ergot preparations like Dihydroergotamine (DHE) nasal spray or oral ergotamine can be used in those not responding to triptans although they are not as effective in acute migraine. &lt;/P&gt;
&lt;P&gt;In the emergency setting, IV Acetylsalicyclic Acid (ASA) and subcutaneous sumatriptan are good options; parenteral phenothiazines like chlorpromazine and prochlorperazine are effective but due attention should be given to side-effects. When the oral route is compromised due to severe nausea and vomiting, subcutaneous sumatriptan or nasally administered zolmitriptan, sumatriptan or DHE are options although these drugs are often swallowed and absorbed in the gastrointestinal tract.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;For migraine prophylaxis, drugs with level A evidence should be tried first. For patients not responding to pharmacological treatment, sub-occipital injections with combination local anesthetic and steroid can be used for chronic migraine and cluster headache although we need more randomized, controlled trials to confirm this. &lt;/P&gt;
&lt;P&gt;Opioids should not be used routinely for treating headaches as there is no good evidence they reduce pain intensity in the long-term and they can cause functional impairment, medication overuse headache, opioid induced hyperalgesia and commonly produce a variety of side-effects. &lt;/P&gt;
&lt;P&gt;Recent studies have shown that in placebo controlled trials of anti-migraine drugs, patients given placebo produce side-effects typical for the active drug with some of the symptoms present in up to 10%. This fact should be borne in mind while conducting placebo controlled trials as this can influence the calculation of placebo subtracted rates.&lt;/P&gt;
&lt;P&gt;For acute cluster headache, sumatriptan 6 mg subcutaneous, zolmitriptan 10 mg nasal and 100% O2 12 L/minute are effective. Other options are sumatriptan nasal 20mg, zolmitriptan 5-10 mg oral and nasal 10% cocaine or 10% lidocaine. For prophylaxis, there is a shortage of randomized, controlled trials. Nasal Cevamide and&amp;nbsp; sub-occipital injections with local anesthetic and steroid are effective in up to 60 % and 85 % respectively but only single trials are available &lt;BR&gt;(advice level B) . Lithium, verapamil and melatonin have advice level C for prophylaxis.&lt;/P&gt;
&lt;P&gt;Professor PJ Goadsby and Dr FH Maniyar have produced a critical appraisal for each of the references they have reviewed, and these are attached to the links in the references below.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H2&gt;References&lt;/H2&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Amanzio M, Latini Corazzini L, Vase L, Benedetti F. (2009) &lt;A href="nelh:396587:0" name=internalLink&gt;&lt;STRONG&gt;A systematic review of adverse events in placebo groups of anti-migraine clinical trials&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Pain&lt;/EM&gt; 146(3):261-69&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Ashkenazi A, Blumenfeld A, Napchan U, Narouze S, Grosberg B, Nett R, DePalma T, Rosenthal B, Tepper S, Lipton RB. (2010) &lt;A href="nelh:396589:0" name=internalLink&gt;&lt;STRONG&gt;Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Headache&lt;/EM&gt; 50(6):943-52&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Francis GJ, Becker WJ, Pringsheim TM. (2010) &lt;A href="nelh:396600:0" name=internalLink&gt;&lt;STRONG&gt;Acute and preventive pharmacologic treatment of cluster headache&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Neurology&lt;/EM&gt; 75(5):463-73&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Kelly AM, Walcynski T, Gunn B. (2009) &lt;A href="nelh:396602:0" name=internalLink&gt;&lt;STRONG&gt;The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Headache &lt;/EM&gt;49(9):1324-32&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Namaka M, Leong C, Grossberndt A, Klowak Meghann, Louizos C, Drummond J, Leligdowicz E, Lichkowski M, Melanson M. (2009) &lt;A href="nelh:396603:0" name=internalLink&gt;&lt;STRONG&gt;Managing migraines: Options for acute abortive treatment&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Canadian Pharmacists Journal&lt;/EM&gt;&amp;nbsp;142(4): 190-198.e1.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. (2010) &lt;A href="nelh:396609:0" name=internalLink&gt;&lt;STRONG&gt;Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Headache&lt;/EM&gt;. 50(5):808-18&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, Neef C, Marcus MA. (2009) &lt;A href="nelh:396610:0" name=internalLink&gt;&lt;STRONG&gt;A review of the clinical pharmacokinetics of opioids,benzodiazepines, and antimigraine drugs delivered intranasally&lt;/STRONG&gt;&lt;/A&gt;. &lt;EM&gt;Clinical Therapeutics&lt;/EM&gt; 31(12):2954-87&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>389293</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=389293]]&gt;</url>
    <title>2010 Annual Evidence Update on Headache | Uncertainties</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Headache | Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Once again, this year's Annual Evidence Update on&amp;nbsp;Headache has involved identifying treatment uncertainties from the papers selected by our reviewers for inclusion. These are listed below. They have also been added to the &lt;A href="http://www.library.nhs.uk/DUETs/Default.aspx" target="_blank"&gt;UK Database of Uncertainties about the Effects of Treatments&lt;/A&gt; (UK DUETs), a&amp;nbsp;project which is being developed to make uncertainties explicit and to help those prioritising research in the UK to take account of the information needs of patients, carers and clinicians. &lt;/P&gt;
&lt;P&gt;Click on the titles below for more information about each.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:396859:0" name=internalLink&gt;&lt;STRONG&gt;Differing dose of normobaric and hyperbaric oxygen therapy combined with other therapies for migraine and cluster headache&lt;/STRONG&gt;&lt;/A&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/LI&gt;&lt;A href="nelh:396861:0" name=internalLink&gt;
&lt;LI&gt;&lt;STRONG&gt;Prophylactic epidural blood patch and post-dural puncture headache&lt;/STRONG&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;/A&gt;&lt;A href="nelh:396862:0" name=internalLink&gt;&lt;STRONG&gt;Aspirin compared to other triptans and NSAIDS and acute migraine&lt;/STRONG&gt;&lt;/LI&gt;&lt;/A&gt;&lt;A href="nelh:396863:0" name=internalLink&gt;
&lt;LI&gt;&lt;STRONG&gt;Doses and administration routes for individual triptans and acute cluster headaches&lt;/STRONG&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;/A&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; COLOR: #ffffff; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#bc3877 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Headache: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #bc3877 1px solid; BORDER-LEFT: #bc3877 1px solid; BORDER-TOP: #bc3877 1px solid; BORDER-RIGHT: #bc3877 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:389283:0" name=internalLink&gt;Introduction&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389289:0" name=internalLink&gt;Prevention&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389290:0" name=internalLink&gt;Treatment&lt;/A&gt; 
&lt;DT&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;Other&lt;/A&gt;&lt;A href="nelh:389291:0" name=internalLink&gt;&lt;/A&gt; &lt;/A&gt;&lt;/DT&gt;&lt;A href="nelh:389292:0" name=internalLink&gt;
&lt;DT&gt;Foreign language articles &lt;/DT&gt;
&lt;DT&gt;&lt;/A&gt;&lt;STRONG&gt;Uncertainties&lt;/STRONG&gt; &lt;/DT&gt;&lt;A href="nelh:389296:0" name=internalLink&gt;
&lt;DT&gt;AEU methodology&lt;/DT&gt;&lt;/A&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345196</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345196]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Aetiology and epidemiology</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Aetiology and epidemiology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Martin Wilson, Consultant Neurologist, The Walton Centre for Neurology and Neurosurgery&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Reviews &lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Alonso A, Hernan MA. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344104" target="_blank"&gt;Temporal trends in the incidence of multiple sclerosis: a systematic review.&lt;/A&gt; &lt;I&gt;Neurology&lt;/I&gt; 2008 Jul 8;71(2):129-35.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; A systematic review of 38 studies publishing age and sex specific incidence rates of MS covering northern Europe, southern Europe, North America and Australia, with study periods varying from the 1950s to 2002. The study draws two main conclusions: the ‘latitude gradient’ of MS incidence is reducing over time (ie relative incidence of MS in equatorial regions is increasing), and the female to male ratio of MS incidence is widening ever further. The possible reasons for this remain speculative for now.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Benamer HT, Ahmed ES, Al-Din AS, Grosset DG. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344105" target="_blank"&gt;Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review.&lt;/A&gt; &lt;I&gt;Journal of the Neurological Sciences&lt;/I&gt; 2009 Mar 15;278(1-2):1-4.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Cristiano E, Patrucco L, Rojas JI. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344106" target="_blank"&gt;A systematic review of the epidemiology of multiple sclerosis in South America.&lt;/A&gt; &lt;I&gt;European Journal of Neurology&lt;/I&gt; 2008 Dec;15(12):1273-8.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments&lt;/B&gt; Two reviews of MS epidemiology covering regions not included in the above study: in &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344105" target="_blank"&gt;Benamer et al.&lt;/A&gt;, a review of all studies (19) describing ‘frequency and clinical patterns’ of MS in Arab countries (Kuwait, Jordan, Libya, Saudi Arabia, Iraq and Palestinians) is published. The incidence and prevalence varied widely, suggesting methodological heterogeneity, but appears lower than Western countries, though also appears to be increasing over time. Clinical patterns were broadly similar to ‘Western MS’, though most studies did not distinguish Devics’ disease / Neuromyelitis optica from MS, which future studies should be able to address using recent diagnostic criteria (including a serological marker for NMO).&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344106" target="_blank"&gt;Cristinao et al.&lt;/A&gt; systematically reviewed population based epidemiological studies of MS in South American countries (9 in total): the reported prevalence of MS was lower than most developed countries, though the role of ascertainment bias (suspicion of undiagnosed MS cases in rural, and developing countries) was acknowledged, and could not be excluded with the quality and quantity of data currently available from these regions.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Poppe AY, Wolfson C, Zhu B. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344136" target="_blank"&gt;Prevalence of multiple sclerosis in Canada: a systematic review.&lt;/A&gt; &lt;I&gt;Canadian Journal of Neurological Sciences&lt;/I&gt; 2008 Nov;35(5):593-601.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; A systematic review of MS prevalence in Canada included studies from various regions of this vast country, and confirmed previous studies showing a relatively high incidence and prevalence of MS (&amp;gt;100/100,000). The review also provided convincing evidence&amp;nbsp;for genuine heterogeneity of prevalence rates in different regions, suggesting that a single ‘national’ prevalence figure for MS may be misleading, certainly in larger countries. This review again demonstrated an increasing incidence of MS in recent years (though acknowledged this could be due to improved case ascertainment), and an increasing female: male ratio.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;STRONG&gt;De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, et al. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344144" target="_blank"&gt;Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.&lt;/A&gt; &lt;EM&gt;Nature Genetics&lt;/EM&gt; 2009 Jul;41(7):776-82.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; In an article published in Nature Genetics, a large international group of collaborators published a meta-analysis of genome-wide association scans in MS. The results confirmed multiple susceptibility loci, all of which have known immunological functions in vivo, supporting the current concept of a primarily inflammatory/autoimmune abnormality in MS, at least in early disease. The study included three newly validated loci (CD6, IRF8 and TNFRSF1A) suggesting a contribution from dysregulated interferon and TNF responses in the development of MS.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;B&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;&lt;B&gt;Aetiology and epidemiology&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties &lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345198</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345198]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Cost</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Cost&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Martin Duddy, Consultant Neurologist/Honorary Lecturer in Clinical Neurology, Royal Victoria Infirmary&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Reviews &lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344277" target="_blank"&gt;Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.&lt;/A&gt; &lt;I&gt;Pharmacoeconomics&lt;/I&gt; 26(7):617-27, 2008.&lt;/B&gt;&lt;/P&gt;&lt;I&gt;
&lt;P&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This is an interesting read for UK neurologists, providing an insight into the process leading to the positive appraisal of natalizumab by NICE. It is a study sponsored by the drug’s manufacturer and first authored by a commercial data analyst. The study was commissioned for application to NICE in support of the drug’s approval for UK use.&lt;/P&gt;
&lt;P&gt;Taking the 2 year drug vs placebo trail from the AFFIRM trial, it seeks to extrapolate over 30 years what the cost differences would be if patients with highly active RRMS (HARRMS, defined as 2 relapses in the last year and MRI evidence of disease activity) were treated with natalizumab as opposed to beta-interferon, glatiramer acetate or best supportive care. In this model, the incremental cost per QALY for natalizumab vs best supportive care is £25500, below the £36 000 set by the Dept Health in 2002 as the “willingness-to-pay” threshold for RRMS. Accepting that these people are likely to be on a DMT rather than nothing, the comparative figures are £18 700 vs IFN and £20 400 vs GA, making the drug look rather more favourable.&lt;/P&gt;
&lt;P&gt;While the work is transparently presented, it is impossible not to be uncomfortable at the assumptions made. Accepting that the group could only work with the best data available, disability progression rates for untreated HARRMS are drawn from the placebo arm of AFFIRM of only 61. Progression rates from RRMS to SPMS are taken from the London, Ontario dataset, which experience from the risk sharing scheme has shown us may not be directly comparable to modern UK cohorts, and in any case does not identify a HARRMS cohort. Utilities scores are derived from the UK MS survey, a survey of self selected MS society members with a response rate of only 19%. It is assumed patients are withdrawn from DMTs when EDSS reaches 6.5. &lt;/P&gt;
&lt;P&gt;When any one of these potential errors is amplified over a 30 year period, a single fault could tip the final result, and indeed in this paper the authors do not give full figures for the earlier time point analyses seen in other papers where the drug’s cost effectiveness is demonstrably less.&lt;/P&gt;
&lt;P&gt;While the assumptions made all seem entirely rational, it would be interesting to know how many of the assumptions and parameters were predetermined and which were added after an initial analysis, especially when the authors explicitly state that “the model…[was] designed and developed to support a reimbursement application”, and not to dispassionately explore the question.&lt;/P&gt;
&lt;P&gt;For the practicing clinician, it is good to know how those who control our access to drugs make their decisions, but sobering to see how shaky the evidence is for cost effectiveness, compared to the standards we require in determining effectiveness in the first place.&lt;/P&gt;&lt;/I&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344278" target="_blank"&gt;Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.&lt;/A&gt; &lt;I&gt;Multiple Sclerosis&lt;/I&gt; 2008;14(5):679-90.&lt;/B&gt;&lt;/P&gt;&lt;I&gt;
&lt;P&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This is a surprisingly readable health economics paper exploring the relative cost effectiveness of natalizumab compared to existing disease modifying treatments. The corresponding author is from a commercial health economics consultancy and the study was supported by the drug’s manufacturers. While based on Swedish data, it serves well to understand the modelling process. Compared to the Gani group, this paper considers universal use of natalizumab in RRMS suitable for DMTs, modelled over 20 years.&lt;/P&gt;
&lt;P&gt;Taking into account all possible cost benefits (direct medical costs, non-medical costs, patient costs, informal care and production loss) over a 20 year period, the superior efficacy of natalizumab over existing DMTs is projected to save €3800 in total with a better health outcome (QALY gain +0.34). Limiting costs to the health care perspective, natalizumab fares less well with the incremental cost per QALY being €38000. 
&lt;P&gt;It is worth pointing out the dramatic effect of time in the modelling. At 10 years, the incremental cost per QALY (all costs) is €124000. While it is fair to assume savings from disability will only come late in such a chronic disease, the errors magnify with time, as is illustrated by another variation, where even allowing for a 5% reduction in efficacy of natalizumab (after the 2 year period of secure trial data), the incremental cost /QALY rises to €30000. Accepting that new drugs the arrival of new drugs will affect the pricing, and changes in risk estimates and thus monitoring may also incur costs, the fragility of the forecasting process is well illustrated. &lt;/P&gt;&lt;/I&gt;&lt;BR&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;&lt;B&gt;Cost&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties &lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345228</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345228]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Diagnosis</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MAGNETIC RESONANCE IMAGING (MRI),INVESTIGATION &amp; DIAGNOSTICS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Diagnosis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Carolyn Young, Consultant Neurologist and Honorary Professor of Neurology, The Walton Centre NHS Foundation Trust&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Reviews &lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Seewann A, Enzinger C, Filippi M, Barkhof F, Rovira A, Gass A, et al. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344317" target="_blank"&gt;MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: A review of reported findings.&lt;/A&gt; &lt;I&gt;Journal of Neurology&lt;/I&gt; 2008 Jan;255(1):1-10.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Describing an MRI appearance as “atypical” lumps the scan result into a heterogenous and poorly studied group. A European collaboration researching MRI in MS advances clarity by clearly describing four different appearances, based on a literature review of atypical inflammatory demyelinating lesions (IDL). They report at least moderate inter-rater agreement defining these subtypes and provide useful descriptions and images. On their data, most “atypical” IDL could be described as ring-like, Balo-like, diffusely infiltrating or megacystic. Further study will help differentiate these types from other ring-like and infiltrative lesions of non-demyelinating aetiology and distinguish the clinical and pathological correlates. Bottom line – Clinicians should advance from merely describing a presumed IDL as atypical and refine to atypical subtype; then retain scan, clinical and any pathological data for further collaborative study. &lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Pichiecchio A, Tavazzi E, Maccabelli G, Precupanu CM, Romani A, Roccatagliata L, et al. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344316" target="_blank"&gt;What insights have new imaging techniques given into aggressive forms of MS--different forms of MS or different from MS?&lt;/A&gt; &lt;I&gt;Multiple Sclerosis&lt;/I&gt; 2009 Mar;15(3):285-93.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; This is a literature review of the MRI appearances of “aggressive forms of MS”. The paper includes neuromyelitis optica, which many now feel is a distinct condition, and diagnoses like myelinoclastic diffuse sclerosis, which have fallen from modern diagnostic usage.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;&lt;B&gt;Diagnosis&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties &lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345231</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345231]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Foreign language articles</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Foreign language articles&lt;/pageTitle&gt;&lt;pageBody&gt;The following articles were identified by the search as being potentially relevant to the AEU, but were not sent out for appraisal because the full text is in a language other than English. They are included here for interest, and for the sake of completeness. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Note:&lt;/STRONG&gt; Links to the full text are provided where available, or to the English abstract where no full text is available. Where neither full text nor an English abstract were freely available, no links have been provided.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Pichon-Riviere A, Augustovski F, Garcia MS, Bardach A, Galante J, Lopez A, et al. (2008) &lt;EM&gt;T-cell vaccines for the treatment of multiple sclerosis&lt;/EM&gt;. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS).&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Language: &lt;/STRONG&gt;Spanish&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Karenberg A. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19280170" target="_blank"&gt;The portrayal of multiple sclerosis in television series&lt;/A&gt;. &lt;EM&gt;Nervenarzt&lt;/EM&gt; 80(4):415-21.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt;&lt;/EM&gt; &lt;EM&gt;German&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Wu F-B, Xu P-R, Jia P, Li J, Tang Y. (2008) Efficacy and safety of different doses of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A systematic review. &lt;EM&gt;Chinese Journal of Evidence-Based Medicine&lt;/EM&gt; 8(11):997-1000.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Chinese&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Fan X, Yang L. (2009) A meta-analysis of interferon-beta in the secondary progressive multiple sclerosis. &lt;EM&gt;Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]&lt;/EM&gt; 89(21):1484-9.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;&lt;STRONG&gt;Language:&lt;/STRONG&gt; Chinese&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;&lt;B&gt;Foreign language articles&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties &lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345265</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345265]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Introduction</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Introduction&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;B&gt;Introduction by Mike Boggild, Consultant Neurologist, Walton Centre for Neurology and Neurosurgery &lt;/B&gt;&lt;/P&gt;
&lt;P&gt;"Never mind the quality, feel the width"; was one of my father's expressions, one which is challenged by this Annual Evidence Update (AEU) - a collection of high quality evidence drawn from the global literature covering the breadth of the enigmatic disease that is Multiple Sclerosis. Another was nothing in life is free - well, this is, and has in addition has been reviewed by our team of experts to add both commentary and context to many of the articles included.&lt;/P&gt;
&lt;P&gt;It is nigh on impossible to keep pace with the expanding literature on any relatively common medical disorder. We all have our strategies; my particular favourite is &lt;A href="http://pubcrawler.gen.tcd.ie/" target="_blank"&gt;pubcrawler&lt;/A&gt;&amp;nbsp;whose tag line "it goes to the library - you go to the pub" has always summed up the dilemma well. The AEU offers a further welcome platform which draws together high level evidence that informs and challenges clinical practice. For this review a structured literature search identified 478 articles. Following a process of filtering and peer review (with thanks to the reviewers listed below) 40 of these form the basis of this AEU.&lt;/P&gt;
&lt;P&gt;The breadth of this review reflects the global interest in drawing together data be it on genetic, environmental factors or therapy - to better understand and manage this disease. I am grateful for the efforts of the team at the Royal Free library in identifying the evidence and those of our experts in reviewing the papers to confirm their relevance and provide context and comment.&lt;/P&gt;
&lt;P&gt;I hope those involved in managing this challenging but ultimately rewarding disease will find this review both helpful and thought provoking.&lt;/P&gt;&lt;BR&gt;
&lt;HR&gt;
&lt;BR&gt;
&lt;P&gt;The 2010 Multiple Sclerosis Annual Evidence Update, our second on this topic, highlights knowledge published in systematic reviews and guidelines in the past 12 months on the diagnosis, treatment and management of MS. By presenting this information in an easily accessible format and with additional expert commentary, we will provide busy healthcare professionals with the information they need to keep up to date. &lt;/P&gt;
&lt;P&gt;The most robust evidence-based systematic reviews from the period under review were selected by our topic advisors after review of almost 500 articles (see &lt;A href="nelh:345232:0" name=internalLink&gt;Methods for retrieving and evaluating the evidence&lt;/A&gt; for more information on this process). &lt;/P&gt;
&lt;P&gt;The evidence has been split into the following sections:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Treatment&lt;/LI&gt;
&lt;UL&gt;
&lt;LI&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse events&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Click on the sections above to find links to critically appraised systematic reviews, expert commentaries and other information of interest. This year we have also identified a number of &lt;A href="nelh:345233:0" name=internalLink&gt;treatment uncertainties&lt;/A&gt; from the reviews included in this Update. These have also been fed into the &lt;A href="http://www.library.nhs.uk/duets" target="_blank"&gt;UK DUETs&lt;/A&gt; database. This AEU is also available in &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=345265" target="_blank"&gt;PDF format&lt;/A&gt; and a &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=345301" target="_blank"&gt;poster&lt;/A&gt; is available for downloading.&lt;/P&gt;
&lt;P&gt;The Multiple Sclerosis Annual Evidence Update has been put together by the Neurological Conditions specialist collection Project Team, with expert advice and commentaries provided by our Multiple Sclerosis Topic Advisors. These are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Mike Boggild, Consultant Neurologist, Walton Centre for Neurology and Neurosurgery &lt;/LI&gt;
&lt;LI&gt;Megan Burgess, MS Nurse Consultant, Salford Royal Hospital&lt;/LI&gt;
&lt;LI&gt;Martin Duddy, Consultant Neurologist/Honorary Lecturer in Clinical Neurology, Royal Victoria Infirmary&lt;/LI&gt;
&lt;LI&gt;Rory O’Connor, Senior Lecturer and Honorary Consultant Physician in Rehabilitation Medicine, University of Leeds &lt;/LI&gt;
&lt;LI&gt;Jenny Thain, MS Specialist Physiotherapist, The Walton Centre for Neurology and Neurosurgery &lt;/LI&gt;
&lt;LI&gt;Martin Wilson, Consultant Neurologist, The Walton Centre for Neurology and Neurosurgery&lt;/LI&gt;
&lt;LI&gt;Carolyn Young, Consultant Neurologist and Honorary Professor of Neurology, The Walton Centre for Neurology and Neurosurgery&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;We wish to thank the Topic Advisors for their generous support with this project.&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=292337" target="_blank"&gt;&lt;/A&gt;
&lt;P&gt;&lt;/P&gt;
&lt;TABLE cellSpacing=0 cellPadding=5 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-RIGHT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-BOTTOM: #003399 1px solid" vAlign=center align=left bgColor=#003399&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-RIGHT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-BOTTOM: #003399 1px solid" vAlign=center align=left bgColor=#ffffff&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;&lt;B&gt;Introduction&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties &lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345232</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345232]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Methods for retrieving and evaluating the evidence</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Methods for retrieving and evaluating the evidence&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;B&gt;&lt;FONT size=3&gt;Methods&lt;/FONT&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;The last Annual Evidence Update on Multiple Sclerosis was published in June 2008. This AEU has therefore focused on updating our previous one with information published in the second half of 2008 and January - October 2009. The specialist collection focuses only on secondary information of use to NHS staff and patients, so our update is focused on guidelines, systematic reviews and other high quality studies written in English. However, foreign language articles were included in the search process. Foreign language articles identified as being potentially relevant to the AEU were not sent out for appraisal but are listed for the sake of completeness. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Search strategy&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;We developed a search strategy based on that of the Cochrane Multiple Sclerosis Review Group. The search strategy was used in combination with slightly modified SIGN systematic review filters for databases via the OvidSP interface. The MEDLINE search strategy was as follows:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;1. exp Multiple Sclerosis/ &lt;BR&gt;2. Myelitis, Transverse/ &lt;BR&gt;3. Demyelinating Diseases/ &lt;BR&gt;4. exp Encephalomyelitis, Acute Disseminated/ &lt;BR&gt;5. exp Optic Neuritis/ &lt;BR&gt;6. 1 or 2 or 3 or 4 or 5 &lt;BR&gt;7. ("multiple sclerosis" or "transverse myelitis" or "optic neuritis" or devic or adem or "neuromyelitis optica" or encephalomyelitis or "demyelinating disease*" or "acute disseminated encephalomyelitis").mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier] &lt;BR&gt;8. 6 or 7 &lt;BR&gt;9. limit 8 to yr="2008 -Current"&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Original SIGN filters available at &lt;A href="http://www.sign.ac.uk/methodology/filters.html#systematic" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html#systematic&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Modified systematic review filter for use with OvidSP Medline:&lt;/P&gt;
&lt;P&gt;1. exp Meta-Analysis as Topic/ &lt;BR&gt;2. exp Meta-Analysis/ &lt;BR&gt;3. (metaanaly* or (meta adj1 analy*) or meta-analy*).ti,ab. &lt;BR&gt;4. (systematic adj1 (review* or overview*)).ti,ab. &lt;BR&gt;5. exp "Review Literature as Topic"/ &lt;BR&gt;6. 1 or 2 or 3 or 4 or 5 &lt;BR&gt;7. cochrane.ab. &lt;BR&gt;8. embase.ab. &lt;BR&gt;9. (medline or pubmed).ab. &lt;BR&gt;10. (psyclit or psychlit or psycinfo or psychinfo).ab. &lt;BR&gt;11. (cinahl or cinhal).ab. &lt;BR&gt;12. (science and citation and index).ab. &lt;BR&gt;13. bids.ab. &lt;BR&gt;14. cancerlit.ab. &lt;BR&gt;15. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 &lt;BR&gt;16. (reference and list*).ab. &lt;BR&gt;17. bibliograph*.ab. &lt;BR&gt;18. ((hand and search*) or hand-search*).ab. &lt;BR&gt;19. (relevant and journals).ab. &lt;BR&gt;20. (manual and search*).ab. &lt;BR&gt;21. 16 or 17 or 18 or 19 or 20 &lt;BR&gt;22. (selection and criteria).ab. &lt;BR&gt;23. (data and extraction).ab. &lt;BR&gt;24. 22 or 23 &lt;BR&gt;25. exp "Review"/ &lt;BR&gt;26. 24 and 25 &lt;BR&gt;27. exp Comment/ &lt;BR&gt;28. exp Letter/ &lt;BR&gt;29. exp Editorial/ &lt;BR&gt;30. 27 or 28 or 29 &lt;BR&gt;31. 6 or 15 or 21 or 26 &lt;BR&gt;32. 31 not 30 &lt;BR&gt;33. Animals/ &lt;BR&gt;34. Humans/ &lt;BR&gt;35. 33 and 34 &lt;BR&gt;36. 33 not 35 &lt;BR&gt;37. 32 not 36&lt;/P&gt;
&lt;P&gt;The search, with minor modifications demanded by differences between databases, was repeated in AMED (Allied &amp;amp; Complementary Medicine Database), EMBASE, CINAHL, PsycINFO, British Nursing Index (BNI), and HMIC (Health Management Information Consortium database). AMED, HMIC and the BNI were searched without a systematic review filter as they contain fewer records. &lt;/P&gt;
&lt;P&gt;
&lt;P&gt;We also searched DARE, HTA, NHS EED, NHS Evidence - National Library of Guidelines, the Cochrane Library, NICE, and SIGN. &lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;After de-duplication 314 articles were retrieved.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Inclusion and exclusion criteria&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Included articles had to meet the following criteria:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Publication types: guideline, protocol, care pathway, systematic review, meta-analysis, consensus statement, health technology assessment, economic evaluation &lt;/LI&gt;
&lt;LI&gt;Published in 2008 or 2009, and not included in the 2008 AEU&lt;/LI&gt;
&lt;LI&gt;Main condition under investigation was Multiple Sclerosis&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Once the inclusion criteria were applied, 64 articles were included for appraisal. Of these, 4 were foreign language articles, 7 were Cochrane systematic reviews and 6 were clinical guidelines.&lt;/P&gt;
&lt;P&gt;Guidelines and Cochrane systematic reviews were automatically included in the Evidence Update. While we were not able to find reviewers for them, the titles of the foreign language articles are included in a separate section of the Evidence Update. This left 47 articles that were sent to our reviewers for appraisal.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Critical appraisal process&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Categories (diagnosis, therapy, risk, prevention etc as relevant) were provisionally assigned to articles by the Information Specialist. Each Topic Advisor or appropriate member of the Editorial Board was then sent the full text of a selection of the articles. The reviewers are: &lt;BR&gt;&lt;BR&gt;Mike Boggild, Consultant Neurologist, Walton Centre for Neurology and Neurosurgery &lt;/P&gt;
&lt;P&gt;Megan Burgess, MS Nurse Consultant, Salford Royal Hospital&lt;/P&gt;
&lt;P&gt;Martin Duddy, Consultant Neurologist/Honorary Lecturer in Clinical Neurology, Royal Victoria Infirmary&lt;/P&gt;
&lt;P&gt;Rory O'Connor, Academic Department of Rehabilitation Medicine, University of Leeds &lt;/P&gt;
&lt;P&gt;Jenny Thain, MS Specialist Physiotherapist, The Walton Centre NHS Foundation Trust&lt;/P&gt;
&lt;P&gt;Martin Wilson, Consultant Neurologist, The Walton Centre for Neurology and Neurosurgery&lt;/P&gt;
&lt;P&gt;Carolyn Young, Consultant Neurologist and Honorary Professor of Neurology, The Walton Centre NHS Foundation Trust&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The reviewers confirmed the article category and recommended inclusion or exclusion from the evidence update on the basis of validity and relevance. Articles were appraised as per standard commentary sheet and expert summaries were written for each category by members of the Editorial Board or Topic Advisors.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The final number of articles included was 27.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;AEU process&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 name=nelh_tempImage0 src="https://rmsadmin.library.nhs.uk/libraryImages/neurological/contentID345232/nelhImp_0000_Flowchart.JPG"&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;&lt;B&gt;AEU methodology&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345230</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345230]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Other</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Other&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Jenny Thain, MS Specialist Physiotherapist, The Walton Centre NHS Foundation Trust&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Reviews &lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Corry M, While A. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344151" target="_blank"&gt;The needs of carers of people with multiple sclerosis: a literature review.&lt;/A&gt; &lt;I&gt;Scandinavian Journal of Caring Sciences&lt;/I&gt; 2009;23(3):569-89.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; MS results in life changing experiences for both the person with MS and the carers who provide much of the everyday support to them. Carers are defined as formal carers (secondary carers) or spousal carers (primary carers). This review analysed 33 studies written in English. Thematic analysis only could be conducted because of the diversity of the studies. The review split the papers into those addressing carers and those addressing spouses. Within each category, subcategories were identified and analysed. For the carers these included the impact of caring (psychological and emotional impact, impact of disease characteristics, carer burden and benefits of caring); services available to carers and gender differences. For the spouses the themes were the impact of caring including losses and gains and marital satisfaction; and gender differences. All the studies had descriptive designs and the reviewers identified significant methodological weaknesses but they suggest the review confirms the findings of previous reviews&amp;nbsp;regarding the major impact that caring has on different aspects of carer’s lives and their well-being. They also suggest that professionals need to recognise the unique needs of carers of those with MS compared to those caring for people with other conditions. Poor support provision for carers is identified and professionals needs to improve access to this support. However some studies suggested some carers experience a personal gain from their caring role. &lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; These studies revealed consistent evidence for the need for additional resources and services to relieve carer burden. While all carers need professional support, spouses also have additional specific needs to be addressed. A national needs analysis to determine appropriate support structures for carers of people with MS is required and such structures need to be specifically tailored to the needs of those carers. In providing an holistic approach to care of the person with MS, professionals should also consider the impact on and the wellbeing of carers. Studies validating instruments to measure carer burden are required, to then allow measurement of outcomes of new interventions and comparison of studies internationally.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Dennison L, Moss-Morris R, Chalder T. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344154" target="_blank"&gt;A review of psychological correlates of adjustment in patients with multiple sclerosis.&lt;/A&gt; &lt;I&gt;Clinical Psychology Review&lt;/I&gt; 2009 Mar;29(2):141-53. &lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; MS poses a challenge for both physical and psychological well-being. And psychological difficulties are more common in people with MS than healthy populations or those with other chronic diseases. This review aimed to identify existing literature addressing psychological factors that may be associated with, predict or explain adjustment outcomes in MS. It sought to look at the strength of the evidence, identify methodological problems or gaps in the literature and set a direction for future research. Definitions for ‘psychological factors’ and ‘adjustment outcomes’ were established. Following database searches and search of reference lists, 72 studies were identified as suitable for inclusion. Psychological factors were grouped into themes (stress and coping; social support and interaction with others; cognitive models of psychopathology; illness and symptom cognitions; perceptions of control and self efficacy; positive psychology; health behaviours and miscellaneous factor) and reviews conducted within each theme. Data is presented on demographics from the studies and a broad overview of each theme presented. The review found strong evidence for links between perceived stress and worse adjustment, consistent evidence of a relationship between high levels of perceived social support and better adjustment and links between cognitive models and higher levels of depression in MS. A small number of studies suggested a strong relationship between patient’s thoughts about their illness and their adjustment but there was an unclear role for control of perceptions and adjustment. Self efficacy was related to better adjustment. Optimism was felt to be correlated with better adjustment as were higher levels of engagement in healthy behaviours. The review then goes on to discuss the implications of these findings in practice and how interventions may target specific areas. They also suggest a model of adjustment based on the findings but acknowledge that there is a requirement for further, more robust research in all areas covered by the review as well as research looking at how interventions might best be delivered. Limitations are reported: only peer-reviewed journals were considered which may have&amp;nbsp;introduced bias by leaving out negative studies; they included only quantitative data; a large number of studies were included, meaning they were vastly heterogeneous and so not conducive to an overall synthesis, and some studies were methodologically weak. &lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; MS poses significant psychological adjustment challenges. They identified factors which are related to adjustment. The strongest and most consistent finding was that perceived stress and certain emotion-focused coping strategies are related to worse adjustment. There was also tentative evidence for relationships between adjustment outcomes and other factors such as social support. The implications of these findings on interventions is suggested but further research is strongly indicated.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Finlayson M. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344162" target="_blank"&gt;Multiple sclerosis and aging: Complexities, concerns and considerations for care.&lt;/A&gt; &lt;I&gt;Aging Health&lt;/I&gt; 2009;5(1):89-102.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Although MS is usually diagnosed in people between ages 20 – 40 years, a&amp;nbsp;recent study suggested that individuals over the age of 65 make up 9.4% of cases. There is discrepancy in the literature as to what the life expectancy of a person with MS is but mean survival time has improved in recent decades consistently with the general population. The review aimed to identify the major themes on aging and MS and to identify gaps in the knowledge for future research. Database searches were conducted with a focus on applied research. The first major theme identified was on the influence of aging on the progression of MS and related activity limitations. The review suggests normal age related changes will complicate the situation for the person with MS, older adults with MS have a greater activity limitation and accumulation of MS disability is age dependant – older patients display accelerated rates of disability progression. The second identified theme was that of the care needs of people aging with MS. The literature suggests most care is given by informal carers who need support to fulfill this role. The aging person with MS needs a wide array of services to support their health and well-being but the role of age in the use of health related services is equivocal. The third theme was the experience of aging with MS. The people in these studies are concerned about their continued loss of mobility, becoming more of a burden on caregivers and having to move into a nursing home. They also have less freedom, need more assistance and have to deal with age related issues sooner. The reviewers accept that using only applied research is a limitation of the review and that they only summarise the findings of the studies and do not look at their quality. &lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; There is evidence that age and aging influence the MS experience; MS progression appears to be age related and age accelerated; the role of age in use and costs of services is variable; and finally that there are many challenges for the aging person with MS to contend with, which have implications for the support and assistance that they will require. Further research is indicated to determine the interventions that are most effective in minimising progression and to further examine the experiences of the aging person with MS. &lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Krokavcova M, van Dijk JP, Nagyova I, Rosenberger J, Gavelova M, Gdovinova Z, et al. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344176" target="_blank"&gt;Perceived health status as measured by the SF-36 in patients with multiple sclerosis: a review.&lt;/A&gt; &lt;I&gt;Scandinavian Journal of Caring Sciences&lt;/I&gt; 2009;23(3):529-39.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Studies report that MS patients have a reduced quality of life compared with groups from the general population. Perceived health status reflects a complex of internalised calculations based on life experience and knowledge of disease and consequences. The concept represents the influences of chronic disease, disability and functional status. The aim of this paper was to review the literature focusing on the associations between disease duration, disability and perceived health status as measured by the SF-36, as well as psychological well being related to perceived health status in MS patients. Following a literature search, 8 papers were selected for inclusion with their main focus being on health measure using the SF-36. 4 of the studies also used various measures of perceived health status. Correlation analyses examining the relationship between the study variables were used in all the reviewed studies. The number of subjects in the studies varied from 42 to 261. One study was a postal questionnaire, one a telephone call interview and the remainder conducted during patients’ clinic visits. The results suggest that time since diagnosis negatively influences perceived health status measured by SF-36, possibly as a consequence of increasing disability. Some of the studies investigated the relationship between disability and perceived health status and those patients with higher scores in disability assessed their health status as worse especially in physical functioning. EDSS correlated with the mental health subscale. One study did indicate that perceived health status does not depend on the physical symptoms. Perceived health status was better in patients with less depression, and mirrors the way a patient feels about and copes with the disease. These results, the authors suggest, may identify potential targets for interventions in MS patients. Patients become more distressed over the cognitive impairment and loss of social relationships than over the loss of motor function. &lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; Disease duration, disability and psychological well-being are significantly associated with perceived health status in MS patients as measured by the SF-36 in 8 studies. The more disabled or the more depressed the patient and the poorer they perceived their health status. Further research should focus on strategies to improve perceived health status and the results may be useful in determining appropriateness of interventions by HCPs.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344185" target="_blank"&gt;Pain associated with multiple sclerosis: systematic review and proposed classification.&lt;/A&gt; &lt;I&gt;Pain&lt;/I&gt; 2008 Jul;137(1):96-111.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Pain is common in patients with MS, affecting as many as 1 in 5 at disease onset. Estimates of the prevalence of pain vary significantly. This systematic review aims to summarize the current knowledge of prevalence of pain, impact of pain on HRQoL and the mechanisms of pain; to produce an evidence based classification of common pain conditions in MS; and identify research priorities. An extensive literature search was completed. 140 articles were considered but the authors identify several factors which made study comparisons difficult. They describe assessment of pain at different time points. They review literature comparing MS patients with pain to persons without MS but with pain. Pain severity is discussed. The presence of pain is associated with poorer HRQoL as described in some of the papers. The review describes the natural history of MS pain and some of the risk factors in pain development. The authors suggest that further studies are necessary on depression and emotional distress. The effects of DMTs on pain were also reviewed but few studies reported on this. Several different types of pain conditions are reported in this review. The authors suggest further research is indicated in this area. They categorise literature on central neuropathic pain (and describe studies on subgroups of this), painful tonic spasms, back pain and headache but conclude further research is required to clearly define these. They review literature on the mechanisms of pain including imaging studies, quantitative sensory testing and other approaches such as autopsies and nerve conduction studies. In their proposed classification of pain they aim to present a framework for generating a hypothesis that will provide an evidence based approach to identifying mechanisms of pain in MS patients. They emphasise the importance of defining neuropathic and non-neuropathic pain and also in identifying pain caused by somatosensory pathways v UMN tracts. Primary and secondary pain can also be described. Their framework suggests categories of continuous central neuropathic pain, intermittent central neuropathic pain, musculoskeletal pain and mixed pain especially headache. With regard to treatment of pain they suggest that few appropriate trials have been conducted in MS although recently there have been a few published on the use of cannabinoids. They conclude that cannabinoids may be effective in some patients but suggest further research. They suggest that we should look at results of RCT in other conditions, e.g. stroke, in light of lack of evidence specifically in MS. &lt;BR&gt;&lt;B&gt;Bottom line conclusion:&lt;/B&gt; It is reported that pain in MS is common and is associated with decreased HRQoL. Several different types of pain in MS can be identified and that these should be distinguished in future research. They suggest that several aspects of pain require further research (as above) and that improved methods for assessing pain in MS are needed, including developing the use of patient questionnaires. Further characterisation of the mechanisms of different types of pain is required and RCT’s to evaluate the efficacy of existing treatments for pain should be conducted.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;&lt;B&gt;Other&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345155</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345155]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Risk factors and adverse events</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Risk factors and adverse events&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Megan Burgess, MS Nurse Consultant, Salford Royal Hospital&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Reviewer's comments&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The paper by &lt;A href="#moses"&gt;Moses and Brandes&lt;/A&gt; gives an overview of potential side effects of disease modifying treatments and their management using evidence derived from a literature search of MEDLINE and EMBASE as a source. The paper provides a useful overview of the side effects people taking these different medications can experience and makes recommendations as to how these potential problems can be minimised and adherence to therapy optimised.&lt;/P&gt;
&lt;P&gt;The paper by &lt;A href="#andersen"&gt;Andersen et al&lt;/A&gt; sets out to determine whether there is any increase in risk of developing a demyelinating disease in people with IBD treated with anti-TNF medications. The authors undertake a rigorous and systematic literature review to try and answer this and conclude that there is a four fold increased risk of demyelinating diseases and particularly MS in IBD patients generally. There did not appear to be any increased risk with treatment with anti-TNF in the cohort of patients studied.&lt;/P&gt;
&lt;P&gt;&lt;A href="#prakash"&gt;Prakash et al&lt;/A&gt; have undertaken a robust review of the literature in this area hoping to clarify the magnitude, nature and influence of cognitive impairment in people with relapsing–remitting MS. They analysed a total of 57 studies and concluded that there is a moderate decline in cognitive function in people with relapsing-remitting MS compared to healthy controls; the largest effects being demonstrated within the domains of motor functioning, mood status, memory and learning.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Reviews &lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=andersen&gt;&lt;/A&gt;&lt;B&gt;Andersen NN, Caspersen S, Jess T, Munkholm P. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=309222" target="_blank"&gt;Occurrence of demyelinating diseases after anti-TNFalpha treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study.&lt;/A&gt; &lt;I&gt;Journal of Crohn's and Colitis&lt;/I&gt; 2008;2(4):304-9.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=moses&gt;&lt;/A&gt;&lt;B&gt;Moses H, Jr., Brandes DW. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344434" target="_blank"&gt;Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.&lt;/A&gt; &lt;I&gt;Current Medical Research &amp;amp; Opinion&lt;/I&gt; 2008 Sep;24(9):2679-90.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=prakash&gt;&lt;/A&gt;&lt;B&gt;Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344441" target="_blank"&gt;Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis.&lt;/A&gt; &lt;I&gt;Multiple Sclerosis&lt;/I&gt; 2008 Nov;14(9):1250-61.&lt;/B&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;&lt;B&gt;Risk factors and adverse effects&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345158</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345158]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Treatment - Disease modifying</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Treatment - Disease modifying&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;FONT size=3&gt;&lt;B&gt;Guidelines&lt;/B&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;EFNS: &lt;A href="http://www.library.nhs.uk/NEUROLOGICAL/ViewResource.aspx?resID=345096" target="_blank"&gt;Guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Multiple Sclerosis Therapy Consensus Group: &lt;A href="http://www.library.nhs.uk/NEUROLOGICAL/ViewResource.aspx?resID=345098" target="_blank"&gt;Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;FONT size=3&gt;&lt;B&gt;Cochrane systematic reviews&lt;/B&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;B&gt;
&lt;P&gt;Burton JM, O'Connor PW, Hohol M, Beyene J. &lt;A href="http://www.library.nhs.uk/NEUROLOGICAL/ViewResource.aspx?resID=320774" target="_blank"&gt;Oral versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 3. Art. No.: CD006921. DOI: 10.1002/14651858.CD006921.pub2.&lt;/P&gt;
&lt;P&gt;Gray O, McDonnell GV, Forbes RB. &lt;A href="http://dx.doi.org/10.1002/14651858.CD002936." target="_blank"&gt;Intravenous immunoglobulins for multiple sclerosis.&lt;/A&gt; &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt; 2003, Issue 3. Art. No.: CD002936. DOI: 10.1002/14651858.CD002936.&lt;/P&gt;
&lt;P&gt;Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E. &lt;A href="http://www.library.nhs.uk/NEUROLOGICAL/ViewResource.aspx?resID=304928" target="_blank"&gt;Interferon Beta for Primary Progressive Multiple Sclerosis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2010, Issue 1. Art. No.: CD006643. DOI: 10.1002/14651858.CD006643.pub3.&lt;/P&gt;&lt;/B&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Other reviews &lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Mike Boggild, Consultant Neurologist, Walton Centre for Neurology and Neurosurgery &lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Freedman MS, Cohen B, Dhib-Jalbut S, Jeffery D, Reder AT, Sandberg-Wollheim M, et al. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344188" target="_blank"&gt;Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command.&lt;/A&gt; &lt;I&gt;Current Medical Research &amp;amp; Opinion&lt;/I&gt; 2009 Oct;25(10):2459-70.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; The authors carefully review the available literature on strategies for identifying and managing patients whose condition is sub-optimally controlled on ‘first-line’ disease modifying therapy. They clearly identify the deficiencies in the current literature and lack of a substantive evidence base for any consistent approach to management in this setting. The paper offers ‘opinion leader’ guidance for a case-by-case management. &lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344190" target="_blank"&gt;Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.&lt;/A&gt; &lt;I&gt;Neurology&lt;/I&gt; 2008;71(10):766-74.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; The authors critically review and summarise the evidence (as available in 2008) on the clinical efficacy and harms of natalizumab. As anticipated in this review further data available subsequently has begun to clarify the risks specifically in relation to PML.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Soelberg SP. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344193" target="_blank"&gt;Intravenous polyclonal human immunoglobulins in multiple sclerosis.&lt;/A&gt; &lt;I&gt;Neurodegenerative Diseases&lt;/I&gt; 2008;5(1):8-15.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Reviews the available literature on use of IVIG in MS and offers a reasonable summary of the uncertainties – specifically in relationship to dosage and lack of evidence in relation to disability progression in RRMS. Concludes that further robust trial data in RRMS is necessary and that there is no role for IVIG in progressive disease or MS relapse. This paper compliments the EFNS task force paper on IVIG in neurological disease which is also included in this evidence update.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;&lt;B&gt;Disease modifying&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345201</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345201]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Treatment - Symptomatic</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Treatment - Symptomatic&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Guidelines&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/NEUROLOGICAL/ViewResource.aspx?resID=313172" target="_blank"&gt;A UK consensus on the management of the bladder in multiple sclerosis&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;MS Society: &lt;A href="http://www.library.nhs.uk/NEUROLOGICAL/ViewResource.aspx?resID=52010" target="_blank"&gt;Translating the NICE and NSF guidance into practice: a guide for physiotherapists&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;NICE: &lt;A href="http://www.library.nhs.uk/NEUROLOGICAL/ViewResource.aspx?resID=305250" target="_blank"&gt;Functional electrical stimulation for drop foot of central neurological origin&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Cochrane systematic reviews&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;&lt;B&gt;
&lt;P&gt;Khan F, Ng L, Turner-Stokes L. &lt;A href="http://www.library.nhs.uk/neurological/ViewResource.aspx?resID=304945" target="_blank"&gt;Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 1. Art. No.: CD007256. DOI: 10.1002/14651858.CD007256.pub2.&lt;/P&gt;
&lt;P&gt;Koch MW, Polman SKL, Uyttenboogaart M, De Keyser J. &lt;A href="http://www.library.nhs.uk/neurological/ViewResource.aspx?resID=320796" target="_blank"&gt;Treatment of seizures in multiple sclerosis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 3. Art. No.: CD007150. DOI: 10.1002/14651858.CD007150.pub2.&lt;/P&gt;
&lt;P&gt;Nicholas RS, Friede T, Hollis S, Young CA. &lt;A href="http://www.library.nhs.uk/neurological/ViewResource.aspx?resID=304881" target="_blank"&gt;Anticholinergics for urinary symptoms in multiple sclerosis.&lt;/A&gt; &lt;I&gt;Cochrane Database of Systematic Reviews&lt;/I&gt; 2009, Issue 1. Art. No.: CD004193. DOI: 10.1002/14651858.CD004193.pub2.&lt;/P&gt;
&lt;P&gt;Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S. &lt;A href="http://dx.doi.org/10.1002/14651858.CD007280.pub2." target="_blank"&gt;Carnitine for fatigue in multiple sclerosis.&lt;/A&gt; &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt; 2010, Issue 2. Art. No.: CD007280. DOI: 10.1002/14651858.CD007280.pub2.&lt;/P&gt;&lt;/B&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Other reviews: Reviewer's comments &lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;&lt;I&gt;Reviewed by Rory O’Connor, Senior Lecturer and Honorary Consultant Physician in Rehabilitation Medicine, Academic Department of Rehabilitation Medicine, University of Leeds&lt;/I&gt; 
&lt;P&gt;With a cure for multiple sclerosis still in the future, many investigators are focusing on the role of a variety of treatment modalities. For many patients, maintaining their walking is key to their quality of life. &lt;A href="#garrett"&gt;Garrett and Coote&lt;/A&gt; examine aerobic and resistance exercises in people with MS with EDSS scores less than 6.0. Activities, participation and quality of life are improved, but outcomes return to baseline soon after stopping the exercise programmes. Supervised exercise programmes are effective (&lt;A href="#snook"&gt;Snook and Motl&lt;/A&gt;) across all levels of disability with an effect size for reducing the rate of progression equal to that of the interferons. Fampiridine, a potassium-channel blocker may improve walking speed and lower limb strength (&lt;A href="#korenke"&gt;Korenke, Rivey, and Allington&lt;/A&gt;), but it has a narrow therapeutic index and serum levels should be monitored, limiting its usefulness in clinical practice.&lt;/P&gt;
&lt;P&gt;Urinary incontinence is another major cause of reduced quality of life. Recently, several studies have examined the use of neurotoxins in managing neurogenic bladder dysfunction. A review of these studies (&lt;A href="#macdonald"&gt;MacDonald et al&lt;/A&gt;) tells us that they may have a role in short-term management of detrusor hyper-reflexivity, but painful side effects and complicated delivery procedures will limit their applicability.&lt;/P&gt;
&lt;P&gt;Cognitive impairments have a major impact on people’s lives and any strategy to reduce this impact would be welcome. There is limited evidence for cognitive rehabilitation strategies for attention and executive function (&lt;A href="#obrien"&gt;O’Brien et al&lt;/A&gt;). More substantial evidence exists for learning and memory strategies.&lt;/P&gt;
&lt;P&gt;Finally, a review of alternative therapies (&lt;A href="#namaka"&gt;Namaka et al&lt;/A&gt;) confirms that when these are studied using robust methodology, they are shown to be ineffective. Not that there was any doubt, but we can continue to advise our patients to avoid these expensive sham treatments.&lt;/P&gt;
&lt;P&gt;Unfortunately, the majority of trials represented in the neurological rehabilitation literature continue to be small, uncontrolled studies. Maybe it is time for us to re-evaluate the ethics of performing small, under-powered studies. This is the challenge for the next decade.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;I&gt;Reviewed by Carolyn Young, Consultant Neurologist and Honorary Professor of Neurology, The Walton Centre NHS Foundation Trust&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="#asano"&gt;Asano et al.&lt;/A&gt;: In 11 RCTs meeting criteria for acceptable methodological quality, types of interventions studied included aerobic exercise, yoga, resistance or strengthening components, usually in paired combinations. A very wide variety of outcome measures were studied between the trials with no commonality; a forrest plot of their effect sizes and 95% confidence intervals (CI) shows a trend to improvement but the small sample sizes meant the 95% CI usually included zero. The authors provide useful recommendations for improving the quality of future research in this important area. Bottom line - Exercise offers some positive benefits on body function, activity, participation and quality of life in people with MS and mild to moderate disability, but more research is needed.&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;List of other reviews&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=asano&gt;&lt;/A&gt;&lt;B&gt;Asano M, Dawes DJ, Arafah A, Moriello C, Mayo NE. &lt;/B&gt;&lt;/A&gt;&lt;B&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344280" target="_blank"&gt;What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials?&lt;/A&gt; &lt;I&gt;Multiple Sclerosis&lt;/I&gt; 2009 Apr;15(4):412-21.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=garrett&gt;&lt;/A&gt;&lt;B&gt;Garrett M, Coote S. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=345224" target="_blank"&gt;Multiple sclerosis and exercise in people with minimal gait impairment: a review.&lt;/A&gt; &lt;I&gt;Physical Therapy Reviews&lt;/I&gt; 2009 Jun;14(3):169-80.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=korenke&gt;&lt;/A&gt;&lt;B&gt;Korenke AR, Rivey MP, Allington DR. &lt;/B&gt;&lt;/A&gt;&lt;B&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344196" target="_blank"&gt;Sustained-release fampridine for symptomatic treatment of multiple sclerosis.&lt;/A&gt; &lt;/B&gt;&lt;B&gt;&lt;I&gt;Annals of Pharmacotherapy&lt;/I&gt; 2008 Oct;42(10):1458-65.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=macdonald&gt;&lt;/A&gt;&lt;B&gt;MacDonald R, Monga M, Fink HA, Wilt TJ. &lt;/B&gt;&lt;/A&gt;&lt;B&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344200" target="_blank"&gt;Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects.&lt;/A&gt;&lt;/B&gt;&lt;B&gt;&lt;I&gt; Journal of Spinal Cord Medicine&lt;/I&gt; 2008;31(2):157-65.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=namaka&gt;&lt;/A&gt;&lt;B&gt;Namaka M, Crook A, Doupe A, Kler K, Vasconcelos M, Klowak M, Gong Y, Wojewnik-Smith A, Melanson M. &lt;/B&gt;&lt;/A&gt;&lt;B&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344202" target="_blank"&gt;Examining the evidence: complementary adjunctive therapies for multiple sclerosis.&lt;/A&gt; &lt;/B&gt;&lt;B&gt;&lt;I&gt;Neurological Research&lt;/I&gt; 2008 Sep;30(7):710-9.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=obrien&gt;&lt;/A&gt;&lt;B&gt;O'Brien AR, Chiaravalloti N, Goverover Y, Deluca J. &lt;/B&gt;&lt;/A&gt;&lt;B&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344204" target="_blank"&gt;Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature.&lt;/A&gt; &lt;/B&gt;&lt;B&gt;&lt;I&gt;Archives of Physical Medicine &amp;amp; Rehabilitation&lt;/I&gt; 2008 Apr;89(4):761-9.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=snook&gt;&lt;/A&gt;&lt;B&gt;Snook EM, Motl RW. &lt;/B&gt;&lt;/A&gt;&lt;B&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344205" target="_blank"&gt;Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis.&lt;/A&gt; &lt;/B&gt;&lt;B&gt;&lt;I&gt;Neurorehabilitation &amp;amp; Neural Repair&lt;/I&gt; 2009 Feb;23(2):108-16.&lt;/B&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE cellSpacing=0 cellPadding=5 align=center border=0&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-RIGHT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-BOTTOM: #003399 1px solid" vAlign=center align=left bgColor=#003399&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-RIGHT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-BOTTOM: #003399 1px solid" vAlign=center align=left bgColor=#ffffff&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;&lt;B&gt;Symptomatic&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345229</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345229]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Trial methodology</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Trial methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;I&gt;Reviewed by Carolyn Young, Consultant Neurologist and Honorary Professor of Neurology, The Walton Centre NHS Foundation Trust&lt;/I&gt;&lt;/P&gt;
&lt;P&gt;Advances in MS trial methodology are crucial because there are more agents to be studied while the pool of eligible participants whose data will translate reliably to our treatment populations is shrinking.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;FONT size=3&gt;Reviews &lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Khan O. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344311" target="_blank"&gt;What can be learned from open direct comparative trials in multiple sclerosis?&lt;/A&gt; &lt;I&gt;Journal of the Neurological Sciences&lt;/I&gt; 2009 Feb 1;277 Suppl 1:S25-S28.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Khan suggests that observational studies using open label or rater-blinded designs may have useful roles. These include preliminary hypothesis testing, checking transferability of results from carefully selected patients eligible for RCTs to wider treatment populations, and ensuring treatment effects hold for real-life conditions, which will differ from carefully monitored trials run by specialists on research volunteers. To support his arguments he shows comparability between results of observational studies and RCTs of the same intervention.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344312" target="_blank"&gt;Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.&lt;/A&gt; &lt;I&gt;Annals of Neurology&lt;/I&gt; 2009 Mar;65(3):268-75.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Another research arena addresses the costs of running RCTs. Important drivers to cost and feasibility concern sample size, study duration and outcome measures chosen. Trials of new treatments rely on clinical primary outcome measures to satisfy prescribers and regulatory authorities, but many drugs fail before large phase 3 studies and there are obvious benefits in finding more efficient ways to conduct phase 2 studies. One approach is to use surrogate end points, i.e. another end point, typically a paraclinical measure, in place of the traditional end point, normally a clinical outcome measure. Sormani et al suggest that phase 2 studies in relapsing remitting MS could be shorter and less expensive if MRI was used as a primary end point, on the assumption that it is a valid surrogate for relapse rate. They base this on a retrospective analysis of MRI data and relapses in 23 RCTs in relapsing remitting MS.&lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;&lt;B&gt;Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP. &lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344282" target="_blank"&gt;Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?&lt;/A&gt; &lt;I&gt;Multiple Sclerosis&lt;/I&gt; 2009 Sep;15(9):1043-7.&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;I&gt;&lt;B&gt;Reviewer's comments:&lt;/B&gt; Bonzano et al. suggest that both T2-weighted and Gadolinium enhanced T1-weighted MRIs can be employed as the MRI measure in relapsing remitting MS trials but it may be unnecessary to do both. They suggest some advantages to using T2-weighted MRI and avoiding the cost and any patient risk from contrast administration. &lt;/I&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;&lt;B&gt;Trial methodology&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;Uncertainties&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>345233</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=345233]]&gt;</url>
    <title>2010 Annual Evidence Update on Multiple Sclerosis | Uncertainties</title>
    <publicationDate>2010-03-08T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions Project Team</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Multiple Sclerosis | Uncertainties&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;A new part of this year's Annual Evidence Update on Multiple Sclerosis has involved identifying treatment uncertainties from the papers selected by our reviewers for inclusion. These are listed below. They have also been added to the UK Database of Uncertainties about the Effects of Treatments (&lt;A href="http://www.library.nhs.uk/duets/" target="_blank"&gt;UK DUETs&lt;/A&gt;), a new project which is being developed to make uncertainties explicit and to help those prioritising research in the &lt;?xml:namespace prefix = st1 /&gt;&lt;st1:country-region w:st="on"&gt;&lt;st1:place w:st="on"&gt;UK&lt;/st1:place&gt;&lt;/st1:country-region&gt; to take account of the information needs of patients, carers and clinicians.&lt;/P&gt;
&lt;P&gt;Click on the titles below for more information about each.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344685" target="_blank"&gt;Anticholinergics for urinary symptoms in multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344682" target="_blank"&gt;Antiepileptic treatments for seizures in multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=345079" target="_blank"&gt;Cognitive rehabilitation (for domains other than memory and learning) in multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344693" target="_blank"&gt;Comprehensive exercise interventions for multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344652" target="_blank"&gt;Interferon beta for primary progressive multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344691" target="_blank"&gt;Intravenous polyclonal human immunoglobins for relapse-remitting multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344689" target="_blank"&gt;Natalizumab (alone or in combination with other therapies) for multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=345083" target="_blank"&gt;Resistance exercise for walking mobility in people with multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344687" target="_blank"&gt;Risk of progressive multifocal leukoencephalopathy after natalizumab treatment of multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=344680" target="_blank"&gt;Vocational rehabilitation for persons with multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=345074" target="_blank"&gt;Water-based exercise programmes for the treatment of mild multiple sclerosis&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/neurological/viewResource.aspx?resid=345073" target="_blank"&gt;Yoga for the treatment of mild multiple sclerosis&lt;/A&gt;&lt;/P&gt;&lt;BR&gt;
&lt;TABLE border=0 cellSpacing=0 cellPadding=5 align=center&gt;
&lt;TBODY&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; COLOR: #ffffff; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#003399 vAlign=center align=left&gt;&lt;B&gt;&lt;FONT size=2&gt;2010 Annual Evidence Update for Multiple Sclerosis: outline&lt;/FONT&gt;&lt;/B&gt;&lt;/TD&gt;&lt;/TR&gt;
&lt;TR&gt;
&lt;TD style="BORDER-BOTTOM: #003399 1px solid; BORDER-LEFT: #003399 1px solid; BORDER-TOP: #003399 1px solid; BORDER-RIGHT: #003399 1px solid" bgColor=#ffffff vAlign=center align=left&gt;
&lt;DL&gt;
&lt;DT&gt;&lt;A href="nelh:345265:0" name=internalLink&gt;Introduction&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345196:0" name=internalLink&gt;Aetiology and epidemiology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345228:0" name=internalLink&gt;Diagnosis&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;Treatment&lt;/DT&gt;
&lt;DD&gt;&lt;A href="nelh:345158:0" name=internalLink&gt;Disease modifying&lt;/A&gt;&lt;/DT&gt; 
&lt;DD&gt;&lt;A href="nelh:345201:0" name=internalLink&gt;Symptomatic&lt;/A&gt;&lt;/DT&gt; 
&lt;DT&gt;&lt;A href="nelh:345155:0" name=internalLink&gt;Risk factors and adverse effects&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345198:0" name=internalLink&gt;Cost&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345229:0" name=internalLink&gt;Trial methodology&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345230:0" name=internalLink&gt;Other&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345231:0" name=internalLink&gt;Foreign language articles&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345233:0" name=internalLink&gt;&lt;B&gt;Uncertainties&lt;/B&gt;&lt;/A&gt;&lt;/DT&gt;
&lt;DT&gt;&lt;A href="nelh:345232:0" name=internalLink&gt;AEU methodology&lt;/A&gt;&lt;/DT&gt;&lt;/DL&gt;&lt;/TD&gt;&lt;/TR&gt;&lt;/TBODY&gt;&lt;/TABLE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325943</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.4.120]]&gt;</url>
    <title>A combination of 4 health behaviours was associated with increasing risk of stroke</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; de Guzman, A. (2009) A combination of 4 health behaviours was associated with increasing risk of stroke. &lt;EM&gt;Evidence Based Nursing&lt;/EM&gt; 12(4):120.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Myint PK, Luben RN, Wareham NJ, Bingham SA, Khaw KT. (2009) &lt;A href="http://dx.doi.org/10.1136/bmj.b349" target="_blank"&gt;Combined effect of health behaviours and risk of first ever stroke in 20,040 men and women over 11 years' follow-up in Norfolk cohort of European Prospective Investigation of Cancer (EPIC Norfolk): prospective population study&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt; 338:b349.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270550</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Neurology%22%5BJour%5D%20AND%2066%5Bvolume%5D%20AND%209%5Bissue%5D%20AND%201310%5Bpage%5D%20AND%202006%5Bpdat%5D]]&gt;</url>
    <title>A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Gamble C., Williamson P.R., Chadwick D.W. et al. 2006; Neurology 66 (9) pp. 1310-7&lt;/P&gt;
&lt;H2&gt;Original article abstract: &lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To compare the effects of carbamazepine and lamotrigine monotherapy for people with partial onset seizures or generalized onset tonic-clonic seizures. METHODS: A systematic review and meta-analysis using data on individual patients from randomized trials comparing lamotrigine with carbamazepine monotherapy. The review draws on the search strategy developed for the Cochrane Epilepsy Group, which searches MEDLINE and the Cochrane Controlled Trials register, and hand searches relevant journals. The outcomes considered were time to antiepileptic drug withdrawal, which would usually be for either inadequate seizure control or unacceptable adverse effects, time to first seizure, and 6-month remission. RESULTS: Five randomized trials were identified containing data for 1,384 participants. Time to treatment withdrawal significantly improved with lamotrigine compared to carbamazepine (hazard ratio 0.55, 95% CI 0.35 to 0.84, random effects), while time to first seizure (hazard ratio 1.14, 95% CI 0.92 to 1.43, fixed effects) and seizure freedom at 6 months (relative risk 0.92, 95% CI 0.81 to 1.04, fixed effects) favor carbamazepine although the results are not significant. CONCLUSIONS: Lamotrigine is significantly less likely to be withdrawn than carbamazepine, but results for time to first seizure suggest a nonsignificant trend that carbamazepine may be superior in terms of seizure control. Trials were of too short a duration to measure clinically important efficacy outcomes such as time to 12-month remission. Current industry-sponsored trials fail to adequately inform clinical practice and further more clinically relevant trials are needed in which longer-term outcomes are assessed before the place of lamotrigine in the treatment of epilepsy is defined.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293387</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16402240?ordinalpos=11&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Springer Milan</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Macedo A et al European Journal of Clinical Pharmacology 2006 Mar;62(3):161-72. Epub 2006 Jan 10.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Migraine is the most common cause of vascular headache and a highly prevalent illness. In the last 20 years, the discovery of new agents has increased clinical research on migraine. In most of clinical trials that have been conducted, the efficacy was established using a placebo as a control treatment. The objective of the study reported here was to analyse the response rate in patients who received a placebo as well as to determine how a number of the methodological factors may affect the effect of the placebo in clinical trials of acute migraine. Computer-based information searches were conducted on the Medline database. Data analysis included the outcomes 'pain relief', 'pain-free', 'associated symptoms', 'recurrence', 'patients' opinion' about pain relief and 'adverse events'. Administration route, study design and country in which the study was carried out were the methodological factors that were analyzed. Meta-analysis was computed using Mantel-Haenszel, and a total of 98 papers were considered in the final analysis. After 2 h, 28.6% of the patients of the placebo group improved and 8.8% were pain-free. The percentage of pain-free patients was the highest in the placebo and active drug groups in which the placebo or drug had been administered subcutaneously, in parallel design studies (vs. cross-over trials) and in studies performed in Europe (vs. North America). Adverse events in the placebo group were significantly higher in studies performed in North America. These data reinforce the need for knowing the magnitude of the placebo response in each specific situation during the planning of clinical trials on acute migraine.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322699</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18359608]]&gt;</url>
    <title>A meta-regression analysis shows no impact of design characteristics on outcome in trials on tension-type headaches</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,NEUROLOGICAL CONDITIONS,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Verhagen AP, de Vet HC, Willemsen S, Stijnen T. (2008) A meta-regression analysis shows no impact of design characteristics on outcome in trials on tension-type headaches. &lt;EM&gt;Journal of Clinical Epidemiology&lt;/EM&gt; 61(8):813-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Included were RCTs from a systematic review on TTH, which were a control group receiving a placebo or no treatment and presented data on recovery or headache severity, intensity, or frequency. Design characteristics were assessed using the Delphi list. Regression analysis is performed on separate design characteristics on size of treatment effect. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Out of the original data set of 146 trials, 61 trials fulfilled our selection criteria. The number of trials presenting only dichotomous data was larger than trials presenting only continuous data. All study characteristics show a nonsignificant relation with the effect estimate. Whether outcome is presented dichotomous or continuous appears to have a significant impact on treatment effect estimates. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In this study, sample design characteristics do not show to have an impact on treatment effect estimates, but the way the treatment effect is measured has a significant impact.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; August 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307827</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Consultations/Responsestoconsultations/DH_081060?IdcService=GET_FILE&amp;dID=160485&amp;Rendition=Web]]&gt;</url>
    <title>A new ambition for stroke: A consultation on a national strategy - Consultation response and analysis</title>
    <publicationDate>2007-12-05T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,DELIVERY OF CARE,CONDITIONS,STRATEGIES AND POLICIES,NATIONAL STROKE STRATEGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;This document gives feedback regarding the responses received to the consultation for 'A new ambition for Stroke: A consultation on a national strategy'.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288439</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18167175?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>LibraPharm</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Kamen, L et al &lt;SPAN title="Current medical research and opinion."&gt;&lt;A href="#javascript:AL_get(this," Opin.?);? Res Med ?Curr ?jour?,&gt;Curr Med Res Opin.&lt;/A&gt;&lt;/SPAN&gt; 2008 Feb;24(2):425-39&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI). While there is widespread use of tizanidine in clinical practice, little practical information is available to assist prescribers with the effective use of tizanidine for spasticity management. The aim of this review is to provide an up-to-date overview of tizanidine and its use in the management of spasticity associated with acquired (SCI), static (stroke), and progressive neurological (MS) diseases. SCOPE: An unfiltered literature search of the term 'tizanidine' was undertaken on the Medline database resulting in 311 papers. As the review focused on tizanidine clinical pharmacokinetics, efficacy, and tolerability, with comparisons limited to the oral antispastic agents baclofen, diazepam, and dantrolene, 53 articles were selected for detailed assessment. FINDINGS: Tizanidine, an alpha(2)-adrenoceptor agonist, is a short-acting drug with larger interpatient variability, and linear pharmacokinetics that is dosage form-dependent. Clinical trials have demonstrated that the efficacy of tizanidine is comparable to that of baclofen or diazepam with global tolerability data favoring tizanidine. A clinical case presentation demonstrated the effective use of tizanidine in combination with baclofen as a logical avenue for improved spasticity control. CONCLUSIONS: There is a large body of evidence for the effective use of tizanidine monotherapy in the management of spasticity. A case study demonstrates that combination therapy can effectively control spasticity while better managing dose-dependent adverse events, although additional studies need to be performed to confirm these results.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;&lt;EM&gt;Full text available to NHS users via NHS Athens password&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344419</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19210141]]&gt;</url>
    <title>A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events</title>
    <publicationDate>2009-01-01T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Brandes DW, Callender T, Lathi E, O'Leary S. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. &lt;EM&gt;Current Medical Research &amp;amp; Opinion&lt;/EM&gt; 2009 Jan;25(1):77-92.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Databases including Medline, CINAHL, and International Pharmaceutical Abstracts were searched for literature pertaining to adherence and AEs in&amp;nbsp;multiple sclerosis (MS)&amp;nbsp;published between January 1970 and August 2008. Clinical studies and case reports of adverse effects (AEs) were included, as were papers that outlined factors that influence adherence. An advisory board with extensive experience in managing patients with MS developed guidelines to assist healthcare providers in maximizing adherence to disease-modifying therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Internally based factors such as self-image, and externally based factors such as AEs, may influence patients' willingness and ability to adhere to therapy. Management of AEs associated with disease-modifying therapies and other therapies is reviewed, including intramuscular and subcutaneous interferon beta (IFNbeta)-1a, IFNbeta-1b, glatiramer acetate, natalizumab, methylprednisolone, mitoxantrone, cyclophosphamide, methotrexate, azathioprine, and intravenous immunoglobulin.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Effective management of MS is an ongoing, dynamic process that can enhance patients' adherence to therapy. Healthcare practitioners may address factors influencing adherence among patients with MS by managing treatment expectations, maintaining good communication with the patient, and managing AEs of treatment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published January 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Currently, full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293388</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17059433?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>A review of evidence-based medicine and meta-analytic reviews in migraine</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Tfelt-Hansen P Cephalalgia 2006 Nov;26(11):1265-74&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;The following systematic reviews and meta-analyses are presented and the results discussed: the evidence-based American guidelines, five systematic reviews on naratriptan, rizatriptan, eletriptan, sumatriptan and propranolol; a meta-analysis of sumatriptan, a meta-analysis of acute migraine therapy, a meta-analysis of triptans available in Canada and a large meta-analysis of oral triptans. The systematic reviews of several randomized trials of one drug overcome random effects in estimating treatment effect of the reviewed drug. The results from the large meta-analysis of several drugs are compared with head-to-head comparative trials. Results are generally the same in the meta-analysis and in the comparative trials, with some exceptions. Head-to-head comparisons should remain the 'gold standard' and meta-analyses are a useful supplement in cases when comparative trials are relatively small and when no comparative trials exist.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344154</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19167801]]&gt;</url>
    <title>A review of psychological correlates of adjustment in patients with multiple sclerosis</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Dennison L, Moss-Morris R, Chalder T. A review of psychological correlates of adjustment in patients with multiple sclerosis. &lt;EM&gt;Clinical Psychology Review&lt;/EM&gt; 2009 Mar;29(2):141-53.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Seventy two studies met inclusion criteria and were included in the review and a narrative synthesis was conducted. A wide range of psychological factors have been studied in relation to adjustment outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The strongest and most consistent finding was that perceived stress and certain emotion-focussed coping strategies are related to worse adjustment in MS. Uncertainty was fairly robustly associated with worse adjustment. There was also more tentative evidence available for relationships between adjustment outcomes and a range of other factors including social support and interactions with others, cognitive errors and biases, illness and symptom cognitions, control perceptions, positive psychology factors, and health behaviours. Implications for therapeutic interventions are discussed and a preliminary model of adjustment to MS is outlined. In light of the shortcomings of extant studies, suggestions for future research are offered.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published March 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384475</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.yebeh.2008.12.004]]&gt;</url>
    <title>A review of sudden unexpected death in epilepsy: prediction of patients at risk</title>
    <publicationDate>2009-01-06T00:00:00</publicationDate>
    <publisher>Epilepsy &amp; Behavior</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Hughes JR. (2009) A review of sudden unexpected death in epilepsy: prediction of patients at risk. &lt;EM&gt;Epilepsy &amp;amp; Behavior&lt;/EM&gt; 14(2):280-7&lt;/P&gt;
&lt;P&gt;This review attempts to provide up-to-date quantitative data from published reports on sudden unexpected death in epilepsy (SUDEP) appearing on Medline and, especially, to provide a means to predict the probability of SUDEP in a given patient. The mean incidence of SUDEP was 1.8/1000, similar to the median of 1.5. The mean standardized mortality ratio was 6.8, and the mean percentage of SUDEP cases among deaths from epilepsy was 16.6. Seventeen risk factors were identified, each given a value according to the number of studies in the literature that specified that condition as a significant risk. The addition of these 17 values then indicated the risk for a given patient. The author calculated these for a group of 91 patients who died of SUDEP and also for 91 live patients. Many of their values for the different risks were significantly different. The sensitivity of these SUDEP values was 71.3%, the specificity 81.8%, and the positive predictive value 84.6%. A discussion includes the question of whether the death in SUDEP is primarily cardiac or pulmonary and the suggestion that it may be either or both in a given patient. The most important risk factor in this study was noncompliance with antiepileptic medication, and the main message of this study to caregivers is that therapeutic drug levels are crucial to avoid SUDEP.&lt;/P&gt;
&lt;P&gt;Epilepsy &amp;amp; Behavior presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396610</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20110035]]&gt;</url>
    <title>A review of the clinical pharmacokinetics of opioids,benzodiazepines, and antimigraine drugs delivered intranasally</title>
    <publicationDate>2010-01-25T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, Neef C, Marcus MA. (2009) A review of the clinical pharmacokinetics of opioids,benzodiazepines, and antimigraine drugs delivered intranasally. &lt;EM&gt;Clinical Therapeutics&lt;/EM&gt; 31(12):2954-87&lt;/P&gt;
&lt;P&gt;Professor Peter Goadsby has critically appraised this paper and you can read his analysis &lt;A href="nelh:396694:0" name=internalLink&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Interest in the development of drug-delivery devices that might improve treatment compliance is growing. A dosage formulation that is easy to use, such as intranasal application with transmucosal absorption, may offer advantages compared with other routes of drug delivery. The literature concerning intranasal application is diffuse, with a large number of published studies on this topic. Some cerebroactive pharmaceuticals delivered intranasally might follow the pathway from the nose to the systemic circulation to the brain. To determine the suitability of these drugs for intranasal drug delivery, a systematic review was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; The aim of this review was to compare the pharmacokinetic properties of intranasal, intravenous, and oral formulations in 3 classes of cerebroactive drugs that might be suitable for intranasal delivery-opioids, benzodiazepines, and antimigraine agents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt;&amp;nbsp;A search of MEDLINE, PubMed, Cumulative Index of Nursing and Allied Health Literature, EMBASE, and Cochrane Database of Systematic Reviews (dates: 1964-April 2009) was conducted for pharmacokinetic studies of drugs that might be suitable for intranasal delivery. A comparison of pharmacokinetic data was made between these 3 routes of administration.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;A total of 45 studies were included in this review. Most of the opioids formulated as an intranasal spray reached a T(max) within 25 minutes. The bioavailability of intranasal opioids was high; in general, &amp;gt;50% compared with opioids administered intravenously. Intranasal benzodiazepines had an overall T(max) that varied from 10 to 25 minutes, and bioavailability was between 38% and 98%. T(max) for most intranasal antimigraine drugs varied from 25 to 90 minutes. Intranasal bioavailability varied from 5% to 40%.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt;&amp;nbsp;This review found that intranasal administration of all 3 classes of drugs was suitable for indications of rapid delivery, and that the pharmacokinetic properties differed between the intranasal, oral, and intravenous formulations (intravenous &amp;gt; intranasal &amp;gt; oral).&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384485</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.amjopharm.2010.02.003]]&gt;</url>
    <title>A review of the effect of anticonvulsant medications on bone mineral density and fracture risk</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>American Journal of Geriatric Pharmacotherapy</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. &lt;EM&gt;American Journal of Geriatric Pharmacotherapy &lt;/EM&gt;8(1):34-46, 2010 Feb.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Osteoporosis and seizure disorders are common diagnoses in older adults and often occur concomitantly.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; The goal of this review was to discuss the current hypothesis for the pathogenesis of anticonvulsantinduced bone density loss and the evidence regarding the risk for osteoporosis and fractures in older individuals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A review of the literature was performed, searching in MEDLINE and CINAHL for articles published between 1990 and October 2009 with the following search terms: anticonvulsant OR antiepileptic; AND osteoporosis OR bone density OR fracture OR absorptiometry, photon. Studies within the pediatric population, cross-sectional studies, and studies whose results were published in a language other than English were excluded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A search of the published literature yielded &amp;gt;300 results, of which 24 met the inclusion and exclusion criteria and were included in this review. Hepatic enzyme induction by certain anticonvulsant medications appears to contribute to increased metabolism of 25-hydroxyvitamin D to inactive metabolites, which results in metabolic bone disease. There is increasing evidence that anticonvulsant use is associated with a higher risk of osteoporosis and clinical fractures, especially among older agents such as phenobarbital, carbamazepine, phenytoin, and valproate. Several observational studies suggest a class effect among anticonvulsant agents, associated with clinically significant reductions in bone mineral density and fracture risk. The use of anticonvulsant medications increases the odds of fracture by 1.2 to 2.4 times. However, only 2 large-scale observational studies have specifically examined the risk among those aged &amp;gt;65 years. This review also identified a randomized controlled trial whose results suggest that supplementation with high-dose vitamin D may be associated with increased bone mineral density in patients taking anticonvulsant medications. However, no randomized controlled trials investigating therapeutic agents to prevent fracture in this population were identified. Consequently, there are no formal practice guidelines for the monitoring, prevention, and management of bone disease among those taking anticonvulsants.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Observational studies suggest an association between use of anticonvulsant medications, reduced bone mineral density, and increased fracture risk. Randomized clinical trials are needed to guide the management of bone disease among those who use anticonvulsants.&lt;/P&gt;
&lt;P&gt;The mission of The American Journal of Geriatric Pharmacotherapy is to provide rapid publication of original reports of recent developments in drug therapy, pharmacoepidemiology, clinical pharmacology, health services research related to drug therapy, and pharmaceutical outcomes research in older patients, as well as in-depth review articles on special topics related to drug therapy in this patient population. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396587</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19781854]]&gt;</url>
    <title>A systematic review of adverse events in placebo groups of anti-migraine clinical trials</title>
    <publicationDate>2009-09-24T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Amanzio M, Latini Corazzini L, Vase L, Benedetti F. (2009) A systematic review of adverse events in placebo groups of anti-migraine clinical trials. &lt;EM&gt;Pain&lt;/EM&gt; 146(3):261-69&lt;/P&gt;
&lt;P&gt;Professor Peter Goadsby has critically appraised this&amp;nbsp;paper and you can read his analysis &lt;A href="nelh:396684:0" name=internalLink&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; In analgesic clinical trials, adverse events are reported for the painkiller under evaluation and compared with adverse events in the placebo group. Interestingly, patients who receive the placebo often report a high frequency of adverse events, but little is understood about the nature of these negative effects. In the present study, we compared the rates of adverse events reported in the placebo arms of clinical trials for three classes of anti-migraine drugs: NSAIDs, triptans and anticonvulsants. We identified 73 clinical trials in 69 studies describing adverse events in placebo groups: 8 were clinical trials with NSAIDs, 56 were trials with triptans, and 9 were trials with anticonvulsants. Studies were selected of all Medline/PubMed or CENTRAL referenced trials published until 2007. Adverse event profiles of the three classes were compared using a systematic review approach. We found that the rate of adverse events in the placebo arms of trials with anti-migraine drugs was high. In addition, and most interestingly, the adverse events in the placebo arms corresponded to those of the anti-migraine medication against which the placebo was compared. For example, anorexia and memory difficulties, which are typical adverse events of anticonvulsants, were present only in the placebo arm of these trials. These results suggest that the adverse events in placebo arms of clinical trials of anti-migraine medications depend on the adverse events of the active medication against which the placebo is compared. These findings are in accordance with the expectation theory of placebo and nocebo effects.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388773</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://cre.sagepub.com/content/24/10/887.abstract?rss=1]]&gt;</url>
    <title>A systematic review of arm activity measures for children with hemiplegic cerebral palsy</title>
    <publicationDate>2010-08-11T00:00:00</publicationDate>
    <publisher>Clinical Rehabilitation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STRUCTURAL,CEREBRAL PALSY,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Klingels K, Jaspers E, Van de Winckel A, De Cock P, Molenaers G, Feys H. (2010) A systematic review of arm activity measures for children with hemiplegic cerebral palsy. &lt;EM&gt;Clinical Rehabilitation&lt;/EM&gt; 24(10):887&lt;/P&gt;
&lt;P&gt;Clinical Rehabilitation is a highly ranked, peer reviewed scholarly journal. It is a multi-professional journal covering the whole field of disability and rehabilitation, combining clinical application of scientific results and theoretical aspects in an ideal form. It gives high priority to articles describing effectiveness of therapeutic interventions and the evaluation of new techniques and methods.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To identify psychometrically sound and clinically feasible assessments of arm activities in children with hemiplegic cerebral palsy for implementation in research and clinical practice. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; PubMed, CINAHL, Cochrane Library, Web of Science and reference lists of relevant articles were searched.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; A systematic search was performed based on the following inclusion criteria: (1) evaluative tools at the activity level according to the International Classification of Functioning, Disability and Health; (2) previously used in studies including children with hemiplegic cerebral palsy aged 2-18 years; (3) at least one aspect of reliability and validity in children with cerebral palsy should be established. Descriptive information, psychometric properties and clinical utility were reviewed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eighteen assessments were identified of which 11 met the inclusion criteria: eight functional tests and three questionnaires. Five functional tests were condition-specific, three were generic. All functional tests measure different aspects of activity, including unimanual capacity and performance during bimanual tasks. The questionnaires obtain information about the child’s abilities at home or school. The reliability and validity have been established, though further use in clinical trials is necessary to determine the responsiveness. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; To obtain a complete view of what the child can do and what the child actually does, we advise a capacity-based test (Melbourne Assessment of Unilateral Upper Limb Function), a performance-based test (Assisting Hand Assessment) and a questionnaire (Abilhand-Kids). This will allow outcome differentiation and treatment guidance for the arm in children with cerebral palsy. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324810</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/jnnp.2008.167924]]&gt;</url>
    <title>A systematic review of delays in seeking medical attention after transient ischaemic attack</title>
    <publicationDate>2009-03-08T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,ISCHAEMIC STROKE,TRANSIENT ISCHAEMIC ATTACK (TIA),CONDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sprigg N, Machili C, Otter ME, Wilson A, Robinson GT. (2009) A systematic review of delays in seeking medical attention after transient ischaemic attack. &lt;EM&gt;Journal of Neurology, Neurosurgery, and Psychiatry&lt;/EM&gt; 80:871-875.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The electronic databases MEDLINE, EMBASE, and Science Citation Index were searched for observational studies assessing patient delay in presentation after TIA. The search was restricted to studies published between December 1995 and September 2008. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The electronic search yielded nine studies with data on presentation delay in patients with TIA; variations existed in study size, population and methodology. One study included patients with TIA only (n = 241), whereas the remaining eight studies recruited both stroke and TIA patients. Overall, TIA patients (n = 821) made up only a small proportion of the total number of patients in this analysis (n = 3,202). Length of delay varied greatly across all studies. In most studies, patients with TIA who attended an emergency department arrived there within hours. Where patients first presented to their general practitioner, 50% attended within 24 hours whereas 25% waited 2 days or more. Recognition of symptoms as stroke/TIA did not reduce the delay.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The majority of delay in seeking assessment after TIA is due to a lack of response by the patient—many patients do not recognise the symptoms of stroke/TIA, and even when they do, many fail to seek emergency medical attention. The public needs educating on the importance of contacting the emergency medical services or attending an emergency department immediately after TIA. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 8 March 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344106</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19049543]]&gt;</url>
    <title>A systematic review of the epidemiology of multiple sclerosis in South America</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cristiano E, Patrucco L, Rojas JI. A systematic review of the epidemiology of multiple sclerosis in South America. &lt;EM&gt;European Journal of Neurology &lt;/EM&gt;2008 Dec;15(12):1273-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed a systematic review of articles of MS epidemiology in South America, with special emphasis on those providing information on the incidence and prevalence of MS (population-based studies).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Six papers provided information on MS epidemiology. One paper used the capture-recapture methodology, while the remainder employed traditional methods to collect the data. Population-based studies showed an MS prevalence rate ranging from 1.48 to 17 per 100 000 inhabitants.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Available data suggest that the prevalence of MS is lower in South America than in developed countries. The reason for this observation is unknown. Some investigators suggest that certain environmental factors like sun exposure and vitamin D supplementation or the called 'hygiene hypothesis' may protect this population. Future studies will contribute to elucidate the etiology of that difference.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in December 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health. The last 12 months are not available.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270557</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Pediatric%20neurology%22%5BJour%5D%20AND%2035%5Bvolume%5D%20AND%201%5Bissue%5D%20AND%201%5Bpage%5D%20AND%202006%5Bpdat%5D]]&gt;</url>
    <title>A systematic review of the use of ketogenic diet in childhood epilepsy</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Keene D.L. 2006; Pediatric Neurology 35 (1) pp. 1-5&lt;/P&gt;
&lt;H2&gt;Original article abstract: &lt;/H2&gt;
&lt;P&gt;The ketogenic diet has been used in the treatment of intractable childhood epilepsy since the 1920s. A systematic review of the efficacy, adverse reactions, and costs associated with using the diet was performed. PubMed and Ovid searches were performed using the keywords epilepsy/therapy, dietary therapy, ketogenic diet, adverse events, and costs. Cochrane library was searched. Bibliographies of papers located by searches and review articles were compiled. Papers published after 1990 were selected if they were written in either English or French and reported on the use of classic ketogenic diet in patients under age 18 years of age with medically refractory epilepsy. Outcome measures were degree of seizure control, duration patient remained on diet, and occurrence of adverse events. Twenty-six studies were found. No prospective-controlled studies were found. Fourteen studies met all criteria for inclusion. The studies indicated that some children report reduction in seizure frequency. The estimated rate for obtaining complete seizure control was 15.6% (95% confidence interval 10.4-20.8%) with 33% (95% confidence interval 24.3-41.8%) reporting greater than 50% reduction in seizures. Adverse events were not frequent; however, 16 cases of death occurring while on the diet were found. No cost/benefit studies were located. There is evidence to support the cautious use of ketogenic diet in children with refractory epilepsy.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270568</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Seizure%20%3A%20the%20journal%20of%20the%20British%20Epilepsy%20Association%22%5BJour%5D%20AND%2014%5Bvolume%5D%20AND%202%5Bissue%5D%20AND%20117%5Bpage%5D%20AND%202005%5B]]&gt;</url>
    <title>A systematic review of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Posner E.B., Mohamed K., Marson A.G. 2005; Seizure 14 (2) pp. 117-22&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;PURPOSE:To evaluate the role of ethosuximide, sodium valproate and lamotrigine in children and adolescents with typical absence seizures (AS). METHODS: A systematic review of randomized controlled trials that included children or adolescents with typical absence seizures who received treatment with ethosuximide, sodium valproate or lamotrigine. RESULTS: Four RCTs fulfilled the inclusion criteria. Due to the heterogeneity of the studies the results could not be pooled in a meta-analysis. CONCLUSIONS: We found no reliable evidence to inform clinical practice. The design of further trials should be pragmatic and compare one drug with another.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388771</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://cre.sagepub.com/content/24/10/867.abstract?rss=1]]&gt;</url>
    <title>A systematic review of wheelchair skills tests for manual wheelchair users with a spinal cord injury: towards a standardized outcome measure</title>
    <publicationDate>2010-06-16T00:00:00</publicationDate>
    <publisher>Clinical Rehabilitation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DELIVERY OF CARE,TRAUMA,REHABILITATION,OUTCOME MEASUREMENTS,SPINAL INJURY,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Fliess-Douer O, Vanlandewijck YC, Lubel Manor G, Van Der Woude LHV. (2010) A systematic review of wheelchair skills tests for manual wheelchair users with a spinal cord injury: towards a standardized outcome measure. &lt;EM&gt;Clinical Rehabilitation&lt;/EM&gt; 24(10):867-886&lt;/P&gt;
&lt;P&gt;Clinical Rehabilitation is a highly ranked, peer reviewed scholarly journal. It is a multi-professional journal covering the whole field of disability and rehabilitation, combining clinical application of scientific results and theoretical aspects in an ideal form. It gives high priority to articles describing effectiveness of therapeutic interventions and the evaluation of new techniques and methods.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To review, analyse, evaluate and critically appraise available wheelchair skill tests in the international literature and to determine the need for a standardized measurement tool of manual wheeled mobility in those with spinal cord injury. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; A systematic review of literature (databases PubMed, Web of Science and Cochrane Library (1970-December 2009).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Subjects:&lt;/STRONG&gt; Hand rim wheelchair users, mainly those with spinal cord injury.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; Studies’ content and methodology were analysed qualitatively. Study quality was assessed using the scale of Gardner and Altman. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirteen studies fell within the inclusion criteria and were critically reviewed. The 13 studies covered 11 tests, which involved 14 different skills. These 14 skills were categorized into: wheelchair manoeuvring and basic daily living skills; obstacle-negotiating skills; wheelie tasks; and transfers. The Wheelchair Skills Test version 2.4 (WST-2.4) and Wheelchair Circuit tests scored best on the Gardner and Altman scale, the Obstacle Course Assessment of Wheelchair User Performances (OCAWUP) test was found to be the most relevant for daily needs in a wheelchair. The different tests used different measurement scales, varying from binary to ordinal and continuous. Comparison of outcomes between tests was not possible because of differences in skills assessed, measurement scales, environment and equipment selected for each test. A lack of information regarding protocols as well as differences in terminology was also detected. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; This systematic review revealed large inconsistencies among the current available wheelchair skill tests. This makes it difficult to compare study results and to create norms and standards for wheelchair skill performance. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314398</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18353615]]&gt;</url>
    <title>A systematic review on MEG and its use in the presurgical evaluation of localization-related epilepsy</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS,NEUROSURGERY,EPILEPSY AND SEIZURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lau M, Yam D, Burneo JG. (2008) A systematic review on MEG and its use in the presurgical evaluation of localization-related epilepsy. &lt;EM&gt;Epilepsy Research&lt;/EM&gt; 79(2-3):97-104.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched MEDLINE, the Cochrane library, and EMBASE between 1987 and 2006 for English articles. References of reviews and book chapters were searched. In addition, we contacted experts in MEG and epilepsy. Studies including a minimum of four patients with at least 6 months follow-up after surgery were reviewed. In each study, surgical outcome (seizure freedom) was correlated with the concordance of MEG source localization and resection area. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The literature search generated 192 articles. Twenty-eight papers satisfied the inclusion criteria. Eleven of the 28 articles were excluded due to an inability to determine the concordance between the MEG epileptic focus and the resected area based on the published data. Analysis of the 17 remaining studies allowed us to obtain sensitivity (range: 0.20-1.0) values for all articles, and specificity (0.06-1.00) values, positive likelihood ratios (0.67-2.0) and negative likelihood ratios (0.40-2.13) for some articles. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is insufficient evidence in the current literature to support the relationship between the use of MEG in surgical planning and seizure-free outcome after epilepsy surgery. Additional studies are needed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325939</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.4.111]]&gt;</url>
    <title>A very low calorie diet plus lifestyle counselling improved mild obstructive sleep apnoea in overweight patients</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,SEPTEMBER 2009,CONDITIONS,SLEEP DISORDERS,OBSTRUCTIVE SLEEP APNOEA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; McMillan DE. (2009) A very low calorie diet plus lifestyle counselling improved mild obstructive sleep apnoea in overweight patients. &lt;EM&gt;Evidence Based Nursing&lt;/EM&gt; 12(4):111.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Tuomilehto HP et al. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19011153" target="_blank"&gt;Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea&lt;/A&gt;. &lt;EM&gt;Am J Respir Crit Care Med.&lt;/EM&gt; 179(4):320-7.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344881</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20157159]]&gt;</url>
    <title>Accuracy of clinical signs, SEP, and EEG in predicting outcome of hypoxic coma: a meta-analysis</title>
    <publicationDate>2010-02-16T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ CLINICAL NEUROPHYSIOLOGY,ELECTROENCEPHALOGRAPHY (EEG),INVESTIGATION &amp; DIAGNOSTICS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EVOKED POTENTIALS (EP),COMA &amp; BRAIN DEATH,MARCH 2010,CONDITIONS,SOMATOSENSORY EVOKED POTENTIALS (SEP)]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lee YC, Phan TG, Jolley DJ, Castley HC, Ingram DA, Reutens DC. (2010) Accuracy of clinical signs, SEP, and EEG in predicting outcome of hypoxic coma: a meta-analysis. &lt;EM&gt;Neurology&lt;/EM&gt; 74(7):572-80.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched PubMed, MEDLINE, and Embase (1966-2007) for reports in English, German, and French and identified 25 suitable studies. An SROC was constructed for each marker (SEP, EEG, M1 and M &amp;lt; or = 3), and the area under the curve (AUC), a measure of diagnostic accuracy, was determined. For comparison, we calculated the differences between the AUC for each test and M1 reference standard. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The AUC for absent SEP was larger than those for M1, M &amp;lt; or = 3, absent pupillary response, and EEG when the examinations were performed within the first 24 hours. The difference between the AUC for SEP (AUC 0.891) and that for M1 (AUC 0.786) was small (0.105, 95% confidence interval 0.023-0.187), only reaching significance on day 1 after coma onset. The use of M &amp;lt; or = 3 improved the diagnostic accuracy of motor signs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This study demonstrated that sensory evoked potential (SEP) is marginally better than M1 at predicting outcome after hypoxic coma. However, the superiority of SEP diminishes after day 1 and when M &amp;lt; or = 3 is used. The findings therefore caution against the tendency to generalize that SEP is a better marker than clinical signs.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 16 February 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323012</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18499526]]&gt;</url>
    <title>Acupuncture for tension-type headache: a meta-analysis of randomized, controlled trials</title>
    <publicationDate>2008-05-22T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE,HEADACHE &amp; PAIN,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Davis MA, Kononowech RW, Rolin SA, Spierings EL. (2008) Acupuncture for tension-type headache: a meta-analysis of randomized, controlled trials. &lt;EM&gt;Journal of Pain&lt;/EM&gt; 9(8):667-77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, and PsycINFO were searched from inception through August 2007. No search or language restrictions were applied. Eight randomized, controlled trials met our inclusion criteria. Pooled data from 5 studies were used for the meta-analysis. Our primary outcome was headache days per month. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We assessed data from 2 time points: During treatment and at long-term follow-up (20-25 weeks). The weighted mean difference (WMD) between acupuncture and sham groups was used to determine effect size, and a validated scale was used to assess the methodological quality of included studies. During treatment, the acupuncture group averaged 8.95 headache days per month compared with 10.5 in the sham group (WMD, -2.93 [95% CI, -7.49 to 1.64]; 5 trials). At long-term follow-up, the acupuncture group reported an average of 8.21 headache days per month compared with 9.54 in the sham group (WMD, -1.83[95% CI, -3.01 to -0.64]; 4 trials). The most common adverse events reported were bruising, headache exacerbation, and dizziness. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This meta-analysis suggests that acupuncture compared with sham for tension-type headache has limited efficacy for the reduction of headache frequency. There exists a lack of standardization of acupuncture point selection and treatment course among randomized, controlled trials. More research is needed to investigate the treatment of specific tension-type headache subtypes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 22 May 2008 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323018</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19020156]]&gt;</url>
    <title>Acupuncture for the management of chronic headache: a systematic review</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CHRONIC DAILY HEADACHE,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sun Y, Gan TJ. (2008) Acupuncture for the management of chronic headache: a systematic review. &lt;EM&gt;Anesthesia &amp;amp; Analgesia&lt;/EM&gt; 107(6):2038-47.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched the databases of Medline (1966-2007), CINAHL, The Cochrane Central Register of Controlled Trials (2006), and Scopus for randomized controlled trials investigating the use of acupuncture for chronic headache. Studies were included in which adults with chronic headache, including migraine, tension-type headache or both, were randomized to receive needling acupuncture treatment or control consisting of sham acupuncture, medication therapy, and other nonpharmacological treatments. We extracted the data on headache intensity, headache frequency, and response rate assessed at early and late follow-up periods.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty-one studies were included in this review. The majority of included trials comparing true acupuncture and sham acupuncture showed a trend in favor of acupuncture. The combined response rate in the acupuncture group was significantly higher compared with sham acupuncture either at the early follow-up period (risk ratio [RR]: 1.19, 95% confidence interval [CI]: 1.08, 1.30) or late follow-up period (RR: 1.22, 95% CI: 1.04, 1.43). Combined data also showed acupuncture was superior to medication therapy for headache intensity (weighted mean difference: -8.54 mm, 95% CI: -15.52, -1.57), headache frequency (standard mean difference: -0.70, 95% CI: -1.38, -0.02), physical function (weighted mean difference: 4.16, 95% CI: 1.33, 6.98), and response rate (RR: 1.49, 95% CI: 1.02, 2.17). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Needling acupuncture is superior to sham acupuncture and medication therapy in improving headache intensity, frequency, and response rate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; December 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Freely available via &lt;A href="http://highwire.stanford.edu/lists/freeart.dtl" target="_blank"&gt;Highwire Press&lt;/A&gt;. The last 12 months are not available.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371754</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20167912?dopt=Abstract]]&gt;</url>
    <title>Acupuncture in poststroke rehabilitation: a systematic review and meta-analysis of randomized trials.</title>
    <publicationDate>2010-02-18T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DELIVERY OF CARE,STROKE,APRIL 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wu, P., Mills, E., Moher, D., Seely, D. (2010) Acupuncture in Poststroke Rehabilitation: A Systematic Review and Meta-Analysis of Randomized Trials. &lt;EM&gt;Stroke&lt;/EM&gt; 41(4):e171-9&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched 7 English and 2 Chinese databases from inception to September 2009. Eligible studies included randomized clinical trials that evaluated the clinical efficacy of acupuncture in adult patients with disability after stroke. We extracted data on trial quality, protocol, and outcomes assessed. A summary OR was calculated based on pooled dichotomous results. I(2) was used to infer heterogeneity and we conducted metaregression to determine if specific covariates explained heterogeneity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty-five articles written in Chinese and 21 articles written in English were included. The overall quality of the studies was "fair" and most studies were small (median n=86; range, 16 to 241). The majority (80%) of the studies reported a significant benefit from acupuncture; however, there was some evidence of publication bias. In 38 trials, data were available for meta-analysis and metaregression, yielding an OR in favor of acupuncture compared with controls (OR=4.33, 95% CI: 3.09 to 6.08; I2=72.4%). Randomization, modes of delivery, method of control, study source country, and reporting of randomization may explain some of the heterogeneity observed between the studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Randomized clinical trials demonstrate that acupuncture may be effective in the treatment of poststroke rehabilitation. Poor study quality and the possibility of publication bias hinder the strength of this recommendation and argue for a large, transparent, well-conducted randomized clinical trial to support this claim and implement changes to clinical practice.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; February 18th 2010 (E-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available from January 1970. The last 5 months are not freely available; ask your local healthcare library if they have a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320690</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.2.47]]&gt;</url>
    <title>Acupuncture reduced frequency and pain intensity of primary migraine or tension-type headaches</title>
    <publicationDate>2009-03-30T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,HEADACHE &amp; PAIN,HEADACHE,RECENT ADDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Haigh, C. Acupuncture reduced frequency and pain intensity of primary migraine or tension-type headaches. &lt;EM&gt;Evidence-Based Nursing&lt;/EM&gt; 2009;12(2):47.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Jena S, Witt CM, Brinkhaus B, et al. Acupuncture in patients with headache. &lt;EM&gt;Cephalalgia&lt;/EM&gt; 2008;28:969–79. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396600</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.neurology.org/content/75/5/463.abstract]]&gt;</url>
    <title>Acute and preventive pharmacologic treatment of cluster headache</title>
    <publicationDate>2010-08-03T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Francis GJ, Becker WJ, Pringsheim TM. (2010) Acute and preventive pharmacologic treatment of cluster headache. &lt;EM&gt;Neurology&lt;/EM&gt; 75(5):463-73&lt;/P&gt;
&lt;P&gt;Professor Peter Goadsby has critically appraised this paper and you can read his analysis &lt;A href="nelh:396690:0" name=internalLink&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Cluster headache (CH) is a rare and disabling primary headache disorder. CH attacks are unilateral, short, severe headaches associated with ipsilateral autonomic symptoms that occur in a periodic fashion. We provide a systematic review and meta-analysis of existing trials of pharmacotherapy for CH and evidence-based suggestions for acute abortive treatment and preventive therapy for cluster headache. Prospective, double-blind, randomized controlled trials of any pharmacologic agent for the symptomatic relief or prevention of CH were included in this evidence-based review. The main outcomes considered were headache response and pain-free response at 15 and 30 minutes for acute treatment trials, and the cessation of CH attacks within a specific time period or the number of days on which CH attacks occurred for preventive trials. Twenty-seven trials were included in the analysis. The American Academy of Neurology quality criteria were used to assess trial quality and to grade advisements. Based on the evidence, for acute treatment of CH, Level A advice can be given for subcutaneous sumatriptan 6 mg, zolmitriptan nasal spray 5 mg and 10 mg, and 100% oxygen 6-12 L/min. Level B advice can be given for sumatriptan nasal spray 20 mg and oral zolmitriptan 5 mg and 10 mg. For the prevention of CH, Level B advice can be given for intranasal civamide 100 microg daily and suboccipital steroid injections, and Level C advice can be given for verapamil 360 mg, lithium 900 mg, and melatonin 10 mg.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314393</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17684419]]&gt;</url>
    <title>Acute confusion or altered mental state: consider nonconvulsive status epilepticus</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Karger</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,STATUS EPILEPTICUS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Beyenburg S, Elger CE, Reuber M. (2007) Acute confusion or altered mental state: consider nonconvulsive status epilepticus. &lt;EM&gt;Gerontology&lt;/EM&gt; 53(6):388-96.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Systematic review of the current literature via Medline search.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Although prospective studies are still lacking, NCSE may be one of the most frequently missed diagnoses in patients presenting with altered mental status. Elderly patients are at particular risk of diagnostic errors because of the broad range of presentations of NCSE, significant comorbidities (especially cerebrovascular disease), limited awareness of this particular seizure emergency or difficulties with access to electroencephalography.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although diagnostic criteria and treatment remain controversial, the diagnosis of NCSE is important because it is potentially reversible.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;August 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff with an NHS Athens password via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;http://www.library.nhs.uk/booksandjournals/journals/default.aspx&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293365</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18451718?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Acute migraine therapy: recent evidence from randomized comparative trials</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,HEADACHE &amp; PAIN,MIGRAINE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Mett A et al Current opinion in Neurology 2008 Jun;21(3):331-7&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;(1) A wide array of data regarding acute migraine treatment are available, but few trials strictly adhere to International Headache Society guidelines for patient inclusion criteria.(2) Triptans appear to have similar efficacy profiles, but among newer triptans, almotriptan offers improved tolerability over sumatriptan.(3) Combination indomethacin/caffeine/prochlorperazine most likely has similar therapeutic efficacy to triptan therapy, with further research needed to complete understanding of any potential differences between these treatments.(4) Multi-targeted combination therapy with a triptan plus a non-steroidal anti-inflammatory (NSAID), such as sumatriptan/naproxen sodium, is more effective in acute migraine treatment than monotherapy with either agent alone.(5) It is unclear whether triptans offer clinically relevant benefits over aspirin or NSAIDs in migraine patients. Thus NSAIDs, particularly effervescent aspirin, should be considered the first-line treatment of migraine attacks.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293093</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18427072?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Acute treatment and prevention of menstrually related migraine headache: evidence-based review</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,MIGRAINE,HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Pringsheim, T et al Neurology 2008 Apr 22;70(17):1555-63&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Menstrually related migraine (MRM) headache is common in women and associated with substantial disability. Compared to nonmenstrual migraine, MRM attacks are more severe, longer in duration, and have a poorer response to analgesics. The purpose of this guideline is to provide a systematic review and meta-analysis of the existing therapy trials for MRM and evidence-based recommendations for acute and short-term preventive treatment of MRM headache. Prospective, double-blind, randomized controlled trials of any pharmacologic agent for the symptomatic relief or prevention of MRM headache were included in the guideline. The main outcomes considered were the pain response and pain-free response at 2 hours for acute treatment trials, and the incidence of MRM or the number of days on which MRM attacks occurred for short-term prevention trials. Nineteen trials were included in the analysis. The US Preventive Services Task Force quality criteria were used to assess trial quality and to grade recommendations. Based on the evidence, grade B recommendations can be made for the use of sumatriptan 50 and 100 mg, mefenamic acid 500 mg, and rizatriptan 10 mg for the acute treatment of MRM. For the preventive treatment of MRM, there are grade B recommendations for the perimenstrual use of transcutaneous estrogen 1.5 mg, frovatriptan 2.5 mg twice daily, and naratriptan 1 mg twice daily. Choosing among treatment strategies must be based on clinical considerations.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314100</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17480176]]&gt;</url>
    <title>Adverse effects of antiepileptic drugs on bone mineral density in children</title>
    <publicationDate></publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Gissel T, Poulsen CS, Vestergaard P. (2007) Adverse effects of antiepileptic drugs on bone mineral density in children. &lt;EM&gt;Expert Opinion on Drug Safety&lt;/EM&gt; 6(3):267-78.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic search of Pubmed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; For phenytoin, one study failed to show a decrease in femur BMD, whereas another study reported a decrease in total body and spine BMD, but only with the use pf phenytoin for&amp;nbsp;&amp;gt; 2 years. With phenytoin combined with a ketogenic diet, a decrease in forearm BMC was seen. For phenobarbital, one study showed a decrease in spine and total body BMD, but only among those who had used phenobarbital for &amp;gt; 2 years. Six studies were available for carbamazepine, and none of these showed a decrease in BMD in any skeletal site. For valproate, results were diverse; two studies reported a decrease in spine BMD, whereas two other studies did not. Two studies reported a decrease in hip BMD with valproate, whereas one did not. All three studies on forearm BMD in users of valproate described a decrease. Three studies reported an improvement in BMC with vitamin D supplementation in children on AEDs. No reports on changes in BMD among users of newer AEDs are available.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; More evidence is needed for the&amp;nbsp; effects on BMD in children, especially for newer AEDs. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;May 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384573</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1468-1331.2010.03187.x]]&gt;</url>
    <title>Allergy and risk of glioma: a meta-analysis</title>
    <publicationDate>2010-08-16T00:00:00</publicationDate>
    <publisher>European Journal of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,NEURO-ONCOLOGY,PRIMARY BRAIN TUMOURS,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y,&amp;nbsp;Wu S, REVIEW ARTICLE: Allergy and risk of glioma: a meta-analysis. &lt;EM&gt;European Journal of Neurology&lt;/EM&gt;, no. doi: 10.1111/j.1468-1331.2010.03187.x&lt;/P&gt;
&lt;P&gt;We evaluated the association between allergic conditions and the risk of glioma in case–control and cohort studies published so far on this issue. A total of 12 studies (10 case–control and 2 cohort studies) were included in the analysis, involving 61 090 participants, of whom 6408 had glioma. When compared with non-allergic conditions, the pooled odds ratio (OR) with any allergic conditions for glioma was 0.60 (95% CI: 0.52–0.69, P &amp;lt; 0.001), suggesting a significant negative association (protective effect) between allergy and glioma. Subgroup analysis showed that the ORs were 0.70 (95% CI: 0.62–0.79, P &amp;lt; 0.001), 0.69 (95% CI: 0.62–0.78, P &amp;lt; 0.001), and 0.78 (95% CI: 0.70–0.87, P &amp;lt; 0.001) for asthma, eczema, and hay fever, respectively. The significant association remained even after excluding the bias of proxy reporting (OR = 0.61; 95% CI: 0.50–0.75, P &amp;lt; 0.001). We conclude that allergic conditions may significantly reduce the risk of glioma.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The &lt;I&gt;European Journal of Neurology&lt;/I&gt; is the official journal of the European Federation of Neurological Societies. It covers all areas of clinical and basic research in neurology. Emphasis is placed on major diseases or large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases). The journal provides a forum for European activity in clinical neuroscience and medical practice and help strengthen the links between research workers and clinicians in Europe and other parts of the world. The journal also publishes the official EFNS taskforce papers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access statement: &lt;/STRONG&gt;Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396712</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20086184]]&gt;</url>
    <title>Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines</title>
    <publicationDate>2010-01-19T00:00:00</publicationDate>
    <publisher>Annals of Pharmacotherapy</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Gales BJ, Bailey EK, Reed AN, Gales MA. (2010) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. &lt;EM&gt;Annals of Pharmacotherapy&lt;/EM&gt; 44(2):360-6&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate the literature examining the efficacy of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for migraine prophylaxis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE (1966-October 2009) and International Pharmaceutical Abstracts were searched using the terms migraine, headache, renin-angiotensin system, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, aldosterone antagonist, and the individual agents in these classes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and data extraction:&lt;/STRONG&gt; English-language human clinical trials, case reports, and systematic reviews were evaluated for efficacy and safety data. The references of reviewed articles were examined to identify additional sources.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data synthesis:&lt;/STRONG&gt; Preventative trials evaluating ACE inhibitors consist of a case series, 2 open-label trials, and a placebo-controlled trial. Lisinopril reduced headache hours 20%, headache days 17%, and migraine days 21% versus placebo in the controlled trial (p &amp;lt; 0.05). Clinically significant (&amp;gt;50%) reductions in migraine measures were more common (52-66%) in open-label ACE inhibitor trials than in the controlled (32-36%) trial. Preventive trials evaluating ARBs consist of a meta-analysis, an open-label trial, and 2 placebo-controlled trials. Candesartan reduced headache hours 31%, headache days 26%, and migraine days 28% versus placebo in the first controlled trial (p &amp;lt; or = 0.001). Telmisartan did not reduce any prespecified primary or secondary outcome measures in the second controlled trial. Clinically significant reductions (&amp;gt;50%) in migraine measures were more common (54-88%) in open-label ARB trials than in the controlled (26-38%) trials. A prescription database review found that ACE inhibitor or ARB therapy halved the use of abortive migraine agents compared to diuretic therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt;&amp;nbsp;ACE inhibitors and ARBs have migraine prophylaxis activity similar to that of some currently utilized agents. Low-dose lisinopril or candesartan may be reasonable second- or third-line agents, particularly in patients with other indications for ACE inhibitor or ARB therapy. Further controlled clinical trials are needed to delineate the role of these agents in migraine prevention.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396710</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19084440]]&gt;</url>
    <title>Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Bakola E, Skapinakisa P, Tzoufic M, Damigosa D, Mavreas V. (2009) Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review. &lt;EM&gt;European Journal of Pain&lt;/EM&gt; 13(9):893-901&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; The use of anticonvulsant drugs for the prevention of migraine in children and adolescents has been supported in the past.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims: &lt;/STRONG&gt;To evaluate the available evidence for the efficacy and safety of anticonvulsants drugs in the prevention of migraine attacks in children and adolescents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Studies were selected through a comprehensive literature search. We included all types of study designs (controlled and uncontrolled) due to the limited evidence. Monthly migraine frequency was used as the primary outcome measure in most of the studies. Studies were classified into levels of evidence according to their design.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Fourteen studies were included with a total of 939 patients. Topiramate (4 randomized controlled trials [RCT], two uncontrolled trials), sodium valproate/divalproex sodium (two RCTs, one uncontrolled trial, two retrospective chart reviews) levetiracetam and zonisamide (both only uncontrolled studies) are the anticonvulsants that have been reported in the literature. The findings show that valproate is not different from placebo and topiramate may not be different but further randomized trials are needed. All drugs were well tolerated in this age group with no serious events reported.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; The use of anticonvulsants in the prevention of migraine in children and adolescents is not adequately supported by methodologically sound RCTs. More research is needed in the future to establish the efficacy and safety of specific agents.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293348</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18454787?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Anticonvulsants in migraine prophylaxis: a Cochrane review</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Mulleners, WM et al Cephalalgia 2008 Jun;28(6):585-97&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Several trials have asserted that some anticonvulsant drugs seem to be useful for the prophylaxis of migraine, but systematic reviews are sparse. We independently searched PubMed, EMBASE and the Cochrane Central Register of Controlled Trials until 2005, as well as Headache and Cephalalgia through April 2006, for prospective, controlled trials of anticonvulsant drugs. Data were calculated and pooled across studies and expressed as standardized mean differences, odds ratios and numbers-needed-to-treat. Anticonvulsants, considered as a class, reduce migraine frequency by about 1.3 attacks per 28 days compared with placebo, and more than double the number of patients for whom migraine frequency is reduced by &amp;gt; or = 50% relative to placebo. Sodium valproate/divalproex sodium and topiramate were better than placebo, whereas acetazolamide, clonazepam, lamotrigine and vigabatrin were not; gabapentin, in particular, needs further evaluation. Trials designed with sufficient power to compare different drugs are also necessary.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371755</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20308684?dopt=Abstract]]&gt;</url>
    <title>Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.</title>
    <publicationDate>2010-03-23T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,MOVEMENT DISORDERS,PARKINSON'S DISEASE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,APRIL 2010,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gagne, J. J., Power, M. C. (2010) Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. &lt;EM&gt;Neurology &lt;/EM&gt;74(12):995-1002.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; MEDLINE and EMBASE were searched for studies that reported risk of PD associated with anti-inflammatory medications. Random-effects meta-analyses were used to pool results across studies for each type of anti-inflammatory drug. Stratified meta-analyses were used to assess duration- and intensity-response. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Seven studies were identified that met the inclusion criteria, all of which reported associations between nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) and PD, 6 of which reported on aspirin, and 2 of which reported on acetaminophen. Overall, a 15% reduction in PD incidence was observed among users of nonaspirin NSAIDS (relative risk [RR] 0.85, 95% confidence interval [CI] 0.77-0.94), with a similar effect observed for ibuprofen use. The protective effect of nonaspirin NSAIDs was more pronounced among regular users (RR 0.71, 95% CI 0.58-0.89) and long-term users (RR 0.79, 95% CI 0.59-1.07). No protective effect was observed for aspirin (RR 1.08, 95% CI 0.92-1.27) or acetaminophen (RR 1.06, 95% CI 0.87-1.30). Sensitivity analyses found results to be robust. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There may be a protective effect of nonaspirin nonsteroidal anti-inflammatory drug use on risk of Parkinson disease (PD) consistent with a possible neuroinflammatory pathway in PD pathogenesis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 23rd March 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if they have a local subscription. Abstracts and tables of contents are free for all to view. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345422</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/cgi/content/short/15/1/15]]&gt;</url>
    <title>Antipyretic drugs do not reduce recurrences of febrile seizures in children with previous febrile seizure.</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lux AL. (2010) Antipyretic drugs do not reduce recurrences of febrile seizures in children with previous febrile seizure.&amp;nbsp; &lt;EM&gt;Evidence Based Medicine&lt;/EM&gt; 15(1):15-6. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Strengell T, Uhari M, Tarkka R, et al. (2009)&amp;nbsp;Antipyretic agents for preventing recurrences of febrile seizures: randomized controlled trial. &lt;EM&gt;Archives of pediatrics &amp;amp; adolescent medicine &lt;/EM&gt;163:799–804.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293088</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16514329?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Are manual therapies effective in reducing pain from tension-type headache?: a systematic review</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Fernández-de-Las-Peñas C&amp;nbsp;et al Clin J Pain 2006 Mar-Apr;22(3):278-85&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVES: A systematic review was performed to establish whether manual therapies have specific efficacy in reducing pain from tension-type headache (TTH). METHODS: Computerized literature searches were performed in MEDLINE, EMBASE, AMED, MANTIS, CINAHL, PEDro, and Cochrane databases. Papers were included if they described clinical (open noncontrolled studies) or randomized controlled trials in which any form of manual therapy was used for TTH, and if they were published after 1994 in the English language. The methodologic quality of the trials was assessed using the PEDro scale. Levels of scientific evidence, based on the quality and the outcomes of the studies, were established for each manual therapy: strong, moderate, limited, and inconclusive evidence. RESULTS: Only six studies met the inclusion criteria. These trials evaluated different manual therapy modalities: spinal manipulation (three trials), classic massage (one trial), connective tissue manipulation (two trials), soft tissue massage (one trial), Dr. Cyriax's vertebral mobilization (one trial), manual traction (one trial), and CV-4 craniosacral technique (one trial). Methodologic PEDro quality scores ranged from 2 to 8 points out of a theoretical maximum of 10 points (mean=5.8+/-2.1). Analysis of the quality and the outcomes of all trials did not provide rigorous evidence that manual therapies have a positive effect in reducing pain from TTH: spinal manipulative therapy showed inconclusive evidence of effectiveness (level 4), whereas soft tissue techniques showed limited evidence (level 3). CONCLUSIONS: The authors found no rigorous evidence that manual therapies have a positive effect in the evolution of TTH. The most urgent need for further research is to establish the efficacy beyond placebo of the different manual therapies currently applied in patients with TTH.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322698</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18987621]]&gt;</url>
    <title>Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine</title>
    <publicationDate>2008-11-05T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Luykx J, Mason M, Ferrari MD, Carpay J. (2009) Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. &lt;EM&gt;Clinical Pharmacology &amp;amp; Therapeutics&lt;/EM&gt; 85(3):283-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; To compare adverse drug reactions (ADRs) to topiramate in patients with migraine and patients with epilepsy, we systematically reviewed all published randomized controlled trials (RCTs) that compare topiramate monotherapy in epilepsy and migraine. We included four epilepsy RCTs (N = 1,179 patients; vs. active comparators) and six migraine RCTs (N = 1,723 patients; vs. placebo). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Behavioral ADRs and headache were found only in the case of epilepsy, whereas cognitive complaints and alteration of taste were found only in the case of migraine. The risk ratios (RRs) for paresthesia in migraine vs. epilepsy trials were 2.5 (99% confidence interval (CI): 1.66-3.77) for 50 mg, 2.7 (99% CI: 1.80-3.97) for 100 mg, and 3.0 (99% CI: 1.95-4.56) for 200 mg. For ADR-related dropouts, the RR was 2.5 (95% CI: 2.03-2.98) for 50 mg but no different for the other doses. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; We conclude that when treated with the same doses of topiramate, migraineurs show different ADRs than patients with epilepsy and are more likely to drop out because of ADRs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 5 November 2008 (e-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320709</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.2.46]]&gt;</url>
    <title>Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke</title>
    <publicationDate>2009-03-31T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sloan, MA. Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke. &lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; 2009;14(2):46-47.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. &lt;EM&gt;N Engl J Med&lt;/EM&gt; 2008;359:1225–37.&lt;/P&gt;
&lt;P&gt;Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended release dipyridamole versus clopidogrel for recurrent stroke. &lt;EM&gt;N Engl J Med&lt;/EM&gt; 2008;359:1238–51.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322989</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18458231]]&gt;</url>
    <title>Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</title>
    <publicationDate>2008-05-06T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, et al. (2008) Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. &lt;EM&gt;Neurology&lt;/EM&gt; 70(19 PART 1):1707-14.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and the selected indications. Authors reviewed, abstracted, and classified articles based on the quality of the study (Class I-IV). Conclusions and recommendations were developed based on the highest level of evidence and put into current clinical context. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The highest quality literature available for the respective indications was as follows: axillary hyperhidrosis (two Class I studies); palmar hyperhidrosis (two Class II studies); drooling (four Class II studies); gustatory sweating (five Class III studies); neurogenic detrusor overactivity (two Class I studies); sphincter detrusor dyssynergia in spinal cord injury (two Class II studies); chronic low back pain (one Class II study); episodic migraine (two Class I and two Class II studies); chronic daily headache (four Class II studies); and chronic tension-type headache (two Class I studies). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Botulinum neurotoxin (BoNT) should be offered as a treatment option for the treatment of axillary hyperhidrosis and detrusor overactivity (Level A), should be considered for palmar hyperhidrosis, drooling, and detrusor sphincter dyssynergia after spinal cord injury (Level B), and may be considered for gustatory sweating and low back pain (Level C). BoNT is probably ineffective in episodic migraine and chronic tension-type headache (Level B). There is presently no consistent or strong evidence to permit drawing conclusions on the efficacy of BoNT in chronic daily headache (mainly transformed migraine) (Level U). While clinicians' practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 6 May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343155</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20042705]]&gt;</url>
    <title>Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review)</title>
    <publicationDate>2009-12-30T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ REHABILITATION,OTHER NEUROPATHIC PAIN,DELIVERY OF CARE,HEADACHE &amp; PAIN,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,SYMPTOM MANAGEMENT,CONDITIONS,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Dubinsky, R.M.,&amp;nbsp; Miyasaki, J. (2010) Assessment: Efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. &lt;EM&gt;Neurology&lt;/EM&gt; 74:173-176.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed a systematic literature search of Medline and the Cochrane Library from inception to April 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There are conflicting reports of TENS compared to sham TENS in the treatment of chronic low back pain, with 2 Class II studies showing benefit, but 2 Class I studies and another Class II study not showing benefit. Because the Class I studies are stronger evidence, TENS is established as ineffective for the treatment of chronic low back pain (2 Class I studies). TENS is probably effective in treating painful diabetic neuropathy (2 Class II studies). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommendations:&lt;/STRONG&gt; Transcutaneous electric nerve stimulation (TENS) is not recommended for the treatment of chronic low back pain (Level A). TENS should be considered in the treatment of painful diabetic neuropathy (Level B). Further research into the mechanism of action of TENS is needed, as well as more rigorous studies for determination of efficacy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 30 December 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345267</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20177124]]&gt;</url>
    <title>Assessment: Symptomatic treatment for muscle cramps (an evidence-based review):Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DELIVERY OF CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Katzberg HD, Khan AH, So YT. (2010) Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.&amp;nbsp;&lt;EM&gt;Neurology&lt;/EM&gt; 74(8):691-6. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A total of 563 potential articles were reviewed, of which 24 met the inclusion criteria of prospective trials evaluating the efficacy of a particular treatment on muscle cramps as a primary or secondary outcome. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There are Class I studies showing the efficacy of quinine derivatives for treatment of muscle cramps. However, the benefit is modest and there are adverse effects from published prospective trials as well as case reports. There is one Class II study each to support the use of Naftidrofuryl, vitamin B complex, lidocaine, and diltiazem in the treatment of muscle cramps. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although likely effective (Level A), quinine derivatives should be avoided for routine use in the management of muscle cramps because of the potential of toxicity, but in select patients they can be considered for an individual therapeutic trial once potential side effects are taken into account. Vitamin B complex, Naftidrofuryl, and calcium channel blockers such as diltiazem are possibly effective and may be considered in the management of muscle cramps (Level C). Further studies are needed to identify agents that are effective and safe for the treatment of muscle cramps.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; February 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344190</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18765653]]&gt;</url>
    <title>Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</title>
    <publicationDate>2008-09-02T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. &lt;EM&gt;Neurology&lt;/EM&gt; 2008;71(10):766-74.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; The clinical and radiologic impact of natalizumab (Tysabri) as therapy for multiple sclerosis (MS) is assessed. On the basis of Class I evidence, natalizumab has been demonstrated to reduce measures of disease activity and to improve measures of disease severity in patients with relapsing-remitting (RR) MS (Level A). The relative efficacy of natalizumab compared to current disease-modifying therapies cannot be defined accurately (Level U). Similarly, the value of natalizumab in the treatment of secondary progressive (SP) MS is unknown (Level U). The value of combination therapy using natalizumab and interferon in the treatment of RRMS is also unknown (Level U). There is an increased risk of developing progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients (Level A for combination therapy, Level C for monotherapy) and possibly an increased risk of other opportunistic infections (Level C). The PML risk in a pooled clinical trial cohort has been estimated to be 1 person for every 1,000 patients treated for an average of 17.9 months, although this figure could change in either direction with more experience with the drug.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396493</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://cep.sagepub.com/content/29/8/818.abstract]]&gt;</url>
    <title>Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>SAGE journals online</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L. (2009) Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis. &lt;EM&gt;Cephalalgia&lt;/EM&gt; 29(8):818-825&lt;/P&gt;
&lt;P&gt;There are conflicting data concerning the association between migraine and C677T polymorphism of the MTHFR gene. The C677T polymorphism reduces enzymatic capability by 50% and causes hyperhomocysteinaemia. We performed a meta-analysis of all published studies investigating the association between the MTHFR gene and migraine. Pooled odds ratios (OR) were estimated using random (RE) and fixed effects (FE) models. Among the overall 2961 migraineurs there was no significant difference compared with controls. Only in migraine with aura was the TT genotype associated with a higher risk of disease compared with the CC genotype [FE OR 1.30, 95% confidence interval (CI) 1.06, 1.58; RE OR 1.66, 95% CI 1.06, 2.59]. In the same subgroup a significant difference was observed in the comparison between TT and CT + CC genotypes (FE OR 1.32, 95% CI 1.10, 1.59; RE OR 1.63, 95% CI 1.10, 2.43). This study provides evidence for an association of the MTHFR gene only in migraine with aura. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314058</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18281914]]&gt;</url>
    <title>Association study between interleukin 1 beta gene and epileptic disorders: a HuGe review and meta-analysis</title>
    <publicationDate></publicationDate>
    <publisher>American College of Medical Genetics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Kauffman MA, Moron DG, Consalvo D, Bello R, Kochen S. (2008)Association study between interleukin 1 beta gene and epileptic disorders: a HuGe review and meta-analysis. &lt;EM&gt;Genetics in Medicine&lt;/EM&gt; 10(2):83-8&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Published studies up to March 2007 of temporal lobe epilepsy, febrile seizures and the IL-1beta-511T single nucleotide polymorphism were identified by searches of Medline and Embase databases. Meta-analysis of temporal lobe epilepsy and febrile seizures case-control data were performed to assess the association of IL-1beta-511T with temporal lobe epilepsy, temporal lobe epilepsy with hippocampal sclerosis, febrile seizures, and other epileptic disorders. Pooled odds ratios (OR) were estimated by means of a genetic-model-free approach. The quality of the included studies was assessed by a score.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The results show a modest association (OR, 1.48; 95% confidence interval, 1.09–2.00; P &amp;lt; 0.01) between the IL-1beta-511T polymorphism and temporal lobe epilepsy with hippocampal sclerosis.&lt;FONT face=FranklinGothic-Book size=1&gt;&lt;FONT face=FranklinGothic-Book size=1&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; To date, there is insufficient evidence to identify absolutely any gene variant as a putative risk factor for the development of epilepsy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; February 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314107</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18410358]]&gt;</url>
    <title>Attention impairment in rolandic epilepsy: systematic review</title>
    <publicationDate></publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kavros PM, Clarke T, Strug LJ, Halperin JM, Dorta NJ, Pal DK. (2008) Attention impairment in rolandic epilepsy: systematic review. &lt;EM&gt;Epilepsia&lt;/EM&gt; 49(9):1570-80.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We used a systematic review of the relevant literature published in English from 1990 to 2006 to evaluate impairment in attention in RE. The Mirsky and Posner models of attention were evaluated for applicability, and studies were reviewed for design, instrumentation, and congruence with the Posner model of attention. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Fourteen studies were identified: seven using a cross-sectional design (six active EEG abnormalities; one EEG remission) and seven longitudinal studies (abnormal EEGs and follow-up until normalized). According to the Posner model of attention, 12 studies employed measures that tapped the alerting network, 11 studies the orienting network, and eight the executive network. Nearly all controlled studies demonstrated impairments in all tested attention networks. In contrast, uncontrolled studies uniformly did not demonstrate impairments. Follow-up studies demonstrated complete or near complete resolution of attention impairments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The weight of evidence, defined as the majority of studies evaluated, suggests that all three attention systems are impaired in children with active centrotemporal spikes (CTS), implying a more widespread functional cortical disturbance in RE than previously held. These impairments resolve upon EEG remission, suggesting a common pathological basis to the autosomal dominant CTS trait. Sources of methodological variation are discussed with recommendations for future investigations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;April 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293385</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16765853?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Autogenic training for tension type headaches: a systematic review of controlled trials</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>STRUCTURED ABSTRACT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,CHRONIC DAILY HEADACHE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Kanji N et al Complementary therapies in medicine 2006 Jun;14(2):144-50. Epub 2006 May 18&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: To determine from the published evidence whether autogenic training as sole therapy is effective for prevention of tension-type headaches in adults. METHOD: Systematic review of controlled trials. Literature searches were performed in January 2005 in six major databases, specifically Medline, EMBASE, AMED, CENTRAL, PsychInfo and CINAHL and information was extracted and evaluated in a pre-defined manner. RESULTS: Seven controlled clinical trials were included in the review. The methodological quality of these studies was low. Patient samples were generally representative of the more severely affected cases. None of the studies show autogenic training to be convincingly superior to other interventions care. Some trials suggested that the effect of autogenic training is no different from hypnosis and inferior to biofeedback. CONCLUSION: There is no consistent evidence to suggest that autogenic training is superior to other interventions for prevention of tension headaches, or different from other forms of relaxation. Further studies should investigate the use of standard autogenic training in patients with moderate headache.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384490</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/jnnp.2009.181438]]&gt;</url>
    <title>Awake seizures after pure sleep-related epilepsy: a systematic review and implications for driving law</title>
    <publicationDate>2009-08-08T00:00:00</publicationDate>
    <publisher>Journal of Neurology, Neurosurgery &amp; Psychiatry</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Thomas RH, King WH, Johnston JA, Smith PE. (2010) Awake seizures after pure sleep-related epilepsy: a systematic review and implications for driving law. &lt;EM&gt;Journal of Neurology, Neurosurgery &amp;amp; Psychiatry &lt;/EM&gt;81(2):130-6&lt;/P&gt;
&lt;P&gt;Who with sleep seizures is safe to drive? Driving law is controversial; ineligibility varies between individual US states and EU countries. Current UK driving law is strongly influenced by a single-centre study from 1974 where most participants were not taking antiepileptic drugs (AEDs). However, pure sleep-related epilepsy is often fully controlled on medication, and its withdrawal can provoke awake seizures. &lt;/P&gt;
&lt;P&gt;This systematic review asked, ‘What is the risk of awake seizures in pure sleep-related epilepsy?’ 9885 titles were identified; 2312 were excluded (not human or adult); 40 full texts were reviewed; six papers met our inclusion criteria; each of these six studies had a different pure sleep-related epilepsy definition.&lt;/P&gt;
&lt;P&gt;Using the largest prospective study, we were able to calculate next year's awake seizure chance (treated with antiepileptic medication). This was maximal in the second year: 5.7% (95% CI 3.0 to 10.4%). European licensing bodies including the UK's Driver and Vehicle Licensing Agency broadly accept a risk of less than 20% for Group 1 licensing. However, this study excluded patients with frontal-lobe epilepsies. Furthermore, follow-up (n=160) varied from 2 to 6 years, yet new awake seizures may occur even after 10–20 years of pure sleep-related epilepsy&lt;/P&gt;
&lt;P&gt;A paucity of evidence underpins present licensing law; current rulings would be difficult to defend if legally challenged. The law may be penalising people with pure sleep-related epilepsy without increased risk of awake seizures, while failing to identify subgroups at unacceptable risk of an awake seizure at the wheel. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The Journal of Neurology, Neurosurgery&amp;nbsp;and Psychiatry is a neurological journal which also includes the supplement Practical Neurology, which is published bi-monthly. Material published by the journal includes original articles, reports, commentaries and editorials.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288485</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18175075?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Azathioprine. Safety profile in multiple sclerosis patients</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>Springer Milan</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=abstract&gt;La Mantia, L et al &lt;SPAN title="Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology."&gt;&lt;A href="#javascript:AL_get(this," Sci.?);? ?Neurol ?jour?,&gt;Neurol Sci.&lt;/A&gt;&lt;/SPAN&gt; 2007 Dec;28(6):299-303&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Azathioprine (Aza) has been proposed in the treatment of multiple sclerosis (MS) since 1971 and continues to be used in MS Clinical Centres. Recent data, suggesting its efficacy in reducing MRI lesion load and in refractory IFN-treated MS patients, has renewed interest in this drug. Its therapeutic index over other immunosuppressive agents is generally considered favourable, but concerns about a possible risk of malignancy have limited its use. On the other hand, the occurrence of unexpected adverse events (AEs) in clinical trials in recent years has aroused the interest in the safety profile of the drugs. No systematic review of AEs in patients affected by MS is available. The aim of this study is to review the safety profile of the drug in patients affected by MS, in order to support a correct management of these patients in the clinical practice. The controlled and observational clinical studies published between 1971 and 2007 have been included. The AEs have been registered in ad hoc form and the frequency has been calculated. The risk of cancer and toxicity on reproductive function has been also considered. Gastrointestinal complaints and leukopenia are the most frequent AEs of Aza therapy in MS, occurring in more than 10% of the patients, while infections, allergy, anaemia, thrombocytopenia and pancytopenia are common (&amp;gt;1%-&amp;lt;10%). Pancreatitis is not common (&amp;gt;0.1%-&amp;lt;1%). Most of them are easily managed by dosage adjustment or therapy interruption. The cancer risk increases with the treatment duration and cumulative dose. No data on reproductive toxicity in MS treated with Aza are available. The safety profile of Aza is acceptable, if strategies for management of expected AEs are adopted, following dosage and treatment duration indications, and if long-term monitoring to evaluate the risk of cancer is warranted.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345098</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1007/s00415-008-0061-1]]&gt;</url>
    <title>Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Springer Milan</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature has been extracted for new evidence from randomized controlled trials, open treatment studies and reported expert opinion, both in original articles and reviews, and evaluates indications and safety issues based on published data. After data extraction from published full length publications and critically weighing the evidence and potential impact of the data, the review has been drafted and circulated within the National MS Societies and the European MS Platform to reach consensus within a very large group of European experts, combining evidence-based criteria and expert opinion where evidence is still incomplete. The review also outlines a few areas of controversy and delineates the need for future research.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information: &lt;/STRONG&gt;Published in October 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Neurologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323020</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19499626]]&gt;</url>
    <title>Behavioral treatments of chronic tension-type headache in adults: are they beneficial?</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CHRONIC DAILY HEADACHE,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Verhagen AP, Damen L, Berger MY, Passchier J, Koes BW. (2009) Behavioral treatments of chronic tension-type headache in adults: Are they beneficial? &lt;EM&gt;CNS Neuroscience and Therapeutics&lt;/EM&gt; 15(2):183-205.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Medline, Cinahl, EMBASE, and the Cochrane library were searched from inception to October 2007 and reference lists were checked. We selected randomized trials evaluating behavioral treatments (e.g., relaxation, electromyographic [EMG] biofeedback, and cognitive behavioral training) in patients with tension-type headache (TTH). We assessed the risk of bias using the Delphi list and extracted data from the original reports. A qualitative analysis was carried out. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We found 44 trials (2618 patients), which were included in this review, of which only 5 studies (11.4%) were considered to have low risk of bias. Most trials lacked adequate power to show statistical significant differences, but frequently, recovery/improvement rates did not reach clinical relevance. In 8 studies, relaxation treatment was compared with waiting list conditions, and in 11 studies, biofeedback was compared with waiting list conditions, both showing inconsistent results.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; On the basis of the available literature, we found no indications that relaxation, EMG biofeedback, or cognitive behavioral treatment is better than no treatment, waiting list, or placebo controls.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Summer 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304836</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/Acupunctureandheadaches.aspx]]&gt;</url>
    <title>Behind the headlines - Acupuncture and headaches</title>
    <publicationDate>2009-01-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,HEADACHE &amp; PAIN,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. &lt;A title="Acupuncture for migraine prophylaxis." href="http://www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/CD001218.pdf" target="_blank"&gt;Acupuncture for migraine prophylaxis.&lt;/A&gt; &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt; 2009, Issue 1&lt;/P&gt;
&lt;P&gt;Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. &lt;A title="Acupuncture for tension-type headache." href="http://www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/CD007587.pdf" target="_blank"&gt;Acupuncture for tension type headache.&lt;/A&gt;&amp;nbsp;&lt;EM&gt;Cochrane Database of Systematic Reviews &lt;/EM&gt;2009, Issue 1&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>315420</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/05May/Pages/AlcoholMajorDementiaCause.aspx]]&gt;</url>
    <title>Behind the headlines - Alcohol 'major cause of dementia'</title>
    <publicationDate>2010-05-20T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ENVIRONMENTAL &amp; TOXIC,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,DRUGS &amp; ALCOHOL,RECREATIONAL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Whiteley C, Wanigaratne S, Marshall J and Curran HV:&amp;nbsp;&lt;A href="http://alcalc.oxfordjournals.org/cgi/content/extract/agp013v1" target="_blank"&gt;Autobiographical Memory in Detoxified Dependent Drinkers.&lt;/A&gt; &lt;EM&gt;Alcohol &amp;amp; Alcoholism&lt;/EM&gt; [Advance Access published March 16, 2009]&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>288740</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/04April/Pages/Alzheimersandintelligence.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer’s and intelligence</title>
    <publicationDate>2008-04-07T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Whalley LJ, Deary IJ, Starr JM, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="n–3 Fatty acid erythrocyte membrane content, APOE e4, and cognitive variation: an observational follow-up study in late adulthoo" href="http://www.ajcn.org/cgi/content/abstract/87/2/449" target="_blank"&gt;n–3 Fatty acid erythrocyte membrane content, &lt;EM&gt;APOE &lt;/EM&gt;e4, and cognitive variation: an observational follow-up study in late adulthood.&lt;/A&gt; &lt;EM&gt;Am J Clinical Nutrition &lt;/EM&gt;2008; 87:449-454&lt;/P&gt;
&lt;H4&gt;Further reading&lt;/H4&gt;
&lt;P&gt;Lim WS, Gammack JK, Van Niekerk JK, Dangour AD. &lt;A title="Omega 3 fatty acid for the prevention of dementia." href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005379/frame.html" target="_blank"&gt;Omega 3 fatty acid for the prevention of dementia.&lt;/A&gt; &lt;EM&gt;Cochrane Database Syst Rev &lt;/EM&gt;2006, Issue 1&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>288749</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2007/January08/Pages/Alzheimersinbothparentsupsrisk.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer’s in both parents ups risk</title>
    <publicationDate>2008-03-11T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ALZHEIMER'S DISEASE,DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Jayadev S, Steinbart EJ, Chi Y-Y, et al. &lt;A title="Conjugal Alzheimer Disease: Risk in Children When Both Parents Have Alzheimer Disease." href="http://archneur.ama-assn.org/cgi/content/abstract/65/3/373?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=jayadev&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=date&amp;amp;resourcetype=HWCIT" target="_blank"&gt;Conjugal Alzheimer Disease: Risk in Children When Both Parents Have Alzheimer Disease.&lt;/A&gt; Arch Neurol 2008; 65: 373-378.&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>309177</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Alzheimersdrugdevelopment.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer's drug development</title>
    <publicationDate>2008-07-30T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation." href="http://www.alz.org/icad/_release_icad_072908_130pm_trials.asp" target="_blank"&gt;Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation.&lt;/A&gt; International Conference on Alzheimer's Disease 2008&lt;/P&gt;
&lt;P&gt;&lt;A title="Media releases: TauRx Therapeutics Ltd &amp;amp; University of Aberdeen - New treatment halts progress of Alzheimer's disease." href="http://www.abdn.ac.uk/mediareleases/alzheimers-breakthrough.shtml" target="_blank"&gt;Media releases: TauRx Therapeutics Ltd &amp;amp; University of Aberdeen - New treatment halts progress of Alzheimer's disease.&lt;/A&gt; University of Aberdeen&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>334408</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/hunger-hormone-Alzheimers-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer's may be linked to hormone</title>
    <publicationDate>2009-12-16T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A hormone linked to appetite “could offer hope to prevent Alzheimer’s disease”, according to The Daily Telegraph. The newspaper reported that people with the highest levels of the hormone leptin were four times less likely to develop Alzheimer’s than those with the lowest.&lt;/P&gt;
&lt;P&gt;The story is based on research that assessed the levels of leptin, a hormone thought to regulate appetite, in a group of 785 healthy older individuals. These people were then followed for an average of eight years, and any new cases of dementia were documented. The study showed that higher leptin levels at the assessment were associated with a decreased risk of developing Alzheimer’s disease. &lt;/P&gt;
&lt;P&gt;This study was relatively small but well conducted, and it encourages further research into the complex associations between leptin, obesity and Alzheimer’s disease. It is too soon to say if leptin can be used as a preventive treatment, but it may have a role in identifying people who are at risk of later developing Alzheimer’s.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study found an association between higher leptin levels and a decreased risk of Alzheimer’s disease. Higher leptin levels were also associated with a lower risk of decreases in brain volume. &lt;/P&gt;
&lt;P&gt;This was a very well conducted study, but as it was a cohort study it can only show that leptin is associated with Alzheimer’s disease and cannot show what role leptin plays in the development of, or the protection against, the disease.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/12December/Pages/hunger-hormone-Alzheimers-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lieb W, Beiser AS, Zasan RS. &lt;A href="http://jama.ama-assn.org/cgi/content/abstract/302/23/2565?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=leptin&amp;amp;searchid=" target="_blank"&gt;Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging&lt;/A&gt;. &lt;EM&gt;JAMA&lt;/EM&gt;, Vol. 302 No. 23, December 16 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334421</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Alzheimers-nutrient-milkshake-souvenaid.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer's nutrient drink tested</title>
    <publicationDate>2010-01-08T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ALZHEIMER'S DISEASE,DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,JANUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have created an “anti-Alzheimer's milkshake” that boosts memory, according to the Daily Mail. The newspaper says that the “once-a-day miracle drink” could be available within two years.&lt;/P&gt;
&lt;P&gt;This news is based on early-stage research that gave a daily nutrient drink to 225 people with early Alzheimer’s disease over a 12-week period. Although this was a well conducted study, its findings have been exaggerated by the news. The shake improved verbal recall, just one aspect of Alzheimer’s disease from a spectrum of potential problems. Improvements in one aspect of the disease may not have a large effect on the overall function of the person.&lt;/P&gt;
&lt;P&gt;The safety and effectiveness of this shake will need to be confirmed in further studies. This single, initial study does not provide sufficient evidence to confirm that the drink either reverses or prevents Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Although this was a well designed randomised controlled trial, it was quite preliminary and has only shown improvement of verbal recall, a single aspect in people affected by mild Alzheimer’s disease. In Alzheimer’s disease a whole spectrum of memory and cognitive functions are impaired, including recognition of people and things, the ability to plan, conversing and understanding, and the ability to carry out normal activities of daily life. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Alzheimers-nutrient-milkshake-souvenaid.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Scheltens, P., Kamphuis, P.J.G.H., Verhey, F.R.J. et al. &lt;A href="http://wurtmanlab.mit.edu/publications/pdf/1041.pdf" target="_blank"&gt;Efficacy of a medical food in mild Alzheimer's disease: a randomized controlled trial.&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Press release: &lt;A href="http://web.mit.edu/newsoffice/2010/fighting-alzheimers" target="_blank"&gt;MIT&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Press release: &lt;A href="http://www.eurekalert.org/pub_releases/2010-01/miot-nat010610.php" target="_blank"&gt;Eurekalert&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319165</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/06June/Pages/AlzheimersBrainSpread.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer's progression probed</title>
    <publicationDate>2009-06-08T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Clavaguera F, Bolmont T, Crowther RA &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.nature.com/ncb/journal/vaop/ncurrent/abs/ncb1901.html" target="_blank"&gt;Transmission and spreading of tauopathy in transgenic mouse brain.&lt;/A&gt; &lt;EM&gt;Nature Cell Biology,&lt;/EM&gt; June 7 2009 (advanced online publication) &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>315419</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/05May/Pages/PillReversesAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer's 'reversed by pill'</title>
    <publicationDate>2009-05-07T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Guan JS, Haggarty SJ, Giacometti E &lt;EM&gt;et al.&lt;/EM&gt;&amp;nbsp;&lt;A href="http://www.nature.com/nature/journal/v459/n7243/full/nature07925.html" target="_blank"&gt;HDAC2 negatively regulates memory formation and synaptic plasticity.&lt;/A&gt; &lt;EM&gt;Nature&lt;/EM&gt; 459, 55-60 (7 May 2009)&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>346822</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/purpose-in-life-Alzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer's risk linked to outlook</title>
    <publicationDate>2010-03-02T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Elderly people with a strong sense of purpose in life face a reduced risk of developing Alzheimer's disease,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; reports. The finding comes from research that assessed the outlook on life in 900 elderly people, following them for several years to see which of them developed cognitive problems.&lt;/P&gt;
&lt;P&gt;This study had a number of strengths including good data collection methods and thorough assessments of its participants’ mental functions. It also adjusted for the influence of factors that might affect results.&lt;/P&gt;
&lt;P&gt;The research does seem to show a link between a perceived greater purpose in life and reduced risk of Alzheimer’s. However, it is difficult to say whether purpose in life directly affects Alzheimer’s risk, if outlook is altered during the early onset of cognition problems or if another related factor is behind the link. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research suggests a link between purpose in life and risk of cognitive impairment and Alzheimer’s disease. There are some points to note on this research, see full article for details.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/03March/Pages/purpose-in-life-Alzheimers.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Boyle PA, Buchman AS, Barnes LL, Bennett DA. &lt;A href="http://archpsyc.ama-assn.org/cgi/content/abstract/67/3/304?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=boyle&amp;amp;searchid=" target="_blank"&gt;Effect of a Purpose in Life on Risk of Incident Alzheimer Disease and Mild Cognitive Impairment in Community-Dwelling Older Persons&lt;/A&gt;. Arch Gen Psychiatry. 2010;67(3):304-310.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304863</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/EpilepsydrugtestedinAlzheimer's.aspx]]&gt;</url>
    <title>Behind the headlines - Alzheimer's story 'overdone'</title>
    <publicationDate>2008-10-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Qing H, He G, Ly PTT et al. &lt;A title="Valproic acid inhibits Aß production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models." href="http://jem.rupress.org/cgi/content/abstract/jem.20081588" target="_blank"&gt;Valproic acid inhibits Aß production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models.&lt;/A&gt; J Exp Med 2008; Oct 27&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>334405</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/12December/Pages/Antidepressants-and-stroke.aspx]]&gt;</url>
    <title>Behind the headlines - Antidepressants and stroke</title>
    <publicationDate>2009-12-15T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,JANUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Postmenopausal women who take antidepressants may be increasing their chance of suffering a stroke and dying prematurely,” reported the Daily Mail. It said a six-year study found a 45% increase in risk of strokes for women who used antidepressants compared to women who did not use them.&lt;/P&gt;
&lt;P&gt;As the newspaper also reported, the absolute increase in risk of stroke (the number of women who might be affected) was small, equating to an increase of about 13 additional women in every 10,000 (0.43% of women on antidepressants compared to 0.3% of women not on them). In addition, depression itself is a known risk factor for stroke, so it is not clear how much of the increase was due to depression rather than the drugs.&lt;/P&gt;
&lt;P&gt;Overall, this increase in risk was small and may not be attributable solely to the drugs themselves. Taking any medication involves weighing up the pros and cons of taking the drug compared to the prospects of leaving the disease untreated. As the British Heart Foundation said, “it is important to weigh up any small increase in the risk of stroke with the benefits of treating depression".&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has collected and pooled a large amount of data from several studies of postmenopausal women. In the full journal article, the researchers are cautious in their interpretations of their results, discussing the issue of residual confounding and other limitations in four pages of comments. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/12December/Pages/Antidepressants-and-stroke.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Smoller JW, Allison M, Cochrane BB, et al.&amp;nbsp;&lt;A href="http://archinte.ama-assn.org/cgi/content/abstract/169/22/2128" target="_blank"&gt;Antidepressant Use and Risk of Incident Cardiovascular Morbidity and Mortality Among Postmenopausal Women in the Women's Health Initiative Study&lt;/A&gt;.&amp;nbsp; &lt;EM&gt;Arch Intern Med&lt;/EM&gt; 2009; 169: 2128-2139&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309182</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Antiepilepticdrugsandbirthdefects.aspx]]&gt;</url>
    <title>Behind the headlines - Antiepileptic drugs and birth defects</title>
    <publicationDate>2008-07-22T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Hunt S, Russell A, Smithson WH, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Topiramate in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register." href="http://www.neurology.org/cgi/content/abstract/71/4/272" target="_blank"&gt;Topiramate in pregnancy: Preliminary experience from the UK Epilepsy and Pregnancy Register.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; 71:272–276 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>331414</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Antipsychotic-use-in-dementia.aspx]]&gt;</url>
    <title>Behind the headlines - Antipsychotic use in dementia</title>
    <publicationDate>2009-11-13T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,LATER LIFE,TREATMENT AND CARE,DEMENTIA,NOVEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“About 145,000 people with dementia are wrongly being prescribed powerful anti-psychotic medication which causes around 1,800 deaths a year,” &lt;EM&gt;The Times&lt;/EM&gt; reported. Many newspapers have reported this finding from a government-commissioned review. The government has responded to the report and agrees with its main findings.&lt;/P&gt;
&lt;P&gt;The report makes several recommendations, mainly that people with dementia should receive antipsychotics only when they really need them, and that reducing their use in this group should be a priority for the NHS. It suggests this can be achieved by various means including training carers and medical staff to use alternatives to antipsychotics, providing psychological therapies for people with dementia and their carers, carrying out further research into alternative treatments, and audits.&lt;/P&gt;
&lt;P&gt;The report estimated that antipsychotic use could be safely reduced to a third of its current usage over a period of three years.&lt;/P&gt;&lt;B&gt;What did the report conclude?&lt;/B&gt; 
&lt;P&gt;Professor Banerjee concluded, “The current level of use of antipsychotics for people with dementia presents a significant issue in terms of quality of care, with negative impacts in patient safety, clinical effectiveness and the patient experience.”&lt;/P&gt;
&lt;P&gt;He says that antipsychotic drugs appear to be used too frequently in dementia and that the potential benefits are likely to be outweighed by the risks. He suggests that this is a worldwide problem, but that actions can be taken to address it.&lt;/P&gt;&lt;B&gt;What recommendations does the review make?&lt;/B&gt; 
&lt;P&gt;The report makes 11 recommendations that aim to reduce the use of antipsychotics to a level where the benefits outweigh the risks. Professor Banerjee estimated that antipsychotic use could be reduced to a third of its current level, and that this could be done safely over 36 months.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/Antipsychotic-use-in-dementia.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_108302.pdf" target="_blank"&gt;The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services by Professor Sube Banerjee.&lt;/A&gt;&amp;nbsp;Department of Health 2009 (PDF)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_108363.pdf" target="_blank"&gt;Government response to the report:&lt;/A&gt;&amp;nbsp;November 12 2009 (PDF)&lt;/P&gt;
&lt;P&gt;Alzheimer’s Society response: &lt;A href="http://www.alzheimers.org.uk/site/scripts/news_article.php?newsID=570" target="_blank"&gt;Review calls for action on dangerous use of antipsychotic drugs for dementia&lt;/A&gt;, 12 November 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288742</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/04April/Pages/AntipsychoticsandAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Antipsychotics and Alzheimer's</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ballard C, Lana MM, Theodoulou M, et al. &lt;A title="A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)." href="http://medicine.plosjournals.org/perlserv/?request=get-document&amp;amp;doi=10.1371/journal.pmed.0050076" target="_blank"&gt;A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial).&lt;/A&gt; PLoS Medicine 2008; Apr 1&lt;/P&gt;
&lt;P&gt;Ballard C, Waite J, Birks J. &lt;A title="Atypical antipsychotics for aggression and psychosis in Alzheimer's disease." href="http://www.cochrane.org/reviews/en/ab003476.html" target="_blank"&gt;Atypical antipsychotics for aggression and psychosis in Alzheimer's disease.&lt;/A&gt; Cochrane Database&amp;nbsp;Syst Rev 2006, Issue 1&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>309173</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/08August/Pages/Antipsychoticsandstrokerisk.aspx]]&gt;</url>
    <title>behind the headlines - Antipsychotics and stroke risk</title>
    <publicationDate>2008-08-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,STROKE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Douglas IJ, Smeeth L. &lt;A title="Exposure to antipsychotics and risk of stroke: self controlled case series study." href="http://www.bmj.com/cgi/content/abstract/337/aug28_2/a1227" target="_blank"&gt;Exposure to antipsychotics and risk of stroke: self controlled case series study.&lt;/A&gt; &lt;EM&gt;BMJ &lt;/EM&gt;2008; 337:a1227&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>386836</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/arthritis-protein-blocks-alzheimers-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Arthritis may block Alzheimer's</title>
    <publicationDate>2010-09-23T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A protein produced in arthritis may “protect against the development of Alzheimer's disease,” reported BBC News. US research on mice has discovered that a protein called GM-CSF, produced in rheumatoid arthritis, may trigger the immune system to destroy the protein plaques found in Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;This research used mice that had been genetically engineered to have a condition similar to Alzheimer’s. It found that these mice performed better in tests of memory and learning after they had been given a GM-CSF injection for 20 days. The protein also helped normal mice to improve their performance in the tests. After the injections, the mouse brains also contained increased levels of microglial cells, types of cells that engulf debris and foreign organisms. It is possible that these&amp;nbsp; microglial cells could combat the build-up of amyloid proteins that characterise Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;The findings help to further the understanding of how rheumatoid disease may offer some protection against the development of Alzheimer’s. However, it remains to be seen whether this research could be a first step towards investigating GM-CSF as a potential treatment, which will now need further testing.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This valuable scientific research has furthered the understanding of how the GM-CSF protein, which is increased in rheumatoid arthritis, could give some protection against Alzheimer’s disease. As the researchers suggest, it is possible that GM-CSF acts by “recruiting” microglia to the brain, which then attack the characteristic amyloid plaques of Alzheimer's.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/08August/Pages/arthritis-protein-blocks-alzheimers-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;Boyd TD, Bennett SP, Mori T et al. (2010) &lt;A href="http://iospress.metapress.com/content/g253421750l20571" target="_blank"&gt;GM-CSF Upregulated in Rheumatoid Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer Mice&lt;/A&gt;. &lt;EM&gt;Journal of Alzheimer's Disease&lt;/EM&gt;, published online June 16 2010 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388818</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/high-dose-aspirin-headache-migraine.aspx]]&gt;</url>
    <title>Behind the headlines - Aspirin for severe headaches</title>
    <publicationDate>2010-09-28T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A jab made from liquid aspirin could be a powerful new treatment for migraine,” reported the Daily Mail. According to the newspaper, research has found that injections containing one gram of aspirin reduced pain in people hospitalised for headache.&lt;/P&gt;
&lt;P&gt;This study reported the experience of researchers from a specialist neurological hospital where intravenous (IV) injection of aspirin was used to treat 168 people who were admitted with severe daily headaches. Most of these people’s headaches appeared to be related to overuse of other types of pain-relief medication. Treatment with IV aspirin was reported to reduce pain by those patients who kept a pain diary, although the study did not formally compare these patients to people who were not receiving the IV treatment. Also, only half the patients in the study kept a written pain diary, which prevents firm conclusions about the effectiveness of IV aspirin.&lt;/P&gt;
&lt;P&gt;This study indicates that IV aspirin may show promise for the treatment of severe medication-overuse headache. However, to confirm these findings, it will take robust trials to formally compare IV aspirin to other drugs or no treatment. Even if this injected treatment is proven to be effective for this purpose, it is unlikely to be used outside hospital.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This study reported one hospital’s experience of using IV aspirin to treat people hospitalised for severe daily headache, mainly medication-withdrawal headache. This study gives some indication that the treatment can be safe and that people experienced some pain relief. However, there are a number of points to note and these are detailed in the &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/high-dose-aspirin-headache-migraine.aspx" target="_blank"&gt;NHS Choices&amp;nbsp;commentary&lt;/A&gt; on this news item.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Weatherall MW, Telzerow AJ, Cittadini E et al. Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache. NEUROLOGY 2010;75:1098-1103&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>346846</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/Awareness-in-vegetative-patients.aspx]]&gt;</url>
    <title>Behind the headlines - Awareness in vegetative patients</title>
    <publicationDate>2010-02-04T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,MARCH 2010,COMA &amp; BRAIN DEATH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"A man who was presumed to be in a vegetative state for five years has answered questions using his thoughts alone", reported &lt;EM&gt;The Times&lt;/EM&gt;. It said the research could allow some patients who are “locked in” by brain injuries to communicate.&lt;/P&gt;
&lt;P&gt;The news is based on a three-year study in 54 patients in a vegetative or minimally conscious state. The patients’ brains were scanned with a technique called functional magnetic resonance imaging (fMRI) to detect signs of awareness. In one man, previously thought to be in a persistent vegetative state, the researchers were able to elicit the correct responses to five out of six questions.&lt;/P&gt;
&lt;P&gt;These results confirm that some patients who meet the current criteria for being in a vegetative state are diagnosed incorrectly and retain thinking and awareness. It should be highlighted that this occurred in only one of the patients tested, and it is unknown how many people are likely to be in the same state.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These results suggest that some patients, who meet the current criteria for being in a vegetative state, are diagnosed incorrectly and retain thinking and awareness. False-negative (misdiagnoses due to a test being negative when someone has a condition) and false-positive results (misdiagnoses due to a test being positive when someone does not have a condition) are possible with any test. Combining tests can improve their accuracy and it is possible that the combination of bedside tests and fMRI scans would provide improved diagnostic accuracy.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/02February/Pages/Awareness-in-vegetative-patients.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Mont MM, Vanhaudenhuyse A, Coleman MR, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://content.nejm.org/cgi/content/full/NEJMoa0905370" target="_blank"&gt;Willful Modulation of Brain Activity in Disorders of Consciousness.&lt;/A&gt; &lt;EM&gt;New England Journal of Medicine&lt;/EM&gt;, February 3 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>313159</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/Backpaintestaidsdiagnosis.aspx]]&gt;</url>
    <title>Behind the headlines - Back pain test 'aids diagnosis'</title>
    <publicationDate>2009-04-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ OTHER NEUROPATHIC PAIN,RECENT ADDITIONS,HEADACHE &amp; PAIN,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Scholz J, Mannion RJ, Hord DE, et al.&amp;nbsp;&lt;A href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000047;jsessionid=5F695B0E7FAFB591C30B9CF2733E7A7C" target="_blank"&gt;A Novel Tool for the Assessment of Pain: Validation in Low Back Pain.&lt;/A&gt; PloS 2009&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>304860</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/11November/Pages/Dementiaandheavydrinking.aspx]]&gt;</url>
    <title>Behind the headlines - Binge drinkers' dementia risk</title>
    <publicationDate>2008-11-03T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Gupta S, and Warner J. &lt;A title="Alcohol-related dementia: a 21st-century silent epidemic?" href="http://bjp.rcpsych.org/cgi/content/abstract/193/5/351" target="_blank"&gt;Alcohol-related dementia: a 21st-century silent epidemic?&lt;/A&gt; The British Journal of Psychiatry 2008; 193: 351-353&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>380400</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/Binge-drinking-teens-risk-brain-damage.aspx]]&gt;</url>
    <title>Behind the headlines - Bingeing teens 'risk brain damage'</title>
    <publicationDate>2010-06-03T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ENVIRONMENTAL &amp; TOXIC,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,JULY 2010,RECREATIONAL,DRUGS &amp; ALCOHOL]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Binge-drinking teenagers could be doing lasting harm to their memories,” The Daily Telegraph has reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Binge-drinking teenagers could be doing lasting harm to their memories,” The Daily Telegraph has reported.&lt;/P&gt;
&lt;P&gt;The story is based on research on the effects of heavy alcohol consumption on the brains of seven rhesus macaque monkeys. It found that heavy alcohol use had a dramatic effect on the normal division of cells in the hippocampus, part of the brain involved in long-term memory. The researchers say this suggests that lasting damage to the brain may happen relatively early, preceding and possibly causing the neurological problems associated with alcoholism in adults.&lt;/P&gt;
&lt;P&gt;Only limited conclusions can be drawn from a study in seven monkeys. A key question is whether excessive drinking during adolescence has not only short-term effects on the brain, but also induces permanent damage. As these monkeys were only followed up for another two months after drinking stopped, the permanence of the damage would need to be established in longer-term studies.&lt;/P&gt;
&lt;P&gt;However, binge drinking is damaging at all ages and has a variety of health consequences. There is widespread concern about the possible long-term effects of excessive alcohol on adolescent development. This type of study makes a useful contribution.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a carefully designed animal study, which looked in detail at the effects of alcohol on the brains of adolescent rhesus monkeys. The fact that it used adolescent primates rather than adult rats or mice makes the results more relevant to humans. It also used a control group for comparison of brain changes. The results suggest that chronic alcohol consumption may alter the process of brain development in adolescents.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/Binge-drinking-teens-risk-brain-damage.aspx" target="_blank"&gt;NHS Choices commentary &lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Taffe MA, Kotzebue RW, Crean Rd, et al. Long-lasting reduction in hippocampal neurogenesis by alcohol consumption in adolescent nonhuman primates. PNAS 2010; Published online June 1&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309462</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/12December/Pages/Blindsight.aspx]]&gt;</url>
    <title>Behind the headlines - 'Blindsight' phenomenon</title>
    <publicationDate>2008-12-23T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,STROKE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;de Gelder B,&amp;nbsp; Tamietto M, van Boxtel G, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Intact navigation skills after bilateral loss of striate cortex." href="http://www.cell.com/current-biology/abstract/S0960-9822(08)01433-4" target="_blank"&gt;Intact navigation skills after bilateral loss of striate cortex.&lt;/A&gt; &lt;EM&gt;Current Biology 2008&lt;/EM&gt;; 18: R1128-R1129, 23 December 2008&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>346105</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Blood-pressure-drugs-and-dementia.aspx]]&gt;</url>
    <title>Behind the headlines - Blood pressure drugs and dementia</title>
    <publicationDate>2010-01-18T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,LATER LIFE,DEMENTIA,CAUSES AND PREVENTION,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Millions of older people who take drugs for high blood pressure or heart problems can more than halve their risk of developing Alzheimer's disease and dementia,” The Guardian reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Millions of older people who take drugs for high blood pressure or heart problems can more than halve their risk of developing Alzheimer's disease and dementia,” &lt;EM&gt;The Guardian&lt;/EM&gt; reported.&lt;/P&gt;
&lt;P&gt;This large study assessed 800,000 people taking blood pressure drugs&amp;nbsp;over a five-year period. People taking angiotensin receptor blockers (ARBs) were 25% less likely to be diagnosed with dementia compared to those on other blood pressure drugs.&lt;/P&gt;
&lt;P&gt;The suggestion that this blood pressure drug might prevent dementia has important implications. However, the study has some limitations, including the fact that the people taking ARBs were less likely to have vascular disease and more likely to have diabetes than people on the other drugs.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large and well-conducted study adds weight to the plausible theory that angiotensin receptor blockers can reduce the risk of Alzheimer’s disease and vascular dementia. However, it is too soon to start using these drugs in a targeted attempt at preventing or slowing dementia.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Blood-pressure-drugs-and-dementia.aspx" target="_blank"&gt;NHS Choices commentary&amp;nbsp;&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;N-C Li, Lee A, Whitmer RA, et al. &lt;A href="http://www.bmj.com/cgi/content/full/340/jan12_1/b5465" target="_blank"&gt;Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis&lt;/A&gt;.&amp;nbsp;&lt;EM&gt;BMJ&lt;/EM&gt; 2010; 340: b5465&lt;/P&gt;
&lt;P&gt;Editorials&lt;BR&gt;Maxwell CJ, Hogan DB.&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/extract/340/jan12_1/b5409?q=w_latest_topic" target="_blank"&gt;Antihypertensive agents and prevention of dementia&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt; 2010; 340: b5409&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>323200</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/BlueDyeSpineDamage.aspx]]&gt;</url>
    <title>Behind the headlines - Blue dye cuts spinal damage</title>
    <publicationDate>2009-07-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SPINAL INJURY,RECENT ADDITIONS,TRAUMA,NEUROLOGICAL CONDITIONS,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Times today reports that a blue food dye “may help cure spinal injuries but will turn patients blue”. The food dye, called Brilliant Blue G (BBG), is “similar to the one used in blue M&amp;Ms and liquorice allsorts”.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Times today reports that a blue food dye “may help cure spinal injuries but will turn patients blue”. The food dye, called Brilliant Blue G (BBG), is “similar to the one used in blue M&amp;amp;Ms and liquorice allsorts”.&lt;/P&gt;
&lt;P&gt;Researchers report that they injected rats with BBG or water 15 minutes after they received a spinal injury. After 42 days none of the rats injected with water could walk, but the best-performing BBG rats were able to co-ordinate their front and back legs enough to support their weight and walk. A side effect of the treatment was that the rats’ skin turned blue for a week.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This animal study has identified some benefits of the dye BBG when injected shortly after spinal cord injury in rats. Although some of the BBG rats were able to make consistent weight-bearing steps, it was unclear exactly what proportion of the rats was able to do this.&lt;/P&gt;
&lt;P&gt;While any research into potential treatments for spinal cord injuries is of great interest, more research into BBG is required. This would initially require further animal research to determine the long-term effectiveness and safety of BBG, both by itself and in combination with other treatments.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/07July/Pages/BlueDyeSpineDamage.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Peng W, Cotrina ML, Han X &lt;EM&gt;et al.&lt;/EM&gt;&amp;nbsp;&lt;A href="http://www.pnas.org/content/early/2009/07/24/0902531106.abstract" target="_blank"&gt;Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury&lt;/A&gt;. &lt;EM&gt;PNAS&lt;/EM&gt;, [Early online publication] July 28 2009 &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.pnas.org/content/early/2009/07/24/0902531106/suppl/DCSupplemental" target="_blank"&gt;Supporting material&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>377511</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/beer-belly-alzheimers-fat-risk.aspx]]&gt;</url>
    <title>Behind the headlines - Body fat 'linked to Alzheimer's'</title>
    <publicationDate>2010-05-24T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ALZHEIMER'S DISEASE,DEMENTIA,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Having a “pot belly” in middle age raises the risk of Alzheimer’s disease and dementia later in life, according to the Daily Mail.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Having a “pot belly” in middle age raises the risk of Alzheimer’s disease and dementia later in life, according to the Daily Mail.&lt;/P&gt;
&lt;P&gt;The news is based on research into whether total brain volume was associated with measurements such as body mass index (BMI), waist size, fat under the skin and fat around the organs. As part of the study, several hundred middle-aged participants had their body fat and brains scanned. The results suggested that a larger waist and more fat surrounding the organs were both associated with decreased brain volume. However, this early research did not examine whether any participants went on to develop Alzheimer’s or dementia. &lt;/P&gt;
&lt;P&gt;This was preliminary research and the implications of these findings are currently unclear, although they should not be seen as evidence that body fat causes Alzheimer’s disease. Further research is needed to further investigate how body fat may affect the brain with age.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study showed that decreased brain volume was associated with higher BMI, waist-to-hip ratio, visceral fat level and subcutaneous fat level in participants aged on average 60 to 67 years. Although this study followed a relatively large group of participants, which is a strength, there are a few limitations that should be taken into account.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/05May/Pages/beer-belly-alzheimers-fat-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Debette S, Beiser A, Hoffmann U &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www3.interscience.wiley.com/journal/123451643/abstract" target="_blank"&gt;Visceral fat is associated with lower brain volume in healthy middle-aged adults&lt;/A&gt;. &lt;EM&gt;Annals of Neurology&lt;/EM&gt; [Early View] Published Online: 20 May 2010.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334391</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Body-shape-and-dementia.aspx]]&gt;</url>
    <title>Behind the headlines - Body shape and dementia</title>
    <publicationDate>2009-11-26T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,DECEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Apple-shaped women face a doubled risk of dementia, according to the Daily Mail.&lt;/P&gt;
&lt;P&gt;This news is based on Swedish research that measured the physical dimensions of 1,500 women and followed them for an average of 32 years. Those women with an “apple shape” (broader in the middle than the hips) faced an increased risk of dementia if they lived beyond 70 years. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-designed study was reported accurately by researchers and news sources. It ran over a long period of time with careful follow-up and measurements. However, only one of the “adiposity” (relating to fat) measurements that the researchers looked at was significant, which suggests that the findings should be treated cautiously. In addition, as the single positive finding was only just statistically significant, it may have occurred by chance alone. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/11November/Pages/Body-shape-and-dementia.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Gustafson DR, Bäckman K, Waern M &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.neurology.org/cgi/content/abstract/73/19/1559" target="_blank"&gt;Adiposity indicators and dementia over 32 years in Sweden.&lt;/A&gt; &lt;EM&gt;Neurology&lt;/EM&gt; 2009; 73: 1559-1566&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>313153</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/AspirinBrainBleeding.aspx]]&gt;</url>
    <title>Behind the headlines - Brain bleeding 'caused by aspirin'</title>
    <publicationDate>2009-04-15T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,STROKE,HAEMORRHAGIC,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Vernooij MW, Haag MDM, van der Lugt A &lt;EM&gt;et al.&lt;/EM&gt;&amp;nbsp;&lt;A href="http://archneur.ama-assn.org/cgi/content/full/2009.42v1?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=aspirin&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=date&amp;amp;resourcetype=HWCIT" target="_blank"&gt;Use of Antithrombotic Drugs and the Presence of Cerebral Microbleeds: The Rotterdam Scan Study.&lt;/A&gt; &lt;EM&gt;Arch Neurol,&lt;/EM&gt;&amp;nbsp;Apr 2009&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>377510</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/Mobile-phones-and-brain-cancer.aspx]]&gt;</url>
    <title>Behind the headlines - Brain cancer not linked to phones</title>
    <publicationDate>2010-05-17T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,PRIMARY BRAIN TUMOURS,NEURO-ONCOLOGY,JUNE 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Half an hour of mobile use a day ‘increases brain cancer risk’”, The Daily Telegraph has claimed. It says a landmark study into the health risks of mobile use has found that 30 minutes a day over 10 years increases the risk of tumours.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Half an hour of mobile use a day ‘increases brain cancer risk’”,&lt;EM&gt; The Daily Telegraph&lt;/EM&gt; has claimed. It says a landmark study into the health risks of mobile use has found that 30 minutes a day over 10 years increases the risk of tumours.&lt;/P&gt;
&lt;P&gt;The research in question was a well-conducted analysis of several international studies that actually found no plausible evidence of a link between cancer and mobile phone use. Some newspapers have selectively quoted a few results in this research that suggest a significant link, but this is misleading in the context of the overall results. The researchers themselves explain these few anomalous results, and conclude that there are no conclusive signs of an increased risk of brain tumours.&lt;/P&gt;
&lt;P&gt;Overall, this study does not provide evidence that mobile phones cause cancer, a finding echoed by the majority of studies on the matter, although sadly not by most newspapers.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has not found conclusive evidence to support a link between mobile phone use and brain tumours. According to the researchers, it is the biggest case-control study on the subject to date, making the findings particularly important.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/05May/Pages/Mobile-phones-and-brain-cancer.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The INTERPHONE Study Group. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case–control study. &lt;EM&gt;International Journal of Epidemiology&lt;/EM&gt; 2010.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309183</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Brainfunctionandtea.aspx]]&gt;</url>
    <title>Behind the headlines - Brain function and tea</title>
    <publicationDate>2008-07-18T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ng T-P, Feng L, Niti M, et al. &lt;A title="Tea consumption and cognitive impairment and decline in older Chinese adults." href="http://www.ajcn.org/cgi/content/abstract/88/1/224" target="_blank"&gt;Tea consumption and cognitive impairment and decline in older Chinese adults.&lt;/A&gt; Am J Clin Nutr; 88: 224-231&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323197</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/NeurologicalSwineFluEffectOnChildren.aspx]]&gt;</url>
    <title>Behind the headlines - Brain problems from swine flu</title>
    <publicationDate>2009-07-24T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INFECTIONS,VIRAL INFECTIONS,COMPLICATING MEDICAL DISORDERS,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Center for Disease Control in the US has published the first report on brain complications from swine flu in children, based on case studies from Texas. Although these complications have been previously described in association with infections from seasonal flu, they have not yet been described in relation to the influenza A (H1N1) virus, swine flu.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The Center for Disease Control in the US has published the first report on brain complications from swine flu in children, based on case studies from Texas. Although these complications have been previously described in association with infections from seasonal flu, they have not yet been described in relation to the influenza A (H1N1) virus, swine flu. &lt;/P&gt;
&lt;P&gt;This case series of four Dallas patients aged 7-17 years gives details of the symptoms and testing of the individuals who had neurological complications such as brain inflammation and seizures. All four patients were treated with antiviral therapies and recovered fully without any long-term brain damage.&lt;/P&gt;
&lt;P&gt;The information shared through such reports is valuable for clinicians across the globe, helping build a profile of the behaviour of this new disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The researchers have concluded that "these findings indicate that, as with seasonal influenza, neurologic complications can occur after respiratory tract infection with novel influenza A (H1N1) virus". &lt;/P&gt;
&lt;P&gt;It is important to note that this was a selected group of children and the overall rate for this complication may not be representative of what could be at present in the US or even in the UK. However, the rate of this complication seems high. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/07July/Pages/NeurologicalSwineFluEffectOnChildren.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5828a2.htm?s_cid=mm5828a2_e" target="_blank"&gt;Neurologic Complications Associated with Novel Influenza A (H1N1) Virus Infection in Children&lt;/A&gt;. Center for Disease Control, July 24 2009.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>298501</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/11November/Pages/Breastcancerandmigraine.aspx]]&gt;</url>
    <title>Behind the headlines - Breast cancer migraine link</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Summary: &lt;/STRONG&gt;“Women who suffer migraines are less likely to get breast cancer" says&amp;nbsp;&lt;EM&gt;The Mirror. &lt;/EM&gt;It reported that women who suffer migraines are 30% less likely to get breast cancer compared with women who don't.&lt;/P&gt; &lt;P&gt;The news story was based on US research that looked at the medical histories of over 3,000 women, and put forward the idea that both breast cancer and migraine were linked to changing hormone levels.&lt;/P&gt; &lt;P&gt;This study combined data from two previous observational studies. It is unable to show for sure whether or not breast cancer development in individual women can be directly affected by the frequency of migraine or by treatments for migraine. Further research will be needed to investigate this association, and to determine whether hormone variations are to blame.&lt;/P&gt; &lt;P&gt;&lt;STRONG&gt;About 'Behind the headlines'&lt;/STRONG&gt;: 'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt; &lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt; &lt;UL&gt; &lt;LI&gt;Where did the story come from? &lt;LI&gt;What kind of scientific study was this? &lt;LI&gt;What were the results of the study? &lt;LI&gt;What interpretations did the researchers draw from these results? &lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt; &lt;P&gt;Mathes RW, Malone KE, Daling JR, et al. &lt;A title="Migraine in Postmenopausal Women and the Risk of Invasive Breast Cancer." href="http://cebp.aacrjournals.org/cgi/content/abstract/17/11/3116" target="_blank"&gt;Migraine in Postmenopausal Women and the Risk of Invasive Breast Cancer.&lt;/A&gt; Cancer Epidemiol Biomarkers Prev 2008; 17: 3116-3122&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>308719</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/Doesadoodlehelpthenoodle.aspx]]&gt;</url>
    <title>Behind the headlines - Can a doodle help the noodle?</title>
    <publicationDate>2009-02-27T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Jackie Andrade. &lt;A title="What does doodling do?" href="http://www3.interscience.wiley.com/journal/122205124/abstract" target="_blank"&gt;What does doodling do?&lt;/A&gt; Applied Cognitive Psychology 2009; Published Online: 27 Feb 2009&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309133</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/Ginkgoandstrokeprevention.aspx]]&gt;</url>
    <title>Behind the headlines - Can ginkgo protect you from strokes?</title>
    <publicationDate>2008-10-10T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Saleem S, Zhuang H; Biswal S, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="" href="http://stroke.ahajournals.org/cgi/content/abstract/STROKEAHA.108.523480v1?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=ginkgo&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;resourcetype=HWCIT" target="_blank"&gt;Biloba Extract Neuroprotective Action Is Dependent on Heme Oxygenase 1 in Ischemic Reperfusion Brain Injury&lt;/A&gt;&lt;BR&gt;Stroke 2008; Oct 09 published online before print&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>288109</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/05May/Pages/Canlimblengthaffectdementiarisk.aspx]]&gt;</url>
    <title>Behind the headlines - Can limb length affect dementia risk?</title>
    <publicationDate>2008-05-06T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Huang TL, Carlson MC, Fitzpatrick Al, &lt;EM&gt;et al.&lt;/EM&gt; &lt;A title="Knee height and arm span: A reflection of early life environment and risk of dementia." href="http://www.neurology.org/cgi/content/abstract/70/19_Part_2/1818" target="_blank"&gt;Knee height and arm span: A reflection of early life environment and risk of dementia.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; 70:1818-1826 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>380382</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/alzheimers-disease-magnet-therapy.aspx]]&gt;</url>
    <title>Behind the headlines - Can magnets ease Alzheimer's?</title>
    <publicationDate>2010-06-24T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>"Applying magnets to the brains of Alzheimer's disease sufferers helps them understand what is said to them”, The Independent has claimed.

The news is based on a small trial of an experimental magnetic therapy called rTMS, which some believe can reorganise brain cells and improve neurological functions.
</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Applying magnets to the brains of Alzheimer's disease sufferers helps them understand what is said to them”, The Independent has claimed.&lt;/P&gt;
&lt;P&gt;The news is based on a small trial of an experimental magnetic therapy called rTMS, which some believe can reorganise brain cells and improve neurological functions. &lt;/P&gt;
&lt;P&gt;Over four weeks, five patients were given rTMS and five were given two weeks of sham treatment followed by two weeks of real rTMS. The rTMS was applied to the area of the brain known to be involved in speech and communication, which are often impaired during Alzheimer’s disease. After two weeks, those treated solely with rTMS showed improvements in sentence comprehension. Those receiving the sham treatment did not improve. The sham group then improved a similar amount after two weeks of real rTMS.&lt;/P&gt;
&lt;P&gt;Unfortunately, the technique did not improve other important language abilities, such as talking, cognitive function or memory. Equally, the design of this small study means that it cannot inform us about the long-term effects or potential harms from rTMS. While the use of rTMS in dementia will be of interest to neuroscientists, it should be seen as an experimental technique until larger, longer-term studies can evaluate it further.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;BR&gt;This is a very small study, which has shown a short-term effect of an experimental technique that delivers repetitive strong magnetic fields to the brain. These researchers have identified some short-term benefits in some people from their new treatment: however, before the headlines and the researchers’ own conclusions can be justified, more research will need to be conducted, preferably through larger, longer placebo controlled studies.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/alzheimers-disease-magnet-therapy.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Cotelli M, Calabria M, Manenti R &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://jnnp.bmj.com/content/early/2010/06/11/jnnp.2009.197848.abstract?sid=" target="_blank"&gt;Improved language performance in Alzheimer disease following brain stimulation&lt;/A&gt;. &lt;EM&gt;Journal of Neurology, Neuroscience and Psychiatry&lt;/EM&gt;: [Published Online First] 23 June 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334411</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/new-mobile-phone-alzheimers-claim.aspx]]&gt;</url>
    <title>Behind the headlines - Can mobile phones halt Alzheimer's?</title>
    <publicationDate>2010-01-07T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,CONDITIONS,JANUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Mobile phone radiation ‘protects’ against Alzheimer’s,” the BBC has reported. &lt;/P&gt;
&lt;P&gt;This story is based on research that looked at the effects of exposing genetically modified mice to the same frequency of electromagnetic field that is generated by mobile phones. These genetically modified mice were created to have some characteristics of Alzheimer’s disease. This allowed the researchers to explore whether the electromagnetic field could alter the biological processes behind an Alzheimer’s-style condition.&lt;/P&gt;
&lt;P&gt;However, this was a small animal study and its direct relevance to mobile phone use in humans is limited. It does not provide sufficient evidence to suggest that mobile phones can protect against or cure Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was an animal study looking at the effect of EMF on memory and Alzheimer’s-like brain changes. However, its direct relevance to humans is limited. The researchers themselves highlight the fact that the genetically modified mice they used do not recapitulate all aspects of Alzheimer’s disease in humans, such as the accompanying death of nerve cells.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/new-mobile-phone-alzheimers-claim.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Arendash GW, Sanchez-Ramosc J, Morie T et al. &lt;A href="http://iospress.metapress.com/content/d6r1371722422hg2/?p=b3c01a1cb2ff484caa05581e1aaee7cc&amp;amp;pi=0" target="_blank"&gt;Electromagnetic Field Treatment Protects Against and Reverses Cognitive Impairment in Alzheimer’s Disease Mice&lt;/A&gt;. &lt;EM&gt;Journal of Alzheimer's Disease&lt;/EM&gt;.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>386847</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/cannabis-and-chronic-nerve-pain.aspx]]&gt;</url>
    <title>Behind the headlines - Cannabis for nerve pain studied</title>
    <publicationDate>2010-08-31T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,OTHER NEUROPATHIC PAIN,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Smoking cannabis from a pipe can significantly reduce chronic pain in patients with damaged nerves,” reported the BBC. It added that improvements in sleep and anxiety were seen.&lt;/P&gt;
&lt;P&gt;This news story is based on a small randomised controlled trial in 23 people, which found that a low dose of inhaled cannabis (lower than that needed to cause euphoria or a “high”) modestly improved reported pain in patients who had neuropathic pain.&lt;/P&gt;
&lt;P&gt;This is a well-conducted study, but its small size means that it is not possible to tell whether the results demonstrate a real association between cannabis and pain relief, or if they are due to chance.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This placebo-controlled trial found that cannabis containing 9.4% THC could reduce neuropathic pain compared to the placebo. However, this was a small trial with only 23 participants, so it is difficult to tell whether these results demonstrate a real association, or if they are due to chance. A much larger trial would be needed for a longer period to assess the long-term outcomes of such a treatment. Additionally, there are health concerns related to the use of smoked cannabis, including mental health problems and lung damage. Further research is needed to assess such potential side effects over the long term.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/cannabis-and-chronic-nerve-pain.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ware MA, Wang T, Shapiro S &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.cmaj.ca/cgi/content/abstract/cmaj.091414v1" target="_blank"&gt;Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.&lt;/A&gt; &lt;EM&gt;Canadian Medical Association Journal&lt;/EM&gt; 2010, Published online ahead of print August 30&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334395</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/brain-eating-cannibals-CJD-mad-cow-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Cannibalism clue to brain disease</title>
    <publicationDate>2009-11-20T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,INFECTIONS,CREUTZFELDT-JAKOB (CJD) DISEASE,PRION DISEASE,DECEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Research on a “brain-eating tribe” may hold the key to understanding and even treating mad cow disease, according to The Daily Telegraph.&lt;/P&gt;
&lt;P&gt;A genetic study of the Fore tribe of Papua New Guinea has shown that certain members have genetic mutations that protect them from a disease called kuru, which can be contracted by eating prion proteins in brain matter. The disease, which kills tribe members who do not have the mutation, is similar to Creutzfeldt–Jakob disease (CJD), which is sometimes wrongly referred to as "mad cow disease".&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has shown that variations in two particular regions of the gene that codes for the prion protein are more common in those people who were exposed to the kuru disease but who had not become infected. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/11November/Pages/brain-eating-cannibals-CJD-mad-cow-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Mead S, Whitfield J, Poulter M &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://content.nejm.org/cgi/content/abstract/361/21/2056" target="_blank"&gt;A novel protective prion protein variant that colocalizes with kuru exposure&lt;/A&gt;. &lt;EM&gt;NEJM,&lt;/EM&gt; Volume 361:2056-2065&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>346828</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/care-for-baby-brain-bleeds-improved.aspx]]&gt;</url>
    <title>Behind the headlines - Care for baby brain bleeds</title>
    <publicationDate>2010-03-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STRUCTURAL,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A technique that ‘washes out’ the brains of severely ill premature babies may aid survival,” says the BBC. The article says that the treatment, called DRIFT (drainage, irrigation and fibrinolytic therapy), could help around 100 babies&amp;nbsp;per year.&lt;/P&gt;
&lt;P&gt;The research behind the news looked at whether DRIFT could reduce the risk of death and disability in premature infants that had a type of bleeding that enlarged the fluid-filled spaces in the centre of the brain. This condition is very serious and can lead to death or severe disabilities such as cerebral palsy. Although DRIFT was associated with more secondary bleeding than standard care, subsequent follow-up showed that DRIFT reduced the proportion of infants that died or had severe disabilities by the age of two. The researchers suggest that modifications to the DRIFT process used in the trial could reduce the risk of second bleeds.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This small study suggests that, compared to standard care, DRIFT reduces the risk of the combined outcome of death or severe disability in premature infants with enlargement of the ventricles in the brain due to bleeding. There are a number of points to note - see the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/03March/Pages/care-for-baby-brain-bleeds-improved.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Whitelaw A, Jary S, Kmita G &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://pediatrics.aappublications.org/cgi/content/abstract/peds.2009-1960v1?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=Pople&amp;amp;searchid=" target="_blank"&gt;Randomized Trial of Drainage, Irrigation and Fibrinolytic Therapy for Premature Infants with Posthemorrhagic Ventricular Filatation: Developmental Outcome at 2 years&lt;/A&gt;. &lt;I&gt;Pediatrics&lt;/I&gt;; published online March 8 2010 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288753</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2007/January08/Pages/Carryonscratching.aspx]]&gt;</url>
    <title>Behind the headlines - Carry on scratching</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MAGNETIC RESONANCE IMAGING (MRI),INVESTIGATION &amp; DIAGNOSTICS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Yosipovitch G, Ishiuji Y, Patel TS, et al. &lt;A title="The Brain Processing of Scratching." href="http://www.nature.com/jid/journal/vaop/ncurrent/abs/jid20083a.html" target="_blank"&gt;The Brain Processing of Scratching.&lt;/A&gt; Journal of Investigative Dermatology 2008 Jan 31[Epub ahead of print]&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>322115</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/EpilepticSeizureGene.aspx]]&gt;</url>
    <title>Behind the Headlines - Cause of epilepsy explored</title>
    <publicationDate>2009-08-04T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Fixing a faulty gene “may cure epilepsy”, according to The Independent. The newspaper said that “epilepsy sufferers have been given fresh hope that a cure may be found after scientists prevented the condition being passed on to mice offspring”. 
</description>
    <body>&lt;![CDATA[ &lt;P&gt;Fixing a faulty gene “may cure epilepsy”, according to The Independent. The newspaper said that “epilepsy sufferers have been given fresh hope that a cure may be found after scientists prevented the condition being passed on to mice offspring”. &lt;/P&gt;
&lt;P&gt;This report is based on a study looking at a mutant strain of mice that are prone to seizures. Scientists found that the mutations that caused these seizures were in a particular gene that contains instructions for making a protein that helps to maintain the sodium and potassium balance in the cell. The researchers found that introducing an extra working copy of the gene into mice carrying the mutant gene prevented seizures from occurring.&lt;/P&gt;
&lt;P&gt;This type of research helps to improve our understanding of the biology of seizures and identify genes that could be mutated in human forms of epilepsy. It also identifies potential targets for drug therapy. However, it is not yet clear whether mutations in the gene identified play a role in human epilepsy. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has identified a gene that when mutated can cause seizures in mice. This type of research is important as it helps to improve our understanding of the biology of seizures and identify mutant genes that could present in humans with epilepsy. The genes and the proteins they produce could be potential targets for drug therapy.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/08August/Pages/EpilepticSeizureGene.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Clapcote SJ, Duffy S, Xie G &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.pnas.org/content/early/2009/07/30/0904817106.abstract?sid=0cc98442-cd2e-4736-9111-5a2d3da43849" target="_blank"&gt;Mutation I810N in the a3 isoform of Na+,K+-ATPase causes impairments in the sodium pump and hyperexcitability in the CNS&lt;/A&gt;. PNAS [Published online before print] August 3, 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>393837</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/cerebral-palsy-in-ivf-babies-studied.aspx]]&gt;</url>
    <title>Behind the headlines - Cerebral palsy after IVF studied</title>
    <publicationDate>2010-11-03T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STRUCTURAL,CEREBRAL PALSY,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has reported that “IVF could double the risk of cerebral palsy”. The newspaper also said “IVF itself could increase the risk rather than it being a consequence of the parents’ impaired fertility”.&lt;/P&gt;
&lt;P&gt;The news is based on Danish research that looked for possible links between time taken to conceive, the use of IVF and the risk of cerebral palsy. The results showed the risk of cerebral palsy bore no relation to the length of time taken to conceive but that there was approximately a two-fold increase in the risk of cerebral palsy in children born following IVF. However, when the researchers excluded twin and triplets and only looked at single births there was no increased risk associated with IVF.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This large cohort study looked at whether there was an association between time needed to conceive, the use of IVF and ICSI and the risk of cerebral palsy.&lt;/P&gt;
&lt;P&gt;The researchers adjusted the data to take into account other factors (such as age) that are known to be associated with cerebral palsy, which adds strength to the study. The incidence rates of cerebral palsy in Denmark were low (around 0.18% of births) and although the researchers found there was an increased association between IVF and ICSI and cerebral palsy, there are a few limitations to this study that the researchers highlight.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/11November/Pages/cerebral-palsy-in-ivf-babies-studied.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Liang Zhu J, Hvidtjørn D, Basso O &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://humrep.oxfordjournals.org/content/early/2010/10/17/humrep.deq206.abstract?sid=" target="_blank"&gt;Parental infertility and cerebral palsy in children&lt;/A&gt;. Human Reproduction, [First published online] November 2 2010&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304846</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/ChildhoodtraumaandME.aspx]]&gt;</url>
    <title>Behind the headlines - Childhood trauma and ME</title>
    <publicationDate>2009-01-06T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,NEUROMUSCULAR,CONDITIONS,CHRONIC FATIGUE SYNDROME/ME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Heim C, Nater UM, Maloney E, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Childhood Trauma and Risk for Chronic Fatigue Syndrome." href="http://archpsyc.ama-assn.org/cgi/content/abstract/66/1/72" target="_blank"&gt;Childhood Trauma and Risk for Chronic Fatigue Syndrome.&lt;/A&gt; &lt;EM&gt;Arch Gen Psychiatry &lt;/EM&gt;2009; 66: 72-80&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>383699</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/genes-may-control-meningitis-b-risk.aspx]]&gt;</url>
    <title>Behind the headlines - Clue to meningitis risk</title>
    <publicationDate>2010-08-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INFECTIONS,BACTERIAL INFECTIONS,BACTERIAL MENINGITIS,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"Researchers have found 'the strongest evidence so far' that genetic factors can increase the risk of a person developing meningitis," reported The Guardian. The newspaper said the discovery could help in the search for a vaccine.&lt;/P&gt;
&lt;P&gt;This was a large, well-conducted study that compared the DNA of children who had contracted meningococcal meningitis with the DNA of healthy children. It identified several genetic variants in a region of DNA containing genes associated with a part of the immune system, including a variant in the gene that produces a protein called complement factor H (CFH). Variations in this region are linked to susceptibility to disease, and the findings may help with the development of a vaccine against type B meningococcal meningitis.&lt;/P&gt;
&lt;P&gt;An effective vaccine against type C meningococcal meningitis is already given to children in the UK and has greatly reduced deaths from this disease in this country. Research into the development of a vaccine effective against type B meningococcal meningitis is likely to continue.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a well-conducted and well-reported genome-wide association study using recognised methods in this field of research. This study did not detect any of the genetic associations with meningococcal disease that other studies have noted, possibly because it used different methods or because these earlier studies were in smaller groups of people and so had less power to detect associations.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/genes-may-control-meningitis-b-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Davila S,&amp;nbsp;Wright VJ, Chuen Khor C &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.nature.com/ng/journal/vaop/ncurrent/abs/ng.640.html" shape=rect target="_blank"&gt;Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease&lt;/A&gt;. &lt;EM&gt;Nature Genetics 2010&lt;/EM&gt;; Published online, August 8 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>320670</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/CoffeeandAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Coffee aids Alzheimer's mice</title>
    <publicationDate>2009-07-07T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Researchers say that “three large cups of coffee a day could help to slow the progress of Alzheimer’s disease and even reverse the condition”, The Times said. Several other newspapers also reported on a study in mice, which suggests that a daily dose of caffeine may suppress the degenerative processes in the brain that lead to impaired cognitive function.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Researchers say that “three large cups of coffee a day could help to slow the progress of Alzheimer’s disease and even reverse the condition”, &lt;EM&gt;The Times&lt;/EM&gt; said. Several other newspapers also reported on a study in mice, which&amp;nbsp;suggests that a daily dose of caffeine may suppress the degenerative processes in the brain that lead to impaired cognitive function.&lt;/P&gt;
&lt;P&gt;Firstly, this study is in mice, so the results may not be applicable to humans. Some of the newspapers rightly caution that these findings do not mean that dementia patients should start using caffeine supplements or drink large amounts of coffee. Dementia is more common in the elderly, in whom there may be a number of reasons why a high caffeine intake would be particularly inadvisable, including high blood pressure and drug interactions.&lt;/P&gt;
&lt;P&gt;The researchers say that “based on the robust protective and treatment effects of caffeine” observed, they have “initiated clinical trials with caffeine”. The fundamental message in this story is that more research is needed, i.e. studies that examine the effects of caffeine in people with Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does the NHS Knowledge Service make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Experiments that simulate human disease in animals, such as the disease in this study, are often used for gaining a better understanding of how diseases work and to test potential new treatments in the early stages. However, given the obvious physiological and metabolic differences between humans and mice, the experiments can only give an approximate idea of the effects in humans. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Arendash GW, Mori T, Cao C, et al.&amp;nbsp;&lt;A href="http://iospress.metapress.com/content/u681451575288860" target="_blank"&gt;Caffeine Reverses Cognitive Impairment and Decreases Brain Amyloid-ß Levels in Aged Alzheimer's Disease Mice.&lt;/A&gt; &lt;EM&gt;Journal of Alzheimer's Disease&lt;/EM&gt; 2009; 17; 1387-2877&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the &lt;A href="http://www.nhs.uk/news/2009/07July/Pages/CoffeeandAlzheimers.aspx" target="_blank"&gt;full National Knowledge Service commentary&lt;/A&gt; on this news item. 'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news &lt;/LI&gt;
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients&lt;/LI&gt;
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309448</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Coffeeandmultiplesclerosis.aspx]]&gt;</url>
    <title>Behind the headlines - Coffee and multiple sclerosis</title>
    <publicationDate>2008-07-02T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Mills JH, Thompson LF, Mueller C, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyel" href="http://www.pnas.org/cgi/content/abstract/0711175105v1" target="_blank"&gt;CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis.&lt;/A&gt; &lt;EM&gt;Proc Natl Acad Sci USA &lt;/EM&gt;2008; Jun 30 [Epub ahead of print]&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>306908</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/Coffee'cutsstrokerisk'.aspx]]&gt;</url>
    <title>Behind the headlines - Coffee 'cuts stroke risk'</title>
    <publicationDate>2009-02-19T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Drinking two cups of coffee a day 'cuts stroke risk by 20%',” reported The Daily Telegraph. It said a study that followed over 80,000 women for more than 20 years showed that those who drank more coffee were less likely to have a clot on the brain. The newspaper said that the results were a “surprise” to researchers, who initially thought that coffee might increase the risk of stroke. It also reported the researchers as stressing that “the protective effect of coffee is only found in those who are already relatively healthy”, and noted that these effects were unlikely to be seen in people with existing heart disease or blood pressure problems.&lt;/P&gt;
&lt;P&gt;This study was large and well conducted. However, the results will need confirmation in further studies. In addition, as the authors point out, the reduction in stroke risk is “modest”, and may not apply to all women. Previous studies have suggested that coffee consumption in women with high blood pressure may increase risk of stroke. &lt;/P&gt;
&lt;P&gt;Women who want to reduce their risk of stroke would be better off targeting known risk factors for stroke by stopping smoking, eating a healthy diet and taking exercise, rather than trying to drink more coffee.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This was a large and well conducted study. Particular strengths include the way that coffee consumption and potential confounders were assessed at multiple time points. The study will no doubt lead to further investigation to identify the “active component” of coffee that may reduce stroke risk. The study has some limitations which should be considered when interpreting its results.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/02February/Pages/Coffee'cutsstrokerisk'.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, Logroscino G, Hu FB, van Dam RM. &lt;A href="http://dx.doi.org/10.1161/CIRCULATIONAHA.108.826164" target="_blank"&gt;Coffee consumption and risk of stroke in women.&lt;/A&gt; &lt;EM&gt;Circulation&lt;/EM&gt; 2009 Mar 3;119(8):1116-23.&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>326691</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/cold-treatment-eases-baby-brain-damage.aspx]]&gt;</url>
    <title>Behind the headlines - Cold 'cuts baby brain damage'</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRAUMA,BRAIN INJURY,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>"Babies who are starved of oxygen at birth have a much lower risk of brain damage if they are given mild hypothermia,” reported BBC News.</description>
    <body>&lt;![CDATA[ &lt;P&gt;"Babies who are starved of oxygen at birth have a much lower risk of brain damage if they are given mild hypothermia,” reported BBC News. The website said research in more than 300 babies found that full-term babies that were affected by&amp;nbsp; oxygen deprivation when born were 57% more likely to survive without brain damage if they were cooled.&lt;/P&gt;
&lt;P&gt;This is a solid study that is part of a growing body of research on this treatment. This study brings the decision on whether this treatment should become standard practice closer. However, the evidence is not quite there yet, some issues about how the treatment is delivered and the extent of any long-term benefit still need to be resolved.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Other studies have investigated similar (but not identical) cooling techniques and the authors discuss these in context. They state that a 2007 review found eight randomised-controlled trials that included 638 term infants. It concluded that cooling of newborn babies who may have suffered from a lack of oxygen at birth reduces death or disability, without increasing disability in survivors. However, they note that the review, done two years ago, was based on less than half of all infants currently known to be randomised into eligible trials of cooling. ...&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/cold-treatment-eases-baby-brain-damage.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Azzopardi, Strohm B, Edwards D &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://content.nejm.org/cgi/content/abstract/361/14/1349" target="_blank"&gt;Moderate Hypothermia to Treat Perinatal Asphyxial Encephalopathy.&lt;/A&gt; &lt;EM&gt;NEJM&lt;/EM&gt;, Volume 361:1349-1358.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304851</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/12December/Pages/ColdsoresandAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Cold sores and Alzheimer's</title>
    <publicationDate>2008-12-08T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;MA Wozniak MA, Mee AP, Itzhaki RF. &lt;A title="Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques." href="http://www3.interscience.wiley.com/journal/121411445/abstract" target="_blank"&gt;Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques.&lt;/A&gt; The Journal of Pathology 2008; 217: 131-138&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313157</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/Dementiaclueintheyoung.aspx]]&gt;</url>
    <title>Behind the headlines - Dementia 'clue' in the young</title>
    <publicationDate>2009-04-07T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-E4 allele. PNAS 2009; early edition&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>304845</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/Dementiadrugdanger.aspx]]&gt;</url>
    <title>Behind the headlines - Dementia medication danger</title>
    <publicationDate>2009-01-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Clive Ballard C, ML Hanney, Theodoulou M, &lt;EM&gt;et al.&lt;/EM&gt;&amp;nbsp; &lt;A title="" href="http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(08)70295-3/abstract" target="_blank"&gt;The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.&lt;/A&gt; Lancet Neurology 2009; early online publication, January 9&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309445</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Dementiamorecommoninwomen.aspx]]&gt;</url>
    <title>Behind the headlines - Dementia more common in women</title>
    <publicationDate>2008-07-03T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Corrada MM, Brookmeyer R, Berlau D, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Prevalence of dementia after age 90. Results from The 90+ Study." href="http://www.neurology.org/cgi/content/abstract/01.wnl.0000310773.65918.cdv1" target="_blank"&gt;Prevalence of dementia after age 90. Results from The 90+ Study.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; Jul 2 [Epub ahead of print] &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>288735</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/04April/Pages/DepressionandAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Depression and Alzheimer's</title>
    <publicationDate>2008-04-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Wilson RS, Arnold SE, Beck TL, et al. &lt;A title="Change in Depressive Symptoms During the Prodromal Phase of Alzheimer Disease." href="http://archpsyc.ama-assn.org/cgi/content/abstract/65/4/439" target="_blank"&gt;Change in Depressive Symptoms During the Prodromal Phase of Alzheimer Disease.&lt;/A&gt; Arch Gen Psychiatry 2008; 65: 439-445&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>380578</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/Depression-and-dementia-risk.aspx]]&gt;</url>
    <title>Behind the headlines - depression linked to dementia</title>
    <publicationDate>2010-07-07T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,COMPLICATING MEDICAL DISORDERS,DEMENTIA,NEUROPSYCHIATRIC,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Having depression may nearly double the risk of developing dementia later in life,” reported BBC News. It said that a 17-year study of nearly 1,000 elderly people, found that 22% of those who were depressed at the start went on to develop dementia, compared with 17% of those who were not depressed.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Having depression may nearly double the risk of developing dementia later in life,” reported BBC News. It said that a 17-year study of nearly 1,000 elderly people, found that 22% of those who were depressed at the start went on to develop dementia, compared with 17% of those who were not depressed.&lt;/P&gt;
&lt;P&gt;This is a well-designed study and was accurately reported by the BBC. It has several strengths and adds to the evidence of a link between the two conditions.&lt;/P&gt;
&lt;P&gt;However, as the researchers say, this does not necessarily mean that depression causes dementia and the reason for the association between the two conditions is still unclear. It is unknown if depression is a risk factor for dementia, whether it is an early sign of cognitive decline or if certain changes in the brain are associated with both conditions. Also, certain lifestyle factors were not measured by this study, such as poor diet, lack of physical activity and social interaction, and these may increase the risk of both depression and dementia.&lt;/P&gt;
&lt;P&gt;Importantly, this study was in elderly people (average 79 years) and it is unknown if depression earlier in life would be associated with dementia in the same way. Further research is needed.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;This is a well-designed study that has been reported on accurately by the BBC. It has numerous strengths including a large sample size, long duration of follow-up, and validated methods of diagnosing dementia at follow-up.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/July07/Pages/Depression-and-dementia-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Saczynski JS, Beiser A, Seshadri S, et al. Depressive symptoms and risk of dementia. The Framingham Heart Study. Neurology 2010; 2010; 75: 35-41&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304849</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/Diabeticsriskofmentalslowdown.aspx]]&gt;</url>
    <title>Behind the headlines - Diabetes and mental ability</title>
    <publicationDate>2009-01-05T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Yeung SE, Fischer AL, and Dixon RA. Exploring Effects of Type 2 Diabetes on Cognitive Functioning in Older Adults. &lt;EM&gt;Neuropsychology &lt;/EM&gt;2009. Online publication January 05&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395098</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/diabetes-drug-tested-in-dementia-study.aspx]]&gt;</url>
    <title>Behind the headlines - Diabetes drug for Alzheimer's explored</title>
    <publicationDate>2010-11-23T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A common diabetes drug could be redeveloped as a new treatment for Alzheimer's,” reported the BBC. It said that metformin may help prevent the formation of “tau tangles”, a key brain abnormality linked to the disease.&lt;/P&gt;
&lt;P&gt;This study investigated whether metformin has any effect on the tau proteins that form these tangles. In studies of mouse cells, metformin increased the activity of an enzyme that can counteract the development of the tangles. Similar findings were also seen in live mice given the drug.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This was an early stage laboratory study in healthy mice without Alzheimer’s disease, which gives insight into the biochemical effect that metformin has within nerve cells. These are promising findings but this study does not tell us whether metformin has the same effect on tau proteins in humans, what dose is safe and effective, and whether it would work in all patients.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/11November/Pages/diabetes-drug-tested-in-dementia-study.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Kicksteina E, Kraussa S, Thornhill P &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.pnas.org/content/early/2010/11/17/0912793107.abstract" target="_blank"&gt;Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.&lt;/A&gt; PNAS, Published online before print November 22, 2010&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304850</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/12December/Pages/Dosnorersburnmorecalories.aspx]]&gt;</url>
    <title>Behind the headlines - Do snorers burn more calories?</title>
    <publicationDate>2008-12-16T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,SLEEP DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Kezirian EJ, Kirisoglu CE, Riley RW, et al. &lt;A title="Resting Energy Expenditure in Adults With Sleep Disordered Breathing." href="http://archotol.ama-assn.org/cgi/content/abstract/134/12/1270" target="_blank"&gt;Resting Energy Expenditure in Adults With Sleep Disordered Breathing.&lt;/A&gt; &lt;EM&gt;Arch Otolaryngol Head Neck Surg&lt;/EM&gt; 2008; 134: 1270-1275&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328262</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Does-a-virus-cause-ME.aspx]]&gt;</url>
    <title>Behind the headlines - Does a virus cause ME?</title>
    <publicationDate>2009-10-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ VIRAL INFECTIONS,INFECTIONS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,NEUROMUSCULAR,OCTOBER 2009,CONDITIONS,CHRONIC FATIGUE SYNDROME/ME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The front page of the Independent for October 9th asks whether scientists have found the cause of ME (myalgic encephalitis), also known as chronic fatigue syndrome (CFS). The newspaper reported that researchers have found a “strong link” with a retrovirus called XMRV.&lt;/P&gt;
&lt;P&gt;This study compared blood samples from 101 CFS patients with samples from 218 people without it. It found evidence of the XMRV virus in about two-thirds of the people with CFS and less than 4% of people without the disease.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has identified an association between the presence of XMRV viral DNA and chronic fatigue syndrome (CFS). However, it is not yet possible to say for certain whether the virus causes CFS, a fact that is acknowledged by the authors of the research. This is because the presence of the virus was assessed in people who already had CFS, and so it is not clear if the infection happened before they developed the disease. [...]&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/10October/Pages/Does-a-virus-cause-ME.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lombardi VC, Ruscetti FW, Das Gupta J, et al.&amp;nbsp;&lt;A href="http://www.sciencemag.org/cgi/content/abstract/sci;1179052v1" target="_blank"&gt;Detection of an Infectious Retrovirus, XMRV, in Blood Cells of Patients with Chronic Fatigue Syndrome.&lt;/A&gt; &lt;EM&gt;Science&lt;/EM&gt;; Published online October 8 2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sciencemag.org/cgi/content/summary/326/5950/215-a" target="_blank"&gt;Chronic Fatigue and Prostate Cancer: A Retroviral Connection?&lt;/A&gt;&amp;nbsp;&lt;EM&gt;Science,&lt;/EM&gt; October 9 2009: 326; p215&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>393841</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/beetroot-and-dementia.aspx]]&gt;</url>
    <title>Behind the headlines - Does beetroot juice combat dementia?</title>
    <publicationDate>2010-11-04T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A daily glass of beetroot juice could combat the onset of dementia among older adults,” reported the Daily Express.&lt;/P&gt;
&lt;P&gt;This news story is a based on a small study in 16 elderly people. The participants were given either a diet that was low or high in nitrates over a four-day period. Nitrates are present at high levels in beetroot and other vegetables, and converted into nitrites in the body, a chemical that is thought to increase blood flow. The participants’ blood flow to different regions of the brain was measured on a scan.&lt;/P&gt;
&lt;P&gt;This was a small study conducted over an extremely short time span. Its findings suggest that adults who eat a diet high in nitrates may experience an increased blood flow to certain areas of the brain within a short interval, compared with eating a diet low in nitrates.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In conclusion, this study does not provide robust evidence that a diet high in nitrates aids cognitive function. Further research is needed in larger numbers of people over a longer period. Plenty of vegetables may be good for your health as part of a balanced diet, but whether or not beetroot juice can have a beneficial effect on blood flow remains to be seen.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/11November/Pages/beetroot-and-dementia.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Presley TD, Morgan AR, Bechtold E, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6WNT-517S818-1&amp;amp;_user=10&amp;amp;_coverDate=10/15/2010&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_origin=search&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=" target="_blank"a&amp;quot;'"&gt;Acute effect of a high nitrate diet on brain perfusion in older adults.&lt;/A&gt; &lt;EM&gt;Nitric Oxide&lt;/EM&gt;, October 15 2010&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288106</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/05May/Pages/Doesceleryfightbraindamage.aspx]]&gt;</url>
    <title>Behind the headlines - Does celery fight brain damage?</title>
    <publicationDate>2008-05-20T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,BRAIN INJURY,TRAUMA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Jang S, Kelley KW, Johnson RW. &lt;A title="Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1." href="http://www.pnas.org/cgi/content/abstract/0802865105v1?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=celery&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=date&amp;amp;resourcetype=HWCIT" target="_blank"&gt;Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1.&lt;/A&gt; &lt;EM&gt;Proc Natl Acad Sci &lt;/EM&gt;2008; Published online on May 19 2008&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>308721</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/03March/Pages/MilkAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Does milk fight Alzheimer's?</title>
    <publicationDate>2009-03-03T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Vogiatzoglou A, Smith AD, Nurk E &lt;EM&gt;et al. &lt;/EM&gt;&lt;A title="" href="http://www.ajcn.org/cgi/content/abstract/ajcn.2008.26598v1?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=smith&amp;amp;fulltext=milk&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=date&amp;amp;resourcetype=HWCIT" target="_blank"&gt;Dietary sources of vitamin B-12 and their association with plasma vitamin B12 concentrations in the general population: the Hordaland Homocysteine Study.&lt;/A&gt; &lt;EM&gt;AJCN&lt;/EM&gt;; February 3, 2009 [published ahead of print]&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>385143</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/the-contraceptive-pill-and-brain-size.aspx]]&gt;</url>
    <title>Behind the headlines - Does the Pill make brains bigger?</title>
    <publicationDate>2010-08-18T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ENVIRONMENTAL &amp; TOXIC,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"Contraceptive pills increase the size of certain parts of women’s brains, improving memory and social skills", reported The Daily Telegraph.&lt;/P&gt;
&lt;P&gt;This news story is based on a small study that looked at brain structure in 14 men and 28 women, half of whom were using hormonal contraception. It found that certain areas of grey matter in the brain were larger in women taking hormonal contraceptives than in women not using hormones, and in women in their early phase of their menstrual cycle compared to later in the cycle. The researchers say that this shows that both these factors can affect the human brain structure.&lt;/P&gt;
&lt;P&gt;However, this study is too small to conclude that the Pill or the menstrual cycle affects the volume of grey matter in the brain. There is no way of knowing what other factors, including genetic factors, may have had an effect on these participants’ brains as no other data was taken. Also, since it did not actually examine or measure cognitive performance, it cannot shed any light on how the Pill might affect cognitive or social skills.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This small study seems to show that in certain regions of the brain, women using hormonal contraception had larger GM volume than naturally cycling women. The researchers suggest that this may be due to differences in hormone levels, specifically “enhanced” oestrogen and/or progesterone levels. They conclude that more clarification is needed on the specific roles of oestrogen and progesterone.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/the-contraceptive-pill-and-brain-size.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Pletzer B, Kronbichler M, Aichhorn M et al. &lt;A href="http://dx.doi.org/10.1016/j.brainres.2010.06.019" target="_blank"&gt;Menstrual cycle and hormonal contraceptive use modulate human brain structure&lt;/A&gt;. Brain Research 2010: 1348; 55-62 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>380398</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/alzheimers-experimental-blood-test.aspx]]&gt;</url>
    <title>Behind the headlines - Early days for Alzheimer's test</title>
    <publicationDate>2010-07-06T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INVESTIGATION &amp; DIAGNOSTICS,ALZHEIMER'S DISEASE,DEMENTIA,JULY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A simple blood test may soon be able to “predict Alzheimer's disease up to 10 years before symptoms appear”, says The Daily Telegraph. The newspaper says researchers have discovered that a rise in levels of a protein called clusterin may be an early sign of the disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A simple blood test may soon be able to “predict Alzheimer's disease up to 10 years before symptoms appear”, says The Daily Telegraph. The newspaper says researchers have discovered that a rise in levels of a protein called clusterin may be an early sign of the disease.&lt;/P&gt;
&lt;P&gt;The observational and laboratory studies that lie behind this report have been well conducted and reported, and its authors have found clusterin levels are linked to cognitive decline, the severity of disease in people with Alzheimer’s and the rate of clinical progression of Alzheimer’s disease. However, the researchers do not suggest that this may be used to diagnose disease, at least not yet. In fact they say that their study does not support the clinical use of clusterin levels as a standalone biomarker for Alzheimer’s disease. These are interesting findings, but early ones that will lead to more research about protein markers of this disease rather than directly to a clinical test.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a well-reported observational study that has identified a particular protein in the blood that was able to distinguish between different degrees of brain atrophy in people with Alzheimer’s disease and mild cognitive impairment, plus between different disease types (aggressive or not). &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/July07/Pages/alzheimers-experimental-blood-test.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Thambisetty M, Simmons A, Velayudhan L et al. Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010;67(7):739-748&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>315424</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/Veryearlydaysformemorypill.aspx]]&gt;</url>
    <title>Behind the headlines - Early days for 'memory pill'</title>
    <publicationDate>2009-04-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,MILD COGNITIVE IMPAIRMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Campolongo P, Roozendaal B, Trezza V et al.&amp;nbsp;&lt;A href="http://www.pnas.org/content/early/2009/04/27/0903038106.abstract?sid=b8590d85-5c99-4672-af61-a89d7e61452b" target="_blank"&gt;Fat-induced satiety factor oleoylethanolamide enhances memory consolidation.&lt;/A&gt; PNAS 2009; Published online before print April 27 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>288752</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2007/Pages/FruitandAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Eat fruit, but not because of this study</title>
    <publicationDate>2008-02-12T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ALZHEIMER'S DISEASE,DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MOVEMENT DISORDERS,PARKINSON'S DISEASE,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Heo HJ, Choi SJ, Choi S-G,&lt;EM&gt; et al.&lt;/EM&gt; &lt;A title="Effects of Banana, Orange, and Apple on Oxidative Stress-Induced Neurotoxicity in PC12 Cells." href="http://www.blackwell-synergy.com/doi/abs/10.1111/j.1750-3841.2007.00632.x" target="_blank"&gt;Effects of Banana, Orange, and Apple on Oxidative Stress-Induced Neurotoxicity in PC12 Cells.&lt;/A&gt;&lt;EM&gt; J Food Sci &lt;/EM&gt;2008; Jan 24 [Epub ahead of print]&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>381978</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/education-delays-dementia-and-alzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Education 'blocks dementia'</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Education ‘helps brain compensate for dementia changes,’” BBC News reported today, saying that people who stay in education longer appear to be less affected by the brain changes that occur during dementia. According to the newstory, European researchers have found that those with more education were as likely to show biological dementia signs in their brains at death but less likely to have displayed symptoms of the disease while alive.&lt;/P&gt;
&lt;P&gt;The underlying study compared education, symptoms of dementia and post-mortem brain samples in about 900 people who donated their brains for research after death. It demonstrated that greater education was linked to reduced clinical dementia but did not have any bearing on changes in brain biology. It seems the brain will change with age regardless of education but that people with more education are more likely to compensate and therefore stave off the symptoms of dementia. &lt;/P&gt;
&lt;P&gt;This study has some shortcomings, including how representative the small sample of people who agreed to post-mortem brain examination were to the general population.&amp;nbsp; However, it will be of interest to neurologists, who must now unpick why more education can reduce clinical symptoms of dementia, but not the brain signs of dementia.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This cohort study has assessed how time spent in education was linked to both brain pathology (that is, biological changes) and symptoms of dementia before death.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/July07/Pages/education-delays-dementia-and-alzheimers.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Brayne C, Ince P, McKeith I, et al. Education, the brain and dementia: neuroprotection or compensation? &lt;EM&gt;Brain&lt;/EM&gt; 2010; 133: 2210-16&amp;nbsp; 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288741</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/04April/Pages/Effectsofcaffeineonrabbits.aspx]]&gt;</url>
    <title>Behind the headlines - Effects of caffeine on rabbits</title>
    <publicationDate>2008-04-04T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Chen X, Gawryluk JW, Wagener JF, et al. &lt;A title="Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease." href="http://www.jneuroinflammation.com/content/5/1/12" target="_blank"&gt;Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease.&lt;/A&gt; Journal of Neuroinflammation 2008, 5: 12&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>346817</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/drug-resistant-epilepsy-brain-stimulation.aspx]]&gt;</url>
    <title>Behind the headlines - Electricity therapy for epilepsy</title>
    <publicationDate>2010-03-18T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Deep brain stimulation is a promising therapy for epilepsy,” reported the BBC. The article said that patients who had resistant epilepsy (a type of epilepsy that does not respond to drug treatment) and who had regular seizures were selected for the new treatment.&lt;/P&gt;
&lt;P&gt;Deep brain stimulation (DBS) is a surgical treatment in which electrodes are implanted into specific areas of the brain along with a device “like a pacemaker” that delivers small electrical impulses. Following the surgery, there was a 41% reduction in seizures for patients who received brain stimulation, compared with a 14.5% decline in seizures in the control group.&lt;/P&gt;
&lt;P&gt;The study points to a promising new treatment for a potentially large number of people with resistant epilepsy. The implant was given to epileptics who had specific types of epileptic seizures starting with a “partial seizure”. As such, the treatment may not be effective in people with other forms of epilepsy. This is likely to be less than the one-third of all people with epilepsy that was implied in news reports.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study provides reliable evidence of the effectiveness of this new treatment for drug-resistant epilepsy.&amp;nbsp;However, the treatment will not be suitable for all patients with epilepsy.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/03March/Pages/drug-resistant-epilepsy-brain-stimulation.aspx" target="_blank"&gt;NHS Choices commentary &lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Fisher R, Salanova V, Witt T et al. &lt;A href="http://www3.interscience.wiley.com/journal/123324051/abstract?CRETRY=1&amp;amp;SRETRY=0" target="_blank"&gt;Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy&lt;/A&gt;. &lt;EM&gt;Epilepsia &lt;/EM&gt;[Early View article online in advance of print]. Published online: 17 March 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309174</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/08August/Pages/Epilepsydrugandweight.aspx]]&gt;</url>
    <title>Behind the headlines - Epilepsy drug and weight loss</title>
    <publicationDate>2008-08-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;DeMarco A, Dalal RM, Kahanda M, et al. &lt;A title="Subchronic racemic gamma vinyl-GABA produces weight loss in Sprague Dawley and Zucker fatty rats." href="http://www3.interscience.wiley.com/journal/121383538/abstract" target="_blank"&gt;Subchronic racemic gamma vinyl-GABA produces weight loss in Sprague Dawley and Zucker fatty rats.&lt;/A&gt; Synapse 2008; 62:870-872&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>346104</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/eye-test-for-diagnosing-Alzheimers-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Eye scan could detect Alzheimer's</title>
    <publicationDate>2010-01-18T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Daily Mirror says there could be a “high street eye test for Alzheimer's” within five years. The newspaper says that new research in mice has shown that placing a harmless fluorescent dye into the retina of the eye could identify dying nerve cells, which are an early sign of Alzheimer's.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;EM&gt;Daily Mirror&lt;/EM&gt; says there could be a “high street eye test for Alzheimer's” within five years. The newspaper says that new research in mice has shown that placing a harmless fluorescent dye into the retina of the eye could identify dying nerve cells, which are an early sign of Alzheimer's.&lt;/P&gt;
&lt;P&gt;The model developed in this study is a novel way of studying the death of eye nerve cells in living animals. This research mainly tested whether the technique could detect cell death in the retinas of rodents, including in animals with rodent versions of the human diseases glaucoma and Alzheimer’s. However, it did not test whether the technique could effectively distinguish between different diseases in animals or what the results can tell us about the health of nerve cells in the brain.&lt;/P&gt;
&lt;P&gt;Diagnosing Alzheimer’s disease is complicated, and additional tests to help&amp;nbsp;identify the condition would be useful. While this technique merits further research, it is too soon to say that the test might be successful in humans or can be used to single out Alzheimer’s disease as a cause of someone’s symptoms.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The model developed in this study is a novel way of studying cell death in the retinas of living animal models and, as such, is likely to be a useful research tool. This study mainly tested whether the technique could detect cell death in the retinas of rodents, including in animal models of the human diseases glaucoma and Alzheimer’s disease. It did not focus on how well the technique could distinguish between different diseases in animals, or what the results of the test can tell us about the health of nerve cells in the brain.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/eye-test-for-diagnosing-Alzheimers-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Cordeiro MF, Guo L, Coxon KM &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.nature.com/cddis/journal/v1/n1/full/cddis20093a.html" target="_blank"&gt;Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo&lt;/A&gt;. &lt;EM&gt;Cell Death and Disease&lt;/EM&gt; (2010)&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>323166</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/FacialSymmetryDecline.aspx]]&gt;</url>
    <title>Behind the headlines - Face shape 'shows mental decline'</title>
    <publicationDate>2009-08-11T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,MILD COGNITIVE IMPAIRMENT,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Face shape is a “clue to mental decline”, BBC News has reported. The website says that men with symmetrical faces are less likely to lose their memory and intelligence in later life.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Face shape is a “clue to mental decline”, BBC News has reported. The website says that men with symmetrical faces are less likely to lose their memory and intelligence in later life. A new Scottish study has apparently found a link between facial symmetry and mental performance between the ages of 79 and 83 years.&lt;/P&gt;
&lt;P&gt;This research analysed data on a small cross section of survivors from a study begun in 1921, and measured the symmetry of their faces at the age of 83. It demonstrated a link in men between their facial symmetry at 83 and changes in cognitive performance in the preceding four years, suggesting that those with less symmetrical faces also had demonstrable cognitive decline during that time. Overall, while this study may contribute to theories of ageing, its practical implications are difficult to appreciate. The study also has limitations, and its findings should be replicated in larger, prospective studies before firm conclusions can be drawn regarding the association between facial symmetry and cognitive function.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This small study has demonstrated a link between facial symmetry and cognition in the elderly. This finding is not particularly surprising given that symmetry is a likely indicator of how successfully the body may have responded to potentially harmful genetic and environmental challenges to its development. On this basis, it could be considered a proxy measure of health.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;See the entire&amp;nbsp;&lt;/EM&gt;&lt;A href="http://www.nhs.uk/news/2009/08August/Pages/FacialSymmetryDecline.aspx" target="_blank"&gt;&lt;EM&gt;NHS Choices commentary&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;&amp;nbsp;on this news item.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Penke L, Bates TC, Gow AJ &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.ehbonline.org/article/S1090-5138(09)00054-3/abstract" target="_blank"&gt;Symmetric faces are a sign of successful cognitive aging&lt;/A&gt;. &lt;EM&gt;Evolution &amp;amp; Human Behavior&lt;/EM&gt;,&amp;nbsp;August 06 2009. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>395103</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/first-stem-cell-trial-in-stroke-patient.aspx]]&gt;</url>
    <title>Behind the headlines - First stem cell trial in stroke patient</title>
    <publicationDate>2010-11-17T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In a world first, a British man has had stem cells injected into his brain to repair the damage caused by stroke. Many newspapers reported this clinical trial, which is designed to test the safety of a new therapy for stroke damage.&lt;/P&gt;
&lt;P&gt;The main purpose of this early experimental trial is to test the safety of a new stem cell therapy for the treatment of ischaemic stroke.&lt;/P&gt;
&lt;P&gt;The stroke survivor reported in the newspapers was the first to receive the therapy in the trial and, should it pass review in a month’s time, another 11 stroke survivors will be given the treatment. The patients will be followed for at least two years. The researchers will also evaluate the treatment’s effectiveness and whether it has any affect on function and disability after stroke.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In general, the media coverage has been accurate. The Daily Express’ photo of an injection into the arm was misleading because in this specific trial the cells were transplanted directly into the patient’s brain.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/11November/Pages/first-stem-cell-trial-in-stroke-patient.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.reneuron.com/news__events/news/document_260_237.php" target="_blank"&gt;ReNeuron announces first patient treated in landmark stroke stem cell clinical trial.&lt;/A&gt;&amp;nbsp;Press release: 16/11/10&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>346841</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02february/pages/fragile-x-syndrome-studied.aspx]]&gt;</url>
    <title>Behind the headlines - 'Fragile X syndrome' studied</title>
    <publicationDate>2010-02-15T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ STRUCTURAL,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A genetic defect that causes children to dislike being hugged and sometimes reject all physical affection is closer to being understood following research into the sensory part of the brain,” &lt;EM&gt;The Times&lt;/EM&gt; reported.&lt;/P&gt;
&lt;P&gt;This story is based on a study in a mouse 'model' of fragile X syndrome, examining the area of the brain involved with processing touch.&amp;nbsp;It&amp;nbsp;found that newborn mice with fragile X syndrome showed subtle differences&amp;nbsp;in the activity of neurones (nerve cells) during the period they were learning how to use their whiskers to sense touch.&amp;nbsp;It also found&amp;nbsp;it took longer for the sensory part of their brains to develop.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This animal study found subtle differences in neurone activity and brain development in mice with fragile X syndrome compared to normal mice.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/02february/pages/fragile-x-syndrome-studied.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Harlow EG,&amp;nbsp; Till SM,&amp;nbsp; Russell TA, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.cell.com/neuron/abstract/S0896-6273(10)00050-4" target="_blank"&gt;Critical Period Plasticity Is Disrupted in the Barrel Cortex of Fmr1 Knockout Mice&lt;/A&gt;. &lt;EM&gt;Neuron&lt;/EM&gt; 2010; 65: 385-398 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288107</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/05May/Pages/Genemutationinrareformofepilepsy.aspx]]&gt;</url>
    <title>Behind the headlines - Gene mutation in rare form of epilepsy</title>
    <publicationDate>2008-05-12T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Dibbens LM, Tarpey PS, Hynes K, &lt;EM&gt;et al.&lt;/EM&gt; &lt;A title="X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment." href="http://www.nature.com/ng/journal/vaop/ncurrent/abs/ng.149.html" target="_blank"&gt;X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment.&lt;/A&gt; &lt;EM&gt;Nat Genet &lt;/EM&gt;2008; May 11 [Epub ahead of print] &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>288750</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2007/January08/Pages/Geneticlinkformotorneuronedisease.aspx]]&gt;</url>
    <title>Behind the headlines - Genetic link for motor neurone disease</title>
    <publicationDate>2008-02-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MOTOR NEURONE DISEASE/AMYOTROPHIC LATERAL SCLEROSIS,NEUROMUSCULAR,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sreedharan J, Blair IP, Tripathi VB, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis." href="http://www.sciencemag.org/cgi/content/abstract/1154584" target="_blank"&gt;TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis.&lt;/A&gt; &lt;EM&gt;Science &lt;/EM&gt;2008; Feb 28 [Epub ahead of print]&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>309137</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/09September/Pages/Geneticlinktochildbraintumour.aspx]]&gt;</url>
    <title>Behind the headlines - Genetic link to child brain tumour</title>
    <publicationDate>2008-09-10T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PRIMARY BRAIN TUMOURS,NEURO-ONCOLOGY,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Rand V, Prebble E, Ridley L,&lt;EM&gt; et al.&lt;/EM&gt; &lt;A title="Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracrani" href="http://www.nature.com/bjc/journal/vaop/ncurrent/abs/6604651a.html" target="_blank"&gt;Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma.&lt;/A&gt; &lt;EM&gt;Br J Cancer &lt;/EM&gt;2008; Sep 9 [Epub ahead of print] &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>384564</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/Immune-system-genes-and-parkinsons-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Genetics of Parkinson's explored</title>
    <publicationDate>2010-08-16T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MOVEMENT DISORDERS,PARKINSON'S DISEASE,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"The immune system may have a key role in the development of Parkinson's disease," reported BBC News. It said that a study has found an association between genes controlling immunity and Parkinson’s disease.&lt;/P&gt;
&lt;P&gt;The news reports appear to be accurate. This well-conducted, genome-wide association study found that particular genetic variants involved in the immune system are associated with Parkinson’s disease. While on its own, this region is only associated with a modest effect on Parkinson’s disease risk, the cumulative effect of this new association and others already identified is thought to be quite substantial.&lt;/P&gt;
&lt;P&gt;These findings may contribute to treatments or better detection of Parkinson’s, but it is too soon to realise the full implications of these findings.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study appears to be well-conducted, reliable research that furthers our understanding of this complex disease. Although other studies have identified several genetic risk factors for Parkinson’s, and this new association has only a “modest effect on Parkinson’s disease risk”, when considered together the cumulative effect is thought to be substantial.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/Immune-system-genes-and-parkinsons-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hamza TH,&amp;nbsp; Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nature Genetics 2010; Published online August 15&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>346859</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02February/Pages/ginkgo-biloba-risk-of-epileptic-seizures.aspx]]&gt;</url>
    <title>Behind the headlines - Gingko herb in seizure warning</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Extracts of the &lt;EM&gt;Ginkgo biloba&lt;/EM&gt; plant may increase the risk of seizures in people with epilepsy, BBC News has reported. The scientists behind the news are reportedly convinced the herbal extract could have detrimental effects.&lt;/P&gt;
&lt;P&gt;The news comes from a scientific report that says one of the herbal extract’s active ingredients has been linked to seizures and deaths in animal studies. Consumption of ginkgo seeds has also been implicated in lethal cases of food poisoning in humans. The researchers raise the possibility that some commercially available ginkgo preparations may contain the toxin behind these adverse effects, mentioning 10 cases of seizures thought to be linked to the use of ginkgo-based products. The authors say it is essential that people are aware of the risks, and for manufacturers to assess the levels of toxin in their products. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ginkgo biloba is a controversial herbal extract and the evidence about its efficacy is contradictory. There have been a number of well-conducted systematic reviews such as two that have investigated the use of Gingko biloba after stroke and to prevent or slow cognitive impairment and dementia. Both conclude that there is no evidence of benefit with this herb. A large six-year trial in published in 2008 followed more than 3000 people and also showed gingko had no effect on new cases of dementia.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/02February/Pages/ginkgo-biloba-risk-of-epileptic-seizures.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Leistner E, Drewke C. &lt;A href="http://pubs.acs.org/doi/full/10.1021/np9005019" target="_blank"&gt;Ginkgo biloba and Ginkgotoxin&lt;/A&gt;. &lt;EM&gt;Journal of Natural Products&lt;/EM&gt;, 2010, 73 (1), pp 86–92&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288728</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/06June/Pages/Ginkgonobenefitfordementia.aspx]]&gt;</url>
    <title>Behind the headlines - Ginkgo 'no benefit' for dementia</title>
    <publicationDate>2008-06-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;McCarney R, Fisher P, Iliffe S, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, place" href="http://www3.interscience.wiley.com/journal/119816224/abstract" target="_blank"&gt;Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.&lt;/A&gt; &lt;EM&gt;Int J Ger Psych &lt;/EM&gt;2008; Jun 9 [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Further reading &lt;/STRONG&gt;Birks J, Grimley Evans J. &lt;A title="Ginkgo biloba for cognitive impairment and dementia." href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003120/frame.html" target="_blank"&gt;Ginkgo biloba for cognitive impairment and dementia.&lt;/A&gt; &lt;EM&gt;Cochrane Database Syst Rev&lt;/EM&gt; 2007, Issue 2&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>288728</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/06June/Pages/Ginkgonobenefitfordementia.aspx]]&gt;</url>
    <title>Behind the headlines - Ginkgo 'no benefit' for dementia</title>
    <publicationDate>2008-06-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;McCarney R, Fisher P, Iliffe S, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, place" href="http://www3.interscience.wiley.com/journal/119816224/abstract" target="_blank"&gt;Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.&lt;/A&gt; &lt;EM&gt;Int J Ger Psych &lt;/EM&gt;2008; Jun 9 [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Further reading &lt;/STRONG&gt;Birks J, Grimley Evans J. &lt;A title="Ginkgo biloba for cognitive impairment and dementia." href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003120/frame.html" target="_blank"&gt;Ginkgo biloba for cognitive impairment and dementia.&lt;/A&gt; &lt;EM&gt;Cochrane Database Syst Rev&lt;/EM&gt; 2007, Issue 2&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>309455</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/06June/Pages/Ginkgonobenefitfordementia.aspx]]&gt;</url>
    <title>Behind the headlines - Ginkgo 'no benefit' for dementia</title>
    <publicationDate>2008-06-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;McCarney R, Fisher P, Iliffe S, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, place" href="http://www3.interscience.wiley.com/journal/119816224/abstract" target="_blank"&gt;Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.&lt;/A&gt; &lt;EM&gt;Int J Ger Psych &lt;/EM&gt;2008; Jun 9 [Epub ahead of print]&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>309455</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/06June/Pages/Ginkgonobenefitfordementia.aspx]]&gt;</url>
    <title>Behind the headlines - Ginkgo 'no benefit' for dementia</title>
    <publicationDate>2008-06-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;McCarney R, Fisher P, Iliffe S, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, place" href="http://www3.interscience.wiley.com/journal/119816224/abstract" target="_blank"&gt;Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.&lt;/A&gt; &lt;EM&gt;Int J Ger Psych &lt;/EM&gt;2008; Jun 9 [Epub ahead of print]&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>304857</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/11November/Pages/Largeginkgostudy.aspx]]&gt;</url>
    <title>Behind the headlines - Ginkgo 'won't stop dementia'</title>
    <publicationDate>2008-11-19T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;DeKosky ST, Williamson JD, Fitzpatrick AL &lt;EM&gt;et al.&lt;/EM&gt; &lt;A title="" href="http://jama.ama-assn.org/cgi/content/full/300/19/2253" target="_blank"&gt;Ginkgo biloba for Prevention of Dementia.&lt;/A&gt; JAMA. 2008;300(19):2253-2262 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>328267</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Gout-chemical-and-Parkinsons.aspx]]&gt;</url>
    <title>Behind the headlines - Gout chemical 'may help' Parkinson's</title>
    <publicationDate>2009-10-14T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PARKINSON'S DISEASE,MOVEMENT DISORDERS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,OCTOBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Researchers have concluded that urate, a naturally occurring chemical in the blood that is known to cause gout, “appears to slow the progression of Parkinson's disease”, BBC News has reported. Researchers claim that urate is a potent antioxidant and “counteracts oxygen-related cell damage thought to contribute to Parkinson's”. The news site said that trials are underway to find a safe way to raise urate levels as a therapy.&lt;/P&gt;
&lt;P&gt;The study involved 800 people with early Parkinson’s disease whose urate levels were measured before some took a treatment (alpha-tocopherol) for Parkinson's in a randomised controlled trial. An analysis of all the people together found that increased urate levels at the start of the study were linked with decreased risk of disease progression. The reason for this link is unclear.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This relatively large study has strengths in that it obtained urate levels from 97% of its participants at the beginning of the study period. The results agree with those from previous studies and suggest that increasing urate concentration in people with Parkinson's may potentially decrease the rate of progression. [...]&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/Gout-chemical-and-Parkinsons.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Alberto Ascherio A, LeWitt PA, Xu K, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://archneur.ama-assn.org/cgi/content/abstract/2009.247v1" target="_blank"&gt;Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease.&lt;/A&gt; &lt;EM&gt;Arch Neurol&lt;/EM&gt; 2009; 66 (12)&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309184</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/HayfeverdrugforAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Hayfever drug for Alzheimer’s</title>
    <publicationDate>2008-07-18T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Doody RS, Gavrilova SI, Sano M, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alz" href="http://www.thelancet.com/journals/lancet/article/PIIS0140673608610740/abstract" target="_blank"&gt;Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.&lt;/A&gt; &lt;EM&gt;Lancet &lt;/EM&gt;2008; 372:207-215&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>309442</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Highbloodpressureanddementia.aspx]]&gt;</url>
    <title>Behind the headlines - High blood pressure and dementia</title>
    <publicationDate>2008-07-08T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Peters R, Beckett N, Forette F, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET" href="http://www.thelancet.com/journals/laneur/article/PIIS1474442208701431/abstract?isEOP=true" target="_blank"&gt;Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial.&lt;/A&gt; &lt;EM&gt;Lancet Neurol &lt;/EM&gt;2008; Jul 8 [Epub ahead of print]&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>308723</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/03March/Pages/Hotweatherheadache.aspx]]&gt;</url>
    <title>Behind the headlines - Hot weather headache</title>
    <publicationDate>2009-03-10T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Mukamal KJ, Wellenius GA, Suh HH, and Mittleman MA. &lt;A title="Weather and air pollution as triggers of severe headaches." href="http://www.neurology.org/cgi/content/abstract/72/10/922" target="_blank"&gt;Weather and air pollution as triggers of severe headaches.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2009; 72: 922-927&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>304840</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/HRTshrinksbrain.aspx]]&gt;</url>
    <title>Behind the headlines - HRT 'can shrink the brain'</title>
    <publicationDate>2009-01-13T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Resnick SM, Espeland MA, Jaramillo SA &lt;EM&gt;et al.&lt;/EM&gt; &lt;A title="" href="http://www.neurology.org/cgi/content/abstract/72/2/135?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=resnick&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;volume=72&amp;amp;issue=2&amp;amp;resourcetype=HWCIT" target="_blank"&gt;Postmenopausal hormone therapy and regional brain volumes.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2009; 72:135-142]]&gt;</body>
  </document>
  <document>
    <id>380391</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/06June/Pages/huntingtons-disease-numbers%20higher.aspx]]&gt;</url>
    <title>Behind the headlines - Huntington's cases underestimated</title>
    <publicationDate>2010-06-30T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MOVEMENT DISORDERS,JULY 2010,CONDITIONS,HUNTINGTON DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“There are far more people with Huntington's disease in the UK than has been assumed,” The Guardian has reported. However, stigma and fear of insurance companies leads many to keep their condition a secret, it added.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“There are far more people with Huntington's disease in the UK than has been assumed,” The Guardian has reported. However, stigma and fear of insurance companies leads many to keep their condition a secret, it added.&lt;/P&gt;
&lt;P&gt;The news is based on two articles about Huntington’s disease - a progressive, inherited disorder that affects the nervous system, for which there is presently no cure. The disease typically appears in middle age, affecting muscle co-ordination and leading to cognitive decline. One article discusses the negative medical and scientific attitudes towards Huntington’s, which, in the past, had supported the sterilisation of families who carry the gene. The other is a commentary that argues that the estimated prevalence of Huntington’s may be double the standard estimates of about six to seven in 100,000, but that stigmatisation and financial penalties in insurance policies may lead people to conceal the condition.&lt;/P&gt;
&lt;P&gt;The articles are timed to coincide with the launch of an all-party parliamentary group to promote greater understanding and awareness of Huntington’s. While both are based to some extent on personal opinion, they highlight a serious issue for sufferers of the disease and their families and will perhaps lead to advances in both treatment and perceptions of this devastating illness.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Huntington’s disease is a distressing disorder for which at present there is no cure. Therefore any articles that can promote awareness of the disease or shed light on its prevalence and historical attitudes, are to be welcomed.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp; &lt;A href="http://www.nhs.uk/news/2010/06June/Pages/huntingtons-disease-numbers%20higher.aspx" target="_blank"&gt;NHS Choices commentary &lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Rawlins M.&amp;nbsp;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60974-9/fulltext" target="_blank"&gt;Huntington's disease out of the closet?&lt;/A&gt; The Lancet, Early Online Publication, 30 June 2010&lt;/P&gt;
&lt;P&gt;Wexler A. &lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60957-9/fulltext" target="_blank"&gt;Stigma, history, and Huntington's disease&lt;/A&gt;. The Lancet, Early Online Publication, 30 June 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319164</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/06June/Pages/HydrangeasandMS.aspx]]&gt;</url>
    <title>Behind the headlines - Hydrangeas and MS</title>
    <publicationDate>2009-06-05T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Sundrud MS, Koralov SB, Feuerer M&lt;EM&gt; et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.sciencemag.org/cgi/content/abstract/sci;324/5932/1334" target="_blank"&gt;Halofuginone Inhibits TH17 Cell Differentiation by Activating the Amino Acid Starvation Response.&lt;/A&gt; &lt;EM&gt;Science &lt;/EM&gt;2009; 324:1334-1338 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>306902</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/Insulinandmemory.aspx]]&gt;</url>
    <title>Behind the headlines - Insulin and memory</title>
    <publicationDate>2009-02-03T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Alzheimer’s sufferers have been given fresh hope after scientists discovered insulin drugs for diabetes can prevent memory loss”, the Daily Express reported. The newspaper said that researchers had treated neurons (brain cells) from the hippocampus (part of the brain involved in memory) with insulin and the diabetes drug rosiglitazone. It said that damage to neurons exposed to toxins was blocked by insulin.&lt;/P&gt;
&lt;P&gt;This laboratory study presents evidence that insulin is linked to Alzheimer’s and may have a role in treating it. It adds to evidence from other studies that have had the same conclusion.&lt;/P&gt;
&lt;P&gt;The drug, Rosiglitazone, is currently being trialled in humans with Alzheimer’s disease. The results will provide a clearer picture of the potential of insulin in treating this condition.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This early laboratory study confirms that insulin receptors are affected by ADDL proteins in brain cells. It indicates that brain cells may be protected from these effects by treatment with insulin and drugs that help cells use insulin. The study adds further evidence to others that have found this link.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/02February/Pages/Insulinandmemory.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL. &lt;A href="http://dx.doi.org/10.1073/pnas.0809158106" target="_blank"&gt;Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aß oligomers.&lt;/A&gt; Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1971-6.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304865</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/Isdementiaaffectedbyyourjob.aspx]]&gt;</url>
    <title>Behind the headlines - Is dementia affected by your job</title>
    <publicationDate>2008-10-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Garibotto V, Borroni B, Kalbe E, et al. &lt;A title="Education and occupation as proxies for reserve in aMCI converters and AD." href="http://www.neurology.org/cgi/content/abstract/71/17/1342" target="_blank"&gt;Education and occupation as proxies for reserve in aMCI converters and AD.&lt;/A&gt; Neurology 2008; 71: 1342-1349&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328295</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Jigsaws-and-dementia-diagnosis.aspx]]&gt;</url>
    <title>Behind the headlines - Jigsaws and dementia diagnosis</title>
    <publicationDate>2009-10-13T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,OCTOBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"A failing memory may not be the first sign of Alzheimer's disease,” according to the BBC. It reported that a study has found that “spatial skills, such as reading a map or completing a jigsaw, seem to be the first to falter”. Researchers found that these skills appeared to decline sharply up to three years before the disease was diagnosed using current methods.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Behind this report is a retrospective cohort study of more than 400 people, some of whom went on to develop Alzheimer’s disease. Before they were diagnosed, periodic measurements were taken of mental functions including working memory, verbal memory and visuospatial skills. These records identified points in time when Alzheimer’s patients showed rapid declines in these skills that differed from the course of normal ageing.&lt;/P&gt;
&lt;P&gt;It is too soon to conclude that this can be used in the diagnosis of Alzheimer’s disease. More research will need to establish whether assessing visuospatial ability improves diagnosis, and specifically how well deteriorating map-reading and jigsaw skills can serve as indicators of the condition.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This retrospective cohort study demonstrates the decline in various cognitive skills that precedes a diagnosis of Alzheimer’s disease. Importantly, it shows that visuospatial ability, tested here by established psychometric tests, has a steeper than normal decline three years before existing clinical diagnosis of Alzheimer’s. [...]&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/Jigsaws-and-dementia-diagnosis.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.telegraph.co.uk/health/healthnews/6308712/Problems-completing-jigsaw-or-reading-map-could-be-earlier-indicator-of-Alzheimers.html" target="_blank"&gt;Problems completing jigsaw or reading map 'could be earlier indicator of Alzheimer’s'.&lt;/A&gt;&amp;nbsp;&lt;EM&gt;The Daily Telegraph&lt;/EM&gt;, October 13 2009&lt;/P&gt;
&lt;P&gt;&lt;A href="http://news.bbc.co.uk/1/hi/health/8302017.stm" target="_blank"&gt;Memory not first Alzheimer's sign.&lt;/A&gt;&amp;nbsp;BBC News, October 13 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309185</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Keepyourbrainactive.aspx]]&gt;</url>
    <title>Behind the headlines - Keep your brain active</title>
    <publicationDate>2008-07-17T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Valenzuela MJ, Sachdev P, Wen W, et al. &lt;A title="Lifespan Mental Activity Predicts Diminished Rate of Hippocampal Atrophy." href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0002598" target="_blank"&gt;Lifespan Mental Activity Predicts Diminished Rate of Hippocampal Atrophy.&lt;/A&gt; PLoS ONE 2008; 3(7):e2598&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>382001</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/head-size-and-Alzheimers-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Large heads give 'dementia benefit'</title>
    <publicationDate>2010-07-13T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Having a big head may protect against dementia,” reported the BBC. The news report said that research in 270 patients with Alzheimer’s disease found that a larger head size (as a marker of brain size) was linked to better performance in cognitive tests, even when patients had the same amount of brain loss assessed by MRI scan.&lt;/P&gt;
&lt;P&gt;This was a preliminary study that requires further research in a larger group of people. It is important to highlight that brain size is largely determined by genes and it is not clear whether it is possible to influence brain size during childhood sufficiently to promote greater brain function resilience following brain loss in later life.&lt;/P&gt;
&lt;P&gt;However, researchers hope that understanding how the brain compensates after being damaged by Alzheimer’s disease may help to develop strategies to keep enhanced function for longer in patients with the condition.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This preliminary study found that a larger head circumference (as an indicator of brain size) was associated with less brain cell death and fewer symptoms of Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/July07/Pages/head-size-and-Alzheimers-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Perneczky R, Waggenpfeil S, Lunetta KL, Cupples LA, Green RC, DeCarli C, Farrer LA, Kurz MD. (2010) Head circumference, atrophy, and cognition: implications for brain reserve in Alzheimer disease. &lt;EM&gt;Neurology&lt;/EM&gt; 75(2): 137-142&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>325816</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/Learning-in-a-vegetative-state.aspx]]&gt;</url>
    <title>Behind the headlines - Learning in a vegetative state</title>
    <publicationDate>2009-09-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,TRAUMA,BRAIN INJURY,CONDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Daily Telegraph today reported that, “people lying in vegetative states in hospital can still learn” and that this “breakthrough could suggest which patients have the potential to recover from their injuries or illness”.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;The Daily Telegraph&lt;/EM&gt; today reported that, “people lying in vegetative states in hospital can still learn” and that this “breakthrough could suggest which patients have the potential to recover from their injuries or illness”.&lt;/P&gt;
&lt;P&gt;The research involved repeatedly playing a musical note to severely brain damaged patients and then blowing a puff of air into their eye. Although the patients initially only blinked after the air puff, over time they started to blink after hearing the note and before the puff of air. Conscious people&amp;nbsp;under anaesthetic did not learn to do this. &lt;/P&gt;
&lt;P&gt;The lead researcher, Dr Tristan Bekinschtein, is quoted in the newspaper as saying, “This test will hopefully become a useful, simple tool to test for consciousness without the need for imaging or instructions.”&lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This small study has shown that people in a vegetative state may be able to learn to respond to stimuli in a trace conditioning test. This research also suggests the test might be useful in predicting which individuals will begin showing signs of recovery.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/09September/Pages/Learning-in-a-vegetative-state.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Bekinschtein TA, Shalom DE, Forcato C &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.nature.com/neuro/journal/vaop/ncurrent/abs/nn.2391.html" target="_blank"&gt;Classical conditioning in the vegetative and minimally conscious state&lt;/A&gt;. &lt;EM&gt;Nature Neuroscience,&lt;/EM&gt; [Published online] September 20 2009.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304864</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/LeukemiadrughaltsMS.aspx]]&gt;</url>
    <title>Behind the headlines - Leukemia drug halts MS</title>
    <publicationDate>2008-10-23T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The CAMMS223 Trial Investigators. &lt;A title="Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis." href="http://content.nejm.org/cgi/content/abstract/359/17/1786" target="_blank"&gt;Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis.&lt;/A&gt; NEJM 2008; 359: 1786-1801&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319166</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/06June/Pages/Lifestyleandtheagingbrain.aspx]]&gt;</url>
    <title>Behind the headlines - Lifestyle and the ageing brain</title>
    <publicationDate>2009-06-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Yaffe K, Fiocco AJ, Lindquist K &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.neurology.org/cgi/content/abstract/72/23/2029" target="_blank"&gt;Predictors of maintaining cognitive function in older adults. The Health ABC Study.&lt;/A&gt; &lt;EM&gt;Neurology&lt;/EM&gt; 2009; 72: 2029-2035&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>346103</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Migraines-and-light.aspx]]&gt;</url>
    <title>Behind the headlines - Light’s effect on migraine studied</title>
    <publicationDate>2010-01-11T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MIGRAINE,HEADACHE &amp; PAIN,HEADACHE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Scientists have worked out why light makes migraines worse, paving the way for new treatments for the crippling headaches,” reported the Daily Mail. It said that the treatments would allow sufferers to endure light without pain so they would no longer need to shut themselves in a darkened room.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Scientists have worked out why light makes migraines worse, paving the way for new treatments for the crippling headaches,” reported the Daily Mail. It said that the treatments would allow sufferers to endure light without pain so they would no longer need to shut themselves in a darkened room.&lt;/P&gt;
&lt;P&gt;This laboratory study identified neural pathways in the brain that may be involved in the worsening of migraines with exposure to light. People often find that migraines are made worse by light, and the fact that some visually impaired people (who lack image-forming sight) are also affected, led researchers to speculate that non-image-forming pathways are responsible. They studied this in rats, finding that exposure to light increased the activity along certain neural pathways.&lt;/P&gt;
&lt;P&gt;These findings will be of interest to scientists, but it is unclear what clinical relevance they have. Whether these pathways can be targeted with treatments that reduce light sensitivity for migraine sufferers will need further research.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;In this laboratory study, researchers identified neural pathways that may be involved in the exacerbation of migraines following exposure to light. Photosensitivity (sensitivity to light)&amp;nbsp;is commonly associated with migraines, and the fact that some people who are visually impaired can experience this led the researchers to hypothesise that non-image-forming pathways are likely to be responsible. They were able to study this in rats, noting that exposure to light increased the activity along certain neural pathways.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Migraines-and-light.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Noseda R, Kainz V, Jakubowski M, et al. &lt;A href="http://www.nature.com/neuro/journal/vaop/ncurrent/full/nn.2475.html" target="_blank"&gt;A neural mechanism for exacerbation of headache by light&lt;/A&gt;. &lt;EM&gt;Nature Neuroscience&lt;/EM&gt; 2010; advance online publication&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>306906</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/LivertargetforAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Liver target for Alzheimer's</title>
    <publicationDate>2009-02-17T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Alzheimer’s could be tackled by treating a sufferer’s liver,” the Daily Mail said. The newspaper reported that researchers have found a link between levels of a toxic protein in the blood and Alzheimer’s disease. It said a study in rats suggests that helping the liver to clear the protein amyloid beta from the blood could fight the disease.&lt;/P&gt;
&lt;P&gt;This is preliminary research and does not have any immediate, direct implications for patients with Alzheimer’s disease. The rats did not have conditions that are similar to Alzheimer’s disease, but underwent surgical procedures before being injected with amyloid beta to affect levels of the protein in the body. These conditions do not reflect what would be seen in a human with Alzheimer’s.&lt;/P&gt;
&lt;P&gt;More research using animal models of Alzheimer’s disease would be needed to determine whether it is possible to accelerate amyloid beta breakdown in the liver. Whether this has any effect on brain clearance of amyloid beta, or the progression of the disease, will also need to be investigated&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is very preliminary research and does not, at this time, have any direct implications for patients with Alzheimer’s disease. The rats in this study did not have Alzheimer’s-like conditions involving a build-up of amyloid beta in the brain, but were injected with amyloid beta directly into the brain and bloodstream. The rats also had high levels of amyloid beta in their blood because of surgery to stop blood flow to their livers. These conditions do not reflect what would be seen in a human with Alzheimer’s.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/02February/Pages/LivertargetforAlzheimers.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Marques MA, Kulstad JJ, Savard CE, Green PS, Lee SP, Craft S, Watson GS, Cook DG. &lt;A href="http://dx.doi.org/10.3233/JAD-2009-0964" target="_blank"&gt;Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system.&lt;/A&gt; &lt;EM&gt;J Alzheimers Dis&lt;/EM&gt; 2009 Feb;16(2):325-9.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334396</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Lorenzos-oil-disease-gene-therapy.aspx]]&gt;</url>
    <title>Behind the headlines - Lorenzo's oil disease gene trial</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ LEUKODYSTROPHIES,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The genetic brain disease that was portrayed in the film Lorenzo’s Oil “has been stopped in its tracks by a gene therapy”, according to The Times.&lt;/P&gt;
&lt;P&gt;This rare but fatal disease, called adrenoleukodystrophy (ALD), is caused by a mutation in a gene. Although the disease can be treated by bone marrow transplant, this requires a suitable bone marrow donor to be found. The study used experimental gene therapy in two seven-year-old boys with ALD who did not have donors. A working copy of the faulty gene was inserted into the boys’ cells to try to improve their condition. The boys continued to develop areas of brain damage for a year, after which they had no further brain damage or decline in brain function. The boys are now aged nine and 10.&lt;/P&gt;
&lt;P&gt;This initial human study illustrates the potential of gene therapy for treating ALD. As yet, it is not known what the longer-term outcome of the gene therapy will be, or what effects it may have in adults with ALD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research indicates the potential of gene therapy in ALD. The study is important as, although the disease is rare, its effects are serious and fatal if not treated. The boys have been followed for about 30 months and the longer-term effects of the treatment are not yet clear. As the authors note, larger studies with longer follow-up are needed to determine the longer-term effects of this treatment and any risks associated with it. Further studies are also needed to determine how well the therapy compares to stem-cell transplant in boys who have a matched donor.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/11November/Pages/Lorenzos-oil-disease-gene-therapy.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Cartier N, Hacein-Bey-Abina S, Bartholomae CC &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.sciencemag.org/cgi/content/abstract/326/5954/818" target="_blank"&gt;Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy.&lt;/A&gt; &lt;EM&gt;Science&lt;/EM&gt; 2009: 326: 818–823&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309175</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/08August/Pages/Lunarphaseandstrokelikesymptoms.aspx]]&gt;</url>
    <title>Behind the headlines - Lunar phase and stroke-like symptoms</title>
    <publicationDate>2008-08-19T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,STROKE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Ahmad F, Quinn TJ, Dawson J, and Walters M. &lt;A title="A link between lunar phase and medically unexplained stroke symptoms: An unearthly influence?" href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6T8V-4SN8VF2-1&amp;amp;_user=10&amp;amp;_coverDate=08/31/2008&amp;amp;_alid=779273322&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_cdi=5096&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_ct=1&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=9ceaac359d2f1a8e5d780b4ec62f5080" target="_blank"&gt;A link between lunar phase and medically unexplained stroke symptoms: An unearthly influence?&lt;/A&gt; Journal of Psychosomatic Research 2008; 65: 131-133&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>346824</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/03March/Pages/headache-migraine-pain-relief-machine.aspx]]&gt;</url>
    <title>Behind the headlines - Machine 'zaps migraines away'</title>
    <publicationDate>2010-03-04T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A handheld device could ‘zap away’ headaches according to several newspapers. They say that the device, which delivers a magnetic pulse to the back of the head, could be an alternative to drug treatments for sufferers.&lt;/P&gt;
&lt;P&gt;The news is based on a well-conducted randomised controlled trial and has found promising results when using a ‘single-pulse transcranial magnetic stimulation’ device to treat people who frequently suffer from migraine with visual distortions (aura). Within two hours of the onset of symptoms more people were pain-free when using the handheld device than those who had used an identical dummy device. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted, double-blind, randomised controlled trial has found promising results when using single-pulse transcranial magnetic stimulation (sTMS) to treat people who frequently suffer from migraine with visual aura. Within two hours of the onset of symptoms, more people were pain-free when using the handheld device than those who had used an identical ‘sham’ device. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/03March/Pages/headache-migraine-pain-relief-machine.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lipton RB, Dodick DW, Silberstein SD&lt;EM&gt; et al.&lt;/EM&gt; &lt;A href="http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(10)70054-5/fulltext" target="_blank"&gt;Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial&lt;/A&gt;. &lt;I&gt;The Lancet Neurology&lt;/I&gt;; early online publication, March 4 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288754</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2007/January08/Pages/Mansmemoryreturns.aspx]]&gt;</url>
    <title>Behind the headlines - Man's memory returns</title>
    <publicationDate>2008-01-30T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hamani C, McAndrews MP, Cohn M, et al. &lt;A title="Memory enhancement induced by hypothalamic/fornix deep brain stimulation." href="http://www3.interscience.wiley.com/cgi-bin/abstract/117902419/ABSTRACT" target="_blank"&gt;Memory enhancement induced by hypothalamic/fornix deep brain stimulation.&lt;/A&gt; Ann Neurol; 63: 119-123&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>319780</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/07July/Pages/Maritalstatusanddementiarisk.aspx]]&gt;</url>
    <title>Behind the headlines - Marital status and dementia risk</title>
    <publicationDate>2009-07-03T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Håkansson K, Rovio S, Helkala E-L &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/abstract/339/jul02_2/b2462" target="_blank"&gt;Association between mid-life marital status and cognitive function in later life: population based cohort study.&lt;/A&gt; BMJ, July 2 2009&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>391495</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/memory-drug-studied-in-mice.aspx]]&gt;</url>
    <title>Behind the headlines - Memory drug studied in mice</title>
    <publicationDate>2010-10-13T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Daily Express reports today of a “drug to stop memory loss”. It said that a British team of researchers have made an amazing breakthrough and are a step closer to an “anti-ageing drug for the brain”.&lt;/P&gt;
&lt;P&gt;Underpinning this news report is a study that tested a new drug in mice. The study found that mice that received the drug had better spatial memory than control mice when they were tested in a maze.&lt;/P&gt;
&lt;P&gt;These findings do not mean that a treatment or a cure for dementia has been found. This is good research within its own right, and well documented by the researchers in their research paper. However, this is still early-stage research in animals. As there was no long-term follow-up of the animals and its effects on other types of memory, the findings have little immediate relevance to the health of people with dementia. The Daily Express’s front-page report is not justified by this research.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The findings from this study have been over-interpreted by the news. It is misleading to suggest that the researchers have found ‘a new drug that can slow the onset of dementia’. There are several reasons why this extrapolation is premature and not supported by this early study.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/memory-drug-studied-in-mice.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sooy K, Webster SP, Noble J &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.jneurosci.org/cgi/content/abstract/30/41/13867?view=short&amp;amp;fp=13867&amp;amp;vol=30&amp;amp;lookupType=volpage" target="_blank"&gt;Partial Deficiency or Short-Term Inhibition of 11 Beta -Hydroxysteroid Dehydrogenase Type 1 Improves Cognitive Function in Aging Mice&lt;/A&gt;. &lt;EM&gt;The Journal of Neuroscience&lt;/EM&gt; 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>323170</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/08August/Pages/Dementiaandanactivebrain.aspx]]&gt;</url>
    <title>Behind the headlines - Mental exercise maintains memory</title>
    <publicationDate>2009-08-04T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,AUGUST 2009,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Performing a mental exercise twice a day could help delay the rapid memory loss associated with dementia for more than a year”, The Daily Telegraph reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Performing a mental exercise twice a day could help delay the rapid memory loss associated with dementia for more than a year”, The Daily Telegraph reported. It said that a study of nearly 500 people aged 75 to 85 years looked at how often they did crosswords or puzzles, read, wrote or played card games. Of those who developed dementia, people who did 11 mental exercises a week developed memory problems about a year and four months later on average than those who did four exercises a week.&lt;/P&gt;
&lt;P&gt;This study suggests that elderly people who will go on to develop dementia may delay their onset of rapid mental decline by taking part in mentally stimulating activities. However, the age at which people were diagnosed with dementia was not affected.&lt;/P&gt;
&lt;P&gt;The study has some limitations, including the fact that it was a relatively small study and only measured participation in the activities at one point in time. Although this study alone does not prove that increased mental activity reduces risk of dementia, keeping mentally and physically active is probably beneficial for people of all ages.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study suggests that the onset of rapid mental decline in elderly people who go on to develop dementia may be delayed by participation in mentally stimulating leisure activities. However, it does not show whether taking part in these activities affects the risk of developing dementia. Also, having participated in more mental activities did not affect the age at which people were diagnosed with dementia, and once memory decline had started was associated with a faster rate of memory decline.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;See the entire&amp;nbsp;&lt;/EM&gt;&lt;A href="http://www.nhs.uk/news/2009/08August/Pages/Dementiaandanactivebrain.aspx" target="_blank"&gt;&lt;EM&gt;NHS Choices commentary&lt;/EM&gt;&lt;/A&gt;&lt;EM&gt;&amp;nbsp;on this news item.&lt;/EM&gt; &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hall CB, Lipton RB, Sliwinski M, et al.&amp;nbsp;&lt;A href="http://www.neurology.org/cgi/content/abstract/73/5/356" target="_blank"&gt;Cognitive activities delay onset of memory decline in persons who develop dementia.&lt;/A&gt; &lt;EM&gt;Neurology&lt;/EM&gt; 2009; 73: 356-361.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304861</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/Metalsinwine.aspx]]&gt;</url>
    <title>Behind the headlines - Metal in wine</title>
    <publicationDate>2008-10-30T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MOVEMENT DISORDERS,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Hague T, Petroczi A, Andrews PLR et al. &lt;A title="" href="http://www.journal.chemistrycentral.com/content/2/1/22" target="_blank"&gt;Determination of metal ion content of beverages and estimation of target hazard quotients: a comparative study.&lt;/A&gt; Chem Cent J 2008; Jun 25&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306907</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/MigraineStrokeHeartRisk.aspx]]&gt;</url>
    <title>Behind the headlines - Migraine and heart risk</title>
    <publicationDate>2009-02-19T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,HEADACHE,HEADACHE &amp; PAIN,MIGRAINE,STROKE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has reported that women with certain genes and blurred or difficult vision during migraines have a doubled risk of heart attack and stroke.These findings come from a US study on 25,000 women aged over 45, which looked at their migraine history, the presence of certain genes and their risk of cardiovascular problems. &lt;/P&gt;
&lt;P&gt;Although this study did find that one particular group of the women did face a doubled risk of cardiovascular problems, it should be highlighted that even this doubled risk remains relatively low. Readers might also misinterpret the news article to mean that of the 1,275 women in this high risk group, 625 went on to have these problems. However, there were actually 625 first-time major cardiovascular episodes in the 25,000 women in the study as a whole. &lt;/P&gt;
&lt;P&gt;This large study has some limitations, and more studies will be needed to confirm the findings, but it does provide impetus for future research. Meanwhile, the advice to women with migraines remains the same as for the general population: cardiovascular risk can be reduced through a healthy diet, not smoking and participating in physical activity.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study provides impetus for future research, although whether the findings will have practical implications remains to be seen. As the authors point out, other population studies have found an association between migraine and ischaemic cardiovascular events, so this is not a novel finding.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/02February/Pages/MigraineStrokeHeartRisk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Schürks M, Zee RYL, Buring JE, Kurth T. &lt;A href="http://dx.doi.org/10.1212/01.wnl.0000342517.97178.f6" target="_blank"&gt;ACE D/I polymorphism, migraine, and cardiovascular disease in women.&lt;/A&gt; Neurology 2009;72(7):650-656&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>380554</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/Aspirin-and-migraine.aspx]]&gt;</url>
    <title>Behind the headlines - Migraine relief from aspirin</title>
    <publicationDate>2010-04-15T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,DELIVERY OF CARE,JULY 2010,CONDITIONS,SYMPTOM MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Migraine sufferers could find relief in three aspirin tablets,” reported The Times. It said that researchers have suggested that one in four migraine sufferers could be pain-free within two hours if they take up to 1,000mg of aspirin in one go.&lt;/P&gt;
&lt;P&gt;This well-conducted Cochrane review combined the results of 13 trials, which compared aspirin to placebo or another migraine drug. It found that 24% of people given aspirin were pain-free at two hours compared to 11% of those given placebo. Nausea and vomiting associated with migraines were improved with the addition of an anti-sickness drug.&lt;/P&gt;
&lt;P&gt;The studies in this review used 900–1,000mg of aspirin. This is a high dose and aspirin is not without adverse effects, nor is it a suitable treatment for everyone. Regular use can increase the risk of stomach irritation and ulceration.&lt;/P&gt;
&lt;P&gt;Also, the review found no evidence that aspirin was any more effective than sumatriptan, the most common migraine treatment, or other migraine treatments. Individuals should refer any questions about their treatment to their GP.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted review has identified and combined the results of 13 trials that compared the use of aspirin with inactive placebo or another medicine to treat a migraine attack in diagnosed sufferers. It combined studies of different populations of migraine sufferers and several different treatments.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/04April/Pages/Aspirin-and-migraine.aspx" target="_blank"&gt;NHS Choices commentary&amp;nbsp;&lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults (Review). The Cochrane Library 2010, Issue 4&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>386846</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/migraines-and-heart-disease-risk.aspx]]&gt;</url>
    <title>Behind the headlines - Migraine with aura and heart risk</title>
    <publicationDate>2010-08-25T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"People who suffer from a severe form of migraine are more likely to die of heart disease and strokes,” reported The Daily Telegraph. It said that people who had migraine with aura were 28% more likely to die from coronary heart disease and 40% more likely to die of stroke.&lt;/P&gt;
&lt;P&gt;The Icelandic study asked people about their migraine history when they were middle aged and then followed them for up to 40 years. People who had migraine with auras (visual or sensory disturbances before their headache) were found to have a slightly higher risk of death from heart disease, stroke or non-cardiovascular diseases. The effect was not seen in people who had migraines without aura.&lt;/P&gt;
&lt;P&gt;The researchers emphasise that this represents only a small increase in absolute risk. Other risk factors such as high blood pressure, diabetes, smoking and high cholesterol all have much stronger effects, and people should focus on reducing these. These findings highlight the need for further research into the causes of migraines with aura and if there is any association with the causes of cardiovascular disease.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is a large, cohort study with a lengthy follow-up. There are several limitations that should be taken into account when interpreting this research.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/migraines-and-heart-disease-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Gudmundsson LS, Scher AI, Aspelund T, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/full/341/aug24_1/c3966" target="_blank"&gt;Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study.&lt;/A&gt; &lt;EM&gt;British Medical Journal&lt;/EM&gt; 2010, 341:c3966&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>387176</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/genetics-migraines-examined.aspx]]&gt;</url>
    <title>Behind the headlines - Migraines linked to genetics</title>
    <publicationDate>2010-09-02T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have discovered genes that may be behind migraines, “opening the door to a cure”, reported the &lt;EM&gt;Daily Mirror&lt;/EM&gt;. The newspaper said that these genes normally control the levels of a brain chemical called glutamate, but a variant form of the gene may lead to a build-up of glutamate within the nerve cells. According to the paper, halting this build-up could help stop migraines.&lt;/P&gt;
&lt;P&gt;The study behind this story scanned the DNA of several thousand people with and without a history of migraine. It compared their genetics and identified a particular gene variant that was more common in migraine sufferers. The study adds to our understanding of the complex processes that lead to migraines and highlights that there may be genetic causes.&lt;/P&gt;
&lt;P&gt;This is important research, but finding genes that are linked to a condition is very different from developing a safe treatment based on this knowledge. Overall, it is premature for newspapers to suggest that this research may soon produce a cure for migraines. Migraine is a complex condition in which the interaction between genes and the environment is likely to be important, meaning there may not be a single cause or cure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This was a well-conducted and well-described genetic study that followed a recognised approach for studies in this field. There are some points to consider, which are detailed in the complete record.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/genetics-migraines-examined.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Anttila V, Stefansson H, Kallela M &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.nature.com/ng/journal/vaop/ncurrent/abs/ng.652.html" target="_blank"&gt;Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1&lt;/A&gt;. &lt;EM&gt;Nature Genetics&lt;/EM&gt;, 29 August 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>328301</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/headache-vascular-problem-danger.aspx]]&gt;</url>
    <title>Behind the headlines - Migraines linked to stroke risk</title>
    <publicationDate>2009-10-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,OCTOBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Women taking the pill are more at risk of a stroke, the Daily Express has warned. The paper reports new research that shows that women who suffer from migraines double their risk if they take the pill. Several news sources have covered this research, although each has focused on different aspects of its findings.&lt;/P&gt;
&lt;P&gt;The study behind these stories is a systematic review analysis of studies that estimated the association between migraine, stroke and events such as heart attacks. The research found that any type of migraine was associated with stroke but not other events. Migraines with aura (visual distortions, such as seeing flashing lights) were responsible for this link, as highlighted in the BBC’s coverage.&lt;/P&gt;
&lt;P&gt;The study’s authors advise that being under 45, female, smoking or a user of oral contraceptives may be stroke risk factors. The review was well-conducted, but there are shortcomings associated with pooling the results from studies with different methodologies. This research adds weight to a growing body of evidence suggesting that the risk of stroke is greater in people with migraine.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This systematic review and meta-analysis provides high quality evidence for the association between migraine and strokes. There are several limitations to the study, many of which the researchers themselves highlight. [...]&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/headache-vascular-problem-danger.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Schürks M, Rist PM, Bigal ME &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.bmj.com/cgi/content/abstract/339/oct27_1/b3914" target="_blank"&gt;Migraine and cardiovascular disease: systematic review and meta-analysis&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt; 2009;339:b3914&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>325935</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/financial-trouble-dementia-warning-sign.aspx]]&gt;</url>
    <title>Behind the headlines - Money trouble 'a sign of dementia'</title>
    <publicationDate>2009-09-22T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Problems managing money, bank accounts and statements could be an early sign of Alzheimer's disease,” according to The Daily Telegraph.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Problems managing money, bank accounts and statements could be an early sign of Alzheimer's disease,” according to &lt;EM&gt;The Daily Telegraph.&lt;/EM&gt; It said these findings come from a study that followed 76 healthy older people and 87 older people with mild cognitive impairment for a year. It found that those people whose mild cognitive impairment progressed to dementia during the study performed worse at certain financial tests at the start of the study and showed greater decline in their scores over the year.&lt;/P&gt;
&lt;P&gt;Although this is a relatively small study that needs confirmation in larger and longer-term studies, these findings seem plausible. Progression to dementia seems likely to affect many areas of cognitive ability, which could include financial ability. &lt;/P&gt;
&lt;P&gt;It is important to note that this study was not looking at whether testing the average person’s financial skills could predict if they would go on to develop dementia. Rather, the study concentrated on older people who had already been diagnosed as having memory problems, and seeing whether those who progressed to dementia showed greater declines in their financial skills.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;There are a number of points to note when interpreting this study...&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/09September/Pages/financial-trouble-dementia-warning-sign.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Triebel KL, Martin R, Griffith HR &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.neurology.org/cgi/content/abstract/73/12/928" target="_blank"&gt;Declining financial capacity in mild cognitive impairment&lt;/A&gt;. &lt;EM&gt;Neurology&lt;/EM&gt;, 2009; 73: 928-934.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334400</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/MS-and-blood-flow-from-the-brain.aspx]]&gt;</url>
    <title>Behind the headlines - MS link to brain blood flow tested</title>
    <publicationDate>2009-11-27T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,DECEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Researchers are testing a “radical new theory that multiple sclerosis (MS) is caused by blockages in the veins that drain the brain”, BBC News reported.&lt;/P&gt;
&lt;P&gt;This theory was tested in 65 people with MS and several different groups of people without MS (controls). The study found that the blood drainage from the brain and spinal cord in people with MS was reduced compared to people without the condition.&lt;/P&gt;
&lt;P&gt;However, as these people already had MS at the beginning of the study, it is difficult to say whether the abnormal drainage was a cause of MS or occurred as a consequence of the disease. A much larger sample of people representing each of the four possible types of MS (disease courses) would need to be examined to confirm the findings.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is valuable research that builds on what is known about the physiological changes that occur in the venous system draining the brain and spinal cord in people with MS. The findings also indicate that there are differences in the venous abnormities in people with the four different disease courses of MS. This suggests that the venous obstruction and its location may have a role in determining the clinical course of MS.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/11November/Pages/MS-and-blood-flow-from-the-brain.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Zamboni P, Galeotti R, Menegatti E, et al.&amp;nbsp;&lt;A href="http://jnnp.bmj.com/content/80/4/392.abstract" target="_blank"&gt;Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis.&lt;/A&gt; &lt;EM&gt;J Neurol Neurosurg Psychiatry&lt;/EM&gt; 2009; 80: 392-399&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334394</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Pregnancy-and-MS.aspx]]&gt;</url>
    <title>Behind the headlines - MS progression and pregnancy</title>
    <publicationDate>2009-11-24T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ COMPLICATING MEDICAL DISORDERS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,DECEMBER 2009,PREGNANCY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Having children could slow down the progression of multiple sclerosis (MS),” The Independent reported. It said researchers have found that, compared to women with MS who have never had children, those who had children after the onset of the disease were 39% less likely to have progressed to a stage where they needed assistance when walking 100m.&lt;/P&gt;
&lt;P&gt;This research looked at the medical records of women attending an MS clinic in Belgium. The study has a number of limitations. For example, rather than childbirth slowing down the progress of MS, an alternative explanation of the results is that women who have less severe MS are more likely to decide to have children than those who have a faster-progressing disease.&lt;/P&gt;
&lt;P&gt;Due to the study's limitations, it does not provide conclusive evidence of the effects of pregnancy on the long-term progression of MS. Larger studies that examine this question are needed.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has a number of limitations that reduce the reliability of its results. Due to these limitations, this study does not provide conclusive evidence about the effects of pregnancy on the long-term progression of MS. Further studies will need to look at this question.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/11November/Pages/Pregnancy-and-MS.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;D’hooghe MB, Nagels G, Uitdehaag BMJ. Long-term effects of childbirth in MS. &lt;EM&gt;J Neurol Neurosurg Psychiatry&lt;/EM&gt; 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>380544</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/05May/Pages/Stem-cells-and-MS.aspx]]&gt;</url>
    <title>Behind the headlines - MS stem cell therapy trialled</title>
    <publicationDate>2010-05-06T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“A controversial trial using bone marrow stem cell therapy for MS patients has helped stabilise the disease,” reported the Daily Mail.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“A controversial trial using bone marrow stem cell therapy for MS patients has helped stabilise the disease,” reported the Daily Mail.&lt;/P&gt;
&lt;P&gt;The research was a phase I clinical trial in six people with chronic multiple sclerosis (MS), investigating whether it was safe to treat them with stem cells from their own bone marrow. Though the newspaper described the trial as controversial and mentions a commercial service that offers stem cells from umbilical cords, this service is seemingly unrelated to this research, and it is unclear where the controversy might stem from.&lt;/P&gt;
&lt;P&gt;The results were promising in that there were no serious side effects up to a year after treatment. Although the patients’ deterioration appeared to halt over this period, there was no control group and the trial involved only six people. It is therefore too early to know how effective it is.&lt;/P&gt;
&lt;P&gt;Despite being preliminary, these results are encouraging and need further investigation. The next stage would be to test the treatment in a larger patient population, comparing it to a placebo or an existing treatment to see whether it stabilises or improves MS symptoms over&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This very preliminary research has demonstrated that transfusing filtered bone marrow cells into people with MS did not cause serious side effects in this small group of six patients. The patients’ disability remained stable, and there was an improvement in their brain response to stimuli compared to before the treatments.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/05May/Pages/Stem-cells-and-MS.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Rice CM, Mallam EA, Whone AL et al. Safety and Feasibility of Autologous Bone Marrow Cellular Therapy in Relapsing-Progressive Multiple Sclerosis. Clinical Pharmacology &amp;amp; Therapeutics (2010); advance online publication May 5 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>334399</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/11November/Pages/Multi-tasking-test-for-Alzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Multi-tasking test for Alzheimer's</title>
    <publicationDate>2009-11-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,DECEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“A multi-tasking test can help avoid confusion between symptoms of depression and early Alzheimer’s,” The Daily Telegraph reported. It said that people with Alzheimer’s often have mildly impaired reasoning and memory, which can easily be mistaken for signs of depression. This can lead to them being wrongly diagnosed.&lt;/P&gt;
&lt;P&gt;This news is based on research that involved a ‘dual test’, in which two different mental tasks were carried out simultaneously. It found that Alzheimer’s patients performed worse than people with depression and healthy people.&lt;/P&gt;
&lt;P&gt;To see whether a test based on this principle improves the overall diagnosis of Alzheimer’s, it will need to be tested alongside the usual assessments in a larger group of patients who are not already known to have Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This series of cross-sectional observations has demonstrated that Alzheimer’s patients perform worse than healthy elderly people and those with depression in this dual task. This seems to be independent from the memory problems commonly associated with Alzheimer’s.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/11November/Pages/Multi-tasking-test-for-Alzheimers.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Kaschel R, Logie RH, Kazén M and Della Sala S.&amp;nbsp;&lt;A href="http://www.springerlink.com/content/pq2454166l568248" target="_blank"&gt;Alzheimer’s disease, but not ageing or depression, affects dual-tasking.&lt;/A&gt; &lt;EM&gt;Journal of Neurology&lt;/EM&gt; 2009; 256: 1860-1868&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288751</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2007/January08/Pages/Musicaidsstrokerecovery.aspx]]&gt;</url>
    <title>Behind the headlines - Music aids stroke recovery</title>
    <publicationDate>2008-02-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,STROKE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INTRACEREBRAL HAEMORRHAGE,HAEMORRHAGIC,REHABILITATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Särkämö T, Tervaniemi M, Laitinen S, et al. &lt;A title="Music listening enhances cognitive recovery and mood after middle cerebral artery stroke." href="http://brain.oxfordjournals.org/cgi/content/abstract/awn013v1" target="_blank"&gt;Music listening enhances cognitive recovery and mood after middle cerebral artery stroke.&lt;/A&gt; Brain 2008; Feb 20 [Epub ahead of print]&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>313155</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/04April/Pages/NewAlzheimerDrug.aspx]]&gt;</url>
    <title>Behind the headlines - New Alzheimer's drug tested</title>
    <publicationDate>2009-04-04T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ALZHEIMER'S DISEASE,DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Ridha BH, Rossor MN, Crutch SJ &lt;EM&gt;et al.&lt;/EM&gt;&amp;nbsp;&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B7W6D-4T25XX0-1RR&amp;amp;_user=10&amp;amp;_rdoc=1&amp;amp;_fmt=&amp;amp;_orig=search&amp;amp;_sort=d&amp;amp;view=c&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=88fd2125fb6d2246a1d05446d75025da" target="_blank"&gt;P2-307: CPHPC depletes serum amyloid P component from the cerebrospinal fluid in Alzheimer's disease.&lt;/A&gt; &lt;EM&gt;PNAS &lt;/EM&gt;2009 [via online press release]&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>324779</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/NewAlzheimersGenesFound.aspx]]&gt;</url>
    <title>Behind the headlines - New Alzheimer's genes identified</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ ALZHEIMER'S DISEASE,DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,LATER LIFE,DEMENTIA,CAUSES AND PREVENTION,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Genetic research has brought a “cure for Alzheimer’s a step closer”, according to The Times, which said scientists have found two genetic mutations that could be the cause of more than one-in-five cases of Alzheimer’s disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Genetic research has brought a “cure for Alzheimer’s a step closer”, according to &lt;EM&gt;The Times&lt;/EM&gt;, which said scientists have found two genetic mutations that could be the cause of more than one-in-five cases of Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;There is already a known association between the APOE gene and late-onset Alzheimer’s disease but the separate French and British studies have confirmed that a new genetic variant on chromosome eight, near the ‘CLU gene’ is associated with the risk of Alzheimer’s disease. This gene contains the code to produce an apolipoprotein, a molecule combining a protein and a fat. The studies also identified associations with two separate gene variants. Overall, these were robust, well-conducted studies. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These two well-conducted genome-wide association studies have similar findings, both identifying a variant called rs11136000 on chromosome eight near the CLU gene. Both studies estimated the ‘population attributable risk fraction’ to be 8.9%, meaning that&amp;nbsp;if the risk factor (i.e. the variant) were removed&amp;nbsp;&amp;nbsp; from the population it would reduce incidence of the disease by about 9%.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/09September/Pages/NewAlzheimersGenesFound.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Harold D, Abraham R, Hollingworth P&lt;EM&gt; et al&lt;/EM&gt;. &lt;A href="http://www.nature.com/ng/journal/vaop/ncurrent/abs/ng.440.html" target="_blank"&gt;Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease&lt;/A&gt;. Nature Genetics&lt;EM&gt;,&lt;/EM&gt;&amp;nbsp;September 6 2009 [Published online]&lt;/P&gt;
&lt;P&gt;Lambert JC, Heath S, Even G et al. &lt;A href="http://www.nature.com/ng/journal/vaop/ncurrent/abs/ng.439.html" target="_blank"&gt;Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease&lt;/A&gt;. Nature Genetics,&amp;nbsp; September 6 2009 [Published online]&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309454</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/06June/Pages/NewpillforMStested.aspx]]&gt;</url>
    <title>Behind the headlines - New pill for MS tested</title>
    <publicationDate>2008-06-20T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Comi G, Pulizzi A, Rovaris M, et al. &lt;A title="Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, r" href="http://www.thelancet.com/journals/lancet/article/PIIS0140673608609186/abstract" target="_blank"&gt;Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.&lt;/A&gt; The Lancet 2008; 371: 2085-2092&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>346106</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/MS-multiple-sclerosis-symptom-relief-tablet.aspx]]&gt;</url>
    <title>Behind the headlines - New pills for MS tested</title>
    <publicationDate>2010-01-21T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“The first tablets to fight multiple sclerosis dramatically reduce the chances of symptoms returning,” The Daily Telegraph has reported.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“The first tablets to fight multiple sclerosis dramatically reduce the chances of symptoms returning,” &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has reported. &lt;/P&gt;
&lt;P&gt;The news is based on clinical trials of two new drugs, fingolimod and cladribine, which cut the likelihood of relapses in people with the most common form of MS. The pills also reduce the chances of the disease progressing, and may be more convenient to take than current MS treatments. The drugs are going through the licensing process, and it is hoped that they will be available by the end of 2011. Their costs have not been announced.&lt;/P&gt;
&lt;P&gt;Overall this is exciting new research. However, based on this study, it is too soon to say whether either pill will “go on sale in the next few months” as the &lt;I&gt;Daily Mirror&lt;/I&gt; claims. While these drugs are close to clearing the final few hurdles of licensing, regulators may still require more data, particularly regarding their long-term safety.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These studies have shown that, when compared to placebo treatment, these new oral medications resulted in reductions in the rates of clinical relapse and the risk of disability progression. Treatment with the drugs also resulted in improvements in brain lesions, as visualised on MRI.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/01January/Pages/MS-multiple-sclerosis-symptom-relief-tablet.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Giovannoni G, Comi G, Cook S et al. &lt;A href="http://content.nejm.org/cgi/content/full/NEJMoa0902533" target="_blank"&gt;A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis&lt;/A&gt;. &lt;I&gt;NEJM&lt;/I&gt;, January 20 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288730</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/06June/Pages/Newtheoryforevolutionofbrainpower.aspx]]&gt;</url>
    <title>Behind the headlines - New theory for evolution of brain power</title>
    <publicationDate>2008-06-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Emes RD, Pocklington AJ, Anderson CNG et al. &lt;A title="Evolutionary expansion and anatomical specialization of synapse proteome complexity." href="http://www.nature.com/neuro/journal/vaop/ncurrent/full/nn.2135.html" target="_blank"&gt;Evolutionary expansion and anatomical specialization of synapse proteome complexity&lt;/A&gt;. Nat Neurosci 2008; June 08 [Epub ahead of print]&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>380550</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/brain-training-games-evidence-tested.aspx]]&gt;</url>
    <title>Behind the headlines - 'No benefit' from brain games</title>
    <publicationDate>2010-04-21T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STRUCTURAL,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Brain-training computer games “do not make users any smarter”, according to The Daily Telegraph. Various other news sources reported that popular celebrity-endorsed games are no more effective at boosting intelligence than spending time surfing the internet.&lt;/P&gt;
&lt;P&gt;These news articles are based on a well-conducted study which looked at the effects of six weeks of computerised brain-training (cognitive-training) tasks. These tasks aimed to improve skills in reasoning, memory, planning, attention and visual and spatial (visuospatial) awareness. The study compared changes in test performance in two groups who performed different brain-training activities with a third group who surfed the internet, looking for the answers to quiz questions. All three groups showed small improvements in post-training tests. This suggests that the improvements were simply due to familiarity with the test procedure. The brain-training groups failed to transfer the skills they learned and show improvement in other test areas that they had not been trained in.&lt;/P&gt;
&lt;P&gt;The study’s strengths include its design and large size. The researchers used recognised tests that were considered accurate to assess cognitive function. However, one limitation of this research is that a large proportion of the participants dropped out of their online training programme. Overall, the research suggests that there are no cognitive benefits from short-term use of brain-training games, although other research will need to test their long-term effects.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted study investigated the effects on cognitive function of cognitive-training tasks, aimed at improving reasoning, memory, planning, attention and visuospatial awareness. The researchers found that performance in four benchmarking tests was slightly improved after six weeks of training activities. Improvements were similar across the two cognitive-training groups and the control group, who were only asked obscure general knowledge questions as their training. This suggests that the improvements seen may be due to a practice effect from repeating the test. In other words, people tend to do better on a test if they have done it before.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/04April/Pages/brain-training-games-evidence-tested.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Owen AM, Hampshire A, Grahn JA et al. Putting brain training to the test (PDF, 233kb). Nature, April 21 2010&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309176</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/08August/Pages/Oilyfishandmemory.aspx]]&gt;</url>
    <title>Behind the headlines - Oily fish and memory</title>
    <publicationDate>2008-08-06T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Virtanen JK, Siscovick DS, Longstreth WT, et al. &lt;A title="Fish consumption and risk of subclinical brain abnormalities on MRI in older adults." href="http://www.neurology.org/cgi/content/abstract/71/6/439" target="_blank"&gt;Fish consumption and risk of subclinical brain abnormalities on MRI in older adults.&lt;/A&gt; Neurology 2008; 71:439-446&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>304854</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/11November/Pages/Elderlydistracted.aspx]]&gt;</url>
    <title>Behind the headlines - Older minds distracted easily</title>
    <publicationDate>2008-11-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,MILD COGNITIVE IMPAIRMENT,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Stevens WD, Hasher L, Chiew KS, and Grady CL. A &lt;A title="" href="http://www.jneurosci.org/cgi/content/abstract/28/48/12820" target="_blank"&gt;Neural Mechanism Underlying Memory Failure in Older Adults.&lt;/A&gt; &lt;EM&gt;The Journal of Neuroscience &lt;/EM&gt;2008; 28: 12820-12824 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>326694</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Olive-oil-and-Alzheimers-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Olive oil and Alzheimer's disease</title>
    <publicationDate>2009-10-02T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,OCTOBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Olive oil could hold key to defeating Alzheimer’s,” reported the Daily Express. The newspaper said that a compound found in the oil has been shown to slow down changes in the brain that lead to Alzheimer’s disease.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Olive oil could hold key to defeating Alzheimer’s,” reported the Daily Express. The newspaper said that a compound found in the oil has been shown to slow down changes in the brain that lead to Alzheimer’s disease. According to the paper, researchers believe that the antioxidant that gives the oil its "peppery bite" will become a key ingredient in new drugs.&lt;/P&gt;
&lt;P&gt;This laboratory study investigated the effects of an olive oil extract (oleocanthal) on chemicals thought to be involved in Alzheimer’s disease. It found that nerve cells exposed to oleocanthal were better protected from the effects of these potential neurotoxins (toxins that damage or destroy nerve cells).&lt;/P&gt;
&lt;P&gt;However, this study does not indicate that eating more olive oil will protect people from Alzheimer’s disease. The olive oil extract and other similar molecules may be important in the future development of drugs for Alzheimer’s disease, but these will require considerable further research and development. It will be some time before the direct relevance of these findings to preventing Alzheimer’s are clear, but this is the first step in the process.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Previous research has indicated that phenols (a group of chemical compounds) such as oleocanthal may have neuroprotective properties, and this laboratory study has uncovered some of the complex reactions that may explain these effects.&lt;/P&gt;
&lt;P&gt;More research is needed to establish how it protects nerve cells (for example, whether it reduces binding at the synapses or whether the protective effect is due to the changes in the structure of ADDLs that it causes).&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/Olive-oil-and-Alzheimers-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Pitt J, Roth W, Lacor P, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;amp;_udi=B6WXH-4WV15KG-1&amp;amp;_user=10&amp;amp;_coverDate=10/15/2009&amp;amp;_alid=1032046085&amp;amp;_rdoc=1&amp;amp;_fmt=high&amp;amp;_orig=search&amp;amp;_cdi=7159&amp;amp;_sort=d&amp;amp;_docanchor=&amp;amp;view=c&amp;amp;_ct=3&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=7243b5c95bcf537baf4eb5e0139a85ef" target="_blank"&gt;Alzheimer's-associated Aß oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal.&lt;/A&gt; &lt;EM&gt;Toxicology and Applied Pharmacology&lt;/EM&gt; 2009; 240: 189-197.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304866</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/Omega6andAlzheimer's.aspx]]&gt;</url>
    <title>Behind the headlines - Omega 6 and Alzheimer's</title>
    <publicationDate>2008-10-20T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sanchez-Mejia RO, Newman JW, Toh S, et al. &lt;A title="Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease." href="http://www.nature.com/neuro/journal/vaop/ncurrent/full/nn.2213.html" target="_blank"&gt;Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease.&lt;/A&gt; Nature Neuroscience 2008; Published online: 19 October&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309464</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/12December/Pages/StemcelltherapyQA.aspx]]&gt;</url>
    <title>Behind the headlines - Online stem cell therapy Q&amp;A</title>
    <publicationDate>2008-12-05T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Links to the headlines&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="Internet stem-cell clinics 'exploiting' MS and Parkinson's patients." href="http://www.timesonline.co.uk/tol/news/uk/health/article5280394.ece" target="_blank"&gt;Internet stem-cell clinics 'exploiting' MS and Parkinson's patients.&lt;/A&gt; The Times, December&amp;nbsp; 04 2008&lt;/P&gt;
&lt;P&gt;&lt;A title="Scientists warn on 'rogue clinics' offering costly stem cell therapies." href="http://www.ft.com/cms/s/0/a430078e-c1a4-11dd-831e-000077b07658.html?nclick_check=1" target="_blank"&gt;Scientists warn on 'rogue clinics' offering costly stem cell therapies.&lt;/A&gt; Financial Times, December 04 2008&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308718</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/WorkHoursDementiaRisk.aspx]]&gt;</url>
    <title>Behind the headlines - Overtime doesn't pay?</title>
    <publicationDate>2009-02-26T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Virtanen M, Singh-Manoux A, Ferrie JE &lt;EM&gt;et al.&lt;/EM&gt; &lt;A title="" href="http://aje.oxfordjournals.org/cgi/content/abstract/169/5/596" target="_blank"&gt;Long Working Hours and Cognitive Function: The Whitehall II Study.&lt;/A&gt; &lt;EM&gt;Am J Epidemiol;&lt;/EM&gt; 2009: Vol. 169, No. 5&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288104</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/05May/Pages/PainkillersandriskofAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Painkillers and risk of Alzheimer's</title>
    <publicationDate>2008-05-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Szekely CA, Green RC, Breitner JCS, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="No advantage of A 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies." href="http://www.neurology.org/cgi/content/abstract/01.wnl.0000313933.17796.f6v1" target="_blank"&gt;No advantage of A 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; May 28 [Epub ahead of print]&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>304868</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/Paralysisstudy.aspx]]&gt;</url>
    <title>Behind the headlines - Paralysis study</title>
    <publicationDate>2008-10-16T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,TRAUMA,STROKE,SPINAL INJURY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Moritz CT, Perlmutter SI and Fetz EE. &lt;A title="Direct control of paralysed muscles by cortical neurons." href="http://www.nature.com/nature/journal/vaop/ncurrent/abs/nature07418.html" target="_blank"&gt;Direct control of paralysed muscles by cortical neurons.&lt;/A&gt; Nature 2008; advance online publication 15 October&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309132</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/VitaminDandParkinson'sdisease.aspx]]&gt;</url>
    <title>Behind the headlines - Parkinson's disease and vitamin D</title>
    <publicationDate>2008-10-14T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MOVEMENT DISORDERS,PARKINSON'S DISEASE,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Evatt ML; DeLong MR; Khazai N et al. &lt;A title="" href="http://archneur.ama-assn.org/cgi/content/abstract/65/10/1348?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=vitamin+d&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;resourcetype=HWCIT" target="_blank"&gt;Prevalence of Vitamin D Insufficiency in Patients With Parkinson Disease and Alzheimer Disease.&lt;/A&gt; Arch Neurol 2008, 65: 1348 - 1352&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>377512</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04april/pages/parkinsons-brain-probe-trialled.aspx]]&gt;</url>
    <title>Behind the headlines - Parkinson's eased by brain probe</title>
    <publicationDate>2010-04-29T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MOVEMENT DISORDERS,PARKINSON'S DISEASE,JUNE 2010,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A brain “pacemaker” can fight Parkinson's disease, according to The Independent. The newspaper said that combining deep brain stimulation (DBS) implant surgery with standard drug treatment has been found to give greater improvement in motor function and to reduce symptoms more than drug treatment alone.</description>
    <body>&lt;![CDATA[ &lt;P&gt;A brain “pacemaker” can fight Parkinson's disease, according to The Independent. The newspaper said that combining deep brain stimulation (DBS) implant surgery with standard drug treatment has been found to give greater improvement in motor function and to reduce symptoms more than drug treatment alone.&lt;/P&gt;
&lt;P&gt;The research behind this news was a trial involving 366 people with advanced Parkinson’s disease that was not being adequately controlled with medication. It found that after a year, those who had a DBS implant had greater improvements in quality of life than those receiving medical treatment alone. This was particularly due to improvements in mobility, bodily discomfort and the ability to carry out the activities of daily living. However, DBS surgery was not without risks, and about 19% of patients had serious adverse effects, mainly infections.&lt;/P&gt;
&lt;P&gt;This trial suggests that combining DBS with medication has some benefits beyond drug therapy alone. Importantly, though, DBS treatment is invasive and will not be appropriate for everyone with Parkinson’s. This means that the potential benefits of DBS would need to be balanced against its risks for each patient.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;This study used a robust design to assess the effects of deep brain stimulation (DBS) on quality of life in people with Parkinson’s disease that had not responded adequately to medical treatment. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/04april/pages/parkinsons-brain-probe-trialled.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Williams A, Gill S, Varma T &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(10)70093-4/abstract" target="_blank"&gt;Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial&lt;/A&gt;. &lt;EM&gt;The Lancet Neurology,&lt;/EM&gt; April 29 2010 (early online publication)&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>380392</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/parkinsons-transplanted-cell-failure.aspx]]&gt;</url>
    <title>Behind the headlines - Parkinson's transplant clues</title>
    <publicationDate>2010-07-01T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MOVEMENT DISORDERS,DELIVERY OF CARE,PARKINSON'S DISEASE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,SYMPTOM MANAGEMENT,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Foetal transplants for Parkinson's disease patients have been “brought closer to reality” by new research, said The Independent today.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Foetal transplants for Parkinson's disease patients have been “brought closer to reality” by new research, said The Independent today.&lt;/P&gt;
&lt;P&gt;Trials of the experimental technique, which implants tissue from foetuses into the brain, had been stopped in the 1990’s after many patients experienced uncontrollable jerky movements known as dyskinesias. This new research was a follow-up study of two patients who had experienced the side effect after being treated with neural transplants some 15 years ago. Its findings suggest that dyskinesias may be due to imbalances in neurotransmitters following the transplants, and that these may be treatable with drugs.&lt;/P&gt;
&lt;P&gt;Although this study only looked at two patients, the ability to control the dyskinesias that led to earlier trials being halted is a potentially exciting prospect in the fight against Parkinson’s disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This interesting research was only conducted on two patients but has important implications for the treatment of this devastating disease. It is important to take into account a few features of the research that affect how rapidly the technique might be approved for use again.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/July07/Pages/parkinsons-transplanted-cell-failure.aspx" target="_blank"&gt;NHS Choices commentary &lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Politis M, Wu K, Loane C et al. Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants. Science Translational Medicine, 30 June 2010:&amp;nbsp; Vol. 2, Issue 38, p. 38ra46&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>306905</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/PassiveSmokeDementia.aspx]]&gt;</url>
    <title>Behind the headlines - Passive smoke and dementia</title>
    <publicationDate>2009-02-16T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Inhaling second-hand smoke could increase the risk of developing dementia,” The Daily Telegraph has reported, saying new research has found that non-smokers with higher levels of a smoking-related chemical in their saliva were at “44% greater risk of early memory problems”. The &lt;EM&gt;Daily Mail&lt;/EM&gt; has claimed that the same group had a 44% increased risk of developing Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;It is already established that smokers are at greater risk of dementia, but the study in question is the first to consider the effects of passive smoking. Researchers looked at data on over 5,000 non-smokers aged over 50 and measured their levels of cotinine, which is produced when the body breaks down nicotine. They found higher cotinine levels were associated with poorer cognitive ability. &lt;/P&gt;
&lt;P&gt;It should be noted that the study assessed degree of cognitive impairment, not a diagnosis of dementia, or in particular the Alzheimer’s disease suggested by the &lt;EM&gt;Daily Mail&lt;/EM&gt;. A diagnosis of Alzheimer’s requires that specific medical criteria be met.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This cross-sectional analysis of population-level data was well conducted, and is representative of the English population. &lt;/P&gt;
&lt;P&gt;The researchers have made adjustments to account for non-response in order to ensure that their results can be generalised to the population in England. The researchers have also taken into account a large number of factors that may be linked to cognitive impairment, and, when adjusting for these factors, found the relationship between high salivary cotinine and cognitive impairment remains. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/02February/Pages/PassiveSmokeDementia.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Llewellyn DJ, Lang IA, Langa KM, Naughton F, Matthews FE. &lt;A href="http://dx.doi.org/10.1136/bmj.b462" target="_blank"&gt;Exposure to secondhand smoke and cognitive impairment in non-smokers: national cross sectional study with cotinine measurement.&lt;/A&gt; &lt;EM&gt;BMJ&lt;/EM&gt; 2009 Feb 12;338:b462.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>304837</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/Personalityaffectsdementiarisk.aspx]]&gt;</url>
    <title>Behind the headlines - Personality and dementia risk</title>
    <publicationDate>2009-01-20T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Wang H. -X, Karp A, Herlitz A, et al. &lt;A title="Personality and lifestyle in relation to dementia incidence." href="http://www.neurology.org/cgi/content/abstract/72/3/253" target="_blank"&gt;Personality and lifestyle in relation to dementia incidence.&lt;/A&gt; Neurology 2009; 72: 253-259&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325812</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/09September/Pages/PesticidesParkinsonsdisease.aspx]]&gt;</url>
    <title>Behind the headlines - Pesticide linked to Parkinson's</title>
    <publicationDate>2009-09-15T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ PARKINSON'S DISEASE,MOVEMENT DISORDERS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Using pesticides at work 'increases risk of Parkinson's three-fold,'” according to The Daily Telegraph, which has reported on new research into Parkinson’s disease and a number of occupations.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Using pesticides at work 'increases risk of Parkinson's three-fold,'” according to &lt;EM&gt;The Daily Telegraph,&lt;/EM&gt; which has reported on new research into Parkinson’s disease and a number of occupations. The newspaper said that overall, the pesticides examined increased the risk by 80%, with three chemicals, including the insecticide permethrin and the weedkiller paraquat, increasing risk three-fold. &lt;/P&gt;
&lt;P&gt;The research behind the story compared information on 519 patients with Parkinson’s disease and 511 healthy people. It found that 44 of the patients with the disease and 27 of the healthy volunteers were exposed to pesticides at work. This research suggests that occupational exposure to certain pesticides can increase risk of Parkinson’s disease, but these results will need interpretation alongside other similar research and in light of its limitations. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;There are a number of limitations to this study.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2009/09September/Pages/PesticidesParkinsonsdisease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Tanner CM, Webster Ross G, Jewell SA, &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://archneur.ama-assn.org/cgi/content/abstract/66/9/1106" target="_blank"&gt;Occupation and Risk of Parkinsonism&lt;/A&gt;. &lt;EM&gt;Arch Neurol&lt;/EM&gt; 2009: 1106-1113.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288745</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/03March/Pages/PesticideslinkedtoParkinsons.aspx]]&gt;</url>
    <title>Behind the headlines - Pesticides linked to Parkinson's</title>
    <publicationDate>2008-03-28T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,PARKINSON'S DISEASE,MOVEMENT DISORDERS,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Hancock DB, Martin ER, Mayhew GM, &lt;EM&gt;et al. &lt;/EM&gt;&lt;A title="Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study." href="http://www.biomedcentral.com/1471-2377/8/6/abstract" target="_blank"&gt;Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study.&lt;/A&gt; &lt;EM&gt;BMC Neurology &lt;/EM&gt;2008, 8:6 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>328297</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Placebo-effect-starts-in-the-spine.aspx]]&gt;</url>
    <title>Behind the headlines - Placebo effect 'starts in the spine'</title>
    <publicationDate>2009-10-16T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,HEADACHE &amp; PAIN,CONDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Research suggests that the placebo effect works, in part, by blocking pain signals in the spinal cord from arriving at the brain in the first place,” The Times reported. The newspaper said the spinal cords of 15 healthy volunteers had been scanned while they received laser 'pinpricks' to their hands.&lt;/P&gt;
&lt;P&gt;An inactive cream was applied to both hands, but sometimes the subjects were told it was analgesic. The volunteers told they had been given a pain relief cream reported feeling 25% less pain and showed “significantly reduced activity in the spinal cord pathway that processes pain”.&lt;/P&gt;
&lt;P&gt;This interesting, small study highlights the powerful 'placebo effect' of suggestion. The 25% improvement in pain scores seen from the placebo effect is similar to the response seen in other studies on active versus placebo pills. This suggests that at least part of the effect can be explained by a neurological mechanism that is prompted by a belief in the effectiveness of a treatment.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The researchers discuss how placebo analgesia may work in terms of accepted theories of&amp;nbsp;pain control, particularly the gate-control theory which was described in the 1960s. That theory suggests that the sensation of physical pain is not a direct result of pain receptors in the skin sending messages up to the brain, but instead is an interaction between different neurons, both pain-transmitting and non-pain-transmitting, working both up and down the spinal cord. The activation of nerves coming down from the brain, and pain-relieving chemicals released by nerves, are then thought to open or shut an imaginary gate that can either inhibit an individual's perception of pain or let that perception pass through to the brain.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/Placebo-effect-starts-in-the-spine.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Eippert F, Finsterbusch J, Bingel U, Bchel C.&amp;nbsp;&lt;A href="http://www.sciencemag.org/cgi/content/abstract/326/5951/404" target="_blank"&gt;Direct Evidence for Spinal Cord Involvement in Placebo Analgesia.&lt;/A&gt; &lt;EM&gt;Science&lt;/EM&gt; 2009; 326: 404&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288748</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/03March/Pages/Potbellylinkedtodementia.aspx]]&gt;</url>
    <title>Behind the headlines - Pot belly linked to dementia</title>
    <publicationDate>2008-03-27T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Whitmer RA, Gustafson DR, Barrett-Connor E, &lt;EM&gt;et al. &lt;/EM&gt;&lt;A title="Central obesity and increased risk of dementia more than three decades later." href="http://www.neurology.org/cgi/content/abstract/01.wnl.0000306313.89165.efv1" target="_blank"&gt;Central obesity and increased risk of dementia more than three decades later.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; Mar 26 [Epub ahead of print] &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>346107</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/prion-protein-nerve-role-explored.aspx]]&gt;</url>
    <title>Behind the headlines - Protein could protect nerves</title>
    <publicationDate>2010-01-25T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The prion proteins that the body produces “may keep nerves healthy”, BBC News reported. The website says that prions play a vital role in maintaining nerve health, and it is possible that an absence of prions causes diseases of the central nervous system.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The prion proteins that the body produces “may keep nerves healthy”, BBC News reported. The website says that prions play a vital role in maintaining nerve health, and it is possible that an absence of prions causes diseases of the central nervous system.&lt;/P&gt;
&lt;P&gt;While malformed prion proteins have been previously implicated in conditions such as variant Creutzfeldt-Jakob Disease (CJD), this laboratory study in mice may have identified a role for normal prion proteins. Through a number of experiments, the researchers found that removing prions directly from nerve cells led to the degeneration of the cells and an associated reduction in nerve function.&lt;/P&gt;
&lt;P&gt;BBC News highlights an important bottom line, saying that it is too early to pick out a particular nerve condition that might correspond to the mouse experiments. Also, the mice in this research were resistant to prion diseases that are equivalent to CJD in humans. This means that it is unclear how these findings apply to the treatment or prevention of human prion diseases. This important science will pave the way for further research into the role of healthy prion proteins in human cell function.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This laboratory study will be of interest to neuroscientists and those interested in the science behind neurological disorders. While prions have been linked to diseases such as CJD and its variants, this study was not investigating this disorder. The study found that mice that were unable to produce the normal version of the prion protein (which occurs in healthy cells) developed long-term peripheral nerve damage. This nerve damage was similar to peripheral neuropathies seen in humans. Researchers therefore&amp;nbsp;investigated the role that PrPC (the healthy prion) plays in maintaining the health of peripheral nerves.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/01January/Pages/prion-protein-nerve-role-explored.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Bremer J, Baumann F, Tiberi C &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.nature.com/neuro/journal/vaop/ncurrent/full/nn.2483.html" target="_blank"&gt;Axonal prion protein is required for&amp;nbsp;peripheral myelin maintenance&lt;/A&gt;. &lt;EM&gt;Nature Neuroscience&lt;/EM&gt;; Published online January 24 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>387179</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/brain-training-speed-dementia-alzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Puzzling claims over brain games</title>
    <publicationDate>2010-09-02T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"People who do puzzles and crosswords may stave off dementia longer,” according to BBC News. The website said that mentally stimulating activities may protect the brain from memory loss but also speed up mental decline once dementia takes hold.&lt;/P&gt;
&lt;P&gt;The story is based on research that followed 1,157 elderly people to examine how mentally stimulating activity in old age affects the development of dementia. The results suggest that being mentally active slows down cognitive decline before the onset of dementia but leads to faster decline after dementia has set in. The authors suggest that mental activity may somehow allow the brain to initially tolerate the brain changes associated with Alzheimer’s, but that decline is swifter once brain changes reach a more advanced stage.&lt;/P&gt;
&lt;P&gt;While it is interesting, the authors’ theory was not conclusively proven by this study and will need further testing. Mental activity is only one factor that may contribute to the risk&amp;nbsp;of dementia, along with genetics, environment and education. The study did not specifically test brain-training games or puzzles, as some newspapers suggested.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study has some strengths, including the large number of patients followed and the long follow-up period. Furthermore, its clinical evaluations and assessments of cognitive function were based on validated measures. The participants also represent a broad spectrum of cognitive function, ranging from no impairment to dementia.&lt;/P&gt;
&lt;P&gt;However, the study also has limitations, which are discussed in the complete record.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/brain-training-speed-dementia-alzheimers.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Wilson RS, Barnes LL, Aggarwal NT &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.neurology.org/cgi/content/abstract/WNL.0b013e3181f25b5ev1" target="_blank"&gt;Cognitive activity and the cognitive morbidity of Alzheimer disease&lt;/A&gt;. &lt;EM&gt;Neurology&lt;/EM&gt;,&amp;nbsp;September 1 2010 (published online before print)&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319169</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/05May/Pages/QAonNiceguidanceforbackpain.aspx]]&gt;</url>
    <title>Behind the headlines - Q&amp;A on Nice guidance for back pain</title>
    <publicationDate>2009-05-27T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ OTHER NEUROPATHIC PAIN,RECENT ADDITIONS,HEADACHE &amp; PAIN,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;&lt;A href="http://guidance.nice.org.uk/CG88" target="_blank"&gt;Low back pain: early management of persistent non-specific low back pain.&lt;/A&gt;&amp;nbsp;NICE; May 2009&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>304852</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/12December/Pages/Stemcellwebsites.aspx]]&gt;</url>
    <title>Behind the headlines - Risks of online stem cell clinics</title>
    <publicationDate>2008-12-04T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MOVEMENT DISORDERS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lau D, Ogbogu U, Taylor B, et al. &lt;A title="Stem Cell Clinics Online: The Direct-to-Consumer Portrayal of StemCell Medicine." href="http://www.cell.com/cell-stem-cell/abstract/S1934-5909(08)00573-0" target="_blank"&gt;Stem Cell Clinics Online: The Direct-to-Consumer Portrayal of StemCell Medicine.&lt;/A&gt; Cell Stem Cell 2008; 3: 591-594&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288110</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/04April/Pages/Sensitiveskinasymptomofmigraine.aspx]]&gt;</url>
    <title>Behind the headlines - Sensitive skin a symptom of migraine</title>
    <publicationDate>2008-04-22T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Bigal ME, Ashina S, Burstein R, &lt;EM&gt;et al.&lt;/EM&gt; &lt;A title="Prevalence and characteristics of allodynia in headache sufferers: A population study." href="http://www.neurology.org/cgi/content/abstract/70/17/1525" target="_blank"&gt;Prevalence and characteristics of allodynia in headache sufferers: A population study.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; 70:1525-1533 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>328260</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/10October/Pages/Shingles-stroke-danger-research.aspx]]&gt;</url>
    <title>Behind the headlines - Shingles linked to stroke risk</title>
    <publicationDate>2009-10-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INFECTIONS,VIRAL INFECTIONS,CONDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;People with shingles are almost a third more likely to have a stroke in the next year, according to The Daily Telegraph, which reported research into stroke risk following shingles. The newspaper also says that people with a “rare” form of shingles affecting the eye were four times more likely to suffer from a stroke.&lt;/P&gt;
&lt;P&gt;The research behind this report followed groups of people with and without shingles, a condition caused by the varicella virus (chickenpox) earlier in life being reactivated years later. This research cannot prove whether or not shingles causes a stroke because it was a cohort study, which cannot establish cause and effect. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;According to the authors, previous infection with the varicella virus (chickenpox) is an important risk factor for stroke in children. In this study they set out to estimate how frequent stroke was in adults following herpes zoster attacks (shingles). [...]&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/10October/Pages/Shingles-stroke-danger-research.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Kang JH, Ho JD, Chen YH and Lin HC. &lt;A href="http://stroke.ahajournals.org/cgi/content/abstract/STROKEAHA.109.562017" target="_blank"&gt;Increased Risk of Stroke After a Herpes Zoster Attack. A Population-Based Follow-Up Study&lt;/A&gt;. &lt;EM&gt;Stroke&lt;/EM&gt; [published online before print] October 8 2009&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>346870</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/02february/pages/shingles-vaccinations-old-people.aspx]]&gt;</url>
    <title>Behind the headlines - shingles vaccination proposed</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INFECTIONS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Millions of people in their seventies could be vaccinated against shingles, according to several newspapers. The news is based on a recommendation from the government’s independent committee on immunisation. It says there may be benefits in vaccinating the elderly against the virus that causes the painful skin condition. &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; says a vaccination programme could be in place by late 2010 if it is proven to be cost-effective.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What will happen now?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The JCVI will release a full statement and recommendations to government about the scope of a universal vaccination programme in this country. They have advised that a programme be initiated if “a licensed vaccine is available at a cost effective price”. The statement also suggests that any such vaccination will only be available for people aged 70 to 79 years old.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/02february/pages/shingles-vaccinations-old-people.aspx" target="_blank"&gt;NHS Choices commentary &lt;/A&gt;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Further reading&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Department of Health&amp;nbsp;statement: &lt;A href="http://www.dh.gov.uk/en/MediaCentre/Pressreleasesarchive/DH_111735" target="_blank"&gt;Shingles vaccine moves a step closer&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319167</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/06June/Pages/SimpleDementiaTest.aspx]]&gt;</url>
    <title>Behind the headlines - Simple new test for Alzheimer's</title>
    <publicationDate>2009-06-10T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Brown J, Pengas G, Dawson K &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.bmj.com/cgi/content/abstract/338/jun08_3/b2030" target="_blank"&gt;Self administered cognitive screening test (TYM) for detection of Alzheimer’s disease: cross sectional study&lt;/A&gt;. &lt;EM&gt;BMJ&lt;/EM&gt;,&amp;nbsp;June 10 2009 (online publication)&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>383442</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/restless-sleep-kicking-parkinsons-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Sleep disorder linked to Parkinson's</title>
    <publicationDate>2010-07-29T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MOVEMENT DISORDERS,PARKINSON'S DISEASE,DEMENTIA,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,SLEEP DISORDERS,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Kicking and lashing out while asleep could mean you’re more likely to develop dementia or Parkinson’s disease,” reported the Daily Mail. It said a study has found a link between a sleep disorder and a higher risk of certain types of dementia up to 50 years later.&lt;/P&gt;
&lt;P&gt;The study looked at people diagnosed with one of several related neurological conditions and analysed their history of a severe form of REM sleep behaviour disorder (RBD), a condition in which people can act out recurrent dreams and move excessively while asleep.&lt;/P&gt;
&lt;P&gt;The study was not designed to look at the strength of the link between RBD and dementias, as patients in the study were selected because they were known to have had both of these conditions. Therefore, it is not possible to say from this study whether restless sleep is a predictor of future dementia as is implied in the newspaper headline. More research into whether RBD could be an early sign of the brain changes that lead to dementia later on would be useful.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;These findings suggest that the brain changes associated with certain neurodegenerative diseases could begin many years before the symptoms start to show.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/July07/Pages/restless-sleep-kicking-parkinsons-disease.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Claassen DO, Josephs KA, Ahlskog JE, &lt;EM&gt;et al.&lt;/EM&gt; &lt;A href="http://www.neurology.org/cgi/content/abstract/WNL.0b013e3181ec7facv1" target="_blank"&gt;REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century&lt;/A&gt;. &lt;EM&gt;Neurology&lt;/EM&gt; 2010, [Published online before print] July 28 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>306904</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/Sleepproblemsandweight.aspx]]&gt;</url>
    <title>Behind the headlines - Sleep problems and weight</title>
    <publicationDate>2009-02-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,CONDITIONS,SLEEP DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“People who cannot sleep at night should lose at least two stone in weight”, the &lt;EM&gt;Daily Express&lt;/EM&gt; reports. The newspaper adds that scientists have said the “best treatment for a sleep disorder is to put the patient on a diet”. It says a study in patients with obstructive sleep apnoea (which causes interruptions in breathing during sleep) found those put on a diet showed marked improvements in their sleep and each lost 20 pounds (9kg).&lt;/P&gt;
&lt;P&gt;This study provides evidence that “lifestyle modification”, which includes advice on diet and exercise, is effective at treating obstructive sleep apnoea if delivered using an intense programme. As such, people with mild obstructive sleep apnoea are advised to follow advice to exercise more and lose weight. Those with serious symptoms need a full assessment.&lt;/P&gt;
&lt;P&gt;The &lt;EM&gt;Daily Express&lt;/EM&gt; may have given the impression that all sleep disorders can be solved by weight loss. This is not the case, as not all sleep disorders are due to obstructive sleep apnoea. There are many other reasons for disturbed sleep that have nothing to do with weight.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This small, randomised controlled trial provides good evidence that weight loss is an appropriate treatment strategy for obstructive sleep apnoea. Clinical guidelines recommend encouraging weight loss in people whose obesity is contributing to their symptoms. This study supports this advice. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/02February/Pages/Sleepproblemsandweight.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Tuomilehto HP, Seppä JM, Partinen MM, Peltonen M, Gylling H, Tuomilehto JO, Vanninen EJ, Kokkarinen J, Sahlman JK, Martikainen T, Soini EJ, Randell J, Tukiainen H, Uusitupa M; Kuopio Sleep Apnea Group. &lt;A href="http://dx.doi.org/10.1164/rccm.200805-669OC" target="_blank"&gt;Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea.&lt;/A&gt; &lt;EM&gt;Am J Respir Crit Care Med&lt;/EM&gt; 2009;179(4):320-7.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>393827</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/heavy-smoking-linked-to-alzheimers-risk.aspx]]&gt;</url>
    <title>Behind the headlines - Smoking linked to Alzheimer's risk</title>
    <publicationDate>2010-10-26T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Heavy smoking in mid-life more than doubles the risk of developing Alzheimer's disease,” reports The Independent. It said that these findings come from a study in more than 21,000 middle-aged men and women in the US, who were followed for an average of 23 years.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;This study looked at data on people’s smoking at age 50 to 60, then followed them to see who developed dementia (either Alzheimer’s disease or vascular dementia). It found that people who smoked more than two packs of cigarettes a day were more than twice as likely to develop dementia as people who never smoked. The study’s strengths include its large size, and the fact that it enrolled people in middle age and followed them up over a long period of time. It does have some limitations: mainly that it had to rely on medical records to identify people with dementia, which means that some people with dementia may have been missed.&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This large study suggests that heavy smoking around the age of 50 to 60 may increase the risk of dementia in later life. The prospective nature of this study and its size are strengths, but there are some limitations.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/heavy-smoking-linked-to-alzheimers-risk.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Rusanen M, Kivipelto M, Quesenberry Jr CP &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://archinte.ama-assn.org/cgi/content/short/archinternmed.2010.393" target="_blank"&gt;Heavy Smoking in Midlife and Long-term Risk of Alzheimer Disease and Vascular Dementia.&lt;/A&gt; &lt;EM&gt;Archives of Internal Medicine&lt;/EM&gt; 2010, Published online October 25&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309180</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Snoringandheartattackrisk.aspx]]&gt;</url>
    <title>Behind the headlines - Snoring and heart attack risk</title>
    <publicationDate>2008-07-23T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,OBSTRUCTIVE SLEEP APNOEA,SLEEP DISORDERS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Sert Kuniyoshi FH, Garcia-Touchard A, Gami AS, et al. &lt;A title="Day–Night Variation of Acute Myocardial Infarction in Obstructive Sleep Apnea." href="http://content.onlinejacc.org/cgi/content/abstract/52/5/343" target="_blank"&gt;Day–Night Variation of Acute Myocardial Infarction in Obstructive Sleep Apnea.&lt;/A&gt; JACC 2008; 52:343-346&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>380546</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/04April/Pages/voice-test-parkinsons-disease-diagnosis.aspx]]&gt;</url>
    <title>Behind the headlines - Speech scan for Parkinson's</title>
    <publicationDate>2010-04-16T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MOVEMENT DISORDERS,PARKINSON'S DISEASE,JULY 2010,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Parkinson’s disease “could be diagnosed by voice changes”, according to The Daily Telegraph. The newspaper said that Parkinson’s disease could be diagnosed earlier by testing for subtle changes in speech that often accompany the condition.&lt;/P&gt;
&lt;P&gt;This news story was based on research that compared different ways of analysing the sound wave patterns generated when vowels are spoken. The researchers found that one method could detect changes in articulation that were present in people with Parkinson’s disease but not a comparison group of healthy individuals.&lt;/P&gt;
&lt;P&gt;One point to note is that the participants with Parkinson’s disease in the study had been diagnosed approximately seven years before this research, so their disease may have been fairly advanced. While this work encourages further research into this area, it remains to be seen to see whether the technique is sensitive enough to detect changes in articulation that may occur very early in the disease. Further research will be needed to judge whether this technique will lead to earlier diagnoses of Parkinson’s disease.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This preliminary research has demonstrated that the FCR analysis method can be used to detect dysarthric speech in people with Parkinson’s disease, and may be superior to the VSA analysis method sometimes currently used. However, the researchers say that there are other techniques to assess dysarthria which they did not test against the FCR method. Therefore, they cannot say that FCR is the overall preferred tool for assessing dysarthria without further research.&lt;/P&gt;
&lt;P&gt;See the entire&lt;A href="http://www.nhs.uk/news/2010/04April/Pages/voice-test-parkinsons-disease-diagnosis.aspx" target="_blank"&gt; NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sapir S, Ramig LO, Spielman JL, Fox C. Formant Centralization Ratio: A Proposal for a New Acoustic Measure of Dysarthric Speech. Journal of Speech, Language, and Hearing Research Vol.53 114-125 February 2010&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309942</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/03March/Pages/SpinalimplantandParkinsons.aspx]]&gt;</url>
    <title>Behind the headlines - Spinal implant for Parkinson's</title>
    <publicationDate>2009-03-20T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MOVEMENT DISORDERS,PARKINSON'S DISEASE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Fuentes R, Petersson P, Siesser WB, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Spinal Cord Stimulation Restores Locomotion in Animal Models of Parkinson's Disease." href="http://www.sciencemag.org/cgi/content/short/323/5921/1578" target="_blank"&gt;Spinal Cord Stimulation Restores Locomotion in Animal Models of Parkinson's Disease.&lt;/A&gt; &lt;EM&gt;Science &lt;/EM&gt;2009; 323: 1578-1582&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>309178</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/Statinsandcognitiveimpairment.aspx]]&gt;</url>
    <title>Behind the headlines - Statins and cognitive impairment</title>
    <publicationDate>2008-07-29T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Cramer C, Haan MN, Galea S, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study." href="http://www.neurology.org/cgi/content/abstract/71/5/344" target="_blank"&gt;Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; 71:344-350&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>308722</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/03March/Pages/StemCellStrokeScaffold.aspx]]&gt;</url>
    <title>Behind the headlines - Stem cells for stroke</title>
    <publicationDate>2009-03-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,STROKE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Bible E, Chau DYS, Alexander MR &lt;EM&gt;et al&lt;/EM&gt;. The support of neural stem cells transplanted into stroke-induced brain cavities by PLGA particles. &lt;EM&gt;Biomaterials &lt;/EM&gt;[via online press release] &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>306901</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/StemcelltreatmentforMS.aspx]]&gt;</url>
    <title>Behind the headlines - Stem cells 'reverse' MS</title>
    <publicationDate>2009-01-30T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Stem cell transplants could provide a cure for multiple sclerosis”, The Sun reported. It said that in a recent trial of 21 patients with MS, 17 had shown improvement three years after being injected with cells from their own bone marrow. The newspaper said the stem cells appear to reduce the inflammation that can worsen the disease. The study leader was quoted as saying: “It seems to prevent neurological progression and reverse disability.”&lt;/P&gt;
&lt;P&gt;The news story is based on an early phase trial, which found that stem cell transplants reversed neurological deficits in people with relapsing-remitting MS, the most common form of the disease. It did not look at other forms of the condition, such as secondary progressive MS. Patients were compared before and after the transplant, and the results were promising, with sustained improvements in disability in 81% of patients.&lt;/P&gt;
&lt;P&gt;As is usual when testing treatments, the intervention will go on to be tested in larger, controlled trials, probably randomised controlled trials across different centres. Until then, the researchers emphasize that it’s not possible to determine whether this treatment is better than existing treatments for relapsing-remitting MS.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study focuses on relapsing-remitting MS, which is the most common of the four types of multiple sclerosis. Many people with this type go on to develop secondary progressive MS (a steady worsening in symptoms and disability). It is important to highlight that the findings only apply to people who have relapsing-remitting MS. The researchers state that studies have found no improvement in neurological disability with transplantation in secondary progressive MS.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/01January/Pages/StemcelltreatmentforMS.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19186105" target="_blank"&gt;Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.&lt;/A&gt; &lt;EM&gt;Lancet Neurol&lt;/EM&gt; 2009 Mar;8(3):244-53.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>288739</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/04April/Pages/StudyfindscluetoParkinsons.aspx]]&gt;</url>
    <title>Behind the headlines - Study finds clue to Parkinson's</title>
    <publicationDate>2008-04-08T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MOVEMENT DISORDERS,PARKINSON'S DISEASE,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Bonilla S, Hall AC, Pinto L, et al. &lt;A title="Identification of midbrain floor plate radial glia-like cells as dopaminergic progenitors." href="http://www3.interscience.wiley.com/cgi-bin/abstract/117944729/ABSTRACT" target="_blank"&gt;Identification of midbrain floor plate radial glia-like cells as dopaminergic progenitors.&lt;/A&gt; Glia 2008; Mar 19 [Epub ahead of print]&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>383451</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/08August/Pages/dementia-prevention-strategies.aspx]]&gt;</url>
    <title>Behind the headlines - Study looks at reducing dementia burden</title>
    <publicationDate>2010-08-06T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Keeping one's brain active, trying not to become depressed and eating a diet rich in fruit and vegetables are the best ways to ward off developing dementia,” according to a report in The Daily Telegraph.&lt;/P&gt;
&lt;P&gt;This study was set up to estimate how eliminating specific risk factors for dementia could reduce the number of people developing the condition. The researchers followed 1,433 elderly adults over seven years, during which they regularly assessed cognitive performance and several known and suspected risk factors for dementia.&lt;/P&gt;
&lt;P&gt;This relatively large, well-conducted study may have implications for public health programmes. The conclusions are only rough estimates and their relevance to individuals is unclear. Little is known about whether any of these risk factors might help to cause the development of dementia. Furthermore, the participants were, on average, 72.5 years old at the start, and the effect of modifying these risk factors earlier in life is unknown.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This well-conducted, prospective study is a useful contribution to the understanding of the role that certain risk factors play in the development of dementia. Its diagnoses of dementia were validated by neurologists and it also includes measures of almost all known modifiable risk factors. It supports the results of previous research showing that these are risk factors, and estimates how much future dementia incidence could be reduced if certain risk factors were tackled at a public health level. However, as the researchers note, their calculations can only provide crude estimates.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/08August/Pages/dementia-prevention-strategies.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ritchie K, Carrière I, Ritchie CW et al.&amp;nbsp;&lt;A href="http://www.bmj.com/cgi/content/abstract/341/aug05_2/c3885" shape=rect target="_blank"&gt;Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors.&lt;/A&gt; &lt;EM&gt;BMJ 2010&lt;/EM&gt;; 341: c3885&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>388776</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/genetic-mutation-cause-of-migraine.aspx]]&gt;</url>
    <title>Behind the headlines - Study points to cause of migraine</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have discovered how to switch off the pain of migraines, The Daily Telegraph reported. The newspaper said that new drugs may soon be able to counteract the debilitating headaches.&lt;/P&gt;
&lt;P&gt;The study behind the news analysed the DNA of over 1,200 people to look for mutations within a gene known to play a role in the working of nerve cells. The analysis found a particular mutation in a woman who had migraines with “aura” (visual disturbances that accompany a migraine). When the mutation was traced back through the woman’s family, it was found that all those who carried the mutation also had migraines with aura. Further testing of the mutation showed that it affects the way cells in the spinal cord and brain chemically transfer signals to each other.&lt;/P&gt;
&lt;P&gt;As yet, we do not know how commonly people with migraine and aura are affected by the mutation, or whether mutations in the gene might play a role in migraine without aura. Also, there is likely to be a variety of genetic and environmental factors that increase the risk of getting migraines. While this genetic discovery may eventually help migraine sufferers, the media have been overly optimistic in interpreting this research as it is too soon to anticipate it leading directly to a treatment.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The study was well conducted and well described, but the media’s interpretation of the results was overly optimistic. The study did not investigate a treatment for migraine or a method to “switch off” the pain of migraines. Several important details are still unknown, including the number of people whose migraines may be caused by this faulty gene. It appears that the key mutation identified (F139WfsX24) was found in only one person out of the 600 or so who had migraines in this study (although it was also found in their family members). Further research will be needed to see whether these findings can be generalised to a larger population. Even if they can be, treatments based on these findings will be a long way off. The findings also only apply to people who have auras with their migraines, while most sufferers do not&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/genetic-mutation-cause-of-migraine.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Lafrenière RG, Cader MZ, Poulin JF &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.2216.html" target="_blank"&gt;A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura&lt;/A&gt;. Nature Medicine, September 26 2010 (published online) &lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>389851</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/tea-coffee-fight-brain-cancer.aspx]]&gt;</url>
    <title>Behind the headlines - Tea, coffee and brain cancer</title>
    <publicationDate>2010-09-29T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,NEURO-ONCOLOGY,PRIMARY BRAIN TUMOURS,CONDITIONS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Caffeine helps cut brain cancer risk,” said the Daily Express, reporting that a daily cup of tea or coffee can stop tumours growing by restricting blood flow to the brain.&lt;/P&gt;
&lt;P&gt;The large study behind this story followed 410,000 men and women across 10 European countries for 8.5 years and looked at the development of two forms of brain tumour. Brain tumours are rare, and during follow-up there were only 588 new cases in total. The researchers found no meaningful associations when they looked at each country separately, although combining all the national results showed a trend between greater caffeine consumption and lower cancer risk.&lt;/P&gt;
&lt;P&gt;The results echo those of a previous study and are likely to lead to further research into how caffeine may affect the working processes in the brain. However, the research has numerous important limitations, including the fact that variable methods were used for measuring caffeine intake across countries. Overall, while this research is of scientific interest, it has limited implications for current medical treatment.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This research has strengths, particularly its size and duration: it followed 410,309 men and women for 8.5 years, allowing a reasonable time for brain tumours to develop. However, while it found a trend towards an association between higher coffee and tea consumption and lower risk of glioma, careful consideration should be given to the possible shortcomings of this study.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/tea-coffee-fight-brain-cancer.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Michaud DS, Gallo V, Schlehofer B et al. &lt;A href="http://www.ajcn.org/cgi/content/abstract/ajcn.2010.29876v1" target="_blank"&gt;Coffee and tea intake and risk of brain tumors in the European Prospective Investigation into Cancer and Nutrition cohort study&lt;/A&gt;. &lt;EM&gt;American Journal of Clinical Nutrition&lt;/EM&gt;, September 15 2010 
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309450</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/06June/Pages/Vasculardementiaandintelligence.aspx]]&gt;</url>
    <title>Behind the headlines - Vascular dementia and intelligence</title>
    <publicationDate>2008-06-26T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS,VASCULAR DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;McGurn B, Deary IJ, Starr JM. &lt;A title="Childhood cognitive ability and risk of late-onset Alzheimer and vascular dementia." href="http://www.neurology.org/cgi/content/abstract/01.wnl.0000319692.20283.10v1" target="_blank"&gt;Childhood cognitive ability and risk of late-onset Alzheimer and vascular dementia.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; [Published online before print June 25, 2008]&lt;/P&gt;&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>334409</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Virus-link-to-CFS-in-doubt.aspx]]&gt;</url>
    <title>Behind the headlines - Virus link to CFS 'in doubt'</title>
    <publicationDate>2010-01-06T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,NEUROMUSCULAR,JANUARY 2010,CONDITIONS,CHRONIC FATIGUE SYNDROME/ME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Serious doubt has been cast on the theory that... chronic fatigue syndrome is caused by a new retrovirus,” The Guardian reported. The newspaper said researchers from London have failed to replicate findings from the US that suggested a possible role for a virus called XMRV in causing CFS, also known as ME (myalgic encephalomyelitis).&lt;/P&gt;
&lt;P&gt;In the new study none of the 186 UK CFS patients tested carried the XMRV virus, in contrast to the US study in 2009, which found that about two-thirds of 101 CFS patients tested had the virus. Why the two studies have different findings is not clear, but the results of the UK study do not support an association between XMRV infection and CFS in UK patients. This highlights the importance of different research groups repeating experiments in different populations.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This study suggests that the XMRV infection is not common in CFS patients in the UK. A previous case-control study from the US found that about two-thirds of the 101 CFS patients tested carried XMRV, compared to about 4% of 218 healthy controls. This led the researchers from the US study to suggest that XMRV might be the cause of CFS in these patients. The reason for the differences between the US and UK studies is not clear, but the authors of the UK study suggest that it could be due to XMRV infection being more common in the US than in Europe.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Virus-link-to-CFS-in-doubt.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Erlwein O, Kaye S, McClure MO, et al. &lt;A href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0008519" target="_blank"&gt;Failure to Detect the Novel Retrovirus XMRV in Chronic Fatigue Syndrome.&lt;/A&gt; &lt;EM&gt;PLoS ONE&lt;/EM&gt;, 2010; 5/ &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309130</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/10October/Pages/AlzheimersandvitB.aspx]]&gt;</url>
    <title>Behind the headlines - Vitamin B can't slow Alzheimer's</title>
    <publicationDate>2008-10-15T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Aisen PS, Schneider LS, Sano M et al. &lt;A title="" href="http://jama.ama-assn.org/cgi/content/abstract/300/15/1774?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=aisen&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;resourcetype=HWCIT" target="_blank"&gt;High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Controlled Trial.&lt;/A&gt; JAMA 2008; 300(15): 1774-1783&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>387536</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/09September/Pages/vitamin-B12-brain-shrink-dementia.aspx]]&gt;</url>
    <title>Behind the headlines - Vitamin B clue to dementia</title>
    <publicationDate>2010-09-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ LATER LIFE,DEMENTIA,CAUSES AND PREVENTION,TREATMENT AND CARE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Vitamin B tablets could slow and even halt the devastating march of Alzheimer's disease,” The Daily Telegraph reported. According to the newspaper, large daily doses of vitamin B can halve the rate of brain shrinkage, a process that can precede Alzheimer’s disease and dementia.&lt;/P&gt;
&lt;P&gt;This story is based on a well-conducted two-year trial, which compared vitamin B pills with inactive placebo pills in 271 elderly people with mild memory problems. The study found that those given vitamin B experienced brain shrinkage (atrophy) 30% slower than those given inactive tablets. However, slower brain shrinkage may not necessarily lead to any improvement in symptoms. &lt;/P&gt;
&lt;P&gt;This research does not show that vitamin B can prevent Alzheimer’s disease or dementia because there is no evidence to confirm that slower brain shrinkage will lead to benefits for people with early dementia symptoms. Nevertheless, these results are promising and clearly warrant more research.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is an important but early study in establishing the effects of vitamin B on the stages of brain atrophy that precede Alzheimer’s disease. It assessed the effects of the vitamin on the rate of brain shrinkage, a process that has been linked to old age, mild cognitive impairment and Alzheimer’s disease in other studies. Although other studies have found that the rate of brain atrophy is linked to cognitive decline, this particular study did not assess whether the participants’ brain changes translated into changes of cognitive ability or memory.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/09September/Pages/vitamin-B12-brain-shrink-dementia.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;David Smith A, Smith SM, de Jager CA &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0012244" target="_blank"&gt;Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial&lt;/A&gt;. &lt;EM&gt;PLoS One&lt;/EM&gt; 5(9): e12244&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309143</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/09September/Pages/VitaminB12andbrainvolume.aspx]]&gt;</url>
    <title>Behind the headlines - Vitamin B12 and brain volume</title>
    <publicationDate>2008-09-09T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Vogiatzoglou A, Refsum H, Johnston C, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Vitamin B12 status and rate of brain volume loss in community-dwelling elderly." href="http://www.neurology.org/cgi/content/abstract/71/11/826" target="_blank"&gt;Vitamin B12 status and rate of brain volume loss in community-dwelling elderly.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; 71:826–832&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>298460</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/11November/Pages/VitaminB3andAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Vitamin B3 and Alzheimer's</title>
    <publicationDate>2008-11-06T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,NEUROLOGICAL CONDITIONS,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Green KN, Steffan JS, Martinez-Coria H, et al. &lt;A title="Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selectiv" href="http://www.jneurosci.org/cgi/content/abstract/28/45/11500" target="_blank"&gt;Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-Phosphotau.&lt;/A&gt; J Neurosci 2008; 28: 11500-11510&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>381994</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/July07/Pages/vitamin-d-Parkinsons-disease.aspx]]&gt;</url>
    <title>Behind the headlines - Vitamin D and Parkinson's</title>
    <publicationDate>2010-07-13T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,PARKINSON'S DISEASE,MOVEMENT DISORDERS,JULY 2010,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Low vitamin D levels may increase a person's risk of developing Parkinson's disease,” BBC News has reported. Its website said that people with the lowest levels of vitamin D had a three-fold higher risk of developing Parkinson’s disease.&lt;/P&gt;
&lt;P&gt;The news is based on research that followed over 3,000 Finnish people aged 50 to 79 years over a period of 29 years. Scientists took a measurement of the participants’ blood vitamin D levels and looked at how the subsequent risk of developing Parkinson’s disease over the period related to their blood vitamin D levels.&lt;/P&gt;
&lt;P&gt;This high-quality, preliminary study showed an increased risk of developing Parkinson’s disease in those patients with the lowest vitamin D levels compared to the highest. However, Finland is a northern latitude country and so all the participants had relatively low levels of vitamin D, which the body produces using sunlight. Further research is needed to follow up whether this association is found in larger cohorts of people from different latitudes, who may have higher vitamin D levels than in this study.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This was a well-conducted study that looked prospectively at the role of vitamin D in the risk of developing Parkinson’s disease, although there are some limitations to the study that the researchers highlight.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/July07/Pages/vitamin-d-Parkinsons-disease.aspx" target="_blank"&gt;&lt;EM&gt;NHS Choices commentary&lt;/EM&gt;&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Knekt P, Kilkkinen A, Rissanen H, et al. (2010) Serum vitamin D and the risk of Parkinson disease. &lt;EM&gt;Archives of Neurology&lt;/EM&gt; 67(7): 808-811&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>306898</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/01January/Pages/DementiaVitaminD.aspx]]&gt;</url>
    <title>Behind the headlines - Vitamin D 'keeps you sharp'</title>
    <publicationDate>2009-01-26T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Taking vitamin D supplements in middle age could cut the risk of Alzheimer's disease in later life,” claims the Daily Mail. The newspaper says new research has showed high levels of vitamin D were “closely linked to staying mentally sharp in old age” and that taking supplements could prove a simple and cheap way of cutting dementia risk. &lt;/P&gt;
&lt;P&gt;The study behind this story has found a link between levels of vitamin D in blood and mental awareness. It did this by comparing almost 2,000 elderly people’s blood levels of vitamin D with performance in simple mental tests. However, participants did not receive clinical diagnoses of Alzheimer’s disease or another form of dementia. &lt;/P&gt;
&lt;P&gt;While scientists found a relationship between vitamin D and mental awareness, this study is early research and its design means it can’t prove that a lack of vitamin D is a cause of lowered mental ability. Other important factors, including general health and fitness, activity levels, vitamin B12 and blood pressure, may explain the difference in cognitive ability seen in this study.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This nationally representative cross-sectional study has shown that there is a relationship between vitamin D levels and cognitive impairment in people aged over 65 years. However, the cross-sectional design of the study means it cannot show causation.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/01January/Pages/DementiaVitaminD.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Llewellyn DJ, Langa KM, Lang IA. &lt;A href="http://dx.doi.org/10.1177/0891988708327888" target="_blank"&gt;Serum 25-hydroxyvitamin D concentration and cognitive impairment.&lt;/A&gt; &lt;EM&gt;J Geriatr Psychiatry Neurol &lt;/EM&gt;2009 Sep;22(3):188-95. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>306903</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/02February/Pages/MSandVitaminD.aspx]]&gt;</url>
    <title>Behind the headlines - Vitamin D linked to MS</title>
    <publicationDate>2009-02-05T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Multiple sclerosis could be prevented through daily vitamin D supplements” reports &lt;EM&gt;The Times&lt;/EM&gt;, stating that scientists have found the first causal link between the “sunshine vitamin” and a gene that increases the risk of the incurable neurological condition, known as MS.&lt;/P&gt;
&lt;P&gt;The news comes from research into how vitamin D interacts with the genes that make certain people more likely to develop MS. The researchers claim their study strongly implies that vitamin D deficiency increases the risk of developing MS among susceptible individuals. This study was not attempting to find a cure or treatment for MS.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is important research and will be of major interest to people living with MS. However, this study concentrated on susceptibility to MS among populations, rather than looking for a cure or treatment to help those already living with the condition. “These are exciting advances, but unfortunately we have yet to find and solve the cause of MS… what I think we’ve done is add another piece to the jigsaw” said Dr Julian Knight, one of the authors. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2009/02February/Pages/MSandVitaminD.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, Deluca GC, Herrera BM, Chao MJ, Sadovnick AD, Ebers GC, Knight JC. &lt;A href="http://dx.doi.org/10.1371/journal.pgen.1000369" target="_blank"&gt;Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D.&lt;/A&gt; PLoS Genet. 2009 Feb;5(2):e1000369. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>309136</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/09September/Pages/Warfarinandbrainhaemorrhage.aspx]]&gt;</url>
    <title>Behind the headlines - Warfarin and brain haemorrhage</title>
    <publicationDate>2008-09-30T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,STROKE,HAEMORRHAGIC,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;&lt;A title="Blood-thinning drug warfarin may raise risk of death from brain haemorrhage." href="http://www.telegraph.co.uk/news/newstopics/politics/health/3102806/Blood-thinning-drug-warfarin-may-raise-risk-of-death-from-brain-haemorrhage.html" target="_blank"&gt;Blood-thinning drug warfarin may raise risk of death from brain haemorrhage.&lt;/A&gt; The Daily Telegraph, September 30, 2008&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>288108</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/05May/Pages/Weightlinktodementia.aspx]]&gt;</url>
    <title>Behind the headlines - Weight link to dementia</title>
    <publicationDate>2008-05-08T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Beydoun MA, Beydoun HA, Wang Y. &lt;A title="Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis." href="http://www.blackwell-synergy.com/doi/abs/10.1111/j.1467-789X.2008.00473.x" target="_blank"&gt;Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis.&lt;/A&gt; &lt;EM&gt;Obes Rev&lt;/EM&gt; 2008; 9:204–218 &lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>309440</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2008/07July/Pages/WillkeepingfitfightAlzheimers.aspx]]&gt;</url>
    <title>Behind the headlines - Will keeping fit fight Alzheimer’s?</title>
    <publicationDate>2008-07-15T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Burns JM, Cronk BB, Anderson HS, &lt;EM&gt;et al&lt;/EM&gt;. &lt;A title="Cardiorespiratory fitness and brain atrophy in early Alzheimer disease." href="http://www.neurology.org/cgi/content/abstract/71/3/210" target="_blank"&gt;Cardiorespiratory fitness and brain atrophy in early Alzheimer disease.&lt;/A&gt; &lt;EM&gt;Neurology &lt;/EM&gt;2008; 71:210–216&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>346108</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/01January/Pages/Will-pumping-iron-fight-dementia.aspx]]&gt;</url>
    <title>Behind the headlines - Will pumping iron fight dementia?</title>
    <publicationDate>2010-01-26T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>“Pensioners should start pumping iron if they want to keep Alzheimer’s at bay,” warned the Daily Mail. It said a study had found that lifting weights can improve cognitive function in those aged 65 to 75.</description>
    <body>&lt;![CDATA[ &lt;P&gt;“Pensioners should start pumping iron if they want to keep Alzheimer’s at bay,” warned the &lt;EM&gt;Daily Mail.&lt;/EM&gt; It said a study had found that lifting weights can improve cognitive function in those aged 65 to 75.&lt;/P&gt;
&lt;P&gt;This study suggests there may be certain cognitive benefits in resistance exercise for older women compared with stretching and toning only. However, the study did not look at&amp;nbsp;its effects on dementia or Alzheimer’s disease. The newspaper’s claim that older people should start “pumping iron” to avoid Alzheimer’s appears to be confused with another paper published in the same journal.&lt;/P&gt;
&lt;P&gt;Maintaining physical activity is beneficial to health, and older people who are not capable of resistance training may find less strenuous activities to be of benefit. Those who do wish to take up resistance training should ensure that they are fit enough to do so and are exercising in the correct way,&amp;nbsp;with advice from their doctor&amp;nbsp;and a trained fitness instructor.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This small study suggests that resistance training can lead to greater improvement in certain cognitive measures than exercises aimed at balance and toning. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/01January/Pages/Will-pumping-iron-fight-dementia.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Liu-Ambrose T, Nagamatsu LS, Graf P &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://archinte.ama-assn.org/cgi/content/abstract/170/2/170" target="_blank"&gt;Resistance Training and Executive Functions.&lt;/A&gt; &lt;EM&gt;Archives of Internal Medicine&lt;/EM&gt; 2010; 170: 170-178&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>319170</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2009/05May/Pages/Workkeepsdementiaatbay.aspx]]&gt;</url>
    <title>Behind the headlines - Work keeps dementia 'at bay'</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>NHS Choices</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DEMENTIA,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;'Behind the headlines' is produced&amp;nbsp;by the NHS Knowledge Service and provides&amp;nbsp;an unbiased and evidence-based analysis of health stories that make the news. &lt;/P&gt;
&lt;P&gt;Health stories that make the headlines are analysed and presented with the following details:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Where did the story come from? 
&lt;LI&gt;What kind of scientific study was this? 
&lt;LI&gt;What were the results of the study? 
&lt;LI&gt;What interpretations did the researchers draw from these results? 
&lt;LI&gt;What does the NHS Knowledge Service make of this study? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;Lupton MK, Stahl C, Archer N, et al.&amp;nbsp;&lt;A href="http://www3.interscience.wiley.com/journal/122394520/abstract" target="_blank"&gt;Education, occupation and retirement age effects on the age of onset of Alzheimer's disease.&lt;/A&gt; &lt;EM&gt;International Journal of Geriatric Psychiatry&lt;/EM&gt; 2009; Published Online 20 May&lt;A href="http://www.library.nhs.uk/gastroliver/RSSFeed.aspx?feed=68" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>398102</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/simple-early-alzheimers-test.aspx]]&gt;</url>
    <title>Behind the headlines: Brain scan is not an Alzheimer's test</title>
    <publicationDate>2010-11-12T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists are developing a “30-second Alzheimer’s screening test” reported The Daily Telegraph. It said that such a test “could be available in as little as two years”.&lt;/P&gt;
&lt;P&gt;This news was based on research that gave MRI scans to 428 healthy people in their forties to look for changes in the intensity of white matter lesions (the nerve fibres) in specific areas of the brain. The study found that these brain changes were each present in 0.4-20% of participants and that their presence in specific areas was linked to poorer performance in some cognitive tests. There were also differences in the way men and women were affected.&lt;/P&gt;
&lt;P&gt;White matter changes have previously been associated with poorer performances on some cognitive tests in older individuals, and this research looked for a similar association in younger people. However, it is important to emphasise that this research has not developed a test for Alzheimer’s or dementia, as some newspapers have reported.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This research has assessed white matter hyperintensities and cognitive performance in a younger population than previously studied, and has found associations between changes, in particular, brain areas and poorer performance, on some cognitive tasks.&lt;/P&gt;
&lt;P&gt;It is important to emphasise that this research has not developed a test for Alzheimer’s, as the newspapers have reported, or indeed any type of dementia.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/11November/Pages/simple-early-alzheimers-test.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Bunce D, Anstey KJ, Cherbuin N, &lt;EM&gt;et al&lt;/EM&gt;. (2010) &lt;A href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013567" target="_blank"&gt;Cognitive Deficits Are Associated with Frontal and Temporal Lobe White Matter Lesions in Middle-Aged Adults Living in the Community&lt;/A&gt;. PLoS ONE 5(10)&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398010</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/effect-of-memory-gene-in-alzheimers-explored.aspx]]&gt;</url>
    <title>Behind the headlines: Effect of memory gene in Alzheimer's explored</title>
    <publicationDate>2010-12-15T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“An injection that may stop Alzheimer’s in its early stages has been developed by scientists,” reported the Daily Mail.&lt;/P&gt;
&lt;P&gt;This news story is based on an animal study that looked at the process by which genes were switched on during memory formation and how this was affected by amyloid beta, a protein that accumulates in Alzheimer’s disease. The protein has been shown to affect neurone activity, memory and to cause neurones to die in the brain.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This preliminary research demonstrated the importance of CREB activity in learning and memory and how this is impaired in a mouse model of Alzheimer’s disease. The researchers showed that injecting mice brains with the gene to make another protein that could restore CREB activity, improved the mice’s performance on memory tasks.&lt;/P&gt;
&lt;P&gt;These are promising findings; however, it should be pointed out this is an animal study and its direct relevance to humans is limited. The researchers say their findings support the idea that gene transfer to adult brains can be used as a therapy for Alzheimer’s disease. But as this technique involved the genes being injected directly into the mouse’s brains, further work is required to assess whether a more appropriate delivery method can be used for humans.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/12December/Pages/effect-of-memory-gene-in-alzheimers-explored.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Caccamo A, Maldonado MA, Bokov AF, &lt;EM&gt;et al&lt;/EM&gt;.&amp;nbsp;&lt;A href="http://www.pnas.org/content/early/2010/12/08/1012851108.abstract?sid=" target="_blank"&gt;CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease.&lt;/A&gt; Proceedings of the National Academy of Science 2010, December 13&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398104</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/memory-drug-studied-in-mice.aspx]]&gt;</url>
    <title>Behind the headlines: Memory drug studied in mice</title>
    <publicationDate>2010-10-13T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Daily Express reports today of a “drug to stop memory loss”. It said that a British team of researchers have made an amazing breakthrough and are a step closer to an “anti-ageing drug for the brain”.&lt;/P&gt;
&lt;P&gt;Underpinning this news report is a study that tested a new drug in mice. The study found that mice that received the drug had better spatial memory than control mice when they were tested in a maze.&lt;/P&gt;
&lt;P&gt;These findings do not mean that a treatment or a cure for dementia has been found. This is good research within its own right, and well documented by the researchers in their research paper. However, this is still early-stage research in animals. As there was no long-term follow-up of the animals and its effects on other types of memory, the findings have little immediate relevance to the health of people with dementia. The Daily Express’s front-page report is not justified by this research.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The findings from this study have been over-interpreted by the news. It is misleading to suggest that the researchers have found ‘a new drug that can slow the onset of dementia’. There are several reasons why this extrapolation is premature and not supported by this early study.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/10October/Pages/memory-drug-studied-in-mice.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Sooy K, Webster SP, Noble J &lt;EM&gt;et al&lt;/EM&gt;. &lt;A href="http://www.jneurosci.org/cgi/content/abstract/30/41/13867?view=short&amp;amp;fp=13867&amp;amp;vol=30&amp;amp;lookupType=volpage" target="_blank"&gt;Partial Deficiency or Short-Term Inhibition of 11 Beta -Hydroxysteroid Dehydrogenase Type 1 Improves Cognitive Function in Aging Mice&lt;/A&gt;. &lt;EM&gt;The Journal of Neuroscience&lt;/EM&gt; 2010&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398014</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/dementia-pesticide-use.aspx]]&gt;</url>
    <title>Behind the headlines: Pesticides and dementia</title>
    <publicationDate>2010-12-02T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Long-term exposure to pesticides leads to a greater risk of dementia, The Independent has reported.&lt;/P&gt;
&lt;P&gt;The news comes from a study of almost 1,000 French vineyard workers. It found that those directly exposed to pesticides over a long period performed less well in tests of mental (cognitive) ability than those who were not exposed at all. When the volunteers were tested again around five years later, the cognitive performance of workers directly exposed to pesticides had declined more in certain tests than that of workers who were not exposed.&lt;/P&gt;
&lt;P&gt;This study appears to show an association between long-term pesticide exposure and a slightly greater risk of decline in mental ability, as measured by certain tests. Although the study raises an important issue, it does not show that pesticides cause dementia. Dementia has several risk factors, including family history of the condition and age. It is possible that other factors influenced participants’ mental performance, including age, education and alcohol intake. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This study seems to have found an association between long-term exposure to pesticides and a mild risk of worsening cognitive ability, compared to non-exposure. It’s important to note that the study’s limitations (listed in the complete record) could have affected the results.&lt;/P&gt;
&lt;P&gt;See the entire&amp;nbsp;&lt;A href="http://www.nhs.uk/news/2010/12December/Pages/dementia-pesticide-use.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Baldi I, Gruber A, Rondeau V &lt;EM&gt;et al.&lt;/EM&gt;&amp;nbsp;&lt;A href="http://oem.bmj.com/content/early/2010/10/18/oem.2009.047811.abstract" target="_blank"&gt;Neurobehavioural effects of long term exposure to pesticides: results from the 4-year follow up of the PHYTONER Study&lt;/A&gt;.&lt;EM&gt; Occupational Environmental Medicine&lt;/EM&gt; 2010 (published online first)&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398022</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/11November/Pages/ephb2-protein-alzheimers-disease-reversal.aspx]]&gt;</url>
    <title>Behind the headlines: Protein provides Alzheimer's clue</title>
    <publicationDate>2010-11-29T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A gene therapy technique designed to ease the memory problems of Alzheimer's disease has been tested in rats, BBC News has reported. The website says that scientists took rats bred to have an Alzheimer’s-like condition and improved their memory problems by increasing levels of a chemical that helps brain cells signal to each other.&lt;/P&gt;
&lt;P&gt;The laboratory study in question has detailed some of the complex pathways that underpin the nerve cell damage that is linked with &lt;A href="http://www.nhs.uk/conditions/Alzheimers-disease/Pages/Introduction.aspx" target="_blank"&gt;Alzheimer’s disease&lt;/A&gt;. The researchers found that the protein deposits commonly found in the brain of people with the disease specifically affect the passage of nerve impulses through some brain cells. This, they discovered, is because the protein deposits interfere with a chemical that affects some important receptors in the brain.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This is another well-conducted and well-described study conducted in rat cells in the laboratory. It is a complex study using methods that are appropriate in this field. That said, it is difficult to see the direct relevance of this research to humans. As with all animal research, it paves the way for similar research into human cells, and the findings of such future studies will have greater relevance for human Alzheimer’s. There are a number of ethical and technical issues associated with gene therapy in humans and a possible area for future research may be whether levels of EphB2 could be raised through other means.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/11November/Pages/ephb2-protein-alzheimers-disease-reversal.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Cissé M, Halabisky B, Harris J et al. &lt;A href="http://www.nature.com/nature/journal/vaop/ncurrent/abs/nature09635.html" target="_blank"&gt;Reversing EphB2 depletion rescues cognitive functions in Alzheimer model&lt;/A&gt;. Published online, November 28 2010&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398016</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/news-claims-purple-fruit-alzheimers-parkinsons.aspx]]&gt;</url>
    <title>Behind the headlines: Purple fruit health claims are premature</title>
    <publicationDate>2010-12-08T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Eating purple-coloured fruit such as blueberries “could help ward off Alzheimer’s, Multiple Sclerosis and Parkinson’s”, &lt;EM&gt;The Daily Telegraph&lt;/EM&gt; has reported. The newspaper says the foods act by soaking up harmful iron compounds.&lt;/P&gt;
&lt;P&gt;This theory is based on a scientific paper that looked at the chemical and biological actions of iron and chemicals that bind to it. The author summarises a body of evidence that suggests that a form of iron may play a role in many different diseases, also providing a number of simple predictions of how this might occur.&lt;/P&gt;
&lt;P&gt;Crucially, this paper only presents a theory, and we do not yet know if the theory is true. Foods that might react with iron, such as blueberries, are also only mentioned in passing in this paper. Stronger evidence is needed to see whether iron plays a role in the development of diseases such as Alzheimer’s disease. If&amp;nbsp;it does,&amp;nbsp;this could be followed by studies looking at how food might intervene in the actions of iron.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This interesting theory of the role of poorly liganded iron may add to the understanding of the complex metabolic pathways that underlie a number of nerve diseases. However, it is too soon to say that there is a definite role for iron chelation in all these diseases, whether achieved through chemical, pharmaceutical or dietary means. The research has also suggested a number of related theories regarding chelation that appear to be interesting candidates for future research.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/12December/Pages/news-claims-purple-fruit-alzheimers-parkinsons.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Kell DB. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20967426" target="_blank"&gt;Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples&lt;/A&gt;. &lt;EM&gt;Archives of&amp;nbsp;Toxicology&lt;/EM&gt; 2010; 577, 825-889&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398015</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/stem-cells-repair-MS-damage-in-rats.aspx]]&gt;</url>
    <title>Behind the headlines: Scientists explore how to repair MS damage</title>
    <publicationDate>2010-12-06T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Scientists have announced a "revolutionary" discovery that could reverse the nerve damage and paralysis caused by multiple sclerosis, reported the Daily Express.&lt;/P&gt;
&lt;P&gt;The news story is based on a laboratory study in animal and human cells. The study established the role of particular substances in the natural repair of myelin, the substance that insulates nerve cells in the brain and that is damaged in multiple sclerosis (MS).&lt;/P&gt;
&lt;P&gt;This type of research is a crucial first step in understanding the neurological processes underlying diseases such as multiple sclerosis. The findings have been called “one of the most exciting developments in recent years” by the Multiple Sclerosis Society, which part-funded the research.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;What does NHS Choices make of this study?&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This type of research is a crucial first step in understanding the neurological processes that lie behind diseases such as multiple sclerosis. The findings have been called “one of the most exciting developments in recent years” by the Multiple Sclerosis Society, which part-funded the research.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/12December/Pages/stem-cells-repair-MS-damage-in-rats.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Huang JK, Jarjour AA, Oumesmar BN, et al.&amp;nbsp;&lt;A href="http://www.nature.com/neuro/journal/vaop/ncurrent/full/nn.2702.html" target="_blank"&gt;Retinoid X receptor gamma signaling accelerates CNS remyelination.&lt;/A&gt;&amp;nbsp;&lt;EM&gt;Nature Neuroscience&lt;/EM&gt; 2010, Advance online publication December 5&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398019</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/12December/Pages/amyloid-imbalance-may-cause-alzheimers.aspx]]&gt;</url>
    <title>Behind the headlines: Study finds Alzheimer's protein clue</title>
    <publicationDate>2010-12-10T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Alzheimer’s disease may result from slow clearance of amyloid protein in brain,” reported &lt;EM&gt;The Guardian.&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The research behind this news took 12 people with mild &lt;A href="http://www.nhs.uk/conditions/Alzheimers-disease/Pages/Introduction.aspx" target="_blank"&gt;Alzheimer’s disease&lt;/A&gt; and 12 people with no dementia and compared the way their brains produced and cleared a protein called amyloid beta. Amyloid beta is normally released in the brain and cleared, but in Alzheimer’s disease the protein accumulates in the brain and causes cell death. &lt;/P&gt;
&lt;P&gt;There has previously been speculation that an imbalance of amyloid production and clearance causes Alzheimer’s disease. However, in this study people with Alzheimer’s disease were found to clear the protein 30% slower than unaffected individuals. This suggests that slower clearance of the protein, rather than overproduction, may be a potential reason for the accumulation of protein in the brain in Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;This useful research further highlighted the importance of impaired clearance of amyloid beta from the brain as a factor that may contribute to the development of Alzheimer’s disease.&lt;/P&gt;
&lt;P&gt;However, as the researchers point out, a limitation of this study was that there were relatively small numbers of people studied (12 in each group), which increases the likelihood of the findings being down to chance. They also say that this research cannot show whether impaired amyloid beta clearance causes Alzheimer’s disease or whether impaired clearance is a consequence of changes to the brain or blood vessels that accompany the disease. In order to establish whether this is a causative factor or not, the researchers would have to follow a far larger group of people over time and from before they had Alzheimer’s disease. &lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/12December/Pages/amyloid-imbalance-may-cause-alzheimers.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt; on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;Mawuenyega KG, Sigurdson W, Ovod V et al. &lt;A href="http://www.sciencemag.org/content/early/2010/12/08/science.1197623.abstract?sid=" target="_blank"&gt;Decreased Clearance of CNS ß-Amyloid in Alzheimer’s Disease&lt;/A&gt;. Science, December 2010&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>391494</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/walking-may-fight-dementia.aspx]]&gt;</url>
    <title>Behind the headlines: Walking and dementia studied</title>
    <publicationDate>2010-10-14T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Walking just one mile a day could keep dementia at bay”, according to the Daily Express. The newspaper said that pensioners who walk between six and nine miles a week are 50% less likely to suffer from future memory problems.&lt;/P&gt;
&lt;P&gt;The story comes from a study which looked at how physical activity (measured by walking) in elderly adults might be associated with any brain volume and risk of cognitive decline. It found that elderly people who reported walking the most at the start of the study showed higher volumes of grey matter in particular areas of the brain when tested nine years later. This increased grey matter was also associated with a 50% reduction in cognitive impairment.&lt;/P&gt;
&lt;P&gt;This study is of interest but it has some important limitations, including its design and the fact that it only measured brain volumes at a single point rather than over time. These limitations mean we cannot confirm that the participants’ walking affected their brain volume or rule out that ill health had contributed to both reduced walking and a shrinkage in brain volume. That said, there are plenty of good reasons to be physically active, and walking is a form of physical activity that is recognised as having health benefits.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The strengths of this study lie in its large sample size, long follow-up period and the validated methods it used to determine both grey matter volume and diagnosis of cognitive impairment. However it has some important weaknesses.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/walking-may-fight-dementia.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Erickson KI, Raji CA, Lopez OL et al. &lt;A href="http://www.neurology.org/cgi/content/abstract/WNL.0b013e3181f88359v1?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=Erickson&amp;amp;searchid=" target="_blank"&gt;Physical activity predicts gray matter volume in late adulthood&lt;/A&gt;. Neurology, October 13 2010&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>391494</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/walking-may-fight-dementia.aspx]]&gt;</url>
    <title>Behind the headlines: Walking and dementia studied</title>
    <publicationDate>2010-10-14T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;“Walking just one mile a day could keep dementia at bay”, according to the Daily Express. The newspaper said that pensioners who walk between six and nine miles a week are 50% less likely to suffer from future memory problems.&lt;/P&gt;
&lt;P&gt;The story comes from a study which looked at how physical activity (measured by walking) in elderly adults might be associated with any brain volume and risk of cognitive decline. It found that elderly people who reported walking the most at the start of the study showed higher volumes of grey matter in particular areas of the brain when tested nine years later. This increased grey matter was also associated with a 50% reduction in cognitive impairment.&lt;/P&gt;
&lt;P&gt;This study is of interest but it has some important limitations, including its design and the fact that it only measured brain volumes at a single point rather than over time. These limitations mean we cannot confirm that the participants’ walking affected their brain volume or rule out that ill health had contributed to both reduced walking and a shrinkage in brain volume. That said, there are plenty of good reasons to be physically active, and walking is a form of physical activity that is recognised as having health benefits.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;The strengths of this study lie in its large sample size, long follow-up period and the validated methods it used to determine both grey matter volume and diagnosis of cognitive impairment. However it has some important weaknesses.&lt;/P&gt;
&lt;P&gt;See the entire &lt;A href="http://www.nhs.uk/news/2010/10October/Pages/walking-may-fight-dementia.aspx" target="_blank"&gt;NHS Choices commentary&lt;/A&gt;&amp;nbsp;on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Erickson KI, Raji CA, Lopez OL et al. &lt;A href="http://www.neurology.org/cgi/content/abstract/WNL.0b013e3181f88359v1?maxtoshow=&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=Erickson&amp;amp;searchid=" target="_blank"&gt;Physical activity predicts gray matter volume in late adulthood&lt;/A&gt;. Neurology, October 13 2010&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398103</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/walking-may-fight-dementia.aspx]]&gt;</url>
    <title>Behind the headlines: Walking and dementia studied</title>
    <publicationDate>2010-10-15T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;***replace this text with the first 2-3 paragraphs from BtH article***&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;***replace this text with the first paragraph found under the heading ‘Conclusion'***&lt;/P&gt;
&lt;P&gt;See the entire ***start link to BtH article*** NHS Choices commentary ***end link to BtH article*** on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;***replace this text with the complete citation found under 'Links to the science'***&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>398103</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.nhs.uk/news/2010/10October/Pages/walking-may-fight-dementia.aspx]]&gt;</url>
    <title>Behind the headlines: Walking and dementia studied</title>
    <publicationDate>2010-10-15T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;***replace this text with the first 2-3 paragraphs from BtH article***&lt;/P&gt;
&lt;P&gt;&lt;B&gt;What does NHS Choices make of this study?&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;***replace this text with the first paragraph found under the heading ‘Conclusion'***&lt;/P&gt;
&lt;P&gt;See the entire ***start link to BtH article*** NHS Choices commentary ***end link to BtH article*** on this news item. &lt;/P&gt;
&lt;P&gt;&lt;B&gt;Citation of original study&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;***replace this text with the complete citation found under 'Links to the science'***&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;HR&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;'Behind the headlines' provides an unbiased and evidence-based analysis of health stories that make the news. The service is intended for both the public and health professionals and endeavours to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;explain the facts behind the headlines and give a better understanding of the science that makes the news 
&lt;LI&gt;provide an authoritative resource for GPs which they can rely on when talking to patients 
&lt;LI&gt;and become a trusted resource for journalists and others involved in the dissemination of health news&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>155409</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bestbets.org/]]&gt;</url>
    <title>BestBets</title>
    <publicationDate></publicationDate>
    <publisher>BestBets</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>BETs were developed in the Emergency Department of Manchester Royal Infirmary, UK, to provide rapid evidence-based answers to real-life clinical questions, using a systematic approach to reviewing the literature.</description>
    <body>&lt;![CDATA[ &lt;P&gt;BETs were developed in the Emergency Department of Manchester Royal Infirmary, UK, to provide rapid evidence-based answers to real-life clinical questions, using a systematic approach to reviewing the literature. BETs take into account the shortcomings of much current evidence, allowing physicians to make the best of what there is.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Audience:&lt;/STRONG&gt; NHS healthcare professionals&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323015</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18726688]]&gt;</url>
    <title>Biofeedback treatment for headache disorders: a comprehensive efficacy review</title>
    <publicationDate>2008-08-26T00:00:00</publicationDate>
    <publisher>Kluwer Academic</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Nestoriuc Y, Martin A, Rief W, Andrasik F. (2008) Biofeedback treatment for headache disorders: a comprehensive efficacy review. &lt;EM&gt;Applied Psychophysiology &amp;amp; Biofeedback&lt;/EM&gt; 33(3):125-40.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Drawing upon two recently published meta-analyses, data from 150 outcome studies, including randomized controlled trials as well as uncontrolled quasi-experimental designs, were screened. Of these, 94 studies were selected for inclusion according to predefined criteria. Meta-analytic integrations were carried out separately for the two conditions of interest. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The main results were medium-to-large mean effect sizes for biofeedback in adult migraine and tension-type headache patients. Treatment effects remained stable over an average follow-up period of 14 months, both in completer and intention-to-treat analyses. Headache frequency was the primary outcome variable and showed the largest improvements. Further significant effects were shown for perceived self-efficacy, symptoms of anxiety and depression, and medication consumption. Reduced muscle tension in pain related areas was observed in electromyographic feedback for tension-type headache. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Biofeedback was more effective than waiting list and headache monitoring conditions in all cases, while electromyographic feedback for tension-type headache showed additional significant effects over placebo and relaxation therapies. Levels of efficacy (migraine: efficacious, level 4; tension-type headache: efficacious and specific, level 5) and recommendations for future research are provided.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 26 August 2008 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326705</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.5.145]]&gt;</url>
    <title>Blood pressure–lowering did not improve short-term mortality or dependency in acute stroke and hypertension</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,OCTOBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Alberts, MJ. (2009) Blood pressure–lowering did not improve short-term mortality or dependency in acute stroke and hypertension. &lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; 14:145.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Potter J, Mistri A, Brodie F, et al. (2009) &lt;A href="http://www.hta.ac.uk/execsumm/summ1309.htm" target="_blank"&gt;Controlling hypertension and hypotension immediately post stroke (CHHIPS)—a randomised controlled trial&lt;/A&gt;. &lt;EM&gt;Health Technol Assess&lt;/EM&gt; 13(9):1–73. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293384</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17014596?ordinalpos=14&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Botulinum toxin--a treatment for migraine? A systematic review.</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Gupta VK Pain Medicine 2006 Sep-Oct;7(5):386-94&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Scalp injection of botulinum toxin type A (BT-A) into the superficial musculature has evoked interest in the management of migraine headache. In clinical trials, prevention of migraine attacks for 3 months or more has been seen in some patients following BT-A scalp injections. In the majority of pain syndromes where BT-A is effective, inhibition of muscle spasms appears to be an important component of its activity. A direct or independent and prolonged analgesic action unrelated to skeletal muscle relaxation is believed to underlie the prophylactic efficacy of BT-A in migraine; peripheral and central modulation of pain impulses by BT-A has also been proposed. A direct peripheral antinociceptive effect was not seen in three controlled studies of BT-A in normal human volunteers. Experimental evidence for BT-A-induced analgesia in rats is suggestive but dose-dependent and lasts only 2 weeks. In migraine patients, a consistent or dose-dependent response to BT-A treatment has not been seen. Peak responses to BT-A in migraine patients are seen at 8-12 weeks, whereas BT-A-affected nerve endings in mice fully recover function between 63 and 91 days; the difference in species limits the interpretation of this dissonance. As BT-A does not normally cross the intact blood-brain barrier, meningeal nociceptors appear unlikely to be influenced by scalp injections of BT-A; the possibility of antidromic transfer of BT-A in the trigeminovascular system should be considered. The extended period for which migraine prophylaxis might be required, the antigenic and headache-provoking potential of BT-A, the inability of BT-A to affect central neuronal processes significantly, including the aura of migraine, the possible placebo effect of needling, and purely subjective outcome measures in headache studies are additional concerns in evaluating this treatment strategy. The clinical utility of BT-A has not been compared against established migraine prophylactic agents. The efficacy of BT-A in preventing migraine headache attacks remains controversial and the underlying scientific rationale is debatable.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322526</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18505457]]&gt;</url>
    <title>Cardiac cephalalgia: case reports and review</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wei JH, Wang HF. Cardiac cephalalgia: case reports and review. &lt;EM&gt;Cephalalgia&lt;/EM&gt; 2008;28(8):892-6.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We present two cases of cardiac headache and analyse 32 cases from MEDLINE or internet resources that presented a headache as one of the myocardial symptoms. Cardiac origin of a headache is extremely rare and has only case reports.&lt;FONT face=Palatino-Roman size=2&gt;&lt;FONT face=Palatino-Roman size=2&gt;&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The data reveal that the mean age of the patients included in our study was 62.5&amp;nbsp;- 12.7 years; 20 (68.7%) patients were male; in risk factors, most (84.3%) patients were elderly. Seventeen (53.1%) patients’ symptoms were exertional. There were 18 (60%) patients whose headaches were revealed as the sole presentation of myocardial ischaemia. Antianginal, mostly nitrate-like, agents will release headache in 18 (56.3%) patients. In clinical cardiovascular events, three (9.4%) patients presented with ventricular fibrillation, 15 (46.9%) had myocardial infarction and 11 (34.4%) suffered from some degree of angina. In general, mortality rates of cardiac cephalalgia were 12.5% (four of 32 patients). All symptoms of headaches disappeared after revascularization or conservative treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The possibilities of failed diagnosis of acute cardiac ischaemia at EDs are increased by atypical presentation or membership of a special subgroup that includes non-Whites, elderly men, and normal electrocardiographic findings (40–42). So far, acute headache as the initial presentation of myocardial ischaemia is extremely rare. Therefore, we do not recommend myocardial ischaemia as the initial differential diagnosis for acute headache.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; August 2008; epub 23 May 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314109</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18262442]]&gt;</url>
    <title>Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Zaccara G, Gangemi PF, Cincotta M. (2008) Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. &lt;EM&gt;Seizure&lt;/EM&gt; 17(5):405-21.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Trial reports found by searching Medline and journals. Outcome was the number of patients complaining of treatment-emergent CNS AEs. Sixteen predefined CNS AEs were considered. Risk differences (RDs) were calculated for individual studies and summary statistics estimated using the random effect model. Predefined CNS AEs in patients treated with active drug (broken down into dose levels) or placebo were extracted and the RDs (95% CI) for CNS AEs were calculated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty-six suitable studies identified. No meta-analysis was possible for oxcarbazepine and tiagabine (only one study each included). For these drugs RDs were calculated from single studies. Gabapentin was significantly associated with somnolence 0.13 (0.06-0.2) and dizziness 0.11 (0.07-0.15); lamotrigine with dizziness 0.11 (0.05-0.17), ataxia 0.12 (0.01-0.24) and diplopia 0.12 (0.00-0.24); levetiracetam with somnolence 0.06 (0.01-0.11); pregabalin with somnolence 0.11 (0.07-0.15), dizziness 0.22 (0.16-0.28), ataxia 0.10 (0.06-0.14) and fatigue 0.04 (0.01-0.08); topiramate with somnolence 0.09 (0.04-0.14), dizziness 0.06 (0.00-0.11), cognitive impairment 0.14 (0.06-0.22) and fatigue 0.06 (0.01-0.12); zonisamide with somnolence 0.06 (0.02-0.11) and dizziness 0.06 (0.00-0.12). The dose-response relationship was analysed only for those CNS AEs significantly associated with the AED. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; No comparison between drugs was possible. One CNS AE was significantly more frequent for levetiracetam, two for zonisamide and gabapentin, three for lamotrigine and four for pregabalin and topiramate.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;February 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295069</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ataxia.org.uk/data/files/ca_guide_for_medical_professionals.pdf]]&gt;</url>
    <title>Cerebellar ataxia: A Guide for the Medical Profession</title>
    <publicationDate>2004-11-01T00:00:00</publicationDate>
    <publisher>Ataxia UK</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,SPINOCEREBELLAR DEGENERATIONS AND ATAXIAS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide written by Ataxia UK covering: clinical presentation, diagnosis, genetic ataxias, management issues</description>
    <body>&lt;![CDATA[ &lt;P&gt;Description:&lt;/P&gt;
&lt;P&gt;This guide has been written for the healthcare professional, and includes information on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;clinical presentaion 
&lt;LI&gt;diagnosis 
&lt;LI&gt;genetic ataxias 
&lt;LI&gt;management issues&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: Freely available to the general public&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Ataxia UK is a registered charity which aims to support all people affected by ataxia.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322537</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1179/174328808X252082]]&gt;</url>
    <title>Cervical musculoskeletal impairments in cervicogenic headache: a systematic review and a meta-analysis</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,HEADACHE,HEADACHE &amp; PAIN,RECENT ADDITIONS,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gadotti IC, Olivo SA, Magee DJ. (2008) Cervical musculoskeletal impairments in cervicogenic headache: a systematic review and a meta-analysis. &lt;EM&gt;Physical Therapy Reviews&lt;/EM&gt; 13(3):149-67.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; For this review, the literature was searched for studies on headache and its association with the cervical region published in all languages. Studies from 1965 up to and including 16 May 2006 were obtained through an extensive search of bibliographic databases including MEDLINE-PubMed (1966 to May, week 1, 2006),Embase (1988 to May, week 19, 2006), Cochrane Library and Best Evidence (1991 to 16 May 2006), ISI Web of Sciences (1965 to 16 May 2006), CINAHL (1982 to May, week 2, 2006). This review was open to include all study designs investigating CMI in CEH. Case reports and literature reviews were not included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Based on our meta-analysis results, patients with CEH were found to have altered ROM in rotation, flexion-extension, cervical rotation in cervical flexion, altered cervical flexor strength, and altered cervical flexor endurance. In addition, it was found that the cervical flexion-rotation test and cervical manual segmental motion can assist in the differential diagnosis of CEH and in the identification of movement impairment at the C1/2 segment in patients with CEH. Regarding the treatment of CEH, there is some evidence through RCTs supporting the use of both manipulative therapy and specific exercise addressing the cervical physical impairments to reduce the headache frequency and intensity. However, more studies are needed to investigate the effect of CMI treatment in patients with CEH in order to support the growing evidence in this field.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; June 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&amp;nbsp;The last 12 months are not available.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>387239</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.neurology.org/cgi/content/abstract/75/10/924]]&gt;</url>
    <title>Challenge of the unknown: a systematic review of acute encephalitis in non-outbreak situations</title>
    <publicationDate>2010-05-12T00:00:00</publicationDate>
    <publisher>Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INFECTIONS,VIRAL INFECTIONS,CONDITIONS,VIRAL ENCEPHALITIS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Granerod J, Tam CC, Crowcroft NS, Davies NWS, Borchert M, Thomas SL. (2010) Challenge of the unknown: a systematic review of acute encephalitis in non-outbreak situations. Neurology 75(10):924-932&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; The threat of emerging infections and recognition of novel immune-mediated forms of encephalitis has raised the profile of this condition in recent years. Incidence is poorly defined and most cases have an unknown cause. There is currently much interest in identification of new microbial agents of encephalitis, but no work has investigated systematically reasons for lack of pathogen identification in studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We systematically reviewed published literature on incidence and etiology of encephalitis in non-outbreak settings and explored possible explanations for the large number of cases of unknown etiology. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Annual incidence ranged from 0.07 to 12.6 cases per 100,000 population with an evident decrease over time (p = 0.01). The proportion of cases with unknown etiology was high across studies (&amp;gt;50% in 26 of 41 studies), with strong evidence of heterogeneity in study findings (p &amp;lt; 0.001). Our meta-regression identified study period, setting, and subsyndrome to be the main contributors to between-study variation, rather than methodologic factors such as study design, case definitions, sample types, and testing strategies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Our findings support the hypothesis that new and emerging infectious agents, or new forms of immune-mediated encephalitis, may be responsible for cases currently of unknown cause and encourage the ongoing global effort to identify these. Our review highlights research areas that might lead to a better understanding of the causes of encephalitis and ultimately reduce the morbidity and mortality associated with this devastating condition. &lt;/P&gt;
&lt;P&gt;Neurology is the official journal of the American Academy of Neurology. The publication is aimed at clinical neurologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398100</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://cre.sagepub.com/content/24/11/963.abstract?rss=1]]&gt;</url>
    <title>Children with cerebral palsy: a systematic review and meta-analysis on gait and electrical stimulation</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>SAGE journals online</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STRUCTURAL,CEREBRAL PALSY,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Cauraugh JH, Naik SK, Hsu WH, Coombes SA, Holt KG. (2010) Children with cerebral palsy: a systematic review and meta-analysis on gait and electrical stimulation. &lt;EM&gt;Clinical Rehabilitation&lt;/EM&gt;&amp;nbsp;24(11):963-978&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To conduct a systematic review and meta-analysis using the International Classification of Functioning to determine the summary effect of electrical stimulation on impairment and activity limitations relevant to gait problems of children with cerebral palsy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We identified 40 cerebral palsy and electrical stimulation studies, and 17 gait studies qualified for inclusion. Applying enablement classification methods to walking abnormalities created two subgroups: impairment (N = 14) and activity limitations (N = 15). Overall, 238 participants experienced electrical stimulation treatments and 224 served as a no stimulation control group. Calculations followed conventional data extraction and meta-analysis techniques: (a) individual standardized mean differences, (b) summary effect size, (c) I 2heterogeneity test, (d) fail-safe N analysis and (e) moderator variable analyses. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Common outcome measures associated with impairment (n = 3) and activity limitations (n = 6) were submitted to separate random effects models meta-analyses, and revealed significant cumulative effect sizes: (a) impairment = 0.616 (SE = 0.10) and (b) activity limitations = 0.635 (SE = 0.14). I 2indicated low and medium amounts of dispersion, whereas fail-safe analyses revealed high N-values for both disablement categories. Moderator variable analyses further confirmed the positive treatment effects from both functional and neuromuscular stimulation. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; The present systematic review and meta-analyses determined medium effect sizes for electrical stimulation on walking impairment and activity limitations of children with cerebral palsy.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Clinical Rehabilitation is a highly ranked, peer reviewed scholarly journal. It is a multi-professional journal covering the whole field of disability and rehabilitation, combining clinical application of scientific results and theoretical aspects in an ideal form. It gives high priority to articles describing effectiveness of therapeutic interventions and the evaluation of new techniques and methods.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384052</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://hkjpaed.org/details.asp?id=731&amp;show=1234]]&gt;</url>
    <title>Clinical guidelines on management of prolonged seizures, serial seizures and convulsive status epilepticus in children.</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Hong Kong Journal of Paediatrics</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Ma L, Yung A, Yau E, Kwong K. (2010) Clinical guidelines on management of prolonged seizures, serial seizures and convulsive status epilepticus in children. &lt;EM&gt;Hong Kong Journal of Paediatrics&lt;/EM&gt; 15(1):52-83&lt;/P&gt;
&lt;P&gt;The publication is a project carried out under Hospital Authority Paediatric Coordinating Committee, Quality Assurance Subcommittee, Working Group on Guideline and Evidence Based Practice. The present guideline is endorsed by Paediatric Coordinating Committee.&lt;/P&gt;
&lt;P&gt;The Hong Kong Journal of Paediatrics is the Official publication of Hong Kong College of Paediatricians (HKCPaed) and The Hong Kong Paediatric Society (HKPS). &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314444</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18090950]]&gt;</url>
    <title>Clinical implications of mechanisms of resistance to antiepileptic drugs</title>
    <publicationDate></publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sanchez Alvarez JC, Serrano Castro PJ, Serratosa Fernandez JM. (2007)&amp;nbsp;Clinical implications of mechanisms of resistance to antiepileptic drugs. &lt;EM&gt;Neurologist&lt;/EM&gt; 13(6 Suppl 1):S38-S46.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We conducted a literature search in PubMed and the Cochrane Library databases with the terms: "Drug Resistance" [MeSH] and "Epilepsy" [MeSH], Limits: added to PubMed in the last 5 years, only items with abstracts, English, Spanish, Humans.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; It is currently known that membrane transporter proteins are increased in brain tissue of refractory epileptic patients and in animal models of epilepsy and that overexpression of these transporters and their inhibition are correlated with a reduction and an increase, respectively, of epileptic drugs in epileptic tissue (pharmacokinetic hypothesis). It has also been shown that alterations in voltage-gated sodium channels and GABAA receptors are responsible for resistance to some epileptic drugs. These changes may be constitutional (genetically determined) or acquired (as a consequence of the seizures themselves or disease progression) and may seem alone or combined with each other (pharmacodynamic hypothesis). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Associations have been shown between certain genetic polymorphisms and resistance to epileptic drugs, and although they have not been replicated by all authors, they constitute a very attractive line of research. More detailed knowledge of these molecular mechanisms will probably lead to the development of new strategies for pharmacological treatment of epilepsy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; November 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344441</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18701571]]&gt;</url>
    <title>Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Sage</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. &lt;EM&gt;Multiple Sclerosis&lt;/EM&gt; 2008 Nov;14(9):1250-61.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We conducted a meta-analysis that quantified the overall magnitude of cognitive impairment in individuals with&amp;nbsp;relapsing-remitting multiple sclerosis (RRMS)&amp;nbsp;and identified the domains of cognition and clinical/demographic variables that were moderators of the overall effect.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We included 57 studies with 3891 participants that yielded a total of 755 effect sizes. Overall, there was a moderate decline in cognitive functioning in individuals with RRMS compared with healthy controls. Larger effects were observed in cognitive domains of motor functioning, mood status and memory and learning. Regarding demographic and clinical variables, age and gender were moderators of cognitive impairment in all cognitive domains, whereas neurological disability and disease duration primarily moderated performance on tasks assessing memory and learning.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The effects of MS on cognition is both general over all cognitive domains, and specific with largest effects on mood, motor functioning, and memory and learning.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in November 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324803</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://stroke.ahajournals.org/cgi/content/abstract/40/8/e523]]&gt;</url>
    <title>Coiling of intracranial aneurysms: a systematic review on initial occlusion and reopening and retreatment rates</title>
    <publicationDate>2009-06-11T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,INTRACEREBRAL HAEMORRHAGE,HAEMORRHAGIC,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The proportion of incompletely occluded aneurysms after coiling varies widely between studies. To assess overall outcome of coiling, we systematically reviewed the literature to determine initial occlusion, reopening, and retreatment rates of coiled aneurysms according to predefined criteria and subgroups. 
</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Ferns, SP et al. (2009) Coiling of intracranial aneurysms:&amp;nbsp;a systematic review on initial occlusion and reopening and retreatment rates. &lt;EM&gt;Stroke&lt;/EM&gt; 40:e523-e529 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched PubMed and EMBASE (January 1999 to September 2008) for studies of &amp;gt;50 coiled aneurysms. Two reviewers independently extracted data. We grouped studies reporting on only ruptured aneurysms, posterior circulation aneurysms, and studies with large proportions of aneurysms &amp;gt;10 mm to assess possible determinants for incomplete occlusion, reopening, and retreatment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Forty-six studies totalling 8161 coiled aneurysms met inclusion criteria. Immediately after coiling, 91.2% (95% CI, 90.6% to 91.9%) of the aneurysms were adequately occluded. Aneurysm reopening occurred in 20.8% (95% CI, 19.8% to 21.9%) and retreatment was performed in 10.3% (95% CI, 9.5% to 11.0%). Reopening rate was lower in studies reporting on ruptured aneurysms only compared with all studies (11.4% versus 20.8%; relative risk, 0.55; 95% CI, 0.47 to 0.64) and higher in studies focusing on posterior circulation aneurysms compared with studies with &amp;gt;85% anterior circulation aneurysms (22.5% versus 15.5%; relative risk, 1.5; 95% CI,1.2 to 1.7). Regression analysis showed higher retreatment rates with increasing proportion of aneurysms &amp;gt;10 mm (ß=0.252; 95% CI, 0.073 to 0.432). We could not find a relation between reopening and type of coils used.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; At follow-up, one fifth of all coiled intracranial aneurysms shows reopening of which half is retreated. Possible risk factors for aneurysm reopening are location in the posterior circulation and size &amp;gt;10 mm. To confirm our findings, a meta-analysis on individual well-reported patient data is desirable. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 11 June 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Freely available via &lt;A href="http://highwire.stanford.edu/lists/freeart.dtl" target="_blank"&gt;Highwire Press&lt;/A&gt; from January 1996. The last 12 months are not available.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325791</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19724046]]&gt;</url>
    <title>Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis</title>
    <publicationDate>2009-09-02T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,NEUROMUSCULAR,CONDITIONS,SEPTEMBER 2009,BELL'S PALSY,PERIPHERAL NERVE DISORDERS,CRANIAL NEUROPATHIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VY, Nedzelski JM, Chen JM. (2009) Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. &lt;EM&gt;JAMA&lt;/EM&gt; 302(9):985-93.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The search included MEDLINE, EMBASE, CENTRAL, PsychInfo, CINAHL, Web of Science, PAPERSFIRST, PROCEEDINGSFIRST, and PROQUEST to identify studies up to March 1, 2009. Eligible studies were randomized controlled trials comparing treatment with either corticosteroids or antiviral agents with a control and measuring at least 1 of the following outcomes: unsatisfactory facial recovery (&amp;gt; or = 4 months), unsatisfactory short-term recovery (6 weeks to &amp;lt; 4 months), synkinesis and autonomic dysfunction, or adverse effects. Two reviewers extracted data on study characteristics, methods, and outcomes. Disagreement was resolved by consensus. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eighteen trials involving 2786 patients were eligible. Regression analysis identified a synergistic effect when corticosteroids and antiviral agents were administered in combination compared with alone (odds ratio for interaction term, 0.54 [95% confidence interval {CI}, 0.35-0.83]; P = .004). Meta-analysis using a random-effects model showed corticosteroids alone were associated with a reduced risk of unsatisfactory recovery (relative risk [RR], 0.69 [95% CI, 0.55-0.87]; P = .001) (number needed to treat to benefit 1 person, 11 [95% CI, 8-25]), a reduced risk of synkinesis and autonomic dysfunction (RR, 0.48 [95% CI, 0.36-0.65]; P &amp;lt; .001) (number needed to treat to benefit 1 person, 7 [95% CI, 6-10]), and no increase in adverse effects. Antiviral agents alone were not associated with a reduced risk of unsatisfactory recovery (RR, 1.14 [95% CI, 0.80-1.62]; P = .48). When combined with antiviral agents, corticosteroids were associated with greater benefit (RR, 0.48 [95% CI, 0.29-0.79]; P = .004) than antiviral agents alone. When combined with corticosteroids, antiviral agents were associated with greater risk reduction of borderline significance compared with corticosteroids alone (RR, 0.75 [95% CI, 0.56-1.00]; P = .05). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In Bell palsy, corticosteroids are associated with a reduced risk of unsatisfactory recovery. Antiviral agents, when administered with corticosteroids, may be associated with additional benefit.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 2 September 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288536</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17438241?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Consensus definitions proposed for pediatric multiple sclerosis and related disorders</title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Krupp, LB et al &lt;SPAN title=Neurology.&gt;&lt;A href="#javascript:AL_get(this," ?Neurology.?);? ?jour?,&gt;Neurology.&lt;/A&gt;&lt;/SPAN&gt; 2007 Apr 17;68(16 Suppl 2):S7-12&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: The CNS inflammatory demyelinating disorders of childhood include both self-limited and lifelong conditions, which can be indistinguishable at the time of initial presentation. Clinical, biologic, and radiographic delineation of the various monophasic and chronic childhood demyelinating disorders requires an operational classification system to facilitate prospective research studies. METHODS: The National Multiple Sclerosis Society (NMSS) organized an International Pediatric MS Study Group (Study Group) composed of adult and pediatric neurologists and experts in genetics, epidemiology, neuropsychology, nursing, and immunology. The group met several times to develop consensus definitions regarding the major CNS inflammatory demyelinating disorders of children and adolescents. RESULTS: Clinical definitions are proposed for pediatric multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), recurrent ADEM, multiphasic ADEM, neuromyelitis optica, and clinically isolated syndrome. These definitions are considered operational and need to be tested in future research and modified accordingly. CONCLUSION: CNS inflammatory demyelinating disorders presenting in children and adolescents can be defined and distinguished. However, prospective research is necessary to determine the validity and utility of the proposed diagnostic categories.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17438241?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384047</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1365-2788.2009.01182.x]]&gt;</url>
    <title>Consensus guidelines into the management of epilepsy in adults with an intellectual disability</title>
    <publicationDate>2009-06-12T00:00:00</publicationDate>
    <publisher>Journal of Intellectual Disability Research</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Kerr M, Scheepers M, Arvio M, Beavis J, Brandt C, Brown S, Huber B, Iivanainen M, Louisse AC, Martin P, Marson AG, Prasher V, Singh BK, Veendrick M, Wallace RA. (2009) Consensus guidelines into the management of epilepsy in adults with an intellectual disability. &lt;EM&gt;Journal of Intellectual Disability Research&lt;/EM&gt; 53(8):687-694&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Epilepsy has a pervasive impact on the lives of people with intellectual disability and their carers. The delivery of high-quality care is impacted on by the complexity and diversity of epilepsy in this population. This article presents the results of a consensus clinical guideline process.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A Delphi process identified a list of priority areas for the development of evidence-based guidelines. All guidelines were graded and consensus on scoring was achieved across the guideline group.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt;&amp;nbsp;There is a dearth of high-quality evidence from well-constructed studies on which to base guidance. However, the development of internationally derived consensus guidelines may further support the management of epilepsy in adults with an intellectual disability.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Journal of Intellectual Disability Research is devoted exclusively to the scientific study of intellectual disability and publishes papers reporting original observations in this field. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328013</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1161/STROKEAHA.109.555169]]&gt;</url>
    <title>Consensus recommendations for transcranial color-coded duplex sonography for the assessment of intracranial arteries in clinical trials on acute stroke</title>
    <publicationDate>2009-08-06T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ INVESTIGATION &amp; DIAGNOSTICS,STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,EMERGENCY CARE,STROKE,CLINICAL LIBRARY,NEUROLOGICAL,CARDIOVASCULAR,STROKE,OCTOBER 2009,CONDITIONS,ULTRASONOGRAPHY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Nedelmann, C et al. (2009) Consensus recommendations for transcranial color-coded duplex sonography for the assessment of intracranial arteries in clinical trials on acute stroke. &lt;EM&gt;Stroke&lt;/EM&gt; 40:3238-3244. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and Purpose:&lt;/STRONG&gt; Transcranial color-coded duplex sonography has become a standard diagnostic technique to assess the intracranial arterial status in acute stroke. It is increasingly used for the evaluation of prognosis and the success of revascularization in multicenter trials. The aim of this international consensus procedure was to develop recommendations on the methodology and documentation to be used for assessment of intracranial occlusion and for monitoring of recanalization. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Thirty-five experts participated in the consensus process. The presented recommendations were approved during a meeting of the consensus group in October 2008 in Giessen, Germany. The project was an initiative of the German Competence Network Stroke and performed under the auspices of the Neurosonology Research Group of the World Federation of Neurology. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Recommendations are given on how examinations should be performed in the time-limited situation of acute stroke, including criteria to assess the quality of the acoustic bone window, the use of echo contrast agents, and the evaluation of intracranial vessel status. The important issues of the examiners’ training and experience, the documentation, and analysis of study results are addressed. One central aspect was the development of standardized criteria for diagnosis of arterial occlusion. A transcranial color-coded duplex sonography recanalization score based on objective hemodynamic criteria is introduced (consensus on grading intracranial flow obstruction [COGIF] score). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; This work presents consensus statements in an attempt to standardize the application of transcranial color-coded duplex sonography in the setting of acute stroke research, aiming to improve the reliability and reproducibility of the results of future stroke studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history:&lt;/STRONG&gt; Published online ahead of print in &lt;EM&gt;Stroke&lt;/EM&gt; on&amp;nbsp;6 August 2009. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text for the latest 12 months is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324792</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.4.115]]&gt;</url>
    <title>Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer disease</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,ALZHEIMER'S DISEASE,CONDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hirsch, C. (2009) Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer disease. &lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; 14(4);115.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Ballard C, Hanney ML, Theodoulou M, et al. (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology 8:151–7.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314083</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18489198]]&gt;</url>
    <title>Cost of epilepsy: a systematic review</title>
    <publicationDate></publicationDate>
    <publisher>Adis International</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Strzelczyk A, Reese JP, Dodel R, Hamer HM. (2008) Cost of epilepsy: a systematic review. &lt;EM&gt;Pharmacoeconomics&lt;/EM&gt; 26(6):463-76.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic literature search was performed in electronic databases using a combined search strategy that included the following keywords: cost(s), burden, expenditure, cost of illness, cost-effectiveness, modeling and epilepsy, convulsion, seizure. The search was first performed on the databases MEDLINE and PreMEDLINE (1980 until June&lt;BR&gt;2007), and the Cochrane’s database of systematic reviews (until first quarter 2007). A more broadly specified search was performed on the databases DARE (Database of Abstracts of Reviews of Effectiveness), NHS EED (Economic Evaluation Database) and HTA (Health Technology Assessment) of the UK NHS Centre for Reviews and Dissemination, and on databases available through DIMDI (German Institute of Medical Documentation and Information). We examined the reference lists of all identified studies for additional studies and asked clinical experts for additional published studies. Articles were also identified through searches of the extensive files of the authors. Furthermore, review articles on COI studies were available.&amp;nbsp; There was no restriction on language or country of origin. However, only studies that evaluated costs due to seizures or epilepsy in adult patients were included.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 22 studies worldwide on costs of epilepsy.&amp;nbsp;The studies utilized different frameworks to evaluate costs. All used a bottom-up approach; however, only 12 studies (55%) evaluated direct as well as indirect costs. The range for the mean annual direct costs lay between 40 International Dollar purchasing power parities (PPP-$) in rural Burundi and PPP-$4748 (adjusted to 2006 values) in a German epilepsy centre. Recent studies suggest AEDs are becoming the main contributor to direct costs. The mean indirect costs ranged between 12% and 85% of the total annual costs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Epilepsy is a cost-intensive disorder. A reliable comparison of the different COI studies in epilepsy is not easily feasible, as the evaluated studies show substantial methodological differences with respect to their patient selection criteria, diagnostic stratifications and evaluated costs. Therefore, there is an urgent need for studies that evaluate direct and indirect costs in a standardized fashion.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;June 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344277</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18563952/]]&gt;</url>
    <title>Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Adis International</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. &lt;EM&gt;Pharmacoeconomics&lt;/EM&gt; 26(7):617-27, 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A 30-year Markov model was developed, based on previously published models for multiple sclerosis, to estimate transition between disability states and the probability of relapse within disability states. The model was parameterized with data from the UK Multiple Sclerosis (MS) Survey 2005 and data from the AFFIRM study, a 2-year multicentre, randomized, double-blind, placebo-controlled trial of natalizumab in RRMS patients. Additional data were sourced from the literature. A UK societal cost perspective was used in the base case, with additional cost perspectives considered in the sensitivity analysis. The baseline characteristics for the patient group were taken from the patient population in the AFFIRM study (mean age 36 years, mean time since diagnosis 5 years and a mean Kurtzke Extended Disability Status Scale [EDSS] score of 2.5). The model and its parameterization were designed and developed to support a reimbursement application for natalizumab submitted to the UK National Institute for Health and Clinical Excellence (NICE). Efficacies for natalizumab and glatiramer acetate were taken from clinical trial data, and for interferon-beta from a meta-analysis of clinical trial data. Disutilities from adverse events for each comparator were also included in the model. Outcomes and costs were discounted at 3.5% per anum. Costs for interferon-beta and glatiramer acetate were based on published prices (year 2006 values) under the UK Risk Sharing Scheme, and for natalizumab the UK NHS list price was used. Diagnostic, administration and adverse event costs were also included. The incremental cost-effectiveness ratios (ICERs) were calculated for the base case, and a probabilistic sensitivity analysis was performed to assess the probability of cost effectiveness at different willingness-to-pay thresholds.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The ICER for natalizumab compared with interferon-beta was 2300 pound per QALY. Compared with glatiramer acetate, it was 2000 pound per QALY, and compared with best supportive care it was 8200 pound per QALY. From a health and social care cost perspective, the ICERs were 18,700 pound, 20,400 pound and 25,500 per QALY, respectively. At a willingness-to-pay threshold of 30,000 pound per QALY, the probability of natalizumab being cost effective against any comparator from a societal perspective was &amp;gt;89%.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; If UK society is willing to pay more than 8200 pound per QALY, or Health and Social Services are willing to pay more than 26,000 pound per QALY, this analysis suggests that natalizumab is likely to be a cost-effective treatment for all patients with HARRMS.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in July 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288874</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.amcp.org/data/jmcp/245-61.pdf]]&gt;</url>
    <title>Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data</title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>Academy of Managed Care Pharmacy</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Bell, C et al &lt;SPAN title="Journal of managed care pharmacy : JMCP."&gt;&lt;A href="#javascript:AL_get(this," Pharm.?);? Care Manag ?J ?jour?,&gt;J Manag Care Pharm.&lt;/A&gt;&lt;/SPAN&gt; 2007 Apr;13(3):245-61&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Before the introduction of the immunomodulatory therapies for multiple sclerosis (MS), treatment options for MS consisted of symptomatic management (physical therapy and pharmacological treatment for symptom management). Symptomatic management for MS has been supplemented in the past decade by 2 new classes of immunomodulatory therapies that have been approved as first-line treatments for relapsing-remitting multiple sclerosis (RRMS): subcutaneous glatiramer acetate (SC GA) and 3 beta-interferons: intramuscular interferon beta-1a (IM IFNbeta-1a), SC IFNbeta-1a, and SC IFNbeta-1b. OBJECTIVE: To estimate the economic outcomes of 5 treatment strategies: symptom management alone, symptom management combined with SC GA, IM IFNbeta1-a, SC IFNbeta1-a, or SC IFNbeta1-b in patients diagnosed with RRMS. METHODS: A literature-based Markov model was developed to assess the cost-effectiveness of 5 treatment strategies for managing a hypothetical cohort of patients diagnosed with RRMS in the United States--4 immunomodulatory drug therapies and symptom management alone. Health states were based on the Kurtzke Expanded Disability Status Scale (EDSS), a widely accepted scale for assessing RRMS (higher EDSS scores = increased disease severity). Baseline relapse and disease progression transition probabilities for symptom management were obtained from natural history studies. Treatment effects of the immunomodulatory therapies were estimated by applying a percentage reduction to the symptom management transition probabilities for relapse (27% reduction) and disease progression (30% reduction). Transition probabilities were subsequently adjusted to account for (1) the effects of neutralizing antibodies, specifically on relapse rates by assuming no additional therapy benefits after the second year of continuous therapy, and (2) treatment discontinuation. Therapy-specific data were obtained from clinical trials and long-term follow-up observational studies. Transitions among health states occurred in 1-month cycles for the lifetime of a patient. Costs (2005 US$) and outcomes were discounted at 3% annually. RESULTS: The incremental cost per quality-adjusted life-year for the 4 immunomodulatory therapies is $258,465, $303,968, $416,301, and $310,691 for SC GA, IM IFNbeta-1a, SC IFNbeta-1a, and SC IFNbeta-1b, respectively, compared with symptom management alone. Sensitivity analyses demonstrated that results were sensitive to changes in utilities, disease progression rates, time horizon, and immunomodulatory therapy cost. CONCLUSIONS: The pharmacoeconomic model determined that SC GA was the best strategy of the 4 immunomodulatory therapies used to manage MS and resulted in better outcomes than symptom management alone. Sensitivity analyses indicated that the model was sensitive to changes in a number of key parameters, and thus changes in these key parameters would likely influence the estimated cost-effectiveness results. Head-to-head randomized clinical trials comparing the immunomodulatory therapies for the treatment of MS are necessary to validate the projections from the pharmacoeconomic analyses, particularly since the results available today from the clinical trials do not account adequately for treatment dropouts.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Free full text available&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293351</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17827966?ordinalpos=4&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Cost-minimization analysis comparing topiramate with standard treatments in migraine prophylaxis</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Karger</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE,MIGRAINE,HEADACHE &amp; PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Ergun, H et al European Neurology 2007;58(4):215-7. Epub 2007 Sep 7&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Migraine is a common disorder with a relatively high burden of disease from the perspective of both society and the individual patient. Optimizing the use of prophylactic treatment may decrease the frequency and severity of attacks thus reducing the burden of disease. In this regard, topiramate has been found to be as effective as propranolol in the prevention of migraine attacks. In the present study, a cost-minimization analysis was performed. Monthly preventive medication cost and price per migraine attack reduced were used as measures. In comparison with propranolol and flunarizine, topiramate was identified as being the most costly option for migraine prophylaxis with a monthly drug cost of USD 24.97-45.04 as compared with propranolol (USD 1.72-6.87) and flunarizine (USD 6.09-12.18). Current treatment options would appear to offer better value for money in achieving effective migraine prophylaxis unless additional benefits can be identified for topiramate in this patient group. (c) 2007 S. Karger AG, Basel.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396694</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396694]]&gt;</url>
    <title>Critical appraisal: A review of the clinical pharmacokinetics of opioids,benzodiazepines, and antimigraine drugs delivered intranasally</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Critical appraisal: A review of the clinical pharmacokinetics of opioids,benzodiazepines, and antimigraine drugs delivered intranasally&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Professor Peter J Goadsby and Dr FH Maniyar have produced a full critical appraisal of all the papers that they have reviewed for the 2010 Headache Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;This is a critical appraisal of the paper by Veldhorst-Janssen NM ... et al - &lt;A href="nelh:396610:0" name=internalLink&gt;A review of the clinical pharmacokinetics of opioids,benzodiazepines, and antimigraine drugs delivered intranasally&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396684</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396684]]&gt;</url>
    <title>Critical appraisal: A systematic review of adverse events in placebo groups of anti-migraine clinical trials</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Critical appraisal: A systematic review of adverse events in placebo groups of anti-migraine clinical trials&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Professor Peter J Goadsby and Dr FH Maniyar have produced a full critical appraisal of all the papers that they have reviewed for the 2010 Headache Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;This is a critical appraisal of the paper by Amanzio M ... et al - &lt;A href="nelh:396587:0" name=internalLink&gt;A systematic review of adverse events in placebo groups of anti-migraine clinical trials&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396690</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396690]]&gt;</url>
    <title>Critical appraisal: Acute and preventive pharmacologic treatment of cluster headache</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Critical appraisal: Acute and preventive pharmacologic treatment of cluster headache&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Professor Peter J Goadsby and Dr FH Maniyar have produced a full critical appraisal of all the papers that they have reviewed for the 2010 Headache Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;This is a critical appraisal of the paper by Francis GJ ... et al - &lt;A href="nelh:396600:0" name=internalLink&gt;Acute and preventive pharmacologic treatment of cluster headache&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396688</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396688]]&gt;</url>
    <title>Critical appraisal: EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Critical appraisal: EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Professor Peter J Goadsby and Dr FH Maniyar have produced a full critical appraisal of all the papers that they have reviewed for the 2010 Headache Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;This is a critical appraisal of the paper by Evers S ... et al - &lt;A href="nelh:396595:0" name=internalLink&gt;EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396692</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396692]]&gt;</url>
    <title>Critical appraisal: Managing migraines: Options for acute abortive treatment</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Critical appraisal: Managing migraines: Options for acute abortive treatment&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Professor Peter J Goadsby has produced a full critical appraisal of all the papers that he has reviewed for the 2010 Headache Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;This is a critical appraisal of the paper by Namaka M ... et al - &lt;A href="nelh:396603:0" name=internalLink&gt;Managing migraines: Options for acute abortive treatment&lt;/A&gt;.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396693</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396693]]&gt;</url>
    <title>Critical appraisal: Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Critical appraisal: Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Professor Peter J Goadsby and Dr FH Maniyar have produced a full critical appraisal of all the papers that they have reviewed for the 2010 Headache Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;This is a critical appraisal of the paper by Suthisisang CC ... et al - &lt;A href="nelh:396609:0" name=internalLink&gt;Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396687</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396687]]&gt;</url>
    <title>Critical appraisal: Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Critical appraisal: Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Professor Peter J Goadsby and Dr FH Maniyar have produced a full critical appraisal of all the papers that they have reviewed for the 2010 Headache Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;This is a critical appraisal of the paper by Ashkenazi A ... et al - &lt;A href="nelh:396589:0" name=internalLink&gt;Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>396691</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=396691]]&gt;</url>
    <title>Critical appraisal: The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis</title>
    <publicationDate>2010-12-13T00:00:00</publicationDate>
    <publisher>NHS Evidence - neurological conditions</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Critical appraisal: The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Professor Peter J Goadsby and Dr FH Maniyar have produced a full critical appraisal of all the papers that they have reviewed for the 2010 Headache Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;This is a critical appraisal of the paper by Kelly AM ... et al - &lt;A href="nelh:396602:0" name=internalLink&gt;The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>270505</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Epilepsia%22%5BJour%5D%20AND%2048%5Bvolume%5D%20AND%205%5Bissue%5D%20AND%20990%5Bpage%5D%20AND%202007%5Bpdat%5D]]&gt;</url>
    <title>Cross-country measures for monitoring epilepsy care</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Begley C.E., Baker G.A., Beghi E. et al. 2007; Epilepsia 48 (5) pp. 990-1001&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;PURPOSE: The International League Against Epilepsy (ILAE) Commission on Healthcare Policy in consultation with the World Health Organization (WHO) examined the applicability and usefulness of various measures for monitoring epilepsy healthcare services and systems across countries. The goal is to provide planners and policymakers with tools to analyze the impact of healthcare services and systems and evaluate efforts to improve performance. METHODS: Commission members conducted a systematic literature review and consulted with experts to assess the nature, strengths, and limitations of the treatment gap and resource availability measures that are currently used to assess the adequacy of epilepsy care. We also conducted a pilot study to determine the feasibility and applicability of using new measures to assess epilepsy care developed by the WHO including Disability-Adjusted Life Years (DALYs), responsiveness, and financial fairness. RESULTS: The existing measures that are frequently used to assess the adequacy of epilepsy care focus on structural or process factors whose relationship to outcomes are indirect and may vary across regions. The WHO measures are conceptually superior because of their breadth and connection to articulated and agreed upon outcomes for health systems. However, the WHO measures require data that are not readily available in developing countries and most developed countries as well. CONCLUSION: The epilepsy field should consider adopting the WHO measures in country assessments of epilepsy burden and healthcare performance whenever data permit. Efforts should be made to develop the data elements to estimate the measures.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324811</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/jnnp.2008.167791]]&gt;</url>
    <title>CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies</title>
    <publicationDate>2009-05-21T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,SEPTEMBER 2009,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Mitchell, AJ. (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies. &lt;EM&gt;Journal of Neurology, Neurosurgery, and Psychiatry&lt;/EM&gt; 80:966-975 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A meta-analysis was performed of 19 robust studies that compared AD with healthy individuals (n = 2300), 18 that compared AD with non-AD dementias (n = 1892), eight that compared MCI with healthy subjects (n = 447) and six in those with MCI who did and did not progress to dementia (n = 388).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; On the basis of levels of p-tau in CSF, AD could be discriminated from those without cognitive impairment with a sensitivity (Se) of 77.6%, a specificity (Sp) of 87.9%, a positive predictive value (PPV) of 90.3% and a negative predictive value (NPV) of 73.0%. The clinical utility of the test was rated as "good". CSF levels of p-tau separated AD from other dementias with an Se of 71.6% and an Sp 77.8% but here the clinical utility was satisfactory to poor. Regarding MCI, p-tau contributed to the separation of MCI from healthy individuals with an Se of 79.6% and an Sp 83.9% (PPV 85.9%, NPV 76.9%). Here the clinical utility was rated as "satisfactory". P-tau was modestly successful in predicting progression to dementia in MCI (Se 81.1%, Sp 65.3%, PPV 63.0%, NPV 83.0%), showing higher predictive value for absence of progression rather than conversion to AD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; CSF p-tau is a good diagnostic biomarker of probable AD, a satisfactory diagnostic biomarker of MCI, a satisfactory prognostic biomarker for progression of MCI but was less adequate in separating AD from other dementias. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 21 may 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377576</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20435319]]&gt;</url>
    <title>Cupping for stroke rehabilitation: A systematic review.</title>
    <publicationDate>2010-04-30T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,STROKE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,REHABILITATION,JUNE 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lee MS, Choi TY, Shin BC, Han CH, Ernst E. (2010) Cupping for stroke rehabilitation: A systematic review. Journal of the Neurological Sciences. Apr 30. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract: &lt;/STRONG&gt;Cupping is often used for stroke rehabilitation in Asian countries. Currently, no systematic review of this topic is available. The aim of this systematic review is to summarize and critically evaluate the evidence for and against the effectiveness of cupping for stroke rehabilitation. Thirteen databases were searched from their inception through March of 2010 without language restrictions. Prospective clinical trials were included if cupping was tested as the sole treatment or as an adjunct to other conventional treatments for stroke rehabilitation. We found 43 potentially relevant articles, of which 5 studies including 3 randomized clinical trials (RCTs) and 2 uncontrolled observational studies (UOSs) met our inclusion criteria. Cupping was compared with acupuncture, electro-acupuncture and warm needling. Some superior effects of cupping were found in two of the RCTs when compared to acupuncture in hemiplegic shoulder pain and high upper-limb myodynamia after stroke. The other RCT failed to show favorable effects of cupping when compared to acupuncture and warm needling in patients with hemiplegic hand edema. The two UOSs reported favorable effects of cupping on aphasia and intractable hiccup after stroke. There are not enough trials to provide evidence for the effectiveness of cupping for stroke rehabilitation because most of the included trials compared the effects with unproven evidence and were not informative. Future RCTs seem warranted but must overcome the methodological shortcomings of the existing evidence.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288527</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18256987?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Current evidence and therapeutic strategies for multiple sclerosis</title>
    <publicationDate>2008-02-01T00:00:00</publicationDate>
    <publisher>Thieme Stratton</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Wingerchuk, DM &lt;SPAN title="Seminars in neurology."&gt;&lt;A href="#javascript:AL_get(this," Neurol.?);? ?Semin ?jour?,&gt;Semin Neurol.&lt;/A&gt;&lt;/SPAN&gt; 2008 Feb;28(1):56-68&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;In the previous two decades several immunomodulatory and immunosuppressive therapies have been shown to favorably impact the inflammatory activity and course of multiple sclerosis. There are now six approved therapies for the disease. Clinical decision-making has become more complex because of the increasing number of available drugs, the lack of head-to-head comparisons that allow direct comparisons of efficacy, and special factors that may influence efficacy such as neutralizing antibodies against beta-interferon preparations. Furthermore, all current therapies are partially effective; therefore, most patients experience breakthrough disease activity while using them, and there are no validated treatment failure definitions or management algorithms. This review outlines current evidence supporting efficacy of available drugs and scenarios for which more studies are required, and highlights the need for emerging therapies and strategies for multiple sclerosis management, including investigative oral and parenteral agents and combination therapy approaches.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270566</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Epilepsy%20%26%20behavior%20%3A%20E%26B%22%5BJour%5D%20AND%209%5Bvolume%5D%20AND%204%5Bissue%5D%20AND%20641%5Bpage%5D%20AND%202006%5Bpdat%5D]]&gt;</url>
    <title>Death from suicide versus mortality from epilepsy in the epilepsies: a meta-analysis</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Academic Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Pompili M., Girardi P., Tatarelli R. et al. 2006; Epilepsy &amp;amp; Behaviour 9 (4) pp. 641-8&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: Epilepsy is associated with an increased risk of mortality, which, however, is rarely due to the epilepsy itself; suicide, on the other hand, is a chief cause of death among persons with epilepsy. We conducted a meta-analysis to compare data reported in representative studies of suicide mortality in epilepsy with data on mortality from epilepsy in the general population. METHODS: We searched Index Medicus to 2006 through MedLine. We also searched the World Health Statistics Annual to ascertain rates of mortality from epilepsy in the age groups indicated in the studies on patients with epilepsy for specific years and countries. RESULTS: We selected 30 studies comprising 51,216 persons, 188 of whom committed suicide and died. Results obtained for each study were processed together to calculate, per 100,000 individuals in the general population per year, the mean number of suicide deaths expected in persons with epilepsy with respect to the current prevalence of epilepsy. We found that the number of suicide deaths among persons with epilepsy is the same as the number of deaths from epilepsy, suggesting that the former are not included in mortality rates for epilepsy. Also, we found that, according to data derived from cohorts we selected, 32.5% of all deaths of persons with epilepsy are due to suicide and at least 13.5% of all registered suicides are committed by these persons. Study findings may not generalize to other samples, settings, and treatments, thus perhaps tending to exaggerate the phenomenon actually attainable under broader clinical conditions. CONCLUSIONS: Our meta-analysis indicates that suicide deaths in persons with epilepsy are a disturbingly frequent phenomenon that should be addressed to reduce mortality among patients with epilepsy dramatically. In particular, mortality rates for persons with epilepsy do not include mortality from suicide, greatly underestimating death rates and the need for suicide prevention strategies for these patients.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381883</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1001/jama.2010.1013]]&gt;</url>
    <title>Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis</title>
    <publicationDate>2010-07-28T00:00:00</publicationDate>
    <publisher>Journal of the American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ LATER LIFE,DEMENTIA,TREATMENT AND CARE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information: &lt;/STRONG&gt;Witlox J, Eurelings SM, de Jonghe JFM, Kalisvaart KJ, Eikelenboom P, van Gool WA. (2010) Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia. &lt;EM&gt;Journal of the American Medical Association&lt;/EM&gt; 304(4): 443-451&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;JAMA&lt;/EM&gt;, published continuously since 1883, is an international peer-reviewed general medical journal published 48 times per year. &lt;EM&gt;JAMA&lt;/EM&gt; is the most widely circulated medical journal in the world. Its key objective is "To promote the science and art of medicine and the betterment of the public health".&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; This meta-analysis provides evidence that delirium in elderly patients is associated with poor outcome independent of important confounders, such as age, sex, comorbid illness or illness severity, and baseline dementia.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Context:&lt;/STRONG&gt; Delirium is a common and serious complication in elderly patients. Evidence suggests that delirium is associated with long-term poor outcome but delirium often occurs in individuals with more severe underlying disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To assess the association between delirium in elderly patients and long-term poor outcome, defined as mortality, institutionalization, or dementia, while controlling for important confounders. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Sources:&lt;/STRONG&gt; A systematic search of studies published between January 1981 and April 2010 was conducted using the databases of MEDLINE, EMBASE, PsycINFO, and CINAHL. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study Selection:&lt;/STRONG&gt; Observational studies of elderly patients with delirium as a study variable and data on mortality, institutionalization, or dementia after a minimum follow-up of 3 months, and published in the English or Dutch language. Titles, abstracts, and articles were reviewed independently by 2 of the authors. Of 2939 references in the original search, 51 relevant articles were identified. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Extraction:&lt;/STRONG&gt; Information on study design, characteristics of the study population, and outcome were extracted. Quality of studies was assessed based on elements of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for cohort studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Synthesis:&lt;/STRONG&gt; The primary analyses included only high-quality studies with statistical control for age, sex, comorbid illness or illness severity, and baseline dementia. Pooled-effect estimates were calculated with random-effects models. The primary analysis with adjusted hazard ratios (HRs) showed that delirium is associated with an increased risk of death compared with controls after an average follow-up of 22.7 months (7 studies; 271/714 patients [38.0%] with delirium, 616/2243 controls [27.5%]; HR, 1.95 [95% confidence interval {CI}, 1.51-2.52]; I2, 44.0%). Moreover, patients who had experienced delirium were also at increased risk of institutionalization (7 studies; average follow-up, 14.6 months; 176/527 patients [33.4%] with delirium and 219/2052 controls [10.7%]; odds ratio [OR], 2.41 [95% CI, 1.77-3.29]; I2, 0%) and dementia (2 studies; average follow-up, 4.1 years; 35/56 patients [62.5%] with delirium and 15/185 controls [8.1%]; OR, 12.52 [95% CI, 1.86-84.21]; I2, 52.4%). The sensitivity, trim-and-fill, and secondary analyses with unadjusted high-quality risk estimates stratified according to the study characteristics confirmed the robustness of these results. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff with an NHS Athens password. Other users should ask their local healthcare library if&amp;nbsp;they have a local subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>299675</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/therapeutics/cns/dementia/workshops/workshop_60minute_elearn_event1.php]]&gt;</url>
    <title>Dementia - &lt;60 minute e-learning workshop</title>
    <publicationDate>2008-10-17T00:00:00</publicationDate>
    <publisher>NPC</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Series of workshops using a multimedia presentation of PowerPoint slides with audio commentary by the NPC team. You will need speakers and a sound card in your computer.&amp;nbsp; &lt;/P&gt;
&lt;P class=content&gt;&lt;STRONG&gt;Contents include:&amp;nbsp;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=content&gt;&lt;SPAN class=style6&gt;Part 1 - Background (13min 40secs)&lt;/SPAN&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV class=content&gt;Types of dementia, prevalence and costs &lt;/DIV&gt;
&lt;LI class=content&gt;Risk factors and prevention&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=content&gt;&lt;SPAN class=style6&gt;Part 2 - Cognitive Symptoms&lt;/SPAN&gt; (26min 13secs) &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV class=content&gt;Cognitive Symptoms &lt;/DIV&gt;
&lt;LI class=content&gt;Non-drug treatment 
&lt;LI class=content&gt;Drug treatment 
&lt;LI class=content&gt;NICE guidance on drug treatment 
&lt;LI class=content&gt;SIGN guidance &lt;/LI&gt;&lt;/UL&gt;
&lt;P style="MARGIN-BOTTOM: 0px" class=content&gt;&lt;SPAN class=style1&gt;Part 3 - Non Cognitive Symptoms&lt;/SPAN&gt; (13min 25secs)&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV style="MARGIN-BOTTOM: 0px" class=content&gt;Non-cognitive symptoms &lt;/DIV&gt;
&lt;LI class=content&gt;Non drug treatments 
&lt;LI class=content&gt;Drug treatments 
&lt;LI class=content&gt;NICE guidance on drug treatments &lt;/LI&gt;&lt;/UL&gt;
&lt;P class=content&gt;"NPCi is a new and radically different NHS learning resource designed specifically for busy health care professionals and managers. The content covers prescribing, therapeutics &amp;amp; medicines management... The philosophy here is ‘bite sized chunks’ – small amounts of the best of the summarised evidence and information on topics you are likely to need because you encounter those conditions or situations often. To supplement your knowledge you can also listen to recorded workshops, read text, test your knowledge and join in discussions."&lt;BR&gt;&lt;/P&gt;&lt;!-- InstanceEndEditable --&gt;]]&gt;</body>
  </document>
  <document>
    <id>305043</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[https://admin.emea.acrobat.com/_a45839050/p41728730/]]&gt;</url>
    <title>Dementia - global or modular?</title>
    <publicationDate>2008-02-13T00:00:00</publicationDate>
    <publisher>Royal College of Physicians of London</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Webcast of lecture delivered by Prof Martin Rossor at the Royal College of physicians on February 13th, 2008.&lt;/P&gt;
&lt;P&gt;The webcast consists of a PowerPoint presentation with accompanying voice recording, and runs for 45 minutes. Click on the above link to view the presentation.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306034</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5004452]]&gt;</url>
    <title>Dementia: diagnosis and assessment</title>
    <publicationDate>2010-04-01T00:00:00</publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ LATER LIFE,DEMENTIA,NEUROLOGICAL CONDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,VASCULAR DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Learning outcomes:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;After completing this module you should know:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Why it is important to screen for cognitive impairment 
&lt;LI&gt;How to screen for cognitive impairment using standard tests 
&lt;LI&gt;How to distinguish between acute and chronic cognitive impairment 
&lt;LI&gt;The main features of the three main types of dementia: 
&lt;UL&gt;
&lt;LI&gt;Alzheimer's disease 
&lt;LI&gt;Vascular dementia 
&lt;LI&gt;Dementia with Lewy bodies &lt;/LI&gt;&lt;/UL&gt;
&lt;LI&gt;When you should refer patients to a specialist&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;These online education tools have been developed by BMJ Learning. BMJ Learning is the best available learning website for medical professionals. It offers a wide range of learning resources, commissioned by the BMJ Group. The learning resources deal with everyday issues in primary care and hospital medicine. They are evidence based and peer reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Free registration with the site is required.&amp;nbsp; To register, click "Start module" and then "Register here".&amp;nbsp; Do not select the option to log in via Athens as access to BMJ Learning is not currently&amp;nbsp;part of NHS Athens accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288535</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17436982?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Dental amalgam and multiple sclerosis: a systematic review and meta-analysis</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Aminzadeh, K &lt;SPAN title="Journal of public health dentistry."&gt;&lt;A href="#javascript:AL_get(this," Dent.?);? Health Public ?J ?jour?,&gt;J Public Health Dent.&lt;/A&gt;&lt;/SPAN&gt; 2007 Winter;67(1):64-6&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVES: Amalgam restorations have long been controversial due to their mercury content. Allegations that the mercury may be linked to nervous disorders such as Alzheimer's, chronic fatigue syndrome, and multiple sclerosis (MS) have fueled the calls for the removal of amalgam restorations from dentists' armamentarium. To explore and quantify the association between amalgam restorations and MS we have conducted a systematic review and meta-analysis of the literature. METHODS: A systematic search in Medline (from 1966 to April 2006), EMBASE (2006, Week 16), and the Cochrane library (Issue 2, 2006) for English-language articles meeting specific definitions of MS and amalgam exposure was conducted. Studies were also identified using the references of retrieved articles. Studies were independently reviewed by two authors and disagreements were resolved by consensus. Studies were selected based on an a priori of defined criteria. Odds ratios (ORs) or relative risks were pooled using the random effects model. Heterogeneity was assessed using Q statistics. RESULTS: The pooled OR for the risk of MS among amalgam users was consistent, with a slight, nonstatistically significant increase between amalgam use and risk of MS. CONCLUSION: Future studies that take into consideration the amalgam restoration size and surface area along with the duration of exposure are needed in order to definitively rule out any link between amalgam and MS.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384276</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1528-1167.2009.02276.x]]&gt;</url>
    <title>Depressive symptoms among mothers of children with epilepsy: a review of prevalence, associated factors, and impact on children</title>
    <publicationDate>2009-08-19T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Ferro MA, Speechley KN. (2009) Depressive symptoms among mothers of children with epilepsy: a review of prevalence, associated factors, and impact on children. &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(11):2344-54. Epub 2009 Aug 19.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The impact of epilepsy is not limited to the child experiencing seizures, but affects all members of the family. As primary caregivers, mothers are particularly at risk for experiencing increased depressive symptoms and risk for clinical depression. &lt;/P&gt;
&lt;P&gt;The objective of this systematic review was to critically assess available evidence regarding the prevalence, associated factors, and impact of maternal depressive symptoms on child outcomes in epilepsy. Using a modified version of the Quality Index, studies were rigorously evaluated in terms of reporting, external validity, and internal validity. Limitations in the study designs and analytic techniques of previous research are discussed, and study methods to overcome these barriers are presented in order to advance this research area. Up to 50% of mothers of children with epilepsy are at risk for clinical depression. Correlates of maternal depressive symptoms include a number of modifiable risk factors such as role ambiguity, worry, and satisfaction with relationships. In addition, studies suggest that depressive symptoms in mothers have a negative impact on child outcomes in epilepsy including behavior problems and health-related quality of life. The overall mean score on the Quality Index was 9.7, indicating a midrange quality score, suggesting a need for more methodologically robust studies.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288538</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://amcp.org/data/jmcp/44-52.pdf]]&gt;</url>
    <title>Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Academy of Managed Care Pharmacy</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Prescott, JD et al &lt;SPAN title="Journal of managed care pharmacy : JMCP."&gt;&lt;A href="#javascript:AL_get(this," Pharm.?);? Care Manag ?J ?jour?,&gt;J Manag Care Pharm.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jan-Feb;13(1):44-52&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Multiple sclerosis (MS) is chronic and debilitating, afflicts patients in the prime of their lives, and requires costly, decades-long disease management. MS prevalence is increasing, and treatment with new drug therapies is expensive. OBJECTIVES: The objectives of this analysis were to (1) determine the average total and component direct medical costs incurred in the treatment of MS patients in 2004, and (2) compare MS treatment costs and cost factors in 2004 with 1995. METHODS: The data for this analysis were abstracted from the PharMetrics Integrated Patient-centric Database, which contains administrative claims data from more than 80 private and public health plans in the United States, representing more than 9.6 million unique patients in 2004. To be included in this analysis, each patient had to have at least 1 medical claim with a diagnosis of MS (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 340) in the date of service period from January 1, 2004, through December 31, 2004. Patients were segmented according to patient age and sex, comorbid conditions, payer type, and use of specific types of disease-modifying drugs (DMDs). Episode Treatment Group (ETG) software (ETG numbers 149 or 150) was used to aggregate medical claims related to MS since not all MS-related medical claims have the ICD-9-CM code 340. ETGs are commonly used to aggregate administrative claims data and to define discrete periods of care (episodes); this study used ETGs only to aggregate administrative claims. Statistical comparisons were subsequently performed using analysis of variance and chi-square analyses. The source of the data for the aggregate MS treatment costs in 1995 was the Medstat MarketScan database. RESULTS: In calendar year 2004, a total of 13,420 patients were identified with a medical or hospital claim with ICD-9-CM code 340, a prevalence of approximately 14.0 per 10,000. The final study population was reduced to 10,099 patents (75.3%) after applying the criterion of 12 full months of available claims data. The total average annual cost for the 10,099 MS patients in 2004 was $12,879 (standard deviation, $18,582), 64.8% of which was attributable to the cost of prescription drugs and 61.4% to the cost of DMDs in particular, 26.2% to outpatient care, 7.8% to inpatient care, and 1.1% to emergency room visits. There was no difference in total average annual medical costs for males compared with females, but costs did differ among age categories and by insurance type and payer. A total of 5,810 patients (57.5% of the study population) reported at least 1 pharmacy claim for a DMD, and these patients had average annual costs of $18,944 compared with $4,662 total annual costs for MS patients who did not receive DMDs. Pharmacy costs represented 75.3% of annual medical costs for the patients who reported at least 1 pharmacy claim for a DMD but only 7.4% for patients who did not receive DMDs. A comparison of 2004 costs with 1995 costs (adjusted for 2004 based on the Consumer Price Index; CPI-U [All Urban Consumers, All Items]; 1982-84=100) demonstrated that total annual MS-related treatment costs increased by 35%, from $9,515 in 1995 to $12,879 in 2004. There was some difference in total annual MS-related treatment costs in 2004 among the 4 DMD therapy groups.$16,928 for glatiramer, $17,987 for IFN beta-1a (intramuscular), $19,616 for IFN beta-1b, and $22,557 for IFN beta-1a (subcutaneous), P &amp;lt;0.001. CONCLUSION: Pharmacy costs accounted for 65% of total MS-related medical costs in 2004 and 75% of total costs for the subset of MS patients(58%) who received at least 1 DMD.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Free full text available online&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396494</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20224942]]&gt;</url>
    <title>Diagnostic criteria for CADASIL in the International Classification of Headache Disorders (ICHD-II): are they appropriate?</title>
    <publicationDate>2010-03-12T00:00:00</publicationDate>
    <publisher>SpringerLink</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Sacco S, Degan D, Carolei A. (2010) Diagnostic criteria for CADASIL in the International Classification of Headache Disorders (ICHD-II): are they appropriate? &lt;EM&gt;Journal of Headache and Pain&lt;/EM&gt; 11(3):181-186&lt;/P&gt;
&lt;P&gt;We reviewed the characteristics of headache in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), to verify the appropriateness of the International Classification of Headache Disorders, second edition (ICHD-II) criteria. Available data were found through Medline/PubMed using the keyword "cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)". The search was restricted to studies published in English in the years between 1993 and 2008. We excluded studies that did not report original data on CADASIL and information regarding the presence of headache. We found 34 studies reporting data on 749 patients overall; 387 (51.7%) patients had headache. According to the authors' definition, 356 (92%) patients were reported as having migraine and 31 (8%) as having headache. Of the 356 patients who were defined as migraineurs, 125 (35.1%) had migraine with aura, 7 (2%) migraine without aura, 156 (43.8%) unspecified migraine and 68 (19.1%) had more than one type of migraine. Among the 31 patients reported as suffering from headache, the headache was not further detailed in 18 (58.1%) patients; it was defined as chronic in 6 (19.3%), as resembling migraine with aura in 4 (12.9%), as resembling migraine without aura in 2 (6.5%) and as tension type in 1 (3.2%) patient. In patients with CADASIL, the headache was usually referred to as migraine and mostly as migraine with aura. However, this referral is formally incorrect since the diagnostic criteria for any type of migraine in the ICHD-II require that the disturbance is not attributed to another disorder. For this reason, we suggest updating the ICHD-II in relation to CADASIL. Our suggestion is to insert a new category referred to as Headache attributed to genetic disorder including Headache attributed to CADASIL.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384229</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1528-1167.2009.02282.x]]&gt;</url>
    <title>Disparities in epilepsy: report of a systematic review by the North American Commission of the International League Against Epilepsy</title>
    <publicationDate>2009-09-03T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Burneo JG, Jette N, Theodore W, Begley C, Parko K, Thurman DJ, Wiebe S; Task Force on Disparities in Epilepsy Care. (2009) Disparities in epilepsy: report of a systematic review by the North American Commission of the International League Against Epilepsy. &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(10):2285-95. Epub 2009 Sep 3.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;PURPOSE:&lt;/STRONG&gt; We undertook a systematic review of the evidence on disparities in epilepsy with a focus on North American data (Canada, United States, and the English-speaking Caribbean). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;METHODS:&lt;/STRONG&gt; We identified and evaluated: access to and outcomes following medical and surgical treatment, disability, incidence and prevalence, and knowledge and attitudes. An exhaustive search (1965-2007) was done, including: (1) disparities by socioeconomic status (SES), race/ethnicity, age, or education of subgroups of the epilepsy population; or (2) disparities between people with epilepsy (PWE) and healthy people or with other chronic illnesses. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;RESULTS:&lt;/STRONG&gt; From 1,455 citations, 278 eligible abstracts were identified and 44 articles were reviewed. Comparative research data were scarce in all areas. PWE have been shown to have lower education and employment status; among PWE, differences in access to surgery have been shown by racial/ethnic groups. Aboriginals, women, and children have been shown to differ in use of health resources. Poor compliance has been shown to be associated with lower SES, insufficient insurance, poor relationship with treating clinicians, and not having regular responsibilities. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DISCUSSION:&lt;/STRONG&gt; Comprehensive, comparative research on all aspects of disparities in epilepsy is needed to understand the causes of disparities and the development of any policies aimed at addressing health disparities and minimizing their impact.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326760</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1161/STROKEAHA.109.560243]]&gt;</url>
    <title>Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis</title>
    <publicationDate>2009-08-13T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,HAEMORRHAGIC,CONDITIONS,OCTOBER 2009,SUBARACHNOID HAEMORRHAGE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kramer, A., Fletcher, J. (2009) Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis. &lt;EM&gt;Stroke&lt;/EM&gt; 40;3403-3406.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed a systematic review and meta-analysis of randomized controlled trials assessing the use of endothelin-receptor antagonists (ETRAs) in patients with SAH. Without language restrictions, we systematically searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (1950 to the present). We also searched the references of selected papers, the proceedings of the International Stroke Conference (2007 to 2009), and Google Scholar. Registered clinical trials were sought at &lt;A href="http://www.who.int/trialsearch/" target="_blank"&gt;http://www.who.int/trialsearch/&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Three studies met eligibility criteria, enrolling 867 patients. ETRAs significantly reduced the occurrence of DINDs (OR 0.68 [0.49 to 0.95]) and radiographic vasospasm (OR 0.31 [0.19 to 0.49]), but did not have any impact on mortality (OR 1.09 [0.69 to 1.72]) or poor neurological outcomes (OR 0.87 [0.63 to 1.20]). Any benefit of ETRAs may have been partially offset by adverse effects, including hypotension(OR 2.39 [1.37 to 4.17]) and pulmonary complications (OR 2.12 [1.51 to 2.98]).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although ETRAs reduce radiographic vasospasm and DINDs, there is currently no evidence that they improve outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; October 2009 (epub ahead of print 13th August 2009)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Older issues are freely available via &lt;A href="http://highwire.stanford.edu/lists/freeart.dtl" target="_blank"&gt;Highwire Press&lt;/A&gt; from January 1996. Full text for the last 12 months is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396711</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/cj15406684656427/]]&gt;</url>
    <title>Does exercise therapy improve headache? A systematic review with meta-analysis</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>SpringerLink</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Fricton J, Velly A, Ouyang W, Look JO. (2009) Does exercise therapy improve headache?&amp;nbsp;A systematic review with meta-analysis. &lt;EM&gt;Current Reports Pain and Headache&lt;/EM&gt; 13(6):413-9&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Therapeutic exercise is one of the most common physical medicine treatments and is recommended by many clinicians for a variety of musculoskeletal conditions. Many forms of therapeutic exercise have been evaluated and described in the scientific literature, including range of motion, isometric, postural, relaxation, strengthening, and aerobic. They are designed to stretch, relax, and improve posture and strength of the muscles, with the goal of improving tenderness, pain, function, and health. However, the use of exercise to manage headaches is low, perhaps because of the lack of understanding of the effectiveness&amp;nbsp; mechanism of exercise for headache disorders such as tension-type headache (TTH). Yet, a number of studies have examined exercise to improve both TTH and temporomandibular disorder (TMD) muscle pain, which can provide us some answers. This commentary presents the results of a systematic review of randomized controlled trials (RCTs) that help shed light on whether exercise will improve headache and TMD muscle pain.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322993</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18976336]]&gt;</url>
    <title>Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature</title>
    <publicationDate>2008-10-25T00:00:00</publicationDate>
    <publisher>Hanley &amp; Belfus</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Singh A, Alter HJ, Zaia B. (2008) Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature. &lt;EM&gt;Academic Emergency Medicine&lt;/EM&gt; 15(12):1223-33.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The authors searched MEDLINE, EMBASE, CINAHL, LILACS, recent emergency medicine scientific abstracts, and several prepublication trial registries for potential investigations related to the research question. The authors included studies that incorporated randomized, double-blind, placebo-controlled methodology and that were performed in the ED. A fixed-effects and random-effects model was used to obtain summary risk ratios (RRs) and 95% confidence intervals (CIs) for the self-reported outcome of moderate or severe headache on follow-up evaluation. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A pooled analysis of seven trials involving 742 patients suggests a modest but significant benefit when dexamethasone is added to standard antimigraine therapy to reduce the rate of patients with moderate or severe headache on 24- to 72-hour follow-up evaluation (RR = 0.87, 95% CI = 0.80 to 0.95; absolute risk reduction = 9.7%). The treatment of 1,000 patients with acute migraine headache using dexamethasone in addition to standard antimigraine therapy would be expected to prevent 97 patients from experiencing the outcome of moderate or severe headache at 24 to 72 hours after ED evaluation. The sensitivity analysis yielded similar results with sequential trial elimination, indicating that no single trial was responsible for the overall result. Adverse effects related to the administration of a single dose of dexamethasone were infrequent, mild, and transient. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; These results suggest that dexamethasone is efficacious in preventing headache recurrence and safe when added to standard treatment for the management of acute migraine headache in the ED. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 25 october 2008 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>385138</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1001/jama.2010.1182]]&gt;</url>
    <title>Does this patient have delirium? Value of bedside instruments</title>
    <publicationDate>2010-08-18T00:00:00</publicationDate>
    <publisher>Journal of the American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic information:&lt;/STRONG&gt; Wong CL, Holroyd-Leduc J, Simel DL, Straus SE. (2010) Does this patient have delirium? Value of bedside instruments. &lt;EM&gt;Journal of the American Medical Association&lt;/EM&gt; 304(7):779-786&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Context:&lt;/STRONG&gt; Delirium occurs in many hospitalized older patients and has serious consequences including increased risk for death and admission to long-term care. Despite its importance, health care clinicians often fail to recognize delirium. Simple bedside instruments may lead to improved identification. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt;&amp;nbsp;To systematically review the evidence on the accuracy of bedside instruments in diagnosing the presence of delirium in adults. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Sources:&lt;/STRONG&gt; Search of MEDLINE (from 1950 to May 2010), EMBASE (from 1980 to May 2010), and references of retrieved articles to identify studies of delirium among inpatients. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study Selection:&lt;/STRONG&gt; Prospective studies of diagnostic accuracy that compared at least 1 delirium bedside instrument to the Diagnostic and Statistical Manual of Mental Disorders –based diagnosis made by a geriatrician, psychiatrist, or neurologist. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Synthesis:&lt;/STRONG&gt; There were 6570 unique citations identified with 25 prospectively conducted studies (N = 3027 patients) meeting inclusion criteria and describing use of 11 instruments. Positive results that suggested delirium with likelihood ratios (LRs) greater than 5.0 were present for the Global Attentiveness Rating (GAR), Memorial Delirium Assessment Scale (MDAS), Confusion Assessment Method (CAM), Delirium Rating Scale Revised-98 (DRS-R-98), Clinical Assessment of Confusion (CAC), and Delirium Observation Screening Scale (DOSS). Normal results that decreased the likelihood of delirium with LRs less than 0.2 were calculated for the GAR, MDAS, CAM, DRS-R-98, Delirium Rating Scale (DRS), DOSS, Nursing Delirium Screening Scale (Nu-DESC), and Mini-Mental State Examination (MMSE). The Digit Span test and Vigilance "A" test in isolation have limited utility in diagnosing delirium. Considering the instrument's ease of use, test performance, and clinical importance of the heterogeneity in the confidence intervals (CIs) of the LRs, the CAM has the best available supportive data as a bedside delirium instrument (summary-positive LR, 9.6; 95% CI, 5.8-16.0; summary-negative LR, 0.16; 95% CI, 0.09-0.29). Of all scales, the MMSE (score &amp;lt;24) was the least useful for identifying a patient with delirium (LR, 1.6; 95% CI, 1.2-2.0). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; The choice of instrument may be dictated by the amount of time available and the discipline of the examiner; however, the best evidence supports use of the CAM, which takes 5 minutes to administer.&amp;nbsp;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;JAMA&lt;/EM&gt;, published continuously since 1883, is an international peer-reviewed general medical journal published 48 times per year. &lt;EM&gt;JAMA&lt;/EM&gt; is the most widely circulated medical journal in the world. Its key objective is "To promote the science and art of medicine and the betterment of the public health".&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff with an NHS Athens password. Other users should ask their local healthcare library if&amp;nbsp;they have a local subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377642</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20407062]]&gt;</url>
    <title>Does this patient with diabetes have large-fiber peripheral neuropathy?</title>
    <publicationDate>2010-04-21T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,COMPLICATING MEDICAL DISORDERS,ENDOCRINE &amp; METABOLIC DISORDERS,CONDITIONS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kanji JN, Anglin RE, Hunt DL, Panju A. (2010)Does this patient with diabetes have large-fiber peripheral neuropathy? &lt;EM&gt;JAMA&lt;/EM&gt; 303(15):1526-32.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; MEDLINE (January 1966-November 2009) and EMBASE (1980-2009 [week 50]) databases were searched for articles on bedside diagnosis of diabetic peripheral neuropathy. Included studies compared elements of history or physical examination with nerve conduction testing as the reference standard.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of 1388 articles, 9 on diagnostic accuracy and 3 on precision met inclusion criteria. The prevalence of diabetic LFPN ranged from 23% to 79%. A score greater than 4 on a symptom questionnaire developed by the Italian Society of Diabetology increases the likelihood of LFPN (likelihood ratio [LR], 4.0; 95% confidence interval [CI], 2.9-5.6; negative LR, 0.19; 95% CI, 0.10-0.38). The most useful examination findings were vibration perception with a 128-Hz tuning fork (LR range, 16-35) and pressure sensation with a 5.07 Semmes-Weinstein monofilament (LR range, 11-16). Normal results on vibration testing (LR range, 0.33-0.51) or monofilament (LR range, 0.09-0.54) make LFPN less likely. Combinations of signs did not perform better than these 2 individual findings. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Physical examination is most useful in evaluating for LFPN in patients with diabetes. Abnormal results on monofilament testing and vibratory perception (alone or in combination with the appearance of the feet, ulceration, and ankle reflexes) are the most helpful signs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 21st April 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345146</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19850894]]&gt;</url>
    <title>Doppler embolic signals in cerebrovascular disease and prediction of stroke risk: a systematic review and meta-analysis.</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INVESTIGATION &amp; DIAGNOSTICS,STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,ULTRASONOGRAPHY,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; King A, Markus HS. (2009) Doppler embolic signals in cerebrovascular disease and prediction of stroke risk: a systematic review and meta-analysis.&amp;nbsp;&lt;EM&gt;Stroke &lt;/EM&gt;40(12):3711-7. Epub 2009 Oct 22&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic review and meta-analysis was performed to determine the prognostic value of ES in different potential cerebral embolic sources. Studies were identified that used transcranial Doppler to detect ES and included prospective stroke/TIA follow-up. Numbers of ES-positive and ES-negative patients were extracted with stroke/TIA and stroke alone outcomes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; ES are most frequent in large artery disease, less frequent in cardioembolic stroke, and infrequent in lacunar stroke. Data relating ES to future stroke risk were available for acute stroke, large artery disease, and the perioperative period of carotid endarterectomy. For symptomatic carotid stenosis, ES predicted stroke alone (OR, 9.57; 95%CI, 1.54 to 59.38; P=0.02) and stroke/TIA (OR, 6.36; 95% CI, 2.90-13.96; P&amp;lt;0.00001). For asymptomatic carotid stenosis, ES predicted stroke alone (OR, 7.46; 95% CI, 2.24-24.89; P=0.001) and stroke/TIA (OR, 12.00; 95% CI, 2.43-59.34; P=0.002) but with heterogeneity (P=0.004). In acute stroke ES predicted stroke alone (OR, 2.44; 95% CI, 1.17-5.08; P=0.02) and stroke/TIA (OR, 3.71; 95% CI, 1.64-8.38; P=0.002). A high frequency of ES immediately after carotid endarterectomy predicted stroke alone (OR, 24.54; 95% CI, 7.88-76.43; P&amp;lt;0.00001) and stroke/TIA (OR, 32.04; 95% CI, 11.36-90.39; P&amp;lt;0.00001). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; ES predict stroke risk in acute stroke, symptomatic carotid stenosis, and postoperatively after carotid endarterectomy; in asymptomatic carotid stenosis, data are less robust. In these conditions ES may be useful in risk stratification and in assessing therapeutic efficacy. For other embolic sources, further prospective data are required.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; October 22 2009 (epub before print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This journal freely available via Highwire Press. Last 12 months available to subscribers only; check with your local healthcare library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313826</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.neurology.org/cgi/content/abstract/71/8/578]]&gt;</url>
    <title>Drowning in people with epilepsy</title>
    <publicationDate>2008-08-19T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. (2008) Drowning in people with epilepsy: how great is the risk? &lt;EM&gt;Neurology&lt;/EM&gt; 71(8):578-82.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method: &lt;/STRONG&gt;A literature search identified 51 cohorts of people with epilepsy in whom the number of deaths by drowning in people with epilepsy and the number of person-years at risk could be estimated. Population data were taken from the WHO Statistical Information Service or from the UK Office for National Statistics where available. Standardized mortality ratios (SMRs) with 95% CIs were calculated for each cohort, for groups of cohorts, and for the total population. Additionally, an SMR for drowning in people with epilepsy in England and Wales (1999–2000) was calculated using National Registries.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&amp;nbsp; &lt;/STRONG&gt;Eighty-eight drowning deaths were observed compared with 4.70 expected, giving an SMR of 18.7 (95% CI 15.0 to 23.1). Compared with community-based incident studies (SMR 5.4), the SMR was significantly raised in prevalent epilepsy (SMR 18.0), in people with epilepsy and learning disability (SMR 25.7), in those in institutional care (SMR 96.9), and in those who had a temporal lobe excision (SMR 41.1). The SMR for people with epilepsy in England and Wales was 15.3.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;The risk of drowning in people with epilepsy is raised 15- to 19-fold compared with people in the general population. It is important that people with epilepsy and their carers be informed of these risks so that deaths can be prevented. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326598</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.movementdisorders.org/publications/ebm_reviews/dysautonomia_scales.php]]&gt;</url>
    <title>Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation - Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease</title>
    <publicationDate>2009-02-09T00:00:00</publicationDate>
    <publisher>Movement Disorders Society</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,PARKINSON'S DISEASE,MOVEMENT DISORDERS,ENT AND AUDIOLOGY,SIALORRHOEA,LARYNX &amp; PHARYNX DISORDERS,SALIVARY GLAND DISORDERS,CONDITIONS,CONDITIONS,OCTOBER 2009,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,DEGLUTITION DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Evatt ML, Chaudhuri KR, Chou KL, Cubo E, Hinson V, Kompoliti K, Yang C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. (2009) Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation - critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. &lt;EM&gt;Movement Disorders&lt;/EM&gt; 24(5):635-46.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. Six clinical researchers and a biostatistician systematically searched the literature for scales of sialorrhea, dysphagia, and constipation, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated "Recommended" if the scale was used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and clinimetric studies have established that it is a valid, reliable, and sensitive. "Suggested" scales met at least part of the above criteria, but fell short of meeting all. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Based on the systematic review, scales for individual symptoms of sialorrhea, dysphagia, and constipation were identified along with three global scales that include these symptoms in the context of assessing dysautonomia or nonmotor symptoms. Three sialorrhea scales met criteria for Suggested: Drooling Severity and Frequency Scale (DSFS), Drooling Rating Scale, and Sialorrhea Clinical Scale for PD (SCS-PD). Two dysphagia scales, the Swallowing Disturbance Questionnaire (SDQ) and Dysphagia-Specific Quality of Life (SWAL-QOL), met criteria for Suggested. Although Rome III constipation module is widely accepted in the gastroenterology community, and the earlier version from the Rome II criteria has been used in a single study of PD patients, neither met criteria for Suggested or Recommended. Among the global scales, the Scales for Outcomes in PD-Autonomic (SCOPA-AUT) and Nonmotor Symptoms Questionnaire for PD (NMSQuest) both met criteria for Recommended, and the Nonmotor Symptoms Scale (NMSS) met criteria for Suggested; however, none specifically focuses on the target gastrointestinal symptoms (sialorrhea, dysphagia, and constipation) of this report. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A very small number of rating scales have been applied to studies of gastrointestinal-related dysautonomia in PD. Only two scales met "Recommended" criteria and neither focuses specifically on the symptoms of sialorrhea, dysphagia, and constipation. Further scale testing in PD among the scales that focus on these symptoms is warranted, and no new scales are needed until the available scales are fully tested clinimetrically.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 15 April 2009 (epub ahead of print 9 February 2009)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text freely available on Movement Disorders Society website.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314079</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18788837]]&gt;</url>
    <title>Economic analysis of newer antiepileptic drugs</title>
    <publicationDate></publicationDate>
    <publisher>Adis International</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Beghi E, Atzeni L, Garattini L. (2008) Economic analysis of newer antiepileptic drugs. &lt;EM&gt;CNS Drugs&lt;/EM&gt; 22(10):861-75.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; MEDLINE and EMBASE electronic databases were systematically searched using a search strategy designed to retrieve cost-effectiveness studies published between 2003 and 2007. Studies published prior to 2003 were retrieved from a comprehensive review of clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy published in 2005.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A number of economic analysis studies of second-generation AEDs have examined these compounds as monotherapy or adjunctive therapy. Almost all monotherapy studies showed newer AEDs as having similar effectiveness but significantly higher acquisition costs than first-generation drugs. The evidence from adjunctive therapy studies was more conflicting. Lamotrigine appeared to be a cost-effective drug when higher thresholds were used, or when savings were defined by the cost of surgery. Levetiracetam also appeared to be cost effective when the costs of surgical investigation were discounted.In a decision model that included quantification of the uncertainty associated with the decision regarding the cost effectiveness of AEDs, second-generation drugs used as monotherapy for newly diagnosed partial epilepsy produced similar benefits but were more expensive than older drugs. The newer AEDs were more effective but more expensive than existing monotherapies in patients with refractory partial epilepsy, but may be cost effective at higher thresholds, and continue to be cost effective in patients responding to the assigned drug. In patients with newly diagnosed generalized epilepsy, valproate was more cost effective than lamotrigine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The results of current economic studies are difficult to assess and compare because of a number of methodological drawbacks. Future studies should be implemented using a standardized approach to define the costs and outcomes of representative cohorts of patients with newly diagnosed epilepsy recruited from different countries and followed prospectively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288489</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17881388?ordinalpos=16&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Sage</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Motl, RW et al &lt;SPAN title="Multiple sclerosis (Houndmills, Basingstoke, England)."&gt;&lt;A href="#javascript:AL_get(this," Scler.?);? ?Mult ?jour?,&gt;Mult Scler.&lt;/A&gt;&lt;/SPAN&gt; 2008 Jan;14(1):129-35. Epub 2007 Sep 19&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Using meta-analytic procedures, this study examined the overall effect of exercise training interventions on quality of life (QOL) among individuals with multiple sclerosis (MS). We searched MEDLINE, PSYCHINFO and CURRENT CONTENTS PLUS for the period of 1960 to November 2006 using the key words exercise, physical activity and physical fitness in conjunction with QOL and MS. We further conducted a manual search of bibliographies of the retrieved papers as well as literature reviews and contacted study authors about additional studies. Twenty-five journal articles were located and reviewed, and only 13 provided enough data to compute effect sizes expressed as Cohen's d. One hundred and nine effect sizes were retrieved from the 13 studies with 484 MS participants and yielded a weighted mean effect size of g=0.23 (95% CI=0.15, 0.31). There were larger effects associated with MS-specific measures of QOL and fatigue as an index of QOL. The nature of the exercise stimulus further influenced the magnitude of the mean effect size. The cumulative evidence supports that exercise training is associated with a small improvement in QOL among individuals with MS.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Full text available to NHS staff using an NHS Athens password&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344205</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18948413]]&gt;</url>
    <title>Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Sage</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,DELIVERY OF CARE,REHABILITATION,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. &lt;EM&gt;Neurorehabilitation &amp;amp; Neural Repair&lt;/EM&gt; 2009 Feb;23(2):108-16.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A search was conducted for published exercise training studies from 1960 to November 2007 using MEDLINE, PsychINFO, CINAHL, and Current Contents Plus. Studies were selected if they measured walking mobility, using instruments identified as acceptable walking mobility constructs and outcome measures for individuals with neurologic disorders, before and after an intervention that included exercise training.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Forty-two published articles were located and reviewed, and 22 provided enough data to compute effect sizes expressed as Cohen's d. Sixty-six effect sizes were retrieved from the 22 publications with 600 multiple sclerosis participants and yielded a weighted mean effect size of g = 0.19 (95% confidence interval, 0.09-0.28). There were larger effects associated with supervised exercise training ( g = 0.32), exercise programs that were less than 3 months in duration (g = 0.28), and mixed samples of relapsing-remitting and progressive multiple sclerosis (g = 0.52).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The cumulative evidence supports that exercise training is associated with a small improvement in walking mobility among individuals with multiple sclerosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in February 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345156</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19875741]]&gt;</url>
    <title>Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.</title>
    <publicationDate>2009-10-29T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,DELIVERY OF CARE,NEUROLOGICAL CONDITIONS,HAEMORRHAGIC,CONDITIONS,SUBARACHNOID HAEMORRHAGE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. (2010) Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.&amp;nbsp;&lt;EM&gt;Stroke&lt;/EM&gt; 41(1):e47-52. Epub 2009 Oct 29. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; All randomized, placebo-controlled trials investigating the effect of statins on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage were included. Outcomes were the number of patients with transcranial Doppler vasospasm, delayed cerebral ischemia, poor outcome, and mortality during follow-up. Effect sizes were expressed in (pooled) risk ratio estimates. Data were pooled using random-effects models. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In 4 studies, a total of 190 patients were included. No statistically significant effect was observed on transcranial Doppler vasospasm (pooled risk ratio, 0.99 [95% CI, 0.66 to 1.48]), delayed cerebral ischemia (pooled risk ratio, 0.57 [95% CI, 0.29 to 1.13]), poor outcome (pooled risk ratio, 0.92 [95% CI, 0.68 to 1.24]), or mortality (pooled risk ratio, 0.37 [95% CI, 0.13 to 1.10]). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The results of the present systematic review do not lend statistically significant support to the finding of a beneficial effect of statins in patients with aneurysmal subarachnoid hemorrhage as reported in a previous meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; October 29 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Journal freely available via Highwire Press. Last 12 months to subscribers only; please check your local healthcare library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293078</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16987643?ordinalpos=5&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Effectiveness of Petasites hybridus preparations in the prophylaxis of migraine: a systematic review</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,MIGRAINE,HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Agosti, R et al Phytomedicine 2006 Nov;13(9-10):743-6. Epub 2006 Sep 20&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;The objective of this review was to evaluate the strength of evidence of effectiveness for Petasites hybridus in the prophylaxis of migraine. Several databases and other sources were searched to identify randomised-controlled trials investigating P. hybridus preparations. Two trials totalling 293 patients (60 and 233 patients) were included in this review. Both trials investigated the proprietary Petasites root extract Petadolex. The trials were described in narrative way, taking into consideration methodological quality scores. Pooling of data was not carried out due to the heterogeneity of the results. The extract at higher dose (150 mg) showed a greater decreased frequency of migraine attacks and a greater number of responders (improvement&amp;gt;50%) after treatment over 3-4 months than the extract at lower dose (100 mg) and placebo. Moderate evidence of effectiveness is, thus, available for a higher than the recommended dose of the proprietary Petasites root extract Petadolex in the prophylaxis of migraine. Further rigorous studies are required to confirm effectiveness and safety in long-term use before treatment with Petasites root extract can be recommended as an alternative option in the treatment schedule for the prophylaxis of migraine.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384221</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1177/0269215510367557]]&gt;</url>
    <title>Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review</title>
    <publicationDate>2010-06-16T00:00:00</publicationDate>
    <publisher>Clinical Rehabilitation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STRUCTURAL,CEREBRAL PALSY,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Koog YH, Min BI. (2010) Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review. &lt;EM&gt;Clinical Rehabilitation&lt;/EM&gt;. Jun 16. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To assess the efficacy of botulinum toxin A injection for the management of spastic calf muscles in children with cerebral palsy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; We reviewed all relevant literature indexed in MEDLINE, CINAHL, EMBASE, PEDro and the Cochrane Registered Trials, and also hand reviewed abstracts.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Eligible studies were randomized controlled trials that compared botulinum toxin A injection with any type of treatment or no treatment with identical conditions. We extracted data on calf muscle tone, passive ankle range of motion, gait speed, ankle kinematics and Gross Motor Function Measure, and assessed methodological qualities.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Fifteen studies met our inclusion criteria. When botulinum injection was compared with a non-sham control, it was found to be effective at improving calf muscle tone (one month: -2.73 (confidence interval (CI) -3.42 to -2.04), three months: -1.72 (-2.68 to -0.76)), passive ankle range of motion (one month: 3.29 (CI 2.52 to 4.05), three months: 1.00 (CI 0.44 to 1.56)) and gait speed (one month: 0.91 (CI 0.29 to 1.53), three months: 0.61 (CI 0.01 to 1.21)) for four months, as well as Gross Motor Function Measure (2.02 (CI 1.30 to 2.75)) for two months. When compared with sham injection, botulinum injection was only effective on Gross Motor Function Measure (0.98 (CI 0.28 to 1.69)) after four months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Although we found evidence supporting the efficacy of botulinum toxin A in studies comparing botulinum injection with non-sham controls, we did not find clear evidence of support in studies comparing botulinum injection with sham injection.&lt;/P&gt;
&lt;P&gt;Clinical Rehabilitation is a highly ranked, peer reviewed scholarly journal. It is a multi-professional journal covering the whole field of disability and rehabilitation, combining clinical application of scientific results and theoretical aspects in an ideal form. It gives high priority to articles describing effectiveness of therapeutic interventions and the evaluation of new techniques and methods.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345423</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://ebn.bmj.com/cgi/content/short/13/1/18]]&gt;</url>
    <title>Effects of physical fitness training on mortality, independence and disability after stroke unclear.</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DELIVERY OF CARE,STROKE,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lutz BJ (2010) Effects of physical fitness training on mortality, independence and disability after stroke unclear. &lt;EM&gt;Evidence Based Nursing&lt;/EM&gt; 13(1):18. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Saunders DH, Greig CA, Mead GE, et al. Physical fitness training for stroke patients. Cochrane Database of&amp;nbsp;Systematic Reviews,&amp;nbsp;Issue 4&amp;nbsp;2009&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398033</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/content/341/bmj.c5702.abstract]]&gt;</url>
    <title>Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials</title>
    <publicationDate>2010-08-25T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. (2010) Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. &lt;EM&gt;British Medical Journal&lt;/EM&gt; 341:c5702&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate the effect of vitamin E supplementation on incident total, ischaemic, and haemorrhagic stroke. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Systematic review and meta-analysis of randomised, placebo controlled trials published until January 2010. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; &amp;nbsp;Electronic databases (Medline, Embase, Cochrane Central Register of Controlled Trials) and reference lists of trial reports. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Selection criteria:&lt;/STRONG&gt; Randomised, placebo controlled trials with =1 year of follow-up investigating the effect of vitamin E on stroke. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods and data extraction:&lt;/STRONG&gt;&amp;nbsp;Two investigators independently assessed eligibility of identified trials. Disagreements were resolved by consensus. Two different investigators independently extracted data. Risk ratios (and 95% confidence intervals) were calculated for each trial based on the number of cases and non-cases randomised to vitamin E or placebo. Pooled effect estimates were then calculated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nine trials investigating the effect of vitamin E on incident stroke were included, totalling 118?765 participants (59?357 randomised to vitamin E and 59?408 to placebo). Among those, seven trials reported data for total stroke and five trials each for haemorrhagic and ischaemic stroke. Vitamin E had no effect on the risk for total stroke (pooled relative risk 0.98 (95% confidence interval 0.91 to 1.05), P=0.53). In contrast, the risk for haemorrhagic stroke was increased (pooled relative risk 1.22 (1.00 to 1.48), P=0.045), while the risk of ischaemic stroke was reduced (pooled relative risk 0.90 (0.82 to 0.99), P=0.02). There was little evidence for heterogeneity among studies. Meta-regression did not identify blinding strategy, vitamin E dose, or morbidity status of participants as sources of heterogeneity. In terms of absolute risk, this translates into one additional haemorrhagic stroke for every 1250 individuals taking vitamin E, in contrast to one ischaemic stroke prevented per 476 individuals taking vitamin E. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; In this meta-analysis, vitamin E increased the risk for haemorrhagic stroke by 22% and reduced the risk of ischaemic stroke by 10%. This differential risk pattern is obscured when looking at total stroke. Given the relatively small risk reduction of ischaemic stroke and the generally more severe outcome of haemorrhagic stroke, indiscriminate widespread use of vitamin E should be cautioned against. &lt;/P&gt;
&lt;P&gt;BMJ publishes original scientific studies, review and educational articles, and papers commenting on the clinical, scientific, social, political, and economic factors affecting health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Free full text is available to NHS staff via &lt;A href="http://ukpmc.ac.uk/" target="_blank"&gt;UK PubMed Central&lt;/A&gt;, with a 1-year embargo. Up-to-date full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314121</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15111659]]&gt;</url>
    <title>Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society</title>
    <publicationDate></publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; French JA, Kanner AM, Bautista J, bou-Khalil B, Browne T, Harden CL, et al. (2007)&amp;nbsp;Appendix C: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. &lt;EM&gt;CONTINUUM Lifelong Learning in Neurology&lt;/EM&gt; 13(4 EPILEPSY):203-11.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A 23-member committee, including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy, evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until September 2002, with selected manual searches up until 2003.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There is evidence either from comparative or dose-controlled trials that gabapentin, lamotrigine, topiramate, and oxcarbazepine have efficacy as monotherapy in newly diagnosed adolescents and adults with either partial or mixed seizure disorders. There is also evidence that lamotrigine is effective for newly diagnosed absence seizures in children. Evidence for effectiveness of the new AEDs in newly diagnosed patients with other generalized epilepsy syndromes is lacking. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with newly diagnosed epilepsy and identify those seizure types and syndromes where more evidence is necessary.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 2007 (January 2005)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314123</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15111660]]&gt;</url>
    <title>Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society</title>
    <publicationDate></publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;French JA, Kanner AM, Bautista J, bou-Khalil B, Browne T, Harden CL, et al. (2007) Appendix D: Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. &lt;EM&gt;CONTINUUM Lifelong Learning in Neurology&lt;/EM&gt; 13(4 EPILEPSY):212-24.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A 23-member committee including general neurologists, pediatric neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review including MEDLINE, Current Contents, and Cochrane library for relevant articles from 1987 until March 2003. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults. Gabapentin can be effective for the treatment of mixed seizure disorders, and gabapentin, lamotrigine, oxcarbazepine, and topiramate for the treatment of refractory partial seizures in children. Limited evidence suggests that lamotrigine and topiramate are also effective for adjunctive treatment of idiopathic generalized epilepsy in adults and children, as well as treatment of the Lennox Gastaut syndrome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The choice of AED depends upon seizure and/or syndrome type, patient age, concomitant medications, AED tolerability, safety, and efficacy. The results of this evidence-based assessment provide guidelines for the prescription of AEDs for patients with refractory epilepsy and identify those seizure types and syndromes where more evidence is necessary.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;2007 (January 2005)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384219</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1177/0269215510367551]]&gt;</url>
    <title>Efficacy and usability of assistive technology for patients with cognitive deficits: a systematic review</title>
    <publicationDate>2010-06-11T00:00:00</publicationDate>
    <publisher>Clinical Rehabilitation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DELIVERY OF CARE,TRAUMA,BRAIN INJURY,REHABILITATION,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;de Joode E, van Heugten C, Verhey F, van Boxtel M. (2010) Efficacy and usability of assistive technology for patients with cognitive deficits: a systematic review. &lt;EM&gt;Clinical Rehabilitation &lt;/EM&gt;Jun 11. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To determine the efficacy of portable electronic aids such as personal digital assistants (PDAs), pagers or mobile phones for patients with cognitive deficits by means of a systematic review. The usability of these aids is also briefly discussed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; PubMed, CINAHL, PsychINFO, EMBASE and MEDLINE were searched up to February 2009. The references of identified and relevant articles were scanned to find additional relevant titles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; Papers referring to 'electronic aids', 'cognition' and 'brain injury' were included. The population had to be adult and have cognitive impairments as a result of acquired brain injury. Outcome measures were change in cognitive or occupational performance or the level of participation in daily life. The criteria of Cicerone et al. were used to evaluate the quality of the retrieved studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-eight papers presenting 25 studies were reviewed. The total number of participants was 423. Most identified papers described case reports or non-randomized clinical trials. Only one randomized controlled trial was identified, in which the NeuroPage proved effective in supporting prospective memory. Other kinds of assistive technology such as PDAs and voice recorders showed positive results in supporting retrospective and prospective memory.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; The efficacy of assistive technology in general is not yet sufficiently studied in randomized controlled trials, although promising results has been reported. Furthermore, several survey studies established that both potential users and clinicians have optimistic expectations about the usability of assistive technology.&lt;/P&gt;
&lt;P&gt;Clinical Rehabilitation is a highly ranked, peer reviewed scholarly journal. It is a multi-professional journal covering the whole field of disability and rehabilitation, combining clinical application of scientific results and theoretical aspects in an ideal form. It gives high priority to articles describing effectiveness of therapeutic interventions and the evaluation of new techniques and methods.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293091</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17084028?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Efficacy of biofeedback for migraine: a meta-analysis</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,MIGRAINE,HEADACHE &amp; PAIN,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Nestoriuc, Y et al Pain 2007 Mar;128(1-2):111-27. Epub 2006 Nov 2&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;In this article, we meta-analytically examined the efficacy of biofeedback (BFB) in treating migraine. A computerized literature search of the databases Medline, PsycInfo, Psyndex and the Cochrane library, enhanced by a hand search, identified 86 outcome studies. A total of 55 studies, including randomized controlled trials as well as pre-post trials, met our inclusion criteria and were integrated. A medium effect size (d =0.58, 95% CI=0.52, 0.64) resulted for all BFB interventions and proved stable over an average follow-up phase of 17 months. Also, BFB was more effective than control conditions. Frequency of migraine attacks and perceived self-efficacy demonstrated the strongest improvements. Blood-volume-pulse feedback yielded higher effect sizes than peripheral skin temperature feedback and electromyography feedback. Moderator analyses revealed BFB in combination with home training to be more effective than therapies without home training. The influence of the meta-analytical methods on the effect sizes was systematically explored and the results proved to be robust across different methods of effect size calculation. Furthermore, there was no substantial relation between the validity of the integrated studies and the direct treatment effects. Finally, an intention-to-treat analysis showed that the treatment effects remained stable, even when drop-outs were considered as nonresponders.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396718</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19558252]]&gt;</url>
    <title>Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Atypon</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR. (2009) Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. &lt;EM&gt;Pharmacotherapy&lt;/EM&gt; 29(7):784-91&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study objective:&lt;/STRONG&gt; To assess the efficacy of botulinum toxin type A in lowering the frequency of migraine headaches in patients with episodic migraines.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Meta-analysis of eight randomized, double-blind, placebo-controlled trials.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Patients:&lt;/STRONG&gt; A total of 1601 patients with a history of episodic migraine headaches classified as those experiencing headaches fewer than 15 times/month over a 3-month period.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Measurements and main results:&lt;/STRONG&gt; PubMed, Google Scholar, and the Cochrane Library were searched from inception to October 2007 in order to locate randomized, double-blind, placebo-controlled trials that compared the efficacy of pericranial botulinum toxin A injections with placebo in the prevention of migraines in patients with a history of episodic migraine headaches. The primary outcome of interest was change from baseline to end point in migraine frequency (number of migraines/month). A random effects model was used to combine study results, and the standardized mean difference (Cohen's d) in migraine frequency between the placebo and botulinum toxin A groups was reported. Effect sizes (d) less than 0.2 were considered small. Quality assessment was performed by using the Downs and Black scale. Eight randomized, double-blind, placebo-controlled clinical trials (1601 patients) presented a quantitative assessment of the efficacy of botulinum toxin A versus placebo. The overall treatment effect size of botulinum toxin A over placebo for 30, 60, and 90 days after injection was d -0.06 (95% confidence interval [CI] - 0.14-0.03, z=1.33, p=0.18), d -0.05 (95% CI -0.14-0.03, z=1.22, p=0.22), and d -0.05 (95% CI -0.13-0.04, z=1.07, p=0.28), respectively. Even after controlling for a high placebo effect, and after dose stratification, no significant effect of botulinum toxin A in reducing migraine frequency/month was seen over placebo.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Botulinum toxin A for the prophylactic treatment of episodic migraine headaches was not significantly different from placebo, both from a clinical and statistical perspective.&lt;BR&gt;&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270554</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Journal%20of%20child%20neurology%22%5BJour%5D%20AND%2021%5Bvolume%5D%20AND%203%5Bissue%5D%20AND%20193%5Bpage%5D%20AND%202006%5Bpdat%5D]]&gt;</url>
    <title>Efficacy of the ketogenic diet as a treatment option for epilepsy: meta-analysis</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>BC Decker</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Henderson C.B., Filloux F.M., Alder S.C. et al. 2006; Journal of Child Neurology 21 (3) pp. 193-8&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;The evidence base for the efficacy of the ketogenic diet was assessed among pediatric epileptic patients by application of a rigorous statistical meta-analysis. Nineteen studies from 392 abstracts met the inclusion criteria. The sample size was 1084 patients (mean age at initiation 5.78 +/- 3.43 years). The pooled odds ratio, using a random effects model, of treatment success (&amp;gt; 50% seizure reduction) among patients staying on the diet relative to those discontinuing the diet was 2.25 (95% confidence interval = 1.69-2.98). The reasons for diet discontinuation included &amp;lt; 50% seizure reduction (47.0%), diet restrictiveness (16.4%), and incurrent illness or diet side effects (13.2%). The results indicate that children with generalized seizures and patients who respond with &amp;gt; 50% seizure reduction within 3 months tend to remain on the diet longer. Although no class I or II studies have been published regarding the efficacy of the ketogenic diet, this meta-analysis shows that current observational studies reporting on the therapeutic effect of the ketogenic diet contain valuable statistical data. Future observational studies should aim for long-term follow-up, patient dropout analysis, and improved seizure type characterization.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396595</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19708964]]&gt;</url>
    <title>EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force</title>
    <publicationDate>2009-08-07T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. (2009) EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. &lt;EM&gt;European Journal of Neurology&lt;/EM&gt; 16(9): 968-81&lt;/P&gt;
&lt;P&gt;Professor Peter Goadsby has critically appraised this paper and you can read his analysis &lt;A href="nelh:396688:0" name=internalLink&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt;&amp;nbsp;Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients' quality of life.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To give evidence-based or expert recommendations for the different drug treatment procedures in the particular migraine syndromes based on a literature search and the consensus of an expert panel.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; All available medical reference systems were screened for the range of clinical studies on migraine with and without aura and on migraine-like syndromes. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies (EFNS) resulting in level A, B, or C recommendations and good practice points.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommendations:&lt;/STRONG&gt; For the acute treatment of migraine attacks, oral non-steroidal antiinflammatory drug (NSAID) and triptans are recommended. The administration should follow the concept of stratified treatment. Before intake of NSAID and triptans, oral metoclopramide or domperidone is recommended. In very severe attacks, intravenous acetylsalicylic acid or subcutaneous sumatriptan are drugs of first choice. Status migrainosus can be treated by cortoicosteroids, although this is not universally held to be helpful, or dihydroergotamine. For the prophylaxis of migraine, betablockers (propranolol and metoprolol) flunarizine, valproic acid, and topiramate are drugs of first choice. Drugs of second choice for migraine prophylaxis include amitriptyline, naproxen, petasites, and bisoprolol.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384057</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1468-1331.2009.02917.x]]&gt;</url>
    <title>EFNS guideline on the management of status epilepticus in adults</title>
    <publicationDate>2009-08-30T00:00:00</publicationDate>
    <publisher>European Journal of Neurology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,STATUS EPILEPTICUS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. (2010) EFNS guideline on the management of status epilepticus in adults. &lt;EM&gt;European Journal of Neurology &lt;/EM&gt;17(3):348-55&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access statement: &lt;/STRONG&gt;Full text is available from the &lt;A href="http://www.efns.org/Guideline-Archive.389.0.html?&amp;amp;docID=1608&amp;amp;eID=dam_frontend_push" target="_blank"&gt;European Foundation of Neurological Societies&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The objective of the current article was to review the literature and discuss the degree of evidence for various treatment strategies for status epilepticus (SE) in adults. We searched MEDLINE and EMBASE for relevant literature from 1966 to January 2005 and in the current updated version all pertinent publications from January 2005 to January 2009. Furthermore, the Cochrane Central Register of Controlled Trials (CENTRAL) was sought. Recommendations are based on this literature and on our judgement of the relevance of the references to the subject. Recommendations were reached by informative consensus approach. Where there was a lack of evidence but consensus was clear, we have stated our opinion as good practice points. The preferred treatment pathway for generalised convulsive status epilepticus (GCSE) is intravenous (i.v.) administration of 4–8 mg lorazepam or 10 mg diazepam directly followed by 18 mg/kg phenytoin. If seizures continue more than 10 min after first injection, another 4 mg lorazepam or 10 mg diazepam is recommended. Refractory GCSE is treated by anaesthetic doses of barbiturates, midazolam or propofol; the anaesthetics are titrated against an electroencephalogram burst suppression pattern for at least 24 h. The initial therapy of non-convulsive SE depends on type and cause. Complex partial SE is initially treated in the same manner as GCSE. However, if it turns out to be refractory, further non-anaesthetising i.v. substances such levetiracetam, phenobarbital or valproic acid should be given instead of anaesthetics. In subtle SE, in most patients, i.v. anaesthesia is required.&lt;/P&gt;
&lt;P&gt;The &lt;I&gt;European Journal of Neurology&lt;/I&gt; is the official journal of the European Federation of Neurological Societies. It covers all areas of clinical and basic research in neurology. Emphasis is placed on major diseases or large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases). The journal provides a forum for European activity in clinical neuroscience and medical practice and help strengthen the links between research workers and clinicians in Europe and other parts of the world. The journal also publishes the official EFNS taskforce papers.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381788</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111%2Fj.1468-1331.2010.03153.x]]&gt;</url>
    <title>EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy</title>
    <publicationDate>2010-07-19T00:00:00</publicationDate>
    <publisher>European Journal of Neurology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ EMERGENCY CARE,CLINICAL LIBRARY,SELECTED SYMPTOMS,NEUROLOGICAL,ABDOMINAL,PSYCHIATRY,LIVER,GASTROINTESTINAL,HEAD / NECK / SPINE,CONFUSED / ALTERED CONSCIOUSNESS / COMA,HEPATIC ENCEPHALOPATHY,HEPATIC ENCEPHALOPATHY,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,COMPLICATING MEDICAL DISORDERS,ENDOCRINE &amp; METABOLIC DISORDERS,ENVIRONMENTAL &amp; TOXIC,DRUGS &amp; ALCOHOL,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Galvin R, Brathen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA. (2010) EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. &lt;EM&gt;European Journal of Neurology&lt;/EM&gt; Jul 19&lt;/P&gt;
&lt;P&gt;The &lt;I&gt;European Journal of Neurology&lt;/I&gt; is the official journal of the European Federation of Neurological Societies. It covers all areas of clinical and basic research in neurology. Emphasis is placed on major diseases or large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases). The journal provides a forum for European activity in clinical neuroscience and medical practice and help strengthen the links between research workers and clinicians in Europe and other parts of the world. The journal also publishes the official EFNS taskforce papers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions and recommendations:&amp;nbsp; &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;The clinical diagnosis of WE should take into account the different presentations of clinical signs between alcoholics and non alcoholics (Recommendation Level C); although prevalence is higher in alcoholics, WE should be suspected in all clinical conditions which could lead to thiamine deficiency (good practice point – GPP). 
&lt;LI&gt;The clinical diagnosis of WE in alcoholics requires two of the following four signs; (i) dietary deficiencies (ii) eye signs, (iii) cerebellar dysfunction, and (iv) either an altered mental state or mild memory impairment (Level B). 
&lt;LI&gt;Total thiamine in blood sample should be measured immediately before its administration (GPP). 
&lt;LI&gt;MRI should be used to support the diagnosis of acute WE both in alcoholics and non alcoholics (Level B). 
&lt;LI&gt;Thiamine is indicated for the treatment of suspected or manifest WE. It should be given, before any carbohydrate, 200 mg thrice daily, preferably intravenously (Level C). 
&lt;LI&gt;The overall safety of thiamine is very good (Level B). 
&lt;LI&gt;After bariatric surgery we recommend follow-up of thiamine status for at least 6 months (Level B) and parenteral thiamine supplementation (GPP). 
&lt;LI&gt;Parenteral thiamine should be given to all at-risk subjects admitted to the Emergency Room (GPP). 
&lt;LI&gt;Patients dying from symptoms suggesting WE should have an autopsy (GPP).&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Although Wernicke encephalopathy (WE) is a preventable and treatable disease it still often remains undiagnosed during life.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To create practical guidelines for diagnosis, management and prevention of the disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched MEDLINE, EMBASE, LILACS, Cochrane Library.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access statement: &lt;/STRONG&gt;Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345096</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2008_use_of_intravenous_immunoglobulin.pdf]]&gt;</url>
    <title>EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>European Federation of Neurological Societies</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, the recent papers of high relevance were reviewed and consensus recommendations are given according to EFNS guidance regulations. The efficacy of IVIG has been proven in Guillain-Barré syndrome (level A), chronic inflammatory demyelinating polyradiculoneuropathy (level A), multifocal mononeuropathy (level A), acute exacerbations of myasthenia gravis (MG) and short-term treatment of severe MG (level A recommendation), and some paraneoplastic neuropathies (level B). IVIG is recommended as a second-line treatment in combination with prednisone in dermatomyositis (level B) and treatment option in polymyositis (level C). IVIG should be considered as a second or third-line therapy in relapsing–remitting multiple sclerosis, if conventional immunomodulatory therapies are not tolerated (level B), and in relapses during pregnancy or post-partum period (good clinical practice point). IVIG seems to have a favourable effect also in paraneoplastic neurological diseases (level A), stiff-person syndrome (level A), some acute-demyelinating diseases and childhood refractory epilepsy (good practice point).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&amp;nbsp;&lt;/STRONG&gt;Published August 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience: &lt;/STRONG&gt;Neurologists&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386649</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/bsc/ene/2010/00000017/00000005/art00007]]&gt;</url>
    <title>EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias</title>
    <publicationDate>2010-05-01T00:00:00</publicationDate>
    <publisher>European Journal of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,EPILEPSY &amp; SEIZURES,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,DEMENTIA,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Burgunder JM, Finsterer J, Szolnoki Z, Fontaine B, Baets J, Van Broeckhoven C,&amp;nbsp;Di Donato S, De Jonghe P, Lynch T, Mariotti C, Schols L, Spinazzola A, Tabrizi SJ, Tallaksen C, Zeviani M, Harbo HF, Gasser T. (2010) EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias. &lt;EM&gt;European Journal of Neurology&lt;/EM&gt; 17(5):641-648&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; These EFNS guidelines on the molecular diagnosis of channelopathies, including epilepsy and migraine, as well as stroke, and dementia are designed to summarize the possibilities and limitations of molecular genetic techniques and to provide diagnostic criteria for deciding when a molecular diagnostic work-up is indicated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Search strategy:&lt;/STRONG&gt; To collect data about planning, conditions, and performance of molecular diagnosis of these disorders, a literature search in various electronic databases was carried out and original papers, meta-analyses, review papers, and guideline recommendations were reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The best level of evidence for genetic testing recommendation (B) can be found for a small number of syndromes, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, severe myoclonic epilepsy of infancy, familial recurrent hemorrhages, familial Alzheimer's disease, and frontotemporal lobar degeneration. Good practice points can be formulated for a number of other disorders.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; These guidelines are provisional, and the future availability of molecular genetic epidemiological data about the neurogenetic disorders under discussion in our article will allow improved recommendation with an increased level of evidence. &lt;/P&gt;
&lt;P&gt;The &lt;I&gt;European Journal of Neurology&lt;/I&gt; is the official journal of the European Federation of Neurological Societies. It covers all areas of clinical and basic research in neurology. Emphasis is placed on major diseases or large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases). The journal provides a forum for European activity in clinical neuroscience and medical practice and help strengthen the links between research workers and clinicians in Europe and other parts of the world. The journal also publishes the official EFNS taskforce papers.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access statement: &lt;/STRONG&gt;Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293090</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16987158?ordinalpos=3&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias</title>
    <publicationDate>2006-10-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ TRIGEMINOVASCULAR HEADACHE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;May, A et al European Journal of Neurology 2006 Oct;13(10):1066-77&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Cluster headache and the other trigeminal-autonomic cephalalgias [paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) syndrome] are rare but very disabling conditions with a major impact on the patient's quality of life. The objective of this study was to give evidence-based recommendations for the treatment of these headache disorders based on a literature search and consensus amongst a panel of experts. All available medical reference systems were screened for any kind of studies on cluster headache, paroxysmal hemicrania and SUNCT syndrome. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies resulting in level A, B or C recommendations and good practice points. For the acute treatment of cluster headache attacks, oxygen (100%) with a flow of at least 7 l/min over 15 min and 6 mg subcutaneous sumatriptan are drugs of first choice. Prophylaxis of cluster headache should be performed with verapamil at a daily dose of at least 240 mg (maximum dose depends on efficacy or tolerability). Although no class I or II trials are available, steroids are clearly effective in cluster headache. Therefore, the use of at least 100 mg methylprednisone (or equivalent corticosteroid) given orally or at up to 500 mg i.v. per day over 5 days (then tapering down) is recommended. Methysergide, lithium and topiramate are recommended as alternative treatments. Surgical procedures, although in part promising, require further scientific evaluation. For paroxysmal hemicranias, indomethacin at a daily dose of up to 225 mg is the drug of choice. For treatment of SUNCT syndrome, large series suggest that lamotrigine is the most effective preventive agent, with topiramate and gabapentin also being useful. Intravenous lidocaine may also be helpful as an acute therapy when patients are extremely distressed and disabled by frequent attacks.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345179</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19926837]]&gt;</url>
    <title>Endovascular treatment of very small (3 mm or smaller) intracranial aneurysms: report of a consecutive series and a meta-analysis.</title>
    <publicationDate>2009-11-19T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,HAEMORRHAGIC,MARCH 2010,STROKE,NEUROSURGERY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Brinjikji W, Lanzino G, Cloft HJ, Rabinstein A, Kallmes DF. (2010) Endovascular treatment of very small (3 mm or smaller) intracranial aneurysms: report of a consecutive series and a meta-analysis.&amp;nbsp;&lt;EM&gt;Stroke&lt;/EM&gt;&amp;nbsp;41(1):116-21. Epub 2009 Nov 19.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We conducted a computerized MEDLINE search of the literature for reports on the treatment of intracranial aneurysms with a maximum dimension of &amp;lt;=3 mm by using search terms small, tiny, intracranial aneurysm, endovascular, coil. A total 7 studies, including our institution's consecutive case series of 71 intracranial aneurysms, were included in this study. We extracted information regarding intraoperative complications, procedural mortality morbidity, immediate- long-term angiographic outcomes, and retreatment rate. The meta-analysis was performed with the statistical package Comprehensive Meta-Analysis.&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Approximately 61% of the aneurysms in this meta-analysis presented as ruptured, whereas 39% of the aneurysms were unruptured. Procedural rupture rates for very small aneurysms was 8.3% (95% CI, 6.0% to 11.4%). The mortality rate due to procedural rupture was 2.4% (95% CI, 1.2% to 4.7%). The morbidity rate due to thromboembolic complications was 1.9% (95% CI, 0.9% to 3.9%). Subarachnoid hemorrhage within 1 month of treatment occurred in 1.6% (95% CI, 0.6% to 3.7%) of cases. There was no statistically significant difference between unruptured and ruptured aneurysms for any of these outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Our meta-analysis suggests that treatment of very small aneurysms is feasible and effective in &amp;gt;90% of treated aneurysms. However, the risk of periprocedural rupture is higher than that reported for larger aneurysms. Similarly, the combined rate of periprocedural mortality and morbidity is not negligible (7.3%) and should be considered when considering the best therapeutic option for these aneurysms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; November 19 2009 (e-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This journal free via Highwire Press. Most recent 12 months available to subscribers only; please check with your local healthcare library&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343161</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19910553]]&gt;</url>
    <title>Epidemiological studies of the effect of stroke on incident dementia: a systematic review</title>
    <publicationDate>2009-11-12T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,DEMENTIA,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Savva GM, Stephan BC; Alzheimer's Society Vascular Dementia Systematic Review Group. (2010) Epidemiological studies of the effect of stroke on incident dementia: a systematic review. &lt;EM&gt;Stroke&lt;/EM&gt; 41(1):e41-6. Epub 2009 Nov 12.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We conducted a systematic review of the excess risk of incident dementia conferred by stroke. Studies of the risk of incident dementia in the population with stroke compared with the population without stroke were identified and compared. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Sixteen studies were identified with all but one conducted in a community setting. A history of stroke doubles the risk of incident dementia in the older population. This increase is not explained by demographic or cardiovascular risk factors or by prestroke cognitive decline. The excess risk of incident dementia diminishes with time after stroke and may be higher in those without an APOE epsilon4 allele. There is no excess risk of incident dementia in those aged &amp;gt;85 years with a history of stroke compared to those aged &amp;gt;85 years without stroke. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The effect of stroke on dementia incidence in the population is not explained by common risk factors. At this time of population aging and increased stroke survival, more research is needed to determine to what extent efforts to reduce the incidence of stroke will affect the incidence of dementia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 12 Nove 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294615</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/cgi-bin/fulltext/120718083/HTMLSTART]]&gt;</url>
    <title>Epidemiology of headache in Europe</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE,HEADACHE &amp; PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Bibliographic details:&lt;/P&gt;
&lt;P&gt;Stovner, LJ et al 2006 European Journal of Neurology 13:4 333 - 345&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Abstract:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=para&gt;The present review of epidemiologic studies on migraine and headache in Europe is part of a larger initiative by the European Brain Council to estimate the costs incurred because of brain disorders. Summarizing the data on 1-year prevalence, the proportion of adults in Europe reporting headache was 51%, migraine 14%, and 'chronic headache' (i.e. =15&amp;nbsp;days/month or 'daily') 4%. Generally, migraine, and to a lesser degree headache, are most prevalent during the most productive years of adulthood, from age 20 to 50&amp;nbsp;years. Several European studies document the negative influence of headache disorders on the quality of life, and health-economic studies indicate that 15% of adults were absent from work during the last year because of headache. Very few studies have been performed in Eastern Europe, and there are also surprisingly little data on tension-type headache from any country. Although the methodology and the quality of the published studies vary considerably, making direct comparisons between different countries difficult, the present review clearly demonstrates that headache disorders are extremely prevalent and have a vast impact on public health. The data collected should be used as arguments to increase resources to headache research and care for headache patients all over the continent.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Journal information:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The European Journal of Neurology is the official journal of the European Federation of Neurological Societies.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The &lt;I&gt;European Journal of Neurology&lt;/I&gt; covers all areas of clinical and basic research in neurology. Emphasis is placed on major diseases or large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases). The journal provides a forum for European activity in clinical neuroscience and medical practice and help strengthen the links between research workers and clinicians in Europe and other parts of the world. The journal also publishes the official EFNS taskforce papers.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Access statement:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This article has been made freely available online as one of the top cited articles from the European Journal of Neurology&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306013</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5004320]]&gt;</url>
    <title>Epilepsy</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Learning/NICE</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Learning outcomes: &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This module should help you know:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;How best to care for patients with epilepsy 
&lt;LI&gt;How best to communicate with patients with epilepsy so they can help to manage their condition 
&lt;LI&gt;When you should refer patients to a specialist 
&lt;LI&gt;How best to care for women of childbearing potential with epilepsy&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; These online education tools have been developed by NICE in collaboration with BMJ Learning. BMJ Learning is the best available learning website for medical professionals. It offers a wide range of learning resources, commissioned by the BMJ Group. The learning resources deal with everyday issues in primary care and hospital medicine. They are evidence based and peer reviewed. 
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Free registration with the site is required.&amp;nbsp; To register, click "Start module" and then "Register here".&amp;nbsp; Do not select the option to log in via Athens as access to BMJ Learning is not currently&amp;nbsp;part of NHS Athens accounts. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314407</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17369102]]&gt;</url>
    <title>Epilepsy and employment: literature review</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Smeets VM, van Lierop BA, Vanhoutvin JP, Aldenkamp AP, Nijhuis FJ. (2007) Epilepsy and employment: literature review. &lt;EM&gt;Epilepsy &amp;amp; Behavior&lt;/EM&gt; 10(3):354-62.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Relevant studies were identified by searching the electronic databases PsycINFO, EMBASE, MEDLINE, PubMed, and Online Contents. Titles of articles and abstracts identified during the search were reviewed for relevance, and if appropriate, the full-text article was retrieved. After selection of the articles, the search was expanded by using&lt;BR&gt;the PubMed function related articles. To supplement this literature research, reference lists of all articles that were identified in the electronic investigation were scanned. Additional articles and conference papers were identified through hand searches in the library holdings Kempenhaeghe and University Maastricht. Thirty-four primary research articles describing factors associated with employment for people with epilepsy are reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; People with epilepsy may face a number of complex and interacting problems in finding and maintaining employment. Stigma, seizure severity, and psychosocial variables such as low self-esteem, passive coping style, and low self-efficacy have been implicated as factors that play an important role in predicting employment. Findings demonstrate the need for specific employment training programs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; We recommend specific training interventions that focus on increasing the self-efficacy and coping skills of people with epilepsy so that these individuals will be able to accept their disorder and make personal and health-related choices that help them to achieve better employment positions in society.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; May 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>303827</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.epilepsy.org.uk/gpresource]]&gt;</url>
    <title>Epilepsy resource pack for general practioners</title>
    <publicationDate>2005-10-01T00:00:00</publicationDate>
    <publisher>Epilepsy Action (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,DELIVERY OF CARE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;In order to help GP practices and their patients with epilepsy benefit from the GMS contract and NICE guidance, Epilepsy Action (UK) have updated their Epilepsy Resource Pack. The pack includes an information booklet and tool kit designed to facilitate: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;the identification of patients with epilepsy 
&lt;LI&gt;the systematic review of all patients with epilepsy 
&lt;LI&gt;the identification and effective referral of patients requiring specialist review 
&lt;LI&gt;the effective recording of data in order to fulfil the requirement of the GMS contract and improve epilepsy management in the long-term. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;About the publisher:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Epilepsy Action is the largest member-led epilepsy organisation in Britain, acting as the voice for the UK's estimated 456,000 people with epilepsy, as well as their friends, families, carers, health professionals and the many other people on whose lives the condition has an impact. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270556</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&amp;Cmd=ShowDetailView&amp;TermToSearch=17484753&amp;ordinalpos=3&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Epilepsy surgery in Tuberous Sclerosis: A systematic review</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,NEUROSURGERY,EPILEPSY AND SEIZURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Jansen F.E., van Huffelen A.C., Algra A. et al. 2007; Epilepsia 48 (8) pp. 1477-84&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;PURPOSE: Tuberous sclerosis complex (TSC) is often associated with intractable epilepsy. Although epilepsy surgery has gained interest in recent years uncertainties exist about which patients are good surgical candidates. A systematic review of the available literature has been undertaken to assess the overall outcome of epilepsy surgery and identify risk factors of seizure recurrence. METHODS: We searched MEDLINE, Embase, and bibliographies of reviews and book chapters to identify articles published in English since 1960. Twenty-five articles, describing postoperative seizure outcome and type of surgery in 177 TSC patients, were included in this study. Seizure outcome was analyzed both as seizure freedom and good outcome, including patients with &amp;gt;90% seizure reduction. RESULTS: Seizure freedom was achieved in 101 patients (57%). Seizure frequency was improved by &amp;gt; 90% in 32 patients (18%). Moderate or severe intellectual disability (IQ &amp;lt; 70) (RR 1.8; 95% CI 1.2-2.8) and the presence of tonic seizures (RR 1.7; 95 % CI 1.2-2.4) were related to seizure recurrence. CONCLUSIONS: A relation between multiple seizures types with early onset, multiple cortical tubers and multifocal epileptogenicity, and poor outcome is not supported by this systematic analysis. Although there is considerable variation among studies reviewed here, the literature suggests that resective surgery may offer benefit in a selected population of TSC patients with drug-resistant epilepsy.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270581</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Epilepsy%20%26%20behavior%20%3A%20E%26B%22%5BJour%5D%20AND%209%5Bvolume%5D%20AND%201%5Bissue%5D%20AND%2014%5Bpage%5D%20AND%202006%5Bpdat%5D]]&gt;</url>
    <title>Epilepsy, intellectual disability, and living environment: a critical review</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;van Blarikom W., Tan I.Y., Aldenkamp A.P. et al. 2006 9 (1) pp. 14-8&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;Epilepsy occurs at a higher incidence and is more prevalent in people with an intellectual disability than in the general population. Nonetheless, we have insufficient knowledge of the extra needs of people with epilepsy and intellectual disability, of their families, and of the living environment. The lack of information about specific needs of the living environment may, in particular, be important. A Medline search revealed that scant attention has been paid to the specific needs for patients with epilepsy and intellectual disability, and only a few studies have focused specifically on this topic. The majority of studies have been focused on medical treatment issues and the organization and availability of health and social services. There is an indication that people with epilepsy and intellectual disability lack skills training appropriate to their intellectual potential. And although several reviews have emphasized the need for information on living environment and quality of life, we did not find such studies in our search.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270582</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Acta%20neurologica%20Scandinavica%22%5BJour%5D%20AND%20112%5Bvolume%5D%20AND%205%5Bissue%5D%20AND%20277%5Bpage%5D%20AND%202005%5Bpdat%5D]]&gt;</url>
    <title>Epilepsy, osteoporosis and fracture risk - A meta-analysis</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Vestgaard P. 2005; Acta Neurologica Scandinavia 112 (5) pp. 277-86&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;This meta-analysis assesses the effects of epilepsy on fracture risk and changes in bone mineral density (BMD) in patients with epilepsy. A search of PubMed was conducted using the key words epilepsy, fracture, and bone mineral. A weighted estimate of relative risk of fractures and changes in BMD (Z-score) was calculated. From the changes in BMD, expected increase in relative fracture risk was calculated. A total of 11 studies on fracture risk and 12 studies on BMD were retrieved. The relative risk of any fracture was increased (2.2, 95% CI: 1.9-2.5, five studies), as was the risk of hip (5.3, 3.2-8.8, six studies), forearm (1.7, 1.2-2.3, six studies), and spine fractures (6.2, 2.5-15.5, three studies). A large proportion of fractures (35%) seemed related to seizures. Spine (mean +/- SEM: -0.38 +/- 0.06) and hip (-0.56 +/- 0.06) BMD Z-scores were significantly decreased, hip more than spine (2P &amp;lt; 0.05). The expected increases in relative risk of any fracture from BMD Z-scores were 1.2-1.3, and significantly lower than observed (2P &amp;lt; 0.05). The deficit in BMD in patients with epilepsy is too small to explain the observed increase in fracture risk. The remainder of the increase in fracture risk may be linked to seizures.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270576</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Expert%20review%20of%20neurotherapeutics%22%5BJour%5D%20AND%206%5Bvolume%5D%20AND%204%5Bissue%5D%20AND%20575%5Bpage%5D%20AND%202006%5Bpdat%5D]]&gt;</url>
    <title>Epileptogenic drugs: A systematic review</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Future Drugs Ltd.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Ruffmann C., Bogliun G., Beghi E. 2006;&amp;nbsp;Expert review of Neurotherapeutics 6(4) pp. 575-89&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;A wide range of substances, including drugs and illicit compounds, increase the risk of epileptic seizures. In this systematic review, the authors address the issue of the epileptogenic potential of marketed drugs, with the aims of providing criteria for the assessment of the cause-effect relationship between drug exposure and the risk of seizures; and to identify the compounds better fulfilling the requirements of an epileptogenic drug. Finding a correlation between drug exposure and occurrence of seizures does not necessarily establish a causal association. In light of the available evidence, even with these limitations, some conclusive remarks can be made on the epileptogenic potential of some active principles. Drugs with high epileptogenic potential include meperidine, sevoflurane, clozapine, phenothiazines and cyclosporine. Drugs with intermediate epileptogenic potential include propofol, maprotiline, tricyclic antidepressants and chlorambucil. Drugs with low epileptogenic potential include fluorquinolones, carbapenems, bupropion and iodinated contrast media. Drugs with minimal or inconclusive epileptogenic potential include interferon alpha.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307829</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsLegislation/DH_081055?IdcService=GET_FILE&amp;dID=160486&amp;Rendition=Web]]&gt;</url>
    <title>Equality Impact Assessment: A new ambition for stroke - a national strategy</title>
    <publicationDate>2007-12-05T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,DELIVERY OF CARE,CONDITIONS,STRATEGIES AND POLICIES,NATIONAL STROKE STRATEGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;This Equality Impact Assessment (EIA) is made in relation to the National Stroke Strategy now being implemented&lt;/P&gt;
&lt;P&gt;This EIA, like all others, considers the possible impact of the new strategy on people according to their age, disability, race, religion and beliefs, gender and sexual orientation. Each of these groups is an important consideration in the development of stroke services since good impacts are even more valuable when they promote equality. The EIA therefore aims to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;assess whether the new strategy is likely to have any adverse effects on any of these groups; and 
&lt;LI&gt;alert commissioners and service providers of health and social care of the need to monitor the strategy's impact on these groups and make changes to mitigate any inequality.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>384288</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1528-1167.2009.02481.x]]&gt;</url>
    <title>Estimation of the burden of active and life-time epilepsy: A meta-analytic approach</title>
    <publicationDate>2010-01-07T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DELIVERY OF CARE,EPILEPSY &amp; SEIZURES,OUTCOME MEASUREMENTS,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. (2010) Estimation of the burden of active and life-time epilepsy: A meta-analytic approach. &lt;EM&gt;Epilepsia&lt;/EM&gt; 51(5):883-890&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Purpose:&amp;nbsp;&lt;/STRONG&gt;To estimate the burden of lifetime epilepsy (LTE) and active epilepsy (AE) and examine the influence of study characteristics on prevalence estimates.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&amp;nbsp;&lt;/STRONG&gt;We searched online databases and identified articles using prespecified criteria. Random-effects meta-analyses were used to estimate the median prevalence in developed countries and in urban and rural settings in developing countries. The impact of study characteristics on prevalence estimates was determined using meta-regression models.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&amp;nbsp;&lt;/STRONG&gt;The median LTE prevalence for developed countries was 5.8 per 1,000 (5th–95th percentile range 2.7–12.4) compared to 15.4 per 1,000 (4.8–49.6) for rural and 10.3 (2.8–37.7) for urban studies in developing countries. The median prevalence of AE was 4.9 per 1,000 (2.3–10.3) for developed countries and 12.7 per 1,000 (3.5–45.5) and 5.9 (3.4–10.2) in rural and urban studies in developing countries. The estimates of burden for LTE and AE in developed countries were 6.8 million (5th–95th percentile range 3.2–14.7) and 5.7 million (2.7–12.2), respectively. In developing countries these were 45 (14–145) million LTE and 17 (10–133) million AE in rural areas and 17 (5–61) million LTE and 10 (5–17) million AE in urban areas. Studies involving all ages or only adults showed higher estimates than pediatric studies. Higher prevalence estimates were also associated with rural location and small study size.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&amp;nbsp;&lt;/STRONG&gt;This study estimates the global burden of epilepsy and the proportions with AE, which may benefit from treatment. There are systematic differences in reported prevalence estimates, which are only partially explained by study characteristics.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386844</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://cre.sagepub.com/content/24/9/771.abstract?rss=1]]&gt;</url>
    <title>Evidence on physiotherapeutic interventions for adults with cerebral palsy is sparse. A systematic review</title>
    <publicationDate>2010-08-31T00:00:00</publicationDate>
    <publisher>Clinical Rehabilitation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STRUCTURAL,CEREBRAL PALSY,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Jeglinsky I, Surakka J, Brogren Carlberg E, Autti-Ramo I. (2010) Evidence on physiotherapeutic interventions for adults with cerebral palsy is sparse. A systematic review. &lt;EM&gt;Clinical Rehabilitation&amp;nbsp;&lt;/EM&gt;24(9):771-778&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To identify evidence evaluating the effectiveness of physiotherapy in adolescents (&amp;gt;16 years of age) and adults with cerebral palsy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Systematic literature search from the earliest available time until March 2009. Additional studies were identified through reference and citation tracking. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; Two reviewers independently agreed on eligibility, methodological quality and quality of evidence assessment. Standard methods were used for quality assessments. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Included were 13 studies, two of which were randomized controlled trials. No article met the criteria for high methodological quality. Evidence of moderate quality was found on gait after strength training. Evidence of low quality was found on balance after strength training and workstation interventions. Low-quality evidence was also found on functionality after strength training in four studies evaluating gross motor capacity. There was very low-quality evidence on increased muscle strength and in outcome measures used to evaluate range of motion. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Evidence for the effect of physiotherapy on adolescents and adults with cerebral palsy is sparse, and therefore there is an urgent need for well-designed physiotherapeutic trials for these people. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Clinical Rehabilitation is a highly ranked, peer reviewed scholarly journal. It is a multi-professional journal covering the whole field of disability and rehabilitation, combining clinical application of scientific results and theoretical aspects in an ideal form. It gives high priority to articles describing effectiveness of therapeutic interventions and the evaluation of new techniques and methods.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377574</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20439849]]&gt;</url>
    <title>Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.</title>
    <publicationDate>2010-05-04T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,DELIVERY OF CARE,CONDITIONS,JUNE 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2010) Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. &lt;EM&gt;Neurology&lt;/EM&gt; 74(18):1463-70.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Relevant articles were obtained through a review of the medical literature and the strength of the available evidence was graded according to the American Academy of Neurology evidence classification scheme. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy. Systolic dysfunction occurs in approximately 12% of patients with MS treated with mitoxantrone, congestive heart failure occurs in approximately 0.4%, and leukemia occurs in approximately 0.8%. The number needed to harm is 8 for systolic dysfunction and 123 for TRAL. There is no new efficacy evidence that would change the recommendation from the previous report. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The risk of systolic dysfunction and leukemia in patients treated with mitoxantrone is higher than suggested at the time of the previous report, although comprehensive postmarketing surveillance data are lacking.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; May 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if they have a local subscription. Abstracts and tables of contents are free for all to view. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288873</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18374010?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,REHABILITATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;O'Brien, AR et al &lt;SPAN title="Archives of physical medicine and rehabilitation."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Arch Phys Med Rehabil.?);?&gt;Arch Phys Med Rehabil.&lt;/A&gt;&lt;/SPAN&gt; 2008 Apr;89(4):761-9&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVES: To conduct evidence-based review of cognitive rehabilitation intervention research conducted in persons with multiple sclerosis (MS), to classify level of evidence, and to generate recommendations for interventions in this area. DATA SOURCES: An open (no year limits set) search of Medline, PsychInfo, and CINAHL (eliminating repetitions) using combinations of the following terms: attention, awareness, cognition, cognitive, communication, executive, executive function, language, learning, memory, perception, problem solving, reasoning, rehabilitation, remediation, training, and working memory. Reference sections of articles found through the sites were also searched. STUDY SELECTION: Studies were chosen based on criteria from previous evidence-based reviews such that articles are excluded from the review if (1) the study was not an intervention, (2) it was a theoretic article, (3) it was a review article, (4) detail was lacking to fully evaluate the intervention, (5) it was not MS-specific, (6) it included a pediatric sample, (7) it was a case report without empirical data to evaluate outcomes, (8) it was not peer-reviewed (also excludes book chapters), (9) it was a pharmacologic intervention, or (10) it was not available for review in English. DATA EXTRACTION: Articles were categorized into interventions for attention, learning and memory, executive functioning, or nonspecified/combined cognitive domains. There were 4 reviewers in the current study. All articles were reviewed independently by at least 2 persons and abstracted according to predetermined criteria. There was a final total of 16 articles, which underwent a full review and classification of a level of evidence based on previously published peer-reviewed methodology used for evidence-based reviews. DATA SYNTHESIS: The current review yielded 16 studies of cognitive rehabilitation for persons with MS, including 4 class I studies, 5 class II studies, 2 class III studies, and 5 class IV studies. Two intervention methodologies in the area of verbal learning and memory received support for a practice guideline and practice option, respectively. CONCLUSIONS: Cognitive rehabilitation in MS is in its relative infancy. More methodologically rigorous research is needed to determine the effectiveness and efficacy of various cognitive rehabilitation interventions. Specific recommendations for future research are given.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288873</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18374010?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,REHABILITATION,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;O'Brien, AR et al &lt;SPAN title="Archives of physical medicine and rehabilitation."&gt;&lt;A href="#javascript:AL_get(this," ?jour?, ?Arch Phys Med Rehabil.?);?&gt;Arch Phys Med Rehabil.&lt;/A&gt;&lt;/SPAN&gt; 2008 Apr;89(4):761-9&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVES: To conduct evidence-based review of cognitive rehabilitation intervention research conducted in persons with multiple sclerosis (MS), to classify level of evidence, and to generate recommendations for interventions in this area. DATA SOURCES: An open (no year limits set) search of Medline, PsychInfo, and CINAHL (eliminating repetitions) using combinations of the following terms: attention, awareness, cognition, cognitive, communication, executive, executive function, language, learning, memory, perception, problem solving, reasoning, rehabilitation, remediation, training, and working memory. Reference sections of articles found through the sites were also searched. STUDY SELECTION: Studies were chosen based on criteria from previous evidence-based reviews such that articles are excluded from the review if (1) the study was not an intervention, (2) it was a theoretic article, (3) it was a review article, (4) detail was lacking to fully evaluate the intervention, (5) it was not MS-specific, (6) it included a pediatric sample, (7) it was a case report without empirical data to evaluate outcomes, (8) it was not peer-reviewed (also excludes book chapters), (9) it was a pharmacologic intervention, or (10) it was not available for review in English. DATA EXTRACTION: Articles were categorized into interventions for attention, learning and memory, executive functioning, or nonspecified/combined cognitive domains. There were 4 reviewers in the current study. All articles were reviewed independently by at least 2 persons and abstracted according to predetermined criteria. There was a final total of 16 articles, which underwent a full review and classification of a level of evidence based on previously published peer-reviewed methodology used for evidence-based reviews. DATA SYNTHESIS: The current review yielded 16 studies of cognitive rehabilitation for persons with MS, including 4 class I studies, 5 class II studies, 2 class III studies, and 5 class IV studies. Two intervention methodologies in the area of verbal learning and memory received support for a practice guideline and practice option, respectively. CONCLUSIONS: Cognitive rehabilitation in MS is in its relative infancy. More methodologically rigorous research is needed to determine the effectiveness and efficacy of various cognitive rehabilitation interventions. Specific recommendations for future research are given.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344204</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18374010]]&gt;</url>
    <title>Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; O'Brien AR, Chiaravalloti N, Goverover Y, Deluca J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. &lt;EM&gt;Archives of Physical Medicine &amp;amp; Rehabilitation&lt;/EM&gt; 2008 Apr;89(4):761-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; An open (no year limits set) search of Medline, PsychInfo, and CINAHL (eliminating repetitions) using combinations of the following terms: attention, awareness, cognition, cognitive, communication, executive, executive function, language, learning, memory, perception, problem solving, reasoning, rehabilitation, remediation, training, and working memory. Reference sections of articles found through the sites were also searched. Studies were chosen based on criteria from previous evidence-based reviews such that articles are excluded from the review if (1) the study was not an intervention, (2) it was a theoretic article, (3) it was a review article, (4) detail was lacking to fully evaluate the intervention, (5) it was not multiple sclerosis (MS)-specific, (6) it included a pediatric sample, (7) it was a case report without empirical data to evaluate outcomes, (8) it was not peer-reviewed (also excludes book chapters), (9) it was a pharmacologic intervention, or (10) it was not available for review in English. Articles were categorized into interventions for attention, learning and memory, executive functioning, or nonspecified/combined cognitive domains. There were 4 reviewers in the current study. All articles were reviewed independently by at least 2 persons and abstracted according to predetermined criteria. There was a final total of 16 articles, which underwent a full review and classification of a level of evidence based on previously published peer-reviewed methodology used for evidence-based reviews.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The current review yielded 16 studies of cognitive rehabilitation for persons with MS, including 4 class I studies, 5 class II studies, 2 class III studies, and 5 class IV studies. Two intervention methodologies in the area of verbal learning and memory received support for a practice guideline and practice option, respectively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Cognitive rehabilitation in MS is in its relative infancy. More methodologically rigorous research is needed to determine the effectiveness and efficacy of various cognitive rehabilitation interventions. Specific recommendations for future research are given.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in April 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344204</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18374010]]&gt;</url>
    <title>Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; O'Brien AR, Chiaravalloti N, Goverover Y, Deluca J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. &lt;EM&gt;Archives of Physical Medicine &amp;amp; Rehabilitation&lt;/EM&gt; 2008 Apr;89(4):761-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; An open (no year limits set) search of Medline, PsychInfo, and CINAHL (eliminating repetitions) using combinations of the following terms: attention, awareness, cognition, cognitive, communication, executive, executive function, language, learning, memory, perception, problem solving, reasoning, rehabilitation, remediation, training, and working memory. Reference sections of articles found through the sites were also searched. Studies were chosen based on criteria from previous evidence-based reviews such that articles are excluded from the review if (1) the study was not an intervention, (2) it was a theoretic article, (3) it was a review article, (4) detail was lacking to fully evaluate the intervention, (5) it was not multiple sclerosis (MS)-specific, (6) it included a pediatric sample, (7) it was a case report without empirical data to evaluate outcomes, (8) it was not peer-reviewed (also excludes book chapters), (9) it was a pharmacologic intervention, or (10) it was not available for review in English. Articles were categorized into interventions for attention, learning and memory, executive functioning, or nonspecified/combined cognitive domains. There were 4 reviewers in the current study. All articles were reviewed independently by at least 2 persons and abstracted according to predetermined criteria. There was a final total of 16 articles, which underwent a full review and classification of a level of evidence based on previously published peer-reviewed methodology used for evidence-based reviews.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The current review yielded 16 studies of cognitive rehabilitation for persons with MS, including 4 class I studies, 5 class II studies, 2 class III studies, and 5 class IV studies. Two intervention methodologies in the area of verbal learning and memory received support for a practice guideline and practice option, respectively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Cognitive rehabilitation in MS is in its relative infancy. More methodologically rigorous research is needed to determine the effectiveness and efficacy of various cognitive rehabilitation interventions. Specific recommendations for future research are given.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in April 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344202</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18631428]]&gt;</url>
    <title>Examining the evidence: complementary adjunctive therapies for multiple sclerosis</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Namaka M, Crook A, Doupe A, Kler K, Vasconcelos M, Klowak M, et al. Examining the evidence: complementary adjunctive therapies for multiple sclerosis. &lt;EM&gt;Neurological Research&lt;/EM&gt; 2008 Sep;30(7):710-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Relevant English-language articles were identified through searches of MEDLINE (1990-2006), PubMed (1999-2006), Cochrane (1995-2006) and Toxnet (2000-2006). Classification of available literature was conducted according to the evidence based guidelines established by the American Academy of Neurology (AAN). However, due to the non-conventional nature of these treatment approaches, most available literature was derived from anecdotal reports and suboptimal clinical studies, lacking the rigor of evidence-based practice.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There is presently only marginal supportive evidence for BVT in&amp;nbsp;multiple sclerosis (MS)&amp;nbsp;treatment. The inability to identify and quantify the active component of bee venom therapy (BVT) combined with the associated risk of anaphylaxis has deterred its widespread use. The most promising evidence comes from prophylactic daily supplementation with vitamin D. Despite beneficial reports regarding non-herbal supplements such as alpha-lipoic acid (ALA), luteolin, evening primrose oil and vitamins such as B12, the lack of evidence does not support their prophylactic use.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Based on available evidence, the prophylactic use of vitamin D is a viable option as an adjunct to conventional medicine. Although there is a lack of conclusive evidence to support the use of other non-conventional treatments, patients are still opting to trial and bare the risks of these products which are accessible without the intervention of a healthcare professional. Controlled, evidence-based trials are essential for healthcare professionals to competently intervene and recommend these products.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326708</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.5.153]]&gt;</url>
    <title>Fetal exposure to valproate was associated with lower IQ scores at 3 years of age than exposure to other antiepileptic drugs</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,FIRST SEIZURE AND EARLY EPILEPSY,OCTOBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Pinzon, R. (2009) Fetal exposure to valproate was associated with lower IQ scores at 3 years of age than exposure to other antiepileptic drugs. &lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; 14:153.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Meador KJ, Baker GA, Browning N, et al. (2009) &lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=19369666" target="_blank"&gt;Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs&lt;/A&gt;. &lt;EM&gt;New England Journal of&amp;nbsp;Medicine&lt;/EM&gt; 360:1597–605. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396715</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://informahealthcare.com/doi/abs/10.1080/19390210902861809]]&gt;</url>
    <title>Feverfew for migraine prophylaxis: a systematic review</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Journal of Dietary Supplements</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. (2009) Feverfew for migraine prophylaxis: a systematic review. &lt;EM&gt;Journal of Dietary Supplements&lt;/EM&gt; 6(2):91-103&lt;/P&gt;
&lt;P&gt;Feverfew has been studied for the treatment of migrane in several studies and the pharmacologic mechanisms are preliminarily understood. We performed a systematic review of randomized controlled trials and present the clinical findings and potential implications. The modality of data collection and reporting in the individual studies does not support a pooling of results, but does suggest benefit of feverfew in migraine prophylaxis for at least subsets of the population with the disorder. Pharmacologically, there is some potential for concern with long-term dosing given its cyclooxygenase-2 inhibiting effects and longer-term studies will be needed to ameliorate these concerns in coronary disease patients.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288436</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17785617?ordinalpos=3&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Fingolimod: a novel immunosuppressant for multiple sclerosis</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books company</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Brown, BA et al &lt;SPAN title="The Annals of pharmacotherapy."&gt;&lt;A href="#javascript:AL_get(this," Pharmacother.?);? ?Ann ?jour?,&gt;Ann Pharmacother.&lt;/A&gt;&lt;/SPAN&gt; 2007 Oct;41(10):1660-8. Epub 2007 Sep 4&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of fingolimod, a novel immune modulator. DATA SOURCES: Information was obtained through a MEDLINE search (1966-February 2007) and from published abstracts. Search terms included fingolimod, FTY720, FTY-720, and sphingosine-1-phosphate receptor agonist. STUDY SELECTION AND DATA EXTRACTION: All English-language studies and abstracts pertaining to fingolimod were considered for inclusion. Preference was given to human data. DATA SYNTHESIS: Fingolimod is the first in a new class of immune modulators known as the sphingosine-1-phosphate receptor agonists. It is administered orally once daily and causes a dose-related reduction in the number of circulating lymphocytes by preventing their egress from secondary lymph organs, but it does not alter T-cell activation or proliferation. Bradycardia and lymphopenia are the most common adverse effects. Clinical trials have evaluated the efficacy of fingolimod in renal transplantation and multiple sclerosis (MS). Further research for renal transplantation will not take place, but Phase 3 studies in MS are underway, as Phase 2 study results are favorable. CONCLUSIONS: Due to its distinct mechanism of action and its oral administration, fingolimod may be a useful therapeutic option for patients with relapsing forms of MS. More data are needed to assess the safety and clinical utility of fingolimod.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344105</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19135686]]&gt;</url>
    <title>Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review</title>
    <publicationDate>2009-03-15T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Benamer HT, Ahmed ES, Al-Din AS, Grosset DG. Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review. &lt;EM&gt;Journal of the Neurological Sciences&lt;/EM&gt; 2009 Mar 15;278(1-2):1-4.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Nineteen articles related to incidence, prevalence and clinical patterns of&amp;nbsp;multiple sclerosis (MS)&amp;nbsp;in Arab populations were identified by keyword searching of Medline and Embase, and review of references in all relevant papers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Data were only available for the Kuwaiti, Jordanian, Libyan, Saudi, Iraqi, Palestinian (including Arabs living in Israel), and Omani populations. The publications ranged from 1975 to 2007. In Israel the incidence of MS was 0.7 per 100,000 per year in Arabs born and living in Greater Jerusalem. In Kuwait, the incidence of MS was 2.08 per 100,000. Prevalence varied from 4 to 42 per 100,000 population. The clinical pattern of MS was generally similar to that in western countries. However, one study from Oman found a high rate of optic-spinal disease (affecting one third of patients) and a low rate of oligoclonal bands (OGBs) (only one third of patients); this pattern resembles that of MS described in Asian countries.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The prevalence of MS among Arabs has a wide reported range. The clinical pattern is generally similar to "Western type" MS but apparent differences in optic-spinal disease and OGBs positivity need further evaluation. There is significant opportunity for further evaluation of MS in Arabs, especially in unstudied areas, including the populous countries of Egypt, Algeria, Syria, and Morocco. Studies of Arab-Americans and Arab immigrants in Europe could help in defining the effect of immigration on MS. Such studies are likely to enhance our knowledge of the environmental, genetic and clinical variation of MS in Arabs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published March 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386541</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1001/archneurol.2010.169]]&gt;</url>
    <title>Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Archives of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,STATUS EPILEPTICUS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Neligan A, Shorvon SD (2010) Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. &lt;EM&gt;Archives of Neurology &lt;/EM&gt;67(8):931-940&lt;/P&gt;
&lt;P&gt;We conducted a systematic review of all studies of status epilepticus (SE) with more than 30 patients published between January 1, 1990, and December 31, 2008, to determine the frequencies of the common underlying causes and the extent to which the underlying causes affect the prognosis of an episode of SE. The frequencies of underlying causes vary among studies and show marked geographic differences, but in most studies, the most common underlying causes were cerebrovascular disease and low antiepileptic drug levels. A relatively good prognosis of SE is found when the underlying cause is associated with low antiepileptic drug levels or alcohol abuse, and a relatively poor outcome occurs when the underlying cause is cerebrovascular disease, particularly in the case of SE due to acute cerebral anoxia, but in most conditions, the reported prognosis is variable. Also, when SE occurs in the context of an acute cerebral insult, such as cerebral infection or cerebrovascular disease, the prognosis of the acute cerebral event is worsened. &lt;/P&gt;
&lt;P&gt;Archives of Neurology has been published in its current form since 1959, and covers all aspects of neurology, including Parkinson's disease, Epilepsy, Cerebrovascular diseases and Neuromuscular diseases. The journal aims include making "timely publication of original research of the nervous system".&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;Some sections are freely available via &lt;A href="http://highwire.stanford.edu/lists/freeart.dtl" target="_blank"&gt;Highwire Press&lt;/A&gt;. The last 12 months are not available.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344282</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19570818]]&gt;</url>
    <title>Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>Sage</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MAGNETIC RESONANCE IMAGING (MRI),INVESTIGATION &amp; DIAGNOSTICS,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bonzano L, Roccatagliata L, Mancardi GL, Sormani MP. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials? &lt;EM&gt;Multiple Sclerosis&lt;/EM&gt; 2009 Sep;15(9):1043-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Data were extracted from published randomized clinical trials in relapsing-remitting multiple sclerosis (MS) with frequent magnetic resonance imaging (MRI), reporting both active T2 and gadolinum (GD)-enhancing lesions. A regression analysis was performed between the treatment effects estimated on the two different MRI endpoints.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A strong association was found between the treatment effect on Gd-enhancing lesions and on active T2 lesions (R(2) = 0.93), and the treatment effect estimates were almost the same (slope = 0.96).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Defining either active T2 or Gd-enhancing lesions as MRI endpoint seems to be not crucial for monitoring MRI activity in MS clinical trials. The choice of the best MRI endpoint should be based on different considerations (e.g., sensitivity, reproducibility, time for assessment, safety, and patients' comfort). Further monitoring active T2 lesions could allow less expensive trials, without requiring injection of Gd-based contrast agents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in September 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320693</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.2.56]]&gt;</url>
    <title>Ginkgo biloba did not prevent dementia or Alzheimer disease in elderly people</title>
    <publicationDate>2009-03-30T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ LATER LIFE,DEMENTIA,CAUSES AND PREVENTION,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Parsons, G. Ginkgo biloba did not prevent dementia or Alzheimer disease in elderly people. &lt;EM&gt;Evidence-Based Nursing&lt;/EM&gt; 2009;12(2):56&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt;&amp;nbsp;Dekosky ST, Williamson JD, Fitzpatrick AL, et al for the Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. &lt;EM&gt;JAMA&lt;/EM&gt; 2008;300:2253–62.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384286</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/bulletin/volumes/88/4/09-064147/en/]]&gt;</url>
    <title>Global disparities in the epilepsy treatment gap: a systematic review</title>
    <publicationDate>2009-09-25T00:00:00</publicationDate>
    <publisher>Bulletin of the World Health Organization</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Meyer A, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. &lt;EM&gt;Bulletin of the World Health Organization&lt;/EM&gt; 2010;88(4):260-73&lt;/P&gt;
&lt;P&gt;Epilepsy affects 50 million people worldwide, and 80% of them live in the developing world. An individual with epilepsy suffers recurrent seizures unprovoked by acute brain insults or metabolic derangements. Seizures are characterized by a brief period of uncontrolled involuntary shaking. They may be partial, involving only one part of the body, or generalized, involving the entire body, and they may be accompanied by loss of consciousness and of control of bowel or bladder function. Some individuals continue to have frequent seizures despite optimal treatment with anti-epileptic drugs. However, more than 70% of patients who are treated achieve long-term remission or freedom from seizures, usually within 5 years of diagnosis.&lt;/P&gt;
&lt;P&gt;The Bulletin of the World Health Organization is an international journal of public health with a special focus on developing countries. Since it was first published in 1948, the Bulletin has become one of the world’s leading public health journals. In keeping with its mission statement, the peer-reviewed monthly maintains an open-access policy so that the full contents of the journal and its archives are available online free of charge.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396490</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://cep.sagepub.com/content/30/5/599.abstract]]&gt;</url>
    <title>Global prevalence of chronic migraine: A systematic review</title>
    <publicationDate>2010-03-09T00:00:00</publicationDate>
    <publisher>SAGE journals online</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. (2010) Global prevalence of chronic migraine: a systematic review. &lt;EM&gt;Cephalalgia&lt;/EM&gt; 30(5):599-609&lt;/P&gt;
&lt;P&gt;The aim of this review was to summarize population-based studies reporting prevalence and/or incidence of chronic migraine (CM) and to explore variation across studies. A systematic literature search was conducted. Relevant data were abstracted and estimates were subdivided based on the criteria used in each study. Sixteen publications representing 12 studies were accepted. None presented data on CM incidence. The prevalence of CM was 0–5.1%, with estimates typically in the range of 1.4–2.2%. Seven studies used Silberstein–Lipton criteria (or equivalent), with prevalence ranging from 0.9% to 5.1%. Three estimates used migraine that occurred =?15 days per month, with prevalence ranging from 0 to 0.7%. Prevalence varied by World Health Organization region and gender. This review identified population-based studies of CM prevalence, although heterogeneity across studies and lack of data from certain regions leaves an incomplete picture. Future studies on CM would benefit from an International Classification of Headache Disorders consensus diagnosis that is clinically appropriate and operational in epidemiological studies. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314442</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.plosmedicine.org/article/fetchObjectAttachment.action;jsessionid=1FA6D2CACEA0DD90848052447F93FDB0?uri=info%3Adoi%2F10.1371%2Fjournal.pmed.0050166&amp;representation=PDF]]&gt;</url>
    <title>Greater response to placebo in children than in adults: A systematic review and meta-analysis in drug-resistant partial epilepsy</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Public Library of Science (PLoS)</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,FOCAL EPILEPSIES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. (2008) Greater response to placebo in children than in adults: A systematic review and meta-analysis in drug-resistant partial epilepsy. &lt;EM&gt;PLoS Medicine&lt;/EM&gt; 5(8):1223-37.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Three electronic databases were searched for RCTs investigating any antiepileptic drug (AED) in the add-on treatment of drug-resistant partial epilepsy in both children and adults. The treatment effect was compared between the two age groups using the ratio of the relative risk (RR) of the 50% responder rate between active AEDs treatment and placebo groups, as well as meta-regression. Differences in the response to placebo and to active treatment were searched using logistic regression. A comparable approach was used for analysing secondary endpoints, including seizure-free rate, total and adverse events-related withdrawal rates, and withdrawal rate for seizure aggravation. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Five AEDs were evaluated in both adults and children with drug-resistant partial epilepsy in 32 RCTs. The treatment effect was significantly lower in children than in adults (RR ratio: 0.67 [95% confidence interval (CI) 0.51-0.89]; p = 0.02 by meta-regression). This difference was related to an age-dependent variation in the response to placebo, with a higher rate in children than in adults (19% versus 9.9%, p &amp;lt; 0.001), whereas no significant difference was observed in the response to active treatment (37.2% versus 30.4%, p = 0.364). The relative risk of the total withdrawal rate was also significantly lower in children than in adults (RR ratio: 0.65 [95% CI 0.43-0.98], p = 0.004 by metaregression), due to higher withdrawal rate for seizure aggravation in children (5.6%) than in adults (0.7%) receiving placebo (p &amp;lt; 0.001). Finally, there was no significant difference in the seizure-free rate between adult and paediatric studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Children with drug-resistant partial epilepsy receiving placebo in double-blind RCTs demonstrated significantly greater 50% responder rate than adults, probably reflecting increased placebo and regression to the mean effects. Paediatric clinical trial designs should account for these age-dependent variations of the response to placebo to reduce the risk of an underestimated sample size that could result in falsely negative trials.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 12 August 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available to all via the publisher and PubMed Central&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384569</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1468-1331.2010.03151.x]]&gt;</url>
    <title>Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force</title>
    <publicationDate>2010-03-22T00:00:00</publicationDate>
    <publisher>European Journal of Neurology</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,NEURO-ONCOLOGY,PRIMARY BRAIN TUMOURS,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Soffietti R, Baumert B, Bello L, Von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W. (2010) Guidelines on management of low-grade gliomas: report of an EFNS–EANO Task Force. &lt;EM&gt;European Journal of Neurology&lt;/EM&gt; 17(9):1124–1133&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background: &lt;/STRONG&gt;Diffuse infiltrative low-grade gliomas of the cerebral hemispheres in the adult are a group of tumors with distinct clinical, histological and molecular characteristics, and there are still controversies in management.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The scientific evidence of papers collected from the literature was evaluated and graded according to EFNS guidelines, and recommendations were given accordingly.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results and conclusions:&lt;/STRONG&gt; WHO classification recognizes grade II astrocytomas, oligodendrogliomas and oligoastrocytomas. Conventional MRI is used for differential diagnosis, guiding surgery, planning radiotherapy and monitoring treatment response. Advanced imaging techniques can increase the diagnostic accuracy. Younger age, normal neurological examination, oligodendroglial histology and 1p loss are favorable prognostic factors. Prophylactic antiepileptic drugs are not useful, whilst there is no evidence that one drug is better than the others. Total/near total resection can improve seizure control, progression-free and overall survival, whilst reducing the risk of malignant transformation. Early post-operative radiotherapy improves progression-free but not overall survival. Low doses of radiation are as effective as high doses and better tolerated. Modern radiotherapy techniques reduce the risk of late cognitive deficits. Chemotherapy can be useful both at recurrence after radiotherapy and as initial treatment after surgery to delay the risk of late neurotoxicity from large-field radiotherapy. Neurocognitive deficits are frequent and can be caused by the tumor itself, tumor-related epilepsy, treatments and psychological distress.&lt;/P&gt;
&lt;P&gt;The &lt;I&gt;European Journal of Neurology&lt;/I&gt; is the official journal of the European Federation of Neurological Societies. It covers all areas of clinical and basic research in neurology. Emphasis is placed on major diseases or large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases). The journal provides a forum for European activity in clinical neuroscience and medical practice and help strengthen the links between research workers and clinicians in Europe and other parts of the world. The journal also publishes the official EFNS taskforce papers.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access statement: &lt;/STRONG&gt;Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293190</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17975726?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Headache treatment with pulsing electromagnetic fields: a literature review</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>Springer Milan</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Vincent W et al Applied psychophysiology and biofeedback 2007 Dec;32(3-4):191-207. Epub 2007 Nov 2&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Pulsing electromagnetic field (PEMF) therapy may be a viable form of complementary and alternative medicine. Clinical applications include the treatment of fractures, wounds, and heart disease. More recent applications involve treatment of recurrent headache disorders. This paper reviews available studies investigating PEMF for headache management. Possible mechanisms for effects (neurochemical, electrophysical, and cardiovascular) are discussed. The available data suggest that PEMF treatment for headache merits further study. Suggestions for future research are provided.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320695</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.2.57]]&gt;</url>
    <title>High-dose vitamin B supplements did not slow cognitive decline in patients with mild-to-moderate Alzheimer disease</title>
    <publicationDate>2009-03-30T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,ALZHEIMER'S DISEASE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,MILD COGNITIVE IMPAIRMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Coker, E. High-dose vitamin B supplements did not slow cognitive decline in patients with mild-to-moderate Alzheimer disease. &lt;EM&gt;Evidence-Based Nursing&lt;/EM&gt; 2009;12(2):57.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. &lt;EM&gt;JAMA&lt;/EM&gt; 2008;300:1774–83.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270551</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16886973]]&gt;</url>
    <title>ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,FIRST SEIZURE AND EARLY EPILEPSY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Glauser T., Ben-Menachem E., Bourgeois B. et al. 2006; Epilpesia 47 (7) pp. 1094-120&lt;/P&gt;
&lt;H2&gt;Original article abstract&lt;/H2&gt;
&lt;P&gt;PURPOSE: To assess which antiepileptic medications (AEDs) have the best evidence for long-term efficacy or effectiveness as initial monotherapy for patients with newly diagnosed or untreated epilepsy. METHODS: A 10-member subcommission of the Commission on Therapeutic Strategies of The International League Against Epilepsy (ILAE), including adult and pediatric epileptologists, clinical pharmacologists, clinical trialists, and a statistician evaluated available evidence found through a structured literature review including MEDLINE, Current Contents and the Cochrane Library for all applicable articles from 1940 until July 2005. Articles dealing with different seizure types (for different age groups) and two epilepsy syndromes were assessed for quality of evidence (four classes) based on predefined criteria. Criteria for class I classification were a double-blind randomized controlled trial (RCT) design, &amp;gt;or=48-week treatment duration without forced exit criteria, information on &amp;gt;or=24-week seizure freedom data (efficacy) or &amp;gt;or=48-week retention data (effectiveness), demonstration of superiority or 80% power to detect a &lt;OR=20% difference versus adequate comparator, appropriate statistical met criteria except having either treatment duration 24 47 weeks or, noninferiority analysis, power only exclude 21-30% relative difference. studies randomized double-blind open-label trials, IV included forms (e.g., expert opinion, case reports). Quality clinical trial was used determine recommendation. RESULTS: total 50 seven meta-analyses contributed analysis. Only four I evidence, whereas II evidence; remainder were evaluated III evidence. Three monotherapy: carbamazepine phenytoin; valproic acid), oxcarbazepine; None), elderly adults partial-onset (level A, gabapentin lamotrigine; B, None). One adult type [adults generalized-onset tonic-clonic (GTC) seizures], pediatric seizure types (GTC seizures), two syndromes (benign centrotemporal spikes juvenile myoclonic epilepsy) had no AEDs A level B monotherapy. CONCLUSIONS: This focused on initial monotherapy epilepsy. absence rigorous comprehensive adverse effects data makes it impossible develop evidence-based guideline aimed at identifying overall optimal recommended initial-monotherapy AED. There is especially alarming lack well-designed, properly conducted generalized seizures epilepsies children general. majority existing have significant methodologic problems limit their applicability guideline?s main question. Multicenter, multinational efforts are needed to design, conduct analyze future clinically RCTs that can answer many outstanding questions identified in this guideline. The ultimate choice an any individual patient newly diagnosed or untreated epilepsy include consideration strength of effectiveness evidence for each along with other such as the AED safety tolerability profile, pharmacokinetic properties, formulations, expense. When selecting a patient?s AED, physicians patients should consider all relevant variables not just efficacy and effectiveness.&lt; P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306161</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_094058?IdcService=GET_FILE&amp;dID=183502&amp;Rendition=Web]]&gt;</url>
    <title>Impact Assessment of National Dementia Strategy</title>
    <publicationDate>2009-01-20T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ LATER LIFE,DEMENTIA,NEUROLOGICAL CONDITIONS,DEMENTIA,CONDITIONS,NATIONAL DEMENTIA STRATEGY,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Examines a number of policy options, giving justifications for the choice of the preferred option. Also sets a review date for the National Dementia Strategy.]]&gt;</body>
  </document>
  <document>
    <id>307828</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsLegislation/DH_081051?IdcService=GET_FILE&amp;dID=160487&amp;Rendition=Web]]&gt;</url>
    <title>Impact Assessment: A new ambition for stroke</title>
    <publicationDate>2007-12-05T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,NATIONAL STROKE STRATEGY,STRATEGIES AND POLICIES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;This impact assessment covers the National Stroke Strategy, launched by the Government on 5 December 2007.&lt;/P&gt;
&lt;P&gt;There are approximately 110,000 strokes in England each year. Stroke is the third largest cause of death in the UK, responsible for 11% of deaths in England, and the largest cause of adult disability. Stroke costs the NHS and the economy about £7bn a year. The National Audit Office, Public Accounts Committee and the National Sentinel Audit for Stroke have all highlighted a number of areas where stroke services are underperforming. Sustained improvement can be achieved through the comprehensive approach described in the Strategy.&lt;/P&gt;
&lt;DIV class="subContent first"&gt;
&lt;H3&gt;Policy objectives and intended effects&lt;/H3&gt;
&lt;P&gt;The National Stroke Strategy will drive improvement in stroke services by:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Providing a quality framework against which local services can secure improvements 
&lt;LI&gt;Providing advice, guidance and support for commissioners, Strategic Health Authorities and Local Authorities in the planning, development and monitoring of services. 
&lt;LI&gt;Informing patients’ and their families’ expectations of health and social care services by providing markers of high quality care.&lt;/LI&gt;&lt;/UL&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>398043</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://stroke.ahajournals.org/cgi/content/abstract/41/11/2625]]&gt;</url>
    <title>Impact of microalbuminuria on incident stroke: a meta-analysis</title>
    <publicationDate>2010-10-07T00:00:00</publicationDate>
    <publisher>American Heart Association American Stroke Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. (2010) Impact of microalbuminuria on incident stroke: a meta-analysis. &lt;EM&gt;Stroke&lt;/EM&gt; 41(11):2625-2631&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and purpose:&lt;/STRONG&gt; Microalbuminuria, a marker of both kidney disease and endothelial dysfunction, may be associated with global vascular risk, but the nature and magnitude of the link between microalbuminuria and incident stroke has not been clearly defined. The purpose of this study was to assess the consistency and strength of the association of microalbuminuria with risk of stroke in prospective studies using meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We conducted a systematic search of electronic databases and bibliographies for studies reporting a multivariate-adjusted estimate, represented as relative risk with 95% CI, of the association between microalbuminuria and stroke risk. Studies were excluded if a majority of study participants had established kidney disease or pre-eclampsia. Estimates were combined using a random-effect model. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 12 studies, with a total of 48 596 participants and 1263 stroke events. Overall, presence of microalbuminuria was associated with greater stroke risk (relative risk, 1.92; 95% CI, 1.61 to 2.28; P&amp;lt;0.001) after adjustment for established cardiovascular risk factors. There was evidence of significant heterogeneity in the magnitude of the association across studies (P for heterogeneity &amp;lt;0.001, I2=68%), which was partially explained by differences in study population, microalbuminuria definition, and different microalbuminuria-related risk among stroke subtypes. However, in stratified analyses, microalbuminuria was associated with increased risk of subsequent stroke in all subgroups (general population, diabetics, those with known stroke). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Microalbuminuria is strongly and independently associated with incident stroke risk. Future studies should explore whether microalbuminuria is just a risk marker or a modifiable risk factor for stroke. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Stroke is a monthly publication and part of AHA Journals, produced&amp;nbsp;by&amp;nbsp;the American Heart Association whose mission is to build healthier lives, free of cardiovascular diseases and stroke.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Most full text is&amp;nbsp;only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Some full text content plus abstracts and tables of contents are freely available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293359</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.painphysicianjournal.com/linkout_vw.php?issn=1533-3159&amp;vol=11&amp;page=187]]&gt;</url>
    <title>Implanted occipital nerve stimulators</title>
    <publicationDate>2008-03-02T00:00:00</publicationDate>
    <publisher>American Society of Interventional Pain Physicians</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,CHRONIC DAILY HEADACHE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Jasper JF et al Pain Physician 2008 Mar-Apr;11(2):187-200&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Chronic headache represents a very significant public health and economic issue. One treatment modality for chronic refractory headache involves the use of subcutaneous implanted neurostimulator leads in the occipital region. Varied types of headache etiologies including migraine, transformed migraine, chronic daily headache, cluster headache, hemicrania continua, occipital neuralgia, and cervicogenic headache have been studied with peripheral nerve field stimulation and found responsive to stimulation of the suboccipital region, known commonly as occipital nerve stimulation (ONS). OBJECTIVE: To evaluate the strength of evidence that occipital nerve stimulation is an effective treatment of benign headache. STUDY DESIGN: A systematic review of occipital nerve stimulation for the treatment of chronic headache. METHODS: A systematic review of the literature through EMBASE and PubMed/Medline for clinical studies was performed. The Agency for Healthcare Research and Quality (AHRQ) criteria was utilized to assess the evidence regarding occipital nerve stimulators and arrives at conclusions as to their efficacy in the treatment of headache. Studies were also graded using AHRQ criteria. The overall body of evidence was then graded on a 5 level scale from Level I (conclusive), Level II (strong), Level III (moderate), Level IV (limited) to Level V (indeterminate). RESULTS: Ten observational studies, of which 4 were prospective, and a number of case series, case reports, and reviews were identified. No randomized controlled trials (RCT) were identified. All of the articles reported positive outcomes including improved pain relief, reduced frequency, intensity, and duration of headaches with reduced medication consumption. ONS was reportedly successful for 70 - 100% of patients. Reduction of pain in patients with occipital headaches and transformed migraine is significant and rapid; for cluster patients the improvement may be less dramatic and it may take several months of occipital stimulation to achieve relief. No long-term adverse events occurred. Several short-term incidents occurred including infection, lead displacement, and battery depletion. The body of evidence as a whole is a level of strength of IV, limited. CONCLUSION: ONS is a useful tool in the treatment of chronic severe headaches with at least Level IV (limited) evidence based on multiple positive studies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345248</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20056489]]&gt;</url>
    <title>Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis.</title>
    <publicationDate>2010-01-05T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,HAEMORRHAGIC,INTRACEREBRAL HAEMORRHAGE,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. (2010) Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. &lt;EM&gt;Lancet Neurol.&lt;/EM&gt;&amp;nbsp;9(2):167-76. Epub 2010 Jan 5. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; From PubMed and Embase searches with predefined inclusion criteria, we identified population-based studies published between January, 1980, and November, 2008. We calculated incidence and case fatality. Incidences for multiple studies were pooled in a random-effects binomial meta-analysis. Time trends of case fatality were assessed with weighted linear-regression analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 36 eligible studies described 44 time periods (mid-year range 1983-2006). These studies included 8145 patients with intracerebral haemorrhage. Incidence did not decrease between 1980 and 2008. Overall incidence was 24.6 per 100 000 person-years (95% CI 19.7-30.7). Incidence was not significantly lower in women than in men (overall incidence ratio 0.85, 95% CI 0.61-1.18). Using the age group 45-54 years as reference, incidence ratios increased from 0.10 (95% CI 0.06-0.14) for people aged less than 45 years to 9.6 (6.6-13.9) for people older than 85 years. Median case fatality at 1 month was 40.4% (range 13.1-61.0) and did not decrease over time, and was lower in Japan (16.7%, 95% CI 15.0-18.5) than elsewhere (42.3%, 40.9-43.6). Six studies reported functional outcome, with independency rates of between 12% and 39%. Incidence of intracerebral haemorrhage per 100 000 person-years was 24.2 (95% CI 20.9-28.0) in white people, 22.9 (14.8-35.6) in black people, 19.6 (15.7-24.5) in Hispanic people, and 51.8 (38.8-69.3) in Asian people. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Incidence of intracerebral haemorrhage increases with age and has not decreased between 1980 and 2006. Case fatality is lower in Japan than elsewhere, increases with age, and has not decreased over time. More data on functional outcome are needed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; January 5 2010 (e-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Most full text of this journal is&amp;nbsp;only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Some full text content plus abstracts and tables of contents are freely available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325770</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.b3016]]&gt;</url>
    <title>Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis</title>
    <publicationDate>2009-08-17T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ INVESTIGATION &amp; DIAGNOSTICS,MAGNETIC RESONANCE IMAGING (MRI),RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,NEURO-ONCOLOGY,PRIMARY BRAIN TUMOURS,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Morris Z, Whiteley WN, Longstreth WT Jr, Weber F, Lee YC, Tsushima Y, Alphs H, Ladd SC, Warlow C, Wardlaw JM, Al-Shahi Salman R. (2009) Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. &lt;EM&gt;BMJ&lt;/EM&gt; 2009 Aug 17;339:b3016.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Ovid Medline (1950 to May 2008), Embase (1980 to May 2008), and bibliographies of relevant articles were searched.&amp;nbsp;Two reviewers sought and assessed studies of people without neurological symptoms who underwent MRI of the brain with or without intravenous contrast for research purposes or for occupational, clinical, or commercial screening. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In 16 studies, 135 of 19 559 people had neoplastic incidental brain findings (prevalence 0.70%, 95% confidence interval 0.47% to 0.98%), and prevalence increased with age (2 for linear trend, P=0.003). In 15 studies, 375 of 15 559 people had non-neoplastic incidental brain findings (prevalence 2.0%, 1.1% to 3.1%, excluding white matter hyperintensities, silent infarcts, and microbleeds). The number of asymptomatic people needed to scan to detect any incidental brain finding was 37. The prevalence of incidental brain findings was higher in studies using high resolution MRI sequences than in those using standard resolution sequences (4.3% v 1.7%, P&amp;lt;0.001). The prevalence of neoplastic incidental brain findings increased with age. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Incidental findings on brain MRI are common, prevalence increases with age, and detection is more likely using high resolution MRI sequences than standard resolution sequences. These findings deserve to be mentioned when obtaining informed consent for brain MRI in research and clinical practice but are not sufficient to justify screening healthy asymptomatic people. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 17 August 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is made freely available by the BMJ under the Creative Commons License.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293379</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16426262?ordinalpos=4&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials.</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>STRUCTURED ABSTRACT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Dahlof, CG Cephalalgia 2006 Feb;26(2):98-106&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;A migraineur can claim to be an infrequent responder ('non-responder') to an oral triptan independent of which triptan he or she is presently using. Four trials of an alternative triptan (zolmitriptan/rizatriptan; eletriptan; naratriptan; almotriptan) in patients with a history of infrequent response to oral sumatriptan were compared and contrasted in terms of study design, patient characteristics, and efficacy and tolerability of the triptan under investigation. Unfortunately, none of the reported studies used an appropriate parallel design, which would have had the non-responding triptan (oral sumatriptan) in one arm and without encapsulation. While the four trials differed in terms of study design (open-label vs. placebo-controlled), definition of sumatriptan 'non-responder' (retrospective vs. prospective) and pain intensity at baseline (30% severe to 70% severe), all four demonstrated that lack of response to sumatriptan did not predict lack of response to an alternative triptan. Changing triptans resulted in 2-h pain-relief rates of 25-81% in patients with a history of poor response to sumatriptan. It can be concluded that migraine patients who respond infrequently to sumatriptan should be switched to a different triptan, as lack of response to one triptan does not predict likelihood of responsiveness to another. A review of the available evidence suggests that almotriptan may be one of the most appropriate choices for an alternative triptan.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288872</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17453980?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Integrated care for MS patients</title>
    <publicationDate>2007-04-01T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,DELIVERY OF CARE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Jansen, DE &lt;SPAN title="Disability and rehabilitation."&gt;&lt;A href="#javascript:AL_get(this," Rehabil.?);? ?Disabil ?jour?,&gt;Disabil Rehabil.&lt;/A&gt;&lt;/SPAN&gt; 2007 Apr 15;29(7):597-603&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;PURPOSE: The problem of complex healthcare to MS patients, together with the rising prevalence of MS and escalating costs, has caused healthcare policy makers to consider innovative approaches to controlling costs and improving the quality of care. An integrated care approach may provide a means for better coordination and delivery of care. The aim is to review recent integrated care initiatives and their significance for MS patients. METHOD: A literature search was conducted to trace relevant literature on integrated care for MS patients published between 1995 and 2003. RESULTS: Although integrated care appears to offer potential for eliminating fragmentation and discontinuity in healthcare for MS patients, there are few published studies which have evaluated its implementation with MS patients. CONCLUSIONS: Even though the potential advantages of integrated care are well known, the applicability of this approach for MS patients has still to be demonstrated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319204</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.3.85]]&gt;</url>
    <title>Intensive nutritional supplementation improved functional outcome after stroke</title>
    <publicationDate>2009-06-26T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,DELIVERY OF CARE,STROKE,REHABILITATION,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; &lt;FONT face=Arial size=2&gt;&lt;FONT face=Arial size=2&gt;Bergstrom, N. Intensive nutritional supplementation improved functional outcome after stroke. &lt;EM&gt;Evid. Based Nurs&lt;/EM&gt;. 2009;12;85&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Abstracted from: &lt;BR&gt;Rabadi MH, Coar PL, Lukin M, et al. Intensive nutritional supplements can improve outcomes in stroke rehabilitation. &lt;EM&gt;Neurology&lt;/EM&gt; 2008;71:1856–61.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398088</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.jns.2010.11.003]]&gt;</url>
    <title>Interferon therapy in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis of the comparative trials</title>
    <publicationDate>2010-12-16T00:00:00</publicationDate>
    <publisher>Elsevier</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Oliver BJ, Kohli E, Kasper LH. (2010) Interferon therapy in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis of the comparative trials. &lt;EM&gt;Journal of Neurological Sciences&lt;/EM&gt; (available online December 16th)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Early and more recent systematic reviews of placebo controlled trials disagree about the relative efficacy of the commercially available INF-ß treatments in studies of adults with RRMS. A limitation of these reviews is that they have derived their findings almost entirely from the pivotal trials and placebo controlled studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To provide the first meta-analytic study of head-to-head and comparative trials of INF-ß agents in RRMS treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; OVID Medline and Cochrane Library electronic databases were searched using keywords “multiple sclerosis”, “interferon beta-1a”, and “interferon beta-1b”. Using a standardized abstraction form, three reviewers independently abstracted MRI, relapse rate, and disability (EDSS) data. RevMan5 software was used to calculate relative risk (RR) and absolute risk differences (RD) based on event rates.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; High dose treatment demonstrated superior relapse reduction and MRI stability compared to low dose treatment. There was also a trend observed in the aggregate analyses of disability progression (EDSS) favoring high dose treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; High dose INF-ß treatment demonstrated superior relapse control and MRI stability compared to low dose treatment in a systematic review of comparative studies. These results contradict those of earlier systematic reviews and support the conclusions of more recent systematic reviews of the placebo controlled trials.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398013</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/content/341/bmj.c6581.abstract]]&gt;</url>
    <title>Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study</title>
    <publicationDate>2010-09-27T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, de Jong-van den Berg L. (2010) Intrauterine exposure to carbamazepine and specific. &lt;EM&gt;British Medical Journal&lt;/EM&gt; 341:c6581&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Setting:&lt;/STRONG&gt; Review of PubMed, Web of Science, and Embase for papers about carbamazepine exposure in the first trimester of pregnancy and specific malformations, and the EUROCAT Antiepileptic Study Database, including data from 19 European population based congenital anomaly registries, 1995-2005. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Participants:&lt;/STRONG&gt; The literature review covered eight cohort studies of 2680 pregnancies with carbamazepine monotherapy exposure, and the EUROCAT dataset included 98?075 registrations of malformations covering over 3.8 million births. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Main outcome measures:&lt;/STRONG&gt; Overall prevalence for a major congenital malformation after exposure to carbamazepine monotherapy in the first trimester. Odds ratios for malformations with exposure to carbamazepine among cases (five types of malformation identified in the literature review) compared with two groups of controls: other non-chromosomal registrations of malformations and chromosomal syndromes. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The literature review yielded an overall prevalence for a major congenital malformation of 3.3% (95% confidence interval 2.7 to 4.2) after exposure to carbamazepine monotherapy in the first trimester. In 131 registrations of malformations, the fetus had been exposed to carbamazepine monotherapy. Spina bifida was the only specific major congenital malformation significantly associated with exposure to carbamazepine monotherapy (odds ratio 2.6 (95% confidence interval 1.2 to 5.3) compared with no antiepileptic drug), but the risk was smaller for carbamazepine than for valproic acid (0.2, 0.1 to 0.6). There was no evidence for an association with total anomalous pulmonary venous return (no cases with carbamazepine exposure), cleft lip (with or without palate) (0.2, 0.0 to 1.3), diaphragmatic hernia (0.9, 0.1 to 6.6), or hypospadias (0.7, 0.3 to 1.6) compared with no exposure to antiepileptic drugs. Further exploratory analysis suggested a higher risk of single ventricle and atrioventricular septal defect. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Carbamazepine teratogenicity is relatively specific to spina bifida, though the risk is less than with valproic acid. Despite the large dataset, there was not enough power to detect moderate risks for some rare major congenital malformations. &lt;/P&gt;
&lt;P&gt;BMJ publishes original scientific studies, review and educational articles, and papers commenting on the clinical, scientific, social, political, and economic factors affecting health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Free full text is available to NHS staff via &lt;A href="http://ukpmc.ac.uk/" target="_blank"&gt;UK PubMed Central&lt;/A&gt;, with a 1-year embargo. Up-to-date full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288494</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18075269?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Intravenous polyclonal human immunoglobulins in multiple sclerosis</title>
    <publicationDate>2008-06-02T00:00:00</publicationDate>
    <publisher>Karger</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Soelberg, S &lt;SPAN title="Neuro-degenerative diseases."&gt;&lt;A href="#javascript:AL_get(this," Dis.?);? ?Neurodegener ?jour?,&gt;Neurodegener Dis.&lt;/A&gt;&lt;/SPAN&gt; 2008;5(1):8-15&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Intravenous immunoglobulin (IVIG) is an established therapy for demyelinating diseases of the peripheral nervous system. IVIG exerts a number of effects that may be beneficial in multiple sclerosis (MS). Four double-blind IVIG trials have been performed in relapsing-remitting MS. A meta-analysis of the four trials has shown that IVIG reduces the relapse rate and, possibly, disease progression. In patients with a first episode of demyelinating disease, IVIG delays the time to the second relapse and thereby to the diagnosis of definite MS. In patients with an acute MS relapse, IVIG as add-on therapy to methylprednisolone does not make remission of symptoms faster or more complete. IVIG does not seem to be of any benefit to chronic visual or motor symptoms in MS. In secondary progressive MS, IVIG has not shown any effect on disease progression, relapses or new magnetic resonance imaging lesions. Experimental studies in the MS model experimental autoimmune encephalomyelitis in rats demonstrate that IVIG has to be administered at the time of induction of a relapse in order to be effective. In conclusion, IVIG can be considered as a second-line treatment to approved therapies for relapsing-remitting MS, but the ideal dosage of IVIG still needs to be determined. In order to be a first-line treatment for MS, the beneficial effect should be confirmed in a large-scale placebo-controlled survey, or in a study comparing the effect with approved therapies for relapsing-remitting MS using appropriate clinical and magnetic resonance imaging outcome measures. Copyright (c) 2008 S. Karger AG, Basel.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288494</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18075269?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Intravenous polyclonal human immunoglobulins in multiple sclerosis</title>
    <publicationDate>2008-06-02T00:00:00</publicationDate>
    <publisher>Karger</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Soelberg, S &lt;SPAN title="Neuro-degenerative diseases."&gt;&lt;A href="#javascript:AL_get(this," Dis.?);? ?Neurodegener ?jour?,&gt;Neurodegener Dis.&lt;/A&gt;&lt;/SPAN&gt; 2008;5(1):8-15&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Intravenous immunoglobulin (IVIG) is an established therapy for demyelinating diseases of the peripheral nervous system. IVIG exerts a number of effects that may be beneficial in multiple sclerosis (MS). Four double-blind IVIG trials have been performed in relapsing-remitting MS. A meta-analysis of the four trials has shown that IVIG reduces the relapse rate and, possibly, disease progression. In patients with a first episode of demyelinating disease, IVIG delays the time to the second relapse and thereby to the diagnosis of definite MS. In patients with an acute MS relapse, IVIG as add-on therapy to methylprednisolone does not make remission of symptoms faster or more complete. IVIG does not seem to be of any benefit to chronic visual or motor symptoms in MS. In secondary progressive MS, IVIG has not shown any effect on disease progression, relapses or new magnetic resonance imaging lesions. Experimental studies in the MS model experimental autoimmune encephalomyelitis in rats demonstrate that IVIG has to be administered at the time of induction of a relapse in order to be effective. In conclusion, IVIG can be considered as a second-line treatment to approved therapies for relapsing-remitting MS, but the ideal dosage of IVIG still needs to be determined. In order to be a first-line treatment for MS, the beneficial effect should be confirmed in a large-scale placebo-controlled survey, or in a study comparing the effect with approved therapies for relapsing-remitting MS using appropriate clinical and magnetic resonance imaging outcome measures. Copyright (c) 2008 S. Karger AG, Basel.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344193</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18075269]]&gt;</url>
    <title>Intravenous polyclonal human immunoglobulins in multiple sclerosis</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>Karger</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Soelberg SP. Intravenous polyclonal human immunoglobulins in multiple sclerosis. Neurodegenerative Diseases 2008;5(1):8-15.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods and results:&lt;/STRONG&gt; Four double-blind intravenous immunoglobulin (IVIG) trials have been performed in relapsing-remitting multiple sclerosis (MS). A meta-analysis of the four trials has shown that IVIG reduces the relapse rate and, possibly, disease progression. In patients with a first episode of demyelinating disease, IVIG delays the time to the second relapse and thereby to the diagnosis of definite MS. In patients with an acute MS relapse, IVIG as add-on therapy to methylprednisolone does not make remission of symptoms faster or more complete. IVIG does not seem to be of any benefit to chronic visual or motor symptoms in MS. In secondary progressive MS, IVIG has not shown any effect on disease progression, relapses or new magnetic resonance imaging lesions. Experimental studies in the MS model experimental autoimmune encephalomyelitis in rats demonstrate that IVIG has to be administered at the time of induction of a relapse in order to be effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Four double-blind IVIG trials have been performed in relapsing-remitting MS. A meta-analysis of the four trials has shown that IVIG reduces the relapse rate and, possibly, disease progression. In patients with a first episode of demyelinating disease, IVIG delays the time to the second relapse and thereby to the diagnosis of definite MS. In patients with an acute MS relapse, IVIG as add-on therapy to methylprednisolone does not make remission of symptoms faster or more complete. IVIG does not seem to be of any benefit to chronic visual or motor symptoms in MS. In secondary progressive MS, IVIG has not shown any effect on disease progression, relapses or new magnetic resonance imaging lesions. Experimental studies in the MS model experimental autoimmune encephalomyelitis in rats demonstrate that IVIG has to be administered at the time of induction of a relapse in order to be effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in December 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344193</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18075269]]&gt;</url>
    <title>Intravenous polyclonal human immunoglobulins in multiple sclerosis</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>Karger</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Soelberg SP. Intravenous polyclonal human immunoglobulins in multiple sclerosis. Neurodegenerative Diseases 2008;5(1):8-15.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods and results:&lt;/STRONG&gt; Four double-blind intravenous immunoglobulin (IVIG) trials have been performed in relapsing-remitting multiple sclerosis (MS). A meta-analysis of the four trials has shown that IVIG reduces the relapse rate and, possibly, disease progression. In patients with a first episode of demyelinating disease, IVIG delays the time to the second relapse and thereby to the diagnosis of definite MS. In patients with an acute MS relapse, IVIG as add-on therapy to methylprednisolone does not make remission of symptoms faster or more complete. IVIG does not seem to be of any benefit to chronic visual or motor symptoms in MS. In secondary progressive MS, IVIG has not shown any effect on disease progression, relapses or new magnetic resonance imaging lesions. Experimental studies in the MS model experimental autoimmune encephalomyelitis in rats demonstrate that IVIG has to be administered at the time of induction of a relapse in order to be effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Four double-blind IVIG trials have been performed in relapsing-remitting MS. A meta-analysis of the four trials has shown that IVIG reduces the relapse rate and, possibly, disease progression. In patients with a first episode of demyelinating disease, IVIG delays the time to the second relapse and thereby to the diagnosis of definite MS. In patients with an acute MS relapse, IVIG as add-on therapy to methylprednisolone does not make remission of symptoms faster or more complete. IVIG does not seem to be of any benefit to chronic visual or motor symptoms in MS. In secondary progressive MS, IVIG has not shown any effect on disease progression, relapses or new magnetic resonance imaging lesions. Experimental studies in the MS model experimental autoimmune encephalomyelitis in rats demonstrate that IVIG has to be administered at the time of induction of a relapse in order to be effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in December 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396722</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://fampra.oxfordjournals.org/content/27/2/151.abstract]]&gt;</url>
    <title>Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review</title>
    <publicationDate>2009-12-22T00:00:00</publicationDate>
    <publisher>Oxford Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Verhagen AP, Damen L, Berger MY, Passchier J, Koes BW. (2009) Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review. &lt;EM&gt;Family Practice&lt;/EM&gt; 27(2):151-165&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To assess the efficacy and tolerability of prophylactic drugs for chronic tension-type headache (TTH) in adults. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched several databases from inception to August 2009. We selected randomized trials that reported the effects of prophylactic drugs in patients with TTH, with a pain measure (intensity, frequency, duration, improvement or index) as outcome measure. Two authors independently assessed risk of bias and extracted data from the original reports. A data synthesis was carried out according to the type of medication. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We included 44 trials (3399 patients), of which 15 (34.1%) were considered to be of low risk of bias. Main types of medications studied were antidepressants, muscle relaxants, benzodiazepines and vasodilator agents. Overall, antidepressants were no more effective than placebo, and there were no significant differences between different types of antidepressants. There was conflicting evidence about the effectiveness of benzodiazepines and vasodilator agents compared with placebo. Furthermore, there was limited evidence that propranolol had negative effects on depression in TTH patients, when compared with placebo or biofeedback. There was no evidence concerning the effectiveness of muscle relaxants alone or 5-HT receptor agonist compared with placebo. &lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Overall, antidepressants were no more effective on headache intensity or frequency and analgesic use than placebo. Propranolol seemed to have negative effects on depression in TTH patients when compared with placebo or biofeedback. No evidence was found for the use of muscle relaxants alone or 5-HT receptor agonist. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386647</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.theannals.com/cgi/content/abstract/43/10/1692]]&gt;</url>
    <title>Levetiracetam use in pregnancy</title>
    <publicationDate>2009-08-18T00:00:00</publicationDate>
    <publisher>Annals of Pharmacotherapy</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Longo B, Forinash AB, Murphy JA. (2009) Levetiracetam use in pregnancy. &lt;EM&gt;Annals of Pharmacotherapy&lt;/EM&gt; 43(10):1692-1695 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;OBJECTIVE:&lt;/STRONG&gt; To review data evaluating levetiracetam management of epilepsy during pregnancy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DATA SOURCES:&lt;/STRONG&gt; A literature search of PubMed (1966–June 2009) was performed using the terms pregnancy, epilepsy, levetiracetam, and anticonvulsants. Bibliographies of all articles retrieved were reviewed to identify additional relevant articles. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;STUDY SELECTION AND DATA EXTRACTION:&lt;/STRONG&gt; All studies including humans and published in English with data describing levetiracetam management during pregnancy were included. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;DATA SYNTHESIS:&lt;/STRONG&gt; The pharmacokinetic studies included in this review demonstrate that the clearance of levetiracetam increases during pregnancy, particularly during the third trimester, which subsequently leads to decreased serum levetiracetam concentrations. The increase in clearance is most likely due to an increase in renal blood flow. The teratogenic studies included in this review included a total of 147 patients. Of these patients, 2% experienced a major congenital malformation (MCM) and 4.8% experienced a minor anomaly. All of the patients who had either an MCM or a minor anomaly were receiving antiepileptic drug (AED) polytherapy. It was unknown whether 10.9% of the 147 patients discussed were receiving levetiracetam monotherapy or AED polytherapy. None of the published literature assessed adherence to AED therapy. Folic acid supplementation was addressed in only one of the case series presented. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;CONCLUSIONS:&lt;/STRONG&gt; If levetiracetam is used during pregnancy, women should receive adequate amounts of folic acid (0.4–5 mg/day) and serum concentrations of levetiracetam should be determined before conception if possible and during each trimester, especially during the middle of the third trimester, to assess therapeutic concentrations. The dose may need to be increased during the third trimester to provide concentrations consistent with those before conception. Patients should be informed that there appears to be a small chance of malformations with levetiracetam, but that the data are limited. &lt;/P&gt;
&lt;P&gt;&lt;SUP&gt;&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;Now in its 44th year, The Annals is an independent, peer-reviewed medical journal that advances pharmacotherapy throughout the world by publishing evidence-based articles on practice and research. The Annals provides an independent forum for the discussion and analysis of professional issues in pharmacotherapy. To fulfill its mission, The Annals will:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;publish research reports, reviews, commentaries, case reports, and other articles that are of high quality, unique, and timely and that will advance patient care and clinical pharmacy practice. 
&lt;LI&gt;provide service that is personal, professional, and prompt to authors, reviewers, and subscribers, surpassing their expectations and building ongoing relationships.&amp;nbsp; 
&lt;LI&gt;maintain an editorial board and referee base of skilled, dedicated clinicians, researchers, and educators with collective expertise in all areas of pharmacy.&amp;nbsp; 
&lt;LI&gt;keep abreast of the latest developments in publishing and information technology, adopting those deemed most likely to enhance the journal’s content and services. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270511</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17461890]]&gt;</url>
    <title>Levetiracetam: Part II, the clinical profile of a novel anticonvulsant drug</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Neva Press, Inc.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: De Smedt T., Raedt R., Vonck K. et al. 2007; CNS Drug Reviews 13 (1) pp. 57-78&lt;/P&gt;
&lt;H2&gt;Original article abstract: &lt;/H2&gt;
&lt;P&gt;The objective of this article was to review and summarize the available reports on the profile of the novel anticonvulsant drug levetiracetam (LEV) in a clinical setting. Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article is devoted to the clinical pharmacology and clinical trials of LEV investigating its efficacy and safety as add-on therapy or monotherapy for various seizure types. Finally, results from postmarketing surveillance of LEV are briefly discussed. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties, a favorable long-term retention rate, and a high responder rate, indicating that LEV is an efficient therapeutic option for the treatment of several types of epilepsy.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306159</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_094058?IdcService=GET_FILE&amp;dID=183635&amp;Rendition=Web]]&gt;</url>
    <title>Living well with dementia: A National Dementia Strategy - accessible summary</title>
    <publicationDate>2009-02-03T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,SYMPTOM MANAGEMENT,NERVOUS SYSTEM DISEASES,CONDITIONS,PALLIATIVE AND SUPPORTIVE CARE,SOCIAL &amp; PSYCHOSOCIAL ISSUES,ALZHEIMER’S DISEASE,CONDITIONS,STRATEGIES AND POLICIES,NATIONAL DEMENTIA STRATEGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Summary version of the Living well with dementia: A National Dementia Strategy document.]]&gt;</body>
  </document>
  <document>
    <id>306162</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_094058?IdcService=GET_FILE&amp;dID=183478&amp;Rendition=Web]]&gt;</url>
    <title>Living well with dementia: A National Dementia Strategy - equality impact assessment</title>
    <publicationDate>2009-02-03T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,DEMENTIA,CONDITIONS,STRATEGIES AND POLICIES,NATIONAL DEMENTIA STRATEGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Equality Impact Assessment (EQIA) considers the possible impact of the National Dementia Strategy on people according to their age, disability, race religion and beliefs, gender and sexual orientation. The EQIA follows on from the equality screening assessment that was issued alongside the consultation on the National Dementia Strategy that ran from June to September 2008. The EQIA therefore aims to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;identify any potential issues contained in the Strategy on any of these groups; and 
&lt;LI&gt;ensure that implementation of the Strategy takes account of the potential issues and informs continuing development to reduce inequality &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>271271</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Long-termNeurologicalConditionsNSF/index.htm]]&gt;</url>
    <title>Long Term (Neurological Conditions) NSF</title>
    <publicationDate>2005-03-01T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,NSF LONG TERM CONDITIONS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Long term (Neurological) Conditions National Service Framework (NSF) was launched in March 2005. The NSF aims to transform the way health and social care services support people to live with long-term neurological conditions. Key themes are independent living, care planned around the needs and choices of the individual, easier, timely access to services and joint working across all agencies and disciplines involved. The principles of the NSF are also relevant to service development for other long term conditions. This NSF is a key tool for delivering the government's strategy to support people with long term conditions outlined in the White Paper Our health, our care, our say and the NHS Improvement Plan: Putting People at the Heart of Public Services. It applies to health and social services working with local agencies involved in supporting people to live independently, such as providers of transport, housing, employment, education, benefits and pensions.&lt;/P&gt;
&lt;P&gt;There is much common ground between the Long Term Conditions strategy and the Long term (Neurological) Conditions NSF, for example, around person-centred care planning, information and support, self care and case management. The strategy will be able to use neurological examples and case studies to illustrate how case management and self care can work. In turn it will rely on the NSF and all other NSF teams (eg renal, diabetes) to lead delivery of disease-specific issues under the broader long term conditions work. However, it is important to ensure that NSF for Long term (Neurological) conditions maintains its neurological focus and a discrete identity under this broader umbrella.&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Text from Introduction to NSF for Long Term (Neurological Conditions)&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386638</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/adis/dsf/2010/00000033/00000001/art00008]]&gt;</url>
    <title>Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: A meta-analysis of cohort studies</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Drug Safety</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Banach R, Boskovic R, Einarson T, Koren G (2010) Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. &lt;EM&gt;Drug Safety&lt;/EM&gt; 33(1):73-79&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Results of studies investigating the long-term effects of intra-uterine exposure to antiepileptic drugs (AEDs) on cognitive functioning are limited and conflicting.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To estimate intellectual development of children prenatally exposed or unexposed to AEDs by assessing IQ scores in a systematic review and meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A literature search using Pubmed, EMBASE and Google Scholar from inception to 30 April 2009 was performed to identify all original cohort studies that investigated cognitive functioning after in utero exposure to AEDs. Studies had to include at least one group exposed to an AED and one unexposed group. Data from drug exposed and unexposed controls were combined using a random effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eleven studies met the inclusion criteria. Eight studies (three for valproic acid and five for carbamazepine) evaluated IQ as a measure of cognitive development. IQ was assessed by the Wechsler, Bayley or McCarthy intelligence scales, depending on age. One study investigated phenytoin and one study investigated phenobarbital (phenobarbitone). Because one study was reported in two different publications, seven studies were included in the meta-analysis. In total, the seven selected studies included 67 children exposed in utero to valproic acid and 151 exposed to carbamazepine, and 494 unexposed controls born to healthy women or to women with untreated epilepsy.&lt;/P&gt;
&lt;P&gt;The mean full-scale IQ (FSIQ), verbal IQ (VIQ) and performance IQ (PIQ) scores in children exposed to valproic acid in utero were 83.9 (95% CI 64.2, 103.6), 93.7 (95% CI 72.6, 114.7) and 88.3 (95% CI 69.9, 106.9), respectively. The mean FSIQ, VIQ and PIQ scores in the control group were 102 (95% CI 90, 116), 101 (95% CI 87, 114) and 99 (95% CI 90, 117), respectively. The mean FSIQ, VIQ and PIQ were all significantly lower in the valproic acid group compared with the unexposed group.&lt;/P&gt;
&lt;P&gt;The FSIQ and VIQ of children exposed to carbamazepine were not statistically different from those of the unexposed control group. In a sub-analysis of carbamazepine exposure in three studies using the Wechsler intelligence scale, PIQ was significantly lower in children exposed to carbamazepine than in unexposed children.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Although our analysis revealed no evidence that untreated maternal epilepsy was associated with a lower IQ in the child, there may have been confounding factors, such as milder epilepsy, in this group. Exposure to valproic acid in pregnancy is associated with significantly reduced intelligence in children whose mothers were treated for epilepsy. Exposure to carbamazepine in pregnancy does not appear to be associated with reduced FSIQ and VIQ in children, although PIQ was lower in the sub-analysis. Clinicians should inform families of the potential cognitive adverse effects of valproic acid. More studies are needed to corroborate these findings. &lt;/P&gt;
&lt;P&gt;Drug Safety&amp;nbsp;contains expert evaluations of drug treatment safety issues. It is the Official Journal of the International Society of Pharmacovigilance, and covers the&amp;nbsp;disciplines of pharmacovigilance, pharmacoepidemiology, benefit-risk assessment, risk management and medication error prevention.&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270578</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17124190]]&gt;</url>
    <title>Long-term outcomes in epilepsy surgery. Antiepileptic drugs, mortality, cognitive and psychological aspects</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,NEUROSURGERY,EPILEPSY AND SEIZURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Tellez-Zenteno J.F., Dhar R., Hernandez-Ronquillo L. 2006; Brain 130 (2) pp. 334-45&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;Assessment of long-term outcomes is essential in brain surgery for epilepsy. Little information exists on long-term non-seizure outcomes after epilepsy surgery. We perform a systematic review and meta-analysis of the evidence on this topic. Our aim was to provide evidence-based estimates of antiepileptic drug, psychosocial, neuropsychological and mortality long-term outcomes following epilepsy surgery, and to identify sources of variation in published results. We searched Medline, Index Medicus, the Cochrane database, bibliographies of reviews, original articles, and book chapters, to identify articles published from 1991 to 2005, containing &amp;gt; or =20 patients of any age, undergoing resective or non-resective epilepsy surgery, and followed for a mean/median of &amp;gt; or =5 years. Two reviewers independently assessed study eligibility and extracted data, resolving disagreements through discussion. Standard meta-analytical techniques were used to pool data. Of the 159 potentially eligible articles reviewed in full-text, 35 (22%) fulfilled eligibility criteria; 6 (17%) were controlled studies; 15 (36%) explored antiepileptic drug outcome; 6 (17%) explored mortality; 11 (31%) reported psychosocial outcomes; and 7 (20%) explored neuropsychological outcomes. On an average, 14% [95% confidence interval (CI(95)) = 11-17] of the patients with temporal lobe surgery achieved long-term antiepileptic drug (AED) discontinuation, 50% (CI(95) = 45-55) achieved monotherapy, and 33% remained on polytherapy (CI(95 =) 29-38). In analyses including all types of surgery, on average, 20% (CI(95) = 18-23) achieved long-term AED discontinuation, while 41% (CI(95) = 37-45) were on monotherapy and 31% (CI(95) = 27-35) remained on polytherapy. Children achieved better AED outcomes than adults. Seizure freedom after surgery was associated with lower mortality, but inconsistent mortality outcomes precluded making strong inferences. Non-controlled studies consistently reported improved long-term psychosocial outcomes, but the effect was less clear in controlled studies. Intelligence was unchanged by surgery, but long-term memory outcomes were associated with seizure freedom and side of temporal lobe resection. Few long-term, controlled studies exist. Longer follow-up was associated with lower rates of AED discontinuation, reflecting lower seizure-free rates over time. Cognitive and psychosocial outcomes were similar to those of short-term studies, and the results were influenced by the presence of controls.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386652</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2008.01997.x/abstract;jsessionid=678E468C4C95810CAB23FCBE9156343A.d03t02?]]&gt;</url>
    <title>Long-term seizure outcome of surgery versus no surgery for drug-resistant partial epilepsy: a review of controlled studies</title>
    <publicationDate>2009-02-23T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,NEUROSURGERY,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Schmidt D, Stavem K. (2009) Long-term seizure outcome of surgery versus no surgery for drug-resistant partial epilepsy: a review of controlled studies. &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(6):1301-1309&lt;/P&gt;
&lt;P&gt;A majority of patients with formerly drug-resistant temporal lobe epilepsy become seizure-free after surgery. However, apart from one 12-month randomized trial, it is unclear how many become seizure-free because of surgery. To determine the net benefit of surgery, we performed a systematic review and meta-analysis of the published evidence of how many patients in similar studies become seizure-free without surgery. Of 155 potentially eligible articles reviewed in full text, 29 (19%) fulfilled eligibility criteria. After excluding 9 publications, 20 studies form the base of evidence. Overall, 719 of 1,621 (44%) of patients with mostly temporal lobe surgery were seizure-free compared to 139 of 1113 (12%) of nonoperated controls [pooled random effects relative risk (RR) 4.26, 95% confidence interval (CI) 3.03–5.98]. The pooled risk difference in favor of surgery was 42% (95% CI 32–51%). We found no comparative outcome data in patients with extratemporal lobe epilepsy only. The available evidence from mostly nonrandomized observational studies indicates that in appropriately selected patients with drug-resistant temporal lobe epilepsy, the combination of surgery with medical treatment is 4 times as likely as medical treatment alone to achieve freedom from seizures.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270580</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15758038]]&gt;</url>
    <title>Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,EPILEPSY AND SEIZURES,NEUROSURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Tellez-Zenteno J.F., Dhar R., Wiebe S. 2005; Brain: a journal of Neurology 128 (5) pp. 1188-98&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;Assessment of long-term outcomes is essential in brain surgery for epilepsy, which is an irreversible intervention for a chronic condition. Excellent short-term results of resective epilepsy surgery have been established, but less is known about long-term outcomes. We performed a systematic review and meta-analysis of the evidence on this topic. To provide evidence-based estimates of long-term results of various types of epilepsy surgery and to identify sources of variation in results of published studies, we searched Medline, Index Medicus, the Cochrane database, bibliographies of reviews, original articles and book chapters to identify articles published since 1991 that contained &amp;gt; or =20 patients of any age, undergoing resective or non-resective epilepsy surgery, and followed for a mean/median of &amp;gt; or =5 years. Two reviewers independently assessed study eligibility and extracted data, resolving disagreements through discussion. Seventy-six articles fulfilled our eligibility criteria, of which 71 reported on resective surgery (93%) and five (7%) on non-resective surgery. There were no randomized trials and only six studies had a control group. Some articles contributed more than one study, yielding 83 studies of which 78 dealt with resective surgery and five with non-resective surgery. Forty studies (51%) of resective surgery referred to temporal lobe surgery, 25 (32%) to grouped temporal and extratemporal surgery, seven (9%) to frontal surgery, two (3%) to grouped extratemporal surgery, two (3%) to hemispherectomy, and one (1%) each to parietal and occipital surgery. In the non-resective category, three studies reported outcomes after callosotomy and two after multiple subpial transections. The median proportion of long-term seizure-free patients was 66% with temporal lobe resections, 46% with occipital and parietal resections, and 27% with frontal lobe resections. In the long term, only 35% of patients with callosotomy were free of most disabling seizures, and 16% with multiple subpial transections remained free of all seizures. The year of operation, duration of follow-up and outcome classification system were most strongly associated with outcomes. Almost all long-term outcome studies describe patient cohorts without controls. Although there is substantial variation in outcome definition and methodology among the studies, consistent patterns of results emerge for various surgical interventions after adjusting for sources of heterogeneity. The long-term (&amp;gt; or =5 years) seizure free rate following temporal lobe resective surgery was similar to that reported in short-term controlled studies. On the other hand, long-term seizure freedom was consistently lower after extratemporal surgery and palliative procedures.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344312</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19334061]]&gt;</url>
    <title>Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MAGNETIC RESONANCE IMAGING (MRI),INVESTIGATION &amp; DIAGNOSTICS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.&lt;EM&gt; Annals of Neurology&lt;/EM&gt; 2009 Mar;65(3):268-75.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We used a pooled analysis of all the published randomized, placebo-controlled clinical trials in relapsing-remitting multiple sclerosis reporting data both on&amp;nbsp;magnetic resonance imaging (MRI)&amp;nbsp;variables and relapses. We extracted data on relapses and on MRI "active" lesions. A regression analysis weighted on trial size and duration was performed to study the relation between the treatment effect on relapses and the treatment effect on MRI lesions. We validated the estimated relation on an independent set of clinical trials satisfying the same inclusion criteria but with a control arm other than placebo. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A set of 23 randomized, double-blind, placebo-controlled trials in relapsing-remitting multiple sclerosis was identified, for a total of 63 arms, 40 contrasts, and 6,591 patients. A strong correlation was found between the effect on the relapses and the effect on MRI activity. The adjusted &lt;I&gt;R&lt;/I&gt;&lt;SUP&gt;2&lt;/SUP&gt; value of the weighted regression line was 0.81. The regression equation estimated using the placebo-controlled trials gave a satisfactory prediction of the treatment effect on relapses when applied to the validation set.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; More than 80% of the variance in the effect on relapses between trials is explained by the variance in MRI effects. Smaller and shorter phase II studies based on MRI lesion end points may give indications also on the effect of the treatment on relapse end points. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in March 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396725</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.worldscinet.com/ajcm/38/3804/S0192415X10008111.html]]&gt;</url>
    <title>Manage migraine with acupuncture: a review of acupuncture protocols in randomized controlled trials</title>
    <publicationDate>2010-03-01T00:00:00</publicationDate>
    <publisher>American Journal of Chinese Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Zheng H, Chen M, Wu X, Li Y, Liang FR. (2010) Manage migraine with acupuncture: a review of acupuncture protocols in randomized controlled trials. &lt;EM&gt;American Journal of Chinese Medicine&lt;/EM&gt;. 2010;38(4):639-50&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; The aim of this article is to present a standardized protocol of acupuncture for the management of migraine. A systematic review of available randomized controlled trials of acupuncture for migraineurs was conducted in the five following electronic databases: Cochrane Central Register of Controlled trials, MEDLINE, EMBASE, PsycINFO and CINAHL. Information of selected acupoints and treatment course was extracted from the included trials. Then we analyzed the treatment methods used in these trials, to identify any similarities of therapeutic approaches. Additionally, quality of all the included trials was assessed. At last, the extracted information of acupuncture protocols was analyzed, and the similarities of therapeutic approaches were summed up. Bilateral use of the following points is recommended: Fengchi (GB20), Taiyang (EX-HN5), etc. De-qi sensation is requested in acupuncture manipulating procedure, and manual stimulation is suggested. The optimal treatment frequency is twice a week with one week rest between the first 10 and the last 10 sessions. Additionally, the duration of one treatment session ought to be 30 minutes, while it is recommended to use about 20 needles in one session. The total duration of an acupuncture treatment should be at least 10 weeks. The protocol analyzed from trials with positive results is different from trials with negative in number of treatment sessions. Therefore in future trials, enough acupuncture treatment sessions should be fully considered.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320733</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/dtb.2009.05.0020]]&gt;</url>
    <title>Management of benign paroxysmal positional vertigo</title>
    <publicationDate>2009-06-05T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROMUSCULAR,NEUROLOGICAL CONDITIONS,PERIPHERAL NERVE DISORDERS,CRANIAL NEUROPATHIES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>In vertigo, people experience an illusion of movement of the environment about them, or of themselves with respect to the environment. Vertigo usually originates in the peripheral nervous system (e.g. due to a disorder of the inner ear) but can, rarely, have a CNS origin (e.g. an intracranial tumour or brainstem lesion). It is commonly
due to a peripheral disorder known as ‘benign paroxysmal positional vertigo’ (BPPV). This review discusses BPPV and the management of patients with the condition, including diagnostic and therapeutic manoeuvres.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Management of benign paroxysmal positional vertigo. &lt;EM&gt;Drug Ther Bull.&lt;/EM&gt; 2009 un;47(6):62-6.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;A patient with BPPV should be reassured of the benign nature of the condition and its underlying mechanism. For posterior canal BPPV, the patient should be offered the Epley manoeuvre, which aims to help clear the canal of debris responsible for the symptoms. There is some evidence to suggest that Brandt-Daroff home exercises might be worth trying. The so-called barbecue manoeuvre is a reasonable treatment option for horizontal canal BPPV, while people with anterior canal BPPV can also be treated with particle-repositioning procedures; however, there are fewer data on the effectiveness of these procedures. The place of vestibular rehabilitation is unclear. There is no convincing evidence to support the use of any medication for BPPV. Surgery carries a risk of hearing loss and is rarely used, but may occasionally be suitable for patients with severe refractory symptoms.&lt;/P&gt;
&lt;P&gt;Patients should be referred to an appropriate specialist if they have associated symptoms not accounted for by BPPV; atypical nystagmus with the possibility of a CNS lesion; or persistent vertigo after therapeutic manoeuvres have been tried.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;About the Drug and Therapeutics Bulletin:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Published monthly by the BMJ Group, the Drug and Therapeutics Bulletin (DTB)'s main aims are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;to provide informed and unbiased assessments of drugs and other treatments (focusing on efficacy, safety, convenience and cost in particular in relation to other available treatments); 
&lt;LI&gt;to comment on how those drugs or other treatments should be used; 
&lt;LI&gt;to assess their place in overall management, and; 
&lt;LI&gt;to review evidence and give practical advice on the overall management of disease. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;DTB's related aims are to comment on how treatments are marketed and promoted, on the quality of the information available to prescribers and patients, and on the indication(s) for which the treatment has been licensed.&lt;/P&gt;
&lt;P&gt;Articles in DTB are produced after wide consultation. The editing process puts most store on data from scientifically valid clinical trials; the opinions of commentators are also taken into account.&lt;/P&gt;
&lt;P&gt;The conclusions reflect interpretation by a team of editors and aim to provide the best available advice on treatment; they represent a weighted assessment of the evidence but not necessarily a consensus. DTB assesses published research and uses this material to reach its conclusions. This allows the reader to verify the data if they so wish.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff via an NHS Athens password.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324797</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/dtb.2009.07.0028]]&gt;</url>
    <title>Management of carpal tunnel syndrome</title>
    <publicationDate>2009-08-05T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROMUSCULAR,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,SEPTEMBER 2009,CARPAL TUNNEL SYNDROME AND MONONEUROPATHIES,PERIPHERAL NERVE DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Estimates suggest that around 1 in 10 people develop carpal tunnel syndrome at some point. The condition comprises potentially disabling sensory and/or motor symptoms in the hand, caused by compression of the median nerve, and carries considerable implications for employment and healthcare costs. Current standard treatment options are splinting, local corticosteroid injections and surgery, and there are a range of other suggested treatments. Here we review how best to manage patients with carpal tunnel syndrome.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Management of carpal tunnel syndrome. &lt;EM&gt;Drug and Therapeutics Bulletin&lt;/EM&gt; 47:86-89&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Carpal tunnel syndrome results from compression of the median nerve in the wrist and has a prevalence of around 2%. About 30% of patients have transient symptoms that&lt;BR&gt;recover completely after a few weeks or months without treatment, while some patients have progressive and eventually permanent median nerve deficit. The diagnosis can usually be made clinically, but should be confirmed with nerve conduction tests if diagnosis is in doubt or surgery is being considered. In mild cases, initial treatment should include the use of wrist splints. If this fails, then a local corticosteroid injection is appropriate, but it is not clear what the best regimen is to use. Patients with severe or persistent impairment, or symptoms that do not respond to splinting or an injection, should be referred for consideration of decompression surgery. There is no evidence that endoscopic surgery is more effective than standard open operation; however, it may permit earlier return to work, and may be aassociated with fewer complications.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;About the Drug and Therapeutics Bulletin:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Published monthly by the BMJ Group, the Drug and Therapeutics Bulletin (DTB)'s main aims are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;to provide informed and unbiased assessments of drugs and other treatments (focusing on efficacy, safety, convenience and cost in particular in relation to other available treatments); 
&lt;LI&gt;to comment on how those drugs or other treatments should be used; 
&lt;LI&gt;to assess their place in overall management, and; 
&lt;LI&gt;to review evidence and give practical advice on the overall management of disease. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;DTB's related aims are to comment on how treatments are marketed and promoted, on the quality of the information available to prescribers and patients, and on the indication(s) for which the treatment has been licensed.&lt;/P&gt;
&lt;P&gt;Articles in DTB are produced after wide consultation. The editing process puts most store on data from scientifically valid clinical trials; the opinions of commentators are also taken into account.&lt;/P&gt;
&lt;P&gt;The conclusions reflect interpretation by a team of editors and aim to provide the best available advice on treatment; they represent a weighted assessment of the evidence but not necessarily a consensus. DTB assesses published research and uses this material to reach its conclusions. This allows the reader to verify the data if they so wish.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384062</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1177/0883073809332768]]&gt;</url>
    <title>Management of prolonged seizures and status epilepticus in childhood: a systematic review</title>
    <publicationDate>2009-03-30T00:00:00</publicationDate>
    <publisher>Journal of Child Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,STATUS EPILEPTICUS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Sofou K, Kristjansdottir R, Papachatzakis NE, Ahmadzadeh A, Uvebrant P. (2010) Management of prolonged seizures and status epilepticus in childhood: a systematic review. &lt;EM&gt;Journal of Child Neurology &lt;/EM&gt;24(8):918-26&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Pediatric prolonged seizures and status epilepticus are medical emergencies necessitating immediate life-support and seizure-control measures. A systematic review of published data on the management of prolonged seizures and status epilepticus showed that buccal midazolam was significantly more effective than rectal diazepam, reaching a seizure-control rate of 70% and recurrence rate of 8%. Intranasal lorazepam was as effective as intramuscular paraldehyde in a cost-restrained setting. In refractory status epilepticus, both intravenous midazolam and valproate were equally effective to intravenous diazepam, with valproate exhibiting significantly faster seizure cessation and safer profile than diazepam, even in infancy. In conclusion, buccal midazolam is efficacious and safe thanks to its convenient route of administration, which may serve as first-line in the treatment of prolonged seizures. Intranasal lorazepam is an effective, easy-to-use, and safe drug for prolonged seizures. Intravenous valproate exhibits favorable efficacy and safety profile as third-line in status epilepticus, refractory to diazepam and phenytoin.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Journal of Child Neurology (JCN) is a monthly publication, which publishes&amp;nbsp;interdisciplinary and peer-reviewed clinical and investigative studies from a wide-variety of neuroscience disciplines. Articles in JCN cover topics ranging from assessment of new and changing therapies and procedures; diagnosis, evaluation, and management of neurologic, neuropsychiatric, and neurodevelopmental disorders; pathophysiology of central nervous system diseases; and neuroradiologic and imaging evaluations. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344434</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18694542]]&gt;</url>
    <title>Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Moses H, Jr., Brandes DW. Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. &lt;EM&gt;Current Medical Research &amp;amp; Opinion&lt;/EM&gt; 2008 Sep;24(9):2679-90.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; MEDLINE and EMBASE were searched for clinical trials and other publications between 1985 and 2007 reporting&amp;nbsp;adverse events (AEs)&amp;nbsp;associated with&amp;nbsp;multiple&amp;nbsp;sclerosis (MS)&amp;nbsp;therapies, using these search terms: multiple sclerosis, interferon, Avonex, Betaseron, Rebif, glatiramer, copolymer 1, Copaxone, mitoxantrone, natalizumab, adverse events.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A class-specific flu-like syndrome associated with IFNbeta can be managed through initial dose escalation and administration of analgesics and antipyretics, prophylactically or symptomatically. Injection-site reactions can occur in patients receiving injectable therapies, particularly SC IFNbeta or glatiramer acetate. The greatest risk to patients receiving mitoxantrone is cardiotoxicity; thus, the cumulative dose is limited. Allergic reactions occur rarely with natalizumab, and there is a potential risk of progressive multifocal leukoencephalopathy. AEs associated with short-term pulse corticosteroid therapy are usually transient and largely resolve after treatment is completed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; To improve adherence to therapy, it is important to educate patients regarding AEs and to manage AEs proactively.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in September 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396603</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.cpjournal.ca/doi/abs/10.3821/1913-701X-142.4.190]]&gt;</url>
    <title>Managing migraines: Options for acute abortive treatment</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Canadian Pharmacists Journal</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Namaka M, Leong C, Grossberndt A, Klowak Meghann, Louizos C, Drummond J, Leligdowicz E, Lichkowski M, Melanson M. (2009) Managing migraines: Options for acute abortive treatment. &lt;EM&gt;Canadian Pharmacists Journal&lt;/EM&gt;&amp;nbsp;142(4): 190-198.e1. &lt;/P&gt;
&lt;P&gt;Professor Peter Goadsby has critically appraised this paper and you can read his analysis &lt;A href="nelh:396692:0" name=internalLink&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Introduction:&lt;/STRONG&gt; Triptans, ergotamine derivatives and nonsteroidal anti-inflammatory drugs are front-line agents used in the acute abortive therapy of migraines. In this article, these medications are reviewed and a treatment algorithm suggested.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A comprehensive review of the literature from 1990 to 2008 was conducted using PubMed, MEDLINE and The Cochrane Library to explore the underlying pathophysiology of migraines and comparatively assess the acute and chronic treatment options available in their management. The information obtained from all literature searches was further categorized as level 1, 2 or 3 based on pre-defined peer-reviewed criteria.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; This review is able to present a relatively preliminary but practical migraine treatment algorithm. Although there is no standard universal treatment strategy to manage migraine headaches in all patients, this review has been put forth to serve as a clinical guideline to assist health professionals in deciding the most appropriate treatment for migraine headaches.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293377</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17883520?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability</title>
    <publicationDate>2007-09-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Pascual J et al Headache 2007 Sep;47(8):1152-68&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: In the current literature, there is neither a reported systematic review comparing the efficacy of triptans at 30 minutes and 1 hour after the migraine treatment, nor data related to efficacy of new marketed triptans. OBJECTIVE: The main objective of this analysis was to compare the efficacy and tolerability of currently marketed oral, non-reencapsulated triptan formulations vs placebo in the treatment of moderate-to-severe migraine attacks. METHODS: A systematic review of double-blind, randomized clinical trials reporting data after a single migraine attack was conducted. Efficacy results are shown using relative risk ratios with 95% confidence intervals. A sensitivity analysis was also conducted. RESULTS: After reviewing 221 publications, 38 studies were included. All marketed triptans provided significant relief and/or absence of pain at 2 hours, and relief at 1 hour when compared with placebo. After 30 minutes, fast-dissolving sumatriptan 50 and 100 mg, sumatriptan 50 mg, and rizatriptan 10 mg showed significant relief when compared to placebo, whereas the fast-dissolving formulation of sumatriptan 100 mg was the only oral triptan that was superior to placebo in meeting the pain-free endpoint. On the other hand, fast-dissolving sumatriptan 50 and 100 mg and eletriptan 40 mg showed a lower rate of recurrence than placebo, whereas rizatriptan 10 mg was the only triptan with a recurrence rate greater than that of placebo. Adverse events associated with treatment with tablet formulations of sumatriptan and zolmitriptan were significantly more frequent than those of the placebo group. The inclusion of trials with reencapsulated triptans in the analysis introduced minor specific changes in these results. CONCLUSION: This analysis updates the comparative data available for the 7 currently marketed oral triptans and clearly demonstrates their efficacy when compared to placebo, even with stricter endpoints, such as efficacy at 30 minutes. No triptan exhibited better tolerability than placebo. Results are diverse, depending on the triptan, which probably is a reflection of heterogeneous pharmacokinetics.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324882</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1161/STROKEAHA.109.556068]]&gt;</url>
    <title>Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis. Results of a systematic review and analysis</title>
    <publicationDate>2009-08-20T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,CONDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Abbott, AL (2009). Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis. Results of a systematic review and analysis. &lt;EM&gt;Stroke&lt;/EM&gt; 20 Aug 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A Medline literature search was performed for prospective studies of direct imaging identified nonoperated, angioplasty/stenting-free, asymptomatic severe (nonsubcategorized 50% to 75%+) proximal ICA stenosis with sufficient original data to calculate an average annual patient rate of stroke (fatal/nonfatal, infarct/hemorrhage). When more than one publication was identified referring to the same data, the first publication was selected. Data clarification was sought from authors if necessary.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In this systematic review and analysis of published data it was found that rates of ipsilateral and any-territory stroke (+/-TIA), with medical intervention alone, have fallen significantly since the mid-1980s, with recent estimates overlapping those of operated patients in randomized trials. However, current medical intervention alone was estimated at least 3 to 8 times more cost-effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis. Results of a systematic review and analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 20 August 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text of the last 12 months is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320728</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/dtb.2009.06.0024]]&gt;</url>
    <title>Melatonin for primary insomnia?</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,INSOMNIA,SLEEP DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Melatonin, a hormone produced by the pineal gland, has a key role in regulating circadian rhythms, most importantly, the sleep-wake cycle. Melatonin’s action has led to its being tried as a treatment for a wide range of sleep disorders. Until recently, it had not been licensed in the UK for any indication. Prolonged-release melatonin (Circadin – Lundbeck) has now been licensed as a treatment for primary insomnia. This review considers whether this product has a place in the management of people with this condition.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Melatonin for primary insomnia? &lt;EM&gt;Drug Ther Bull&lt;/EM&gt;. 2009 Jul;47(7):74-7.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Prolonged-release melatonin (?Circadin) is licensed as shortterm (3 weeks) treatment for primary insomnia in patients aged 55 years and over. In contrast to other hypnotic drugs, there appears to be no evidence of dependence, withdrawal effects or rebound insomnia associated with its use. However, while published trials suggest some benefit with Circadin compared with placebo for people with primary insomnia, the limited evidence on efficacy does not provide a convincing basis for recommending its use. Furthermore, Circadin has not been directly compared with other non-drug or drug treatments in published trials.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;About the Drug and Therapeutics Bulletin:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Published monthly by the BMJ Group, the Drug and Therapeutics Bulletin (DTB)'s main aims are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;to provide informed and unbiased assessments of drugs and other treatments (focusing on efficacy, safety, convenience and cost in particular in relation to other available treatments); 
&lt;LI&gt;to comment on how those drugs or other treatments should be used; 
&lt;LI&gt;to assess their place in overall management, and; 
&lt;LI&gt;to review evidence and give practical advice on the overall management of disease. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;DTB's related aims are to comment on how treatments are marketed and promoted, on the quality of the information available to prescribers and patients, and on the indication(s) for which the treatment has been licensed.&lt;/P&gt;
&lt;P&gt;Articles in DTB are produced after wide consultation. The editing process puts most store on data from scientifically valid clinical trials; the opinions of commentators are also taken into account.&lt;/P&gt;
&lt;P&gt;The conclusions reflect interpretation by a team of editors and aim to provide the best available advice on treatment; they represent a weighted assessment of the evidence but not necessarily a consensus. DTB assesses published research and uses this material to reach its conclusions. This allows the reader to verify the data if they so wish.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395102</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/content/15/6/168.short?rss=1]]&gt;</url>
    <title>Meta analysis suggests that folic acid supplementation does not reduce risk of stroke, but there may be some benefit when given in combination with vitamins B6 and B12 and in primary prevention</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Saposnik G. (2010) Meta analysis suggests that folic acid supplementation does not reduce risk of stroke, but there may be some benefit when given in combination with vitamins B6 and B12 and in primary prevention. &lt;EM&gt;Evidence Based Medicine&lt;/EM&gt; 15(6):168-170&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Hyperhomocysteinemia has been associated with premature atherosclerosis with an increased risk of cardiovascular events. Folate and cyanocobalamin (vitamin B12) are important regulators of the metabolism of homocysteine, and studies have shown an inverse relationship between levels of these factors and levels of homocysteine in the blood. On the basis of epidemiological studies, clinicians and scientists expected that homocysteine-lowering therapy (HLT) would reduce the incident risk of cardiovascular diseases (including stroke).&lt;/P&gt;
&lt;P&gt;Evidence-Based Medicine surveys a wide range of international medical journals applying strict criteria for the quality and validity of research. Practising clinicians assess the clinical relevance of the best studies. The key details of these essential studies are included in a succinct, informative expert commentary on their clinical application. Published bi-monthly, Evidence-Based Medicine offers comprehensive coverage of primary care medicine. It includes a wide array of clinical disciplines, including family practice, internal medicine, paediatrics, obstetrics, gynaecology, psychiatry, and surgery.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288438</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17257464?ordinalpos=7&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>LibraPharm</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Iskedjian, M et al &lt;SPAN title="Current medical research and opinion."&gt;&lt;A href="#javascript:AL_get(this," Opin.?);? Res Med ?Curr ?jour?,&gt;Curr Med Res Opin.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jan;23(1):17-24&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: Debilitating pain, occurring in 50-70% of multiple sclerosis (MS) patients, is poorly understood and infrequently studied. We summarized efficacy and safety data of cannabinoid-based drugs for neuropathic pain. DATA SOURCES: Studies were identified from Medline, Embase, and Cochrane databases; Bayer Healthcare provided additional trials. STUDY SELECTION: Accepted were randomized, double-blinded placebo-controlled trials of cannabinoid-based treatments for MS-related/neuropathic pain in adults &amp;gt; or = 18 years of age. DATA EXTRACTION: Two reviewers identified studies and extracted data; a third adjudicated disagreements. Data included baseline and endpoint pain scores on visual analog or 11-point ordinal scales. DATA SYNTHESIS: Of 18 articles and three randomized controlled trial (RCT) reports identified, 12 articles and two reports were rejected (9 = inappropriate disease or outcome, 1 = duplicate, 1 = review, and 1 = abstract); six accepted articles and one RCT-report involved 298 patients (222 treated, 76 placebo); four examined Sativex (a cannabidiol/delta-9-tetrahydrocannabinol (THC) buccal spray) (observations = 196), five cannabidiol (n = 41), and three dronabinol (n = 91). Homogeneity chi(2) values were non-significant, allowing data combination. Analyses focused on baseline-endpoint score differences. The cannabidiol/THC buccal spray decreased pain 1.7 +/- 0.7 points (p = 0.018), cannabidiol 1.5 +/- 0.7 (p = 0.044), dronabinol 1.5 +/- 0.6 (p = 0.013), and all cannabinoids pooled together 1.6 +/- 0.4 (p &amp;lt; 0.001). Placebo baseline-endpoint scores did not differ (0.8 +/- 0.4 points, p = 0.023). At endpoint, cannabinoids were superior to placebo by 0.8 +/- 0.3 points (p = 0.029). Dizziness was the most commonly observed adverse event in the cannabidiol/THC buccal spray arms (39 +/- 16%), across all cannabinoid treatments (32.5 +/- 16%) as well as in the placebo arms (10 +/- 4%). CONCLUSION: Cannabinoids including the cannabidiol/THC buccal spray are effective in treating neuropathic pain in MS. LIMITATIONS: This review was based on a small number of trials and patients. Pain related to MS was assumed to be similar to neuropathic pain.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Full text available to NHS users via NHS Athens password&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344144</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757648/]]&gt;</url>
    <title>Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci</title>
    <publicationDate>2009-07-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. &lt;EM&gt;Nature Genetics&lt;/EM&gt; 2009 Jul;41(7):776-82.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We report the results of a meta-analysis of genome-wide association scans for multiple sclerosis (MS) susceptibility that includes 2,624 subjects with MS and 7,220 control subjects. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Replication in an independent set of 2,215 subjects with MS and 2,116 control subjects validates new MS susceptibility loci at TNFRSF1A (combined P = 1.59 x 10(-11)), IRF8 (P = 3.73 x 10(-9)) and CD6 (P = 3.79 x 10(-9)). TNFRSF1A harbors two independent susceptibility alleles: rs1800693 is a common variant with modest effect (odds ratio = 1.2), whereas rs4149584 is a nonsynonymous coding polymorphism of low frequency but with stronger effect (allele frequency = 0.02; odds ratio = 1.6). We also report that the susceptibility allele near IRF8, which encodes a transcription factor known to function in type I interferon signaling, is associated with higher mRNA expression of interferon-response pathway genes in subjects with MS.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in July 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text freely available via PubMed Central.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395099</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/content/15/6/193.short?rss=1]]&gt;</url>
    <title>Meta-analysis of results from case control and cohort studies finds that migraine is associated with approximately twice the risk of ischaemic stroke</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,ISCHAEMIC STROKE,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Cole JW, Kittner SJ. (2010)&lt;STRONG&gt; &lt;/STRONG&gt;Meta-analysis of results from case control and cohort studies finds that migraine is associated with approximately twice the risk of ischaemic stroke. &lt;EM&gt;Evidence Based Medicine&lt;/EM&gt; 15(6):193-194 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Context:&lt;/STRONG&gt; Several studies have linked ischaemic stroke with migraine headache. To better define this relationship, investigators performed a meta-analysis to quantitatively summarise the strength of association between migraine and ischaemic stroke risk. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic search identified relevant published reports regarding ischaemic stroke risk as associated with migraine. Prespecified criteria: (1) included studies with case-control or cohort study designs with reported or extractable adjusted quantitative estimates of the risk of ischaemic stroke in migraineurs compared with non-migraineurs and (2) excluded studies of transient stroke-like syndromes, migrainous infarction, silent infarction and those that reported outcomes as associated with mixed stroke types (eg, haemorrhagic and ischaemic stroke). Of note, all but two studies from the most recent prior meta-analysis1 and nine additional studies were included in the present study. Included studies were required to implement standard definitions, or reasonable variations thereof, for both stroke and migraine. &lt;/P&gt;
&lt;P&gt;Evidence-Based Medicine surveys a wide range of international medical journals applying strict criteria for the quality and validity of research. Practising clinicians assess the clinical relevance of the best studies. The key details of these essential studies are included in a succinct, informative expert commentary on their clinical application. Published bi-monthly, Evidence-Based Medicine offers comprehensive coverage of primary care medicine. It includes a wide array of clinical disciplines, including family practice, internal medicine, paediatrics, obstetrics, gynaecology, psychiatry, and surgery.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386656</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2009.02401.x/abstract]]&gt;</url>
    <title>Meta-analysis of the association between cysticercosis and epilepsy in Africa</title>
    <publicationDate>2009-11-16T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Quet F, Guerchet M, Pion SDS, Ngoungou EB, Nicoletti A, Preux P-M. (2009) Meta-analysis of the association between cysticercosis and epilepsy in Africa. &lt;EM&gt;Epilepsia&lt;/EM&gt; 51(5):830-837&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Purpose:&lt;/STRONG&gt; The association between cysticercosis and epilepsy has been widely studied in Latin America and Asia and has proven to be one of the main causes of epilepsy. Despite high prevalences of both diseases in Africa, their association remains unclear. In this article we quantified the strength of the association between epilepsy and cysticercosis in Africa and we proposed some guidelines for future studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed a systematic review of literature on cysticercosis (considered as exposure) and epilepsy (considered as the disease) and collected data from both cross-sectional and case–control studies. A common odds ratio was estimated using a random-effects meta-analysis model of aggregate published data.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Among 21 retrieved documents, 11 studies located in 8 African countries were included in the meta-analysis. Odds ratio of developing epilepsy when presenting cysticercosis (defined as Taenia solium seropositivity) ranged from 1.3–6.1. Overall, association between cysticercosis and epilepsy was found significant with a common odds ratio of 3.4 [95% confidence interval (CI) 2.7–4.3; p &amp;lt; 0.001].&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Discussion:&lt;/STRONG&gt; The variability of the association found between the studies could be due to differences in study design or in pathogenesis of cysticercosis. Further studies should overcome identified problems by following some guidelines to improve epidemiologic and clinical assessment of the association. Better understanding of the relation between cysticercosis and epilepsy is a key issue in improving prevention of epilepsy in Africa.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396609</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20236345]]&gt;</url>
    <title>Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine</title>
    <publicationDate>2010-03-05T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. (2010) Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. &lt;EM&gt;Headache&lt;/EM&gt;. 50(5):808-18&lt;/P&gt;
&lt;P&gt;Professor Peter Goadsby has critically appraised this paper and you can read his analysis &lt;A href="nelh:396693:0" name=internalLink&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract&lt;BR&gt;&lt;/STRONG&gt;&lt;BR&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To assess the efficacy and safety of naproxen sodium in the treatment of acute migraine attacks.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Non-steroidal anti-inflammatory drugs including naproxen sodium have been used in treating migraine attack. A number of clinical trials of naproxen sodium in migraine have been reported. However, it remains to be established whether naproxen sodium unequivocally offers clinical benefits taken into account the desired outcomes in acute migraine therapy as recommended by the International Headache Society.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Clinical trials were identified through electronic searches (MEDLINE, EMBASE, EBM review, and the Cochrane Library) up to June 2009 and historical searches of relevant articles. Studies were included in the meta-analysis if they were (1) double-blind, randomized, placebo-controlled trials that evaluated naproxen sodium tablet in moderate or severe migraine attacks in adult patients, and (2) reporting the efficacy in terms of headache relief, pain-free, relief of migraine-associated symptoms, sustained headache relief, sustained pain-free, or headache recurrence. Data extraction and study quality assessment were performed independently by 2 investigators. Disagreements were resolved by a third investigator. Treatment effects and adverse effects were expressed as risk ratio. A random effects model was used when significant heterogeneity existed, otherwise the fixed effects model was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt;&amp;nbsp;We identified 16 published randomized controlled trials of naproxen in the treatment of migraine. Four trials met the inclusion criteria and were included in the meta-analysis. Naproxen sodium was more effective than placebo in reducing pain intensity and providing pain-free within 2 hours in adults with moderate or severe migraine attacks. The pooled risk ratios were 1.58 (95% confidence interval [CI] 1.41-1.77, P &amp;lt; .00001), and 2.22 (95% CI 1.46-3.37, P = .0002), respectively, for headache relief at 2 hours and pain-free at 2 hours. It was also effective in achieving headache relief at 4 hours, relief of migraine-associated symptoms, sustained headache relief, and sustained pain-free responses. There was no significant difference in headache recurrence rate between naproxen sodium and placebo. The risk of any adverse event was greater with naproxen sodium than with placebo (pooled risk ratio 1.29, 95% CI 1.04-1.60, P = .02). The adverse events commonly associated with naproxen sodium were nausea, dizziness, dyspepsia, and abdominal pain.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; The available evidence suggests that naproxen sodium is more effective but may cause more adverse events than placebo in the acute treatment of moderate to severe migraine. It is effective in reducing headache intensity, rendering pain-free at 2 hours and improving migraine-associated symptoms. However, its effectiveness relative to other active comparators needs to be better defined by appropriate head-to-head clinical trials.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328305</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/339/oct27_1/b3914]]&gt;</url>
    <title>Migraine and cardiovascular disease: systematic review and meta-analysis</title>
    <publicationDate>2009-10-27T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,CONDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. &lt;EM&gt;BMJ&lt;/EM&gt; 2009;339:b3914 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate the association between migraine and cardiovascular disease, including stroke, myocardial infarction, and death due to cardiovascular disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Data sources: Electronic databases (PubMed, Embase, Cochrane Library) and reference lists of included studies and reviews published until January 2009. &lt;/P&gt;
&lt;P&gt;Selection criteria: Case-control and cohort studies investigating the association between any migraine or specific migraine subtypes and cardiovascular disease. &lt;/P&gt;
&lt;P&gt;Review methods: Two investigators independently assessed eligibility of identified studies in a two step approach. Disagreements were resolved by consensus. Studies were grouped according to a priori categories on migraine and cardiovascular disease. &lt;/P&gt;
&lt;P&gt;Data extraction: Two investigators extracted data. Pooled relative risks and 95% confidence intervals were calculated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Studies were heterogeneous for participant characteristics and definition of cardiovascular disease. Nine studies investigated the association between any migraine and ischaemic stroke (pooled relative risk 1.73, 95% confidence interval 1.31 to 2.29). Additional analyses indicated a significantly higher risk among people who had migraine with aura (2.16, 1.53 to 3.03) compared with people who had migraine without aura (1.23, 0.90 to 1.69; meta-regression for aura status P=0.02). Furthermore, results suggested a greater risk among women (2.08, 1.13 to 3.84) compared with men (1.37, 0.89 to 2.11). Age less than 45 years, smoking, and oral contraceptive use further increased the risk. Eight studies investigated the association between migraine and myocardial infarction (1.12, 0.95 to 1.32) and five between migraine and death due to cardiovascular disease (1.03, 0.79 to 1.34). Only one study investigated the association between women who had migraine with aura and myocardial infarction and death due to cardiovascular disease, showing a twofold increased risk. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Migraine is associated with a twofold increased risk of ischaemic stroke, which is only apparent among people who have migraine with aura. Our results also suggest a higher risk among women and risk was further magnified for people with migraine who were aged less than 45, smokers, and women who used oral contraceptives. We did not find an overall association between any migraine and myocardial infarction or death due to cardiovascular disease. Too few studies are available to reliably evaluate the impact of modifying factors, such as migraine aura, on these associations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 27 October 2009 (published online ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328305</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/339/oct27_1/b3914]]&gt;</url>
    <title>Migraine and cardiovascular disease: systematic review and meta-analysis</title>
    <publicationDate>2009-10-27T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,CONDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. &lt;EM&gt;BMJ&lt;/EM&gt; 2009;339:b3914 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate the association between migraine and cardiovascular disease, including stroke, myocardial infarction, and death due to cardiovascular disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Data sources: Electronic databases (PubMed, Embase, Cochrane Library) and reference lists of included studies and reviews published until January 2009. &lt;/P&gt;
&lt;P&gt;Selection criteria: Case-control and cohort studies investigating the association between any migraine or specific migraine subtypes and cardiovascular disease. &lt;/P&gt;
&lt;P&gt;Review methods: Two investigators independently assessed eligibility of identified studies in a two step approach. Disagreements were resolved by consensus. Studies were grouped according to a priori categories on migraine and cardiovascular disease. &lt;/P&gt;
&lt;P&gt;Data extraction: Two investigators extracted data. Pooled relative risks and 95% confidence intervals were calculated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Studies were heterogeneous for participant characteristics and definition of cardiovascular disease. Nine studies investigated the association between any migraine and ischaemic stroke (pooled relative risk 1.73, 95% confidence interval 1.31 to 2.29). Additional analyses indicated a significantly higher risk among people who had migraine with aura (2.16, 1.53 to 3.03) compared with people who had migraine without aura (1.23, 0.90 to 1.69; meta-regression for aura status P=0.02). Furthermore, results suggested a greater risk among women (2.08, 1.13 to 3.84) compared with men (1.37, 0.89 to 2.11). Age less than 45 years, smoking, and oral contraceptive use further increased the risk. Eight studies investigated the association between migraine and myocardial infarction (1.12, 0.95 to 1.32) and five between migraine and death due to cardiovascular disease (1.03, 0.79 to 1.34). Only one study investigated the association between women who had migraine with aura and myocardial infarction and death due to cardiovascular disease, showing a twofold increased risk. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Migraine is associated with a twofold increased risk of ischaemic stroke, which is only apparent among people who have migraine with aura. Our results also suggest a higher risk among women and risk was further magnified for people with migraine who were aged less than 45, smokers, and women who used oral contraceptives. We did not find an overall association between any migraine and myocardial infarction or death due to cardiovascular disease. Too few studies are available to reliably evaluate the impact of modifying factors, such as migraine aura, on these associations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 27 October 2009 (published online ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396504</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/content/339/bmj.b3914.full]]&gt;</url>
    <title>Migraine and cardiovascular disease: systematic review and meta-analysis</title>
    <publicationDate>2009-10-27T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. &lt;EM&gt;British Medical Journal&lt;/EM&gt; 339:b3914&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate the association between migraine and cardiovascular disease, including stroke, myocardial infarction, and death due to cardiovascular disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Electronic databases (PubMed, Embase, Cochrane Library) and reference lists of included studies and reviews published until January 2009. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Selection criteria:&lt;/STRONG&gt; Case-control and cohort studies investigating the association between any migraine or specific migraine subtypes and cardiovascular disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; Two investigators independently assessed eligibility of identified studies in a two step approach. Disagreements were resolved by consensus. Studies were grouped according to a priori categories on migraine and cardiovascular disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data extraction:&lt;/STRONG&gt; Two investigators extracted data. Pooled relative risks and 95% confidence intervals were calculated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Studies were heterogeneous for participant characteristics and definition of cardiovascular disease. Nine studies investigated the association between any migraine and ischaemic stroke (pooled relative risk 1.73, 95% confidence interval 1.31 to 2.29). Additional analyses indicated a significantly higher risk among people who had migraine with aura (2.16, 1.53 to 3.03) compared with people who had migraine without aura (1.23, 0.90 to 1.69; meta-regression for aura status P=0.02). Furthermore, results suggested a greater risk among women (2.08, 1.13 to 3.84) compared with men (1.37, 0.89 to 2.11). Age less than 45 years, smoking, and oral contraceptive use further increased the risk. Eight studies investigated the association between migraine and myocardial infarction (1.12, 0.95 to 1.32) and five between migraine and death due to cardiovascular disease (1.03, 0.79 to 1.34). Only one study investigated the association between women who had migraine with aura and myocardial infarction and death due to cardiovascular disease, showing a twofold increased risk. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Migraine is associated with a twofold increased risk of ischaemic stroke, which is only apparent among people who have migraine with aura. Our results also suggest a higher risk among women and risk was further magnified for people with migraine who were aged less than 45, smokers, and women who used oral contraceptives. We did not find an overall association between any migraine and myocardial infarction or death due to cardiovascular disease. Too few studies are available to reliably evaluate the impact of modifying factors, such as migraine aura, on these associations. &lt;/P&gt;
&lt;P&gt;BMJ publishes original scientific studies, review and educational articles, and papers commenting on the clinical, scientific, social, political, and economic factors affecting health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is available on open access. Free full text is available to NHS staff via &lt;A href="http://ukpmc.ac.uk/" target="_blank"&gt;UK PubMed Central&lt;/A&gt;, with a 1-year embargo. Up-to-date full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396504</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/content/339/bmj.b3914.full]]&gt;</url>
    <title>Migraine and cardiovascular disease: systematic review and meta-analysis</title>
    <publicationDate>2009-10-27T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. &lt;EM&gt;British Medical Journal&lt;/EM&gt; 339:b3914&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate the association between migraine and cardiovascular disease, including stroke, myocardial infarction, and death due to cardiovascular disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Electronic databases (PubMed, Embase, Cochrane Library) and reference lists of included studies and reviews published until January 2009. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Selection criteria:&lt;/STRONG&gt; Case-control and cohort studies investigating the association between any migraine or specific migraine subtypes and cardiovascular disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; Two investigators independently assessed eligibility of identified studies in a two step approach. Disagreements were resolved by consensus. Studies were grouped according to a priori categories on migraine and cardiovascular disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data extraction:&lt;/STRONG&gt; Two investigators extracted data. Pooled relative risks and 95% confidence intervals were calculated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Studies were heterogeneous for participant characteristics and definition of cardiovascular disease. Nine studies investigated the association between any migraine and ischaemic stroke (pooled relative risk 1.73, 95% confidence interval 1.31 to 2.29). Additional analyses indicated a significantly higher risk among people who had migraine with aura (2.16, 1.53 to 3.03) compared with people who had migraine without aura (1.23, 0.90 to 1.69; meta-regression for aura status P=0.02). Furthermore, results suggested a greater risk among women (2.08, 1.13 to 3.84) compared with men (1.37, 0.89 to 2.11). Age less than 45 years, smoking, and oral contraceptive use further increased the risk. Eight studies investigated the association between migraine and myocardial infarction (1.12, 0.95 to 1.32) and five between migraine and death due to cardiovascular disease (1.03, 0.79 to 1.34). Only one study investigated the association between women who had migraine with aura and myocardial infarction and death due to cardiovascular disease, showing a twofold increased risk. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Migraine is associated with a twofold increased risk of ischaemic stroke, which is only apparent among people who have migraine with aura. Our results also suggest a higher risk among women and risk was further magnified for people with migraine who were aged less than 45, smokers, and women who used oral contraceptives. We did not find an overall association between any migraine and myocardial infarction or death due to cardiovascular disease. Too few studies are available to reliably evaluate the impact of modifying factors, such as migraine aura, on these associations. &lt;/P&gt;
&lt;P&gt;BMJ publishes original scientific studies, review and educational articles, and papers commenting on the clinical, scientific, social, political, and economic factors affecting health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;This article is available on open access. Free full text is available to NHS staff via &lt;A href="http://ukpmc.ac.uk/" target="_blank"&gt;UK PubMed Central&lt;/A&gt;, with a 1-year embargo. Up-to-date full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396508</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.amjmed.com/article/S0002-9343(10)00129-4/abstract]]&gt;</url>
    <title>Migraine headache and ischemic stroke risk: An updated meta-analysis</title>
    <publicationDate>2010-05-20T00:00:00</publicationDate>
    <publisher>Association of Professors of Medicine</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,ISCHAEMIC STROKE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. (2010) Migraine headache and ischemic stroke risk: An updated meta-analysis. &lt;EM&gt;The American Journal of Medicine&lt;/EM&gt; 123(7):612-624&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Observational studies, including recent large cohort studies that were unavailable for prior meta-analysis, have suggested an association between migraine headache and ischemic stroke. We performed an updated meta-analysis to quantitatively summarize the strength of association between migraine and ischemic stroke risk.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We systematically searched electronic databases, including MEDLINE and EMBASE, through February 2009 for studies of human subjects in the English language. Study selection using a priori selection criteria, data extraction, and assessment of study quality were conducted independently by reviewer pairs using standardized forms.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-one (60%) of 35 studies met the selection criteria, for a total of 622,381 participants (13 case-control, 8 cohort studies) included in the meta-analysis. The pooled adjusted odds ratio of ischemic stroke comparing migraineurs with nonmigraineurs using a random effects model was 2.30 (95% confidence interval [CI], 1.91-2.76). The pooled adjusted effect estimates for studies that reported relative risks and hazard ratios, respectively, were 2.41 (95% CI, 1.81-3.20) and 1.52 (95% CI, 0.99-2.35). The overall pooled effect estimate was 2.04 (95% CI, 1.72-2.43). Results were robust to sensitivity analyses excluding lower quality studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Migraine is associated with increased ischemic stroke risk. These findings underscore the importance of identifying high-risk migraineurs with other modifiable stroke risk factors. Future studies of the effect of migraine treatment and modifiable risk factor reduction on stroke risk in migraineurs are warranted.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294548</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=294548]]&gt;</url>
    <title>MND Year of Care pathway</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Motor Neurone Disease Association</publisher>
    <publicationType>CARE PATHWAY</publicationType>
    <topics>&lt;![CDATA[ NEUROMUSCULAR,MOTOR NEURONE DISEASE/AMYOTROPHIC LATERAL SCLEROSIS,RECENT ADDITIONS,NSF LONG TERM CONDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,STRATEGIES AND POLICIES,TOOLKITS,NEUROLOGICAL SYSTEM PROBLEMS,DISEASE/CONDITION GROUPS,COMMISSIONING]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;MND Year of Care pathway&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The Motor Neurone Disease (MND) Association has developed an &lt;A href="http://www.library.nhs.uk/SpecialistLibrarySearch/Download.aspx?resID=294548" target="_blank"&gt;MND Year of Care Pathway&lt;/A&gt; for Heath and Adult Social Care Commissioners and practitioners.&amp;nbsp; The MND Year of Care Pathway is an innovative new tool to help the NHS and Adult Social Care improve the provision of services for people with the complex neurological condition MND.&amp;nbsp; It will also play an important role in helping to implement the National Service Framework for Long Term (Neurological) Conditions.&amp;nbsp; The Pathway will help commissioners comply with the competencies expected as part of World Class Commissioning.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The Pathway lists the full range of interventions over the course of a year in “commissioning currency”.&amp;nbsp; The result is a user-friendly guidance document which lists costs for each aspect of care and equipment and provides information for both commissioners and service providers.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Also available for download,&amp;nbsp;the report: Learning from Leeds - How the patient, carer and professional perspective from Leeds improved the MND Year of Care Pathway Commissioning Tool.&amp;nbsp; Please use the link under 'related files' below&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>344278</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18566030]]&gt;</url>
    <title>Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Sage</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. &lt;EM&gt;Multiple Sclerosis&lt;/EM&gt; 2008;14(5):679-90.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A Markov model was constructed to illustrate disease progression based on functional disability (the Expanded Disability Status Scale (EDSS)). The effectiveness of natalizumab was based on a 2-year clinical trial in 942 patients (AFFIRM). The effectiveness of current DMDs was estimated from a matched sample of 512 patients in the Stockholm MS registry. Patients withdrawing from treatment were assumed to follow the disease course of 824 patients with relapsing-remitting disease at onset in the Ontario natural history cohort. Costs and utilities are based on a recent observational study in 1339 patients. All data sets were available at the patient level. Main results are presented from the societal perspective, over a 20-year time frame, in 2005 Euros (euro1 = 9.25 SEK).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In the base case, treatment with natalizumab was less expensive and more effective than treatment with current DMDs. When only healthcare costs were considered, the cost per quality-adjusted life year gained with natalizumab was euro38 145. Results are sensitive only to the time horizon of the analysis and assumptions about effectiveness of natalizumab beyond the trial. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The analysis results suggest that for the population considered, natalizumab provides an additional health benefit at a similar cost to current DMDs from a societal perspective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in June 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313836</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;TransSchema=title&amp;term=4%5Bvolume%5D%20AND%2011%5Bissue%5D%20AND%20610%5Bpage%5D%20AND%202008%5Bpdat%5D%20AND%20chungath%5Bauthor%5D%20AND%20mortality]]&gt;</url>
    <title>Mortality and morbidity of febrile seizures</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>Nature Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,NON-EPILEPTIC SEIZURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Chungath M, Shorvon S. (2008) The mortality and morbidity of febrile seizures. Nature Clinical Practice Neurology 4(11):610-21.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The information for this review was extracted from datrabase searches of papers published between January 1993 and June 2007. Seaches were conducted of the PubMed, Embase, Cochrane and TRIP databases, and the searches were supplemented by the identification of articles in the reference lists of publicationsidentified from this database search. The seraches were restricted to articles in English and articles pertaining to humans.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key points:&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Simple febrile seizures are not associated with notable mortality or the risk of hippocampal changes, and these seizures carry only a small risk of subsequent epilepsy 
&lt;LI&gt;Complex febrile seizures are associated with a small increase in the risk of death and with a higher risk of development of subsequent epilepsy compared with simple febrile seizures 
&lt;LI&gt;Hippocampal sclerosis or mesial temporal sclerosis can develop after FSE, but the risk of such development is probably low 
&lt;LI&gt;MRI abnormalities are common in the aftermath of FSE, but most of these abnormalities are largely attributable to reversible - possibly edematous changes in the hippocampus; only a small proportion of cases evolve to hippocampal sclerosis&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;November 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313848</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=%22Epilepsy%20%26%20behavior%20%3A%20E%26B%22%5BJour%5D%20AND%2010%5Bvolume%5D%20AND%20363%5Bpage%5D%20AND%20hitiris%5Bauthor%5D]]&gt;</url>
    <title>Mortality in epilepsy</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hitiris N, Mohanraj R, Norrie J, Brodie MJ. (2007) Mortality in epilepsy. &lt;EM&gt;Epilepsy &amp;amp; Behavior&lt;/EM&gt; 10(3):363-76.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Methods: &lt;/B&gt;Studies were identified by searching PubMed using the terms epilepsy, mortality, sudden unexpected death in epilepsy (SUDEP), accidents, status epilepticus, pregnancy, and surgery. Relevant textbooks and other sources were also explored. Only articles in English were reviewed. This review applies predominantly to adults and adolescents with epilepsy. Mortality associated with childhood epilepsies has not been systematically assessed. Fatalities from adverse reactions to antiepileptic drugs (AEDs) and around the time of epilepsy surgery are not discussed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; All studies report an increased mortality risk for people with epilepsy compared with the general population. Population-based studies have demonstrated that the increased mortality is often related to the cause of the epilepsy. Common etiologies include neoplasia, cerebrovascular disease, and pneumonia. Deaths in selected cohorts, such as sudden unexpected death in epilepsy (SUDEP), status epilepticus (SE), suicides, and accidents are more frequently epilepsy-related. SUDEP is a particular cause for concern in younger people, and whether and when SUDEP should be discussed with patients with epilepsy remain problematic issues. Risk factors for SUDEP include generalized tonic–clonic seizures, increased seizure frequency, concomitant learning disability, and antiepileptic drug polypharmacy. The overall incidence of SE may be increasing, although case fatality rates remain constant. Mortality is frequently secondary to acute symptomatic disorders. Poor compliance with treatment in patients with epilepsy accounts for a small proportion of deaths from SE. The incidence of suicide is increased, particularly for individuals with epilepsy and comorbid psychiatric conditions. Late mortality figures in patients undergoing epilepsy surgery vary and are likely to reflect differences in case selection.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A range of studies have demonstrated an increased mortality for patients with epilepsy compared with the general population, although there are wide differences in methodology between studies. There is good evidence from population studies that mortality is elevated in the early years after diagnosis. This is due largely to the underlying cause of symptomatic epilepsies. Mortality is increased for all patients with refractory epilepsy, and there is a clear increase in mortality from remote symptomatic epilepsy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;May 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>338986</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19934425]]&gt;</url>
    <title>Motor development in very preterm and very low-birth-weight children from birth to adolescence: a meta-analysis</title>
    <publicationDate>2009-11-25T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STRUCTURAL,JANUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; de Kieviet JF, Piek JP, Aarnoudse-Moens CS, Oosterlaan J. (2009) Motor development in very preterm and very low-birth-weight children from birth to adolescence: a meta-analysis. &lt;EM&gt;JAMA&lt;/EM&gt; 302(20):2235-42.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The computerized databases EMBASE, PubMed, and Web of Knowledge were used to search for English-language peer-reviewed articles published between January 1992 and August 2009. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; In comparison with term-born peers, very preterm and VLBW children obtained significantly lower scores on all 3 motor tests: BSID-II: d = -0.88 (95% confidence interval [CI], -0.96 to -0.80; P &amp;lt; .001), MABC: d = -0.65 (95% CI, -0.70 to -0.60; P &amp;lt; .001), and BOTMP: d = -0.57 (95% CI, -0.68 to -0.46; P &amp;lt; .001). Whereas motor outcomes on the BSID-II show a catch-up effect in the first years of development (r = 0.50, P = .01), the results on the MABC demonstrate a nonsignificantly greater deficit with increasing age during elementary school and early adolescence (r = -0.59, P = .07).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Being born preterm or VLBW is associated with significant motor impairment persisting throughout childhood.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 25 November 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371757</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20150551?dopt=Abstract]]&gt;</url>
    <title>Moxibustion for stroke rehabilitation: systematic review.</title>
    <publicationDate>2010-02-11T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,STROKE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Lee, M. S., Shin, B. C., Kim, J. I., Han, C. h., Ernst, E. (2010) Moxibustion for Stroke Rehabilitation: Systematic Review. &lt;EM&gt;Stroke &lt;/EM&gt;41(4):817-20. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Fourteen databases were searched without language restriction. Randomized clinical trials were included if moxibustion was tested as the sole treatment or as an adjunct to other treatments for stroke rehabilitation. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nine randomized clinical trials met our inclusion criteria. Three randomized clinical trials reported favorable effects of moxibustion plus standard care on motor function versus standard care alone (N=142; standardized mean difference=0.72; 95% confidence interval, 0.37 to 1.08; P&amp;lt;0.0001). Three randomized clinical trials compared the effects of moxibustion on activities of daily living alone but failed to show favorable effects of moxibustion. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This systematic review found limited effectiveness of moxibustion as an adjunct to standard care in stroke rehabilitation.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 11th February 2010 (E-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This journal freely available to NHS England staff from January 1970. The last 5 months are not available. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344317</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18004634]]&gt;</url>
    <title>MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>Springer Milan</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MAGNETIC RESONANCE IMAGING (MRI),INVESTIGATION &amp; DIAGNOSTICS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Seewann A, Enzinger C, Filippi M, Barkhof F, Rovira A, Gass A, et al. MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. Journal of Neurology 2008 Jan;255(1):1-10.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed a PubMed search from January 1984 through December 2004 for articles in English reporting on&amp;nbsp;idiopathic inflammatory demyelinating lesions (IIDLs) which had been considered as morphologically atypical (66 articles; 270 cases reported). From these publications 69 individual patient reports allowed the extraction of adequate information on magnetic resonance imaging (MRI) and associated disease characteristics.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Reported atypical IIDLs most frequently manifested as large ring-like lesions (n = 27) which are now considered quite suggestive of an antibodymediated form of multiple sclerosis (MS). Truly atypical IIDLs were less common and exhibited appearances which we termed megacystic (n = 8), Balolike (n = 11) and diffusely infiltrating (n = 11). Despite limitations imposed by the absence of original data the inter-rater agreement in defining these subtypes of atypical IIDLs was moderate to substantial (kappa 0.48-0.68) and we noted trends for their association with certain demographic, clinical and paraclinical variables. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; We suggest that IIDLs reported as atypical in the literature can be segregated into several distinct subtypes based on their MRI appearance. The recognition of these patterns may be useful for the differential diagnosis and for a future classification. Because of the limitations inherent in our review this will have to be confirmed by a prospective registry.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt;&amp;nbsp;Published in January 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>309126</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://author.pathwaysforhealth.org/xpath2007/xeditor/publisher.asp?d_ref=17538D65C6FF442B93F54AFAFB0791BD&amp;d_name=&amp;o_mode=0]]&gt;</url>
    <title>Multiple sclerosis - commissioning pathway for 18 weeks and long term condition management</title>
    <publicationDate>2008-11-03T00:00:00</publicationDate>
    <publisher>Multiple Sclerosis Trust</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,NSF LONG TERM CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,STRATEGIES AND POLICIES,CONDITIONS,COMMISSIONING,DISEASE/CONDITION GROUPS,NEUROLOGICAL SYSTEM PROBLEMS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;World class commissioning for MS requires complex knowledge. The process has now been simplified by the launch of an MS commissioning pathway. The pathway has been built involving all the major organisations with MS expertise, and based on the 18-week software used for the Department of Health’s 18-week pathways. The MS pathway provides information on the requirements for MS commissioning from diagnosis to end of life.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344162</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.2217/1745509X.5.1.89]]&gt;</url>
    <title>Multiple sclerosis and aging: complexities, concerns and considerations for care.</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Future Medicine</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Finlayson M. Multiple sclerosis and aging: Complexities, concerns and considerations for care. &lt;EM&gt;Aging Health&lt;/EM&gt; 2009;5(1):89-102.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Bibliographic searches were conducted to identify current applied research literature concerning aging with MS. Articles were reviewed to identify major themes, gaps in the current knowledge and directions for future research.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Three major content themes were uncovered: the influence of aging on the progression of MS and related activity limitations (17 articles), family and professional care needs of people aging with MS (13 articles) and the experience of aging with MS (seven articles).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Findings suggest that MS progression and related activity limitations are age-related and age-accelerated. While age-related factors play a role in care needs, other factors may be more salient. People with MS report several similarities between their aging experience and that of their peers, but also key differences. Together, findings from these reviews point to the need for comparison studies between people aging with MS and other aging populations, studies examining the effectiveness of interventions for people aging with MS, and translational research that can inform multidisciplinary care provision.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in February 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345224</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1179/174328809X435295]]&gt;</url>
    <title>Multiple sclerosis and exercise in people with minimal gait impairment - a review</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>Ingenta Connect</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Garrett M, Coote S. Multiple sclerosis and exercise in people with minimal gait impairment: a review. &lt;EM&gt;Physical Therapy Reviews&lt;/EM&gt; 2009 Jun;14(3):169-80.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic search of the literature was conducted. Quality was assessed using a simple method to evaluate bias. All trials since 2004 that have included people who walk with at most one stick have been included (i.e. EDSS =6).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Aerobic, progressive resistance exercise (PRE), combined exercises and other interventions appear to have positive effects on body structure and function, activities and participation in people with mild MS. No harmful effects were seen in any intervention. Both aerobic exercise and PRE have very defined and reproducible parameters. A combination of aerobic exercise and PRE is feasible and potentially offers the most favourable results in terms of the negative symptomology and physiological profile. Yoga and aqua aerobics also had positive effects and are feasible for this population. However, there is a moderate to high risk of bias in studies conducted since 2004 limiting their validity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The effectiveness of interventions for patients with different impairments remains unclear due to the levels of bias in studies evaluating exercise in people with MS. Future studies should focus on the randomised controlled trial (RCT) paradigm. A high quality, RCT comparing a combined exercise programme, yoga and a control, with a long term follow up, is required.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in June 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288699</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.rcgp.org.uk/professional_development/distance_learning/multiple_sclerosis.aspx]]&gt;</url>
    <title>Multiple Sclerosis e-Learning</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>RCGP</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;"This web-based learning module has been designed for doctors working in primary care who wish to develop their knowledge and skills in the diagnosis and management of multiple sclerosis.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The module consists of six learning sessions based on the core competencies of general practice described in the RCGP Curriculum. Click on the relevant section of the image to start a session. Each session can be taken individually and takes between twenty to thirty minutes to complete."&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Contents include:&lt;/P&gt;
&lt;P&gt;Primary Care Management&lt;/P&gt;
&lt;P&gt;Person Centred Care&lt;/P&gt;
&lt;P&gt;Specific Problem Solving Skills&lt;/P&gt;
&lt;P&gt;Comprehensive Approach&lt;/P&gt;
&lt;P&gt;Community Orientation&lt;/P&gt;
&lt;P&gt;Holistic Approach&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;"Multiple sclerosis in general practice: web-based learning module&lt;/EM&gt; has been developed in collaboration with the MS Society. This web-based learning module was designed and edited by Dr Ben Riley (RCGP Curriculum Development Fellow) from original material developed by the RCGP Learning Unit and published in Multiple Sclerosis in General Practice, part of the Professional Development Series.&lt;BR&gt;The module is published by the RCGP and was constructed by the RCGP’s web team."&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314129</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2194733&amp;blobtype=pdf]]&gt;</url>
    <title>Multiple treatment comparisons in epilepsy monotherapy trials</title>
    <publicationDate></publicationDate>
    <publisher>Biomed Central</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Smith CT, Marson AG, Chadwick DW, Williamson PR. (2008)&amp;nbsp;Multiple treatment comparisons in epilepsy monotherapy trials. &lt;EM&gt;Trials&lt;/EM&gt; 8(1):34.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Multiple treatment comparisons from epilepsy monotherapy trials were synthesized in a single stratified Cox regression model adjusted for treatment by epilepsy type interactions and making use of direct and indirect evidence. Primary outcomes were time to treatment failure and time to 12 month remission from seizures. A secondary outcome was time to first seizure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Individual patient data for 6418 patients from 20 randomised trials comparing eight antiepileptic drugs were synthesized. For partial onset seizures (4628 (72%) patients), lamotrigine, carbamazepine and oxcarbazepine provide the best combination of seizure control and treatment failure. Lamotrigine is clinically superior to all other drugs for treatment failure but estimates suggest a disadvantage compared to carbamazepine for time to 12 month remission [Hazard Ratio (95% Confidence Interval) = 0.87(0.73 to 1.04)] and time to first seizure [1.29(1.13 to 1.48)]. Phenobarbitone may delay time to first seizure [0.77(0.61 to 0.96)] but at the expense of increased treatment failure [1.60(1.22 to 2.10)]. For generalized onset tonic clonic seizures (1790 (28%) patients) estimates suggest valproate or phenytoin may provide the best combination of seizure control and treatment failure but some uncertainty remains about the relative effectiveness of other drugs. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; For patients with partial onset seizures, results favour carbamazepine, oxcarbazepine and lamotrigine. For generalized onset tonic clonic seizures, results favour valproate and phenytoin.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;November 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Freely available to all via the publisher and Pubmed Central.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398094</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.hqip.org.uk/assets/National-Team-Uploads/NAD-Interim-Final-Report2.doc]]&gt;</url>
    <title>National audit of dementia: care in general hospitals</title>
    <publicationDate>2010-12-16T00:00:00</publicationDate>
    <publisher>Healthcare Quality Improvement Partnership (HQIP)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,NATIONAL DEMENTIA STRATEGY,STRATEGIES AND POLICIES,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Royal College of Psychiatrists' Centre for Quality Improvement. (2010) National audit of dementia - care in general hospitals. &lt;EM&gt;Healthcare Quality Improvement Partnership (HQIP)&lt;/EM&gt; 16th December&lt;/P&gt;
&lt;P&gt;In this interim report we summarise the key findings from a preliminary analysis of aggregated hospital-level data collected as part of the ‘core audit’ of the National Audit of Dementia.&amp;nbsp; All but one of the 151 provider organisations in England and Wales that were eligible to participate took part in the audit and 210 hospitals (88% of the total number) submitted data.&lt;/P&gt;
&lt;P&gt;The final report for the first wave of the national audit, which will be published in late 2011, will include findings from a more in-depth evaluation of practice at the level of the hospital ward and recommendations informed by action planning events that will take place in the spring and early summer of 2011.&amp;nbsp; This short interim report is published at this time so that there will be no delay in making preliminary findings public.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>318939</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/media/Documents/press-release-documents/Carotid-Endarterectomy-audit-Public-Report.pdf]]&gt;</url>
    <title>National carotid endarterectomy audit - Round 1</title>
    <publicationDate></publicationDate>
    <publisher>Royal College of Physicians of London</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,SURGERY,CEREBROVASCULAR CONDITIONS,SURGERY,BRAIN,HEAD &amp; NECK,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoPlainText&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;A joint audit commissioned by the Healthcare Quality Improvement Partnership (HQIP) and carried out by the Royal College of Physicians and the Vascular Society shows that patients with symptoms of stroke or transient ischemic attack (TIA or brain attack) are missing out on potentially life saving treatment because they are routinely considered by the NHS as low priority cases.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Firm evidence shows that timely surgery of the neck arteries (carotid endarterectomy (CEA)) for those experiencing symptoms of TIA can prevent a major stroke, but the vast majority of patients are receiving treatment far too late to make a difference. The report also highlights significant variations in quality of care provision across the UK and a complete lack of cohesive referral pathways in most hospital trusts.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access&lt;/STRONG&gt;: available to the general public.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date&lt;/STRONG&gt;: 2008&lt;/o:p&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271275</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Browsable/DH_072815]]&gt;</url>
    <title>National Service Framework for Long-term Conditions - Good Practice Guide</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,NSF LONG TERM CONDITIONS,OUTCOMES,LONG TERM CONDITIONS,NATIONAL SERVICE FRAMEWORKS,QUALITY REQUIREMENTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,MANAGEMENT &amp; POLICY,FRAMEWORKS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Good Practice Guide has been written in response to requests from NHS and social service organisations to help them implement the National Service Framework for Long-term Conditions at a local level.&lt;/P&gt;
&lt;P&gt;Contents:&lt;/P&gt;
&lt;UL class=mpctNav&gt;
&lt;LI&gt;How to use this guide 
&lt;LI&gt;Getting started 
&lt;LI&gt;Self-assessment 
&lt;LI&gt;Tackling the key issues 
&lt;LI&gt;Examples of innovation and good practice 
&lt;LI&gt;Information about the Implementation Group&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306099</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081062?IdcService=GET_FILE&amp;dID=155577&amp;Rendition=Web]]&gt;</url>
    <title>National Stroke Strategy</title>
    <publicationDate>2007-12-05T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,STROKE,NATIONAL STROKE STRATEGY,STRATEGIES AND POLICIES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Department of Health (DH) has developed a new national strategy for stroke services in England. The strategy is intended to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;provide a quality framework against which local services can secure improvements to stroke services and address health inequalities relating to stroke over the next ten years; 
&lt;LI&gt;provide advice, guidance and support for commissioners, strategic health authorities, the voluntary sector and social care, in the planning, development and monitoring of services; and 
&lt;LI&gt;inform the expectations of those affected by stroke and their families, by providing a guide to high-quality health and social care services. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The strategy does not act as a detailed clinical guideline – the &lt;A href="nelh:302133:0" name=internalLink&gt;Royal College of Physicians (RCP) guidelines&lt;/A&gt; and the forthcoming &lt;A href="nelh:290693:0" name=internalLink&gt;National Institute for Health and Clinical Excellence (NICE) guidelines&lt;/A&gt; fulfil these roles. The strategy does not apply to children’s stroke services. Paediatric stroke services are covered by the RCP guidelines. &lt;/P&gt;
&lt;P&gt;The strategy applies to stroke services in England only. &lt;/P&gt;
&lt;P&gt;&lt;EM&gt;(Text taken from Purpose and Scope, National Stroke Strategy)&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>307825</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_083506?IdcService=GET_FILE&amp;dID=161784&amp;Rendition=Web]]&gt;</url>
    <title>National Stroke Strategy easy access version</title>
    <publicationDate>2008-03-14T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,NATIONAL STROKE STRATEGY,STRATEGIES AND POLICIES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;This booklet is a shorter version of the full-length National Stroke Strategy. It tells you about most of the points in the full-length Strategy but in less detail.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313850</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;TransSchema=title&amp;term=271%5Bvolume%5D%20AND%201%5Bpage%5D%20AND%20nicolai%5Bauthor%5D%20AND%20Neurodevelopmental%20delay]]&gt;</url>
    <title>Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: a critical review directed at structural study-bias</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Nicolai J, Vles JS, Aldenkamp AP. (2008) Neurodevelopmental delay in children exposed to antiepileptic drugs in utero: a critical review directed at structural study-bias. &lt;EM&gt;Journal of the Neurological Sciences&lt;/EM&gt; 271(1-2):1-14.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Literature was searched using MEDLINE and other relevant databases: 56 studies were identified and interpreted.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The identified studies do not allow definite conclusions. The possibility of neurodevelopmental delay, behavioural disorders, or learning disabilities as an outcome of in utero exposure to AEDs and especially VPA, needs to be considered seriously. The literature however does not provide evidence for a valid risk estimate. Moreover the evidence found for a specific increased risk for VPA could be structurally biased.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Discussion:&lt;/STRONG&gt; The major problem in this field is the methodology and in particular the existence of important confounding factors that complicate any attempt to correlate intra-uterine exposure to AEDs with neurodevelopmental delay. We propose a number of guidelines for studies on behavioural teratogenicity.&lt;FONT face=AdvTT6120e2aa size=1&gt;&lt;FONT face=AdvTT6120e2aa size=1&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;/FONT&gt;&lt;/FONT&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345359</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20144981]]&gt;</url>
    <title>Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data.</title>
    <publicationDate>2010-02-09T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DELIVERY OF CARE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STRUCTURAL,MARCH 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzopardi D. (2010) Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. &lt;EM&gt;BMJ &lt;/EM&gt;340:c363. doi: 10.1136/bmj.c363. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A meta-analysis was performed using a fixed effect model. Risk ratios, risk difference, and number needed to treat, plus 95% confidence intervals, were measured. Studies were identified from the Cochrane central register of controlled trials, the Oxford database of perinatal trials, PubMed, previous reviews, and abstracts. Review methods: Reports that compared whole body cooling or selective head cooling with normal care in neonates with hypoxic-ischaemic encephalopathy and that included data on death or disability and on specific neurological outcomes of interest to patients and clinicians were selected. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We found three trials, encompassing 767 infants, that included information on death and major neurodevelopmental disability after at least 18 months' follow-up. We also identified seven other trials with mortality information but no appropriate neurodevelopmental data. Therapeutic hypothermia significantly reduced the combined rate of death and severe disability in the three trials with 18 month outcomes (risk ratio 0.81, 95% confidence interval 0.71 to 0.93, P=0.002; risk difference -0.11, 95% CI -0.18 to -0.04), with a number needed to treat of nine (95% CI 5 to 25). Hypothermia increased survival with normal neurological function (risk ratio 1.53, 95% CI 1.22 to 1.93, P&amp;lt;0.001; risk difference 0.12, 95% CI 0.06 to 0.18), with a number needed to treat of eight (95% CI 5 to 17), and in survivors reduced the rates of severe disability (P=0.006), cerebral palsy (P=0.004), and mental and the psychomotor developmental index of less than 70 (P=0.01 and P=0.02, respectively). No significant interaction between severity of encephalopathy and treatment effect was detected. Mortality was significantly reduced when we assessed all 10 trials (1320 infants; relative risk 0.78, 95% CI 0.66 to 0.93, P=0.005; risk difference -0.07, 95% CI -0.12 to -0.02), with a number needed to treat of 14 (95% CI 8 to 47). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In infants with hypoxic-ischaemic encephalopathy, moderate hypothermia is associated with a consistent reduction in death and neurological impairment at 18 months.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; February 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is available to NHS staff via &lt;A href="http://ukpmc.ac.uk/" target="_blank"&gt;UK PubMed Central&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344200</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2565485/]]&gt;</url>
    <title>Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>American Paraplegia Society</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,TRAUMA,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,SPINAL INJURY,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; MacDonald R, Monga M, Fink HA, Wilt TJ. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. &lt;EM&gt;Journal of Spinal Cord Medicine &lt;/EM&gt;2008;31(2):157-65.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Studies were included if published in English, presented randomized adults with spinal chord injury (SCI) or multiple sclerosis (MS), and reported UI outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten trials randomizing 288 subjects with SCI (43%), MS (52%), or other spinal conditions (5%) and UI refractory to oral antimuscarinics were included. The overall mean age was 41 years, and 46% were women. Study durations ranged from 1 to 18 months. Treatments included botulinum toxin-A (BTX-A, 2 trials) and 2 vanilloid compounds, capsaicin (6 trials) and resiniferatoxin (4 trials). BTX-A was superior to placebo and resiniferatoxin in reducing daily UI episodes, mainly in individuals with SCI, although significant reductions vs placebo were not evident throughout the study duration. There were 1.1 fewer daily UI episodes in the BTX-A 200 unit group vs 0.1 fewer for the placebo group at the final week 24 assessment. Capsaicin was generally superior to placebo. The weighted difference between capsaicin and placebo in a pooled analysis of 2 trials enrolling subjects with either paraplegia or tetraplegia (n = 32) was -3.8 daily UI episodes [95% Cl -4.7 to -2.9] after 30 days. Capsaicin was comparable to resiniferatoxin. Pelvic pain and facial flushing were associated with capsaicin.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Neurotoxins may improve refractive UI in adults with SCI or MS, although trial results were inconsistent. Trials were small in size and relatively short in duration. Further studies are needed to determine the efficacy and tolerability of long-term application.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text freely available via PubMed Central.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288544</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/contents/700f3a0e-32ed-463f-be05-191494875e15.pdf]]&gt;</url>
    <title>NHS services for people with multiple sclerosis: a national survey</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Royal College of Physicians of London</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ An audit of commissioning, provision and experience of services used by people with multiple sclerosis in 2005-6, against recommendations from NICE Clinical Guideline 8 Written by the Royal College of Physicians and the MS Trust]]&gt;</body>
  </document>
  <document>
    <id>345379</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/content/15/1/6]]&gt;</url>
    <title>No difference between short-course and long-course antibiotics for bacterial meningitis in children, but available evidence limited.</title>
    <publicationDate>2010-02-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DELIVERY OF CARE,INFECTIONS,BACTERIAL INFECTIONS,MARCH 2010,CONDITIONS,BACTERIAL MENINGITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; van de Beek D, Brouwer MC. (2010) No difference between short-course and long-course antibiotics for bacterial meningitis in children, but available evidence limited. &lt;EM&gt;Evidence Based Medicine&lt;/EM&gt;&amp;nbsp;15(1):6-7. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Karageorgopoulos DE, Valkimadi PE, Kapaskelis A, et al. (2009)&amp;nbsp;Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. &lt;EM&gt;Archives of Disease in&amp;nbsp;Childhood&lt;/EM&gt; 94:607–14.&lt;/P&gt;
&lt;DIV id=cit-15.1.6.1 class="cit ref-cit ref-journal no-rev-xref"&gt;
&lt;DIV class=cit-metadata&gt;&lt;CITE&gt;&lt;/CITE&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314509</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17720628]]&gt;</url>
    <title>Nondrug treatments for psychogenic nonepileptic seizures: what's the evidence?</title>
    <publicationDate>2007-08-27T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,NON-EPILEPTIC SEIZURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Brooks JL, Goodfellow L, Bodde NM, Aldenkamp A, Baker GA. (2007) Nondrug treatments for psychogenic nonepileptic seizures: what's the evidence? &lt;EM&gt;Epilepsy &amp;amp; Behavior&lt;/EM&gt; 11(3):367-77.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Six hundred eight references were identified using a search strategy designed with the support of the Cochrane Review Epilepsy Group library. The search employed Medline and PsychInfo, and included hand searches of relevant journals (Seizure, Epilepsia, Epilepsy &amp;amp;Behavior, Epilepsy Research). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Three studies were found that met the inclusion criteria; two used hypnosis and one used paradoxical therapy. None included detailed reports of improved seizure frequency or quality of life, although reduction in seizure frequency was mentioned. All three studies concluded that the intervention used was beneficial in the treatment of psychogenic nonepileptic seizures.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The limited number of studies and poor methodology preclude these results from being generalizable. There is a need for well-designed clinical trials to identify the most suitable treatments for this population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 27 August 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381821</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://archneur.ama-assn.org/cgi/content/abstract/67/6/670]]&gt;</url>
    <title>Nonmotor symptoms in genetic Parkinson disease</title>
    <publicationDate>2010-06-01T00:00:00</publicationDate>
    <publisher>Archives of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,PARKINSON'S DISEASE,MOVEMENT DISORDERS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Kasten M, Kertelge L, Bruggemann N, van der Vegt J, Schmidt A, Tadic V, Buhmann C, Steinlechner S, Behrens MI, Ramirez A, Binkofski F, Siebner H, Raspe H, Hagenah J, Lencer R, Klein C. (2010) Nonmotor symptoms in genetic Parkinson disease. &lt;EM&gt;Archives of Neurology&lt;/EM&gt; 67(6): 670-676&lt;/P&gt;
&lt;P&gt;Archives of Neurology has been published in its current form since 1959, and covers all aspects of neurology, including Parkinson's disease, Epilepsy, Cerebrovascular diseases and Neuromuscular diseases. The journal aims include making "timely publication of original research of the nervous system".&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt;&amp;nbsp; Data on NMS in genetic PD are limited. Specific data needs include a systematic approach to NMS assessment reporting permitting comparability of studies. Overall, the frequency of NMS in genetic PD does not appear to be higher and may even be lower than in idiopathic PD. Nonmotor symptoms have a high impact on the patients' quality of life and caregiver burden and should be considered important and often treatable concomitant features of genetic PD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To review current knowledge on nonmotor symptoms (NMS), particularly psychiatric features, in genetic Parkinson disease (PD) and to provide original data for genetic and idiopathic PD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Sources:&lt;/STRONG&gt; A MEDLINE search using Parkinson and known PD genes focused on the presence of depression, anxiety, hallucinations, and dementia was performed. Original data from 82 outpatients with idiopathic (n = 55) and genetic (n = 27) PD were obtained. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study Selection:&lt;/STRONG&gt; All studies including information on NMS and patients with genetic PD. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Extraction:&lt;/STRONG&gt;&amp;nbsp;Study methods and clinical and genetic information were summarized. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Synthesis:&lt;/STRONG&gt;&amp;nbsp;The literature search yielded 1855 citations; 305 included genetic information on PD patients, of which 119 also contained information on any type of NMS (990 cases). Availability of information varied by gene and type of NMS; studies differed by recruitment and examination method. Literature search and original data showed high frequencies of the following NMS: depression, 8% to 37% (literature) and 33% to 40% (our data); anxiety, 7% to 37% (literature) and 10% to 22% (our data); hallucinations, 3% to 23% (literature) and 23% to 29% (our data); and dementia, 5% to 26% (literature), absent in our own data. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;Some sections are freely available via &lt;A href="http://highwire.stanford.edu/lists/freeart.dtl" target="_blank"&gt;Highwire Press&lt;/A&gt;. The last 12 months are not available.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>393843</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_121493.pdf]]&gt;</url>
    <title>'Nothing ventured, nothing gained': risk guidance for people with dementia</title>
    <publicationDate>2010-11-10T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS,STRATEGIES AND POLICIES,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;‘Nothing ventured, nothing gained’ is a rallying call to everyone involved in supporting persons with dementia to take a proportionate, measured and enabling approach to risk. The National Dementia Strategy focuses on enabling people to live well with dementia. Personalisation is about positioning choice, control and independence with the individual and it is within this context that this guidance is applied.&lt;/P&gt;
&lt;P&gt;This guidance is for the use of everyone involved in supporting people with dementia using health and care services (including housing support) within any setting. These may be in people’s own homes, in the community or in care homes, in primary care or in hospital, and in the public, independent or third sectors. &lt;/P&gt;
&lt;P&gt;Section A of this guidance provides a summary of the key issues relating to risk enablement and risk management.&lt;/P&gt;
&lt;P&gt;Section B provides a review of the evidence on risk and dementia.&lt;/P&gt;
&lt;P&gt;Section C is a framework for assessing and managing risks for people with dementia. The framework can be used to assess an individual’s risks across a wide range of areas and also as a framework to assess and manage specific issues of risk or ‘risky behaviours’.&lt;/P&gt;
&lt;P&gt;Practitioners of all disciplines may wish to familiarise themselves with the evidence presented in Section B before they use the framework in Section C.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271276</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/DH_4105454]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Evaluated examples of good practice - introduction and overview</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NSF LONG TERM CONDITIONS,NEUROLOGICAL CONDITIONS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This section demonstrates to service commissioners and providers how some organisations have already tackled aspects of service delivery described in the NSF. Examples of good practice are included here under each of the NSF's Quality Requirements to help service providers and commissioners take practical steps to improve services. These examples will, of course, need to be adapted to suit your local organisation.]]&gt;</body>
  </document>
  <document>
    <id>271277</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Personcentred/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 1: A person-centred service</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,NSF LONG TERM CONDITIONS,DELIVERY OF CARE,STRATEGIES AND POLICIES,QUALITY REQUIREMENTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=itemContainer&gt;
&lt;DIV&gt;
&lt;H3&gt;Quality requirement 1&lt;/H3&gt;
&lt;P&gt;People with long-term neurological conditions are offered integrated assessment and planning of their health and social care needs. They are to have the information they need to make informed decisions about their care and treatment and, where appropriate, to support them to manage their condition themselves.&lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271293</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Supportingfamiliesandcarers/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 10: Supporting families and carers</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,NSF LONG TERM CONDITIONS,QUALITY REQUIREMENTS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=itemContainer&gt;
&lt;DIV&gt;
&lt;H3&gt;Quality requirement 10&lt;/H3&gt;
&lt;P&gt;Carers of people with long-term neurological conditions are to have access to appropriate support and services that recognise their needs both in their role as carer and in their own right.&lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271294</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Admissionwithneurologicalconditions/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 11: Caring for people with neurological conditions during admission to hospital or other health and social care settings</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NSF LONG TERM CONDITIONS,NEUROLOGICAL CONDITIONS,STRATEGIES AND POLICIES,QUALITY REQUIREMENTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=itemContainer&gt;
&lt;DIV&gt;
&lt;H3&gt;Quality requirement 11&lt;/H3&gt;
&lt;P&gt;People with long-term neurological conditions are to have their specific neurological needs met while receiving care for other reasons in any health or social care setting.&lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271278</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Recognitionanddiagnosis/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 2: Early recognition, prompt diagnosis and treatment</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NSF LONG TERM CONDITIONS,NEUROLOGICAL CONDITIONS,QUALITY REQUIREMENTS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;People suspected of having a neurological condition are to have prompt access to specialist neurological expertise for an accurate diagnosis and treatment as close to home as possible.&lt;/P&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271279</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Emergencyacutemanagement/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 3: Emergency and acute management</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,NSF LONG TERM CONDITIONS,STRATEGIES AND POLICIES,QUALITY REQUIREMENTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=introContent&gt;
&lt;H2&gt;Quality requirement 3: Emergency and acute management&lt;/H2&gt;
&lt;P class=introText&gt;People needing hospital admission for a neurosurgical or neurological emergency are to be assessed and treated in a timely manner by teams with the appropriate neurological and resuscitation skills and facilities.&lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;Contains examples of good practice by various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271280</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Earlyspecialistrehabilitation/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 4: Early and specialist rehabilitation</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NSF LONG TERM CONDITIONS,NEUROLOGICAL CONDITIONS,DELIVERY OF CARE,REHABILITATION,QUALITY REQUIREMENTS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=itemContainer&gt;
&lt;DIV&gt;
&lt;H3&gt;Quality requirement 4&lt;/H3&gt;
&lt;P&gt;People with long-term neurological conditions who would benefit from rehabilitation are to receive timely, ongoing, high quality rehabilitation services in hospital or other specialist settings to meet their continuing and changing needs. When ready, they receive the help they need to return home for ongoing community rehabilitation and support ('home' in this context means the place where the individual chooses to live, which may be their own accommodation or may be a residential or care home).&lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271281</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Communityrehabilitation/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 5: Community rehabilitation and support</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ REHABILITATION,DELIVERY OF CARE,NEUROLOGICAL CONDITIONS,NSF LONG TERM CONDITIONS,STRATEGIES AND POLICIES,QUALITY REQUIREMENTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=itemContainer&gt;
&lt;DIV&gt;
&lt;H3&gt;Quality requirement 5&lt;/H3&gt;
&lt;P&gt;People with long-term neurological conditions living at home are to have ongoing access to a comprehensive range of rehabilitation, advice and support, to meet their continuing and changing needs, to increase their independence and autonomy and help them to live as they wish.'Home' in this context means the place where the individual chooses to live, which may be their own accommodation or may be a residential or care home.&lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271282</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Vocationalrehabilitation/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 6: Vocational rehabilitation</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NSF LONG TERM CONDITIONS,NEUROLOGICAL CONDITIONS,DELIVERY OF CARE,REHABILITATION,QUALITY REQUIREMENTS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=introContent&gt;
&lt;H2&gt;Quality requirement 6: Vocational rehabilitation&lt;/H2&gt;
&lt;P class=introText&gt;People with long-term neurological conditions are to have access to appropriate vocational assessment, rehabilitation and ongoing support, to enable them to find, regain or remain in work and access other occupational and educational opportunities.&lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271290</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Equipmentaccommodation/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 7: Providing equipment and accommodation</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NSF LONG TERM CONDITIONS,NEUROLOGICAL CONDITIONS,STRATEGIES AND POLICIES,QUALITY REQUIREMENTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=introContent&gt;
&lt;H2&gt;Quality requirement 7: Providing equipment &amp;amp; accommodation&lt;/H2&gt;
&lt;P class=introText&gt;People with long-term neurological conditions are to receive timely, appropriate assistive technology/ equipment and adaptations to accommodation to support them to live independently, help them with their care, maintain their health and improve their quality of life.&lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271291</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Personalcareandsupport/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 8: Personal care and support</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,NSF LONG TERM CONDITIONS,QUALITY REQUIREMENTS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;DIV class=itemContainer&gt;
&lt;DIV&gt;
&lt;H3&gt;Quality requirement 8&lt;/H3&gt;
&lt;P&gt;Health and social care services work together to provide care and support to enable people with long-term neurological conditions achieve maximum choice about living independently at home. Health and social care services work together to provide care and support to enable people with long-term neurological conditions achieve maximum choice about living independently at home.&lt;/P&gt;&lt;/DIV&gt;&lt;/DIV&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271292</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Longtermconditions/Bestpractice/Palliativecare/index.htm]]&gt;</url>
    <title>NSF Long Term Neurological Conditions | Quality Requirement 9: Palliative care</title>
    <publicationDate>2007-03-09T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NSF LONG TERM CONDITIONS,NEUROLOGICAL CONDITIONS,STRATEGIES AND POLICIES,QUALITY REQUIREMENTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;H3&gt;A Gold Standards Framework (GSF) for Palliative Care&lt;/H3&gt;
&lt;P&gt;The framework was established by a Macmillan GP facilitator at John Taylor Hospice in Birmingham and has now been rolled out across the UK as part of national policy. The GSF improves the supportive palliative care of people towards the end of their life, and is used by primary health care teams to optimise the care provided for people living in the community, so that most care is delivered at home or to people attending GP surgeries. It is now being piloted in care homes and will be piloted in community hospitals in the future. It is being used increasingly with people who have long-term conditions. The facilitator is willing to share a number of resources.&lt;/P&gt;
&lt;P&gt;Contains examples of good practice from various organisations.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325940</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.4.112]]&gt;</url>
    <title>Nurse-led care was non-inferior to physician-directed care in symptomatic moderate to severe obstructive sleep apnoea</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,OBSTRUCTIVE SLEEP APNOEA,SLEEP DISORDERS,CONDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Floyd, JA. (2009) Nurse-led care was non-inferior to physician-directed care in symptomatic moderate to severe obstructive sleep apnoea. &lt;EM&gt;Evidence Based Nursing&lt;/EM&gt; 12(4):112.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Antic NA et al. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19136368" target="_blank"&gt;A randomized controlled trial of nurse-led care for symptomatic moderate-severe obstructive sleep apnea&lt;/A&gt;. &lt;EM&gt;Am J Respir Crit Care Med.&lt;/EM&gt; 179(6):501-8.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384565</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/S1474-4422]]&gt;</url>
    <title>Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis</title>
    <publicationDate>2010-08-17T00:00:00</publicationDate>
    <publisher>Lancet Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INVESTIGATION &amp; DIAGNOSTICS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,COMPUTED TOMOGRAPHY (CT),MULTIPLE SCLEROSIS,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C. (2010) Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. &lt;EM&gt;The Lancet Neurology&lt;/EM&gt;, 9(9):921-932&lt;/P&gt;
&lt;P&gt;Optical coherence tomography (OCT) is a new method that could aid analysis of neurodegeneration in multiple sclerosis (MS) by capturing thinning of the retinal nerve fibre layer (RNFL). Meta-analyses of data for time domain OCT show RNFL thinning of 20·38 µm (95% CI 17·91—22·86, n=2063, p&amp;lt;0·0001) after optic neuritis in MS, and of 7·08 µm (5·52—8·65, n=3154, p&amp;lt;0·0001) in MS without optic neuritis. The estimated RNFL thinning in patients with MS is greater than the extent expected in normal ageing, probably because of retrograde trans-synaptic degeneration and progressive loss of retinal ganglion cells, in addition to the more pronounced thinning caused by optic neuritis if present. RNFL thickness correlates with visual and neurological functioning as well as with paraclinical data. Developments that could improve understanding of the relation between structure and function in MS pathophysiology include spectral or Fourier domain OCT technology, polarisation-sensitive OCT, fluorescence labelling, structural assessment of action-potential propagation, and segmentation algorithms allowing quantitative assessment of retinal layers.&lt;/P&gt;
&lt;P&gt;Lancet was established in 1823 and is an independent journal without affiliation to any medical or scientific organisation. The journal publishes high quality clinical trials, as well as editorials and comment and correspondance.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Most full text is&amp;nbsp;only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Some full text content plus abstracts and tables of contents are freely available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314518</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18823325]]&gt;</url>
    <title>Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group</title>
    <publicationDate></publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>CONSENSUS STATEMENT</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, Buchhalter JR, Caraballo RH, Helen Cross J, Dahlin MG, Donner EJ, Klepper J, Jehle RS, Kim HD, Christiana Liu YM, Nation J, Nordli DR Jr, Pfeifer HH, Rho JM, Stafstrom CE, Thiele EA, Turner Z, Wirrell EC, Wheless JW, Veggiotti P, Vining EP; Charlie Foundation, Practice Committee of the Child Neurology Society; Practice Committee of the Child Neurology Society; International Ketogenic Diet Study Group. (2008) Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. &lt;EM&gt;Epilepsia&lt;/EM&gt;. 2009 Feb;50(2):304-17. Epub 2008 Sep 23.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt; This document addresses issues such as patient selection, pre-KD counseling and evaluation, specific dietary therapy selection, implementation, supplementation, follow-up management, adverse event monitoring, and eventual KD discontinuation. This paper highlights recommendations based on best evidence, including areas of agreement and controversy, unanswered questions, and future research.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; September 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293358</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18285561?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books company</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,MIGRAINE,HEADACHE &amp; PAIN,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Azzopardi TD et al Annals of Pharmacotherapy 2008 Mar;42(3):397-402. Epub 2008 Feb 19&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: To compare the combination of oral metoclopramide plus an analgesic with oral triptan monotherapy in the treatment of migraine attacks in outpatients. DATA SOURCES: A search of PubMed (1966-October 2007), EMBASE (1974-October 2007), and International Pharmaceutical Abstracts (1970-October 2007) was conducted using the search terms metoclopramide, migraine, and oral. References of articles identified initially were also reviewed. STUDY SELECTION AND DATA EXTRACTION: Studies evaluating the efficacy and safety of oral metoclopramide compared with oral triptans for migraine treatment were included. Studies of non-oral forms of metoclopramide or studies that compared oral metoclopramide with placebo, analgesics, ergotamine, or other migraine therapies were excluded. Studies in which oral metoclopramide was combined with a triptan were also excluded. DATA SYNTHESIS: In the studies identified, oral metoclopramide was combined with aspirin or a similar analgesic. All of the studies assessed headache severity using a 4-point scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain). Headache relief was defined as a decrease in headache pain from grade 3 or 2 to grade 1 or 0 and was commonly assessed at 2 hours. For all primary and secondary efficacy outcomes-including migraine-associated nausea and vomiting-oral triptans were similar or superior to oral metoclopramide plus an analgesic. The combination was better tolerated, with no reports of serious metoclopramide adverse events such as extrapyramidal symptoms or tardive dyskinesia. CONCLUSIONS: Combinations containing oral metoclopramide plus an analgesic may be an option for patients in whom triptans are contraindicated or who experience intolerable adverse effects, or when cost is an issue. However, patients and physicians should be aware that the combination will likely be less effective than oral triptans in treatment of migraine and its associated symptoms. To determine the role of combination therapy that includes oral metoclopramide in mild-to-moderate migraines, further studies are warranted.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270569</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16914405]]&gt;</url>
    <title>Outcome of paediatric convulsive status epilepticus: a systematic review</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Lancet Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS,FIRST SEIZURE AND EARLY EPILEPSY,STATUS EPILEPTICUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Raspall-Chaure M., Chin R.F. Neville B.G. 2006; 5 (9) pp. 769-79&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;We did a systematic review on the outcome of paediatric convulsive status epilepticus (CSE) and investigated the role of biological and non-biological variables in reported outcomes. The methodological quality of the 63 studies that met our inclusion criteria was assessed. Study design, type of study, and length of follow-up influenced the outcome. The studies with highest methodological quality are associated with better outcome: short-term mortality between 2.7% and 5.2% and morbidity other than epilepsy less than 15%. The incidence of subsequent epilepsy is not increased after cryptogenic CSE. Causal factor is the main determinant of outcome and the effect of age or duration is difficult to separate from the underlying cause. The risk of sequelae in unprovoked and febrile CSE is low. There is some evidence that CSE, especially febrile CSE, might cause hippocampal injury, although its role in the development of mesial temporal sclerosis is unknown.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314433</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18515046]]&gt;</url>
    <title>Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Maguire MJ, Hemming K, Hutton JL, Marson AG. (2008) Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies. &lt;EM&gt;Epilepsy Research&lt;/EM&gt; 80(2-3):201-12.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Searches of MEDLINE (1966-2006), EMBASE (1974-2006), CINAHL (1982-2006), the Cochrane database of systematic reviews, the Cochrane Controlled Trials register, the DARE database and hand-searching congress proceedings were conducted. Randomised controlled trials, follow-on randomised controlled trials and prospective and retrospective cohort studies of gabapentin, topiramate, or levetiracetam as add-on therapy in adults (&amp;gt;12 years old) were identified. Outcomes were 50% responders and proportion seizure free. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirty-eight non-randomised gabapentin studies, 82 topiramate and 84 levetiracetam studies were identified. There was marked heterogeneity of effect estimates from observational studies which prohibited the pooling of estimates in random effects models. Median effect estimates were larger and more varied for observational studies than randomised placebo-controlled trials (RCTs). For example, the median value (10th and 90th percentile) for 50% responders for gabapentin was 36% (15 and 71%) compared to 23% (19 and 38%) for gabapentin RCTs. Patient and study covariates in meta-regression models could not explain the vast heterogeneity. Publication bias was evident and a sensitivity analysis, allowing for the effects of publication bias, showed that effect estimates could increase by up to 6% for seizure freedom rates. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Reports of observational anti-epileptic studies give limited information on patient selection and characteristics. Systematic reviews of observational studies are prone to significant heterogeneity and bias which cannot adequately be explained by reported study characteristics. Reporting standards for observational studies of anti-epileptic drugs could be improved by following guidelines for reporting non-randomised studies of interventions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; August 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344185</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17928147]]&gt;</url>
    <title>Pain associated with multiple sclerosis: systematic review and proposed classification</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. &lt;EM&gt;Pain&lt;/EM&gt; 2008 Jul;137(1):96-111.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We undertook a systematic review in order to summarize current understanding of the association between multiple sclerosis (MS) and pain and provide a basis for the design and interpretation of future studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The point prevalence of pain in patients with MS is nearly 50%, and approximately 75% of patients report having had pain within one month of assessment. Pain adversely affects most aspects of health-related quality of life, including functional domains such as the ability to work. The presence of pain in patients with MS is associated with increased age, duration of illness, depression, degree of functional impairment, and fatigue.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Several different types of pain are found in patients with MS, including extremity pain, trigeminal neuralgia, Lhermitte's sign, painful tonic spasms, back pain, and headache. Putative mechanisms of pain in patients with MS are discussed, and a classification of pain in MS is proposed. Few randomized clinical trials of treatments for MS pain have been conducted, and the limitations of current knowledge regarding approaches for treating MS pain are discussed. Suggestions for future studies that would increase understanding of the natural history, mechanisms, and treatment of pain in patients with MS are presented.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in July 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322979</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.39566.806725.BE]]&gt;</url>
    <title>Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence</title>
    <publicationDate>2008-06-09T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,RECENT ADDITIONS,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Colman I, Friedman BW, Brown MD, Innes GD, Grafstein E, Roberts TE, et al. (2008) Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. &lt;EM&gt;BMJ &lt;/EM&gt;336(7657):1359-61.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Electronic databases (Cochrane Central Register of Controlled Trials, Medline, Embase, LILACS, and CINAHL), conference proceedings, clinical practice guidelines, contacts with industry, and correspondence with authors. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Selection criteria:&lt;/STRONG&gt; Randomised controlled trials in which corticosteroids (alone or combined with standard abortive therapy) were compared with placebo or any other standard treatment for acute migraine in adults. REVIEW METHODS: Two reviewers independently assessed relevance, inclusion, and study quality. Weighted mean differences and relative risks were calculated and are reported with 95% confidence intervals. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; From 666 potentially relevant abstracts, seven studies met the inclusion criteria. All included trials used standard abortive therapy and subsequently compared single dose parenteral dexamethasone with placebo, examining pain relief and recurrence of headache within 72 hours. Dexamethasone and placebo provided similar acute pain reduction (weighted mean difference 0.37, 95% confidence interval -0.20 to 0.94). Dexamethasone was, however, more effective than placebo in reducing recurrence rates (relative risk 0.74, 95% confidence interval 0.60 to 0.90). Side effect profiles between dexamethasone and placebo groups were similar. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; When added to standard abortive therapy for migraine headache, single dose parenteral dexamethasone is associated with a 26% relative reduction in headache recurrence (number needed to treat=9) within 72 hours.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 9 June 2008 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text freely available via Pubmed Central and publisher's website.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306040</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=10009040]]&gt;</url>
    <title>Parkinson's disease - initial assessment and referral</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,MOVEMENT DISORDERS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Learning outcomes:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;After completing this module, you should know:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;How to take a history and examine a patient with a tremor 
&lt;LI&gt;How to assess a patient with suspected Parkinson's disease 
&lt;LI&gt;When and how to refer a patient with suspected Parkinson's disease&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;These online education tools have been developed by BMJ Learning. BMJ Learning is the best available learning website for medical professionals. It offers a wide range of learning resources, commissioned by the BMJ Group. The learning resources deal with everyday issues in primary care and hospital medicine. They are evidence based and peer reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Free registration with the site is required.&amp;nbsp; To register, click "Start module" and then "Register here".&amp;nbsp; Do not select the option to log in via Athens as access to BMJ Learning is not currently&amp;nbsp;part of NHS Athens accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293349</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18355348?ordinalpos=3&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Patent foramen ovale and migraine: a quantitative systematic review</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,MIGRAINE,HEADACHE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Schwedt, TJ et al Cephalalgia 2008 May;28(5):531-40. Epub 2008 Mar 17&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Initial studies indicate an increased prevalence of patent foramen ovale (PFO) in migraineurs with aura, and an increased prevalence of migraine and migraine with aura in persons with PFO. Retrospective analyses of PFO closure suggest clinically significant improvements in migraine patterns. The aim of this study was to examine the prevalence of migraine in patients with PFO, the prevalence of PFO in migraineurs, and the effect of PFO closure on migraine. We conducted a quantitative systematic review of articles on migraine and PFO that met inclusion criteria, then reviewed, appraised, and subjected them to data extraction. Of 134 articles identified, 18 met a priori selection criteria. The estimated strength of association between PFO and migraine, reflected by summary odds ratios (ORs), was 5.13 [95% confidence interval (CI) 4.67, 5.59], and between PFO and migraine with aura the OR was 3.21 (95% CI 2.38, 4.17). The grade of evidence was low. The association between migraine and PFO was OR 2.54 (95% CI 2.01, 3.08). The grade of evidence was low to moderate. Six studies of PFO closure suggested improvement in migraine, but had a very low grade of evidence. The low-to-moderate grade of evidence from observational studies supports an apparent association between PFO and migraine. Although PFO closure seemed to affect migraine patterns favourably, the very low grade of available evidence to support this association precludes definitive conclusions.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314409</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.expert-reviews.com/doi/abs/10.1586/14737167.7.4.373]]&gt;</url>
    <title>Patient-reported outcomes measurements in epilepsy</title>
    <publicationDate></publicationDate>
    <publisher>Expert Reviews Ltd</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Stafford M, Gavriel S, Lloyd A. (2007) Patient-reported outcomes measurements in epilepsy. &lt;EM&gt;Expert Review of Pharmacoeconomics and Outcomes Research&lt;/EM&gt; 7(4):373-84.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Literature searches were conducted through EMBASE.com and supplemented with hand searching of relevant articles. References obtained through hand searches were compared with EMBASE.com citations until we were confident that the review had reached a point of saturation. The search included English language papers published between January 1997 and March 2007.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 61 studies were considered relevant to the current review and were included in the study. Several instruments that have been designed and validated to measure patient-reported outcomes in an epilepsy population are currently being used, including the Quality of Life in Epilepsy (QOLIE)-89 and -31, the Liverpool Seizure Severity Scale and the Washington Psychosocial Seizure Inventory. In addition, the QOLIE-adolescent (QOLIE-AD)-48 and the Adolescent Psychosocial Seizure Inventory have been designed for use with adolescent epileptic patients. We found a paucity of valid condition-specific instruments assessing patient preference and patient satisfaction in this population. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Several condition-specific instruments exist to measure patient-reported outcomes in epilepsy, specifically in the areas of health-related quality of life, patient-reported symptoms and psychosocial functioning. However, measures designed to assess other areas of patient-reported outcomes, such as patient preference and satisfaction, are poorly developed.&lt;!-- /abstract content --&gt;&lt;!-- fulltext content --&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; August 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293080</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17940243?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Pediatric headache: an examination of process variables in treatment</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>Sage</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Cvengros, JA et al Journal of Child Neurology 2007 Oct;22(10):1172-81&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;The goal of this article is to provide a rational methodological review of studies addressing the treatment of childhood headache. In particular, the goal is to provide a review of process variables that may be associated with the efficacy of behavioral and psychological treatments for childhood headache. A search for studies that examined the efficacy of treatment for headache among children younger than 12 years of age was conducted using Medline from 1966 to 2005. A total of 9 studies were selected for the present systematic review. The findings from this study suggest that although research supports the use of behavioral treatments for headache among this patient population, process variables such as child demographics, as well as treatment characteristics such as time in treatment, may moderate treatment efficacy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293081</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17550953?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Pediatric migraine: pharmacologic agents for prophylaxis</title>
    <publicationDate>2007-07-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books company</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,MIGRAINE,HEADACHE &amp; PAIN,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Eiland, LS et al Annals of Pharmacotherapy&amp;nbsp;2007 Jul;41(7):1181-90. Epub 2007 Jun 5.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: To identify and evaluate the data regarding medication use for migraine prophylaxis in the pediatric population. DATA SOURCES: Literature was obtained through searches in PubMed (Mid 1950s-March 2007), Iowa Drug Information Service/Web (1966-February 2007), International Pharmaceutical Abstracts (1970-February 2007), and the Cochrane Library. The terms migraine, prophylaxis, child, and children were used and cross referenced with all drug names. Reference citations from publications identified were also reviewed and included. STUDY SELECTION AND DATA EXTRACTION: Only trials that evaluated migraine headaches in the pediatric population were included. Trials including adolescent and adult populations are briefly listed, but not reviewed. Trials involving non-prescription medication were also included in the evaluation. Due to the limited information, all clinical trials, retrospective reviews, and abstracts evaluated were included in this review. DATA SYNTHESIS: Few controlled clinical trials regarding prophylaxis therapy are available. Currently, no medications are approved by the Food and Drug Administration for prophylaxis of migraines in children. Seventeen drugs were identified and included in the review. Of the drugs with available data, topiramate, valproic acid, flunarizine, amitriptyline, and cyproheptadine have shown efficacy in decreasing migraine frequency and duration in children. However, larger clinical trials are necessary to validate the utility of these agents. Conflicting data exist for propranolol and pizotifen, and additional data are needed for gabapentin, levetiracetam, zonisamide, naproxen, and trazodone. In clinical trials, nimodipine, clonidine, and natural supplements have shown a lack of efficacy versus placebo for prophylaxis of migraines in children. CONCLUSIONS: Topiramate, valproic acid, and amitriptyline have the most data on their use for prophylaxis of migraines in children. Numerous agents have limited data in this population and several agents lack efficacy. Prospective, well designed, controlled clinical trials that include quality-of-life and functional outcomes are needed for guiding therapy of migraine prophylaxis for children.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344176</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19302397]]&gt;</url>
    <title>Perceived health status as measured by the SF-36 in patients with multiple sclerosis: a review</title>
    <publicationDate>2009-03-02T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Krokavcova M, van Dijk JP, Nagyova I, Rosenberger J, Gavelova M, Gdovinova Z, et al. Perceived health status as measured by the SF-36 in patients with multiple sclerosis: a review. &lt;EM&gt;Scandinavian Journal of Caring Sciences&lt;/EM&gt; 2009;23(3):529-39.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; This review of literature gives an overview of recent studies about perceived health status as measured by the Short-Form-36 (SF-36) Health Survey in patients with multiple sclerosis (MS). The SF-36 is one of the tools measuring health status in patients used in international research and clinical practice. It measures two main health concepts - physical and mental. The SF-36 represents a valid instrument able to detect differences in perceived health status in patients. A computer-aided search in Medline and PsycINFO resulted in 504 articles in English published from 1996 to August 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; After the screening process on the basis of abstracts, eight articles consisting of empirical studies remained in which perceived health status was evaluated using the SF-36 Health Survey. Seven studies focused on disability and perceived health status in the SF-36. Two studies focused on the relationship between depression and perceived health status. These studies showed that MS patients with low disability and minor depression scored significantly better than patients with high disability and major depression in the SF-36 health dimensions. Gender seems to have no influence on perceived health status in MS patients. The longer the disease duration and the more severe the disease, the lower the patients scored in perceived health status. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The more disabled, the more depressive and the older the patients, the poorer their perceived health status was.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in March 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396589</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20487039]]&gt;</url>
    <title>Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research</title>
    <publicationDate>2010-05-07T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Ashkenazi A, Blumenfeld A, Napchan U, Narouze S, Grosberg B, Nett R, DePalma T, Rosenthal B, Tepper S, Lipton RB. (2010) Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research. &lt;EM&gt;Headache&lt;/EM&gt; 50(6):943-52&lt;/P&gt;
&lt;P&gt;Professor Peter Goadsby has critically appraised this&amp;nbsp;paper and you can read his analysis &lt;A href="nelh:396687:0" name=internalLink&gt;here&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;Abstract: Interventional procedures such as peripheral nerve blocks (PNBs) and trigger point injections (TPIs) have long been used in the treatment of various headache disorders. There are, however, little data on their efficacy for the treatment of specific headache syndromes. Moreover, there is no widely accepted agreement among headache specialists as to the optimal technique of injection, type, and doses of the local anesthetics used, and injection regimens. The role of corticosteroids in this setting is also debated. We performed a PubMed search of the literature to find studies on PNBs and TPIs for headache treatment. We classified the abstracted studies based on the procedure performed and the treated condition. We found few controlled studies on the efficacy of PNBs for headaches, and virtually none on the use of TPIs for this indication. The most widely examined procedure in this setting was greater occipital nerve block, with the majority of studies being small and non-controlled. The techniques, as well as the type and doses of local anesthetics used for nerve blockade, varied greatly among studies. The specific conditions treated also varied, and included both primary (eg, migraine, cluster headache) and secondary (eg, cervicogenic, posttraumatic) headache disorders. Trigeminal (eg, supraorbital) nerve blocks were used in few studies. Results were generally positive, but should be taken with reservation given the methodological limitations of the available studies. The procedures were generally well tolerated. Evidently, there is a need to perform more rigorous clinical trials to clarify the role of PNBs and TPIs in the management of various headache disorders, and to aim at standardizing the techniques used for the various procedures in this setting.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314439</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18778117]]&gt;</url>
    <title>Pharmacological management of epilepsy: recent advances and future prospects</title>
    <publicationDate></publicationDate>
    <publisher>Adis International</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Johannessen LC, Johannessen SI. (2008) Pharmacological management of epilepsy: recent advances and future prospects. &lt;EM&gt;Drugs&lt;/EM&gt; 68(14):1925-39.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The present review is based on recently published articles and searches in MEDLINE via PubMed (October 2007 to July 2008).&amp;nbsp; The content in the present review was limited to AEDs that have recently been approved or drugs in late-stage development (phase III and onwards). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Rufinamide, brivaracetam and stiripentol have been given the status of orphan drugs. Rufinamide was approved in Europe in 2007 for the use in Lennox-Gastaut syndrome. Brivaracetam has gained orphan status for development in progressive and symptomatic myoclonic seizures in Europe and the US, respectively. Stiripentol has gained orphan status in children with Dravet's syndrome and pharmaco-resistant epilepsy. All of these drugs demonstrate efficacy as adjunctive therapy in partial seizures. Three of the drugs are derivatives of existing AEDs: brivaracetam is a derivative of levetiracetam with improved affinity for the target molecule; carisbamate is a derivative of felbamate with improved tolerability; and eslicarbazepine is a derivative of carbamazepine with less interaction potential and no auto-induction. Lacosamide, retigabine, rufinamide and stiripentol are new compounds, unrelated to other AEDs.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Further investigation and development of new broad-spectrum drugs is important for improved treatment of patients with epilepsy and other neurological and psychiatric disorders.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270564</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17356688]]&gt;</url>
    <title>Phenobarbitol for childhood epilepsy: systematic review</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>LibraPharm</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,FIRST SEIZURE AND EARLY EPILEPSY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Pal D.K. 2006; Paediatric and Perinatal Drug Therapy 7 (1) pp. 31-42&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;INTRODUCTION: Against a background of concern about the safety of new pharmaceutical products, there has been renewed interest in one of the oldest antiepileptic drugs (AEDs), phenobarbital. Although still in widespread use in developing countries, its popularity has slipped in Western countries over the past century, partly because of controversy about its adverse effect profile. This critical review examines the evidence supporting its effectiveness and its associated behavioural adverse effects for febrile convulsions and childhood epilepsy. METHODS: Relevant randomised controlled trials (RCTs) of phenobarbital vs other antiepileptic drugs or placebo between 1970-2005 were identified through a comprehensive manual and computer database search of the world biomedical literature. Eleven RCTs of febrile convulsions and nine RCTs of childhood epilepsy were systematically reviewed against a conventional set of quality criteria. RESULTS: With a few exceptions, the overall quality of clinical trial methodology, especially in the early studies conducted in the 1970s and 1980s, was poor. There is no evidence for a difference in antiepileptic efficacy between phenobarbital and any other compared AED, yet no evidence for absolute efficacy. No convincing evidence exists for an excess of behavioural adverse effects, over other AEDs, attributable to phenobarbital. Masked studies of phenobarbital in childhood epilepsy have shown no significant differences in behavioural or cognitive adverse effects compared to other AEDs. This is in contrast to the excess of such adverse effects reported in studies open to observer bias. However, the one finding of reduction in cognitive ability associated with phenobarbital treatment for febrile convulsions remains a concern. Future areas of clinical and genetic epidemiological research are outlined.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270514</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16146439]]&gt;</url>
    <title>Photic- and pattern-induced seizures: A review for the epilepsy foundation of america working group</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Fisher R.S., Harding G., Erba G. et al. 2005; Epilepsia 46 (9) pp. 1426-41&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;PURPOSE: This report summarizes background material presented to a consensus conference on visually provoked seizures, convened by the Epilepsy Foundation of America. METHODS: A comprehensive review of literature was performed. RESULTS: Photosensitivity, an abnormal EEG response to light or pattern stimulation, occurs in approximately 0.3-3% of the population. The estimated prevalence of seizures from light stimuli is approximately 1 per 10,000, or 1 per 4,000 individuals age 5-24 years. People with epilepsy have a 2-14% chance of having seizures precipitated by light or pattern. In the Pokemon cartoon incident in Japan, 685 children visited a hospital in reaction to red-blue flashes on broadcast television (TV). Only 24% who had a seizure during the cartoon had previously experienced a seizure. Photic or pattern stimulation can provoke seizures in predisposed individuals, but such stimulation is not known to increase the chance of subsequent epilepsy. Intensities of 0.2-1.5 million candlepower are in the range to trigger seizures. Frequencies of 15-25 Hz are most provocative, but the range is 1-65 Hz. Light-dark borders can induce pattern-sensitive seizures, and red color also is a factor. Seizures can be provoked by certain TV shows, movie screen images, video games, natural stimuli (e.g, sun on water), public displays, and many other sources. CONCLUSIONS: Recommendations on reducing risk of seizures have been developed by agencies in the United Kingdom, Japan, and the International Telecommunications Union, affiliated with the United Nations. The Epilepsy Foundation of America has developed a consensus of medical experts and scientists on this subject, reported in an accompanying work.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384291</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.yebeh.2009.10.007]]&gt;</url>
    <title>Placebo responses in randomized trials of antiepileptic drugs</title>
    <publicationDate>2009-11-17T00:00:00</publicationDate>
    <publisher>Epilepsy &amp; Behavior</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Guekht AB, Korczyn AD, Bondareva IB, Gusev EI. (2009) Placebo responses in randomized trials of antiepileptic drugs. &lt;EM&gt;Epilepsy &amp;amp; Behavior&lt;/EM&gt; 17(1):64-9. Epub 2009 Nov 17.&lt;/P&gt;
&lt;P&gt;This meta-analysis of published, randomized, controlled trials (RCTs) of antiepileptic drugs in adults with focal drug-resistant epilepsy was performed to estimate a mean placebo effect, to evaluate variability in placebo response rates, to investigate associations between placebo effect rates and study characteristics, and to determine whether there were changes in placebo response rates over recent years in RCTs (so-called “placebo drift”). One hundred ninety-eight potentially appropriate studies were identified after MEDLINE search and carefully reviewed. Twenty-seven RCTs (with 5662 randomized patients, including 1887 patients in placebo arms) were included in the meta-analysis. A random effects meta-analytic model estimated the pooled placebo response at 12.5% (95% CI: 10.03–14.94%). A statistically significant correlation between baseline median seizure frequency and placebo response rates was not observed. “Placebo drift” was not considered statistically significant.&lt;/P&gt;
&lt;P&gt;Epilepsy &amp;amp; Behavior presents original peer-reviewed articles based on laboratory and clinical research. Topics are drawn from a variety of fields, including clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neurophysiology, neuropharmacology, and neuroimaging. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384458</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1528-1167.2009.02299.x]]&gt;</url>
    <title>Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis</title>
    <publicationDate>2009-09-10T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Beyenburg S, Stavem K, Schmidt D. (2009) Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. &lt;EM&gt;Epilepsia&lt;/EM&gt; 51(1):7-26&lt;/P&gt;
&lt;P&gt;Although adjunctive treatment with modern antiepileptic drugs (AEDs) is standard care in refractory epilepsy, it is unclear how much of the effect can be attributed directly to the AEDs and how much to the beneficial changes seen with placebo. Therefore, we performed a systematic review and meta-analysis of the evidence to determine the placebo-corrected net efficacy of adjunctive treatment with modern AEDs on the market for refractory epilepsy. Of 317 potentially eligible articles reviewed in full text, 124 (39%) fulfilled eligibility criteria. After excluding 69 publications, 55 publications of 54 studies in 11,106 adults and children with refractory epilepsy form the basis of evidence. The overall weighted pooled-risk difference in favor of AEDs over placebo for seizure-freedom in the total sample of adults and children was 6% [95% confidence interval (CI) 4–8, z = 6.47, p &amp;lt; 0.001] and 21% (95% CI 19–24, z = 17.13, p &amp;lt; 0.001) for 50% seizure reduction. Although the presence of moderate heterogeneity may reduce the validity of the results and limit generalizations from the findings, we conclude that the placebo-corrected efficacy of adjunctive treatment with modern AEDs is disappointingly small and suggest that better strategies of finding drugs are needed for refractory epilepsy, which is a major public health problem.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320124</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.parkinsons.org.uk/PDF/APPG_Report_Please_Mind_the_Gap.pdf]]&gt;</url>
    <title>Please mind the gap: Parkinson’s disease services today</title>
    <publicationDate></publicationDate>
    <publisher>All Party Parliamentary Group for Parkinson’s Disease</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DELIVERY OF CARE,MOVEMENT DISORDERS,PARKINSON'S DISEASE,HEALTH MANAGEMENT,QUALITY AND MONITORING,SERVICE DELIVERY,NHS ACTIVITIES,LATER LIFE,PARKINSON'S DISEASE,CONDITIONS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,QUALITY IMPROVEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;FONT face=HelveticaNeue-Roman size=2&gt;&lt;FONT face=HelveticaNeue-Roman size=2&gt;
&lt;P&gt;This All Party Parliamentary Group for Parkinson's Disease inquiry was carried out in response to growing concerns about variations in access to the comprehensive services and expert multi-disciplinary care needed by people with this complex condition.&lt;/P&gt;
&lt;P&gt;The evidence submitted painted a stark picture of inequalities in access to services for people with Parkinson’s disease and their carers across England, Wales and Northern Ireland. These inequalities persist despite clear, evidence-based guidelines for the provision of services, including the National Institute for Health and Clinical Excellence (NICE) guideline for Parkinson’s disease, Welsh Neurosciences Expert Review and National Service Framework (NSF) for long-term neurological conditions in England.&lt;/P&gt;
&lt;P&gt;The evidence also pointed to a number of major barriers to the delivery of consistent, high quality services.&lt;/P&gt;&lt;/FONT&gt;&lt;/FONT&gt;]]&gt;</body>
  </document>
  <document>
    <id>386655</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2008.01858.x/abstract]]&gt;</url>
    <title>Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(4):898-903&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Approximately one-third of patients with epilepsy patients have recurrent seizures despite therapy. It has been suggested that therapeutic failure is associated with high expression of the multidrug efflux ABCB1 (MDR1) drug-transporter; specifically, that patients with the 3435CC genotype have higher efflux of anticonvulsants out of brain tissue, with correspondingly lower concentrations in the central nervous system.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We conducted a meta-analysis to examine the association between MDR1 polymorphisms and the response to anticonvulsants. We included all published studies until September 2007, in which patients with responsive and unresponsive seizure disorders underwent genotyping for ABCB1 C3435T. Individual and summary odds ratios were calculated using a random effects model. A secondary analysis was also performed, stratifying the studies by their ethnic distribution to account for genetic heterogeneity. We also performed a cumulative analysis by date of publication for the included studies using a random effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 11 case-control studies involving 3,371 patients (1,646 patients with drug-resistant epilepsy and 1,725 controls). We identified no significant association between anticonvulsant drug resistance and MDR1 polymorphism [odds ratio 1.15; 95% confidence interval (CI) 0.78–1.70; p = 0.48). Subanalysis of studies according to ethnicity yielded similar findings [European cohort: OR = 1.31; 95% CI 0.89–1.94, p = 0.18; Asian cohort: OR = 0.99; 95% CI 0.51–1.89, p = 0.96).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; We found no association between ABCB1 genotype and response to anticonvulsant drugs. At the present time, genetic typing for MDR1 polymorphism is not warranted for patients with drug-resistant epilepsy.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288491</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17463073?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Pooled historical MRI data as a basis for research in multiple sclerosis--a statistical evaluation</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Houndsmills</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN title="Multiple sclerosis (Houndmills, Basingstoke, England)."&gt;Schach, S et al &lt;A href="#javascript:AL_get(this," Scler.?);? ?Mult ?jour?,&gt;Mult Scler.&lt;/A&gt;&lt;/SPAN&gt; 2007 May;13(4):509-16&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Pooled data from placebo groups of different trials can serve as historical control for ongoing or future therapeutic studies and as a reference for power calculations. In order to assess their usefulness for this purpose, we investigated the degree of heterogeneity of placebo arm data from 14 controlled studies included in the database of the Sylvia Lawry Centre for Multiple Sclerosis Research. Since different criteria for the inclusion/exclusion of patients were used in these studies, an attempt was made to adjust the distribution of magnetic resonance imaging (MRI) measures for the differences in the study populations. The analyses showed that, even after adjustment, significant differences remained. This heterogeneity does not reduce the usefulness of the database for statistical analysis of inter-relationships between variables, provided that it is explicitly taken into account as a stratification factor. However, care must be taken when trying to compare the results of a newly treated group with the patients of this pool. Heterogeneity in some MRI variables was greatly reduced when only studies from the same image analysis centre were compared.&lt;/P&gt;
&lt;P class=abstract&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Full text available to NHS users via NHS Athens password&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314131</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17364531]]&gt;</url>
    <title>Post-traumatic seizure disorder following acquired brain injury</title>
    <publicationDate>2007-02-01T00:00:00</publicationDate>
    <publisher>Taylor &amp; Francis</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,ACUTE SYMPTOMATIC SEIZURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Teasell R, Bayona N, Lippert C, Villamere J, Hellings C. (2007) Post-traumatic seizure disorder following acquired brain injury. &lt;EM&gt;Brain Injury&lt;/EM&gt; 21(2):201-14.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic review of the literature from 1980-2005 was conducted focusing on treatment interventions available for post-traumatic seizures following ABI. The evidence for the efficacy of a given intervention was ranked as strong (supported by at least two randomized controlled trials (RCTs), moderate (supported by a single RCT), or limited (supported by other types of studies in the absence of RCTs). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Based on a previous meta-analysis and the findings of this review, there is strong evidence that prophylactic anticonvulsant therapy decreases the occurrence of early seizures but only within the first week post-injury. Moreover, the evidence indicates that prophylactic anticonvulsant therapy does not decrease the incidence of seizure onset more than one week post-injury. In children, there is moderate evidence that prophylactic phenytoin does not reduce the incidence of early or late seizures. The efficacy of anticonvulsants after the development of seizures has not been specifically studied in ABI.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Prophylactic anti-convulsants are effective in reducing seizures in the first week post-injury in adults. However, they do not reduce the occurrence of seizures after the first week.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;February 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386645</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.neurology.org/cgi/content/abstract/WNL.0b013e3181a6b2f8v1]]&gt;</url>
    <title>Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review). Obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society</title>
    <publicationDate>2009-03-23T00:00:00</publicationDate>
    <publisher>Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Harden CL, Hopp J, Ting TY, Pennell PB, French JA, Hauser WA, Wiebe S, Gronseth GS, Thurman D, Meador KJ, Koppel BS, Kaplan PW, Robinson JN Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Le Guen C. Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review). Obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. &lt;EM&gt;Neurology&lt;/EM&gt; 2009;73(2):126-13&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy, including the risk of pregnancy complications or other medical problems during pregnancy in WWE compared to other women, change in seizure frequency, the risk of status epilepticus, and the rate of remaining seizure-free during pregnancy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A 20-member committee including general neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review and classification of relevant articles published between 1985 and February 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; For WWE taking antiepileptic drugs, there is probably no substantially increased risk (greater than two times expected) of cesarean delivery or late pregnancy bleeding, and probably no moderately increased risk (greater than 1.5 times expected) of premature contractions or premature labor and delivery. There is possibly a substantially increased risk of premature contractions and premature labor and delivery during pregnancy for WWE who smoke. Seizure freedom for at least 9 months prior to pregnancy is probably associated with a high likelihood (84%–92%) of remaining seizure-free during pregnancy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommendations:&lt;/STRONG&gt; Women with epilepsy (WWE) should be counseled that seizure freedom for at least 9 months prior to pregnancy is probably associated with a high rate (84%–92%) of remaining seizure-free during pregnancy (Level B). However, WWE who smoke should be counseled that they possibly have a substantially increased risk of premature contractions and premature labor and delivery during pregnancy (Level C).&lt;/P&gt;
&lt;P&gt;Neurology is the official journal of the American Academy of Neurology. The publication is aimed at clinical neurologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386646</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.neurology.org/cgi/content/abstract/73/2/142]]&gt;</url>
    <title>Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review). Vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society</title>
    <publicationDate>2009-04-27T00:00:00</publicationDate>
    <publisher>Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, Hopp MD, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen C (2009) Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review). Vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. &lt;EM&gt;Neurology&lt;/EM&gt; 73(2):142-149&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy, including preconceptional folic acid use, prenatal vitamin K use, risk of hemorrhagic disease of the newborn, clinical implications of placental and breast milk transfer of antiepileptic drugs (AEDs), risks of breastfeeding, and change in AED levels during pregnancy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A 20-member committee evaluated the available evidence based on a structured literature review and classification of relevant articles published between 1985 and October 2007. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Preconceptional folic acid supplementation is possibly effective in preventing major congenital malformations in the newborns of WWE taking AEDs. There is inadequate evidence to determine if the newborns of WWE taking AEDs have a substantially increased risk of hemorrhagic complications. Primidone and levetiracetam probably transfer into breast milk in amounts that may be clinically important. Valproate, phenobarbital, phenytoin, and carbamazepine probably are not transferred into breast milk in clinically important amounts. Pregnancy probably causes an increase in the clearance and a decrease in the concentration of lamotrigine, phenytoin, and to a lesser extent carbamazepine, and possibly decreases the level of levetiracetam and the active oxcarbazepine metabolite, the monohydroxy derivative. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommendations:&lt;/STRONG&gt; Supplementing women with epilepsy with at least 0.4 mg of folic acid before they become pregnant may be considered (Level C). Monitoring of lamotrigine, carbamazepine, and phenytoin levels during pregnancy should be considered (Level B) and monitoring of levetiracetam and oxcarbazepine (as monohydroxy derivative) levels may be considered (Level C). A paucity of evidence limited the strength of many recommendations. &lt;/P&gt;
&lt;P&gt;Neurology is the official journal of the American Academy of Neurology. The publication is aimed at clinical neurologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386644</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.neurology.org/cgi/content/abstract/73/2/133]]&gt;</url>
    <title>Practice parameter update: management issues for women with epilepsy - focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society</title>
    <publicationDate>2010-04-27T00:00:00</publicationDate>
    <publisher>Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C. (2009) Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. &lt;EM&gt;Neurology&lt;/EM&gt; 73(2):133-141&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Systematic review of relevant articles published between January 1985 and June 2007. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine. Compared to untreated WWE, it is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. It is probable that antiepileptic drug (AED) polytherapy as compared to monotherapy regimens contributes to the development of MCMs and to reduced cognitive outcomes. For monotherapy, intrauterine exposure to VPA probably reduces cognitive outcomes. Further, monotherapy exposure to phenytoin or phenobarbital possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of &amp;lt;7. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommendations:&lt;/STRONG&gt; If possible, avoidance of valproate (VPA) and antiepileptic drug (AED) polytherapy during the first trimester of pregnancy should be considered to decrease the risk of major congenital malformations (Level B). If possible, avoidance of VPA and AED polytherapy throughout pregnancy should be considered to prevent reduced cognitive outcomes (Level B). If possible, avoidance of phenytoin and phenobarbital during pregnancy may be considered to prevent reduced cognitive outcomes (Level C). Pregnancy risk stratification should reflect that the offspring of women with epilepsy taking AEDs are probably at increased risk for being small for gestational age (Level B) and possibly at increased risk of 1-minute Apgar scores of &amp;lt;7 (Level C). &lt;/P&gt;
&lt;P&gt;Neurology is the official journal of the American Academy of Neurology. The publication is aimed at clinical neurologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270571</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Neurology%22%5BJour%5D%20AND%2067%5Bvolume%5D%20AND%209%5Bissue%5D%20AND%201542%5Bpage%5D%20AND%202006%5Bpdat%5D]]&gt;</url>
    <title>Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review) - Report of the quality standards subcommittee of the American academy of neurology and the practice committee of the child neurology society</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,STATUS EPILEPTICUS,FIRST SEIZURE AND EARLY EPILEPSY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Riviello J.J. Jr, Ashwal S., Hirtz D.&amp;nbsp; 2006; Neurology 67 (9) pp. 1542-50&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To review evidence on the assessment of the child with status epilepticus (SE). METHODS: Relevant literature were reviewed, abstracted, and classified. When data were missing, a minimum diagnostic yield was calculated. Recommendations were based on a four-tiered scheme of evidence classification. RESULTS: Laboratory studies (Na(++) or other electrolytes, Ca(++), glucose) were abnormal in approximately 6% and are generally ordered as routine practice. When blood or spinal fluid cultures were done on these children, blood cultures were abnormal in at least 2.5% and a CNS infection was found in at least 12.8%. When antiepileptic drug (AED) levels were ordered in known epileptic children already taking AEDs, the levels were low in 32%. A total of 3.6% of children had evidence of ingestion. When studies for inborn errors of metabolism were done, an abnormality was found in 4.2%. Epileptiform abnormalities occurred in 43% of EEGs of children with SE and helped determine the nature and location of precipitating electroconvulsive events (8% generalized, 16% focal, and 19% both). Abnormalities on neuroimaging studies that may explain the etiology of SE were found in at least 8% of children. RECOMMENDATIONS: Although common clinical practice is that blood cultures and lumbar puncture are obtained if there is a clinical suspicion of a systemic or CNS infection, there are insufficient data to support or refute recommendations as to whether blood cultures or lumbar puncture should be done on a routine basis in children in whom there is no clinical suspicion of a systemic or CNS infection (Level U). AED levels should be considered when a child with treated epilepsy develops SE (Level B). Toxicology studies and metabolic studies for inborn errors of metabolism may be considered in children with SE when there are clinical indicators for concern or when the initial evaluation reveals no etiology (Level C). An EEG may be considered in a child with SE as it may be helpful in determining whether there are focal or generalized epileptiform abnormalities that may guide further testing for the etiology of SE, when there is a suspicion of pseudostatus epilepticus (nonepileptic SE), or nonconvulsive SE, and may guide treatment (Level C). Neuroimaging may be considered after the child with SE has been stabilized if there are clinical indications or if the etiology is unknown (Level C). There is insufficient evidence to support or refute routine neuroimaging in a child presenting with SE (Level U).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>343146</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20101040]]&gt;</url>
    <title>Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review)</title>
    <publicationDate>2010-01-26T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DELIVERY OF CARE,STRUCTURAL,REHABILITATION,JANUARY 2010,CONDITIONS,CEREBRAL PALSY,SYMPTOM MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, Morrison LA, Shrader MW, Tilton A, Vargus-Adams J. (2010) Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. &lt;EM&gt;Neurology&lt;/EM&gt; 74(4):336-43.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A multidisciplinary panel systematically reviewed relevant literature from 1966 to July 2008. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; For localized/segmental spasticity, botulinum toxin type A is established as an effective treatment to reduce spasticity in the upper and lower extremities. There is conflicting evidence regarding functional improvement. Botulinum toxin type A was found to be generally safe in children with cerebral palsy; however, the Food and Drug Administration is presently investigating isolated cases of generalized weakness resulting in poor outcomes. No studies that met criteria are available on the use of phenol, alcohol, or botulinum toxin type B injections. For generalized spasticity, diazepam is probably effective in reducing spasticity, but there are insufficient data on its effect on motor function and its side-effect profile. Tizanidine is possibly effective, but there are insufficient data on its effect on function and its side-effect profile. There were insufficient data on the use of dantrolene, oral baclofen, and intrathecal baclofen, and toxicity was frequently reported. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Recommendations:&lt;/STRONG&gt; For localized/segmental spasticity that warrants treatment, botulinum toxin type A should be offered as an effective and generally safe treatment (Level A). There are insufficient data to support or refute the use of phenol, alcohol, or botulinum toxin type B (Level U). For generalized spasticity that warrants treatment, diazepam should be considered for short-term treatment, with caution regarding toxicity (Level B), and tizanidine may be considered (Level C). There are insufficient data to support or refute use of dantrolene, oral baclofen, or continuous intrathecal baclofen (Level U). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 26 January 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314513</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.aan.com/elibrary/continuum/?event=home.showIssue&amp;issue=ovid.com:/issue/ovftdb/00132979-200708000-00000]]&gt;</url>
    <title>Practice parameter: temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons</title>
    <publicationDate></publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,NEUROSURGERY,EPILEPSY AND SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Engel J, Wiebe S, French J, Sperling M, Williamson P, Spencer D, et al. (2007)&amp;nbsp;Practice parameter: Temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons. &lt;EM&gt;CONTINUUM Lifelong Learning in Neurology&lt;/EM&gt; 13(4 EPILEPSY):225-34.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Systemic review and analysis of the literature since 1990. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; One intention-to-treat Class I randomized controlled trial of surgery for mesial temporal lobe epilepsy found that 58% of patients randomized to be evaluated for surgical therapy (64% of those who received surgery) were free of disabling seizures and 10 to 15% were unimproved at the end of 1 year, compared with 8% free of disabling seizures in the group randomized to continued medical therapy. There was a significant improvement in quantitative quality-of-life scores and a trend toward better social function at the end of 1 year for patients in the surgical group, no surgical mortality, and infrequent morbidity. Twenty-four Class IV series of temporal lobe resections yielded essentially identical results. There are similar Class IV results for localized neocortical resections; no Class I or II studies are available. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; A single Class I study and 24 Class IV studies indicate that the benefits of anteromesial temporal lobe resection for disabling complex partial seizures is greater than continued treatment with antiepileptic drugs, and the risks are at least comparable. For patients who are compromised by such seizures, referral to an epilepsy surgery center should be strongly considered. Further studies are needed to determine if neocortical seizures benefit from surgery, and whether early surgical intervention should be the treatment of choice for certain surgically remediable epileptic syndromes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371756</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20231670?dopt=Abstract]]&gt;</url>
    <title>Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.</title>
    <publicationDate>2010-03-16T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,PARKINSON'S DISEASE,MOVEMENT DISORDERS,PARKINSON'S DISEASE &amp; AKINETIC RIGID SYNDROMES,CONDITIONS,APRIL 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Zesiewicz, T. A., Sullivan, K. L., Arnulf, I., Chaudhuri, K. R., Morgan, J. C., Gronseth, G. S., Miyasaki, J., Iverson, D. J., Weiner, W. J. (2010) Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74(11):924-31.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A literature search of MEDLINE, EMBASE, and Science Citation Index was performed to identify clinical trials in patients with nonmotor symptoms of PD published between 1966 and August 2008. Articles were classified according to a 4-tiered level of evidence scheme and recommendations were based on the level of evidence. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results and recommendations:&lt;/STRONG&gt; Sildenafil citrate (50 mg) may be considered to treat erectile dysfunction in patients with Parkinson disease (PD) (Level C). Macrogol (polyethylene glycol) may be considered to treat constipation in patients with PD (Level C). The use of levodopa/carbidopa probably decreases the frequency of spontaneous nighttime leg movements, and should be considered to treat periodic limb movements of sleep in patients with PD (Level B). There is insufficient evidence to support or refute specific treatments for urinary incontinence, orthostatic hypotension, and anxiety (Level U). Future research should include concerted and interdisciplinary efforts toward finding treatments for nonmotor symptoms of PD.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 16th March 2010&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if they have a local subscription. Abstracts and tables of contents are free for all to view. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398046</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://stroke.ahajournals.org/cgi/content/short/41/11/2525?rss=1]]&gt;</url>
    <title>Predictors of hospital readmission: a systematic review</title>
    <publicationDate>2010-10-07T00:00:00</publicationDate>
    <publisher>American Heart Association American Stroke Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Lichtman JH, Leifheit-Limson EC, Jones SB, Watanabe E, Bernheim SM, Phipps MS, Bhat KR, Savage SV, Goldstein LB. (2010) Predictors of hospital readmission: a systematic review. &lt;EM&gt;Stroke&lt;/EM&gt; 41(11):2525-2533&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and purpose:&lt;/STRONG&gt; Risk-standardized hospital readmission rates are used as publicly reported measures reflecting quality of care. Valid risk-standardized models adjust for differences in patient-level factors across hospitals. We conducted a systematic review of peer-reviewed literature to identify models that compare hospital-level poststroke readmission rates, evaluate patient-level risk scores predicting readmission, or describe patient and process-of-care predictors of readmission after stroke. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Relevant studies in English published from January 1989 to July 2010 were identified using MEDLINE, PubMed, Scopus, PsycINFO, and all Ovid Evidence-Based Medicine Reviews. Authors of eligible publications reported readmission within 1 year after stroke hospitalization and identified 1 predictors of readmission in risk-adjusted statistical models. Publications were excluded if they lacked primary data or quantitative outcomes, reported only composite outcomes, or had &amp;lt;100 patients. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of 374 identified publications, 16 met the inclusion criteria for this review. No model was specifically designed to compare risk-adjusted readmission rates at the hospital level or calculate scores predicting a patient’s risk of readmission. The studies providing multivariable models of patient-level and/or process-of-care factors associated with readmission varied in stroke definitions, data sources, outcomes (all-cause and/or stroke-related readmission), durations of follow-up, and model covariates. Few characteristics were consistently associated with readmission. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; This review identified no risk-standardized models for comparing hospital readmission performance or predicting readmission risk after stroke. Patient-level and system-level factors associated with readmission were inconsistent across studies. The current literature provides little guidance for the development of risk-standardized models suitable for the public reporting of hospital-level stroke readmission performance. &lt;/P&gt;
&lt;P&gt;Stroke is a monthly publication and part of AHA Journals, produced&amp;nbsp;by&amp;nbsp;the American Heart Association whose mission is to build healthier lives, free of cardiovascular diseases and stroke.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Most full text is&amp;nbsp;only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Some full text content plus abstracts and tables of contents are freely available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313841</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2660205&amp;blobtype=pdf]]&gt;</url>
    <title>Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts</title>
    <publicationDate>2008-06-18T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. (2008)Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. &lt;EM&gt;Epilepsy Research&lt;/EM&gt; 81(1):1-13&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed a systematic literature review to identify all published registries and cohort studies of births from pregnant women with epilepsy (WWE) that reported incidence of CMs. Overall incidences were calculated using a random effects model.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&amp;nbsp; &lt;/STRONG&gt;The review included 59 studies that met inclusion/exclusion criteria, involving 65,533 pregnancies in WWE and 1,817,024 in healthy women. The calculated incidence of births with CM in WWE [7.08%; 95% CIs 5.62, 8.54] was higher than healthy women [2.28%; CIs 1.46, 3.10]. Incidence was highest for AED polytherapy [16.78%; CIs 0.51, 33.05]. The AED with the highest CM incidence was valproate, which was 10.73% [CIs 8.16, 13.29] for valproate monotherapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion: &lt;/STRONG&gt;Results of this systematic literature review suggest that the overall incidence of CMs in children born of WWE is approximately threefold that of healthy women. The risk is elevated for all AED monotherapy and further elevated for AED polytherapy compared to women without epilepsy. The risk was significantly higher for children exposed to valproate monotherapy and to polytherapy of 2 or more drugs when the polytherapy combination included phenobarital, phenytoin, or valproate. Further research is needed to delineate the specific risk for each individual AED and to determine underlying mechanisms including genetic risk factors.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is freely available via PubMed Central.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320119</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.alzheimers.org.uk/site/scripts/download.php?fileID=735]]&gt;</url>
    <title>Prepared to care: challenging the dementia skills gap</title>
    <publicationDate>2009-06-01T00:00:00</publicationDate>
    <publisher>All-Party Parliamentary Group on Dementia</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,SERVICE SECTORS,EDUCATION / CPD,HEALTH AND SOCIAL CARE,WORKFORCE,MENTAL HEALTH SERVICES,LATER LIFE,DEMENTIA,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DELIVERY OF CARE,DEMENTIA,CONDITIONS,SOCIAL CARE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The All-Party Parliamentary Group (APPG) on Dementia was created to build support for dementia to be a publicly stated health and social care priority in order to meet one of the greatest challenges presented by our ageing population.&lt;/P&gt;
&lt;P&gt;In this report the All-Party Parliamentary Group on Dementia examines the readiness of the social care workforce to deliver personalised care to people with dementia.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322509</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1001/jama.300.6.711]]&gt;</url>
    <title>Prevalence of chronic pain after traumatic brain injury: a systematic review</title>
    <publicationDate>2008-08-13T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE,HEADACHE &amp; PAIN,TRAUMA,BRAIN INJURY,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Nampiaparampil DE. Prevalence of chronic pain after traumatic brain injury: a systematic review. &lt;EM&gt;JAMA&lt;/EM&gt; 2008;300(6):711-9. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The Ovid/MEDLINE database was searched for articles published between 1951 and February 2008 using any combination of the terms brain injury, pain, headache, blast injury, and combat (combat disorders, war, military medicine, wounds and injuries, military personnel, veterans). The PubMed and MD Consult databases were searched in a similar fashion. The Cochrane Collaboration, National Institutes of Health Clinical Trials Database, Meta-Register of Current Controlled Trials, and CRISP databases were searched using the keyword brain injury. All articles in peer-reviewed journals reporting original data on pain syndromes in adult patients with TBI with regard to pain prevalence, pain category, risk factors, pathogenesis, and clinical course were selected, and manual searches were performed of their reference lists. The data were pooled and prevalence rates calculated. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-three studies (15 cross-sectional, 5 prospective, and 3 retrospective) including 4206 patients were identified. Twelve studies assessed headache pain in 1670 patients. Of these, 966 complained of chronic headache, yielding a prevalence of 57.8% (95% confidence interval [CI], 55.5%-60.2%). Among civilians, the prevalence of chronic pain was greater in patients with mild TBI (75.3% [95% CI, 72.7%-77.9%]) compared with moderate or severe TBI (32.1% [95% CI, 29.3%-34.9%]). Twenty studies including 3289 civilian patients with TBI yielded a chronic pain prevalence of 51.5% (95% CI, 49.8%-53.2%). Three studies assessed TBI among 917 veterans and yielded a pain prevalence of 43.1% (95% CI, 39.9%-46.3%). PTSD may mediate chronic pain, but brain injury appears to have an independent correlation with chronic pain. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Chronic pain is a common complication of TBI. It is independent of psychologic disorders such as PTSD and depression and is common even among patients with apparently minor injuries to the brain. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 13 August 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; The &lt;A href="http://dx.doi.org/10.1001/jama.300.6.711" target="_blank"&gt;full text&lt;/A&gt; of this article is freely available at the publisher's website.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344136</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://cjns.metapress.com/link.asp?id=46078564343w4674]]&gt;</url>
    <title>Prevalence of multiple sclerosis in Canada: a systematic review</title>
    <publicationDate>2008-11-01T00:00:00</publicationDate>
    <publisher>MetaPress</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Poppe AY, Wolfson C, Zhu B. Prevalence of multiple sclerosis in Canada: a systematic review. &lt;EM&gt;Canadian Journal of Neurological Sciences&lt;/EM&gt; 2008 Nov;35(5):593-601.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic review of all studies addressing the prevalence of multiple sclerosis (MS) in Canada or regions within Canada, published in English or French since 1985, was conducted. Studies were identified using MEDLINE, EMBASE and bibliographic review. Ten studies were evaluated for methodological rigour and a test of heterogeneity across studies was performed and a measure of consistency (&lt;I&gt;I&lt;SUP&gt;2&lt;/SUP&gt;&lt;/I&gt;) estimated.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Studies were generally of high quality. Nine were restricted to regions within Canada and one provided an estimated national prevalence based on self-reported cases. All reported a high prevalence (&amp;gt;50 per 100,000). Latitude and longitude gradients were not striking while assessment of heterogeneity confirmed that regional differences were unlikely to be the result of sampling variability.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This review confirms Canada as a country of very high MS prevalence and it is the first study to demonstrate that variation in regional estimates represents true differences in prevalence within Canada. Avenues for future MS prevalence research, including adoption of a national MS registry, are proposed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published November 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325923</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/S1474-4422(09)70236-4]]&gt;</url>
    <title>Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis</title>
    <publicationDate>2009-09-24T00:00:00</publicationDate>
    <publisher>Lancet Publishing Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ LATER LIFE,DEMENTIA,STROKE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,DEMENTIA,COMPLICATING MEDICAL DISORDERS,CARDIOVASCULAR DISEASE,CONDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Pendlebury ST, Rothwell PM. (2009) Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. &lt;EM&gt;Lancet Neurology&lt;/EM&gt;, Early Online Publication, 24 September 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Studies published between 1950 and May 1, 2009, were identified from bibliographic databases, reference lists, and journal contents pages. Studies were included if they were on patients with symptomatic stroke, were published in English, reported on a series of consecutive eligible patients or volunteers in prospective cohort studies, included all stroke or all ischaemic stroke, measured dementia by standard criteria, and followed up patients for at least 3 months after stroke. Pooled rates of dementia were stratified by study setting, inclusion or exclusion of pre-stroke dementia, and by first, any, or recurrent stroke. Pooled odds ratios were calculated for factors associated with pre-stroke and post-stroke dementia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 22 hospital-based and eight population-based eligible cohorts (7511 patients) described in 73 papers. The pooled prevalence of pre-stroke dementia was higher (14·4%, 95% CI 12·0—16·8) in hospital-based studies than in population-based studies (9·1%, 6·9—11·3). Although post-stroke (=1 year) dementia rates were heterogeneous overall, 93% of the variance was explained by study methods and case mix; the rates ranged from 7·4% (4·8—10·0) in population-based studies of first-ever stroke in which pre-stroke dementia was excluded to 41·3% (29·6—53·1) in hospital-based studies of recurrent stroke in which pre-stroke dementia was included. The cumulative incidence of dementia after the first year was little greater (3·0%, 1·3—4·7) per year in hospital-based studies than expected on the basis of recurrent stroke alone. Medial temporal lobe atrophy, female sex, and a family history of dementia were strongly associated with pre-stroke dementia, whereas the characteristics and complications of the stroke and the presence of multiple lesions in time and place were more strongly associated with post-stroke dementia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; After study methods and case mix are taken into account, reported estimates of the prevalence of dementia are consistent: 10% of patients had dementia before first stroke, 10% developed new dementia soon after first stroke, and more than a third had dementia after recurrent stroke. The strong association of post-stroke dementia with multiple strokes and the prognostic value of other stroke characteristics highlight the central causal role of stroke itself as opposed to the underlying vascular risk factors and, thus, the likely effect of optimum acute stroke care and secondary prevention in reducing the burden of dementia.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 24 September 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is&amp;nbsp;only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325928</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19752296]]&gt;</url>
    <title>Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis</title>
    <publicationDate>2009-09-01T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,CONDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; van de Beek D, Wijdicks EF, Vermeij FH, de Haan RJ, Prins JM, Spanjaard L, Dippel DW, Nederkoorn PJ. (2009) Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis. &lt;EM&gt;Arch Neurol&lt;/EM&gt;. 66(9):1076-81.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The MEDLINE (1966-February 2009) and Cochrane databases and reference lists of retrieved articles. Randomized controlled trials on preventive antibiotic treatment in stroke. For inclusion, at least case fatality or infection rate had to be recorded. Each study was scored for methodological key issues and appraised by the Jadad scale. We extracted the data using a predetermined protocol and included all patients who were randomized or who started therapy in an intent-to-treat analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 4 randomized clinical trials including 426 patients; 94% had ischemic stroke. Study interventions were fluoroquinolones in 2 and tetracycline or a combination of beta-lactam antibiotic with beta-lactamase inhibitor in 1. Therapy was started within 24 hours of stroke onset. Duration of therapy varied between 3 and 5 days. The methodological quality ranged from 2 to 5 on the Jadad scale, and studies were subject to potential bias. The proportion of patients with infection was significantly smaller in the antibiotic group than in the placebo/control group (32 of 136 [23.5%] vs 53 of 139 [38.1%] patients). The pooled odds ratio for infection was 0.44 (95% confidence interval, 0.23-0.86). Ten of 210 patients (4.8%) in the antibiotic group died, compared with 13 of 216 (6.0%) in the placebo/control group. The pooled odds ratio for mortality was 0.63 (95% confidence interval, 0.22-1.78). No major harm or toxicity was reported. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In adults with acute stroke, preventive antibiotics reduced the risk of infection, but did not reduce mortality. The observed effect warrants evaluation of preventive antibiotics in large stroke trials.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; September 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288966</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.msif.org/en/resources/msif_resources/msif_publications/quality_of_life_principles/index.html]]&gt;</url>
    <title>Principles to Promote the Quality of Life</title>
    <publicationDate>2008-06-24T00:00:00</publicationDate>
    <publisher>Multiple Sclerosis International Foundation</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,DELIVERY OF CARE,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,REHABILITATION,CONDITIONS,SYMPTOM MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ To enhance the lives of people with multiple sclerosis, this report presents “principles” to improve Quality of Life.&lt;BR&gt;
&lt;UL&gt;
&lt;LI&gt;Independence and Empowerment&lt;BR&gt;
&lt;LI&gt;Medical Care&lt;BR&gt;
&lt;LI&gt;Continuing (Long-Term or Social) Care&lt;BR&gt;
&lt;LI&gt;Health Promotion and Disease Prevention&lt;BR&gt;
&lt;LI&gt;Support for Family Members&lt;BR&gt;
&lt;LI&gt;Transportation&lt;BR&gt;
&lt;LI&gt;Employment and Volunteer Activities&lt;BR&gt;
&lt;LI&gt;Disability Benefits and Cash Assistance&lt;BR&gt;
&lt;LI&gt;Education&lt;BR&gt;
&lt;LI&gt;Housing and Accessibility of Buildings in the Community&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>389844</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.neurology.org/cgi/content/short/75/15/1333?rss=1]]&gt;</url>
    <title>Prior antiplatelet therapy and outcome following intracerebral hemorrhage</title>
    <publicationDate>2010-09-08T00:00:00</publicationDate>
    <publisher>Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,OCTOBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Thompson BB,&amp;nbsp;Béjot Y,&amp;nbsp;Caso V,&amp;nbsp;Castillo J,&amp;nbsp;Christensen H,&amp;nbsp;Flaherty ML,&amp;nbsp;Foerch C,&amp;nbsp;Ghandehari K,&amp;nbsp;Giroud M,&amp;nbsp;Greenberg SM,&amp;nbsp;Hallevi H, Hemphill JC,&amp;nbsp;Heuschmann P,&amp;nbsp;Juvela S,&amp;nbsp;Kimura K,&amp;nbsp;Myint PK,&amp;nbsp;Nagakane Y, Naritomi H,&amp;nbsp;Passero S,&amp;nbsp;Rodríguez-Yáñez MR,&amp;nbsp;Roquer J,&amp;nbsp;Rosand J,&amp;nbsp;Rost NS,&amp;nbsp;Saloheimo P,&amp;nbsp;Salomaa V,&amp;nbsp;Sivenius J,&amp;nbsp;Sorimachi T,&amp;nbsp;Togha M, MD, K. Toyoda, MD, W. Turaj, MD, K.N. Vemmos, MD, C.D.A. Wolfe, MD, D. Woo, MD and E.E. Smith, MD, MPH&lt;/P&gt;
&lt;P&gt;Neurology is the official journal of the American Academy of Neurology. The publication is aimed at clinical neurologists.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>394682</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.neurology.org/content/75/15/1333.abstract?etoc]]&gt;</url>
    <title>Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review</title>
    <publicationDate>2010-10-12T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,HAEMORRHAGIC,INTRACEREBRAL HAEMORRHAGE,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Thompson BB, Bejot Y, Caso V, Castillo J, Christensen H, Flaherty ML, Foerch C, Ghandehari K, Giroud M, Greenberg SM, Hallevi H, Hemphill JC, Heuschmann P, Juvela S, Kimura K, Myint PK, Nagakane Y, Naritomi H, Passero S, Rodriguez-Yanez MR, Roquer J, Rosand J, Rost NS, Saloheimo P, Salomaa V, Sivenius J, Sorimachi T, Togha M, Toyoda K, Turaj W, Vemmos KN, Wolfe CDA, Woo D, Smith EE. (2010) Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. &lt;EM&gt;Neurology&lt;/EM&gt; 75(15): 1333-1342&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; Antiplatelet therapy (APT) promotes bleeding; therefore, APT might worsen outcome in patients with intracerebral hemorrhage (ICH). We performed a systematic review and meta-analysis to address the hypothesis that pre-ICH APT use is associated with mortality and poor functional outcome following ICH. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The Medline and Embase databases were searched in February 2008 using relevant key words, limited to human studies in the English language. Cohort studies of consecutive patients with ICH reporting mortality or functional outcome according to pre-ICH APT use were identified. Of 2,873 studies screened, 10 were judged to meet inclusion criteria by consensus of 2 authors. Additionally, we solicited unpublished data from all authors of cohort studies with &amp;gt;100 patients published within the last 10 years, and received data from 15 more studies. Univariate and multivariable-adjusted odds ratios (ORs) for mortality and poor functional outcome were abstracted as available and pooled using a random effects model. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We obtained mortality data from 25 cohorts (15 unpublished) and functional outcome data from 21 cohorts (14 unpublished). Pre-ICH APT users had increased mortality in both univariate (OR 1.41, 95% confidence interval [CI] 1.21 to 1.64) and multivariable-adjusted (OR 1.27, 95% CI 1.10 to 1.47) pooled analyses. By contrast, the pooled OR for poor functional outcome was no longer significant when using multivariable-adjusted estimates (univariate OR 1.29, 95% CI 1.09 to 1.53; multivariable-adjusted OR 1.10, 95% CI 0.93 to 1.29). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; In cohort studies, APT use at the time of ICH compared to no APT use was independently associated with increased mortality but not with poor functional outcome. &lt;/P&gt;
&lt;P&gt;Neurology is the official journal of the American Academy of Neurology. The publication is aimed at clinical neurologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293354</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16556238?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Prophylactic treatment of migraine in children. Part 1. A systematic review of non-pharmacological trials.</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE,MIGRAINE,HEADACHE &amp; PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Damen, L et al Cephalalgia 2006 Apr;26(4):373-83&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;The aim of this study was to assess the efficacy of non-pharmacological prophylactic treatments of migraine in children. Databases were searched from inception to June 2004 and references were checked. We selected controlled trials reporting the effects of non-pharmacological prophylactic treatments in children with migraine. We assessed trial quality using the Delphi list and extracted data. Analyses were carried out according to type of intervention. A total of 19 trials were included. Relaxation, relaxation + biofeedback, relaxation + biofeedback + cognitive behavioural treatment were more effective compared with waiting list controls. Relaxation + behavioural therapy was more effective than placebo. There is conflicting evidence for the use of oligoantigenic diets. A few non-pharmacological treatments such as relaxation may be effective as prophylactic treatment for migraine in children. Because of the small number of studies and the methodological shortcomings, conclusions on effectiveness have to be drawn with caution.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293355</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16674757?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Prophylactic treatment of migraine in children. Part 2. A systematic review of pharmacological trials</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,MIGRAINE,HEADACHE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Damen, L et al Cephalalgia 2006 May;26(5):497-50&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;The aim of this study was to assess the efficacy of pharmacological prophylactic treatments of migraine in children. Databases were searched from inception to June 2004 and references were checked. We selected controlled trials on the effects of pharmacological prophylactic treatments in children with migraine. We assessed trial quality using the Delphi list and extracted data. Analyses were carried out according to type of intervention. A total of 20 trials were included. Headache improvement was significantly higher for flunarizine compared with placebo (relative risk 4.00, 95% confidence interval 1.60, 9.97). There is conflicting evidence for the use of propranolol. Nimodipine, clonidine, L-5HTP, trazodone and papaverine showed no effect when compared with placebo. All medications were well tolerated and adverse events showed no significant differences. Flunarizine may be effective as prophylactic treatment for migraine in children. Because of the small number of studies and the methodological shortcomings, conclusions regarding effectiveness have to be drawn with caution.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396713</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20159899]]&gt;</url>
    <title>Prophylaxis of migraine headache</title>
    <publicationDate>2010-02-16T00:00:00</publicationDate>
    <publisher>Canadian Medical Association Journal</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Pringsheim T, Davenport WJ, Becker WJ. (2010) Prophylaxis of migraine headache. &lt;EM&gt;Canadian Medical Association Journal&lt;/EM&gt; 182(7):E269-76&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Key points: &lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The choice of prophylactic therapy for migraine is based on existing comorbidities, contraindications, reported efficacy, and adverse effect profiles.&lt;/LI&gt;
&lt;LI&gt;Prophylaxis should be considered for patients whose migraines affect their quality of life despite appropriate symptomatic treatment, or who are at risk for medication overuse headache.&lt;/LI&gt;
&lt;LI&gt;The period that successful migraine prophylaxis should be continued is not clear; patients should be followed up regularly to ensure that their medication is still beneficial.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270559</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ingentaconnect.com/content/adis/dmho/2005/00000013/00000003/art00004]]&gt;</url>
    <title>Psychoeducational programs for patients with epilepsy</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; May T.W., Pfafflin M. 2005; Disease Management and Health Outcomes 13 (3) pp. 185-99&lt;/P&gt;
&lt;H2&gt;Original article abstract: &lt;/H2&gt;
&lt;P&gt;Epilepsy is a common neurological disease, which affects people of all ages. Patients often have deficits regarding their knowledge of epilepsy. Many of them have recurrent seizures, psychosocial, and emotional problems and report restrictions in daily living as a result of their epilepsy. Meanwhile, a variety of psychoeducational programs have been developed with the intention to improve knowledge, coping with epilepsy, quality of life, compliance, and health status.&lt;/P&gt;
&lt;P&gt;This review article discusses the content and designs of formal patient educational programs for persons with epilepsy and reviews their role in improving patient outcomes. A systematic research of medical and psychological literature reveals that a sizeable amount of literature has been produced within the last decade that focuses on (psycho-) educational programs for adults, adolescents, and children with epilepsy as well as their families. These educational programs vary considerably in regard to content, didactic approach, and objectives. It is sometimes difficult to differentiate educational programs from psychological treatments or other interventions (e.g. by specialist epilepsy nurses). Information given about the theoretical frameworks guiding interventions, teaching strategies, and methodological approach of the programs is often sparse or lacking.&lt;/P&gt;
&lt;P&gt;The crucial point is that only very few educational programs have been evaluated in a randomized controlled trial. Furthermore, the methods of evaluation (e.g. questionnaires, inclusion and exclusion criteria, randomization, follow-up period) vary substantially and sometimes the number of subjects included in the study is too small for sufficient statistical evaluation.&lt;/P&gt;
&lt;P&gt;Overall, from the small number of evaluated programs it is evident that educational programs can improve epilepsy-related knowledge, improve the management of seizures, and reduce misinformation and misconceptions about epilepsy. They can support adults, adolescents, and children with epilepsy and their families and enable them to cope with the disease; they can sometimes also reduce seizure frequency and improve compliance with antiepileptic drugs. The effects on emotional disorders (e.g. depression) and quality of life are less obvious.&lt;/P&gt;
&lt;P&gt;Evaluated or standardized psychoeducational programs are available for specific target groups of patients with epilepsy. The review indicates that it is reasonable to perform or to adapt these educational programs for the benefit of the patients. Future research should focus on controlled evaluation studies of educational programs.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314396</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19019531]]&gt;</url>
    <title>Psychogenic non-epileptic seizures - Diagnostic issues: A critical review</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,NON-EPILEPTIC SEIZURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bodde NMG, Brooks JL, Baker GA, Boon PAJM, Hendriksen JGM, Aldenkamp AP. (2009) Psychogenic non-epileptic seizures - Diagnostic issues: A critical review. &lt;EM&gt;Clinical Neurology and Neurosurgery &lt;/EM&gt;111(1):1-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Relevant studies were identified by searching the electronic databases. Case reports were not considered. Articles were included when published after 1980 up till 2005 (26 years). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The incidence of PNES in the general population is low. However, a relatively high prevalence is seen in patients referred to epilepsy centres (15-30%). Caution is needed in the clinical interpretation of ictal features suggested to be pathognomic for PNES. Video-EEG is widely considered to be the gold standard for diagnosing PNES. Still the differential diagnosis epileptic/non-epileptic seizures can be difficult. Despite the current available technical facilities, the mean latency between onset of PNES and final diagnosis as being non-epileptic and psychogenic is approximately 7 years. One of the reasons for diagnostic delay is that the diagnosis of PNES is often limited to a 'negative' process and consequently PNES is characterized as a 'non-disease' (i.e. 'not epilepsy'). The psychological diagnosis is thus an important, although not a conclusive, 'second phase' aspect of medical decision making. Specific relations between seizure presentation and underlying psychological mechanisms are not conclusive. A classification between major motor manifestations and unresponsiveness is recognized. With respect to psychological etiology, a heterogeneous set of factors have been identified that may be involved in the causation, development and provocation of PNES.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; September 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388819</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://jnnp.bmj.com/content/81/10/1128.short?rss=1]]&gt;</url>
    <title>Psychological approaches to treatment of postconcussion syndrome: a systematic review</title>
    <publicationDate>2010-08-27T00:00:00</publicationDate>
    <publisher>Journal of Neurology, Neurosurgery and Psychiatry with Practical Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,TRAUMA,BRAIN INJURY,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Al Sayegh, Sandford D, Carson AJ. (2010) Psychological approaches to treatment of postconcussion syndrome: a systematic review. &lt;EM&gt;Journal of Neurology, Neurosurgery, and Psychiatry&lt;/EM&gt; 81(10):1128-1134&lt;/P&gt;
&lt;P&gt;The Journal of Neurology, Neurosurgery&amp;nbsp;and Psychiatry is a neurological journal which also includes the supplement Practical Neurology, which is published bi-monthly. Material published by the journal includes original articles, reports, commentaries and editorials.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and aim:&lt;/STRONG&gt; Postconcussion syndrome (PCS) is a term used to describe the complex, and controversial, constellation of physical, cognitive and emotional symptoms associated with mild brain injury. At the current time, there is a lack of clear, evidence-based treatment strategies. In this systematic review, the authors aimed to evaluate the potential efficacy of cognitive behavioural therapy (CBT) and other psychological treatments in postconcussion symptoms. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Four electronic databases were searched up to November 2008 for studies of psychological approaches to treatment or prevention of postconcussion syndrome or symptoms. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The search identified 7763 citations, and 42 studies were included. This paper reports the results of 17 randomised controlled trials for psychological interventions which fell into four categories: CBT for PCS or specific PCS symptoms; information, reassurance and education; rehabilitation with a psychotherapeutic element and mindfulness/relaxation. Due to heterogeneity of methodology and outcome measures, a meta-analysis was not possible. The largest limitation to our findings was the lack of high-quality studies. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; There was evidence that CBT may be effective in the treatment of PCS. Information, education and reassurance alone may not be as beneficial as previously thought. There was limited evidence that multifaceted rehabilitation programmes that include a psychotherapeutic element or mindfulness/relaxation benefit those with persisting symptoms. Further, more rigorous trials of CBT for postconcussion symptoms are required. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293357</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17116091?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Psychological treatment of recurrent headache in children and adolescents--a meta-analysis</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,CHRONIC DAILY HEADACHE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Trautmann, E et al Cephalalgia 2006 Dec;26(12):1411-26.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Psychologically based interventions such as relaxation training, biofeedback and cognitive-behavioural therapy are increasingly discussed as options for the treatment of migraine and tension-type headache in children and adolescents. In order to determine the state of evidence regarding the efficacy of these treatments, a meta-analysis of randomized controlled studies was conducted. In a comprehensive literature search including data from 1966 to 2004, 23 studies were found meeting the inclusion criteria. Due to the application of the random effects model, generalization of the results is possible. Specific statistical procedures were used to account for a possible publication bias. Significantly more patients improved to a clinically relevant extent (headache reduction &amp;gt; or =50%) in treatment conditions compared with waiting list conditions (high effect sizes). Long-term stability was also confirmed. The analysed treatments lead to improvement (up to 1 year) in headache status in children and adolescents with primary headache. However, more well-designed studies are needed to support and consolidate the conclusions of this meta-analysis and to compare the effects of psychological treatment with those of prophylactic medical interventions (in migraine), to examine potential differences between treatments, to identify moderators of efficacy and to determine effects of treatment on other health-related variables such as quality of life.&lt;/P&gt;
&lt;P class=pmid&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384042</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1601-5215.2009.00376.x]]&gt;</url>
    <title>Psychological treatments for functional non-epileptic attacks: a systematic review</title>
    <publicationDate>2010-08-01T00:00:00</publicationDate>
    <publisher>Acta Neuropsychiatrica</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DELIVERY OF CARE,SYMPTOM MANAGEMENT,NEUROSURGERY,EPILEPSY AND SEIZURES,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Gaynor D, Cock H, Agrawal N. (2010) Psychological treatments for functional non-epileptic attacks: a systematic review. &lt;EM&gt;Acta Neuropsychiatrica&lt;/EM&gt; 21(4):158-168&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; There is a lack of clarity about the most useful intervention for functional non-epileptic attacks (FNEA). Outcomes for this condition remain often poor, with considerable personal, social and economic impact. In order to guide clinical practice and future research in this area, we have performed a systematic review of the published literature on the psychological treatment of FNEA. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A comprehensive literature search was carried out using key words: non-epileptic seizures; psychogenic seizures; psychogenic non-epileptic seizures; pseudoseizures; funny turns; non-epileptic attack; hysterical seizures; and pseudoepileptic. Studies specifically looking at psychological treatment of FNEA were identified. Studies of patients also having comorbid organic seizure disorders were excluded.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 17 studies that met the inclusion criteria were identified. A broad variety of psychological interventions for FNEA has been investigated. Only one randomised controlled trial has been completed to date. Existing evidence appears to suggest that various psychological treatments, including presenting the diagnosis, psychoeducation, behavioural therapies and mixed modality treatments, may be effective. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; While a range of psychological treatments may be beneficial for this patient group, we do not have clear evidence to suggest which treatment is most efficacious. Specific elements of presenting the diagnosis and psychoeducation may be required in addition to traditional cognitive behavioural therapeutic approaches. Large, methodologically robust studies are urgently required to establish the most effective form of treatment.&lt;/P&gt;
&lt;P&gt;Acta Neuropsychiatrica is an international journal that publishes high-quality research papers in neuropsychiatry and neuroscience. The journal provides a forum for original basic and clinical research from all disciplines and research areas relevant to the pathophysiology, neurobiology, and treatment of neuropsychiatric disorders. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396500</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://pediatrics.aappublications.org/cgi/content/abstract/126/2/323]]&gt;</url>
    <title>Psychopathology in children and adolescents with migraine in clinical studies: a systematic review</title>
    <publicationDate>2010-07-05T00:00:00</publicationDate>
    <publisher>American Academy of Pediatrics</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Bruijn J, Locher H, Passchier J, Dijkstra N, Arts WF. (2010) Psychopathology in children and adolescents with migraine in clinical studies: a systematic review. &lt;EM&gt;Pediatrics&lt;/EM&gt; 126(2):323-332&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; In past decades, numerous population- and hospital-based studies have revealed a relationship between migraine or headache and psychopathology in children. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To describe and assess all clinical studies on the prevalence and manifestations of psychological functioning and psychiatric comorbidity in children with migraine and to provide recommendations for its diagnosis and treatment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A literature search was performed in Medline, Embase, PsycINFO, and the Cochrane Database to identify clinical studies that assessed psychological functioning and/or psychiatric comorbidity in children with migraine. Trial quality was assessed according to a standardized and validated set of criteria.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Seven studies met our inclusion criteria. Evidence assessment was performed by using the best-evidence synthesis method of Slavin. On the basis of this method, we found strong evidence that children with migraine in a clinical setting do not exhibit more withdrawn behavior, do not have more thought problems, do not have more social problems, and do not exhibit more delinquent or aggressive behavior than healthy children. Furthermore, there is strong evidence that children with migraine have more somatic complaints and exhibit internalizing behavior which is, given the construct of the outcome measure used, a consequence of the nature of their disease rather than a sign of psychological dysfunctioning. Finally, compared with healthy children, there is limited evidence that children with migraine in a clinical setting are more frequently diagnosed with oppositional defiant disorder, and they are not more frequently diagnosed with attention-deficit/hyperactivity disorder, conduct disorder, dysthymia, or depression. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; On the basis of this review, we conclude that children with migraine at referral to a specialist do not exhibit more psychological dysfunctioning and (to a lesser extent) do not exhibit more psychiatric comorbidity compared with healthy controls.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270573</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16055484]]&gt;</url>
    <title>Psychopathology in children with epilepsy: a meta-analysis</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Rodenburg R., Stams G.J., Meijer A.M. et al. 2005; Journal of Pediatric Psychology 30 (6) pp. 453-68&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To examine the types and severity of psychopathology in children with epilepsy. METHODS: A series of meta-analyses were conducted to review 46 studies, including 2,434 children with epilepsy. RESULTS: Effect sizes were medium to large for comparisons with children from the general population, which indicates that children with epilepsy are at increased risk for psychopathology, including internalizing and externalizing behavior problems. Comparisons with children with another chronic illness revealed small to medium effect sizes, indicating that psychopathology in children with epilepsy may partly be attributed to chronicity of the disease. Attention problems, thought problems, and social problems proved to be relatively specific to epilepsy. Comparisons with siblings suggested that psychopathology in children with epilepsy may be associated with family factors, especially where behavioral disorders appear to be more generic. CONCLUSIONS: Clinicians should consider both neurological and psychosocial factors, including the family system, when treating psychopathology in children with epilepsy.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386845</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://cre.sagepub.com/content/24/9/789.abstract?rss=1]]&gt;</url>
    <title>Psychosocial adjustment in children and adolescents with a parent with multiple sclerosis: a systematic review</title>
    <publicationDate>2010-08-04T00:00:00</publicationDate>
    <publisher>Clinical Rehabilitation</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Bogosian A, Moss-Morris R, Hadwin J. (2010) Psychosocial adjustment in children and adolescents with a parent with multiple sclerosis: a systematic review. &lt;EM&gt;Clinical Rehabilitation &lt;/EM&gt;24(9):789-801&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; This systematic review explored the potential impact of parental multiple sclerosis on their offspring. It considered adjustment to parental multiple sclerosis at different developmental stages and the factors associated with good versus poor adjustment. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; MEDLINE, EMBASE, PsycINFO, CINAHL and Web of Science were searched for studies on children with a parent with multiple sclerosis. Inclusion and exclusion criteria were formulated. Hand-searching journals and reference lists, contacting authors and multiple sclerosis societies for additional unpublished papers complemented the searches. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Review methods:&lt;/STRONG&gt; Twenty studies that satisfied the inclusion criteria were included. The research articles were ranked according to a quality assessment checklist and were categorized as good, medium or poor quality. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The review found good evidence to suggest that parental multiple sclerosis has a negative impact on children’s social and family relationships and their psychological well-being. The review also identified potential factors associated with poor adjustment. These factors included parental negative emotions, increased illness severity, family dysfunction, children’s lack of knowledge about the illness and lack of social support. Adolescent children also seemed to be more at risk for psychosocial problems than school-age children. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; There is good evidence that parental multiple sclerosis has a negative psychosocial impact on children, especially on adolescents. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Clinical Rehabilitation is a highly ranked, peer reviewed scholarly journal. It is a multi-professional journal covering the whole field of disability and rehabilitation, combining clinical application of scientific results and theoretical aspects in an ideal form. It gives high priority to articles describing effectiveness of therapeutic interventions and the evaluation of new techniques and methods.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288870</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17508135?ordinalpos=5&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Psychosocial interventions in people with multiple sclerosis: a review</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Steinkopff</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Malcolmson, KS et al &lt;SPAN title="Journal of neurology."&gt;&lt;A href="#javascript:AL_get(this," Neurol.?);? ?J ?jour?,&gt;J Neurol.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jan;254(1):1-13. Epub 2007 Feb 14&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;BACKGROUND: Upon diagnosis individuals with Multiple Sclerosis (MS) must cope with both day to day and disease-related stressors in addition to unpredictable, fluctuating and confusing symptoms. Furthermore, disease progression may interfere with employment, family life, relationships and social activities. Psychosocial interventions aim to help individuals manage these psychological, social and emotional challenges. However, there are no specific guidelines available regarding the most effective intervention content, format or delivery. Therefore, a review of the research that has utilised these interventions, specifically those which, by definition, aimed to improve quality of life (QoL) and/or well-being in people with MS, was considered essential in order to identify which aspects of these interventions may help alleviate the psychosocial challenges associated with MS. OBJECTIVES: To identify all randomised controlled trials (RCTs), quasi-experimental, cohort, case control and case series studies that have investigated psychosocial interventions in people with MS which aimed to improve QoL and/or well-being, to establish the methodological quality of such studies, and to determine the effectiveness of the interventions. SEARCH STRATEGY: Searches were carried out using computerised databases with predefined search terms; this was supplemented by manual searches of reference lists of all retrieved articles. Relevant journals were also hand searched. SELECTION CRITERIA: Studies written in English and published before January 2006, investigating the effectiveness of psychosocial interventions on QoL and/or well-being in people with MS, were eligible for inclusion. DATA COLLECTION AND ANALYSIS: Methodological quality was independently assessed by two reviewers using the Downs and Black quality scoring checklist. The qualitative and quantitative characteristics of studies were extracted using a data extraction sheet. MAIN RESULTS: Thirty-three studies fulfilled the inclusion criteria; however, interventions varied widely in content, delivery and duration. Furthermore, failure to report full methodological details, as well as weaknesses in study design, reduced the strength of inferences that could be drawn from these studies. These notwithstanding, there were three studies of sufficient quality to provide some evidence regarding the value of education/information, goal setting, homework assignments, exercise, discussion forums and multidisciplinary team support. Thus, this review has identified the potential benefit of the aforementioned activities in the psychosocial management of this population. However, further well designed clinical trials are warranted to determine, definitively, the effectiveness, or otherwise, of these components.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Full text available to NHS staff using NHS Athens password&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270513</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17159095]]&gt;</url>
    <title>Psychotropic effects of antiepileptic drugs</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Ettinger A.B. 2006; Neurology 67 (11) pp. 1916-25&lt;/P&gt;
&lt;H2&gt;Original article abstract: &lt;/H2&gt;
&lt;P&gt;BACKGROUND: Mood disorder symptoms are common in patients with epilepsy. Since antiepileptic drugs (AEDs) can affect these symptoms, knowledge of the psychotropic properties of AEDs is crucial. We review most studies of the psychotropic effects of AEDs that have involved potential psychiatric applications and have been reported in the psychiatric literature. METHODS: We conducted a comprehensive literature search to identify relevant clinical trial reports on the efficacy of AEDs for mood disorders. RESULTS: There have been few randomized controlled trials studying AED psychotropic properties in patients with epilepsy, but some randomized controlled trials of potential psychiatric indications for AEDs have been published. Data from these studies suggest that specific AEDs have mood stabilizing, anxiolytic, and antidepressant properties, while others may elicit depression, agitation, or psychosis. CONCLUSION: Antiepileptic drug selection should consider potential effects on mood and behavior.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293346</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16817055?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Public health support to policies in the fields of headache. Different ways of producing data and modalities of reading them with the aid of the meta-analytic approach</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Sprin</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Leonardi, M Journal of Headache and Pain 2006 Jun;7(3):157-9. Epub 2006 Jun 15&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;No abstract available&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388775</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_119828.pdf]]&gt;</url>
    <title>Quality outcomes for people with dementia: building on the work of the National Dementia Strategy</title>
    <publicationDate>2010-09-28T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,NHS ACTIVITIES,POLICY,SERVICE SECTORS,QUALITY AND MONITORING,NATIONAL SERVICE FRAMEWORKS,SERVICE DELIVERY,MENTAL HEALTH,LATER LIFE,ADULT CONDITIONS,DEMENTIA,DEMENTIA,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,INNOVATION AND IMPROVEMENT,CHANGE MANAGEMENT,LEADING IMPROVEMENT,CONDITIONS,NATIONAL DEMENTIA STRATEGY,EVALUATION,OUTCOMES,STRATEGIES AND POLICIES,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document presents the Department’s revised, outcomes focused implementation plan for ‘Living well with dementia: A National Dementia Strategy’, which was published in February 2009. It updates the previous implementation plan for the Strategy, which was published in July 2009.&lt;/P&gt;
&lt;P&gt;The key purpose of this revised implementation plan is to set out for health and social care localities and their delivery partners:&lt;/P&gt;
&lt;P&gt;the Department of Health’s role and its priorities during 2010/11 for supporting local delivery of and local accountability for the implementation of 'Living well with dementia – A National Dementia Strategy';&lt;BR&gt;the Strategy’s fit with the new vision for the future of health and care as set out in the White Paper Equity and Excellence: Liberating the NHS; and&lt;BR&gt;it's fit with the consultation document 'Liberating the NHS: Transparency in outcomes - a framework for the NHS'.&lt;BR&gt;At the heart of this vision is the Government’s commitment to putting patients and the public first; improving health and social care outcomes; ensuring autonomy, accountability and democratic legitimacy and improving efficiency.&lt;/P&gt;
&lt;P&gt;This document is not setting priorities for delivery by the NHS, social care or its delivery partners. It does not state what services should be planned, commissioned, provided and delivered. As highlighted in the National Dementia Strategy, the pace of implementation will vary depending on local circumstances and the level and development of services within each NHS and Local Authority area. It describes what the Department of Health considers as its priorities for policy development in its role of enabler for continued progress in improving outcomes for people with dementia and their carers.&lt;/P&gt;
&lt;P&gt;Please note this document is for print only, a fully accessible version will be made available.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371751</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20167915?dopt=Abstract]]&gt;</url>
    <title>Radiological Investigation of Spontaneous Intracerebral Hemorrhage</title>
    <publicationDate>2010-02-18T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,APRIL 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Cordonnier, C., Klijn, C. J. M., van Beijnum, J., Al-Shahi Salman, R. (2010) Radiological Investigation of Spontaneous Intracerebral Hemorrhage: Systematic Review and Trinational Survey. &lt;EM&gt;Stroke &lt;/EM&gt;(41):&amp;nbsp;685-690.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We systematically reviewed Ovid MEDLINE and EMBASE databases for studies of the diagnostic utility of radiological investigations of the cause(s) of ICH. We sent a structured survey to neurologists, stroke specialists, neurosurgeons, and neuroradiologists in the United Kingdom, the Netherlands, and France to assess whether, how, and when they would investigate supratentorial ICH. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; This systematic review detected 20 relevant studies (including 1933 patients), which either quantified the yield of a radiological investigation/imaging strategy (n=15) or compared 2 imaging techniques (n=5). Six hundred ninety-two (49%) physicians responded to the survey. Further investigation would have been undertaken by the following: 99% of respondents, for younger (38 to 43 years), normotensive adults with lobar or deep ICH; 76%, for older (age 72 to 83 years), normotensive adults with deep ICH; and 31%, for older adults with deep ICH and prestroke hypertension. Younger patient age was the strongest influence on the decision to further investigate ICH (odds ratio=16; 95% confidence interval, 13 to 20), followed by the absence of prestroke hypertension (odds ratio=5; 95% confidence interval, 4 to 6) and lobar ICH location (odds ratio=2; 95% confidence interval, 1 to 2). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The paucity of studies on the diagnostic utility of imaging investigations of the cause(s) of ICH may contribute to the variation observed in when and how and which patients are investigated in current clinical practice. Studies comparing different types of diagnostic strategies are required. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 18th February 2010 (E-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available from January 1970. The last 5 months are not freely available; ask your local healthcare library if they have a subscription.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395024</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://jnnp.bmj.com/content/early/2010/11/03/jnnp.2010.224501.abstract?papetoc]]&gt;</url>
    <title>Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis</title>
    <publicationDate>2010-11-03T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,NEUROMUSCULAR,MOTOR NEURONE DISEASE/AMYOTROPHIC LATERAL SCLEROSIS,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, McLaughlin R, Hardiman O. (2010) &lt;EM&gt;Journal of Neurology, Neurosurgery and Psychiatry with Practical Neurology&lt;/EM&gt; 3rd November&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; The population rate of familial amyotrophic lateral sclerosis (FALS) is frequently reported as 10%. However, a systematic review and meta-analysis of the true population based frequency of FALS has never been performed. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Method:&lt;/STRONG&gt; A Medline literature review identified all original articles reporting a rate of FALS. Studies were grouped according to the type of data presented and examined for sources of case ascertainment. A systematic review and meta-analysis of reported rates of FALS was then conducted to facilitate comparison between studies and calculate a pooled rate of FALS. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 38 papers reported a rate of FALS. Thirty-three papers were included in analysis and the rate of FALS for all studies was 4.6% (95% CI 3.9% to 5.5%). Restricting the analysis to prospective population based registry data revealed a rate of 5.1% (95% CI 4.1% to 6.1%). The incidence of FALS was lower in southern Europe. There was no correlation between rate of FALS and reported SOD1 mutation rates. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; The rate of FALS among prospective population based registries is 5.1% (CI 4.1 to 6.1%), and not 10% as is often stated. Further detailed prospective population based studies of familial ALS are required to confirm this rate. &lt;/P&gt;
&lt;P&gt;The Journal of Neurology, Neurosurgery&amp;nbsp;and Psychiatry is a neurological journal which also includes the supplement Practical Neurology, which is published bi-monthly. Material published by the journal includes original articles, reports, commentaries and editorials.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314397</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17967993]]&gt;</url>
    <title>Reassessment: neuroimaging in the emergency patient presenting with seizure (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</title>
    <publicationDate></publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,INVESTIGATION &amp; DIAGNOSTICS,FIRST SEIZURE AND EARLY EPILEPSY,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Harden CL, Huff JS, Schwartz TH, Dubinsky RM, Zimmerman RD, Weinstein S, et al. (2007) Reassessment: neuroimaging in the emergency patient presenting with seizure (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. &lt;EM&gt;Neurology&lt;/EM&gt; 69(18):1772-80.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A broad-based panel with topic expertise evaluated the available evidence based on a structured literature review using a Medline search from 1966 until November 2004.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The 15 articles meeting criteria were Class II or III evidence since interpretation was not masked to the patient's clinical presentation; most were series including 22 to 875 patients. There is evidence that for adults with first seizure, cranial CT will change acute management in 9 to 17% of patients. CT in the emergency department for children presenting with first seizure will change acute management in approximately 3 to 8%. There is no clear difference between rates of abnormal emergent CT for patients with chronic seizures vs first. Children &amp;lt;6 months presenting with seizures have clinically relevant abnormalities on CT scans 50% of the time. Persons with AIDS and first seizure have high rates of abnormalities, and CNS toxoplasmosis is frequently found. Abnormal neurologic examination, predisposing history, or focal seizure onset are probably predictive of an abnormal CT study in this context. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Immediate noncontrast CT is possibly useful for emergency patients presenting with seizure to guide appropriate acute management especially where there is an abnormal neurologic examination, predisposing history, or focal seizure onset.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; October 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293383</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/content/full/332/7532/25]]&gt;</url>
    <title>Recent advances in the diagnosis and management of migraine</title>
    <publicationDate>2006-01-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,HEADACHE,HEADACHE &amp; PAIN,MIGRAINE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Goadsby PJ BMJ 2006 Jan 7;332(7532):25-9&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;No abstract available&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344188</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19678753]]&gt;</url>
    <title>Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Freedman MS, Cohen B, Dhib-Jalbut S, Jeffery D, Reder AT, Sandberg-Wollheim M, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. &lt;EM&gt;Current Medical Research &amp;amp; Opinion&lt;/EM&gt; 2009 Oct;25(10):2459-70.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; In the absence of evidence-based data, identifying and treating MS patients with suboptimal response to the available platform therapies remains challenging. Developing algorithms able to quantify breakthrough disease activity and suboptimal response to disease-modifying drugs (DMDs) in individual&amp;nbsp;multiple sclerosis (MS)&amp;nbsp;patients remains an important target for the MS community. Consideration should be given for all reasons why a particular DMD may not be working for a given patient and for the use of an individualized step therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Several groups have created recommendations for evaluating suboptimal response to disease-modifying drugs (DMDs) in MS. Currently no robust evidence-based data exist to guide treatment decisions in patients who have suboptimal response to a particular therapy. In the absence of data, several treatment paradigms for suboptimally controlled MS have been proposed using a step therapy or platform therapy approach. Therapy modifications require consideration of disease- and patient-specific factors while accounting for the risk-benefit profile of the agent(s). Unapproved drugs and combination therapies should be reserved as agents of last resort because of the experimental nature of these treatments.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; In the absence of evidence-based data, identifying and treating MS patients with suboptimal response to the available platform therapies remains challenging. Developing algorithms able to quantify breakthrough disease activity and suboptimal response to DMDs in individual MS patients remains an important target for the MS community. Consideration should be given for all reasons why a particular DMD may not be working for a given patient and for the use of an individualized step therapy.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in October 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Will be available to NHS England staff via an NHS Athens password once a year has passed since publication. Access will be via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&amp;nbsp; In the interim, ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>328012</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1161/STROKEAHA.108.192616]]&gt;</url>
    <title>Recommendations for Imaging of Acute Ischemic Stroke: A Scientific Statement From the American Heart Association</title>
    <publicationDate>2009-09-24T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ISCHAEMIC STROKE,COMPUTED TOMOGRAPHY (CT),MAGNETIC RESONANCE IMAGING (MRI),STROKE,INVESTIGATION &amp; DIAGNOSTICS,OCTOBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Latchaw, RE et al. (2009) Recommendations for Imaging of Acute Ischemic Stroke: A Scientific Statement From the American Heart Association. &lt;SPAN class=journalname title="Stroke; a journal of cerebral circulation"&gt;&lt;EM&gt;Stroke&lt;/EM&gt;&lt;/SPAN&gt; 2009 Sep 24 [epub ahead of print]. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Aims:&lt;/STRONG&gt;&amp;nbsp;A review of the literature was undertaken to determine the current state of various imaging techniques and procedures in terms of what they offer relative to what practitioners need to know to provide proper medical management of acute ischaemic stroke. This imaging analysis can be divided into 3 components: Imaging of the cerebral parenchyma,&lt;BR&gt;imaging of the blood vessels, and perfusion imaging to assess tissue viability.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Intended audience:&lt;/STRONG&gt; Healthcare professionals specialised in neurological care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication history information:&lt;/STRONG&gt; This scientific statement was published online ahead of print in Stroke (&lt;A href="http://stroke.ahajournals.org/" target="_blank"&gt;http://stroke.ahajournals.org&lt;/A&gt;) on 24 September 2009.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text for the latest 12 months is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377648</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19797189]]&gt;</url>
    <title>Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association.</title>
    <publicationDate>2009-11-01T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ISCHAEMIC STROKE,STROKE,JUNE 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Introduction:&lt;/STRONG&gt; Stroke is a common and serious disorder, with an incidence of 795 000 each year in the United States alone. Worldwide, stroke is a leading cause of death and disability. Recombinant tissue plasminogen activator (rtPA) was approved a decade ago for the treatment of acute ischemic stroke. The guidelines for its use include stroke onset within 3 hours of intravenous drug administration, preceded by a computed tomographic (CT) scan to exclude the presence of hemorrhage, which is a contraindication to the use of the drug. Although randomized, controlled studies in Europe and North America demonstrated the efficacy of this treatment, it also was associated with an incidence of intracranial hemorrhage of 6.4%,1,2 which was shown on subsequent studies to be even greater if there was not strict adherence to the administration protocol.3 The goal of these controlled studies was to evaluate patient outcome. There was no attempt to determine the site, or even the actual presence, of a vascular occlusion, the degree of tissue injury, or the amount of tissue at risk for further injury that might be salvageable. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; November 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available via &lt;A href="http://highwire.stanford.edu/lists/freeart.dtl" target="_blank"&gt;Highwire Press&lt;/A&gt; from January 1970. The last 12 months are not freely available; ask your local healthcare libray.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386641</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20051609]]&gt;</url>
    <title>Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents</title>
    <publicationDate>2010-01-04T00:00:00</publicationDate>
    <publisher>Canadian Journal of Clinical Pharmacology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Cheng LS, Prasad AN, Rieder MJ. (2010) Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents. &lt;EM&gt;Canadian Journal of Clinical Pharmacology/Journal Canadien de Pharmacologie Clinique&lt;/EM&gt; 17(1):e5-46&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; Epilepsy is a neurological disorder, relatively common in the paediatric population. These children are often treated with antiepileptic drugs (AEDs) for several years. The consequence of such long-term&lt;BR&gt;exposure may lead to variations in plasma homocysteine and serum lipoprotein concentrations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective(s):&lt;/STRONG&gt; To review the cardiovascular effects of anticonvulsant therapy and their use in childhood epilepsy with special reference to homocysteine and lipoprotein.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A literature search was conducted on PubMed (1966-May 2009) and MEDLINE (1966-May 2009). Key terms included antiepileptic drugs, epilepsy, homocysteine, cardiovascular events, and children.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Certain AEDs including carbamazepine, phenobarbital, phenytoin and valproic acid, as well as the presence of a homozygous 5-methylenetetrahydrofolate reductase polymorphism in the genotype, are&lt;BR&gt;potential causes of elevation in plasma homocysteine and serum lipoprotein concentrations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Persistent elevation in these biochemical markers has shown to be associated with the development of long-term sequelae such as cardiovascular diseases, prompting concerns about the long-term implications of chronic AED use in children and cardiovascular risk. Further research is needed to assess the relationship between specific chronic AED use, homocysteine and lipoprotein concentrations, the influence of genotype, as well as the risk of long-term sequelae in the paediatric population.&lt;/P&gt;
&lt;P&gt;Since its inception in 1994, The Canadian Journal of Clinical Pharmacology has filled an important gap in therapeutics research in Canada. In April 2004, The Canadian Journal of Clinical Pharmacology was innovative in becoming one of the first peer review, Medline indexed scientific journal in the field of therapeutics to be published on the Internet and available at no charge to the readers. This change reflected a vision and philosophy of the Canadian Society for Clinical Pharmacology that original information on rational therapeutics needs to be accessible to all health professionals prescribing or administering medications, as well as for all other stakeholders, including patients and families. In the fall of 2007, the Journal of Fetal Alcohol Syndrome International was amalgamated with the Canadian Journal of Clinical Pharmacology.&amp;nbsp;In 2008, the Canadian Society for Clinical Pharmacology merged with the Pharmacological Society of Canada to form the Canadian Society of Pharmacology and Therapeutics. In 2010 the journal changed its name to the Journal of Population Therapeutics and Clinical Pharmacology. This change reflected the international sphere of the authors submitting publications to the journal and as well, the broad scope of topics covered in the journal. In addition to publishing articles in the field of clinical pharmacology the journal has embraced articles related to pharmacoepidemiology, pharmacoeconomics and drug policy, hence 'population therapeutics'.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324885</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1161/STROKEAHA.109.557256]]&gt;</url>
    <title>Reliability of the modified rankin scale. A systematic review</title>
    <publicationDate>2009-08-13T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Quinn TJ, Dawson J, Walters MR, Lees KR.. (2009) Reliability of the modified rankin scale. A systematic review. &lt;EM&gt;Stroke&lt;/EM&gt; 2009 Aug 13. (Epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Two researchers independently reviewed the literature. Crossdisciplinary electronic databases were interrogated using the following key words: Stroke*; Cerebrovasc*; Modified Rankin*; Rankin Scale*; Oxford Handicap*; Observer variation*. Data were extracted according to prespecified criteria with decisions on inclusion by consensus. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; From 3461 titles, 10 studies (587 patients) were included. Reliability of modified Rankin Scale varied from weighted kappa=0.95 to kappa=0.25. Overall reliability of mRS was kappa=0.46; weighted kappa=0.90 (traditional modified Rankin Scale) and kappa=0.62; weighted kappa=0.87 (structured interview). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There remains uncertainty regarding modified Rankin Scale reliability. Interobserver studies closest in design to large-scale clinical trials demonstrate potentially significant interobserver variability.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 13 August 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text for the last 12 months is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314435</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18514485]]&gt;</url>
    <title>Reporting and analysis of open-label extension studies of anti-epileptic drugs</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Maguire MJ, Hemming K, Hutton JL, Marson AG. (2008) Reporting and analysis of open-label extension studies of anti-epileptic drugs. &lt;EM&gt;Epilepsy Research&lt;/EM&gt; 81(1):24-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A systematic review of FORCTs and randomised controlled trials (RCT) of topiramate, levetiracetam and gabapentin as adjuvant therapy in refractory adult epilepsy was conducted. Sample sizes and numbers of responders, along with reported outcomes were extracted. To evaluate the feasibility of the assumptions underlying the various methods of analysis, the most common causes of discontinuation were evaluated. For each FORCT, we compared the reported outcome to the proposed ITT analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The 10 FORCT reports identified all excluded from the analysis patients who dropped out of the RCT. Adverse events or inefficacy were the main reasons for treatment discontinuation. Analysis based on the ITT method, led to smaller effect estimates than those reported. For example, a FORCT of levetiracetam reported a responder rate of 43%, which reduced to 28% under an ITT analysis, comparable to an ITT analysis outcome of 26% for the parent RCT.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; FORCTs can provide important information about long-term efficacy and tolerability of newer therapies. However, current reporting methods are likely to be misleading as outcomes are reported for the subset of patients continuing with treatment at the end of the FORCT. Since the majority of patients who discontinue treatment do so for reasons associated with inefficacy, an analysis based on the ITT approach more closely reflects the outcomes of the patients.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; September 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384461</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1742-6723.2010.01269.x]]&gt;</url>
    <title>Review article: Phenytoin use and efficacy in the ED</title>
    <publicationDate>2010-04-19T00:00:00</publicationDate>
    <publisher>Emergency Medicine Australasia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Gallop K. (2010) Review article: Phenytoin use and efficacy in the ED. &lt;EM&gt;Emergency Medicine Australasia&lt;/EM&gt; 22(2):108-18&lt;/P&gt;
&lt;P&gt;This article reviews the evidence regarding the use of phenytoin in adult and paediatric patients experiencing seizures in the ED in Australasia, including relevant pharmacokinetics, dosage, therapeutic drug monitoring and methods of administration. It summarizes current evidence regarding the use of phenytoin in a number of seizure types commonly seen in ED. A search of Medline, Embase and Cochrane was performed using appropriate keyword and MeSH headings. A loading dose of phenytoin should be given to phenytoin naïve patients for the emergency treatment of seizures; parenteral administration results in therapeutic concentration sooner than oral administration but is associated with more frequent and significant adverse effects. Diluting phenytoin is safe but there is limited evidence regarding adverse effects of diluted phenytoin; a filter is probably not needed. Free phenytoin concentrations correlate best with antiseizure efficacy. Phenytoin is used in the treatment of status epilepticus although evidence here is limited; it may also be given to prevent early post-traumatic seizures. It should not be given to treat or prevent eclamptic or alcohol-related seizures. There is insufficient evidence regarding its use in preventing febrile convulsions, treating or preventing seizures due to space occupying lesions or intracerebral haemorrhage and thrombosis. In conclusion, phenytoin is appropriate for treatment of some seizures seen in the ED; it is associated with significant adverse effects; trials are ongoing regarding the use of other anticonvulsants in the treatment of status epilepticus.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Emergency Medicine Australasia is the official journal of the Australasian College for Emergency Medicine (ACEM) and the Australasian Society for Emergency Medicine (ASEM) and aims to present papers and opinions on all aspects of emergency care in the prehospital and hospital environment. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>324793</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.4.121]]&gt;</url>
    <title>Review: adding dexamethasone to standard therapy reduces short-term relapse for acute migraine in the emergency department</title>
    <publicationDate>2009-08-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MIGRAINE,HEADACHE &amp; PAIN,HEADACHE,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Carpenter, CR. (2009) Review: adding dexamethasone to standard therapy reduces short-term relapse for acute migraine in the emergency department. &lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; 14(4);121&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Singh A, Alter HJ, Zaia B. (2008) Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature. &lt;EM&gt;Acad Emerg Med&lt;/EM&gt; 15:1223–33.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326698</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.5.141]]&gt;</url>
    <title>Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ STRUCTURAL,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,OCTOBER 2009,CONDITIONS,CEREBRAL PALSY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Marlow, N. (2009) Review: antenatal magnesium sulphate prevents cerebral palsy in preterm infants. &lt;EM&gt;Evidence Based Medicine&lt;/EM&gt; 14;141.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. &lt;A href="http://dx.doi.org/10.1002/14651858.CD004661.pub3" target="_blank"&gt;Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus&lt;/A&gt;. &lt;EM&gt;Cochrane Database of Systematic Reviews&lt;/EM&gt; 2009, Issue 1.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>326701</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.5.143]]&gt;</url>
    <title>Review: continuous positive airway pressure devices are effective and cost-effective for obstructive sleep apnoea</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,OBSTRUCTIVE SLEEP APNOEA,SLEEP DISORDERS,CONDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Chatterjee, AB. (2009) Review: continuous positive airway pressure devices are effective and cost-effective for obstructive sleep apnoea. &lt;EM&gt;Evidence-Based Medicine&lt;/EM&gt; 14:143.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; McDaid C, Griffin S, Weatherly H, et al. &lt;A href="http://www.hta.ac.uk/execsumm/summ1304.htm" target="_blank"&gt;Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis&lt;/A&gt;. Health Technol Assess 2009;13(4);1–119.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345369</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/content/14/6/180]]&gt;</url>
    <title>Review: evidence for the effectiveness of non-surgical interventions for low back pain and radiculopathy is limited</title>
    <publicationDate>2009-12-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ OUTCOME MEASUREMENTS,REHABILITATION,NEUROLOGICAL CONDITIONS,DELIVERY OF CARE,NEUROMUSCULAR,CONDITIONS,SYMPTOM MANAGEMENT]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Rothschild, B. Review: evidence for the effectiveness of non-surgical interventions for low back pain and radiculopathy is limited. &lt;EM&gt;Evidence Based Medicine&lt;/EM&gt; 2009;14:180&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Chou R, Atlas SJ, Stanos SP, &lt;EM&gt;et al.&lt;/EM&gt; Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. &lt;EM&gt;Spine&lt;/EM&gt; 2009;&lt;STRONG&gt;34&lt;/STRONG&gt;:1078–93. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via an NHS Athens password.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>320691</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.2.49]]&gt;</url>
    <title>Review: immediate antiplatelet therapy after acute ischaemic stroke reduces death or dependency and risk of recurrent stroke</title>
    <publicationDate>2009-03-30T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,STROKE,ISCHAEMIC STROKE,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; MacKenzie, G. Review: immediate antiplatelet therapy after acute ischaemic stroke reduces death or dependency and risk of recurrent stroke. &lt;EM&gt;Evidence-Based Nursing&lt;/EM&gt; 2009;12(2):49.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Sandercock PA, Counsell C, Gubitz GJ, et al. Antiplatelet therapy for acute ischaemic stroke. &lt;EM&gt;Cochrane Database Syst Rev&lt;/EM&gt; 2008;(3):CD000029. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319184</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.3.87]]&gt;</url>
    <title>Review: long-term annual conversion rate to dementia was 3.3% in elderly people with mild cognitive impairment</title>
    <publicationDate>2009-06-26T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Buchanan, D. Review: long-term annual conversion rate to dementia was 3.3% in elderly people with mild cognitive impairment.&amp;nbsp;&lt;EM&gt;Evid. Based Nurs.&lt;/EM&gt; 2009;12(3): 87.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Abstracted from:&lt;BR&gt;Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. &lt;EM&gt;J Neurol Neurosurg Psychiatry&lt;/EM&gt; 2008;79:1386–91.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319184</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.3.87]]&gt;</url>
    <title>Review: long-term annual conversion rate to dementia was 3.3% in elderly people with mild cognitive impairment</title>
    <publicationDate>2009-06-26T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Buchanan, D. Review: long-term annual conversion rate to dementia was 3.3% in elderly people with mild cognitive impairment.&amp;nbsp;&lt;EM&gt;Evid. Based Nurs.&lt;/EM&gt; 2009;12(3): 87.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Abstracted from:&lt;BR&gt;Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. &lt;EM&gt;J Neurol Neurosurg Psychiatry&lt;/EM&gt; 2008;79:1386–91.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319209</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.3.90]]&gt;</url>
    <title>Review: long-term annual conversion rate to dementia was 3.3% in elderly people with mild cognitive impairment</title>
    <publicationDate>2009-06-26T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Burke, D. Review: long-term annual conversion rate to dementia was 3.3% in elderly people with mild cognitive impairment. &lt;EM&gt;Evid. Based Med&lt;/EM&gt;. 2009;14(3): 90.&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Abstracted from: &lt;BR&gt;Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. &lt;EM&gt;J Neurol Neurosurg Psychiatry&lt;/EM&gt; 2008;79:1386–91.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>319209</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebm.14.3.90]]&gt;</url>
    <title>Review: long-term annual conversion rate to dementia was 3.3% in elderly people with mild cognitive impairment</title>
    <publicationDate>2009-06-26T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DEMENTIA,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Medicine is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Burke, D. Review: long-term annual conversion rate to dementia was 3.3% in elderly people with mild cognitive impairment. &lt;EM&gt;Evid. Based Med&lt;/EM&gt;. 2009;14(3): 90.&lt;FONT size=2 face=Arial&gt;&lt;FONT size=2 face=Arial&gt;&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; Abstracted from: &lt;BR&gt;Mitchell AJ, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. &lt;EM&gt;J Neurol Neurosurg Psychiatry&lt;/EM&gt; 2008;79:1386–91.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293191</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16426277?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Right-to-left shunt and migraine: the strength of the relationship</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,MIGRAINE,HEADACHE &amp; PAIN,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Wammes-van der Heijden EA et al Cephalalgia 2006 Feb;26(2):208-13&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Several studies have shown that the prevalence of a cardial right-to-left shunt (RLS) in patients with migraine with aura is significantly higher than in patients without migraine. To assess the strength of the possible relationship between RLS and migraine, the literature concerning this subject was systematically reviewed. We identified seven relevant studies. Among patients with RLS migraine with aura was 3.5 times more prevalent than among subjects without RLS [Mantel-Haenszel odds ratio (ORMH) 3.5; 95% confidence interval (CI) 2.1, 5.8]. In patients with ischaemic stroke migraine was more than two times more prevalent in patients with RLS than in patients without RLS (ORMH 2.1; 95% CI 1.6, 2.9). Our review shows that there is a clear association between RLS and migraine, especially migraine with aura. The relationship between RLS and migraine is further substantiated by the observations of disappearance and improvement of migraine symptoms after closure of the foramen ovale. However, the mechanism as well as the question about causality of this association has to be further elucidated.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396723</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://adisonline.com/cnsdrugs/Abstract/2010/24010/Role_of_Antiepileptic_Drugs_as_Preventive_Agents.3.aspx]]&gt;</url>
    <title>Role of antiepileptic drugs as preventive agents for migraine</title>
    <publicationDate>2010-01-01T00:00:00</publicationDate>
    <publisher>Adis</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Vikelis, M, Rapoport, AM. (2010) Role of antiepileptic drugs as preventive agents for migraine. &lt;EM&gt;CNS Drugs&lt;/EM&gt; 24(1):21-33&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Migraine is a common neurological disease affecting about 12% of the population in Western Europe and North America, and causing a considerable burden both to migraineurs and to society. Severe, frequent and disabling migraine attacks, as well as those poorly responsive to acute care medication, require preventive treatment, which is often under-utilized.&lt;/P&gt;
&lt;P&gt;Antiepileptic drugs are used in the prevention of migraine.&lt;BR&gt;We performed a literature search of PubMed through June 2008 for controlled trials of antiepileptic drugs in the prevention of migraine. The search identified 70 papers for a full-text review. The majority of these papers referred to valproate and topiramate, and showed that these drugs are effective and well tolerated in migraine prevention and are suitable for first-line clinical use. On the other hand, acetazolamide, lamotrigine, oxcarbazepine and vigabatrin have been shown to be not effective and gabapentin requires further evaluation. For the rest of the antiepileptic drugs, no data from controlled trials are available.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314505</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17493877]]&gt;</url>
    <title>Safety and tolerability of repetitive transcranial magnetic stimulation in patients with epilepsy: a review of the literature</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bae EH, Schrader LM, Machii K, Alonso-Alonso M, Riviello JJ, Pascual-Leone A, et al. (2007) Safety and tolerability of repetitive transcranial magnetic stimulation in patients with epilepsy: a review of the literature. &lt;EM&gt;Epilepsy and Behavior&lt;/EM&gt; 10(4):521-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed an English-language literature search, and reviewed all studies published from January 1990 to February 2007 in which patients with epilepsy were treated with rTMS, and complemented the literature search with personal correspondence with authors when necessary. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We identified 30 publications that described patients with epilepsy who underwent rTMS, and noted total number of relevant subjects, medication usage, incidence of adverse events, and rTMS parameters including stimulus frequency, number of stimuli, train duration, intertrain interval, coil type, and stimulation sites. The data were analyzed for adverse events related to rTMS. Crude per-subject risk, as well as per-subject mean risk weighted by sample size and risk per 1000 stimuli weighted by number of stimuli in each study, were computed for seizures and for other adverse events. Adverse events or lack thereof was reported in 26 studies (n=280 subjects). Adverse events attributed to rTMS were generally mild and occurred in 17.1% of subjects. Headache was most common, occurring in 9.6%. The most serious adverse event was seizure during treatment, which occurred in four patients (1.4% crude per-subject risk). All but one case were the patients' typical seizures with respect to duration and semiology, and were associated with low-frequency rTMS. A single case of an atypical seizure appearing to arise from the region of stimulation during high-frequency rTMS is reported. No rTMS-related episodes of status epilepticus were reported.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; We cautiously conclude that the risk of seizure in patients with epilepsy undergoing rTMS is small, and the risk of other mild adverse events is comparable to that seen when rTMS is used to treat other diseases. Status epilepticus or life-threatening seizures have not been reported in patients undergoing rTMS treatment. rTMS thus appears to be nearly as safe in patients with epilepsy as in nonepileptic individuals, and warrants further investigation as a therapy in this population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; June 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>339011</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/reprint/339/nov24_1/b4567]]&gt;</url>
    <title>Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies</title>
    <publicationDate>2009-11-24T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ COMPLICATING MEDICAL DISORDERS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,JANUARY 2010,CONDITIONS,CARDIOVASCULAR DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. (2009) Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. &lt;EM&gt;BMJ&lt;/EM&gt; Nov 24;339:b4567.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Medline (1966-2008), Embase (from 1988), AMED (from 1985), CINAHL (from 1982), Psychinfo (from 1985), and the Cochrane Library. Review methods For each study, relative risks and 95% confidence intervals were extracted and pooled with a random effect model, weighting for the inverse of the variance. Heterogeneity, publication bias, subgroup, and meta-regression analyses were performed. Criteria for inclusion were prospective adult population study, assessment of salt intake as baseline exposure, assessment of either stroke or total cardiovascular disease as outcome, follow-up of at least three years, indication of number of participants exposed and number of events across different salt intake categories. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; There were 19 independent cohort samples from 13 studies, with 177 025 participants (follow-up 3.5-19 years) and over 11 000 vascular events. Higher salt intake was associated with greater risk of stroke (pooled relative risk 1.23, 95% confidence interval 1.06 to 1.43; P=0.007) and cardiovascular disease (1.14, 0.99 to 1.32; P=0.07), with no significant evidence of publication bias. For cardiovascular disease, sensitivity analysis showed that the exclusion of a single study led to a pooled estimate of 1.17 (1.02 to 1.34; P=0.02). The associations observed were greater the larger the difference in sodium intake and the longer the follow-up. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; High salt intake is associated with significantly increased risk of stroke and total cardiovascular disease. Because of imprecision in measurement of salt intake, these effect sizes are likely to be underestimated. These results support the role of a substantial population reduction in salt intake for the prevention of cardiovascular disease.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 24 November 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271116</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17285784]]&gt;</url>
    <title>Second-generation antiepileptic drugs' impact on balance: a meta-analysis</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Dowden health media</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Sirven et al, &lt;SPAN class=ti&gt;&lt;SPAN title="Mayo Clinic proceedings. Mayo Clinic."&gt;&lt;A href="#javascript:AL_get(this," Proc.?);? Clin ?Mayo ?jour?,&gt;Mayo Clin Proc.&lt;/A&gt;&lt;/SPAN&gt; 2007 Jan;82(1):40-7.&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;OBJECTIVE: To systematically review available evidence regarding whether second-generation antiepileptic drugs (AEDs) contribute to the risk of balance disorders. METHODS: We systematically evaluated data from randomized controlled trials that compared adjunctive therapy with a second-generation AED (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topIramate, or zonisamide) vs placebo for partial epilepsy and that reported dose-specific rates of ataxia or Imbalance for each group. Random-effects meta-analysis was used to pool ratios (risk ratio [RR]) and associated 95% confidence Intervals to determine whether there was evidence of an overall AED class effect or a dose-response effect and whether there were differences between Individual AEDs. RESULTS: Sixteen studies met inclusion criteria, representing 4279 individuals randomized to a second-generation AED and 1830 patients to placebo. Pooled analyses of all AEDs demonstrated that they Increase imbalance risk at any dose (RR, 2.73; 95% confidence interval, 2.07-3.61) and at lowest dose (RR, 1.76; 95% confidence interval, 1.26-2.46). The highest dose analysis showed heterogeneity; evaluation of individual AEDs revealed that oxcarbamazepine and topiramate increased imbalance risk at all doses, whereas gabapentin and levetiracetam did not increase imbalance risk at any dose. A dose-response effect was observed for most AEDs. CONCLUSION: Second-generation AEDs at standard dosages, except for gabapentin and levetiracetam, increase the imbalance risk, and evidence exists for a dose-response effect. The mechanisms, risk factors, and consequences of this risk for individual AEDs warrant further study.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384466</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.2165/10898530-000000000-00000]]&gt;</url>
    <title>Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis</title>
    <publicationDate>2010-03-26T00:00:00</publicationDate>
    <publisher>Drugs</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, et al. (2010) Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. &lt;EM&gt;Drugs&lt;/EM&gt; 70(5):605-21&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background:&lt;/STRONG&gt; The automatic substitution of bioequivalent generics for brand-name antiepileptic drugs (AEDs) has been linked by anecdotal reports to loss of seizure control.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate studies comparing brand-name and generic AEDs, and determine whether evidence exists of superiority of the brand-name version in maintaining seizure control.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Sources:&lt;/STRONG&gt; English-language human studies identified in searches of MEDLINE, EMBASE and International Pharmaceutical Abstracts (1984 to 2009).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study Selection:&lt;/STRONG&gt; Randomized controlled trials (RCTs) and observational studies comparing seizure events or seizure-related outcomes between one brand-name AED and at least one alternative version produced by a distinct manufacturer.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Extraction:&lt;/STRONG&gt; We identified 16 articles (9 RCTs, 1 prospective nonrandomized trial, 6 observational studies). We assessed characteristics of the studies and, for RCTs, extracted counts for patients whose seizures were characterized as ‘controlled’ and ‘uncontrolled’.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data Synthesis:&lt;/STRONG&gt; Seven RCTs were included in the meta-analysis. The aggregate odds ratio (n?=?204) was 1.1 (95% CI 0.9, 1.2), indicating no difference in the odds of uncontrolled seizure for patients on generic medications compared with patients on brand-name medications. In contrast, the observational studies identified trends in drug or health services utilization that the authors attributed to changes in seizure control.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Although most RCTs were short-term evaluations, the available evidence does not suggest an association between loss of seizure control and generic substitution of at least three types of AEDs. The observational study data may be explained by factors such as undue concern from patients or physicians about the effectiveness of generic AEDs after a recent switch. In the absence of better data, physicians may want to consider more intensive monitoring of high-risk patients taking AEDs when any switch occurs.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;For over 35 years Drugs has been the definitive journal of drugs and therapeutics, providing independent and crucial information authored by leading international clinicians and researchers. Through a rigorous and comprehensive program of peer-reviewed evaluations Drugs provides detailed and genuinely objective analysis covering the full spectrum of new and established drug therapies in all disease areas.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270509</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15878291]]&gt;</url>
    <title>Sensitivity and specificity of procedures for the differential diagnosis of epilpetic and non-epileptic seizures: a systematic review</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>W. B. Saunders</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Cuthill F.M., Espie C.A. 2005; Seizure 14 (5) pp. 293-303&lt;/P&gt;
&lt;H2&gt;Original article abstract: &lt;/H2&gt;
&lt;P&gt;OBJECTIVES: Non-epileptic seizures (NES) present a considerable challenge in clinical practice. This paper reviews published evidence for the reliability of a number of procedures for the differential diagnosis of NES and epilepsy. METHODS: Papers identified from MEDLINE and PsychInfo Databases (1980-2001) and additional hand searches were independently reviewed using methods for evaluating evidence in systematic reviews [Liddle, J., Williamson, M. Irwig, L. Method for evaluating research guideline evidence. New South Wales Department of Health; 1996 [State Health publication no. (CEB) 96-204]; SIGN. An introduction to SIGN methodology for the development of evidence based clinical guidelines. Scottish Intercollegiate Network; 1999]. Included studies had to have an NES group and a control group of people with epilepsy (each n&amp;gt; or =10), allocated using EEG linked video-recording of concurrent behaviour, and sensitivity and specificity values had to be stated or be calculable. RESULTS: Thirty-three papers were identified, of which 13 satisfied criteria. Excluded studies are briefly described. Those retained comprised a range of procedures [seizure induction, MMPI assessment, physiological assessment (prolactin, SPECT), pre-ictal pseudosleep, and ictal/post-ictal characteristics]. No procedure emerged with both high sensitivity and specificity and adequately replicated findings, although high levels of specificity were more commonly reported than high levels of sensitivity. This suggests that procedures were generally better at excluding a possible diagnosis. CONCLUSIONS: No procedure attains reliability equivalent to EEG video-telemetry. Further rigorous evaluation, using standardised and replicable methodologies, is required. The range of symptoms presented in NES suggests that a multi-method approach may be required. This too would require evaluation.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314440</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18028411]]&gt;</url>
    <title>Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data</title>
    <publicationDate></publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MYOCLONIC EPILEPSIES,FIRST SEIZURE AND EARLY EPILEPSY,GENERALISED EPILEPSIES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Kassai B, Chiron C, Augier S, Cucherat M, Rey E, Gueyffier F, et al. (2008) Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. &lt;EM&gt;Epilepsia&lt;/EM&gt; 49(2):343-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Databases searched included Medline, Embase, and Cochrane. We used a fixed effect model to summarize the odds ratio of seizures rates and a logistic model to evaluate the influence of patient characteristics on treatment effect. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; We found 23 uncontrolled studies and 2 randomized controlled trials (RCTs) that compared stiripentol with placebo. Overall, 64 children aged between 3 and 20 years were included in the two RCTs. The odds ratio of responding to stiripentol relative to placebo was 32 (CI: 6.2, 161) and stiripentol reduced seizure rate by 70% (93%; 47%). The multivariate analysis does not suggest any differences within subgroups of participants and cotherapy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Results of uncontrolled studies in children with SMEI are potentially biased and do not provide valid information on the benefits and harms of treatments. The two RCTs identified, however, were performed with the same objectives and design and showed that seizure frequency is greatly reduced by stiripentol in children with SMEI after 2 months of treatment.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; February 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314102</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.hwbooks.com/jpt/abstracts/volume23/january-february/30.html]]&gt;</url>
    <title>Should gabapentin be dose adjusted: What are the clinical consequences?</title>
    <publicationDate></publicationDate>
    <publisher>Association of Pharmacy Technicians</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Gonyeau MJ, Rooney CA. (2007) Should gabapentin be dose adjusted: What are the clinical consequences? &lt;EM&gt;Journal of Pharmacy Technology&lt;/EM&gt; 23(1):30-4.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Medical literature (1966–February 2006, week 2) was accessed through MEDLINE, EMBASE, Pre-MEDLINE, International Pharmaceutical Abstracts, and the manufacturer’s package insert. Search terms included gabapentin, side effects/adverse effects, overdose, toxicity, and renal impairment. Literature references were consulted for relevant information.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Although gabapentin possesses a favorable safety profile and is generally well tolerated, there have been cases reporting serious adverse effects. While clinical studies and the majority of case reports demonstrate minimal adverse effects, there is some concern that select patients may experience serious outcomes if the drug is not dose adjusted. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The recommendation for dosage adjustment is suitably based upon the pharmacokinetic properties of gabapentin, yet healthcare practitioners should determine the need for gabapentin dosage adjustment in specific patients. There should be continued emphasis on recommending renal dose adjustments, with the most concern applied to the elderly and patients with significant renal impairment/end-stage renal disease. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;January / February 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398057</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://jnnp.bmj.com/content/81/11/1249.abstract]]&gt;</url>
    <title>Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis</title>
    <publicationDate>2010-07-16T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,NEUROMUSCULAR,MOTOR NEURONE DISEASE/AMYOTROPHIC LATERAL SCLEROSIS,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Alonso A, Logroscino G, Hernan MA. (2010) Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. &lt;EM&gt;Journal of Neurology, Neurosurgery and Psychiatry with Practical Neurology&lt;/EM&gt; 81(11):1249-1252&lt;/P&gt;
&lt;DIV id=sec-1 class=subsection&gt;
&lt;P id=p-1&gt;&lt;STRONG&gt;Background: &lt;/STRONG&gt;Epidemiologic studies have provided inconsistent results on the association of cigarette smoking with the incidence of amyotrophic lateral sclerosis (ALS). To summarise published evidence and explore sources of heterogeneity, we conducted a systematic review and meta-analysis of studies that evaluated this association. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-2 class=subsection&gt;
&lt;P id=p-2&gt;&lt;STRONG&gt;Methods: &lt;/STRONG&gt;Published studies evaluating the association of smoking with incidence of ALS were searched in bibliographic databases, with relevant information collected from each article. A random effects approach was used to pool the relative rate (RR) estimates from different studies. Between study heterogeneity was explored with a meta-regression approach. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-3 class=subsection&gt;
&lt;P id=p-3&gt;&lt;STRONG&gt;Results: &lt;/STRONG&gt;18 publications reported associations between smoking and ALS risk in 15 case control studies and five cohort studies. The pooled RR (95% CI) of ALS was 1.28 (0.97 to 1.68) for current versus never smokers and 1.12 (0.98 to 1.27) for ever versus never smokers. The study specifics RRs were heterogeneous (p&amp;lt;0.01). The proportion of women in the study population explained 46% of between study variability. The estimated RR (95% CI) of ALS for ever versus never smokers was 0.86 (0.71 to 1.03) in men and 1.66 (1.31 to 2.10) in women. &lt;/P&gt;&lt;/DIV&gt;
&lt;DIV id=sec-4 class=subsection&gt;
&lt;P id=p-4&gt;&lt;STRONG&gt;Interpretation:&lt;/STRONG&gt; This meta-analysis does not support an overall strong association of smoking with ALS risk but suggests that smoking might be associated with a higher risk of ALS in women. &lt;/P&gt;&lt;/DIV&gt;
&lt;P&gt;The Journal of Neurology, Neurosurgery&amp;nbsp;and Psychiatry is a neurological journal which also includes the supplement Practical Neurology, which is published bi-monthly. Material published by the journal includes original articles, reports, commentaries and editorials.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>338888</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19917993]]&gt;</url>
    <title>Smoking may be considered an established risk factor for sporadic ALS</title>
    <publicationDate>2009-11-17T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROMUSCULAR,MOTOR NEURONE DISEASE/AMYOTROPHIC LATERAL SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,JANUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Armon, C. (2009) Smoking may be considered an established risk factor for sporadic ALS. &lt;EM&gt;Neurology&lt;/EM&gt; Nov 17;73(20):1693-8.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A Medline literature search was conducted for the period between 2003 and April 2009 using the search terms smoking and (ALS or "amyotrophic lateral sclerosis" or MND or "motor neuron disease"). The references of primary articles and reviews were checked to assure completeness of the search. Primary articles published since the previous review were classified as before.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-eight titles were identified, but only 7 articles met inclusion criteria. Of these, 1 provided class II evidence, and 1 class III evidence: both showed increased risk of ALS with smoking. The class II study showed a dose-response effect, and risk decreasing with number of years since quitting smoking. Five articles provided class IV or V evidence, which may not be relied upon to draw conclusions. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Smoking may be considered an established risk factor for sporadic amyotrophic lateral sclerosis (ALS) (level A rating; 3 class II studies, 1 class III study). Evidence-based analysis of epidemiologic data shows concordance among results of better-designed studies linking smoking to ALS, and lets those results drive the conclusions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 17 November 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if they have a local subscription. Abstracts and tables of contents are free for all to view.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>389553</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//neurological/ViewResource.aspx?resID=389553]]&gt;</url>
    <title>Sodium Valproate (VPA)</title>
    <publicationDate>2010-10-11T00:00:00</publicationDate>
    <publisher>NHS Evidence</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,OCTOBER 2010]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Sodium Valproate (VPA)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;H2&gt;Sodium Valproate (VPA)&lt;/H2&gt;
&lt;P&gt;Dr Paul Gissen&lt;BR&gt;Lecturer Inherited Metabolic Diseases/Honorary Consultant in Paediatric Inherited Metabolic Diseases&lt;BR&gt;GSK Clinician Scientist&lt;BR&gt;Room WX 2.62, IBR West Extension&lt;BR&gt;The Medical School&lt;BR&gt;Edgbaston&lt;BR&gt;Birmingham B15 2TT&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;BR&gt;0121 414 2538 email: &lt;A href="mailto:p.gissen@bham.ac.uk" target="_blank"&gt;p.gissen@bham.ac.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Dr Raj Gupta &lt;BR&gt;Consultant Paediatric Neurologist&lt;BR&gt;Neurology Department&lt;BR&gt;Birmingham Children’s Hospital, Steelhouse Lane, Birmingham B4 6NH UK&lt;BR&gt;0121 333 8156 email: &lt;A href="mailto:rajat.gupta@bch.nhs.uk" target="_blank"&gt;rajat.gupta@bch.nhs.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Satwinder Chana&lt;BR&gt;Inherited Metabolic Diseases Pharmacist&lt;BR&gt;Pharmacy Department, Birmingham Children’s Hospital&lt;BR&gt;0121 333 9782 email: &lt;A href="mailto:satwinder.chana@bch.nhs.uk" target="_blank"&gt;satwinder.chana@bch.nhs.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Deirdre Kelly&lt;BR&gt;Professor of Paediatric Hepatology&lt;BR&gt;The Liver Unit, Birmingham Children’s Hospital&lt;BR&gt;0121 333 8253 email: &lt;A href="mailto:deirdre.kelly@bch.nhs.uk" target="_blank"&gt;deirdre.kelly@bch.nhs.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Sodium Valproate (VPA)&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;Epilepsy is one of the most common chronic neurological disorders and is characterised by a tendency to have recurrent unprovoked seizures.&lt;SUP&gt;1,2&lt;/SUP&gt;&amp;nbsp; There are over 50 million sufferers of epilepsy worldwide and nearly 90% live in developing countries.3 Globally, there are an estimated 2.4 million new cases each year, at least 50% of whom are children or adolescents.&lt;SUP&gt;3&lt;/SUP&gt;&amp;nbsp; Studies have shown that up to 70% of newly diagnosed children and adults with epilepsy can be successfully treated with anti-epileptic drugs.&lt;SUP&gt;4&lt;/SUP&gt;&amp;nbsp;&amp;nbsp;Sodium Valproate is an 8-carbon short, branched fatty acid with broad spectrum anticonvulsant activity.&amp;nbsp; Its usefulness as an anti-epileptic drug (AED) was discovered in 1963, and it was approved for the treatment of epilepsy in 1967 in France, 1973 in the UK and 1978 in the USA.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Sodium Valproate is an effective AED that is usually well tolerated in children and adults.&amp;nbsp; All AEDs have a relatively high incidence of adverse reactions, particularly central nervous system adverse effects such as behavioural problems and cognitive dysfunction.&lt;SUP&gt;5&lt;/SUP&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Drug Interactions&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;Valproate reduces the metabolism of lamotrigine to almost double its half life.&amp;nbsp; In patients on valproate, lamotrigine is used in reduced doses.&amp;nbsp; Phenobarbital concentrations may increase with valproate and result in excessive sedation. This interaction is caused by the inhibition of the metabolism of phenobarbital by valproate, by increasing its elimination half life.&lt;SUP&gt;6&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Adverse Events&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;Adverse events include VPA hepatotoxicity, VPA-associated hyperammonemia and pancreatitis.&amp;nbsp; The VPA associated hyperammonemia (VHE) may occur with or without&amp;nbsp; significant CNS and liver toxicity. &lt;SUP&gt;7,8,9,10&lt;/SUP&gt;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The typical features of VHE are acute onset of impaired consciousness, focal neurological symptoms, increased seizure frequency, with an elevated ammonia level and normal liver function tests. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The VPA-induced hepatotoxicity is classified into four subtypes: transient elevation of liver transaminases which occurs in about 20% of patients, reversible hyperammonemia, toxic hepatitis, and liver failure.&lt;SUP&gt;11&lt;/SUP&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The estimated risk for liver failure increases in combination with other anti-epileptic medications, and inversely with age and is higher in patients on polytherapy with other AEDs and in younger patients.&amp;nbsp; The risk of liver failure in children aged less than 2 years is 1:8,000 if on Sodium Valproate monotherapy and 1:550 if on polytherapy.&amp;nbsp; For children aged 3-10 years the risk of liver failure decreases to 1:6,000-12,000 and for children over 10 years of age decreases to less than 1:50,000.&lt;SUP&gt;11,12&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Apart from age, other risk factors include neurodevelopmental delay, fatty acid oxidation defects, urea cycle disorders and mitochondrial diseases.&lt;SUP&gt;13,14&lt;/SUP&gt; For example patients with Alpers disease, chronic progressive external ophthalmoplegia, and carnitine palmitoyl-transferase type-II deficiency have developed significant deterioration of liver function when treated with&amp;nbsp; valproate.&lt;SUP&gt;15,16,17&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Clinical presentation of liver failure and management&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;The onset of significant hepatotoxicity is typically within 5 months of starting treatment, and manifests as acute liver failure due to hepatocellular necrosis, usually with macro- and sometimes extensive microvesicular fatty change in the liver.&lt;SUP&gt;8,9&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The most common presenting symptoms in patients are: diminished conscious level; jaundice; vomiting; bleeding; increased frequency of convulsions; anorexia; oedema, pancreatitis. The onset is usually provoked by an infection at the onset of symptoms.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;If symptoms do develop, the drug should be immediately discontinued and liver dysfunction may resolve in approximately 50% of patients.&lt;SUP&gt;9&lt;/SUP&gt; The early administration of intravenous l-carnitine is associated with improved hepatic survival.&lt;SUP&gt;11,12,18&lt;/SUP&gt;&amp;nbsp; Treatment is otherwise supportive, as for fulminant hepatic failure. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The role of transplantation is controversial: the presence of an underlying metabolic or mitochondrial disorder with likely progressive multisystem manifestations, not reversible by liver transplantation, should be sought. Transplantation is contra-indicated in children with multisystem involvement. &lt;SUP&gt;19,20 &lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Metabolic pathology in sodium valproate toxicity&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;Research into underlying pathophysiology produced substantial evidence for effect of VPA administration on numerous metabolic pathways including urea cycle, cholesterol metabolism, mitochondrial fatty acid oxidation and others.&lt;SUP&gt;21,22&lt;/SUP&gt; As a branched chain carboxylic acid, VPA is extensively metabolized by the liver via glucuronic acid conjugation, mitochondrial beta- and cytosolic omega-oxidation to produce multiple metabolites, some of which may be involved in its toxicity.&lt;SUP&gt;23,24,25&lt;/SUP&gt;&amp;nbsp;&amp;nbsp;Omega oxidation of VPA in the cytoplasm produces metabolites that impair the function of carbamoyl phosphate synthetase I, essential enzyme in the urea cycle, resulting in impaired urea production and hyperammonemia, which is the proposed mechanism of VPA-induced hyperammonemia without hepatotoxicity. &lt;SUP&gt;18,25&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;The histological markers of organ damage include hepatotoxicity and microvesicular steatosis, whereas proteomic studies have indicated reduced function of multiple enzymes &lt;SUP&gt;21,26&lt;/SUP&gt;, altered gene expression profiles are seen after VPA administration &lt;SUP&gt;22&lt;/SUP&gt; with particularly striking changes in the synthesis of enzymes associated with fatty acid and steroid metabolism. Metabolomic studies demonstrated functional impairment of liver cells after VPA administration in laboratory animals as was evident by the significantly decreased glycogen turnover with a concomitant and comparable decrease in RNA ribose synthesis.&lt;SUP&gt;27&lt;/SUP&gt;&amp;nbsp; In addition it has been shown that VPA inhibits glucose re-absorption by the proximal tubules of the kidneys &lt;SUP&gt;28&lt;/SUP&gt; and brain glucose transport and metabolism by inhibiting glucose transporter-1 (GLUT1) by 20–30%.&lt;SUP&gt;23&lt;/SUP&gt; &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Carnitine is an amino acid derivative that is an essential cofactor in the beta-oxidation of fatty acids. It is synthesized endogenously from the essential amino acids, methionine and lysine. VPA inhibits the biosynthesis of carnitine by decreasing the concentration of alpha-ketoglutarate and may contribute to carnitine deficiency.&amp;nbsp; It has been suggested that carnitine supplementation may increase the beta-oxidation of VPA, thereby limiting cytosolic omega-oxidation and the production of toxic metabolites that are involved in liver toxicity and ammonia accumulation. VPA-induced hepatotoxicity and hyperammonemic encephalopathy may be promoted either by a pre-existing carnitine deficiency or by deficiency induced by VPA per se. Carnitine administration has been shown to speed the decrease of hyperammonaemia in patients with VPA-induced encephalopathy although a correlation between ammonia concentrations and the clinical condition was not always observed.&lt;SUP&gt;18,26&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Prevention of hepatotoxicity&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;Although asymptomatic laboratory elevation hepatic&amp;nbsp; or transaminases is common, the onset of hepatitis is a sign of potentially serious hepatotoxicity. Routine monitoring of liver function tests may not distinguish those with impending liver failure from those with minor enzyme elevation. Fulminant failure may occur without any preceding biochemical abnormality and may progress despite discontinuation of valproate.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;A role for carnitine supplementation to prevent hepatotoxicity in children receiving valproic acid has also been proposed.&lt;SUP&gt;18&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;Summary&lt;/H3&gt;
&lt;H3&gt;&amp;nbsp;&lt;/H3&gt;
&lt;P&gt;Sodium valproate is an effective anti epileptic drug. Clinicians need to be aware of the potential for hepatotoxicity, especially in young children with developmental delay, or on multiple anti-epileptic medications.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;H3&gt;References&lt;/H3&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Commission on Epidemiology and Prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia 1993; 34 (4): 592–596.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Blume W, Lüders H, Mizrahi E, Tassinari C, van Emde Boas W, Engel J. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001; 42 (9): 1212–1218.&lt;/LI&gt;
&lt;LI&gt;World Health Organization. Epilepsy Facts. Available from &lt;A href="http://www.who.int/mental_health/neurology/epilepsy/en/print.html" target="_blank"&gt;http://www.who.int/mental_health/neurology/epilepsy/en/print.html&lt;/A&gt; (Accessed on 5th June 2010).&lt;/LI&gt;
&lt;LI&gt;World Health Organization. Epilepsy.&amp;nbsp; Fact sheet No 999, January 2009.&amp;nbsp; Available from &lt;A href="http://www.who.int/mediacentre/factsheets/fs999/en/print.html" target="_blank"&gt;http://www.who.int/mediacentre/factsheets/fs999/en/print.html&lt;/A&gt; (Accessed on 5th June 2010).&lt;/LI&gt;
&lt;LI&gt;Aldenkamp AP, Bodde N. Behaviour, cognition and epilepsy. Acta Neurologica Scandinavica 2005; 112 (s182): 5-32.&lt;/LI&gt;
&lt;LI&gt;Dollery C. Valproic acid. Theraupeutic Drugs. Second Edition. Churchill Livingston 1999: v1-v6.&lt;/LI&gt;
&lt;LI&gt;Gomcelli YB, Kutlu G, Cavdar L, Sanivar F, Inan LE.&amp;nbsp; Different clinical&amp;nbsp;manifestations of&amp;nbsp; hyperammonemic encephalopathy. Epilepsy Behavior 2007;&amp;nbsp;10(4): 583-587.&lt;/LI&gt;
&lt;LI&gt;Bryant AE, Dreifuss FE.&amp;nbsp; Valproic acid hepatic fatalities. III. U.S. experience since 1986.&amp;nbsp; Neurology 1996; 46: 465-469.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Koenig SA, Buesing D, Longin E et al.&amp;nbsp; Valproic acid-induced hepatopathy: nine&amp;nbsp;new fatalities in Germany from 1994 to 2003. Epilepsia 2006; 47(12): 2027-2031. &lt;/LI&gt;
&lt;LI&gt;Gerstner T, Büsing D, Bell N, et al.&amp;nbsp; Valproic acid-induced pancreatitis: 16 new&amp;nbsp;cases and a&amp;nbsp; review of the literature.&amp;nbsp; J Gastroentology 2007; 42(1): 39-48.&lt;/LI&gt;
&lt;LI&gt;Sztajnkrycer MD.&amp;nbsp; Valproic acid toxicity: overview and management. J Toxicology:&amp;nbsp;Clinical&amp;nbsp;&amp;nbsp; Toxicology 2002; 40: 789-801.&lt;/LI&gt;
&lt;LI&gt;Verotti A, Greco R, Latini G, Chiarelli F. Endocrine and metabolic changes in&amp;nbsp;epileptic patients receiving valproic acid.&amp;nbsp; J Pediatric Endocrinology Metabolism&amp;nbsp;2005; 18: 423-430.&lt;/LI&gt;
&lt;LI&gt;Lam CW et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and&amp;nbsp;stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr, 1997.&amp;nbsp;156: 562-564.&lt;/LI&gt;
&lt;LI&gt;Krahenbuhl, S et al. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver, 2000. 20: 346-348.&lt;/LI&gt;
&lt;LI&gt;Fromenty C, Pessayre D, Impaired mitochondrial function in microvesicular&amp;nbsp;steatosis. J Hepatol, 1997; 26(suppl 2): 43-53.&lt;/LI&gt;
&lt;LI&gt;Narkewicz, MR et al. Liver involvement in Alpers disease. J Pediatr 1991; 119:&amp;nbsp;260-267.&lt;/LI&gt;
&lt;LI&gt;McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan PJ,&amp;nbsp;Chinnery PF, Ramesh V.&amp;nbsp; Reversible valproate hepatotoxicity due to mutations in&amp;nbsp;mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child. 2008&amp;nbsp;Feb; 93(2):151-153.&lt;/LI&gt;
&lt;LI&gt;Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila). 2009 Feb; 47(2): 101-111. &lt;/LI&gt;
&lt;LI&gt;Thomson M, McKiernan P, Buckels J, Mayer D, Kelly D. Generalised mitochondrial cytopathy is an absolute contraindication to orthotopic liver transplant in childhood. J Pediatr Gastroenterol Nutr 1998 Apr; 26(4): 478-481.&lt;/LI&gt;
&lt;LI&gt;Thomson MA, Lynch S, Strong R, Shepherd RW, Marsh W. Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure; a need for critical risk-benefit appraisal in the use of valproate. Transplant Proc 2000 Feb; 32(1): 200-203.&lt;/LI&gt;
&lt;LI&gt;Schnackenberg LK, Jones RC, Thyparambil S, Taylor JT, Han T, Tong W, Hansen DK, Fuscoe JC, Edmondson RD, Beger RD, Dragan YP. An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS. 2006 Spring; 10(1): 1-14.&lt;/LI&gt;
&lt;LI&gt;Lee MH, Hong I, Kim M, Lee BH, Kim JH, Kang KS, Kim HL, Yoon BI, Chung H, Kong G, Lee MO. Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol Appl Pharmacol. 2007 Apr 1; 220(1): 45-59. &lt;/LI&gt;
&lt;LI&gt;Wong HY, Chu TS, Lai JC, Fung KP, Fok TF, Fujii T, Ho YY. Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro. J Cell Biochem 2005 Nov 1; 96(4): 775-785.&lt;/LI&gt;
&lt;LI&gt;Wong H, Tong V, Riggs KW, Rurak DW, Abbott FS, Kumar S..Kinetics of valproic&amp;nbsp;acid glucuronidation: evidence for in vivo autoactivation. Drug Metab Dispos. 2007 Aug; 35(8): 1380-6. &lt;/LI&gt;
&lt;LI&gt;Silva MF, Aires CC, Luis PB, Ruiter JP, Ijlst L, Duran M, Wanders RJ, Tavares de&amp;nbsp;Almeida I. Valproic acid metabolism and its effects on mitochondrial fatty acid&amp;nbsp;oxidation: A review. J Inherit Metab Dis. 2008 Apr; 31: 205-216. &lt;/LI&gt;
&lt;LI&gt;Aires CC, Ijlst L, Stet F, Prip-Buus C, de Almeida IT, Duran M, Wanders RJ, Silva MF. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol. 2010 Mar 1; 79(5): 792-799.&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;Beger RD, Hansen DK, Schnackenberg LK, Cross BM, Fatollahi JJ, Lagunero&amp;nbsp;&amp;nbsp; FT, Sarnyai Z, Boros LG. Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-C(6)]-d-glucose tracer in mice. Metabolomics. 2009 Sep; 5(3): 336-345.&lt;/LI&gt;
&lt;LI&gt;Shaik ZP, Fifer EK, Nowak G. Protein kinase B/Akt modulates nephrotoxicant-induced necrosis in renal cells. Am J Physiol Renal Physiol. 2007 Jan; 292(1): F292-303. &lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>395101</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://ebm.bmj.com/content/15/6/183.short?rss=1]]&gt;</url>
    <title>Specific clinical findings, including coma, neck stiffness and seizures, increase the likelihood of haemorrhagic stroke, but no combination of features is definitively diagnostic</title>
    <publicationDate>2010-12-01T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,HAEMORRHAGIC,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Hill MD. (2010) Specific clinical findings, including coma, neck stiffness and seizures, increase the likelihood of haemorrhagic stroke, but no combination of features is definitively diagnostic. &lt;EM&gt;Evidence Based Medicine&lt;/EM&gt; 15(6):183-184&lt;/P&gt;
&lt;P&gt;Stroke presentations should be conceptualised as stroke syndromes, much in the same way that we now think about acute coronary syndromes. The clinical manifestations reflect brain dysfunction, but not necessarily the underlying cause. Ischaemic stroke is the most common stroke type, comprising 65–85% of all stroke, varying by location in the world. Ischaemic stroke is potentially treatable with systemic and endovascular thrombolysis, or minimally with antithrombotic medication (ie, ASA). In contrast, such treatment is inappropriate in the hyperacute setting for the two main haemorrhagic forms of stroke – intracerebral haemorrhage (ICH) and subarachnoid haemorrhage. In the emergency evaluation of patients, it is, therefore, critical to know whether the patient has an ischaemic or haemorrhagic stroke.&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Evidence-Based Medicine surveys a wide range of international medical journals applying strict criteria for the quality and validity of research. Practising clinicians assess the clinical relevance of the best studies. The key details of these essential studies are included in a succinct, informative expert commentary on their clinical application. Published bi-monthly, Evidence-Based Medicine offers comprehensive coverage of primary care medicine. It includes a wide array of clinical disciplines, including family practice, internal medicine, paediatrics, obstetrics, gynaecology, psychiatry, and surgery.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295085</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ataxia.org.uk/data/files/sca1.pdf]]&gt;</url>
    <title>Spinocerebellar ataxia type 1 (SCA1)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Ataxia UK</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,SPINOCEREBELLAR DEGENERATIONS AND ATAXIAS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide written by Ataxia UK on SCA1</description>
    <body>&lt;![CDATA[ &lt;P&gt;Description:&lt;/P&gt;
&lt;P&gt;A guide written by Ataxia UK about SCA1.&amp;nbsp; It includes information on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;symptoms 
&lt;LI&gt;causes 
&lt;LI&gt;diagnosis 
&lt;LI&gt;management&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Access: This guide is freely available to the general public&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Ataxia UK is a registered charity which aims to support all people affected by ataxia.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295092</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ataxia.org.uk/data/files/sca2.pdf]]&gt;</url>
    <title>Spinocerebellar ataxia type 2 (SCA2)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Ataxia UK</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ SPINOCEREBELLAR DEGENERATIONS AND ATAXIAS,DEMENTIA,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide written by Ataxia UK about SCA2</description>
    <body>&lt;![CDATA[ &lt;P&gt;Description:&lt;/P&gt;
&lt;P&gt;A guide written by Ataxia UK about SCA2.&amp;nbsp; It includes information on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;symptoms 
&lt;LI&gt;causes 
&lt;LI&gt;diagnosis 
&lt;LI&gt;management&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Access: This guide is freely available to the general public&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Ataxia UK is a registered charity which aims to support all people affected by ataxia.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295094</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ataxia.org.uk/data/files/sca3.pdf]]&gt;</url>
    <title>Spinocerebellar ataxia type 3 (SCA3)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Ataxia UK</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,SPINOCEREBELLAR DEGENERATIONS AND ATAXIAS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide written by Ataxia UK about SCA3</description>
    <body>&lt;![CDATA[ &lt;P&gt;Description:&lt;/P&gt;
&lt;P&gt;A guide written by Ataxia UK about SCA3.&amp;nbsp; It includes information on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;symptoms 
&lt;LI&gt;causes 
&lt;LI&gt;diagnosis 
&lt;LI&gt;management&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Access: This guide is freely available to the general public&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Ataxia UK is a registered charity which aims to support all people affected by ataxia.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295095</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ataxia.org.uk/data/files/sca6.pdf]]&gt;</url>
    <title>Spinocerebellar ataxia type 6 (SCA6)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Ataxia UK</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ SPINOCEREBELLAR DEGENERATIONS AND ATAXIAS,DEMENTIA,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide by Ataxia UK about SCA6</description>
    <body>&lt;![CDATA[ &lt;P&gt;Description:&lt;/P&gt;
&lt;P&gt;A guide written by Ataxia UK about SCA6.&amp;nbsp; It includes information on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;symptoms 
&lt;LI&gt;causes 
&lt;LI&gt;diagnosis 
&lt;LI&gt;management&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Access: This guide is freely available to the general public&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Ataxia UK is a registered charity which aims to support all people affected by ataxia.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>295096</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ataxia.org.uk/data/files/sca7.pdf]]&gt;</url>
    <title>Spinocerebellar ataxia type 7 (SCA7)</title>
    <publicationDate>2005-06-01T00:00:00</publicationDate>
    <publisher>Ataxia UK</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DEMENTIA,SPINOCEREBELLAR DEGENERATIONS AND ATAXIAS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A guide by Ataxia UK about SCA7</description>
    <body>&lt;![CDATA[ &lt;P&gt;Description:&lt;/P&gt;
&lt;P&gt;A guide written by Ataxia UK about SCA7.&amp;nbsp; It includes information on:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;symptoms 
&lt;LI&gt;causes 
&lt;LI&gt;diagnosis 
&lt;LI&gt;management&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Access: This guide is freely available to the general public&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Ataxia UK is a registered charity which aims to support all people affected by ataxia.&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293381</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16702841?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Status on the use of botulinum toxin for headache disorders</title>
    <publicationDate>2006-06-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evers, S Current opinion in neurology 2006 Jun;19(3):310-5&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;PURPOSE OF REVIEW: Reports and studies on botulinum toxin A in headache treatment are increasing. The studies available from reference systems and published congress contributions on the prophylactic treatment of idiopathic and symptomatic headache with botulinum toxin were analyzed with respect to the study design, the headache diagnosis, and the significance of results. RECENT FINDINGS: For the prophylactic treatment of tension-type headache and migraine, no sufficient positive evidence for a treatment with botulinum toxin A is obtained from randomized, double-blind, and placebo-controlled trials to date. For the treatment of chronic daily headache (including medication overuse headache), there is inconsistent positive evidence for subgroups (e.g. patients without other prophylactic treatment). SUMMARY: The majority of double-blind and placebo-controlled studies do not confirm the assumption that botulinum toxin A is efficacious in the treatment of idiopathic headache disorders. It is possible that subgroups of patients with chronic daily headache benefit from a long-term treatment with this substance. Future clinical trials should focus on these defined patient groups.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288532</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17676453?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Stereotactic neurosurgery for disabling tremor in multiple sclerosis</title>
    <publicationDate>2007-08-01T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Yap, L et al &lt;SPAN title="British journal of neurosurgery."&gt;&lt;A href="#javascript:AL_get(this," Neurosurg.?);? J ?Br ?jour?,&gt;Br J Neurosurg.&lt;/A&gt;&lt;/SPAN&gt; 2007 Aug;21(4):349-54&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Disabling tremor is common in multiple sclerosis and up to 75% of patients experience tremor at some point during their disease. The treatment of this tremor, however, remains challenging. Pharmacotherapy in general has been disappointing and stereotactic neurosurgery is becoming increasingly popular. However, the results of stereotactic treatments reported are variable and no systematic review has been performed. The aim of this study was to assess the role of thalamotomy and deep brain stimulation in the treatment of tremor in multiple sclerosis, and to compare the differences in efficacy and safety between the two techniques. We identified the relevant published studies and cases by searching the MEDLINE, EMBASS and the references lists of related articles, and performed a systematic review and assessment of the full texts of all articles selected. Initial tremor suppression was seen in 93.8% of patients who had thalamotomy and 96% in those who had deep brain stimulation. A total of 63.5% of patients had persistent tremor suppression at 12 months or more after thalamotomy. Twelve results for deep brain stimulation were not available in the reviewed literature. Functional improvement was seen only in 47.8% of those who underwent thalamotomy as opposed to 85.2% of those who had deep brain stimulation. While three of the four reported deaths were in patients who underwent thalamotomy, three of the four procedure-related haemorrhages followed DBS. Other common adverse effects like hemiparesis, dysarthria, swallowing difficulties, balance disorder, etc., was reported in both procedures. Numerous studies have attempted to assess the efficacy and safety of thalamotomy and DBS in the treatment of MS tremor, but no standardized outcome measures were used. Nonetheless, the data suggest that both thalamotomy and thalamic DBS are comparable procedures for tremor suppression and that adverse effects can occur with both procedures.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384279</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1016/j.eplepsyres.2009.08.014]]&gt;</url>
    <title>Stigma and health-related quality of life in Asian adults with epilepsy</title>
    <publicationDate>2009-09-25T00:00:00</publicationDate>
    <publisher>Epilepsy Research UK</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DELIVERY OF CARE,EPILEPSY &amp; SEIZURES,OUTCOME MEASUREMENTS,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Lim Y-J, Chan S-Y, Ko Y. (2009) Stigma and health-related quality of life in Asian adults with epilepsy. &lt;EM&gt;Epilepsy Research&lt;/EM&gt; 87(2-3):107-119&lt;/P&gt;
&lt;P&gt;This study aims to (1) review the impact of epilepsy on the health-related quality of life (HRQoL) of Asian adult persons with epilepsy (PWE), and (2) identify the extent of stigma they experience and the associated factors. The electronic databases Medline, PsycINFO, ISI Web of Science, and the International Pharmaceutical Abstracts were searched using a combination of keywords to identify relevant journal articles published before October 2007, and supplemental manual searches of article bibliographies and the journal Neurology Asia were conducted. Thirty-six articles that met the predetermined inclusion criteria were selected and reviewed. The HRQoL of Asian adult PWE was lower than that of the general population. These PWE had difficulties in both physical and psychosocial functioning. Psychosocial factors appeared to have a more significant impact on PWE's HRQoL than physical factors. Stigma and negative attitudes towards marriage and employment of PWE was prevalent in many Asian countries, and the stigma's associated factors were multifaceted. Given the prevalent negative attitudes towards epilepsy, public education campaigns targeting misconceptions and associated factors may help reduce stigma and, together with psychosocial support, the HRQoL of Asian adult PWE can be improved.&lt;/P&gt;
&lt;P&gt;Epilepsy Research provides for rapid publication of high quality articles in both experimental and clinical epileptology. It is intended to provide a forum for the many disciplines involved, such as neurology, neurosurgery, neurophysiology, neuropharmacology, neurochemistry, neuroanatomy, neuropathology, neuroendocrinology, neurotoxicology, neurogenetics, neuroimaging, neuropsychology, neuropsychiatry, molecular neurobiology, clinical chemistry and child neurology. As such the journal will publish original papers from any of these areas or studies of a multidisciplinary nature. Clinical and experimental research papers adopting fresh conceptual approaches to the study of epilepsy and its treatment are encouraged. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345245</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19940277]]&gt;</url>
    <title>Strength training improves upper-limb function in individuals with stroke: a meta-analysis.</title>
    <publicationDate>2009-11-25T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,DELIVERY OF CARE,STROKE,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Harris JE, Eng JJ. (2010) Strength training improves upper-limb function in individuals with stroke: a meta-analysis. &lt;EM&gt;Stroke&lt;/EM&gt; 41(1):136-40. Epub 2009 Nov 25.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed a meta-analysis of randomized controlled trials. Electronic databases were searched from 1950 through April 2009. Strength training articles were assessed according to outcomes: strength, upper-limb function, and activities of daily living. The standardized mean difference (SMD) was calculated to estimate the pooled effect size with random-effect models. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; From the 650 trials identified, 13 were included in this review, totaling 517 individuals. A positive outcome for strength training was found for grip strength (SMD=0.95, P=0.04) and upper-limb function (SMD=0.21, P=0.03). No treatment effect was found for strength training on measures of activities of daily living. A significant effect for strength training on upper-limb function was found for studies including subjects with moderate (SMD=0.45, P=0.03) and mild (SMD=0.26, P=0.01) upper-limb motor impairment. No trials reported adverse effects.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is evidence that strength training can improve upper-limb strength and function without increasing tone or pain in individuals with stroke.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; November 25 2009 (e-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This journal freely available via Highwire Press. The most recent 5 months available to subscribers only; please check with your local healthcare library.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294622</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/cgi-bin/fulltext/118554596/HTMLSTART]]&gt;</url>
    <title>Stroke incidence and prevalence in Europe: a review of available data</title>
    <publicationDate>2006-06-06T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Bibliographic details:&lt;/P&gt;
&lt;P&gt;Truelsen, T et al European Journal of Neurology 13:6 581 - 598&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Abstract:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=para&gt;Reliable data on stroke incidence and prevalence are essential for calculating the burden of stroke and the planning of prevention and treatment of stroke patients. In the current study we have reviewed the published data from EU countries, Iceland, Norway, and Switzerland, and provide WHO estimates for stroke incidence and prevalence in these countries. Studies on stroke epidemiology published in peer-reviewed journals during the past 10&amp;nbsp;years were identified using Medline/PubMed searches, and reviewed using the structure of WHO's stroke component of the WHO InfoBase. WHO estimates for stroke incidence and prevalence for each country were calculated from routine mortality statistics. Rates from studies that met the 'ideal' criteria were compared with WHO's estimates. Forty-four incidence studies and 12 prevalence studies were identified. There were several methodological differences that hampered comparisons of data. WHO stroke estimates were in good agreement with results from 'ideal' stroke population studies. According to the WHO estimates the number of stroke events in these selected countries is likely to increase from 1.1&amp;nbsp;million per year in 2000 to more than 1.5&amp;nbsp;million per year in 2025 solely because of the demographic changes. Until better and more stroke studies are available, the WHO stroke estimates may provide the best data for understanding the stroke burden in countries where no stroke data currently exists. A standardized protocol for stroke surveillance is recommended.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Journal information:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The European Journal of Neurology is the official journal of the European Federation of Neurological Societies.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The &lt;I&gt;European Journal of Neurology&lt;/I&gt; covers all areas of clinical and basic research in neurology. Emphasis is placed on major diseases or large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases). The journal provides a forum for European activity in clinical neuroscience and medical practice and help strengthen the links between research workers and clinicians in Europe and other parts of the world. The journal also publishes the official EFNS taskforce papers.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Access statement:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This article has been made freely available online as one of the top cited articles from the European Journal of Neurology&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>306043</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://learning.bmj.com/learning/search-result.html?moduleId=5004318]]&gt;</url>
    <title>Stroke: a guide to diagnosis and assessing severity</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Learning</publisher>
    <publicationType>LEARNING MATERIAL%2FCOURSEWARE</publicationType>
    <topics>&lt;![CDATA[ STROKE,NEUROLOGICAL CONDITIONS,CONDITIONS,STROKE,DIAGNOSIS,ISCHAEMIC STROKE,DIAGNOSIS,HAEMORRHAGIC STROKE,JAN-MAR 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Learning outcomes:&lt;/STRONG&gt; "Stroke is the third most common cause of death in the UK and the largest single cause of severe disability. Stroke causes death in one-third of patients at six months and leaves another third permanently dependent on the help of others. Despite the high prevalence of stroke it has, until recently, been a relatively neglected disease. We wrote this module to inform doctors how best to promptly diagnose patients with a stroke and assess the severity of the stroke." &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;These online education tools have been developed by BMJ Learning. BMJ Learning is the best available learning website for medical professionals. It offers a wide range of learning resources, commissioned by the BMJ Group. The learning resources deal with everyday issues in primary care and hospital medicine. They are evidence based and peer reviewed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to the general public.&amp;nbsp; Free registration with the site is required.&amp;nbsp; To register, click "Start module" and then "Register here".&amp;nbsp; Do not select the option to log in via Athens as access to BMJ Learning is not currently&amp;nbsp;part of NHS Athens accounts.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270562</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17134918]]&gt;</url>
    <title>Sudden unexpected death in epilepsy patients: Risk factors. A systematic review</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Monte C.P., Arends J.B., Tan I.Y. et al. 2007; 16 (1) pp. 1-7&lt;/P&gt;
&lt;H2&gt;Original article abstract: &lt;/H2&gt;
&lt;P&gt;INTRODUCTION: Several risk factors for sudden unexplained death in epilepsy patients (SUDEP) have been proposed, but subsequent work has yielded conflicting data. The relative importance of various risk factors for SUDEP was never explored. The aim of this study is to review systematically risk factors for SUDEP and also to determine their relevance for SUDEP by calculating relative risk factor ratios. METHODS AND MATERIALS: Authors performed a literature-search on "SUDEP" in Medline, the Cochrane Library and EMBASE. Studies with unknown number of SUDEP cases or with less than five SUDEP cases and reviews were excluded from further analysis. The value of each paper was assessed, based on the quality of the study and the reliability of the diagnosis of SUDEP. This value ranged from 1 (low quality) to 10 (high quality). Papers with a value below 7 were eliminated for further analysis. For each analysed factor, a risk factor ratio was determined, with a higher ratio for a stronger risk factor. RESULTS: A number of strong risk factors for SUDEP: young age, early onset of seizures, the presence of generalized tonic clonic seizures, male sex and being in bed. Weak risk factors for SUDEP: prone position, one or more subtherapeutic bloodlevels, being in the bedroom, a strucural brain lesion and sleeping. CONCLUSIONS: In this study, authors have designed a quality scale to select papers. The relative importance of risk factors for SUDEP is demonstrated.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270579</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=PubMed&amp;cmd=Search&amp;term=%22Epilepsy%20research%22%5BJour%5D%20AND%2065%5Bvolume%5D%20AND%20101%5Bpage%5D%20AND%202005%5Bpdat%5D]]&gt;</url>
    <title>Sudden unexpected death in epilepsy: evidence-based analysis of incidence and risk-factors</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Tellez-Zenteno J.F., Ronquillo L.H., Wiebe S. 2006; Epilepsy Research 65 (1-2) pp. 101-15&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;PURPOSE: To provide an evidence-based analysis of the risk factors and incidence of SUDEP, and to assess methodological aspects and sources of variation in studies dealing with SUDEP. METHODS: An expert in library resources and electronic databases comprehensively searched Medline, Index Medicus, and the Cochrane library. We included case-control or cohort studies focusing on SUDEP in children or adults, published in the English language. Two reviewers independently applied study eligibility criteria and extracted data, resolving disagreements through discussion. RESULTS: Of 404 citations identified, 83 potentially eligible articles were reviewed in full text and 36 studies fulfilled eligibility criteria (29 cohort and 8 case-control studies). In studies using non-SUDEP deaths as controls the most consistent risk factors were a seizure preceding death, and subtherapeutic antiepileptic drug levels. In studies that used persons living with epilepsy as controls the main risk factors for SUDEP were youth, high seizure frequency, high number of antiepileptic drugs and long duration of epilepsy. The annual incidence of SUDEP ranged from 0 to 10:1000. It was highest in studies of candidates for epilepsy surgery and epilepsy referral centers (2.2:1000-10:1000), intermediate in studies including patients with mental retardation (3.4:1000-3.6:1000), and lowest in children (0-0.2:1000). The incidence was similar in autopsy series (0.35:1000-2.5:1000) and in studies of epilepsy patients in the general population (0-1.35:1000). The median proportion of SUDEP in relation to overall mortality in epilepsy was 40 and 4% in high- and low-risk groups, respectively. CONCLUSIONS: Although studies on SUDEP are heterogeneous in methodology, consistent patterns in incidence and risk factors emerge. Low- and high-risk patient groups are identified, which determine the relative contribution of SUDEP to overall mortality in epilepsy. In addition to patient population, risk factors for SUDEP depend on the type of controls used for comparison (dead versus live patients with epilepsy). Risk factors found in different studies are not necessarily contradictory, but are often complementary.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>384471</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1111/j.1528-1167.2009.02106.x]]&gt;</url>
    <title>Suicide in people with epilepsy: how great is the risk?</title>
    <publicationDate>2009-05-12T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. (2009) Suicide in people with epilepsy: how great is the risk? &lt;EM&gt;Epilepsia&lt;/EM&gt; 50(8):1933-42&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Purpose: &lt;/STRONG&gt;Suicide is more common in populations with epilepsy, but estimates vary concerning the magnitude of the risk. We aimed to estimate the risk using meta-analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A literature search identified 74 articles (76 cohorts of people with epilepsy) in whom the number of deaths by suicide in people with epilepsy and the number of person–years at risk could be estimated. Standardized mortality ratios (SMRs) with 95% confidence intervals (CIs) were calculated for each cohort, for groups of cohorts, and for the total population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The overall SMR was 3.3 (95% CI 2.8–3.7) based on 190 observed deaths by suicide compared with 58.4 expected. The SMR was significantly increased in people with incident or newly diagnosed epilepsy in the community (SMR 2.1), in populations with mixed prevalence and incidence cases (SMR 3.6), in those with prevalent epilepsy (SMR 4.8), in people in institutions (SMR 4.6), in people seen in tertiary care clinics (SMR 2.28), in people with temporal lobe epilepsy (SMR 6.6), in those following temporal lobe excision (SMR 13.9), and following other forms of epilepsy surgery (SMR 6.4). The SMR was significantly low overall in two community-based studies of people with epilepsy and developmental disability.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Discussion:&lt;/STRONG&gt; We confirm that the risk of suicide is increased in most populations of people with epilepsy. Psychiatric comorbidity has been demonstrated to be a risk factor for suicide in the general population and in people with epilepsy, and such comorbidity should thus be identified and treated.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271108</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15996526]]&gt;</url>
    <title>Suicide in the epilepsies: a meta-analytic investigation of 29 cohorts</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Pompili, M et al&amp;nbsp;&lt;SPAN class=ti&gt;&lt;B&gt;&amp;nbsp;&lt;/B&gt;&lt;SPAN title="Epilepsy &amp;amp; behavior : E&amp;amp;B."&gt;&lt;A href="#javascript:AL_get(this," Behav.?);? ?Epilepsy ?jour?,&gt;Epilepsy Behav.&lt;/A&gt;&lt;/SPAN&gt; 2005 Sep;7(2):305-10.&lt;/SPAN&gt;&lt;SPAN class=featured_linkouts&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3048&amp;amp;itool=AbstractPlus-def&amp;amp;uid=15996526&amp;amp;db=pubmed&amp;amp;url=http://linkinghub.elsevier.com/retrieve/pii/S1525-5050%2805%2900183-6" target="_blank"&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;H2&gt;Suicide in the epilepsies: a meta-analytic investigation of 29 cohorts.&lt;/H2&gt;
&lt;P&gt;OBJECTIVES: Suicide in epilepsy is a major cause of death and is very often underestimated. We conducted a meta-analysis to compare data reported in representative studies of suicide in epilepsy with data for the general population. METHODS: We searched the Index Medicus until 2005 through MedLine. We also searched the World Health Statistics Annual to ascertain the suicide rates in the age groups indicated in the studies on epileptic patients for specific years and country. RESULTS: We selected 29 studies comprising 50,814 patients, 187 of whom committed suicide. Results obtained for each study were processed together to calculate the mean number of suicides per 100,000 individuals suffering from epilepsy for each year. CONCLUSIONS: Our meta-analysis shows that suicide in patients with epilepsy is more frequent than in the general population. Nevertheless, a number of cohorts of epileptic patients had a suicide rate lower than that of the general population. Possible explanations for this heterogeneous trend and risk factors are discussed.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270503</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16713183]]&gt;</url>
    <title>Surgery for epilepsy: assessing evidence from observational studies</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,EPILEPSY AND SEIZURES,NEUROSURGERY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Beghi E., Tonini C. 2007; Epilpesy Research 70 (2-3) pp. 97-102&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;The effectiveness of epilepsy surgery is mostly based on the results of observational studies because an experimental design in surgical patients has several ethical implications. However, observational studies suffer from methodological drawbacks, which prevent meaningful conclusions and represent a serious limitation when data from different reports are pooled for systematic reviews and meta-analyses. These include the retrospective design, the use of referral populations, the small sample size, the enrolment of patients at differing inception points, the use of differing inclusion criteria, differing definitions of prognostic predictors and outcome measures, the unmasked assessment of outcome, the short follow-up, the changing technologies and surgical procedures, and the inadequate statistical methods. With these limitations in mind, a systematic review was performed of epilepsy surgery studies aiming at identifying the positive and negative prognostic predictors of surgical outcome. In this review, extent of surgical resection, abnormal MRI, mesial temporal sclerosis, febrile seizures, EEG/MRI concordance, and tumor were in decreasing order the principal indicators of the success of surgery of epilepsy. By contrast, intracranial monitoring and post-operative discharges tended to predict an unfavorable prognosis. Although the heterogeneity of the study results was fairly low, the results may be affected by pooling of data from heterogeneous reports (different patient series assessed with differing methods) or unexamined or unknown confounders. These data must be considered preliminary and cannot replace well-conducted prognostic studies (representative study populations, well-defined inception cohorts, satisfactory and complete follow-up, prospective design, and standard definition of prognostic factors).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386650</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.springerlink.com/content/5506024516520435/]]&gt;</url>
    <title>Surgery for extratemporal nonlesional epilepsy in children: a meta-analysis</title>
    <publicationDate>2009-12-15T00:00:00</publicationDate>
    <publisher>Child's Nervous System</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,NEUROSURGERY,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Ansari SF, Maher CO, Tubbs RS, Terry CL, Cohen-Gadol AA. (2010) Surgery for extratemporal nonlesional epilepsy in children: a meta-analysis. &lt;EM&gt;Childs Nervous System &lt;/EM&gt;26(7):945-951 &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Purpose:&lt;/STRONG&gt; Previous small studies have demonstrated that seizure outcomes following surgery for extratemporal lobe epilepsy (ETLE) in children are worse than those for temporal lobe epilepsy. We have conducted a meta-analysis of the available literature to better understand ETLE surgical outcomes in children.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched PubMed (1990–2009) for appropriate studies using the following terms: ETLE, ETLE surgery, ETLE surgery outcome, frontal lobe epilepsy, occipital lobe epilepsy, and parietal lobe epilepsy. Our collected data included patient age at seizure onset and surgery, the cerebral lobe involved with epileptogenesis, MRI findings, predominant seizure semiology, intracranial monitoring use (electrode implantation), epileptic region histopathology, and postoperative seizure outcome. Statistical analysis was performed to determine associations among these variables and postoperative outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ninety-five patients from 17 studies satisfied the inclusion criteria. Pathological findings (p?=?0.039) and seizure type (p?=?0.025) were significantly associated with outcome: A larger proportion of patients with cortical dysplasia and complex partial seizures experienced better outcomes. Age at surgery (p?=?0.073) and the cerebral resection site (p?=?0.059) were marginally associated with seizure outcome. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; This study confirms previous reports: Surgical outcomes for ETLE epilepsy are significantly worse than those for temporal lobe epilepsy. The reasons for this difference may include the diffuse nature of the pathology involved in ETLE, difficulty in localizing the seizure focus in young children, and involvement of “eloquent” nonresectable cortex in epileptogenesis. Because of the reporting variability among different epilepsy centers, more uniform protocols are necessary for fair evaluation and comparison of outcomes among the different centers.&lt;/P&gt;
&lt;P&gt;The official journal of the International Society for Pediatric Neurosurgery (ISPN) was founded in 1972 as Child's Brain. As of 1 January 1985, the Society changed publishers. The new official journal, Child's Nervous System has been expanded to encompass all aspects of the pediatric neurosciences: development and growth, degenerative disorders, hereditary diseases, neurology, neurosurgery, neurooncology, neurophysiology, and trauma. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>327527</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1161/STROKEAHA.109.561928]]&gt;</url>
    <title>Surgery for primary supratentorial intracerebral hematoma. a meta-analysis of 10 randomized controlled trials</title>
    <publicationDate>2009-09-24T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,HAEMORRHAGIC,INTRACEREBRAL HAEMORRHAGE,CONDITIONS,OCTOBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Prasad K, Mendelow AD, Gregson B. (2009) Surgery for primary supratentorial intracerebral hematoma. a meta-analysis of 10 randomized controlled trials. &lt;EM&gt;Stroke&lt;/EM&gt; Sep 24. [Epub ahead of print] &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched the Cochrane Stroke Group Trials Register (up to June 2007), monographs, and reference lists of relevant articles and contacted authors of relevant trials. Meta-analysis was done using fixed effects model with odds ratio as effect measure.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Ten trials with 2059 participants were included. The quality of most of the trials was acceptable but not high. Surgery was associated with statistically significant reduction in the odds of being dead or dependent at final follow up (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.58 to 0.88; 2P=0.001) with no significant heterogeneity (P=0.22; I&lt;SUP&gt;2&lt;/SUP&gt;=24.7%) among the study results. Surgery was also associated with significant reduction in the odds of death at final follow up (OR 0.74, 95% CI 0.61 to 0.90; 2P=0.003); however, there was significant heterogeneity (P=0.04; I&lt;SUP&gt;2&lt;/SUP&gt;=49%) for death as outcome.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; This updated review provides evidence that the surgical treatment of PSIH is associated with a reduction in the odds of being dead or dependent. Patients who have altered consciousness or neurological deterioration are likely to benefit from surgery. The review does not provide evidence to support surgery after 72 hours. This review has demonstrated the need for further studies of surgical treatment of PSIH to identify those patients most likely to benefit, and to find effective but less invasive methods of removing the hematoma.&lt;/P&gt;
&lt;P&gt;This is a brief summary of a Cochrane systematic review, with the &lt;A href="http://dx.doi.org/10.1002/14651858.CD000200.pub2" target="_blank"&gt;full text&lt;/A&gt; available in the Cochrane Library.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 24 September 2009 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text for the latest 12 months is&amp;nbsp;only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386653</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://linkinghub.elsevier.com/retrieve/pii/S0920-1211(10)00041-0]]&gt;</url>
    <title>Surgical outcomes in lesional and non-lesional epilepsy: a systematic review and meta-analysis</title>
    <publicationDate>2010-03-15T00:00:00</publicationDate>
    <publisher>Epilepsy Research</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,NEUROSURGERY,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Tellez-Zenteno JF, Hernandez RL, Moien-Afshari F, Wiebe S. (2010) Surgical outcomes in lesional and non-lesional epilepsy: a systematic review and meta-analysis. &lt;EM&gt;Epilepsy Research &lt;/EM&gt;89(2-3):310-318&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Purposes:&lt;/STRONG&gt; To provide evidence-based quantitative summary estimates of seizure outcomes in patients with non-lesional and lesional epilepsy treated with surgery, and to assess the consistency of results among published studies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; An exhaustive literature search identified articles published since 1995, describing outcomes according to lesional status in patients of any age who underwent resective epilepsy surgery. Two reviewers independently assessed study eligibility and extracted the data. Disagreements were resolved through discussion. Random effects meta-analyses were used after assessing the dataset for heterogeneity.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Forty articles fulfilled eligibility criteria and described outcomes in 697 patients with non-lesional epilepsy and 2860 patients with lesional epilepsy. Overall, the odds of being seizure-free after surgery were 2.5 times higher in patients with lesions on MRI or histopathology (OR 2.5, 95%CI 2.1, 3.0, p &amp;lt; 0.001). In patients with temporal lobe epilepsy surgery the odds were 2.7 times higher in those with lesions (OR 2.7, 95%CI 2.1, 3.5, p &amp;lt; 0.001). In patients with extratemporal epilepsy surgery the odds were 2.9 higher in those with lesions (OR 2.9, 95%CI 1.6, 5.1, p &amp;lt; 0.001). Outcomes were similar in children, adults, and studies that used MRI or histopathology to identify lesions.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Discussion:&lt;/STRONG&gt; Overall, the odds of seizure freedom after surgery are two to three times higher in the presence of a lesion on histopathology or MRI. The results are clinically and statistically significant, consistent across various subgroups, and quite homogeneous across studies.&lt;/P&gt;
&lt;P&gt;Epilepsy Research provides for rapid publication of high quality articles in both experimental and clinical epileptology. It is intended to provide a forum for the many disciplines involved, such as neurology, neurosurgery, neurophysiology, neuropharmacology, neurochemistry, neuroanatomy, neuropathology, neuroendocrinology, neurotoxicology, neurogenetics, neuroimaging, neuropsychology, neuropsychiatry, molecular neurobiology, clinical chemistry and child neurology. As such the journal will publish original papers from any of these areas or studies of a multidisciplinary nature. Clinical and experimental research papers adopting fresh conceptual approaches to the study of epilepsy and its treatment are encouraged. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381766</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/doi:10.1212/WNL.0b013e3181ea15aa]]&gt;</url>
    <title>Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach</title>
    <publicationDate>2010-06-23T00:00:00</publicationDate>
    <publisher>Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS,MAGNETIC RESONANCE IMAGING (MRI),MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,INVESTIGATION &amp; DIAGNOSTICS,DELIVERY OF CARE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,OUTCOME MEASUREMENTS,JULY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Sormani MP, Bonzano L, Roccatagliata MD, Mancardi GL, Uccelli A, Bruzzi P. (2010) Surrogate endpoints for EDSS worsening in multiple sclerosis. &lt;EM&gt;Neurology&lt;/EM&gt; 75(4): 302-309&lt;/P&gt;
&lt;P&gt;Neurology is the official journal of the American Academy of Neurology. The publication is aimed at clinical neurologists.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; These findings support the use of commonly used surrogate markers of EDSS worsening as endpoints in multiple sclerosis clinical trials. Further research is warranted to validate surrogate endpoints at the individual level rather than at the trial level, to draw important conclusions in the management of the individual patient. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate whether the effects on potential surrogate endpoints, such as MRI markers and relapses, observed in trials of experimental treatments are able to predict the effects of these treatments on disability progression as defined in relapsing-remitting multiple sclerosis (RRMS) trials. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We used a pooled analysis of all the published randomized controlled clinical trials in RRMS reporting data on Expanded Disability Status Scale (EDSS) worsening and relapses or MRI lesions or both. We extracted data on relapses, MRI lesions, and the proportion of progressing patients. A regression analysis weighted on trial size and duration was performed to study the relationship between the treatment effect observed in each trial on relapses and MRI lesions and the observed treatment effect on EDSS worsening. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A set of 19 randomized double-blind controlled trials in RRMS were identified, for a total of 44 arms, 25 contrasts, and 10,009 patients. A significant correlation was found between the effect of treatments on relapses and the effect of treatments on EDSS worsening: the adjusted R2 value of the weighted regression was 0.71. The correlation between the treatment effect on MRI lesions and EDSS worsening was slightly weaker (R2 = 0.57) but significant. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abbreviations:&lt;/STRONG&gt; CI = confidence interval; DIS-effect = treatment effect on disability progression; EDSS = Expanded Disability Status Scale; MRI-effect = treatment effect on MRI lesions; REL-effect = treatment effect on relapses; RRMS = relapsing-remitting multiple sclerosis.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344196</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18780812]]&gt;</url>
    <title>Sustained-release fampridine for symptomatic treatment of multiple sclerosis</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Harvey Whitney Books company</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Korenke AR, Rivey MP, Allington DR. Sustained-release fampridine for symptomatic treatment of multiple sclerosis. &lt;EM&gt;Annals of Pharmacotherapy&lt;/EM&gt; 2008 Oct;42(10):1458-65.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; An English-language human data search was done using PubMed/MEDLINE (1966-August 2008) to retrieve relevant material using the search terms fampridine-SR, 4-aminopyridine, and multiple sclerosis. References of selected articles and information from the drug developer were used to further identify pertinent trials. Article selection was based primarily on studies that evaluated the pharmacokinetics, safety, and efficacy of sustained-release (SR) fampridinein in patients with multiple sclerosis (MS). Relevant meeting abstracts were also included as part of the analysis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Fampridine-SR is a sustained-release, orally administered potassium-channel blocker acting in the central nervous system to enhance conduction in demyelinated axons. Several small trials have evaluated the safety and efficacy of fampridine-SR in patients with MS to improve their walking ability. Data from a recent large Phase 3 trial indicated that walking speed improved in 42.9% of patients with MS who were treated with fampridine-SR compared with 9.3% of those who received placebo (p &amp;lt; 0.001). Treatment-related adverse events associated with the use of fampridine-SR include dizziness, insomnia, nausea, and paresthesia. More severe adverse events, such as seizure, have occurred in patients receiving doses higher than those currently recommended.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Positive results from 2 Phase 3 clinical trials have put fampridine-SR on the path toward approval as a medication for improving walking speed and lower extremity strength in patients with MS.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in October 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322693</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.painphysicianjournal.com/2009/march/2009;12;461-470.pdf]]&gt;</url>
    <title>Systematic assessment of the quality of research studies of conventional and alternative treatment(s) of primary headache</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>American Society of Interventional Pain Physicians</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ COMPLEMENTARY AND ALTERNATIVE MEDICINE,CONDITIONS A-Z,HEADACHE,CONDITIONS F-H,CONDITIONS M-O,MIGRAINE,CAM GENERAL,HEADACHE,RECENT ADDITIONS,HEADACHE &amp; PAIN,NEUROLOGICAL CONDITIONS,RESEARCH,AUGUST 2009,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Crawford CC, Huynh MT, Kepple A, Jonas WB. (2009) Systematic assessment of the quality of research studies of conventional and alternative treatment(s) of primary headache. &lt;EM&gt;Pain Physician&lt;/EM&gt; 12(2):461-70.&lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Randomized, controlled clinical trials (RCTs) of treatment(s) of chronic primary headache (in English between 1979 to June 2004) were searched through MEDLINE, PsycInfo, EMBASE, Cochrane Library, and the NIH databases. Studies were evaluated using standard approaches for assessing and analyzing quality indicators.&amp;nbsp; &lt;/P&gt;
&lt;P class=abstract&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 125 studies of conventional, and 121 CAM treatments met inclusion criteria. 80% of studies of conventional treatment(s) reported positive effects (p&amp;lt;0.05), versus 73% of studies of CAM approaches (chi(2) = 3.798, 1 df, p=0.051). Overall, the literature addressing the treatment of primary headache received a mean Jadad score of 2.72 out of 5 (SD 1.1). The mean Jadad score for studies of conventional therapeutics was significantly better than for those studies of CAM approaches: 3.21 +/- 0.9 vs 2.23 +/- 1.1 (t=7.72, 246 df, mean difference 0.98, p &amp;lt; 0.0005). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Studies of conventional treatments scored higher on reporting quality than studies of CAM approaches. It is possible that these differences may reflect distinctions in 1) methodologic integrity, 2) therapeutic paradigm(s), and/or 3) bias(es) in the approach(es) used to evaluate certain types of therapies. Each of these possibilities - and the implications - is addressed and considered.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; March - April 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Free full text available at publisher's site. Follow above link to view article (PDF).&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396487</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20088014]]&gt;</url>
    <title>Systematic review and meta-analysis of currently available clinical evidence on migraine and patent foramen ovale percutaneous closure: much ado about nothing?</title>
    <publicationDate>2009-07-28T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Butera G, Biondi-Zoccai GG, Carminati M, Caputi L, Usai S, Bussone G, Meola G, Delogu AB, Sheiban I, Sangiorgi G. (2009) Systematic review and meta-analysis of currently available clinical evidence on migraine and patent foramen ovale percutaneous closure: much ado about nothing? &lt;EM&gt;Catheterization and Cardiovascular Interventions&lt;/EM&gt; 75(4):494-504&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To investigate the role of transcatheter closure of patent foramen ovale on the occurrence of migraine. Background: In recent years, a potential relationship between, migraine, stroke, and patent foramen ovale (PFO) has emerged. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; BioMedCentral, Google Scholar, and PubMed from January 2000 to December 2008 were systematically searched for pertinent clinical studies. Secondary sources were also used. Secondary prevention studies of transcatheter closure for patent foramen ovale were required to include at least more than 10 patients followed for more than 6 months. The primary end-point was the rate of cured or significantly improved migraine after percutaneous PFO closure. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; After excluding 637 citations, we finally included a total of 11 studies for a total of 1,306 patients. Forty percent of the subjects included suffered from migraine, while most had a previous history of transient ischemic attack/stroke and were investigated retrospectively. Quantitative synthesis showed that complete cure of migraine in 46% (95% C.I.25–67%), while resolution or significant improvement of migraine occurred in 83% (95% C.I. 78–88%) of cases. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Notwithstanding the limitations inherent in the primary studies, this systematic review suggests that a significant group of subjects with migraine, in particular if treated after a neurological event, may benefit from percutaneous closure of their patent foramen ovale. However, many questions remain unsolved. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>371753</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/20185786?dopt=Abstract]]&gt;</url>
    <title>Systematic Review and Pooled Analysis of Published and Unpublished Validations of the ABCD and ABCD2 Transient Ischemic Attack Risk Scores</title>
    <publicationDate>2010-02-25T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ STROKE,INVESTIGATION &amp; DIAGNOSTICS,ISCHAEMIC STROKE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,APRIL 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Giles, M. F., Rothwell, P. M. (2010)&amp;nbsp;Systematic Review and Pooled Analysis of Published and Unpublished Validations of the ABCD and ABCD2 Transient Ischemic Attack Risk Scores. &lt;EM&gt;Stroke&lt;/EM&gt; 41(4):667-73.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Validations of the ABCD and ABCD2 scores were identified by searching electronic databases, reference lists, relevant journals, and conference abstracts. Unpublished tabulated data were obtained where available. Predictive value, expressed as pooled areas under the receiver operator characteristic curves (AUC), was calculated using random-effects meta-analysis, and analyses for heterogeneity were performed by categorization according to study setting and method. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty cohorts were identified reporting the performance of the ABCD system in 9808 subjects with 456 strokes at 7 days. Among the 16 studies of both the ABCD and ABCD2 scores, pooled AUC for the prediction of stroke at 7 days were 0.72 (0.66 to 0.78) and 0.72 (0.63 to 0.82), respectively (P diff=0.97). The pooled AUC for the ABCD and ABCD2 scores in all cohorts reporting relevant data were 0.72 (0.67 to 0.77) and 0.72 (0.63 to 0.80), respectively (both P&amp;lt;0.001). Predictive value varied significantly between studies (P&amp;lt;0.001), but 75% of the variance was accounted for by study method and setting, with the highest pooled AUC for face-to-face clinical evaluation and the lowest for retrospective extraction of data from emergency department records. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Independent validations of the ABCD system showed good predictive value, with the exception of studies based on retrospective extraction of nonsystematically collected data from emergency department records. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 25th February 2010 (E-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp; Freely available from January 1970. The last 5 months are not freely available; ask your local healthcare library if they have a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270501</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17034289]]&gt;</url>
    <title>Systematic review of the efficacy of meditation techniques as treatments for medical illness</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Mary Ann Liebert Inc.</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: A.J., Steinber K., Banga A. et al. 2006; Journal of Alternative and Complementary Medicine &lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P class=abstract&gt;BACKGROUND: Meditative techniques are sought frequently by patients coping with medical and psychological problems. Because of their increasingly widespread appeal and use, and the potential for use as medical therapies, a concise and thorough review of the current state of scientific knowledge of these practices as medical interventions was conducted. PURPOSE: To systematically review the evidence supporting efficacy and safety of meditative practices in treating illnesses, and examine areas warranting further study. Studies on normal healthy populations are not included. METHODS: Searches were performed using PubMed, PsycInfo, and the Cochrane Database. Keywords were Meditation, Meditative Prayer, Yoga, Relaxation Response. Qualifying studies were reviewed and independently rated based on quality by two reviewers. Mid-to-high-quality studies (those scoring above 0.65 or 65% on a validated research quality scale) were included. RESULTS: From a total of 82 identified studies, 20 randomized controlled trials met our criteria. The studies included 958 subjects total (397 experimentally treated, 561 controls). No serious adverse events were reported in any of the included or excluded clinical trials. Serious adverse events are reported in the medical literature, though rare. The strongest evidence for efficacy was found for epilepsy, symptoms of the premenstrual syndrome and menopausal symptoms. Benefit was also demonstrated for mood and anxiety disorders, autoimmune illness, and emotional disturbance in neoplastic disease. CONCLUSIONS: The results support the safety and potential efficacy of meditative practices for treating certain illnesses, particularly in nonpsychotic mood and anxiety disorders. Clear and reproducible evidence supporting efficacy from large, methodologically sound studies is lacking.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345013</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19892997]]&gt;</url>
    <title>Systematic review of the perioperative risks of stroke or death after carotid angioplasty and stenting.</title>
    <publicationDate>2010-11-05T00:00:00</publicationDate>
    <publisher>American Heart Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,STROKE,NEUROSURGERY,STROKE,CONDITIONS,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; &lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri; FONT-SIZE: 11pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"&gt;Touzé E, Trinquart L, Chatellier G, Mas JL. Systematic review of the perioperative risks of stroke or death after carotid angioplasty and stenting. &lt;/SPAN&gt;&lt;SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri; FONT-SIZE: 11pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: IT; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=IT&gt;Stroke. 2009 Dec;40(12):e683-93. Epub 2009 Nov 5&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We sought articles published between January 1990 and June 2008 by using MEDLINE, EMBASE, the COCHRANE databases, hand-searching, abstract books from conferences, and official websites. Two reviewers independently and in duplicate selected articles on the risks of CAS, irrespective of the type of treatment, study design, setting, or language. The 2 reviewers abstracted data and assessed the quality of the studies. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Two hundred six independent studies (with 54 713 patients) were included. The overall 30-day risk of stroke or death was 4.7% (95% CI, 4.1 to 5.2) with substantial heterogeneity across studies. Symptomatic patients were about twice as likely as those with asymptomatic stenoses to have complications. The 30-day risk of stroke or death was 7.6% (3.6 to 9.1) in symptomatic and 3.3% (2.6 to 4.1) in asymptomatic patients. Risks increased with age, hypertension, and history of coronary artery disease; were unrelated to sex and the presence of contralateral carotid occlusion; and were lower in patients who had carotid restenosis after CEA and in those treated with the use of a cerebral protection device. Risks have also decreased over time. &lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Risks of CAS vary substantially across studies. Risks are overall higher than those of CEA in symptomatic patients. Some factors are likely to help select good candidates for CAS.&lt;BR&gt;&lt;BR&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Nov 5 2009 (Epub)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Freely available via Highwire Press from January 1970. The last 12 months are not available. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344104</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18606967]]&gt;</url>
    <title>Temporal trends in the incidence of multiple sclerosis: a systematic review</title>
    <publicationDate>2008-07-08T00:00:00</publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. &lt;EM&gt;Neurology &lt;/EM&gt;2008 Jul 8;71(2):129-35.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Systematic review of incidence studies of MS published in Medline between 1966 and February 2007. Age- and sex-specific incidence rates were collected from eligible publications. We computed age-adjusted rates using the world population as standard, and assessed differences in rates according to latitude and period of case ascertainment. Additionally, we evaluated the association between period of case ascertainment and the female-to-male ratio.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The overall incidence rate of MS was 3.6 cases per 100,000 person-years (95% CI 3.0, 4.2) in women and 2.0 (95% CI 1.5, 2.4) in men. Higher latitude was associated with higher MS incidence, though this latitude gradient was attenuated after 1980, apparently due to increased incidence of MS in lower latitudes. The female-to-male ratio in MS incidence increased over time, from an estimated 1.4 in 1955 to 2.3 in 2000.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The latitude gradient present in older incidence studies of multiple sclerosis (MS) is decreasing. The female-to-male MS ratio has increased in the last five decades.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published July 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293361</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18187725?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Tension-type headache</title>
    <publicationDate>2008-01-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CHRONIC DAILY HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Loder, E et al BMJ 2008 Jan 12;336(7635):88-92.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;No abstract avaiable&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325803</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.b3354]]&gt;</url>
    <title>The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis</title>
    <publicationDate>2009-09-07T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROMUSCULAR,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CRANIAL NEUROPATHIES,PERIPHERAL NERVE DISORDERS,BELL'S PALSY,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Quant EC, Jeste SS, Muni RH, Cape AV, Bhussar MK, Peleg AY. (2009) The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. &lt;EM&gt;BMJ&lt;/EM&gt; 339:b3354.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched for studies published in all languages from 1984 to January 2009. Additional studies were identified from cited references. Selection criteria Randomised controlled trials that compared steroids with the combination of steroids and antivirals for the treatment of Bell's palsy were included in this study. At least one month of follow-up and a primary end point of at least partial facial muscle recovery, as defined by a House-Brackmann grade of at least 2 (complete palsy is designated a grade of 6) or an equivalent score on an alternative recognised scoring system, were required. Review methods Two authors independently reviewed studies for methodological quality, treatment regimens, duration of symptoms before treatment, length of follow-up, and outcomes. Odds ratios with 95% confidence intervals were calculated and pooled using a random effects model. &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Six trials were included, a total of 1145 patients; 574 patients received steroids alone and 571 patients received steroids and antivirals. The pooled odds ratio for facial muscle recovery showed no benefit of steroids plus antivirals compared with steroids alone (odds ratio 1.50, 95% confidence interval 0.83 to 2.69; P=0.18). A one study removed analysis showed that the highest quality studies had the greatest effect on the lack of difference between study arms shown by the odds ratio. Subgroup analyses assessing causes of heterogeneity defined a priori (time from symptom onset to treatment, length of follow-up, and type of antiviral studied) showed no benefit of antivirals in addition to that provided by steroids. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Antivirals did not provide an added benefit in achieving at least partial facial muscle recovery compared with steroids alone in patients with Bell's palsy. This study does not, therefore, support the routine use of antivirals in Bell's palsy. Future studies should use improved herpes virus diagnostics and newer antivirals to assess whether combination therapy benefits patients with more severe facial paralysis at study entry.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 7 September 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is freely available under the Creative Commons License.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322697</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18671771]]&gt;</url>
    <title>The burden of migraine in the United States: Current and emerging perspectives on disease management and economic analysis</title>
    <publicationDate>2008-07-30T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,NEUROLOGICAL CONDITIONS,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Hazard E, Munakata J, Bigal ME, Rupnow MFT, Lipton RB. (2009) The burden of migraine in the United States: Current and emerging perspectives on disease management and economic analysis. &lt;EM&gt;Value in Health&lt;/EM&gt; 12(1):55-64.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; This study traced the history of economic articles published on migraine by performing a literature search using PubMed MEDLINE database and ancestral searches of relevant articles. The intention was not to provide an exhaustive review of every article or adjudicate between studies with different findings. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Migraine affects millions of individuals worldwide, generally during the most productive years of a person's life. Studies show that migraineurs are underdiagnosed, undertreated, and experience substantial decreases in functioning and productivity, which in turn translates into diminished quality of life for individuals, and financial burdens to both health-care systems and employers. Economic evaluations of migraine therapies have evolved with new clinical developments beginning with cognitive-behavioral therapy, introduction of triptans, concern over medication overuse, and emergence of migraine prophylaxis. Now recent clinical studies suggest that migraine may be a progressive disease with cardiovascular, cerebrovascular, and long-term neurologic effects. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Migraine imposes a substantial burden on patients, families, employers and societies. The economic standards by which migraine and treatment are evaluated have evolved in response to clinical developments. Emerging evidence suggests that migraine is a chronic and progressive disease. If confirmed, approaches to acute and prophylactic treatments and economic evaluations of migraine treatment may require major reconsideration.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 30 July 2008 (e-pub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Abstracts and tables of contents are free for all to view. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381781</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/bmj.c3666]]&gt;</url>
    <title>The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis</title>
    <publicationDate>2010-07-26T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INVESTIGATION &amp; DIAGNOSTICS,STROKE,MAGNETIC RESONANCE IMAGING (MRI),ISCHAEMIC STROKE,DEMENTIA,HAEMORRHAGIC,CONDITIONS,JULY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Debette S, Markus HS. (2010) The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. &lt;EM&gt;British Medical Journal&lt;/EM&gt; 341: c3666&lt;/P&gt;
&lt;P&gt;BMJ publishes original scientific studies, review and educational articles, and papers commenting on the clinical, scientific, social, political, and economic factors affecting health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; White matter hyperintensities predict an increased risk of stroke, dementia, and death. Therefore white matter hyperintensities indicate an increased risk of cerebrovascular events when identified as part of diagnostic investigations, and support their use as an intermediate marker in a research setting. Their discovery should prompt detailed screening for risk factors of stroke and dementia. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives:&lt;/STRONG&gt; To review the evidence for an association of white matter hyperintensities with risk of stroke, cognitive decline, dementia, and death. &lt;BR&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Systematic review and meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; PubMed from 1966 to 23 November 2009. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection:&lt;/STRONG&gt; Prospective longitudinal studies that used magnetic resonance imaging and assessed the impact of white matter hyperintensities on risk of incident stroke, cognitive decline, dementia, and death, and, for the meta-analysis, studies that provided risk estimates for a categorical measure of white matter hyperintensities, assessing the impact of these lesions on risk of stroke, dementia, and death.&lt;STRONG&gt; &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data extraction:&lt;/STRONG&gt; Population studied, duration of follow-up, method used to measure white matter hyperintensities, definition of the outcome, and measure of the association of white matter hyperintensities with the outcome. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data synthesis:&lt;/STRONG&gt; 46 longitudinal studies evaluated the association of white matter hyperintensities with risk of stroke (n=12), cognitive decline (n=19), dementia (n=17), and death (n=10). 22 studies could be included in a meta-analysis (nine of stroke, nine of dementia, eight of death). White matter hyperintensities were associated with an increased risk of stroke (hazard ratio 3.3, 95% confidence interval 2.6 to 4.4), dementia (1.9, 1.3 to 2.8), and death (2.0, 1.6 to 2.7). An association of white matter hyperintensities with a faster decline in global cognitive performance, executive function, and processing speed was also suggested. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Free full text is available to NHS staff via &lt;A href="http://ukpmc.ac.uk/" target="_blank"&gt;UK PubMed Central&lt;/A&gt;, with a 1-year embargo. Up-to-date full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270583</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17532231]]&gt;</url>
    <title>The contribution of 18F-FDG PET in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy. A meta-analysis</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,COMPUTED TOMOGRAPHY (CT),INVESTIGATION &amp; DIAGNOSTICS,NEUROLOGICAL CONDITIONS,CONDITIONS,NEUROSURGERY,EPILEPSY AND SEIZURES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details: &lt;/STRONG&gt;Willmann O., Wennberg R., May T. et al. 2007; Seizure 16 (6) pp. 509-20&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;OBJECTIVE: To assess the predictive diagnostic added value of positron emission tomography (PET) in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy (TLE). METHODS: A meta-analysis of publications from 1992 to 2006 was performed. Forty-six studies were identified that met inclusion criteria presenting detailed diagnostic test results and a classified postoperative outcome. Studies exclusively reporting on patients with brain tumors or on children were excluded. RESULTS: The analyses were complicated by significant differences in study design and often by lack of precise patient data. Ipsilateral PET hypometabolism showed a predictive value of 86% for good outcome. The predictive value was 80% in patients with normal MRI and 72% in patients with non-localized ictal scalp EEG. In a selected population of 153 TLE patients with a follow-up of &amp;gt;12 months PET correlated well with other non-invasive diagnostic tests, but none of the odds ratios of any test combination was significant. CONCLUSION: Our data confirm that ipsilateral PET hypometabolism may be an indicator for good postoperative outcome in presurgical evaluation of drug-resistant TLE, although the actual diagnostic added value remained questionable and unclear. PET does not appear to add value in patients localized by ictal scalp EEG and MRI. Prospective studies limited to non-localized ictal scalp EEG or MRI-negative patients are required for validation.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270549</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15804240]]&gt;</url>
    <title>The epidemiology of epilepsy in Europe - a systematic review</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Forsgren L., Beghi E., Oun A. et al. 2005; European Journal of Neurology 12 (4) pp. 245-53&lt;/P&gt;
&lt;H2&gt;Original article abstract:&lt;/H2&gt;
&lt;P&gt;Population-based epidemiological studies on epilepsy are available mainly from the UK and the Nordic, Baltic and western Mediterranean countries. No studies were identified from large areas of Europe, especially from the former eastern Europe (except the Baltic countries) and the eastern Mediterranean countries. Based on the prevalence of epilepsy in different studies and accounting for incomplete case identification the estimated number of children and adolescents in Europe with active epilepsy is 0.9 million (prevalence 4.5-5.0 per 1000), 1.9 million in ages 20-64 years (prevalence six per 1000) and 0.6 million in ages 65 years and older (prevalence seven per 1000). Approximately 20-30% of the epilepsy population have more than one seizure per month. Based on the age-specific incidence rates in European studies, the estimated number of new cases per year amongst European children and adolescents is 130,000 (incidence rate 70 per 100,000), 96,000 in adults 20-64 years (incidence rate 30 per 100,000) and 85,000 in the elderly 65 years and older (incidence 100 per 100,000). The proportion of both new and established cases with epilepsy in the young, adults and elderly in individual countries may differ substantially from total European distribution because of differences in age structure.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294618</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www3.interscience.wiley.com/cgi-bin/fulltext/118554640/HTMLSTART]]&gt;</url>
    <title>The epidemiology of multiple sclerosis in Europe</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Bibliographic details:&lt;/P&gt;
&lt;P&gt;Pugliatti, M et al 2006 European Journal of Neurology 13:7 700 - 722&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Abstract:&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=para&gt;Multiple sclerosis (MS) is a chronic and potentially highly disabling disorder with considerable social impact and economic consequences. It is the major cause of non-traumatic disability in young adults. The social costs associated with MS are high because of its long duration, the early loss of productivity, the need for assistance in activities of daily living and the use of immunomodulatory treatments and multidisciplinary health care. Available MS epidemiological estimates are aimed at providing a measure of the disease burden in Europe. The total estimated prevalence rate of MS for the past three decades is 83 per 100&amp;nbsp;000 with higher rates in northern countries and a female:male ratio around 2.0. Prevalence rates are higher for women for all countries considered. The highest prevalence rates have been estimated for the age group 35–64&amp;nbsp;years for both sexes and for all countries. The estimated European mean annual MS incidence rate is 4.3 cases per 100&amp;nbsp;000. The mean distribution by disease course and by disability is also reported. Despite the wealth of epidemiological data on MS, comparing epidemiological indices among European countries is a hard task and often leads only to approximate estimates. This represents a major methodological concern when evaluating the MS burden in Europe and when implementing specific cost-of-illness studies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Journal information:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;The European Journal of Neurology is the official journal of the European Federation of Neurological Societies.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The &lt;I&gt;European Journal of Neurology&lt;/I&gt; covers all areas of clinical and basic research in neurology. Emphasis is placed on major diseases or large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases). The journal provides a forum for European activity in clinical neuroscience and medical practice and help strengthen the links between research workers and clinicians in Europe and other parts of the world. The journal also publishes the official EFNS taskforce papers.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Access statement:&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;This article has been made freely available online as one of the top cited articles from the European Journal of Neurology&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>386657</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2009.02423.x/abstract]]&gt;</url>
    <title>The Epilepsy Genetic Association Database (epiGAD): analysis of 165 genetic association studies, 1996-2008</title>
    <publicationDate>2010-01-13T00:00:00</publicationDate>
    <publisher>Epilepsia</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,AUGUST 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;:&amp;nbsp;Tan NC, Berkovic SF. (2010) The Epilepsy Genetic Association Database (epiGAD): analysis of 165 genetic association studies, 1996-2008. &lt;EM&gt;Epilepsia&lt;/EM&gt; 51(4):686-689&lt;/P&gt;
&lt;P&gt;We have created the Epilepsy Genetic Association Database (epiGAD), &lt;A href="http://www.epigad.org/" target="_blank"&gt;http://www.epigad.org&lt;/A&gt;, an online database of epilepsy genetic association studies. A systematic search using several search engines identified 165 studies. Herein we analyze the types of studies available, the sample sizes used, and the strength of the findings. Common questions examined were susceptibility to idiopathic generalized epilepsy, focal epilepsy, or febrile seizures, and pharmacogenomic approaches to drug-resistant epilepsy. Sample sizes were generally small; 80% of studies had 200 or fewer cases, although more recent studies published from 2005–2008 incorporated slightly larger sample sizes. No association was judged as “strong” using current criteria for assessing genetic associations—this is probably due to inadequate sample sizes. Sample sizes need to increase, either by research collaboration or via systematic reviews and meta-analyses. We believe epiGAD will facilitate future meta-analyses.&lt;/P&gt;
&lt;P&gt;Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314404</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18557778]]&gt;</url>
    <title>The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies</title>
    <publicationDate></publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Mbuba CK, Ngugi AK, Newton CR, Carter JA. (2008) The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. &lt;EM&gt;Epilepsia&lt;/EM&gt; 49(9):1491-503.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We carried out a systematic review to investigate the magnitude, causes, and intervention strategies to improve outcomes in developing countries. We systematically searched MEDLINE, EMBASE, and PsycINFO databases, supplemented by a hand search of references in the key papers. The degree of heterogeneity and a pooled TG estimate were determined using metaanalysis techniques. The estimates were further stratified by continent and location of study (urban, rural).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Twenty-seven studies met the inclusion criteria: twelve from Africa, nine from Asia and six from Latin America. We observed a high degree of heterogeneity and inconsistency between studies. The overall estimate of the TG was 56/100 [95% confidence interval (CI) 31.1-100.0]. The variation in estimates could possibly be explained by nonuniform TG estimation methods and the diverse study populations, among other factors. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The TG was mainly attributed to inadequate skilled manpower, cost of treatment, cultural beliefs, and unavailability of antiepileptic drugs (AEDs). These factors have been addressed using different intervention strategies, such as education and supply of AEDs. Future research should estimate the TG coherently and develop sustainable interventions that will address the causes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; September 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293189</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17381554?ordinalpos=25&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>The global burden of headache: a documentation of headache prevalence and disability worldwide</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,HEADACHE &amp; PAIN,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Stovner LJ et al Cephalalgia 2007 Mar;27(3):193-210&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This study, which is a part of the initiative 'Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide', assesses and presents all existing evidence of the world prevalence and burden of headache disorders. Population-based studies applying International Headache Society criteria for migraine and tension-type headache, and also studies on headache in general and 'chronic daily headache', have been included. Globally, the percentages of the adult population with an active headache disorder are 46% for headache in general, 11% for migraine, 42% for tension-type headache and 3% for chronic daily headache. Our calculations indicate that the disability attributable to tension-type headache is larger worldwide than that due to migraine. On the World Health Organization's ranking of causes of disability, this would bring headache disorders into the 10 most disabling conditions for the two genders, and into the five most disabling for women.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322689</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2676126&amp;blobtype=pdf]]&gt;</url>
    <title>The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research</title>
    <publicationDate>2009-05-01T00:00:00</publicationDate>
    <publisher>Dowden health media</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,HEADACHE &amp; PAIN,MIGRAINE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,AUGUST 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Burton WN, Landy SH, Downs KE, Runken MC. (2009) The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. &lt;EM&gt;Mayo Clinic Proceedings&lt;/EM&gt; 84(5):436-45.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A MEDLINE search was conducted from January 1, 1990 to July 31, 2008. Articles were included if the results were from a prospective or retrospective study that reported work-specific productivity outcomes in adults with migraine in the United States. Twenty-six studies were included. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Nine studies found that diagnosed and/or undiagnosed migraine had a negative impact on worker productivity. Although one migraine prophylactic study found a statistically significant improvement in worker productivity for topiramate-treated patients, another found an insignificant difference in lisinopril-treated patients. Fifteen studies compared the impact of triptan therapy with a control group. The control groups in these studies differed with regard to recall periods, time to follow-up, and types of questionnaires used. Almost all studies found that triptan therapy was associated with a statistically significant improvement in loss in worker productivity vs the control group. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Health care professionals can reduce the impact of migraine on worker productivity with appropriate therapy. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; May 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text freely available through Pubmed Central. Follow link above to access PDF.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293089</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18422717?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>The incidence and prevalence of cluster headache: a meta-analysis of population-based studies</title>
    <publicationDate>2008-06-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,HEADACHE &amp; PAIN,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,TRIGEMINOVASCULAR HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Fischera, M et al Cephalalgia 2008 Jun;28(6):614-8. Epub 2008 Apr 16&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Cluster headache is a trigemino-autonomic cephalgia with a low prevalence. Several population-based studies on its prevalence and incidence have been performed, but with different methodology resulting in different figures. We analysed all available population-based epidemiological studies on cluster headache and compared the data in a meta-analysis. The pooled data showed a lifetime prevalence of 124 per 100,000 [confidence interval (CI) 101, 151] and a 1-year prevalence of 53 per 100,000 (CI 26, 95). The overall sex ratio was 4.3 (male to female), it was higher in chronic cluster headache (15.0) compared with episodic cluster headache (3.8). The ratio of episodic vs. chronic cluster headache was 6.0. Our analysis revealed a relatively stable lifetime prevalence, which suggests that about one in 1000 people suffers from cluster headache, the prevalence being independent of the region of the population study. The sex ratio (male to female) is higher than published in several patient-based epidemiological studies.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293352</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://jama.ama-assn.org/cgi/content/full/295/15/1824]]&gt;</url>
    <title>The influence of estrogen on migraine: a systematic review</title>
    <publicationDate>2006-04-01T00:00:00</publicationDate>
    <publisher>American Medical Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,MIGRAINE,HEADACHE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Brandes JL JAMA 2006 Apr 19;295(15):1824-30.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;CONTEXT: Menstrual migraine affects approximately 50% to 60% of female migraineurs, but knowledge regarding the role of hormones, especially estrogen, appears incomplete. OBJECTIVE: To conduct a systematic review to determine the role of hormones on menstrual migraine. EVIDENCE ACQUISITION: MEDLINE (January 1966 through September 1, 2005) and EMBASE Drugs and Pharmacology (January 1991 through September 1, 2005) were searched for articles published in the English language using the keywords migraine, estrogen, menstrual migraine, pure menstrual migraine, true menstrual migraine, menstrually-associated migraine, menstrually-related migraine, pregnancy, breast-feeding, perimenopause, menopause, nitric oxide, and estrogen receptors. A total of 643 unique articles were reviewed for relevance, scientific rigor, and generalizability. For each relevant citation, the bibliography was reviewed to identify additional sources of pertinent data. EVIDENCE SYNTHESIS: The influence of estrogen on migraine is evident by a 3-fold greater prevalence among women compared with men, and by significant changes in migraine incidence with changes in female reproductive status. Menstrual migraines are usually more resistant to treatment, generally not associated with aura, of longer duration, and associated with more functional disability compared with attacks at other times of the month. Biochemical and genetic evidence suggest central and peripheral roles for estrogen in the pathophysiology of menstrual migraine, with potential interactions with excitatory circuits, including serotonergic components. Although evidence for estrogen as a preventive treatment for menstrual migraine is inconsistent, serotonin receptor agonists (triptans) provide acute relief and also may have a role in prevention. CONCLUSIONS: Epidemiological, pathophysiological, and clinical evidence link estrogen to migraine headaches. Triptans appear to provide acute relief and also may be useful for headache prevention. Clear, focused, and evidence-based treatment algorithms are needed to support primary care physicians, neurologists, and gynecologists in the treatment of this common condition.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314097</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17845866]]&gt;</url>
    <title>The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Chicharro AV, de Marinis AJ, Kanner AM. (2007) The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist &lt;EM&gt;Epilepsy &amp;amp; Behavior&lt;/EM&gt; 11(3):361-6.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; A search of MEDLINE and Cochrane Database of Systematic Reviews, between 1980 and 2005 was performed.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The prevalence of HA in the prospective studies ranged between 70% and 100%, while in cross-sectional studies it varied between 16% and 100%. Ammonia (NH3) blood levels increased by a two-fold average relative to the baseline levels. There was no association between HA and clinical symptoms. Concomitant administration of other antiepileptic drugs (AEDs) was the factor most frequently associated with HA.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Measurement of NH3 blood levels in asymptomatic patients taking VPA is unnecessary and can only lead to diagnostic confusion. Furthermore, VPA should not be discontinued solely on the basis of HA. Ammonia blood levels should be measured only in patients taking VPA exhibiting signs of an acute encephalopathic process.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;12 September 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>377577</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/sites/pubmed/20441995]]&gt;</url>
    <title>The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: A meta-analysis.</title>
    <publicationDate>2010-05-02T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ DEMENTIA,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,INVESTIGATION &amp; DIAGNOSTICS,CONDITIONS,JUNE 2010,VASCULAR DEMENTIA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Liu H, Yang M, Li GM, Qiu Y, Zheng J, Du X, Wang JL, Liu RW. (2010) The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: A meta-analysis. Journal of the Neurological Sciences. May 2. [Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We applied a random-effects or fixed-effects model to combine odds ratio (OR) and 95% confidence intervals (95%CI). Q statistic was used to evaluate the homogeneity, and Egger's test and Funnel plot were used to assess publication bias.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 11 studies, comprising 672 cases and 1038 controls, were included worldwide. Publication bias was not observed. This meta-analysis demonstrated that the MTHFR T allele or TT genotype had an increased risk for VaD in general populations (OR, 95%CI: 1.27, 1.01-1.59; 1.41, 1.06-1.88, respectively), and a significant association was found in allele contrast, recessive, and dominant model in Asian populations, but not in Caucasian populations.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt;&amp;nbsp;&amp;nbsp;The MTHFR C677T polymorphism (mainly TT genotype) is associated with developing VaD in general populations or Asian populations. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 2nd May 2010&amp;nbsp;[Epub ahead of print]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344151</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19077062]]&gt;</url>
    <title>The needs of carers of people with multiple sclerosis: a literature review</title>
    <publicationDate>2008-12-09T00:00:00</publicationDate>
    <publisher>Wiley Interscience</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Corry M, While A. The needs of carers of people with multiple sclerosis: a literature review. &lt;EM&gt;Scandinavian Journal of Caring Sciences&lt;/EM&gt; 2009;23(3):569-89.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; People with multiple sclerosis depend heavily upon their families and other informal carers as they receive limited support from health-care professionals or health-care services. Adopting the carer role results in a life-changing experience, which may bring rewards and challenges to the carer. This paper reviews the research addressing the experiences of carers of people with multiple sclerosis published between 2002 and 2007 building upon an earlier review.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The literature suggests that carers have needs across various domains and that spouses/partners have particular needs. Much of the evidence has limited generalizibility although the geographical spread of the evidence indicates considerable consistency of need. The review describes ongoing carer needs which require supportive care and provides the basis for the development and testing of carer interventions for use by health-care professionals.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published December 2008.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>271273</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.longtermconditions.csip.org.uk]]&gt;</url>
    <title>The NSF for Long Term (Neurological Conditions) Community</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>Care Services Improvement Partnership</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,NSF LONG TERM CONDITIONS,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Introduction from website home page:&lt;/P&gt;
&lt;P&gt;This website unites people and knowledge. The National Service Framework for Long-Term Conditions sets out a vision for the next ten years of how we can provide the best possible care for people living with long-term neurological conditions. It draws on exhaustive research of best practices and sets them out as the eleven quality requirements of a first-class service.&lt;/P&gt;
&lt;P&gt;Our purpose is to help anyone with an interest in implementing the Long-Term Conditions NSF.&amp;nbsp; Three interlinked parts of this website work together:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To bring information about the NSF together in one place 
&lt;LI&gt;To enable you to assess how you are doing, point you towards information and expertise to help you change and track your own journey as you progress 
&lt;LI&gt;To allow a community of people with a common interest in long-term neurological conditions to work together, share ideas and knowledge and achieve more than we can as individuals.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>322985</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18632186]]&gt;</url>
    <title>The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials</title>
    <publicationDate>2008-07-16T00:00:00</publicationDate>
    <publisher>Mosby</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,NEUROLOGICAL CONDITIONS,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Friedman BW, Kapoor A, Friedman MS, Hochberg ML, Rowe BH. (2008) The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. &lt;EM&gt;Annals of Emergency Medicine&lt;/EM&gt; 52(6):705-13.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched multiple sources (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, and LILACS, emergency and headache medicine conference proceedings) for randomized controlled trials comparing parenteral opioid and nonopioid active comparators for the treatment of acute migraine headache. Our primary outcome was relief of headache. If this was unavailable, we accepted rescue medication use or we transformed visual analog scale change scores by using an established procedure. We grouped studies by comparator: a regimen containing dihydroergotamine, antiemetic alone, or ketorolac. For each study, we calculated an odds ratio (OR) of headache relief and then assessed clinical and statistical heterogeneity for the group of studies. We then pooled the ORs of headache relief with a random-effects model. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; From 899 citations, 19 clinical trials were identified, of which 11 were appropriate and had available data. Four trials involving 254 patients compared meperidine to dihydroergotamine, 4 trials involving 248 patients compared meperidine to an antiemetic, and 3 trials involving 123 patients compared meperidine to ketorolac. Meperidine was less effective than dihydroergotamine at providing headache relief (OR=0.30; 95% confidence interval [CI] 0.09 to 0.97) and trended toward less efficacy than the antiemetics (OR=0.46; 95% CI 0.19 to 1.11); however, the efficacy of meperidine was similar to that of ketorolac (OR=1.75; 95% CI 0.84 to 3.61). Compared to dihydroergotamine, meperidine caused more sedation (OR=3.52; 95% CI 0.87 to 14.19) and dizziness (OR=8.67; 95% CI 2.66 to 28.23). Compared to the antiemetics, meperidine caused less akathisia (OR=0.10; 95% CI 0.02 to 0.57). Meperidine and ketorolac use resulted in similar rates of gastrointestinal adverse effects (OR=1.27; 95% CI 0.31 to 5.15) and sedation (OR=1.70; 95% CI 0.23 to 12.72). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Clinicians should consider alternatives to meperidine when treating acute migraine with injectable agents.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 16 July 2008 (epub ahead of print)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396602</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19496829]]&gt;</url>
    <title>The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis</title>
    <publicationDate>2009-06-02T00:00:00</publicationDate>
    <publisher>Wiley Online Library</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Kelly AM, Walcynski T, Gunn B. (2009) The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis. &lt;EM&gt;Headache &lt;/EM&gt;49(9):1324-32&lt;/P&gt;
&lt;P&gt;Professor Peter Goadsby has critically appraised this paper and you can read his analysis &lt;A href="nelh:396691:0" name=internalLink&gt;here&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective and background:&lt;/STRONG&gt; Ranges of agents are used in the emergency departments to treat migraine headache. Some experts suggest that phenothiazines are among the most effective; clinical trials have been small with varied results. We performed a systematic review and meta-analysis to determine the relative effectiveness of phenothiazines compared with placebo and other active agents for the treatment of acute migraine.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched MEDLINE, EMBASE, CINAHL, Cochrane database, and international clinical trial registers for randomized controlled trials comparing parenteral phenothiazines with placebo or another active parenteral agent for treatment of acute migraine in adults. The primary outcome was relief of headache, and secondary outcome was clinical success. Analysis was for phenothiazines vs placebo, pooled other active agents, and metoclopramide for each outcome. Odds ratios (ORs) were calculated and pooled by using a random effects model (RevMan v5).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirteen trials were appropriate and had available data. Phenothiazines were compared with placebo in 5 trials and to another active agent in 10 (metoclopramide 4). Phenothiazine was more effective than placebo for headache relief (OR 15.02, 95% confidence interval [CI] 7.57-29.82) and clinical success (OR 8.92, 95% CI 4.08-19.51). Phenothiazines were more effective than other agents combined (OR 2.04, 95% CI 1.25-3.31) and the metoclopramide subgroup (OR 2.25, 95% CI 1.29-3.92) for clinical success, but no differences were found for headache relief. The clinical success rate of phenothiazines was 78% (95% CI 74-82).&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusion:&lt;/STRONG&gt; Phenothiazines are more effective than placebo for the treatment of migraine headache and have higher rates of clinical success than other agents against which they have been compared.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>323201</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103330.pdf]]&gt;</url>
    <title>The risk of secondary vCJD infection of patients receiving a high number of blood transfusions</title>
    <publicationDate>2009-07-24T00:00:00</publicationDate>
    <publisher>Department of Health (UK)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,COMPLICATING MEDICAL DISORDERS,INFECTIONS,AUGUST 2009,CONDITIONS,PRION DISEASE,CREUTZFELDT-JAKOB (CJD) DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This paper provides estimates of the risk of secondary variant Creutzfeld-Jakob disease (vCJD) infections for patients receiving a high number of blood transfusions.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This paper provides estimates of the risk of secondary variant Creutzfeld-Jakob disease (vCJD) infections for patients receiving a high number of blood transfusions.&lt;/P&gt;
&lt;P&gt;This paper is as originally presented to the CJD Incidents Panel on 19 January 2006 except for the addition of a disclaimer and a more recent reference.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293173</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18318747?ordinalpos=2&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>The role of cervical dysfunction in migraine: a systematic review</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE,MIGRAINE,HEADACHE &amp; PAIN,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Robertson, BA et al Cephalalgia 2008 May;28(5):474-83. Epub 2008 Mar 3&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review evaluates the strength of the evidence for the role of cervical musculoskeletal dysfunction in migraine. In this review, cervical musculoskeletal dysfunction will refer to the abnormal sensory afferentation from cervical region structures contained within the receptive field of the trigeminocervical nucleus. Electronic database searches using MEDLINE, PubMed and CINAHL were performed, and 17 studies investigating cervical musculoskeletal dysfunction in people with migraine were selected for review. The methodological quality of the included studies was assessed by two independent reviewers using a customized checklist. The review found that intersubject differences were inadequately reported and controlled, which resulted in grouping of participants with varying pathologies and symptoms. A diverse range of assessment procedures was used by the reviewed studies, which made comparison of their findings difficult. The assessment procedures were mainly used to quantify the degree of cervical musculoskeletal dysfunction, rather than to identify a cause and effect relationship between cervical structure and migrainous pain. Although animal study evidence proposes a role for cervical musculoskeletal dysfunction in migraine, this systematic review of the literature found that there is currently no convincing evidence to confirm this phenomenon in humans.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>288483</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17480177?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Kremenchutzky, M et al &lt;SPAN title="Expert opinion on drug safety."&gt;&lt;A href="#javascript:AL_get(this," Saf.?);? Drug Opin ?Expert ?jour?,&gt;Expert Opin Drug Saf.&lt;/A&gt;&lt;/SPAN&gt; 2007 May;6(3):279-88&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Multiple sclerosis, a chronic demyelinating disease of the CNS, is now a treatable disease. Phase III clinical trials of three recombinant IFN-beta products conducted in relapsing-remitting multiple sclerosis have shown, albeit modest, significant effects on relapses and short-term progression of disability, and a more substantial effect on MRI parameters. However, these effects do not correlate well with clinical disease activity or long-term disability. Overall, IFN-beta is safe and generally well tolerated, and reported adverse events were comparable between preparations. Systemic side effects can be effectively managed by dose escalation, use of an auto-injector and careful clinical monitoring.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;EM&gt;Full text not available to NHS staff, please contact your local library for more information on obtaining a copy of this article&lt;/EM&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314117</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://web.ebscohost.com/ehost/detail?vid=3&amp;hid=105&amp;sid=7a3103af-a44a-4279-8cfb-5b1b3a678489%40sessionmgr108&amp;bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#db=c8h&amp;AN=2009641362]]&gt;</url>
    <title>The treatment of neonatal seizures: a critical review of the evidence</title>
    <publicationDate>2007-07-01T00:00:00</publicationDate>
    <publisher>Australian Confederation of Paediatric &amp; Child Health Nurses</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS,NON-EPILEPTIC SEIZURES,FIRST SEIZURE AND EARLY EPILEPSY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Foster M, Lewis P. (2007) The treatment of neonatal seizures: a critical review of the evidence. &lt;EM&gt;Neonatal Paediatric &amp;amp; Child Health Nursing&lt;/EM&gt; 10(2):11-9.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The electronic databases – British Nursing Index, Cumulative Index to Nursing and Allied Literature, Cochrane Library (including the Cochrane controlled trials registers Cochrane Database of Sytematic Reviews [CDSR], Database of Abstracts of Reviews of Effectiveness [DARE], and Cochrane Neonatal Group), Medline, National Library of Medicine, Oldmedline, ProQuest, Pubmed, PubMed Central, Science Direct, Best Evidence, and Joanna Briggs Institute for Evidence Based Nursing and Midwifery – were searched for all trials dated from 1990 through to March 2007, in relation to the efficacy of monotherapy and/or combinant AC treatment for pre-term or term neonates who had EEG confirmed seizures.A hand search of the Canterbury Medical and Neonatal Clinical Library yielded a few relevant articles that were not electronically available, as well as articles and journals from non-English speaking countries. Personal communication with the librarians, paediatric neurologists, medical teams, neonatal intensive care unit nurse educators and the clinical nurse specialists yielded further unpublished data such as videos, education seminars, pilot schemes and personal opinions. The reference lists of collected journals, reviews, trials and guidelines yielded further searches.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Each study used phenobarbital for monotherapy with doses reaching a maximum of 40mg/kg. Anticonvulsant drugs used in conjunction with phenobarbitone for combinant therapy included midazolam, clonazepam, lorazepam, phenytoin and lignocaine. Each study used an electroencephalograph for seizure diagnosis and neonatal monitoring when determining therapy efficacy and final outcome assessments. Collectively the studies suggest neither monotherapy nor combinant therapy are entirely effective in seizure control. Monotherapy demonstrated a 29% - 50% success rate for complete seizure control whereas combinant therapy administered after the failure of monotherapy demonstrated a success rate of 43% - 100%. When these trials were combined the overall success for monotherapy was 44% (n = 34/78) and for combinant therapy 72% ( n = 56/78). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Though the evidence was inconclusive, it would appear that combinant therapy is of greater benefit to infants unresponsive to monotherapy. Further research such as multi-site randomised controlled trials using standardised criteria and data collection are required within this specialised area.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;July 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS staff with an NHS Athens password via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;http://www.library.nhs.uk/booksandjournals/journals/default.aspx&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>396720</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://jpharmtechnol.com/abstracts/volume25/march_april/vol25-num2-pg100.php]]&gt;</url>
    <title>Topiramate for use in adult migraine prophylaxis</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Journal of Pharmacy Technology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic record:&lt;/STRONG&gt; Sinert MR, Epstein BJ. (2009) Topiramate for use in adult migraine prophylaxis. &lt;EM&gt;Journal of Pharmacy Technology&lt;/EM&gt; 25(2):100-10&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To review studies comparing topiramate with placebo or other migraine prophylaxis agents in order to outline the role of topiramate in the pharmacologic prevention of adult migraine and to provide clinicians with evidence for rationale of its use. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Primary studies and review articles were identified via a MEDLINE search (1960-November 2008). Search terms included topiramate, antiepileptic, anticonvulsant, migraine prophylaxis, and migraine prevention. Additional references were obtained from bibliographies of those resources. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Study selection and data extraction:&lt;/STRONG&gt; All relevant information extracted from randomized, controlled studies and systematic reviews evaluating the efficacy, safety, and pharmacology of topiramate in the prevention of adult migraine were included. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data synthesis:&lt;/STRONG&gt; Topiramate is approved for the prevention of adult migraine. It has historically been used in the treatment of seizure disorders but received approval for migraine prophylaxis in 2004. The exact mechanism of its antimigraine effect remains unknown, but modulation of sodium channels, ?-aminobutyric acid, and glutamate activity seem to be involved, given the proposed shared pathophysiology between seizure and migraine. Two pivotal trials comparing topiramate with placebo led to approval for migraine prophylaxis in the US and a third similar trial that compared topiramate with propranolol secured licensure in Europe. Additional studies evaluated optimal dosing up to 200 mg daily and duration of therapy through 14 months. These trials demonstrated the ability of topiramate 50 mg twice daily, administered for up to 14 months, to safely reduce migraine frequency, duration, and severity. Limited information from comparative studies suggests a similar effect of topiramate and other agents, including divalproex sodium, propranolol, and timolol. The most common adverse effect observed among all trials was mild-to-moderate paresthesias that were transient in nature. Other adverse effects commonly reported include gastrointestinal upset and cognitive impairment. Adverse effects were more likely to occur during titration periods. Topiramate’s safety profile appears to be as good as or better than that of other prophylactic agents. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Topiramate is an appropriate first-line drug to consider for prevention of adult migraine. The efficacy and safety of topiramate in migraine prophylaxis has been well established in clinical trials and is comparable with other approved agents for this indication. When choosing among these agents, prescribers should consider the adverse effect profile, route of administration, cost, and comorbidities. &lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293181</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17107372?ordinalpos=12&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Transcatheter closure of patent foramen ovale in patients with migraine headache</title>
    <publicationDate>2006-12-01T00:00:00</publicationDate>
    <publisher>Blackwell Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,MIGRAINE,HEADACHE,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Spies, C et al Journal of Interventional Cardiology 2006 Dec;19(6):552-7&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Our objective is to review the epidemiology and pathophysiology of migraine headache, its association with patent foramen ovale (PFO), and the impact of PFO closure on migraine. Upon reviewing English-language publications listed in MEDLINE relating to migraine headache, PFO, and transcatheter closure of PFO, we selected case series, retrospective and prospective studies relevant to the topic.Primarily retrospective case-control studies demonstrate a link between PFO closure and improvement of migraine headache. Few prospective data confirm the initial results. However, the only randomized, controlled trial finished to date analyzing the effect of PFO closure on migraine failed to reach its primary outcome of resolution of migraine following the intervention. The evidence of a benefit on migraine headache following PFO closure is not convincing, but certainly intriguing. With currently ongoing trials, more information related to this topic can be expected.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314060</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18334734]]&gt;</url>
    <title>Transcriptionally less active prodynorphin promoter alleles are associated with temporal lobe epilepsy: a case-control study and meta-analysis</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>IOS Press</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ EPILEPSY &amp; SEIZURES,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS,TEMPORAL LOBE,FOCAL EPILEPSIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation: &lt;/STRONG&gt;Kauffman MA, Consalvo D, Gonzalez MD, Kochen S. (2008)Transcriptionally less active prodynorphin promoter alleles are associated with temporal lobe epilepsy: a case-control study and meta-analysis. &lt;EM&gt;Disease Markers&lt;/EM&gt; 24(3):135-40&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We performed an association study in a population of patients with Mesial Temporal Lobe Epilepsy (TLE) with Hippocampal Sclerosis (MTEHS) together with a systematic revision of the literature to investigate the role of transcriptionally less active polymorphic alleles of Prodynorphin (PDYN) gene in this pathology. We included 102 patients with a diagnosis of MTEHS and 86 healthy controls. The positive antecedent of family history for epileptic events defined a TLE subgroup with familial predisposition for epileptic disorders. The PDYN promoter polymorphism was genotyped by means of a PCR assay. For meta-analysis, we identified case-control association studies between TLE and PDYN by searching PUBMED. The pooled OR was estimated using a fixed effects model under dominant and co-dominant heredity models.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; No differences in genotypic and allelic frequencies were found between cases and controls (p = 0.61) in our population, neither in the whole cohort nor in the analysis limited to TLE with familial predisposition (p = 0.71). The Meta-Analysis included 591 TLE patients and 1117 healthy controls. We found an association between L allele (p = 0.003; OR = 1.40; IC 95 = 1.12–1.74) and a modestly higher risk to develop TLE in the group of patients with familial predisposition.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; The available evidence to date indicates that subjects with a familial predisposition to epileptic disorders carrying L alleles of PDYN gene promoter have, at least, a 40% greater risk to suffer from TLE than those homozygous for the H alleles.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date: &lt;/STRONG&gt;2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322972</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18496120]]&gt;</url>
    <title>Treatment of children with migraine in the emergency department: a qualitative systematic review</title>
    <publicationDate>2008-05-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Bailey B, McManus BC. (2008) Treatment of children with migraine in the emergency department: a qualitative systematic review. &lt;EM&gt;Pediatric Emergency Care&lt;/EM&gt; 24(5):321-30.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Databases (Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Controlled Trials Register, MedLine, and EMBASE) were searched for RCTs that evaluated treatment of migraine in children (&amp;lt;18 years of age). Guidelines published on the subject were checked for missed references. Characteristics of the identified studies as well as primary outcome (headache relief), other recognized primary outcomes, and adverse events were abstracted. Quality of the RCTs was evaluated using the Jadad score. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Of the 14 trials included in the review, only 1 was performed in an ED after other treatments have failed. In that situation, prochlorperazine was more effective than ketorolac in relieving pain at 1 hour. Other treatments were evaluated by neurologists on their outpatients who started the studied drugs early at the beginning of the migraine without previous treatment. In that situation, ibuprofen (n = 3) and acetaminophen (n = 1) were better than placebo for pain relief. The efficacy of intranasal sumatriptan (n = 4), oral rizatriptan (n = 3), and oral zolmitriptan (n = 2) for pain relief was unclear. Oral sumatriptan (n = 1) and oral dihydroergotamine (n = 1) were not effective. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is a lack of studies addressing the question of treatment in the ED for children experiencing migraine. Although other treatments were found effective in children with migraine, none was evaluated in the ED except prochlorperazine and ketorolac.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; May 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322507</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18803445]]&gt;</url>
    <title>Treatment of migraine with prophylactic drugs</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MIGRAINE,HEADACHE &amp; PAIN,HEADACHE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Evers S. (2008) Treatment of migraine with prophylactic drugs. &lt;EM&gt;Expert Opinion on Pharmacotherapy&lt;/EM&gt; 9(15):2565-73.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Based on the American and European guidelines for the treatment of migraine, the evidence for different drugs in the prophylaxis of migraine was evaluated. In addition, all trials on migraine drug prophylaxis published since the publication of the guidelines were included in the evaluation. These trials were identified by a literature search in MedLine, Embase and the Cochrane library. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; The drugs of first choice are beta-blockers, flunarizine, valproic acid and topiramate and, in the US, amitriptyline is also grouped among the first-choice drugs. Drugs of second choice, with less efficacy or poorer evidence, are venlafaxine, gabapentin, naproxen, butterbur root, vitamin B(2) and magnesium. The potential side effects are considered when choosing the appropriate prophylactic drug. All drugs used in migraine prophylaxis have been detected by chance and not by pathophysiological considerations. In the future, drugs developed on the basis of the current knowledge of migraine pathophysiology will hopefully be more effective.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Drug prophylaxis of migraine is a safe and effective way of reducing the attack frequency and, thus, the burden of migraine. However, there are still a relevant minority of migraine patients that do not derive any benefit from any migraine prophylactic drug.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; October 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>395106</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/content/341/bmj.c5222.full]]&gt;</url>
    <title>Tricyclic antidepressants and headaches: systematic review and meta-analysis</title>
    <publicationDate>2010-08-09T00:00:00</publicationDate>
    <publisher>BMJ Journals</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,CONDITIONS,NOVEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details:&lt;/STRONG&gt; Jackson JL, Shimeall W, Sessums L, DeZee KJ, Becher D, Diemer M, Berbano E, O'Malley PG. (2010) Tricyclic antidepressants and headaches: systematic review and meta-analysis.&amp;nbsp;&lt;EM&gt;British Medical Journal&lt;/EM&gt; 341:c5222&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Objective:&lt;/STRONG&gt; To evaluate the efficacy and relative adverse effects of tricyclic antidepressants in the treatment of migraine, tension-type, and mixed headaches. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Design:&lt;/STRONG&gt; Meta-analysis. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data sources:&lt;/STRONG&gt; Medline, Embase, the Cochrane Trials Registry, and PsycLIT. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Studies&amp;nbsp;reviewed:&lt;/STRONG&gt; Randomised trials of adults receiving tricyclics as only treatment for a minimum of four weeks. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Data extraction:&lt;/STRONG&gt; Frequency of headaches (number of headache attacks for migraine and number of days with headache for tension-type headaches), intensity of headache, and headache index. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 37 studies met the inclusion criteria. Tricyclics significantly reduced the number of days with tension-type headache and number of headache attacks from migraine than placebo (average standardised mean difference -1.29, 95% confidence interval -2.18 to -0.39 and -0.70, -0.93 to -0.48) but not compared with selective serotonin reuptake inhibitors (-0.80, -2.63 to 0.02 and -0.20, -0.60 to 0.19). The effect of tricyclics increased with longer duration of treatment (ß=-0.11, 95% confidence interval -0.63 to -0.15; P&amp;lt;0.0005). Tricyclics were also more likely to reduce the intensity of headaches by at least 50% than either placebo (tension-type: relative risk 1.41, 95% confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely to cause adverse effects than placebo (1.53, 95% confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry mouth (P&amp;lt;0.0005 for both), drowsiness (P&amp;lt;0.0005 for both), and weight gain (P&amp;lt;0.001 for both), but did not increase dropout rates (placebo: 1.22, 0.83 to 1.80, selective serotonin reuptake inhibitors: 1.16, 0.81 to 2.97). &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Tricyclic antidepressants are effective in preventing migraine and tension-type headaches and are more effective than selective serotonin reuptake inhibitors, although with greater adverse effects. The effectiveness of tricyclics seems to increase over time. &lt;/P&gt;
&lt;P&gt;BMJ publishes original scientific studies, review and educational articles, and papers commenting on the clinical, scientific, social, political, and economic factors affecting health.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt;&amp;nbsp;Free full text is available to NHS staff via &lt;A href="http://ukpmc.ac.uk/" target="_blank"&gt;UK PubMed Central&lt;/A&gt;, with a 1-year embargo. Up-to-date full text articles are available via an NHS Athens password. Other users should ask whether their local healthcare library has a subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>322691</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19047667]]&gt;</url>
    <title>Trigeminal autonomic cephalalgias: a review and implications for dentistry</title>
    <publicationDate>2008-12-01T00:00:00</publicationDate>
    <publisher>American Dental Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,HEADACHE &amp; PAIN,HEADACHE,TRIGEMINOVASCULAR HEADACHE,AUGUST 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Balasubramaniam R, Klasser GD, Delcanho R. (2008) Trigeminal autonomic cephalalgias: a review and implications for dentistry. &lt;EM&gt;Journal of the American Dental Association&lt;/EM&gt; 139(12):1616-24.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; The authors conducted PUBMED searches for the period from 1968 through 2007 using the terms "trigeminal autonomic cephalalgias," "cluster headache," "paroxysmal hemicrania," "short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing," "epidemiology," "pathophysiology," "treatment," "oral," "facial" and "dentistry." They gave preference to articles reporting randomized, controlled trials and those published in English-language peer-reviewed journals. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; TACs refers to a group of headaches characterized by unilateral head pain, facial pain or both with accompanying autonomic features. Although their pathophysiologies are unclear, CH, PH and SUNCT may be differentiated according to their clinical characteristics. Current treatments for each of the TACs are useful in alleviating the pain, with few refractory cases requiring surgical intervention. Patients with TACs often visit dental offices seeking relief for their pain. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Clinical implications:&lt;/STRONG&gt; Although the prevalence of TACs is small, it is important for dentists to recognize the disorder and refer patients to a neurologist. This will avoid the pitfall of administering unnecessary and inappropriate traditional dental treatments in an attempt to alleviate the neurovascular pain.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; December 2008&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health. The last 12 months are not available.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>398035</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://stroke.ahajournals.org/cgi/content/short/41/11/2669?rss=1]]&gt;</url>
    <title>Triggers of ischemic stroke: a systematic review</title>
    <publicationDate>2010-10-14T00:00:00</publicationDate>
    <publisher>American Heart Association American Stroke Association</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,ISCHAEMIC STROKE,CONDITIONS,DECEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Guiraud V, Ben Amor Mejdi, Mas J-L, Touze E. (2010) Triggers of ischemic stroke. &lt;EM&gt;Stroke&lt;/EM&gt; 41(11):2669-2677&lt;/P&gt;
&lt;P&gt;&lt;SUP&gt;&lt;/SUP&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and purpose:&lt;/STRONG&gt; Several studies have suggested that exposure to "triggers," could precipitate the onset of ischemic stroke (IS). We performed a systematic review of the potential triggers of IS. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Two independent reviewers identified studies published between January 1980 and June 2010 from MEDLINE and Embase. Where appropriate, odds ratios (ORs) were combined. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; A total of 26 studies identified 12 potential triggers. Twenty-two studies used a case–control design, and hazard period durations ranged from 2 hours to 3 months. The majority of studies were dedicated to alcohol abuse (n=10) and clinical infection (n=12). There was a significant association between IS and alcohol abuse of &amp;gt;40 to 60 g within the preceding 24 hours (OR=2.66; 95% CI, 1.54 to 4.61) or &amp;gt;150 g within the previous week (OR=2.47; 95% CI, 1.52 to 4.02) and infection within the previous week (OR=2.91; 95% CI, 1.41 to 6.00) or within the previous month (OR=2.41; 95% CI, 1.78 to 3.27). Other triggers have been far less investigated. There was a significant association between IS and anger, heavy eating, negative or positive emotions, sudden posture change in response to a startling event, birthday, and psychological distress and no significant association with drug abuse or heavy physical exertion. Regarding methodological issues, patients were rarely blinded to study objectives, and interviewers were rarely blinded to patient status. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Research on triggers of IS has been mainly focused on acute alcohol abuse and clinical infection. More research is needed on factors such as physical exertion or acute stress. Future studies should use more appropriate designs and examine different hazard periods. &lt;/P&gt;
&lt;P&gt;Stroke is a monthly publication and part of AHA Journals, produced&amp;nbsp;by&amp;nbsp;the American Heart Association whose mission is to build healthier lives, free of cardiovascular diseases and stroke.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Most full text is&amp;nbsp;only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Some full text content plus abstracts and tables of contents are freely available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293374</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17723158?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Use of almotriptan in triptan-experienced and triptan-naïve patients</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>LibraPharm</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MIGRAINE,HEADACHE,HEADACHE &amp; PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Pascual J et al Current medical research and opinion 2007 Oct;23(10):2433-40.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: To evaluate the efficacy of oral almotriptan 12.5 mg as an acute treatment for migraine with a focus on triptan-experienced versus triptan-naïve patients. RESEARCH DESIGN AND METHODS: Four recent Almirall-sponsored clinical trials of oral almotriptan 12.5 mg in acute migraine, in which data regarding previous acute therapy were collected, are reviewed. The results and conclusions are limited by the open-label and post hoc design of some of these trials and analyses. RESULTS: In two trials, almotriptan 12.5 mg was used to treat migraine sufferers who were dissatisfied with or were receiving inadequate results with their previous therapy. One of these trials enrolled only patients whose dissatisfaction with their current therapy was confirmed by a validated questionnaire; the other looked at almotriptan 12.5 mg efficacy in patients with previous poor response to sumatriptan. In the other two trials, patients had been achieving satisfactory results with their migraine therapy; one was a randomized, double-blind clinical trial of almotriptan 12.5 mg and zolmitriptan 2.5 mg, the other was an open-label almotriptan 12.5 mg satisfaction trial. Almotriptan 12.5 mg is shown to be effective, well-tolerated, and preferred to previous agents in both patients who were satisfied with, and those who were dissatisfied with, their previous therapy. CONCLUSIONS: Almotriptan should, therefore, not only be considered as first-line therapy for acute migraine but should also be considered for patients who are not satisfied with or not receiving optimal relief from their current acute therapy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293079</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16413849?ordinalpos=6&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Use of combined oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review</title>
    <publicationDate>2006-02-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,STROKE,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Curtis, KM et al Contraception 2006 Feb;73(2):189-94. Epub 2005 Oct 21.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;This systematic review examines evidence evaluating whether women with headaches who use combined oral contraceptives (COCs) have a greater risk of stroke than women with headaches who do not use COCs. We searched MEDLINE for articles published from 1966 through March 2005 relevant to headaches and COC use as risk factors for stroke. Of the 79 articles identified, nine met our selection criteria (eight reports of six observational studies plus one meta-analysis). All studies reported specifically on migraine headaches. Evidence from six case-control studies suggested that COC users with a history of migraine were two to four times as likely to have an ischemic stroke as nonusers with a history of migraine. The odds ratios for ischemic stroke ranged from 6 to almost 14 for COC users with migraine compared with nonusers without migraine. The three studies that provided evidence on hemorrhagic stroke reported low or no risk associated with migraine or with COC use.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270507</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16157897]]&gt;</url>
    <title>Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology</title>
    <publicationDate>2007-10-29T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,EPILEPSY &amp; SEIZURES,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Chen D.K., So Y.T., Fisher R.S. et al. 2005; Neurology 65 (5) pp. 668-75&lt;/P&gt;
&lt;H2&gt;Original article abstract: &lt;/H2&gt;
&lt;P&gt;OBJECTIVE: The purpose of this article is to review the use of serum prolactin assay in epileptic seizure diagnosis. METHODS: The authors identified relevant studies in multiple databases and reference lists. Studies that met inclusion criteria were summarized and rated for quality of evidence, and the results were analyzed and pooled where appropriate. RESULTS: Most studies used a serum prolactin of at least twice baseline value as abnormal. For the differentiation of epileptic seizures from psychogenic nonepileptic seizures, one Class I and seven Class II studies showed that elevated serum prolactin was highly predictive of either generalized tonic-clonic or complex partial seizures. Pooled sensitivity was higher for generalized tonic-clonic seizures (60.0%) than for complex partial seizures (46.1%), while the pooled specificity was similar for both (approximately 96%). Data were insufficient to establish validity for simple partial seizures. Two Class II studies were consistent in showing prolactin elevation after tilt-test-induced syncope. Inconclusive data exist regarding the value of serum prolactin following status epilepticus, repetitive seizures, and neonatal seizures. RECOMMENDATIONS: Elevated serum prolactin assay, when measured in the appropriate clinical setting at 10 to 20 minutes after a suspected event, is a useful adjunct for the differentiation of generalized tonic-clonic or complex partial seizure from psychogenic nonepileptic seizure among adults and older children (Level B). Serum prolactin assay does not distinguish epileptic seizures from syncope (Level B). The use of serum PRL assay has not been established in the evaluation of status epilepticus, repetitive seizures, and neonatal seizures (Level U).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325769</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/doi:10.1136/bmj.b3060]]&gt;</url>
    <title>Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis</title>
    <publicationDate>2009-08-18T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,STROKE,SEPTEMBER 2009,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Boffetta, P., Straif, K. (2009) Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. &lt;EM&gt;BMJ&lt;/EM&gt; 2009;339:b3060&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Meta-analysis of observational studies from Sweden and the United States. Data sources included electronic databases and reference lists. Data extraction involved quantitative estimates of the association between use of smokeless tobacco products and risk of myocardial infarction and stroke among never smokers. Summary relative risks were estimated on the basis of random effects models. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; 11 studies, mainly in men, were included. Eight risk estimates were available for fatal myocardial infarction: the relative risk for ever use of smokeless tobacco products was 1.13 (95% confidence 1.06 to 1.21) and the excess risk was restricted to current users. The relative risk of fatal stroke, on the basis of five risk estimates, was 1.40 (1.28 to 1.54). The studies from both the United States and Sweden showed an increased risk of death from myocardial infarction and stroke. The inclusion of non-fatal myocardial infarction and non-fatal stroke lowered the summary risk estimates. Data on dose-response were limited but did not suggest a strong relation between risk of dying from either disease and frequency or duration of use of smokeless tobacco products. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; An association was detected between use of smokeless tobacco products and risk of fatal myocardial infarction and stroke, which does not seem to be explained by chance. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; 18 August 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; This article is made freely available by the BMJ under a creative Commons license.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293372</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17190530?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>CNS Drugs</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Dodick DW et al CNS Drugs 2007;21(1):73-82.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;OBJECTIVE: To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan, but not frovatriptan) in order to provide a rationale for the use of the rate of patients who are SPF plus no AE (SNAE) as an endpoint in trials of medications for acute migraine. BACKGROUND: The attributes of drug treatment for acute migraine that are most important to people who experience them are complete pain relief, lack of recurrence, rapid onset and lack of AEs. The endpoints used to assess therapy for acute migraine do not always address these elements. METHODS: The relationship between SPF and AE rates was explored using nonparametric regression techniques, and the box-plot method was used to identify outliers. The estimated SNAE rate for each triptan was calculated with and without assuming independence between efficacy and tolerability. RESULTS: At the level of the individual agent, there was a significant relationship between the efficacy and tolerability of each triptan, with the exception of almotriptan 12.5 mg, which had an AE rate approximately 30% lower than would be expected, and eletriptan 20 mg, which had an AE rate approximately 20% higher than would be expected, on the basis of their efficacy. Almotriptan 12.5 mg and eletriptan 20 mg had the highest and lowest base-case values for SNAE, respectively, and both qualified statistically as outliers to the distribution of SNAE values obtained with the other triptans. The probability that each triptan was superior to the reference agent (sumatriptan 100 mg) in terms of SNAE was calculated across all possible values (at the level of the individual patient) for the relationship between efficacy and tolerability. Again, almotriptan 12.5 mg and eletriptan 20 mg had the highest and lowest values for their SNAE rates, respectively, and almotriptan 12.5 mg qualified statistically as an outlier from the distribution of the probabilities obtained for the other triptans. CONCLUSION: This analysis determined that higher SPF rates were strongly associated with higher AE rates, with the notable exception of almotriptan 12.5 mg, which had a lower than expected AE rate, resulting in the highest SNAE rate of the included triptans and doses. SNAE is a useful measure that can be used to discriminate between therapies and this endpoint incorporates the attributes that are most relevant to patient satisfaction with treatment. We recommend calculation of the SNAE rate at the level of the individual patient in future clinical trials of medication for the treatment of acute migraine to facilitate selection of a treatment for acute migraine that offers the best chance for effective management.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293386</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16988536?ordinalpos=5&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ HEADACHE &amp; PAIN,HEADACHE,MIGRAINE,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Kelman L et al American journal of therapeutics 2006 Sep-Oct;13(5):411-7&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;The objective of this study was to use the patient-centered efficacy measurements of sustained pain free and sustained pain free with no adverse events to compare the relative cost-effectiveness of 6 oral triptans in the treatment of acute migraine. Adverse event and sustained pain-free rates were obtained from a comprehensive meta-analysis of 53 clinical trials of oral triptans. Efficacy and tolerability were assumed to be independent. Average wholesale prices were in US dollars as of May 10, 2004. The meta-analysis of oral triptans reported that almotriptan 12.5 mg (Axert) exhibited the highest sustained pain-free rate (25.9%), with the lowest rate associated with eletriptan 20 mg (Relpax) (10.6%). In addition, almotriptan 12.5 mg possessed the lowest overall absolute adverse event rate (14.2%), with the highest adverse event rate exhibited by eletriptan 80 mg (53.9%). To attain 100 sustained pain-free patients, almotriptan 12.5 mg and rizatriptan 10 mg (Maxalt) proved to be the most cost-effective triptans, costing $7120 and $7427, respectively; the least cost-effective were naratriptan 2.5 mg (Amerge) ($13,736) and eletriptan 20 mg ($16,104). To attain 100 sustained pain-free with no adverse events patients, almotriptan 12.5 mg was the most cost-effective triptan ($8298) and the least cost-effective were eletriptan 20 mg ($25,521) and eletriptan 80 mg ($29,614). At average wholesale prices as of May 10, 2004, almotriptan 12.5 mg achieved the highest level of cost-effectiveness using either sustained pain free or sustained pain free with no adverse events as endpoints.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344311</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19200861]]&gt;</url>
    <title>What can be learned from open direct comparative trials in multiple sclerosis?</title>
    <publicationDate>2009-02-01T00:00:00</publicationDate>
    <publisher>Elsevier Science</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Khan O. What can be learned from open direct comparative trials in multiple sclerosis? &lt;EM&gt;Journal of the Neurological Sciences&lt;/EM&gt; 2009 Feb 1;277 Suppl 1:S25-S28.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; Randomised, placebo-controlled, double-blind clinical trials are considered the "gold standard" for clinical research. A corollary of this is that data from observational open- label studies are viewed as having less validity, and as not providing accurate estimates of treatment effects. However, a number of systematic reviews have shown that well- designed observational studies are quantitatively or qualitatively similar to those measured in randomised controlled trials. Moreover, these observational studies performed under standard conditions of care provide useful reassurance that the findings of randomised controlled trials can be considered as broadly representative of the population at risk. Several such observational studies have been performed in multiple sclerosis in order to compare the effectiveness and tolerability of the different disease-modifying therapies available for the treatment of relapsing remitting disease. One of these was a prospective study conducted in 156 patients that compared the effects of high-dose interferon-beta and glatiramer acetate. This study indicated that the two treatments had similar efficacy on all measures evaluated. The effect sizes observed were very comparable to those observed in the pivotal trials of these two agents. This study predates by a decade a much larger randomised study which also failed to demonstrate a difference between the efficacy of high-dose interferon-beta and that of glatiramer acetate. Observational studies such as this can thus provide useful and reliable information on treatment effects and can be used for preliminary hypothesis testing at a fraction of the cost and constraints of pivotal trials. In the context of the increasing difficulty and expense of conducting randomised, placebo-controlled trials in multiple sclerosis, comparative studies using an open-label design or a rater-blinded design are likely to be increasingly employed in comparing existing and future therapies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in February 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>314405</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17928576]]&gt;</url>
    <title>What constitutes high quality of care for adults with epilepsy?</title>
    <publicationDate></publicationDate>
    <publisher>American Academy of Neurology</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,EPILEPSY &amp; SEIZURES,NEUROLOGICAL CONDITIONS,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Pugh MJ, Berlowitz DR, Montouris G, Bokhour B, Cramer JA, Bohm V, et al. (2007) What constitutes high quality of care for adults with epilepsy? &lt;EM&gt;&amp;nbsp;Neurology &lt;/EM&gt;69(21):2020-7.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We reviewed existing national clinical guidelines and systematic reviews of the literature to develop an initial list of quality indicators; supplemented the list with indicators derived from patient focus groups; and convened a 10-member expert panel to rate the appropriateness, reliability, and necessity of each quality indicator. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; From the original 37 evidence-based and 10 patient-based quality indicators, the panel identified 24 evidence-based and 5 patient-based indicators as appropriate indicators of quality. Of these, the panel identified 9 that were not necessary for high quality care.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; There is, at best, a poor understanding of the quality of care provided for adults with epilepsy. These indicators, developed based on published evidence, expert opinion, and patient perceptions, provide a basis to assess and improve the quality of care for this population.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; November 2007&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Full text is only available to subscribers and is not available via an NHS Athens password.&amp;nbsp;You are advised to&amp;nbsp;ask your local healthcare library if&amp;nbsp;they have a subscription.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344280</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19324979]]&gt;</url>
    <title>What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials?</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Sage</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,FEBRUARY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Asano M, Dawes DJ, Arafah A, Moriello C, Mayo NE. What does a structured review of the effectiveness of exercise interventions for persons with multiple sclerosis tell us about the challenges of designing trials? &lt;EM&gt;Multiple Sclerosis&lt;/EM&gt; 2009 Apr;15(4):412-21.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; We searched CINAHL, COCHRANE, EMBASE, and MEDLINE between 1950 and December 2007 with combinations of MeSH terms and keywords. We assessed the methodological quality of selected randomized controlled trials (RCTs) of exercise interventions using the Physiotherapy Evidence Database scale and evaluated the effects of the exercise interventions by calculating effect sizes (ES) for the target outcomes.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Eleven RCTs met the criteria, all with acceptable methodological quality. The ES ranged from -0.36 to 3.50 on the target outcomes. Only one study had 95% confidence intervals clearly excluding a value of 0. Measures of body functions and structures and activities were the most common target outcomes of interventions. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Bottom-line conclusion:&lt;/STRONG&gt; Although there was some evidence to support positive effects of exercise on physical and psychosocial functioning and on quality of life, our review revealed insufficient research in this area, making it difficult to guide regular exercise prescription. Furthermore, it also emphasizes the methodological challenges in these RCTs leading us to believe that there is a great need for high quality RCTs in this area, contributing evidence for regular exercise and physical activity prescription for persons with multiple sclerosis.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt;&amp;nbsp;Published in April 2009.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293369</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17508184?ordinalpos=8&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum]]&gt;</url>
    <title>What does the evidence show? Efficacy of behavioural treatments for recurrent headaches in adults</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>Springer Milan</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,HEADACHE,HEADACHE &amp; PAIN,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Andrasik, F Neurological Sciences 2007 May;28 Suppl 2:S70-7&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=abstract&gt;Behavioural treatments (predominantly biofeedback, relaxation and cognitive-behavioural) have been utilised in headache management for nearly 4 decades. This paper examines their clinical efficacy, drawing upon 2 primary sources of evidence: meta-analytic and evidenced-based reviews. Behavioural treatments have demonstrated efficacy and have been endorsed by various reviewing groups, such as the US Headache Consortium. Outcomes from behavioural treatments appear to endure over longer-term follow-up intervals as well. Meta-analyses comparing behavioural and pharmacological treatments have revealed similar levels of outcome. The article closes with a brief discussion of methods investigators are exploring to make behavioural treatments more available and affordable to headache patients.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>344316</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19039023/]]&gt;</url>
    <title>What insights have new imaging techniques given into aggressive forms of MS--different forms of MS or different from MS?</title>
    <publicationDate>2009-03-01T00:00:00</publicationDate>
    <publisher>Sage</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,INVESTIGATION &amp; DIAGNOSTICS,MAGNETIC RESONANCE IMAGING (MRI),MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,CONDITIONS,FEBRUARY 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Pichiecchio A, Tavazzi E, Maccabelli G, Precupanu CM, Romani A, Roccatagliata L, et al. What insights have new imaging techniques given into aggressive forms of MS--different forms of MS or different from MS? Multiple Sclerosis 2009 Mar;15(3):285-93.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstract:&lt;/STRONG&gt; "Aggressive" multiple sclerosis (MS) is still a challenging diagnosis, in spite of the relevant progresses concerning the comprehension of the disease mechanisms, especially through pathology studies and the advent of conventional magnetic resonance imaging (MRI). Some reviews have been already published on their clinical and therapeutical aspects, but no systematic review is available in literature about the neuroradiological features, using both conventional and advanced techniques. In particular, advanced MRI techniques, namely diffusion-weighted and tensor imaging, magnetization transfer imaging, and proton magnetic resonance spectroscopy, are giving new insights to find specific and appropriate radiological parameters that can help in targeting the diagnosis. We report a review of literature on the neuroradiological findings of aggressive forms of MS, focusing specifically on the role of advanced MRI techniques in the diagnostic phase and during follow-up.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Publication date:&lt;/STRONG&gt; Published in March 2009&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Available to NHS England staff via an NHS Athens password. Access via &lt;A href="http://www.library.nhs.uk/booksandjournals/journals/default.aspx" target="_blank"&gt;My Journals&lt;/A&gt; in the National Library for Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>381899</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1161/STROKEAHA.109.570390]]&gt;</url>
    <title>What works in falls prevention after stroke? A systematic review and meta-analysis</title>
    <publicationDate>2010-07-08T00:00:00</publicationDate>
    <publisher>Stroke</publisher>
    <publicationType>SYSTEMATIC REVIEW</publicationType>
    <topics>&lt;![CDATA[ RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,DELIVERY OF CARE,STROKE,REHABILITATION,JULY 2010,CONDITIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Bibliographic details&lt;/STRONG&gt;: Batchelor F, Hill K, Mackintosh S, Said C. (2010) What works in falls prevention after stroke? A systematic review and meta- analysis. &lt;EM&gt;Stroke&lt;/EM&gt; 41(8): 1715-1722&lt;/P&gt;
&lt;P&gt;Stroke is a monthly publication and part of AHA Journals, produced&amp;nbsp;by&amp;nbsp;the American Heart Association whose mission is to build healthier lives, free of cardiovascular diseases and stroke.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; Fall risk is high in stroke survivors; however, the only intervention shown to be effective in reducing falls in this review was vitamin D supplementation. Consistency in outcome measurement would enable comparisons across studies. Additionally, further research evaluating a range of single and multifactorial interventions for fall prevention in the stroke population is required. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Background and Purpose:&lt;/STRONG&gt; Falls are common after stroke. Despite evidence that single and multifactorial interventions can reduce falls in older people, this issue remains relatively underexplored in stroke survivors. Effective fall prevention in this population has the potential to prevent injury, improve quality of life, and decrease the likelihood of subsequent fear of falling and activity restriction. The aim of this article was to review and integrate the research evidence relating to interventions that reduce falls after stroke. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Methods:&lt;/STRONG&gt; Published studies evaluating interventions to reduce falls in stroke survivors were retrieved and screened according to predetermined criteria. Included studies were independently assessed. Quality of trials was assessed using the Physiotherapy Evidence Database score. Pooling of results was undertaken for similar interventions with comparable outcomes using the inverse variance method. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Results:&lt;/STRONG&gt; Thirteen studies met the inclusion criteria, with pooling of results possible for only 2 types of intervention. Methodological quality of the included studies was variable with the main bias because of lack of blinding of participants and those administering the intervention. Variability in falls data reporting was seen across the studies. The only intervention shown to be effective in reducing falls was vitamin D for female stroke survivors in an institutional setting. Other interventions were no more effective than usual care. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access:&lt;/STRONG&gt; Most full text is&amp;nbsp;only available to subscribers; ask your local healthcare library if&amp;nbsp;they have a local subscription.&amp;nbsp;Some full text content plus abstracts and tables of contents are freely available.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325948</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://dx.doi.org/10.1136/ebn.12.4.124]]&gt;</url>
    <title>Women who coped successfully with progressive MS learned to confront their diagnosis and live with its unpredictable changes</title>
    <publicationDate>2009-10-01T00:00:00</publicationDate>
    <publisher>BMJ Group</publisher>
    <publicationType>CRITICALLY APPRAISED TOPIC</publicationType>
    <topics>&lt;![CDATA[ MULTIPLE SCLEROSIS &amp; OTHER DEMYELINATING DISEASES,MULTIPLE SCLEROSIS,NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,CONDITIONS,SEPTEMBER 2009]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Evidence-Based Nursing is a secondary evidence journal, containing informative abstracts and expert commentaries about the best quality research from primary care medicine.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Carr T. (2009) Women who coped successfully with progressive MS learned to confront their diagnosis and live with its unpredictable changes. &lt;EM&gt;Evidence Based Nursing&lt;/EM&gt; 12(4):124.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abstracted from:&lt;/STRONG&gt; Kirkpatrick Pinson DM, Ottens AJ, Fisher TA. (2009) &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19092142" target="_blank"&gt;Women coping successfully with multiple sclerosis and the precursors of change&lt;/A&gt;. &lt;EM&gt;Qual Health Res.&lt;/EM&gt; 19(2):181-93.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;Available to NHS staff via Athens.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325718</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.basiccharity.org.uk/images/voc_rehab_modelreport.pdf]]&gt;</url>
    <title>Working towards employment</title>
    <publicationDate>2009-04-01T00:00:00</publicationDate>
    <publisher>Brain and Spinal Injury Centre</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SPINAL CORD INJURY,REHABILITATION,SPINAL INJURY,NSF LONG TERM CONDITIONS,RECENT ADDITIONS,NEUROLOGICAL CONDITIONS,TRAUMA,BRAIN INJURY,DELIVERY OF CARE,TRAUMA AND ORTHOPAEDICS,SPINE,DISEASE MANAGEMENT,DISABILITY MANAGEMENT,CONDITIONS,SEPTEMBER 2009,STRATEGIES AND POLICIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report has been produced by BASIC in response to the government's NSFs for Long-term Conditions and Vocational rehabilitation, wherein the aim is established to provide vocational rehabilitation to clients with a range of neurological and long-term conditions by 2015. Government strategy involves the pubic sector working in partnership with the voluntary sector.&lt;/P&gt;
&lt;P&gt;This report consists of 5 sections:&lt;/P&gt;
&lt;P&gt;Section 1 considers the role of BASIC in developing VR services in the Northwest comparable to those already developed in Scotland.&lt;/P&gt;
&lt;P&gt;Section 2 sets out BASIC's model of vocational rehabilitation practice. &lt;/P&gt;
&lt;P&gt;Section 3 considers community links.&lt;/P&gt;
&lt;P&gt;Section 4 is a discussion on the way NHS Trusts and BASIC could work together.&lt;/P&gt;
&lt;P&gt;section 5 is an annex containing a summary of the examples of good practice identified by the Department of Health.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>388358</id>
    <name>&lt;![CDATA[ Neurological Conditions]]&gt;</name>
    <rootDirectory>/neurological</rootDirectory>
    <url>&lt;![CDATA[http://www.alz.co.uk/research/worldreport/]]&gt;</url>
    <title>World Alzheimer Report 2010: the global economic impact of dementia</title>
    <publicationDate>2010-09-21T00:00:00</publicationDate>
    <publisher>Alzheimer's Disease International</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ NEUROLOGICAL CONDITIONS,RECENT ADDITIONS,ALZHEIMER'S DISEASE,DEMENTIA,CONDITIONS,SEPTEMBER 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;STRONG&gt;Citation:&lt;/STRONG&gt; Wimo A, Prince M. (2010) World Alzheimer Report 2010: the global economic impact of dementia. &lt;EM&gt;Alzheimer's Disease International&lt;/EM&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Summary:&lt;/STRONG&gt; The World Alzheimer Report 2010 provides the clearest, most comprehensive global picture yet of the economic impact of Alzheimer's disease and dementia.&lt;/P&gt;
&lt;P&gt;The report includes an estimate of the worldwide cost of dementia, including direct medical costs, direct non-medical costs and costs of informal (family) care. The estimates are broken down by world region and include analysis of the differences between low and high income countries. The report also contains important policy recommendations and makes clear to key decision-makers that doing nothing is not an option.&lt;/P&gt;]]&gt;</body>
  </document>
</documents>